<SEC-DOCUMENT>0000950170-23-016436.txt : 20230502
<SEC-HEADER>0000950170-23-016436.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502072117
ACCESSION NUMBER:		0000950170-23-016436
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sage Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001597553
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36544
		FILM NUMBER:		23876610

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-299-8380

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sage-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-05-01T11:19:11.2574+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:sage="http://www.sagerx.com/20230331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_21484654-1747-43a0-a65e-1ae6c9c7e6e4" name="dei:DocumentFiscalPeriodFocus" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548">Q1</ix:nonNumeric><ix:nonNumeric id="F_02aacb61-99a8-43ba-8bb8-3474e32fbedc" name="us-gaap:LessorOperatingLeaseOptionToExtend" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548">true</ix:nonNumeric><ix:nonNumeric id="F_f626faa3-d234-4588-bb64-a0e2e90343a1" name="dei:AmendmentFlag" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548">false</ix:nonNumeric><ix:nonFraction id="F_722165e9-8516-4f03-ba84-faf866355366" name="us-gaap:PreferredStockValue" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0bb4eff4-2c78-4ed6-a5dc-d2873b5f55dc" name="dei:EntityCentralIndexKey" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548">0001597553</ix:nonNumeric><ix:nonFraction id="F_4c74dc23-2f32-4cdf-9616-71a40e398db1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_9fe7857e-17e4-49cf-93b3-30d78c5acea7" name="sage:MarketableSecuritiesMaturityPeriod" contextRef="C_90692949-732e-4bb8-962a-750c256e3415">P1Y</ix:nonNumeric><ix:nonNumeric id="F_daac0f6d-a17b-45b7-8238-999b9f5345f2" name="dei:CurrentFiscalYearEndDate" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548">--12-31</ix:nonNumeric><ix:nonFraction id="F_bc779985-800d-437e-b177-c597d5bba68a" name="us-gaap:PreferredStockValue" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_15ef7878-1081-4815-8372-c33bbdbbcbd7" name="sage:MarketableSecuritiesMaturityPeriod" contextRef="C_f8c25304-e6ec-4215-ad71-34b22a23bf68">P1Y</ix:nonNumeric><ix:nonFraction id="F_894d0bec-ae52-4ca9-a5f4-73ac643e9e66" name="us-gaap:CommitmentsAndContingencies" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sage-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_afad7b91-c063-484c-8b27-af3fdd038f98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b7a5ab4-63f6-4561-8f6d-b3de184d3551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fae74238-7ce3-4af5-9f76-7ddc34eb01f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad149366-134a-4672-9147-ddac23ada4ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1260202e-e0d1-44c6-91a1-7328082cd6ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_694b1751-ca21-4b1a-8ae0-231f74098b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66eb2bc3-a6d2-4d81-939a-2ee9abc0d88c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e45cbb2e-3c5f-498a-a209-b241cd20689d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_053c255f-d2dc-471e-bb1d-70b5c18befc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_631cae3a-ac3e-456e-a8b7-57e54ff8a7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc0e2088-ed2f-4615-ae09-35dc9db057e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b41ee00a-05a1-4445-a768-1bb17e0a6c84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96f30eb5-acb2-4f40-a8d3-bcc1575d5f47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef9f0eeb-8bd0-48d2-8cef-1b949dcabefb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2914001-6eb8-4b83-a2c2-bd94ddbe5fe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_041cce77-afef-4aed-92c7-1df0dfbc91eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1978be30-cc7c-4cc4-a992-11e42d4bd0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34e9c797-7ce4-4b4b-b51e-18629a1f9429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_473be90c-b2bd-4a46-8157-218452e72424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51b62e2e-6e5b-43f1-9a64-7a9fc0694111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9d6d818-4da5-4eb9-903b-f6a198d8f733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbfc6e76-8aca-485a-914b-f8d69d2c7389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59e5900f-8174-4b14-bfc1-b7d19f8176e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96c58346-5075-4864-bc24-0ddf5e57105c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbb07196-2b75-47c6-80e5-725f729861d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9308d0f-6e5f-4493-9625-38e3eaaea53c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1377c2db-8563-423b-b496-c6079553d1b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22abec7d-1872-4be4-b3da-b134f50ffb38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2eed04fd-66bf-403b-b097-ca6cfcbcd5d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80624434-96c6-446e-ada9-fe739d3d9e5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9a17952-5137-4cb5-9321-ceda02cb88c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90273a42-5bc2-4c8a-b365-81b8b3294dbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75423cb0-1c5c-451b-8f34-441ea3df08c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sage:ConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0417f1bf-3a90-4585-8698-483b60daf578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ThirdAndFourthRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bb6c209-64a4-4fa9-9e19-b14c178a0c67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:RegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-29</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b34f602-7812-4da1-a117-ccb5aabeb0c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a4f411b-755b-4edb-9b9a-1c815418b4e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73403fc5-d8c9-42ee-a01a-11d2ee5fe21a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_859555c6-3449-4a1e-829a-27a34b936e07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27bf7966-adaf-4a98-8cd4-cf044ac22be7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08b2b642-fbe6-4621-9e25-1ad7325fb6fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41166faf-b133-46b7-89f9-98cc0e4a309b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_872fc801-16d0-407b-a188-71e78a10b66e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a812fff-cfeb-4da1-8230-6cd1569cea05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0558d4b-6d1c-4376-8c22-956a113e11fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df2b4db8-ae1e-400c-96db-0a5ee962f62b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90692949-732e-4bb8-962a-750c256e3415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7f34c5e-d698-4850-9998-3b9d55aa69dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff1b2d86-e176-4930-a80e-46e442e30f10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9558178b-ee96-4bb9-98b8-32cd20923e46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_159c0b2e-4b20-4fe8-842e-d19291806674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a4476f1-f818-43ff-b2be-89e56448a77d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20237446-69f4-4551-93d5-fee5a4bf888c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8fdbb15-6c4b-4e31-80ed-4104897dd692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd88a57a-5b9d-49be-a744-23e0bf41890a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9077cfbe-fe30-4100-87f2-a75b18e864fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4abf962a-8014-45c8-8864-72250359e195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2204d339-5d64-45be-917c-4696379675ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fafe567-6ae5-44ee-8496-6f5bb08d136a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f39072ec-f2ce-4670-be4f-b0f1f4bcf30f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_184f14a5-c851-40db-a3ad-edc0666d719c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c148acc4-eb89-4bb9-b863-bbc6f10137ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sage:OperatingLeaseThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_378410ff-522b-42f9-9391-4818fc9692a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_699a6647-c36c-4a33-a3f4-ae8e7184b152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:SAGE324Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-29</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a762d75-188f-4244-ab8c-58366e1a3a7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e166f395-27e9-4ed3-b61a-0efed3d9f77f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:SAGE324Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:RegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-29</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3319e980-82fb-4d89-a8c2-15e306377f32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cfbb3fe-a778-45b0-a709-a4a4a1292a25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a27e3064-3e8b-4d7c-97fd-d2f5bdd6bd44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sage:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a046e3a-d734-4572-ba58-9c70fe1e9fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a300dcf-c0cb-47b1-a0fc-9cd53edc84b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandElevenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04077a28-e57f-48bf-be52-866b6f516e9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1dfde7f5-0e05-4477-b311-a6bafe7de036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4873c8c-5811-4fbb-bbcc-4e44f6387941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ThirdAndFourthClinicalDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f864b66-2233-436e-9a55-3a656e209f1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:FirstCommercialSaleOfZuranoloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-29</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f717451a-6a70-4aef-9347-14e48ca9154e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ac07274-fc3a-4894-82ec-ea46b3499663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b95b663e-2b75-4278-99c2-2c62b7b11486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f08fa5ab-3d5a-498f-8805-b37168240ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sage:ScenarioOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-30</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a87f9c6e-2ef9-466a-ae7a-ee5de7690022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1781ce27-35bc-4e2c-9a64-0b8ce5fdfda1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59765745-97e9-4396-b431-ab2d3335cfad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_758d45bc-86ac-4f04-b85e-741bffc1d6f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e663c40a-15ae-4907-b98c-552196067f88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1eaf741-1b2c-4c28-bfe7-5c8db9a38dfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d91e179-f711-4e4d-aaa6-c27f609457e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2aeaf62-e210-498e-b523-527707b39cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_150eb2ee-5e12-4af8-9658-d633a3fc51a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7010b40-0dcd-4f49-8b91-0d384171fed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d696c64-4852-4448-9e18-cca9af20998a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e880326-ed6e-48e7-a99c-374dfaae0004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe878ea5-22df-4ead-ab1d-48438facdfb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sage:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e922eff6-ae97-4689-ab0c-b231d4614194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2ae6c1e-1913-47c9-8778-3d00309c407f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee76c540-63b2-44a9-af22-8b7f35a27ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cec5550d-a16c-4e00-9894-1a8d869e5bae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b6f49c8-d774-48fb-b187-986662265c23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaf26748-7cbb-49a2-a010-8177fc4192d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8c25304-e6ec-4215-ad71-34b22a23bf68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d3496d1-3be0-413b-9f3a-0b624246add1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_985df593-5059-41c1-979c-cfad810abdef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_110148da-fe96-4b69-87ce-8a98365c120f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f338a222-b449-4bcc-a112-e91bc99cd864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9010a77-202b-457f-a93d-645d7cf2ae6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be15177a-d746-4e38-b283-8b06ad56dd5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e009878c-16d0-44dd-938b-4ab63e464396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sage:ScenarioTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-30</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27dd408f-5b77-4383-b146-868c9ccf1126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5072417-0f0f-44a9-8e76-a71228d6ebf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_398f2f38-b40a-44f3-b42a-adb45a79772b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_deab43ad-3c90-4a47-ae84-57cc9e11dfaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1249121-8d96-4038-9762-31833df70a85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c31a15fe-00ba-4870-b61b-89dd2a4980ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_328aba2f-fb20-4a39-964e-4eee7f038c9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2b10c3e-e417-48ea-a3c8-37953b52b9c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43b0053b-716b-4f02-839f-ad6443d25548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbed26d2-cc37-4226-abd6-049e70ee76cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_415d3116-954c-4e68-b279-376d06d7f3f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4fdb95a-3eb7-454b-aa35-9c3868eab086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b20c727-7972-478a-9e8f-c96192d5a8c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3733b62f-9978-46fa-ae1f-0ca914403f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_281fc868-2fdb-4949-a787-87a97e7468c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32d6c0d5-c8be-40ce-8635-6583447c427f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb341859-3071-42f6-bc53-4b0e98b5f8a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstAndSecondClinicalDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec5cbc69-f530-4cf4-94cc-314aa3b6a25a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3499aa63-1335-4278-afe4-3af8c03e1236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94d7d66d-d764-476a-bdb7-7e62dfec2d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebde5ad9-f57b-4a0d-a856-31c668cee290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62a04c01-c554-489b-94ff-f68796238daf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bd63346-2edc-4d25-8792-a77d046eb774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e328e10-72d6-410f-80ac-3d76258027a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94d81f85-dbf8-4abd-8cc2-b5a8a0cbec84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce43f41b-b49a-4a4d-ac4f-591e551f6206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_850361db-7291-43d8-8579-6031f3718f59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ea38295-87e6-4099-8ab6-a32ad999eac8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-29</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7472141-c913-4194-b3cf-9b99dbf32ab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a954ef97-2d5d-474e-85f1-993cfd4ef26c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d275e93b-4da3-49de-a49e-a35ac74b5238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6308113-5edd-45dc-ae2f-49266a225055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b581abc-0b6e-4877-a6fd-ea611d7c0a1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstAndSecondRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c3096d1-dec2-4b13-9d67-bef02783497c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ae85a8f-70ca-4220-93dc-e4da3306dc78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sage:ConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_263ee25c-c855-4e19-8a9f-8283bd620ab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryAndSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23999eda-d8e5-4c17-ae2e-ed2f30bd77ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34f017d3-fc3a-40f4-a32a-6e68c12be396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8887f83-2b64-4c67-9ed6-bf1f704f02eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3351468-5ac6-43c1-8075-f9f598ae56b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d205233-d11d-421a-9604-3d24b788eaa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandSixteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ac1b81a-4423-47d2-b61e-3baceb754609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88622809-97e6-415e-84af-28e0cecdedb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7db4793-3d03-4e12-aff2-9ea90996fb1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sage:OperatingLeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_414c6759-f1c6-41b9-b865-55fecfa38284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b379d84e-292f-4ec3-8309-f2e399adad4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fb3fbe9-a1c0-46ce-b650-af5e52d18ce1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-30</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdd95323-8fa2-447a-b407-594cf62cbf26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff91b6cd-d80c-40f0-b294-2711aab14ffb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a131c6ed-00ee-4297-b3ee-b15e20f02a2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed9cf729-5356-4b5d-ad2b-e3ed67efc846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sage:OperatingLeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39f2ebec-0b4d-4975-8d61-08994c517086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5673061c-1475-40d8-a68f-d13874d6120e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-30</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe4b519c-5caf-4568-8a3a-2efeec719a51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c36d2239-87f1-407c-91da-2330c526026f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe000172-bb4d-4a08-9a7f-f806a292fa6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95a6685d-c914-4c9f-b57b-5ca39c0070ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd11ff6a-3076-4878-b379-411eea2932d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27a73613-5f17-4ab4-b5a6-643c79010992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca2e20ac-ec64-49a3-90db-a61de00d3168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8b28052-9239-40b1-9476-79d5174ad674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0418523-3fbf-4353-b5fc-b74fa6275d25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfcf2c3b-ff61-431f-b715-71fc37e86066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4eb33dd9-e498-40d6-b3ab-aed72488e0a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24252855-7fbc-49c5-993c-ccdb3e3e73e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cc6f749-3572-4a07-9837-a838d91c9606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9b8b2ef-3e7c-4781-829b-f175d048affc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d08e78d2-6122-4a68-a2fa-efacb6e5afb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2824d78-7fd0-4324-bd17-8138321ed536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe2f65bc-c1a3-4823-84d8-2de25bace4b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryAndSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c906b10e-a37d-4bef-9c1a-2f9273872ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d098601-3538-45a4-aa05-ee4216c06e54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_565d202e-3bb5-4101-a291-f12dafc51a69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_218b8633-84a1-4518-ac04-a09bb4743a05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-29</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25ec2f51-a9c3-49be-9f2a-0f5e21581ba9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001597553</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestone"><xbrli:measure>sage:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:2.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form </span><span style="font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_71f37d5b-ed46-4c11-9134-1ce927638453" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:2.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.38%;"></td>
    <td style="width:96.62%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_19e5434c-21f1-4209-98b4-7353ee7996b9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b282236d-bc49-4ebc-bfbf-14af552b1ca1" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16d4f0d6-c627-4de8-b96c-eaa7ce09e3b1" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.38%;"></td>
    <td style="width:96.62%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_b71f5023-1843-409f-a0bc-5df6e2c04aef" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                    </span><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission file number: </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c7d8053-6cf8-401e-b42c-ada6c1aa5bae" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-36544</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:2.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc468799-099d-41d1-8c27-2dc72c754f1b" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db2e891d-ddf3-44bc-9cd8-1da91695f233" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17606b56-fc7e-4200-90c2-98f08d630de9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27-4486580</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_005ab3d0-298b-46c4-9f66-c8d3e43009a7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215 First Street</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_af025a85-5aa5-40f2-9698-6210b9ca7508" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c3d1198f-cea1-4c9e-972a-e271da48840a" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e52e542-a1d5-4898-9b70-7795671399d7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02142</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive office) (Zip Code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_01742252-d6f5-472c-b3c5-57625bde8a8c" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e240f7d1-0ef5-4253-a684-442465ba379a" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299-8380</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:40.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b9c817db-88b6-4bc3-b405-d7acb972180a" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b964c55f-7112-4659-8ce6-aed5cdf1c715" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11096860-8cc7-4d50-bdd2-ec00e1dc43d9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0a10b9d-d438-471f-b1f4-743c955c7bf0" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    No  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4f114027-91fc-452b-8b8b-6889edaf8f9e" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    No   </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#x201c;large accelerated filer&#x201d;, &#x201c;accelerated filer&#x201d;, &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.34%;"></td>
    <td style="width:1.68%;"></td>
    <td style="width:58.56%;"></td>
    <td style="width:18.58%;"></td>
    <td style="width:1.84%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a6709f9-3126-4cd1-a9d7-6f114e009cde" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_9e3e191b-0e03-4843-82d5-49e2ee8318d4" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_4085be57-efb1-40be-b723-30b9424bc504" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_4d736a1d-2c80-414b-a53b-ddc026659640" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    No  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of April 25, 2023, there were </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dabec0c-7b0d-47d1-a5ca-b52cc16d0681" contextRef="C_c36d2239-87f1-407c-91da-2330c526026f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,762,106</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the registrant&#x2019;s common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;may&#x201d;, &#x201c;will&#x201d;, &#x201c;should&#x201d;, &#x201c;expects&#x201d;, &#x201c;intends&#x201d;, &#x201c;plans&#x201d;, &#x201c;anticipates&#x201d;, &#x201c;believes&#x201d;, &#x201c;estimates&#x201d;, &#x201c;predicts&#x201d;, &#x201c;potential&#x201d;, &#x201c;continue&#x201d; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our views as to the potential for approval by the U.S. Food and Drug Administration, or FDA of our new drug application, or NDA, for zuranolone (SAGE-217) as a treatment for major depressive disorder, or MDD, and postpartum depression, or PPD; our belief in the adequacy of the data we submitted in support of our NDA for zuranolone; the expected review timelines of such NDA; and the potential for future launch and commercialization of zuranolone in MDD and/or PPD, and the potential timing of such activities, if our NDA is approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our views as to the potential for zuranolone for the treatment of MDD and PPD, if approved, including the potential product profile and treatment benefit, our commercialization strategy, plans, and expectations and the potential for zuranolone to be developed in additional indications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans for the development of our other product candidates for the treatment of brain health diseases and disorders, and potentially for other indications; our plans with respect to other research and development activities; and expected timelines for our planned activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability, within the expected time frames, to initiate clinical trials and non-clinical studies of existing or future product candidates, including pivotal clinical trials, and to successfully enroll, complete and announce the results of ongoing or future clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our belief as to potential outcomes of our clinical development and commercialization activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our views as to potential future results of our ongoing commercialization efforts in the U.S. with respect to ZULRESSO&#174; (brexanolone) CIV injection, which is approved in the U.S. for the treatment of PPD in adults;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans and potential outcomes with respect to interactions with regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans for and the potential costs, benefits and outcomes of our existing collaborations with Biogen MA Inc., or BIMA, and Biogen International GmbH, or, together with BIMA, Biogen, and Shionogi &amp; Co., Ltd., or Shionogi, and our plans for and potential outcomes of any additional business development efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans and expectations with respect to the potential development of any product or product candidate for markets outside the U.S.;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations and estimates regarding: the level of expenses we may incur in connection with our activities; use of cash and projected cash on hand at any given timepoint; timing of future cash needs; capital requirements; sources of future financings; timing of receipt of potential milestone payments; and our ability to obtain additional financing when needed to fund future operations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations with respect to the availability of supplies of ZULRESSO or of zuranolone and our other product candidates, and the expected performance of our third-party manufacturers, including conformity with applicable regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our proprietary assets and other forms of exclusivity relevant to our business;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the estimated number of patients with diseases or disorders of interest to us and the potential size of the market for ZULRESSO in PPD, for zuranolone for the treatment of MDD and PPD, if approved, and for our other product candidates in the indications we are pursuing or plan to study; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential for our current product and current or future product candidates, if successfully developed and approved, for the indications and in the markets for which they are approved and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential for success of competing products that are or become available for PPD or MDD or any of the other indications that we are pursuing or may pursue in the future with our products and our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of changes to the macroeconomic environment and geopolitical events on our activities, business and results of operations, and the potential success of our efforts to address or mitigate such impact; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties, including those listed under Part II, Item 1A, Risk Factors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, Risk Factors and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may from time to time provide estimates, projections and other information concerning, among other things, our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information we provide in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry and business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties; industry, medical and general publications; government data; and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Risks Related to our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business, prospects, financial condition, and operating results are subject to numerous risks and uncertainties that you should be aware of before making an investment decision, as more fully described under Part II, Item 1A, Risk Factors and elsewhere in this Quarterly Report. These risks may include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future business prospects depend heavily on our ability, with our collaborator Biogen, to gain regulatory approval of zuranolone (SAGE-217) for the treatment of adults with MDD and PPD, and to successfully commercialize zuranolone in those indications, if approved. While our NDA for zuranolone is currently under review by the FDA, we cannot be certain that the FDA will grant approval of zuranolone in the indications we are seeking. The FDA may find that the design and results of our development program are not sufficient for regulatory approval of zuranolone for the treatment of either or both of MDD and PPD or may decline to approve our NDA for other reasons or may impose unexpected limitations or restrictions on use. Although we have been granted priority review, the FDA may not meet expected review timelines. Even if zuranolone is approved as a treatment for MDD and PPD, we may not be successful in our commercialization efforts.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any setback or delay in obtaining regulatory approval for zuranolone or in our ability to market zuranolone, if approved, may have a material adverse effect on our business and prospects.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future business prospects also depend heavily on our ability to successfully develop and gain regulatory approval of other product candidates beyond zuranolone. We cannot be certain that we or our collaborators, where applicable, will be able to initiate new clinical trials, complete ongoing enrollment, dosing or data </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analysis of clinical trials, or announce results of ongoing or future clinical trials of our other product candidates in each case on the timelines we expect or at all, or that the results of our development programs will be positive or sufficient to file for regulatory approval. Decisions or actions of the FDA or other regulatory agencies may adversely affect our plans, progress or results at any stage of development. We cannot be certain that we or our collaborators will be able to successfully file or obtain regulatory approval for, or successfully commercialize, if approved, any such product candidates on the timelines we expect or at all. Any setback or delay in obtaining regulatory approval for any of our product candidates or in our ability to commence marketing of our products, if approved, may have a material adverse effect on our business and prospects.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may never be able to generate meaningful revenues from sales of ZULRESSO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (brexanolone) CIV injection, or revenues at levels or on timing necessary to support our investment and goals. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the affected populations for indications our products and product candidates are targeting, including the addressable markets within such populations, or the number of patients within such markets who are actually treated with our products, including zuranolone, if successfully developed and approved, are smaller than we anticipate, or our other assumptions with respect to the potential markets for our products and product candidates are incorrect, our ability to achieve profits from the commercialization of such products, if approved, at the levels or on the timing we expect could be materially adversely impacted.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Positive results from non-clinical studies and clinical trials of our product candidates are not necessarily predictive of the results of later non-clinical studies and clinical trials of our product candidates in the same indications or other indications. Interim results from non-clinical studies and clinical trials may not be predictive of results of such non-clinical studies or clinical trials once completed. The results of non-clinical studies or clinical trials of our product candidates at any stage may not support further development or may not be sufficient to file for and obtain regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If serious adverse events or other undesirable side effects are identified during the use of any of our marketed products or product candidates, including during commercial use, in clinical trials or under an expanded access program, if initiated for any of our products or product candidates, such events may adversely affect market acceptance or result in other significant negative consequences for an approved product; delay or prevent further development or regulatory approval with respect to product candidates; or cause regulatory authorities to require labeling statements, such as boxed warnings, or a Risk Evaluation and Mitigation Strategy, on approved products.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any impairment of the ability of our third-party suppliers to supply product or to meet applicable regulatory standards may significantly negatively impact our ability to achieve our goals and plans and to meet the expectations for our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Zuranolone, if approved, and any of our other current product candidates, if successfully developed and approved, and other future products, if any, may not have the profile we expect in clinical practice after launch or may not achieve broad market acceptance for the approved indications, or reimbursement at sufficient levels, and the results of our commercialization efforts may not meet our expectations, which may limit the revenue that we generate from sales of such products.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of ZULRESSO, zuranolone, if approved, or any of our other current or future product candidates, if successfully developed and approved. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our existing collaborations with Biogen and Shionogi, and any future collaborations, may not lead to the successful development or regulatory approval of product candidates or commercialization of products. Our collaborators may have competing priorities, conflicting incentives, or different views than us on key decisions, including appropriate program spending, that may hamper or delay our development and commercialization efforts or increase our costs. Our business may be adversely affected if any of our collaborators fails to perform its obligations or terminates our collaboration in whole or in part.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to identify new targets, generate new compounds, and successfully bring such new compounds through investigational NDA-enabling non-clinical studies. We may expend our </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents sufficient to protect our products or product candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we were to lose our rights to certain licensed intellectual property, or if we are not able to obtain licenses to intellectual property we may determine we need in the future, we may not be able to continue developing or commercializing certain of our products or product candidates, if approved.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Existing or future laws, regulations, executive orders or policies aimed at reducing healthcare costs may have a material adverse effect on our business or results of operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to healthcare laws and regulations, which could expose us to the risk of criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings if we or our employees are alleged or determined not to have complied with such laws and regulations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not achieve events tied to cash milestone payments from our collaboration partners on the timelines we expect or at all, or generate revenues from zuranolone, if approved, or any other of our products that may be successfully developed, at the levels we expect. Our expenses may also be higher than we expect, including as a result of unexpected events or changes in plans. As a result, our expectations as to our cash runway and the sufficiency of cash to fund our future operations may prove not to be correct. We may need to raise additional funding in the future, which may not be available on acceptable terms, or at all. Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish valuable rights.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse impacts from changes to the macroeconomic environment, including as a result of the COVID-19 pandemic, may continue to adversely impact our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022 and other existing, pending or future federal and state reforms aimed at reducing healthcare costs, including pricing and reimbursement of pharmaceutical products, may in the future result in reduced reimbursement and access for our approved products or cause us to curtail certain development plans because of concerns about commercial viability, any of which could adversely affect our ability to commercialize our products and generate revenue and negatively impact our business, results of operations and financial condition.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:84.117%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:6.601%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I &#x2013; FINANCIAL INFORMATION</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_changes_in_stock"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#x2019; Equity for the three months ended March 31, 2023 and 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Condensed Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II &#x2013; OTHER INFORMATION</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii_item_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="part_i_financial_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I &#x2014; FINANCI</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL INFORMATION</span></p>
  <p style="text-indent:-9.987%;padding-left:9.08%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.	Financi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">al Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolida</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ted Balance Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.536%;"></td>
    <td style="width:1.505%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.727%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.505%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.727%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31,<br />2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbfd8acf-8921-4c62-a3b4-59a4e954f5f3" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb89847c-5829-4bd7-8ba5-46be95d53878" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_546e4af9-e48d-4198-bb8a-f7e6fff811b7" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eef32bb5-4b4b-4d09-b50a-804fa1900452" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea5e6078-f5df-4cf5-a86e-dd46b32f46d2" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82535d17-622e-49ea-9b9c-d9e5c13e8789" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration receivable - related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a91738f3-8cc5-4f8a-a389-3d6539ed4e53" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4f762f0-5f8a-4993-9e03-bfc21325f1f0" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,660</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08d17728-b15c-4a9e-a4b9-a3ded913ab28" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,203,437</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6caa4499-ae5e-4d62-817b-f13a2c822b1a" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,336,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25695f94-54a6-4a54-9799-9f3f3b130c0f" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,663</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc74cbbf-2146-4f5e-98b4-1d62809fe405" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,898</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d499316e-844e-4754-ae5e-860b7e10a34e" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64c4a448-18bb-4d7b-9bb4-09207000f23e" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use operating asset</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24d3d60d-6914-4138-af67-4d027e56c0cd" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,062</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b99fb7a-d9e5-4725-a2d8-f684b9576e7a" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fbe74e7-aaf6-4226-98c2-a5b2e31960ca" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_864a5971-0131-48d1-8a7d-43ce3569b292" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_651fa7a4-497e-43f6-82ab-65bb3cad009c" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,220,686</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95f5674f-90fc-4c82-8347-13003f8da707" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,356,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2788b2e7-31f7-4a82-a9f8-7f1384ebf74a" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91add304-8efb-4a0d-adf9-504e73969b07" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcd1cbbb-df7f-4116-ba15-cf86e024b256" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a79de10f-6c1f-4dcf-a3dd-4e0eebdd0864" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,666</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9585b93-6294-4407-bafd-e0ec2526523b" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_229ba4d4-be2f-4667-9db9-55f81d2e45bd" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e0d2767-730f-459c-aec6-5ea28ebda3c2" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75928d44-6f58-4be7-a3dc-638ecc79d059" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b3a864d-12bb-432c-8f2f-768eb64631bd" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83d108c5-2172-46fd-ae08-67acd5bca57a" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83d7e8af-00d5-4df1-bf93-06e0c0b74f54" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8edac4f3-2203-4866-862e-ec6eb6faa1c2" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9800d1d-b21b-4358-a537-5aade448e004" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_186dd8fe-82e7-4cf6-be7e-4a887be47b12" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4c74dc23-2f32-4cdf-9616-71a40e398db1;"><span style="-sec-ix-hidden:F_894d0bec-ae52-4ca9-a5f4-73ac643e9e66;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 5)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5fc754e-52ad-4948-b501-88032ecf9e9f" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c1c00af1-1aec-42fc-b396-4debea59e366" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_944b38de-b384-4d10-978b-6fb743e6b071" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_68bf4643-1428-4556-943a-71ee7d6011dc" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;authorized at March 31, 2023 and December 31, 2022; </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6663014-056a-46ab-97e5-594f2aedf4d6" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a5d98363-e71d-43e8-a598-cff9cbf3ee65" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c1146a9a-8abf-4144-b839-bff3dae17336" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_418cde14-e922-4da2-9f0f-d1ad300f04a6" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;issued or outstanding at March 31, 2023 and December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_bc779985-800d-437e-b177-c597d5bba68a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_722165e9-8516-4f03-ba84-faf866355366;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad534995-a1de-498b-9a64-4fce93188441" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_762fc7be-cc55-4de5-a938-e152f08b236d" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20b7b99f-3dd3-4a41-8738-09154b2345db" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d974f708-3462-4822-93c5-f85bf448065e" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">120,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;authorized at March 31, 2023 and December 31, 2022;<br />&#160;&#160;&#160;</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02d159b2-3358-4885-98dd-207b2c2c3d0d" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,765,034</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e88ffd8-99c7-494f-bbc6-0f57b093d470" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,512,158</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued at<br />&#160;&#160;&#160;March 31, 2023 and December 31, 2022; </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65c68aa6-7c1a-4b10-ab21-98a69b7919e9" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,762,001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />&#160;&#160;&#160;and </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cedc339-d384-4c59-90fb-1bdaa78220fd" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,509,125</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares outstanding at March 31, 2023 and<br />&#160;&#160;&#160;December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_684e4715-1b9b-4b11-80b1-93000d4d34e2" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be764312-eced-4e12-a19f-5c2a11857aca" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury stock, at cost, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_674e8374-1c34-49f5-b036-5ed75a45e1e5" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8fb34b4e-4278-414a-ba7e-7e65bd998f21" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,033</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares at March 31, 2023 and December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e38c8649-5d09-4645-ae17-dd48b47da797" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00a18c46-fd1f-4276-a9e7-2434dea2c00f" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_013fee83-8079-4fb6-898c-8ba3831f34cb" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,313,609</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f94da8c2-58fa-4ba2-845c-82dad994c329" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,291,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afd6205d-0f72-456e-a01f-48ba521e88f6" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,174,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79aa99b1-3789-4c1d-8cde-d66e763b9572" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,028,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3876fa93-329c-4f75-8294-c242b3363ee5" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d19ebe28-0e24-46fb-bfa7-255edd8a8c34" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c763134-ef31-4840-9172-3409d5e80330" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,133,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31c2d073-9fe4-40e9-8fbf-0849fc812539" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,252,599</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b16a65ef-0d6d-4def-88f4-3f9340689337" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,220,686</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c072a33e-cdd0-4a8e-a5fd-e71914f456b5" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,356,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolidated Statements of Oper</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ations and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.501%;"></td>
    <td style="width:1.806%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:17.863%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.806%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.024%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product revenue, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa630da6-e5a3-4858-ac26-0985420e47fd" contextRef="C_80624434-96c6-446e-ada9-fe739d3d9e5b" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,294</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f42886ba-91ee-452b-9331-a837a53b73e1" contextRef="C_8d91e179-f711-4e4d-aaa6-c27f609457e6" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating costs and expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of goods sold</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42bedce7-692a-4e50-9b55-b0cbfc21fad1" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:CostOfSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0d59703-8ece-400e-b3dd-039a0415f98e" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="sage:CostOfSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6424e6e9-d292-43f8-9c6b-a9e495b198d5" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34f69b42-4e08-4daa-a437-a50267c3c1d4" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1e9381c-91a7-42ee-af5f-22e55d949c1b" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46144922-dd4e-426d-ab12-8ea64d3c94d8" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating costs and expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffb84a50-c190-4bd4-907d-f23551a3534d" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23cd9bad-4fb6-4d6d-a3a7-4379caf74c01" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf373a36-56d4-4eb6-b44b-cbf376a361d7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">155,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84bba483-7039-427d-b1c6-a28984cc5d0c" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">123,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5591b326-d146-4a51-a27e-18cc0a637755" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fca15b90-3e6d-478a-a916-5f0f0743f8f0" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,168</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0acbd2b-d553-4e90-a364-cb0663873df0" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fd89a63-eddc-42a5-9c0c-34b526c67bdc" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41dc41d9-e31b-42fd-a556-a7919c020ac9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bda99b6b-5498-486e-9e67-1db1c9fba7ce" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,055</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79829790-f07f-446b-a362-5366fc1f2f95" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_1f9ddbf9-7864-4c86-ad67-4dac785afb30" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.46</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23990e9a-b355-4636-a145-bb2907ed6128" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_aeb3ed48-ba16-4a94-8492-b23f77577d93" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.07</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average number of common shares<br />&#160;&#160;&#160;outstanding&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78ec86f8-170a-499b-a2f7-001e63a5435d" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d2f952f7-8871-4e8a-948a-182eadc7aca9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,674,127</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13ddb1b3-d2ef-44b7-8fe1-0ab20f65ba27" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_417f36d1-6d49-4fcd-8923-87a8b46f658a" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,028,858</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d371ae8-7749-41fe-9a0d-4cfcf1f25c4f" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_977b212b-a918-415d-b9f5-901c81db5c68" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,055</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive items:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain (loss) on marketable<br />&#160;&#160;&#160;securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55215690-aa32-4627-8396-ec3af808473d" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdf411ca-a7e9-4f46-96c7-b38c6ebec541" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,541</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other comprehensive gain (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6a2ef44-1fbe-46d7-bf1d-43fcafbc3799" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_756dd892-2500-419a-8e29-fe91c81a97f8" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,541</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dde52d3-7ddd-4a68-93e9-9ad147f823d0" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">141,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_219042c2-bde3-463b-af72-9935458e543c" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">130,596</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.64%;"></td>
    <td style="width:1.585%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.165000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.445%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.165000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f3d5cfb-4803-47f7-827b-dba59057b4ce" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d49b5133-d2ee-4f71-acb0-2fb623911c49" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,055</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash<br />&#160;&#160;&#160;(used in) operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c110ce9-a3cc-4431-bb1c-a71ab2dc73e2" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c79e5bb-ccf1-423e-b2e4-3646002934cf" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Premium on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daa12745-ac11-49f0-87cb-e596ade7cef7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:PremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d36f27d-bd5e-4058-81f1-644b25b9775c" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="sage:PremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of premium (discount) on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_244a86ea-365a-470a-9ce4-cafe80ed8420" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bebccf8b-5d93-41de-8c8e-570a8dbcebc4" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55382147-74e2-4fda-bd18-48cbb1946af8" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbf1e1d0-71a6-444b-8936-66e4c80658b9" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">275</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df7f0e8b-f86b-4190-8495-a9cf6dc8008e" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eeb903a3-87e4-4a4e-bc04-73f8e2895910" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration receivable - related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b74389f-6f7e-4dc0-9e85-398185788acf" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d71e6d4-05d2-460d-beb9-cd5fc405d131" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,291</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be42cd24-6a48-4322-b299-350073e735a5" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">515</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2694a18e-8c4b-4d13-bdf4-ed82bbc0c731" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use operating asset</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c29585e2-d647-4491-9b56-fdc92e3b4ce8" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de4d0682-96b5-48c6-b478-2dd67d9ee266" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="sage:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caf406c7-2053-42e1-a16a-19ebdb73ebdc" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49317ce2-b49d-4af5-8761-cae73b3b79b9" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="sage:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27922e86-bd6b-46b3-8a7b-f785b1ded523" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,728</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45224de2-adf0-4a97-bfbd-44371ce20e7a" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="sage:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40a996a2-cbdf-46d8-b5e9-4d9de4c712d9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0beead26-1772-4149-a6ed-744867591920" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,251</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d8a47db-23f4-494f-95ad-06accc8f4c29" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_702973d0-4acb-4414-ad7f-9792e412a89e" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd6680cd-2bed-429c-864c-d0b5997e79f3" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">153,682</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52505438-9841-4008-bba7-0c96612bffd7" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sales and maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21738257-376b-455f-893f-a4ce709e0076" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351,982</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d6a61d5-004d-432f-8444-756ae19b5a62" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82c9af42-b1e8-450f-a7ae-a13e8983dd51" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156,890</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3423a3e-ec59-4dbb-a2e2-afbf78bf0cc4" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301,928</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c1b8f98-40db-4ccc-9357-6d68de041929" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bfb8fc9-82e6-4efa-a6ec-7cb29dd326bf" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91c584b1-b7f7-44d2-8c31-80a69296ec12" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cf40bac-cebe-41a4-85a0-367d6070275d" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,558</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from stock option exercises and employee stock purchase<br />&#160;&#160;&#160;plan issuances</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd299e73-f7d5-49e1-bc23-6f4fafb1a19e" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a2ebaac-3ddf-45b3-a5f0-5bdfa46d1d61" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of employee tax obligations related to vesting of restricted<br />&#160;&#160;&#160;stock units</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9314d92-34a0-4149-a3f7-d08dad8930f6" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb35ce5f-a87f-4703-9ed4-3a76ffe3106b" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_692d9939-044c-4db5-a337-deb9bdeacfa0" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b941e980-0668-4d15-ae8c-8be6be5ff5ea" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65511ed4-9369-43ad-bd74-5f6543e6395d" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">115,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04414ec2-8442-46f6-bd79-ad142efd196c" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163,969</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0dcdef5-77ee-44a5-8e32-8e1fa9451b93" contextRef="C_cd11ff6a-3076-4878-b379-411eea2932d1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">295,502</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3f02daa-c99c-4fc1-80b0-2d66f0a736eb" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c65a197-7442-4bd1-9617-b7f32ca90cca" contextRef="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc. and Subsidiaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_changes_in_stock"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Condensed Consolidated Statements of Cha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nges in Stockholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.06%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.38%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.18%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.86%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.52%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.32%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.52%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.68%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.48%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e831a684-67a4-4f89-998c-87417b58b4d9" contextRef="C_34f017d3-fc3a-40f4-a32a-6e68c12be396" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">58,937,050</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dfe5ff2-2e3f-4c75-8b06-ffca168a4251" contextRef="C_34f017d3-fc3a-40f4-a32a-6e68c12be396" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_895d283a-d03d-4106-af24-66ae01171add" contextRef="C_9d696c64-4852-4448-9e18-cca9af20998a" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a324e7b3-3482-4f3a-8e48-6bf5d5feed31" contextRef="C_9d696c64-4852-4448-9e18-cca9af20998a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04b99004-80fd-45ed-9083-b123fc2edc18" contextRef="C_25ec2f51-a9c3-49be-9f2a-0f5e21581ba9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,227,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c14ab140-1271-4dad-b1ae-05fbc9844283" contextRef="C_3499aa63-1335-4278-afe4-3af8c03e1236" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,660</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e65df97a-1396-4147-a503-ad85886f0ad7" contextRef="C_96c58346-5075-4864-bc24-0ddf5e57105c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,495,386</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae46ccd3-41fc-41bf-b093-24adc5787269" contextRef="C_cd11ff6a-3076-4878-b379-411eea2932d1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,729,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock from exercises of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be5d0270-dd44-4b6c-87b5-bdcc2e926b4e" contextRef="C_cc0e2088-ed2f-4615-ae09-35dc9db057e2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">105,474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c8bee7c-76e7-4816-b9b8-89eed4890aad" contextRef="C_b2824d78-7fd0-4324-bd17-8138321ed536" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">646</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbf87b5b-7697-4274-91e5-94055ef83787" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">646</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under the employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fde71233-2573-4147-80f2-46f6edc4422a" contextRef="C_cc0e2088-ed2f-4615-ae09-35dc9db057e2" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,625</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16c4cb5f-ee6b-4fa2-9a4d-00de160f4d21" contextRef="C_b2824d78-7fd0-4324-bd17-8138321ed536" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abe3d7bf-989d-48e1-b0c6-3b695d22235d" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caa50524-97ce-484a-b458-bfa620f1ea32" contextRef="C_b2824d78-7fd0-4324-bd17-8138321ed536" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52310b8c-8b72-4362-9f01-6a1a5f1f8b97" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f95849a-6440-482c-848a-5f9e3474d91e" contextRef="C_cec5550d-a16c-4e00-9894-1a8d869e5bae" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,541</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e295facf-03a2-4989-87d7-70b84eeaf3c0" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,541</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aa3fc90-2d57-487c-86a5-6b26f237316f" contextRef="C_e45cbb2e-3c5f-498a-a209-b241cd20689d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,055</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39dcf672-3750-4722-abd3-8cff61674a7f" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,055</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at March 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94605b6e-242e-4d2d-b199-54b8ac50cda1" contextRef="C_758d45bc-86ac-4f04-b85e-741bffc1d6f8" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,066,149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80544610-6184-41d4-ac23-4757911815a5" contextRef="C_758d45bc-86ac-4f04-b85e-741bffc1d6f8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3396722a-634b-498c-a866-d85807fa6886" contextRef="C_110148da-fe96-4b69-87ce-8a98365c120f" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ea097e1-cefb-4892-94f3-edda1df7f8d4" contextRef="C_110148da-fe96-4b69-87ce-8a98365c120f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60334ce8-2fde-4715-b15b-a90cb85d9b54" contextRef="C_e663c40a-15ae-4907-b98c-552196067f88" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,247,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64d89467-c8df-4a2e-b5ba-bad4057dec68" contextRef="C_8fafe567-6ae5-44ee-8496-6f5bb08d136a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_659c7acb-0929-4266-a5c0-dbb7327f652c" contextRef="C_32d6c0d5-c8be-40ce-8635-6583447c427f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,617,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51226b68-892f-4b7f-aada-98cec88a50f8" contextRef="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,618,502</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f785fad0-4b04-4895-bd69-64c7f84a4302" contextRef="C_deab43ad-3c90-4a47-ae84-57cc9e11dfaa" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,509,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d350fa1-4552-439b-be7d-a164bc781591" contextRef="C_deab43ad-3c90-4a47-ae84-57cc9e11dfaa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04008266-d236-4e4e-9e99-e4eba7b04292" contextRef="C_872fc801-16d0-407b-a188-71e78a10b66e" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31f26fa8-2360-4003-bc0a-cd9628e6e4c7" contextRef="C_872fc801-16d0-407b-a188-71e78a10b66e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b181a9d-d62c-4dd7-9d1a-5d390fdfd22b" contextRef="C_9b6f49c8-d774-48fb-b187-986662265c23" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,291,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_733650aa-0cc6-4214-ac0a-b8148b885154" contextRef="C_dbfc6e76-8aca-485a-914b-f8d69d2c7389" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60ca7794-6f11-4630-921e-03467182aa3a" contextRef="C_94d7d66d-d764-476a-bdb7-7e62dfec2d61" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,028,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b8c6f16-b039-45a9-9225-6a64fa83d998" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,252,599</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock from exercises of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f01e539b-a0be-4fd7-ba89-2392d954d5c0" contextRef="C_473be90c-b2bd-4a46-8157-218452e72424" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">52,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdf0a91f-6cf8-424d-8c1e-68f8e06153e8" contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_976e1cc8-8250-4295-9b8f-855f9e5511f7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under the employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bcac7c9-472c-45e4-8a78-e0133123724d" contextRef="C_473be90c-b2bd-4a46-8157-218452e72424" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">76,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e47009e0-ae6d-4c02-98a9-62f949046f6d" contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,863</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a61a975-7fce-4874-895d-683260c80253" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,863</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b02edac-104e-46d6-ad0b-46d3061bc2c5" contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e0ee895-d699-48b5-84f8-6cdee9c6cc7e" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9af0c02e-f496-44c9-8132-19dff9514ae6" contextRef="C_0a046e3a-d734-4572-ba58-9c70fe1e9fda" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07c58864-e5db-408c-bb2d-f28c88f16e3d" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted stock units, net of employee tax obligations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20e5baee-9a80-435f-8c83-f4e8d8689b7b" contextRef="C_473be90c-b2bd-4a46-8157-218452e72424" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">124,713</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85d2842c-7e07-4dd9-a834-49b650a2ea06" contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5736363d-e0a2-4b68-81fd-760fec33f5e5" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec2ffedb-3b24-4d9b-8147-10c3b174aa07" contextRef="C_90273a42-5bc2-4c8a-b365-81b8b3294dbe" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa356daf-ef1e-40ae-ba8a-ade88f878f64" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at March 31, 2023</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87b6f5bf-42ee-4658-9f8d-9756c2d3dfb2" contextRef="C_f1249121-8d96-4038-9762-31833df70a85" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,762,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3311b078-a29d-4cf3-8c14-9e74ecab3f91" contextRef="C_f1249121-8d96-4038-9762-31833df70a85" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3a220ae-39f2-4240-9168-7bee108f614f" contextRef="C_24252855-7fbc-49c5-993c-ccdb3e3e73e2" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8986040c-f505-4ac3-a17e-831ab159ea25" contextRef="C_24252855-7fbc-49c5-993c-ccdb3e3e73e2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_928cca8f-70a5-4e6f-8a23-d8432293a9d8" contextRef="C_41166faf-b133-46b7-89f9-98cc0e4a309b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,313,609</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6577923-170e-416f-b471-dcc6a88f382a" contextRef="C_ff91b6cd-d80c-40f0-b294-2711aab14ffb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa8cd971-885c-4a96-8bb1-73fe53a286d0" contextRef="C_7d098601-3538-45a4-aa05-ee4216c06e54" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,174,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d01bb5c5-edde-4985-9a7f-63c42d4ce633" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,133,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE THERAPEUTICS, INC. AND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Condensed Consolidated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Unaudited)</span></p>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_75978d56-69ab-4ddd-85d1-ad26919562c7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of the Business</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc. (&#x201c;Sage&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company with a mission to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s first product, ZULRESSO&#174; (brexanolone) CIV injection, is approved in the U.S. as a treatment for postpartum depression (&#x201c;PPD&#x201d;) in adults. The Company launched ZULRESSO commercially in the U.S. in June 2019. The Company's submission of a new drug application (an &#34;NDA&#34;) for its lead investigational product candidate, zuranolone, for the treatment of major depressive disorder (&#x201c;MDD&#x201d;) and PPD was accepted for filing and granted priority review by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in February 2023, with a Prescription Drug User Fee Act, as amended (&#x201c;PDUFA&#x201d;) target action date of August 5, 2023. The Company has a portfolio of other product candidates with a current focus on modulating two critical central nervous system (&#x201c;CNS&#x201d;) receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. The Company is currently targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was incorporated under the laws of the State of Delaware on April 16, 2010, and commenced operations on January 19, 2011 as Sterogen Biopharma, Inc. On September 13, 2011, the Company changed its name to Sage Therapeutics, Inc.</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df460751-9ea7-4c80-a896-4e8934a6db18" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:BusinessRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with the marketing and sale of pharmaceutical products; the potential for development by third parties of new technological innovations that may compete with the Company&#x2019;s products and product candidates; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; the uncertainty of being able to secure additional capital when needed to fund operations; and the direct or indirect impacts of the macroeconomic environment and geopolitical events on its development activities, operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The product candidates developed by the Company require approvals from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the current and future product candidates of the Company will receive, or that the Company&#x2019;s current product, ZULRESSO, will maintain, the necessary approvals. If the Company fails to successfully complete clinical development and generate results sufficient to file for regulatory approval or is denied approval or approval is delayed for any of its product candidates, including zuranolone, such occurrences may have a material adverse impact on the Company&#x2019;s business and its financial condition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also subject to additional risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events, including disruption to the U.S. healthcare system that began as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been and continue to be healthcare staffing shortages and other changes to the macroeconomic environment as downstream effects of the COVID-19 pandemic have continued. These factors have had a significant and sustained negative impact on the Company&#x2019;s revenue from sales of ZULRESSO. While the Company has seen slower patient recruitment in certain clinical trials due to the COVID-19 pandemic and its downstream effects, and has</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experienced some challenges in qualifying and activating clinical trial sites, including due to capacity and resource constraints and employee attrition at our vendors and at sites, the Company has not experienced other significant impacts to the Company&#x2019;s development activities as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, U.S. and global financial markets have experienced volatility and disruption due to other macroeconomic and geopolitical events such as rising inflation, the risk of a recession and the ongoing conflict between Russia and Ukraine. In addition, if equity and credit markets deteriorate, including as a result of recent and potential future bank failures, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to our existing stockholders. The Company cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6ee38989-5882-46fd-980a-56c0a8d17ccb" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:GoingConcernPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements&#x2014;Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Subtopic 205-40), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The Company has incurred losses and negative cash flows from operations in each year since its inception, except for net income of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9012ca6d-bc36-4ea9-8ec4-066c07abbf64" contextRef="C_23999eda-d8e5-4c17-ae2e-ed2f30bd77ac" name="us-gaap:DeferredRevenueAdditions" unitRef="U_USD" scale="6" decimals="-5">606.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2020, reflecting revenue recognized under a collaboration and license agreement with Biogen MA Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (collectively with BIMA, &#x201c;Biogen&#x201d;) (the &#x201c;Biogen Collaboration Agreement&#x201d;). As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6a98866-8044-4a14-82d7-ae59c84e99b8" contextRef="C_75423cb0-1c5c-451b-8f34-441ea3df08c3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="9" decimals="-8" sign="-" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. From its inception through March 31, 2023, the Company has received aggregate net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46ff96fb-ac08-4924-9105-89c8f0fb8ea5" contextRef="C_2ae85a8f-70ca-4220-93dc-e4da3306dc78" name="sage:ProceedsFromIssuanceOrSaleOfEquityAndNotes" unitRef="U_USD" scale="9" decimals="-8">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion from the sales of redeemable convertible preferred stock prior to its initial public offering (&#x201c;IPO&#x201d;), the issuance of convertible notes, and the sales of common stock in its IPO in July 2014, in follow-on public offerings, and to BIMA under a stock purchase agreement executed in connection with the Biogen Collaboration Agreement. The Company has also received $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10290745-3ac3-4e80-8e90-27a4b8c2948f" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="9" decimals="-8">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in upfront payments under its collaborations with Biogen and Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). Until such time, if ever, as the Company can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding. If the Company is unable to raise additional funds through equity or debt financings or other sources of funding when needed, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects that, based on its current operating plans, the Company&#x2019;s existing cash, cash equivalents and marketable securities will be sufficient to fund its currently planned operations for </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements (&#x201c;condensed consolidated financial statements&#x201d;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At some point after that time, the Company anticipates it will require additional financing to fund its future operations. Even if the Company believes it has sufficient funds for its current or future operating plans, the Company may seek to raise additional capital if market conditions are favorable or in light of other strategic considerations.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_01be12b7-4988-4eb4-b9e2-b87271cdb94f" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_912a5728-d7fa-4ec0-a5aa-9a097750aee8" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">audited consolidated financial statements as of and for the year ended December 31, 2022, included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company&#x2019;s management, the accompanying condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, its results of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, its cash flows for the three months ended March 31, 2023 and 2022, and its statements of changes in stockholders&#x2019; equity for the three months ended March 31, 2023 and 2022. The consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but does not include all disclosures required by GAAP. The results for the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.</span></p></ix:nonNumeric></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b546dd33-bcee-4648-b70b-ab2850a89099" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as disclosed in Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, within the &#x201c;Notes to Consolidated Financial Statements&#x201d; accompanying its Annual Report on Form 10-K for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Intercompany accounts and transactions have been eliminated.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_03750040-9d83-49a1-a5f8-3d74b294a078" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full extent to which the COVID-19 pandemic and its downstream effects may directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition will depend in large part on future developments, which cannot be predicted with confidence at this time. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Company has made estimates of the impact of the COVID-19 pandemic within its condensed consolidated financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the evolving nature of the COVID-19 pandemic, its downstream effects, and their impacts,</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> there may be changes to those estimates in future periods, and a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ctual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9b7825f0-59e4-4159-a021-072c837b97c7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, overhead costs, depreciation, contract services and other related costs. Research and development costs are expensed to operations as the related obligation is incurred.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside of the U.S. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_914fd5eb-06d4-44f4-960f-b6ebcb79e30e" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue from the sale of ZULRESSO, which was approved by the FDA in March 2019 and the Company subsequently began selling in June 2019, and from collaboration and supply agreements with the Company&#x2019;s collaborators. To date, revenue from collaboration agreements has come from initial, upfront payments allocated to licenses of intellectual property delivered to the Company&#x2019;s collaborators and from the supply of material for clinical trials under a supply agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when or as performance obligations are satisfied by transferring control of promised goods or services to a customer, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For contracts determined to be within the scope of Topic 606, the Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Revenue</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promised good or service is distinct in the evaluation of a collaboration or license arrangement subject to Topic 606, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the standalone selling price is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its arrangements with Shionogi and Biogen and concluded that a significant financing component does not exist for either arrangement. For arrangements with licenses of intellectual property that include sales-based royalties or milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty or milestone payment has been allocated has been satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Revenue from the Company&#x2019;s collaboration agreement with Shionogi has come from initial, upfront consideration upon execution of the agreement and for the supply of drug product for Shionogi&#x2019;s clinical trials. Revenue from the Company&#x2019;s collaboration agreement with Biogen has come from initial, upfront consideration related to the execution of the Biogen Collaboration Agreement. For additional information, refer to Note 6, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Revenue, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes product revenue, net of variable consideration related to certain allowances and accruals that are determined using the expected value method, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for ZULRESSO is to deliver the product to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within selling, general and administrative expenses on its condensed consolidated statements of operations and comprehensive loss. The Company expenses incremental costs of obtaining a contract as incurred if the expected amortization period of the asset would be </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_58a63175-343d-4fb3-bb83-f45c55500446" contextRef="C_80624434-96c6-446e-ada9-fe739d3d9e5b" name="us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">less than one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the Company were to incur incremental costs with an amortization period greater than a year, such costs would be capitalized as contract assets, as they are expected to be recovered, and would be expensed by amortizing on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company did not have any contract assets (unbilled receivables) at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, as customer invoicing generally occurs before or at the time of revenue recognition. The Company did not have any contract liabilities at March 31, 2023, as the Company did not receive any payments in advance of satisfying its performance obligations to its customers. Amounts billed or invoiced that are considered trade accounts receivable are included in prepaid expenses and other current assets on the condensed consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and December 31, 2022, the Company had not provided any allowance for bad debts against the trade accounts receivable, and the amount of trade accounts receivable was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records reserves, based on contractual terms, for the following components of variable consideration related to product sold during the reporting period, as well as its estimate of product that remains in the distribution channel inventory of its customers at the end of the reporting period. On a quarterly basis, the Company updates its estimates, if necessary, and records any material adjustments in the period they are identified.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chargebacks</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company estimates chargebacks from its customers who directly purchase the product from the Company for discounts resulting from contractual commitments to sell products to eligible healthcare settings at prices lower than the list prices charged to its customers. Customers charge the Company for the difference between what they pay to the Company for the product and the selling price to the eligible healthcare settings. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at the end of each reporting period that the Company expects will be sold to eligible healthcare settings, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Rebates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company is subject to discount obligations under government programs, including Medicaid. The Company records reserves for rebates in the same period the related product revenue is recognized, resulting in a reduction of ZULRESSO product revenue and a current liability that is included in accrued expenses on its condensed consolidated balance sheets. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trade Discounts and Allowances</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company generally provides customary invoice discounts on ZULRESSO sales to its customers for prompt payment and the Company pays fees for sales order management, data, and distribution services. The Company estimates its customers will earn these discounts and fees and deducts these discounts and fees in full from gross ZULRESSO revenue and accounts receivable at the time the Company recognizes the related revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company provides voluntary financial assistance programs to patients with commercial insurance that have coverage and reside in states that allow financial assistance. The Company estimates the financial assistance amounts for ZULRESSO and records any such amounts within accrued expenses on its condensed consolidated balance sheets. The calculation of the accrual for financial assistance is based on an estimate of claims and the cost per claim that the Company expects to receive using demographics for patients who have registered and been approved for assistance. Any adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the condensed consolidated balance sheets.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Consistent with industry practice, the Company offers product return rights to customers for damaged, defective or expiring product, provided it is within a specified period around the product expiration date as set forth in the Company&#x2019;s return goods policy. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reserve within accrued expenses on the condensed consolidated balance sheets. Product returns have not been significant to date and are not expected to be significant in the future.</span></p></ix:nonNumeric></div><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e60d3dfe-9396-488c-8c34-019d083a4fb0" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:CollaborativeArrangementAccountingPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above, and presents the arrangement as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as research and development expense or selling, general and administrative expense, in the event of a payment to the collaborative partner in a period, or a reduction to these expense line items in the event of a reimbursement from the collaboration partner in a period, as appropriate.</span></p></ix:nonNumeric></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_32ec00ae-8c7c-48c5-a994-01eeea6a1930" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:7.0%;"></td>
        <td style="width:2.0%;"></td>
        <td style="width:91.0%;"></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted market prices in active markets for identical assets or liabilities.</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s cash equivalents and marketable securities at March 31, 2023 and December 31, 2022 were carried at fair value, determined according to the fair value hierarchy; see Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts reflected in the condensed consolidated balance sheets for the collaboration receivable &#x2013; related party, accounts payable and accrued expenses approximate their fair values due to their short-term maturities at March 31, 2023 and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bac2d237-e6ec-4345-94de-a30d4c239edd" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements upon adoption.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b94add1b-84f7-4d11-84fc-5376911e67a7" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s cash equivalents are classified within Level 1 and Level 2 of the fair value hierarchy. The Company&#x2019;s investments in marketable securities are classified within Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of the Company&#x2019;s marketable securities are based on prices obtained from independent pricing sources. Consistent with the fair value hierarchy described in Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, marketable securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates. The Company performs validation procedures to ensure the reasonableness of this data. The Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of March 31, 2023 and December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_65e861b7-f231-4b71-ac67-e60b947d8580" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.108%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_586eb026-1f58-44fa-ac82-bde3a9a89315" contextRef="C_fe4b519c-5caf-4568-8a3a-2efeec719a51" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d88fd8-ff54-498b-aab1-79b5ac4dd598" contextRef="C_59765745-97e9-4396-b431-ab2d3335cfad" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0232fd3-6bd9-4932-a310-6a8a5f23de98" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,965</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ead5c66-cd07-4c7a-b03e-0b674df41120" contextRef="C_415d3116-954c-4e68-b279-376d06d7f3f7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,965</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_680d4b82-8247-4a10-8fe0-a3a80ed32419" contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca92690d-3221-4c9d-b4df-2f8fe82517be" contextRef="C_27a73613-5f17-4ab4-b5a6-643c79010992" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_735b6cb7-d837-46e2-82a9-6bb93da7e0a4" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189,088</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8d67e4a-9513-4698-96bc-ccf32429042e" contextRef="C_1dfde7f5-0e05-4477-b311-a6bafe7de036" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb8c3f21-68d2-482e-a9c3-3328cb25a0b9" contextRef="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,949</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e185e9cf-234a-48c2-834a-d67972dd9975" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98c4537d-b961-4d0c-9be8-4c5aba6cee2c" contextRef="C_88622809-97e6-415e-84af-28e0cecdedb9" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa191f9a-08d1-45c7-b0ab-e40051915fe5" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">267,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5011eb58-fb85-46ea-b806-4df0538f7260" contextRef="C_415d3116-954c-4e68-b279-376d06d7f3f7" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">267,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b3dffe6-6f67-450f-8a6a-e0bbde8152cb" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae474802-9b6a-4777-b6e5-e83fec002344" contextRef="C_3733b62f-9978-46fa-ae1f-0ca914403f18" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7258c1e5-f052-43c3-b3db-1524ae2533eb" contextRef="C_850361db-7291-43d8-8579-6031f3718f59" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_045b2f7b-6ba0-4e20-9f45-311580eba982" contextRef="C_2eed04fd-66bf-403b-b097-ca6cfcbcd5d0" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_813fd7a9-6824-475e-8738-b6a7ba8ee7c6" contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5cd5020-7dc5-494e-8e88-356e28049664" contextRef="C_27a73613-5f17-4ab4-b5a6-643c79010992" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_021450c3-a6c1-4993-9880-3c3da9a86b1a" contextRef="C_cd88a57a-5b9d-49be-a744-23e0bf41890a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2448303f-fbee-4ddb-94b2-e5c86b10e216" contextRef="C_b95b663e-2b75-4278-99c2-2c62b7b11486" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf7b6bb7-85cb-4535-9609-7f5dc53c18f1" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,551</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49d0368f-1548-465a-b714-e8cc5ff9e015" contextRef="C_6e880326-ed6e-48e7-a99c-374dfaae0004" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,551</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b49f5547-0786-4371-b5f0-1649f433c2a7" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdae5f1c-966c-4e38-9cc4-0243db81a1b1" contextRef="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_960bcc94-93fa-4824-a07b-fe559c624cc5" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,112,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c04416a3-db70-4dd5-95c1-fc0c84c83898" contextRef="C_1dfde7f5-0e05-4477-b311-a6bafe7de036" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30de32cb-1b1e-445f-8465-e7fb4db41633" contextRef="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">947,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.108%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.128%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.096%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_279e9e8b-dd8b-40df-aea1-13be36db09a0" contextRef="C_b2b10c3e-e417-48ea-a3c8-37953b52b9c3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71a7bade-37e9-4a34-b3c8-0ad16cf9b165" contextRef="C_1978be30-cc7c-4cc4-a992-11e42d4bd0b9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0143ebd4-c256-492b-a403-b82dd1621d22" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ed4612d-b080-4bc6-b6b1-e1b3eeec12be" contextRef="C_c9b8b2ef-3e7c-4781-829b-f175d048affc" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f169f8e-5558-47da-b91f-d822b695e00f" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1f62023-fce1-42f8-a27e-c7b8d8939972" contextRef="C_73403fc5-d8c9-42ee-a01a-11d2ee5fe21a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2635002b-b630-46e8-b4a3-1b73eab5490d" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0269ad44-ad56-4bf0-8429-ffe7cb945a5a" contextRef="C_d4fdb95a-3eb7-454b-aa35-9c3868eab086" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fe2aeb8-5b4a-4058-82b3-592116698df0" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69f67274-d851-4866-9310-bd95de4dbb5b" contextRef="C_fae74238-7ce3-4af5-9f76-7ddc34eb01f4" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a23837dd-01ab-4e8d-a315-bd9cd5f15def" contextRef="C_62a04c01-c554-489b-94ff-f68796238daf" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eec797c1-d7e7-4740-990a-53ce36283624" contextRef="C_8d3496d1-3be0-413b-9f3a-0b624246add1" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe61c817-c854-45f1-b334-7ebf47183168" contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c78294d1-1dd8-498d-ab99-b823a924917b" contextRef="C_c7472141-c913-4194-b3cf-9b99dbf32ab2" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e955b1bb-56d7-42e5-9340-09b3934622c4" contextRef="C_b2914001-6eb8-4b83-a2c2-bd94ddbe5fe5" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,613</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3834c9d-dc35-40f1-b43e-b084ab182e01" contextRef="C_ff1b2d86-e176-4930-a80e-46e442e30f10" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,613</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51341176-7b94-481d-958f-12e14896a653" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f0834fd-cfdd-497e-b0e6-d64204d1962f" contextRef="C_22abec7d-1872-4be4-b3da-b134f50ffb38" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67ff7ca5-690b-4e8d-8efb-b0acf79e6e3b" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_550fce5d-472b-4d63-83d2-8500a34b5a76" contextRef="C_c8fdbb15-6c4b-4e31-80ed-4104897dd692" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aee4740d-b071-485c-a97d-8442ae2256a4" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,270,979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_193aa368-431c-42b8-8e7f-3d658196c6ab" contextRef="C_c9b8b2ef-3e7c-4781-829b-f175d048affc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fec24da-b6dd-4637-801f-38d9eba3db36" contextRef="C_c8fdbb15-6c4b-4e31-80ed-4104897dd692" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e87aec2-150a-4ff3-80dc-278fcf0e97f3" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5da26f48-7329-4839-b634-aa77aa3c044f" contextRef="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e" name="sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers among the Level 1, Level 2 and Level 3 categories.</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db5719e8-49f2-4359-ae9e-405c17a51295" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the gross unrealized gains and losses of the Company&#x2019;s marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.75%;"></td>
        <td style="width:1.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.733%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.141%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.018%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.818%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.153%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.774%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab1c0f7d-c821-41a9-8ed3-2b86161283d1" contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f054ea82-8dfe-4ccd-81d0-5faeaeb39190" contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c058ef66-c37a-411f-ad46-50dfdf87f8e2" contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6468b33-3e9e-4e65-a9df-502bee74c17b" contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47f8b441-2235-4f86-99fa-b877e3d6bdd7" contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269,052</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36589725-3b33-4cca-b39e-f198ded54ec0" contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4e1d02e-f9e7-4bb5-8255-d7947d7bbb17" contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,808</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ce14fea-a9cd-476d-b08b-804a75fbd56d" contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">267,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a5b8db3-99f1-4887-8207-50921e939909" contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,313</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14198963-471e-49b0-b3f9-5121707dfd66" contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72fa2572-2a96-4c66-ac46-4edcd11c262f" contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2187b49b-6409-40b2-a18a-863e446723ec" contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c50f96e-4d28-4fcd-bd93-20308e766e76" contextRef="C_985df593-5059-41c1-979c-cfad810abdef" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_154e85ad-b16f-4c5c-ad05-72c8e86f4068" contextRef="C_985df593-5059-41c1-979c-cfad810abdef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b9534bd-4928-4d87-a9d3-709f003522e2" contextRef="C_985df593-5059-41c1-979c-cfad810abdef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09280513-d699-4285-a471-a10dc7bbaf97" contextRef="C_985df593-5059-41c1-979c-cfad810abdef" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36d8d4f7-2ade-4793-99b8-f8f2869f63c4" contextRef="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51a7533f-fa0f-495b-aced-cf5bcd0d5d83" contextRef="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3aa36695-40fb-4d6f-a900-a802cca71585" contextRef="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac9fbc0c-5ed6-47ee-ba5e-e18eac748b45" contextRef="C_95a6685d-c914-4c9f-b57b-5ca39c0070ef" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ca9eda8-911f-4705-922e-d1fd6999cf6d" contextRef="C_95a6685d-c914-4c9f-b57b-5ca39c0070ef" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53102e3f-49fc-4215-a955-4acf29974b50" contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53f6ae60-117e-471b-beb2-74a88b438fa1" contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcd1b6f6-f313-4703-a29d-5792a6425eb1" contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">778</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19d8e82d-0b65-45ef-a2fb-3359c32d6e49" contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,551</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_175f8023-634f-460f-9b4a-50d9442b38ad" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">928,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46e99310-285a-4846-af8a-442c436bfbaf" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15e0ffe4-b1e8-4393-9877-18a2508d7b37" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aaa02f3-7e75-4a55-9e21-4c4a9950c025" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.648%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.22%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ebdb27e-8283-413b-a1ae-184134a9b8fa" contextRef="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">307,173</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34b07709-6fca-4eff-be90-bedb472ff992" contextRef="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,262</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c85211c8-9786-4ce3-ace5-849f2b2ed72d" contextRef="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbe31e63-1e96-46b6-94f7-0abe8443a810" contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">358,019</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3643e03a-c82a-4640-b9e7-516fe9564ddd" contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32aa49cd-650d-4045-ad76-daac434f0d05" contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b774b4d-4b46-4fa1-a433-0c5cf8f7bb4b" contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55e33d18-3129-4d07-a8ec-e0f5ec2fbf59" contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,374</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac04af6c-1ab0-44fc-b7ab-c076c9d6844c" contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c4f4692-042e-4d69-b992-aceff932f2fd" contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4a5198c-b9c4-480c-8581-95fe0cfa6659" contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_122ec467-0441-420a-a9a1-a0cb0f0d47e8" contextRef="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,234</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66fab008-1398-4d89-a8fd-1dc56fc3b386" contextRef="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_794592bf-3e37-4a1c-8a59-6053df73c417" contextRef="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c62a7a96-1302-4199-b0a4-75017251e9bd" contextRef="C_e0418523-3fbf-4353-b5fc-b74fa6275d25" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83904f6a-1e49-4de4-b910-35bdda2ed108" contextRef="C_e0418523-3fbf-4353-b5fc-b74fa6275d25" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_120b09e3-ba8d-4c79-a63a-8f21bbcedf2f" contextRef="C_e0418523-3fbf-4353-b5fc-b74fa6275d25" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b233b15d-49cb-46b5-b0a8-363057a5cdd2" contextRef="C_5b7a5ab4-63f6-4561-8f6d-b3de184d3551" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,613</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04a56f16-e64f-49ab-8725-059658cf5ce7" contextRef="C_5b7a5ab4-63f6-4561-8f6d-b3de184d3551" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,613</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5504c3b-6aa7-4053-b3e4-36acaec08d8c" contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,249</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e1cadda-f5a7-4456-b500-d22f836c7bc8" contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcdac7d5-65c2-44a6-af63-9c01f4de0a8f" contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73c3b8ab-9654-4a22-bebc-0b16417dc6db" contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea9bfd9c-88b3-4a6d-805d-4f8fe27eba7f" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,120,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12c80133-c0c3-4615-bcf7-b1972a490c4b" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a3eb231-c3ba-42c2-a5bf-a080272163ec" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4434ce5-a269-4696-af98-083e9fbe82d5" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_80b0c7ce-880e-4b1c-953f-fa9162fc6209" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value and the unrealized losses of the Company&#x2019;s marketable securities that have been in a loss position for either less than twelve months or greater than twelve months as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.018%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.971%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Greater than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c0d8aaf-74ad-4b2f-8143-c9a58bd1542e" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_580c4d21-0735-4c71-a9ec-4523a8f7169f" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">548</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_692b1d10-e2b1-4407-b8cf-f7817b9d35f3" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,845</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_289596d2-cbfe-4702-b2a9-a32966c3a553" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,601</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a3aff6d-44cf-439c-b3cb-b45095687405" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dac0ebe6-55c4-42b2-9abc-a57c7f02c0bb" contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19fddbbd-a6b6-4995-bee0-d87c06379407" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">144,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c479a9e-4d49-4de2-8d04-61527d48431f" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b06763a3-a718-4343-a2ca-4595c933309d" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3d02fdc-0de3-4b0d-8df3-b6f9e9a7f302" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">830</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61d5e0b2-21a0-40a8-91f7-88690c104e7b" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e299cb7-9895-4a73-924c-b04867aa3a0a" contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,808</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65266708-7b30-46ea-8430-8b86ace77bb3" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da3c294d-7dd1-4118-848c-1529a2fcc0df" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de0c96f4-d877-4f0a-a400-eb93ad1e0204" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,015</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dd2e660-f362-4744-8174-f2c54cabe2cc" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_527ce713-043d-4d03-9bbc-a7dbf783a442" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,447</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eef28081-f165-4398-ba11-8ebb3cd6417d" contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_432ee8b4-965c-4c3f-bf65-67bbf20205ab" contextRef="C_850361db-7291-43d8-8579-6031f3718f59" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,712</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1afbbf2-5bcb-4d48-a5b0-2d749f372017" contextRef="C_850361db-7291-43d8-8579-6031f3718f59" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5046a3ec-8e1f-4620-ae77-1e59166624df" contextRef="C_850361db-7291-43d8-8579-6031f3718f59" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,712</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7deffe1d-c5b0-48ec-8426-6db71df664dd" contextRef="C_850361db-7291-43d8-8579-6031f3718f59" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c0f51ac-9eed-4297-860b-e368e212eef2" contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41bde811-fa53-48f0-897a-dfc977814a53" contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c86bb63-4a01-4665-88a4-5253b701f0af" contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9852182-9665-41ea-af26-6f81109880db" contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9538cd44-b3d8-46ae-8952-7f0b01aff05c" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,307</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20984a72-ac98-475c-b279-8d2dec9db752" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a660259-ccd0-464d-bf52-7b24c370e8fb" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79a8bc14-a3f9-4f92-b7a4-447e0f96f3f0" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_789c7343-124e-4900-a6f6-b8198f2443fb" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,321</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6ed8545-6333-4eed-9e17-ab9e2a66d0ef" contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">778</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baf05272-9fe6-46a1-880d-e131fd33583f" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">430,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68a0a9e0-4df6-4b8d-9d77-6f2f5062b4d0" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,322</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a83bd9a1-171d-46d2-b528-ca922a32f6c5" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253,971</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2ee059d-de17-4e4d-be1f-e557d5f0c44e" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b9d4929-aabd-467e-89f2-221f6beb2055" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">684,391</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5eb978b-de93-4f7c-acdb-07708b8054fa" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.018%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.971%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Greater than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd1c08cb-75ff-4ca3-b1a8-ddcfa461cfd2" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,243</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6b98129-c21d-4f53-ae1e-66a2b803970f" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,517</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be16eabc-d13a-4a6f-980e-f4d9737d702a" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3737c0e-5851-4d1d-9e28-53f6346011d8" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,745</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83e1edbd-5754-4720-a2b7-f3e628780f01" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">297,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ad464a6-274e-43f8-a4e3-86f6d988ac60" contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,262</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1480137c-e104-41a9-8712-6c94b8033b6c" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">208,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_074ccf6c-6bda-401c-af95-2da92fb98a02" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,989</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c891f590-63fe-480e-b0b6-d8716e0c0057" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d72edc67-51da-425d-8919-3cda9bb52f63" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b84b4d50-a9d8-4a8c-b655-31a4d2927746" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25d366bf-1715-4815-a494-e1c15d2f6153" contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06183ec1-e4f8-49f5-a5e2-8c43283632b0" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,982</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55f4f954-9f2c-4239-902c-d5710f4769f0" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">497</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48f73e4c-99ba-4325-b30a-247015ffff32" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b50350d0-2a7e-47d6-be9a-7f714f18a4b7" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b599587-8f15-40ab-9a99-4e7777a2982c" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1bf37cc-5f55-4881-933a-8ca6a7a466e2" contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53ec2bec-b8eb-4a9e-943b-7e12d1f757c2" contextRef="C_62a04c01-c554-489b-94ff-f68796238daf" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3db38295-95e8-4333-866d-9cc1c13eed1b" contextRef="C_62a04c01-c554-489b-94ff-f68796238daf" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2cccc47-58c7-46c4-b3b7-0d9b00fc2d4f" contextRef="C_62a04c01-c554-489b-94ff-f68796238daf" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95616d1c-fda1-491f-a4c8-f815acfb5388" contextRef="C_62a04c01-c554-489b-94ff-f68796238daf" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42c826b4-45ac-4c7d-9c79-4a2a8dcdea0a" contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d643b1b-a345-45d3-a2a6-f275f8e5c57e" contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed7248a4-8045-44af-97eb-f10209350523" contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd8d54de-2561-4363-80ce-f824eace0f93" contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_686dab8c-50e3-4ecf-a10d-ed0c0949de42" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6132f2f7-2c34-4d82-a134-adb25b13bba2" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">497</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f4bbe7f-da45-4416-bf5d-490f5e8710e1" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8526477a-ed82-445e-bd3e-a1750d2f9551" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">533</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c7f17ab-7a75-4084-97da-d78d6fdc8e02" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,717</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6d4bf8e-fa08-4747-88aa-17a3340370e4" contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93318e19-f491-4353-a8ab-3c83927f3659" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">513,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05d2f70e-afeb-44ce-b5cd-bd320a567a41" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fb77cdf-bd53-4047-acad-741dddaac987" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">399,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dff6bad-a730-44ac-af11-4b54f0bfd5d8" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,455</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faf2e7b8-e3ae-4a81-a543-b52c82412bc9" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">913,521</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6e2d7f9-77de-4016-bce6-33b02d0dbe8d" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and December 31, 2022, the unrealized losses on the Company&#x2019;s investments in U.S. government securities, U.S. corporate bonds, and international corporate bonds were caused by interest rate increases. The Company purchased those investments at a premium relative to their face amount. The current credit ratings are all within the guidelines of the investment policy of the Company and the Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment. The Company does not intend to sell the investments and it is not probable that the Company will be required to sell the investments before recovery of their amortized cost basis.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all marketable securities held by the Company had remaining contractual maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3dfde8cd-a7bf-4543-8f2c-16f711c8ee9e" contextRef="C_2b34f602-7812-4da1-a117-ccb5aabeb0c5" name="sage:MarketableSecuritiesRemainingContractualMaturities" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less, except for U.S. government securities, U.S. corporate bonds, international corporate bonds and municipal securities with a fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a1a6771-aad4-4fce-8c97-b8eec44a5620" contextRef="C_ebde5ad9-f57b-4a0d-a856-31c668cee290" name="sage:MarketableSecuritiesHeldToMaturityFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">186.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_15ef7878-1081-4815-8372-c33bbdbbcbd7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f9fdad20-5734-4289-8542-74525f0a170f" contextRef="C_08b2b642-fbe6-4621-9e25-1ad7325fb6fa" name="sage:MarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all marketable securities held by the Company had remaining contractual maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_437ebd50-c191-44d5-844a-bd5ebe581bc8" contextRef="C_1a762d75-188f-4244-ab8c-58366e1a3a7d" name="sage:MarketableSecuritiesRemainingContractualMaturities" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less, except for U.S. government securities, U.S. corporate bonds, international corporate bonds and municipal securities with a fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f677a04-1400-457f-b507-bbe6e0a50034" contextRef="C_d3351468-5ac6-43c1-8075-f9f598ae56b3" name="sage:MarketableSecuritiesHeldToMaturityFairValue" unitRef="U_USD" scale="6" decimals="-5">211.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9fe7857e-17e4-49cf-93b3-30d78c5acea7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0dd1067d-8ae0-4606-a93d-f860fd89e510" contextRef="C_b5072417-0f0f-44a9-8e76-a71228d6ebf1" name="sage:MarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities, including those with remaining contractual maturities of more than one year, are classified as current assets on the balance sheet because they are considered to be &#x201c;available for sale&#x201d; and the Company can convert them into cash to fund current operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adcf5107-f909-44dc-9954-a79bee3d38ed" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_00b979e1-f39c-4e1f-8d42-db2070575fc5" contextRef="C_398f2f38-b40a-44f3-b42a-adb45a79772b" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments of the Company&#x2019;s assets measured and carried at fair value during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec453388-35c8-432b-84b9-303a20f7165a" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c70e19c7-5707-4177-83ce-a7e04417e058" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes accrued expenses as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.507%;"></td>
        <td style="width:2.046%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.201%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.046%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.201%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_189bf619-7752-4985-8150-0e62e4c44de6" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="sage:AccruedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19928e69-226b-43c7-acee-1ab3391fdab9" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="sage:AccruedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee-related</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c96d8cc-6bdf-4e51-8f33-c20c187db315" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdab7f8d-78d4-4577-ba88-bee1efa3217f" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8b548dd-5481-49fd-822a-1482469c6f3b" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,922</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ae0b4be-58f5-44eb-aa38-42cf900fa7f3" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26202bf3-320c-42b4-bf16-ca99e80d4858" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f890585-3d63-4242-a787-a27d89150b4a" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d0d82bf-abfd-45cf-bd9b-b31b189b1890" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,745</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0171d638-943d-4daa-84a8-cc0813fa0be7" contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a25712b-e1e3-4d7d-808d-202af862c0b4" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:7.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases, Commitments and Contingencies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases office space and certain equipment. All of the leases recorded on the condensed consolidated balance sheets are operating leases. The Company&#x2019;s leases have remaining lease terms ranging from less than </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_425efdcb-7c15-4b93-83b4-aabb1cd09840" contextRef="C_27bf7966-adaf-4a98-8cd4-cf044ac22be7" name="sage:LessorOperatingLeaseRemainingLeaseTerms" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to approximately </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0488177-629a-4c0a-a4bc-d77e8296387e" contextRef="C_a131c6ed-00ee-4297-b3ee-b15e20f02a2b" name="sage:LessorOperatingLeaseRemainingLeaseTerms" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.75</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. Some of the leases include </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_02aacb61-99a8-43ba-8bb8-3474e32fbedc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options to extend</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the leases for up to </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d841126-b24d-47ab-ad6d-cd80c62cdbbd" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:LessorOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These options were not included for the purpose of determining the right-of-use assets and associated lease liabilities as the Company determined that the renewal of these leases is not reasonably certain so only the original lease term was taken into consideration. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of January 1, 2022, the Company leased office space in two multi-tenant buildings in Cambridge, Massachusetts, consisting of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcea16a4-0a4e-42a7-b8d3-b9258b8ff7f8" contextRef="C_ed9cf729-5356-4b5d-ad2b-e3ed67efc846" name="sage:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">63,017</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in the first building, under an operating lease that will expire on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8170116-5e0d-4273-aed4-9bd7c87b336b" contextRef="C_ed9cf729-5356-4b5d-ad2b-e3ed67efc846" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c0daf09-48e6-480f-98c0-5b15e2d981a2" contextRef="C_a7db4793-3d03-4e12-aff2-9ea90996fb1c" name="sage:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">40,419</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in the second building, under an operating lease that will expire on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6313fdd-e37a-4532-9327-fe8fe7196cd8" contextRef="C_a7db4793-3d03-4e12-aff2-9ea90996fb1c" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; and in a multi-tenant building in Raleigh, North Carolina, consisting of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0fbeafc-68ce-4ec4-98fc-cc19ad247b46" contextRef="C_c148acc4-eb89-4bb9-b863-bbc6f10137ff" name="sage:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">15,525</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet under an operating lease that will expire on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_76d1da3b-4f75-4559-9519-71e31ae7ca5e" contextRef="C_c148acc4-eb89-4bb9-b863-bbc6f10137ff" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 30, 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CyDex License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2015, the Company amended and restated its existing commercial license agreement with CyDex Pharmaceuticals, Inc. (&#x201c;CyDex&#x201d;), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated. Under the terms of the commercial license agreement as amended and restated, CyDex has granted to the Company an exclusive license to CyDex&#x2019;s Captisol drug formulation technology and related intellectual property for the manufacture of pharmaceutical products incorporating brexanolone and the Company&#x2019;s compound known as SAGE-689, and the development and commercialization of the resulting products for the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i) the ocular treatment of any disease or condition with a formulation, including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration. The Company is required to pay a royalty to CyDex on sales of brexanolone and will be required to pay a royalty on any sales of SAGE-689, if such product candidate is successfully developed in the future. Royalty rates are in the low single digits based on levels of net sales. From the effective date of the agreement to March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has paid to CyDex $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccd23f16-59ca-4f11-b5e0-cb928659d0af" contextRef="C_184f14a5-c851-40db-a3ad-edc0666d719c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for licensing fees, which was recorded as research and development expense.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the amended and restated license agreement with CyDex, the Company agreed to make milestone payments on the achievement of clinical development and regulatory milestones in the amount of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61912f19-92f0-407c-a9b1-383e5425390f" contextRef="C_cb341859-3071-42f6-bc53-4b0e98b5f8a5" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in clinical milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5ed912e-1ec6-40bb-9771-c1eb20a220a9" contextRef="C_8b581abc-0b6e-4877-a6fd-ea611d7c0a1d" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in regulatory milestones for each of the first two fields with respect to brexanolone; up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be3c1640-4032-440f-8a4c-4a92213b6d78" contextRef="C_d4873c8c-5811-4fbb-bbcc-4e44f6387941" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in clinical milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_416e7e6a-0cdd-4e99-846a-bc57a8cc42c8" contextRef="C_0417f1bf-3a90-4585-8698-483b60daf578" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in regulatory milestones for each of the third and fourth fields with respect to brexanolone; and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ad81739-d3a3-4dc3-abe5-9296979b7a5f" contextRef="C_631cae3a-ac3e-456e-a8b7-57e54ff8a7ca" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in clinical milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fd5a5c6-7350-4ba9-8715-7fb983467bfe" contextRef="C_39f2ebec-0b4d-4975-8d61-08994c517086" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in regulatory milestones for one field with respect to SAGE-689. From the effective date of the agreement to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has recorded research and development expense and made cash payments of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_375304d0-f9c8-4737-8eac-2d0b4f3ff424" contextRef="C_ce43f41b-b49a-4a4d-ac4f-591e551f6206" name="sage:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_58591aba-c71f-4b2e-8206-7d6a2c81b33f" contextRef="C_ce43f41b-b49a-4a4d-ac4f-591e551f6206" name="sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment" unitRef="U_USD" scale="6" decimals="-5">3.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these clinical development and regulatory milestones and has recorded an intangible asset and made a cash payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_347e5d30-4a22-4bee-896e-c3024ae27db0" contextRef="C_27dd408f-5b77-4383-b146-868c9ccf1126" name="sage:IntangibleAssetRelatedToMilestone" unitRef="U_USD" scale="6" decimals="-5">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these regulatory milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0390cfc-a8a5-4734-ba23-b74fefc2a0c8" contextRef="C_c906b10e-a37d-4bef-9c1a-2f9273872ad0" name="sage:IntangibleAssetRelatedToMilestone" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_141e63ee-7a3c-4514-8dd5-16ae1c561926" contextRef="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f" name="sage:MilestonePayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fa58103f-d792-4bd0-bec2-990487bc1a56" contextRef="C_bdd95323-8fa2-447a-b407-594cf62cbf26" name="sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7821cc0f-60ef-43eb-b056-07db2241bf34" contextRef="C_bdd95323-8fa2-447a-b407-594cf62cbf26" name="sage:MilestonePayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_de25007e-60db-497f-8fea-ef074ee74650" contextRef="C_0a4f411b-755b-4edb-9b9a-1c815418b4e7" name="sage:MilestonePaymentsRelatedToIntangibleAssets" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_363677fa-55e6-4a65-ac99-24f276ec8b68" contextRef="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f" name="sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f256d26a-e537-4503-8c87-56df28ab086a" contextRef="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f" name="sage:MilestonePaymentsRelatedToIntangibleAssets" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any expense or intangible asset, or make any milestone payments related to clinical development or regulatory milestones for the brexanolone program or SAGE-689 under the license agreement with CyDex.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">University of California License Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2013, the Company entered into a non-exclusive license agreement with the Regents of the University of California (&#34;the Regents&#x201d;) under which the Company was granted a non-exclusive license to certain clinical data and clinical material related to brexanolone for use in the development and commercialization of biopharmaceutical products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the licensed field, including status epilepticus and postpartum depression. In May 2014, the license agreement was amended to add the treatment of essential tremor to the licensed field of use, materials and milestone fee provisions of the agreement. The Company paid to the Regents clinical development milestones of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c23dede2-c45e-4921-b2cd-12ec3f504a15" contextRef="C_5fb3fbe9-a1c0-46ce-b650-af5e52d18ce1" name="sage:PaymentForClinicalDevelopmentMilestones" unitRef="U_USD" scale="6" decimals="INF">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, prior to December 31, 2015; </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf596add-b722-4ad3-80fc-1a7b5bdd2482" contextRef="C_5fb3fbe9-a1c0-46ce-b650-af5e52d18ce1" name="sage:MilestoneOutstandingLicenseAgreement" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> other milestones are outstanding under this non-exclusive license agreement. The Company is required to pay royalties of less than </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97a2b18a-51cb-4563-ad3e-fb02b63e857f" contextRef="C_5673061c-1475-40d8-a68f-d13874d6120e" name="sage:PercentageOfNetSalesRequiredForRoyaltyEntitlement" unitRef="U_pure" scale="-2" decimals="INF">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on net sales for a period of fifteen years following the sale of the first product developed using the data and materials, and the Company began to pay these royalties in 2019. The license will terminate on the earlier to occur of (i) </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dafea361-5c63-4dbc-866e-0830bf6049e4" contextRef="C_f08fa5ab-3d5a-498f-8805-b37168240ab1" name="sage:LicenseAgreementMaximumTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the effective date or (ii) </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_135246e4-e124-43b1-a0ca-37d3ca40b638" contextRef="C_e009878c-16d0-44dd-938b-4ab63e464396" name="sage:LicenseAgreementMaximumTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the last-derived product is first commercially sold.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2015, the Company entered into an exclusive license agreement with the Regents whereby the Company was granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In exchange for such license, the Company paid an upfront payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f758504-0318-468a-b068-023398dce961" contextRef="C_9b20c727-7972-478a-9e8f-c96192d5a8c6" name="sage:UpFrontPayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was required to make payments of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eff87e28-3067-4254-8584-2271b50f7b69" contextRef="C_c8887f83-2b64-4c67-9ed6-bf1f704f02eb" name="sage:LicenseMaintenanceCostAnnual" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for annual maintenance fees until the calendar year following the first sale of ZULRESSO. The Company is obligated to make milestone payments following the achievement of specified regulatory and sales milestones of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1b31237-739f-4a35-82b9-2571ffa846cb" contextRef="C_a87f9c6e-2ef9-466a-ae7a-ee5de7690022" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6059072c-da97-41bf-a170-23ffbad3f976" contextRef="C_66eb2bc3-a6d2-4d81-939a-2ee9abc0d88c" name="sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, respectively. The Company pays royalties at a low single digit percentage of net sales of ZULRESSO, subject to specified minimum annual royalty amounts. Unless terminated by operation of law or by acts of the parties under the terms of the agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire, whichever is later. From the effective date of the agreement to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has recorded research and development expense and made cash payments of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7735ee36-07de-4b33-a861-bab7342374bd" contextRef="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd" name="sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_d0e82fd3-8526-4d8d-aa97-3c2c4f7ddf1f" contextRef="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd" name="sage:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these regulatory and sales milestones; and has recorded an intangible asset and made a cash payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7926c4ed-a72c-470d-ac1a-9ebef4aa8318" contextRef="C_fe2f65bc-c1a3-4823-84d8-2de25bace4b8" name="sage:IntangibleAssetRelatedToMilestone" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_72d96474-69a2-48ef-bc41-7ae4f42bb23e" contextRef="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd" name="sage:MilestonePaymentsRelatedToIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these regulatory and sales milestones.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00c626f7-025b-48c3-9637-641a7ee5f497" contextRef="C_ec5cbc69-f530-4cf4-94cc-314aa3b6a25a" name="sage:MilestonePayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9fef8a8c-3d4a-421e-8756-71330aa2240b" contextRef="C_51b62e2e-6e5b-43f1-9a64-7a9fc0694111" name="sage:MilestonePayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any expense or make any milestone payments under the license agreements with the Regents.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7902285-e186-4a13-b638-26aaf7d0f3b6" contextRef="C_20237446-69f4-4551-93d5-fee5a4bf888c" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shionogi</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, the Company entered into a strategic collaboration with Shionogi for the clinical development and commercialization of zuranolone for the treatment of MDD and other potential indications in Japan, Taiwan and South Korea (the &#x201c;Shionogi Territory&#x201d;). In October 2018, the Company entered into a supply agreement with Shionogi for the Company to supply zuranolone clinical material to Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the collaboration agreement, Shionogi is responsible for all clinical development and regulatory filings for zuranolone in MDD and other indications in the Shionogi Territory and would be responsible for commercialization of zuranolone in the Shionogi Territory, if zuranolone is successfully developed and obtains marketing approval in any of the countries within the Shionogi Territory. Shionogi was required to make an upfront payment to the Company of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38ba8ce1-509a-48de-afc9-b6a6c03a6881" contextRef="C_2204d339-5d64-45be-917c-4696379675ab" name="sage:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5">90.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and the Company will be eligible to receive additional payments of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_988b2707-b627-42bb-a72a-48e3041a6d3c" contextRef="C_afad7b91-c063-484c-8b27-af3fdd038f98" name="sage:CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="INF">485.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million if certain regulatory and commercial milestones are achieved by Shionogi. The potential future milestone payments include up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_366e2003-805d-4403-8fb9-c7f2cad2e359" contextRef="C_1260202e-e0d1-44c6-91a1-7328082cd6ac" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">70.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified regulatory milestones, up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47b4855b-a4f5-43be-9a02-9238c79f0516" contextRef="C_9077cfbe-fe30-4100-87f2-a75b18e864fe" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified commercialization milestones, and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e18a29b-346d-41d2-8042-21f168dba8a8" contextRef="C_b0558d4b-6d1c-4376-8c22-956a113e11fa" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">385.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified net sales milestones. The Company is eligible to receive tiered royalties on sales of zuranolone in the Shionogi Territory, if development efforts are successful, with tiers averaging in the low to mid-</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1501c989-1ee6-4a3d-8d93-8795138d2c8a" contextRef="C_2204d339-5d64-45be-917c-4696379675ab" name="sage:AveragePercentageOnTieredRoyalties" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">twenty</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent range, subject to other terms of the agreement. Shionogi has also granted to the Company certain rights to co-promote zuranolone in Japan. As between the Company and Shionogi, the Company maintains exclusive rights to develop and commercialize zuranolone outside of the Shionogi Territory. The upfront cash payment and any payments for milestones and royalties are non-refundable and non-creditable. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments from Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that Shionogi meets the definition of a customer because the Company is delivering intellectual property and know-how rights for the zuranolone program in support of territories in which the parties are not jointly sharing the risks and rewards. In addition, the Company determined that the Shionogi collaboration met the requirements to be accounted for as a contract, including that it was probable that the Company will collect the consideration to which the Company was entitled in exchange for the goods or services that will be delivered to Shionogi.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the performance obligations in the Shionogi collaboration agreement included the license to zuranolone and the supply of certain materials during the clinical development phase, which includes the supply of active pharmaceutical ingredient (&#x201c;API&#x201d;). The performance obligation related to the license to zuranolone was determined to be distinct from other performance obligations and therefore was a separate performance obligation for which control was transferred upon signing. The obligation to provide certain clinical materials, including API for use during the development period, was determined to be a separate performance obligation. Given that Shionogi is not obligated to purchase any minimum amount or quantities of commercial API, the supply of API to Shionogi for commercial use was determined to be an option for Shionogi, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that there was no separate material right in connection with the supply of API for commercial use as the expected pricing was not at a discount. Given this fact pattern, the Company has concluded the agreement has two performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the clinical supply agreement, the Company is obligated to manufacture and supply to Shionogi (i) clinical quantities of API reasonably required by Shionogi for the development of licensed products in the Shionogi territory under the collaboration and license agreement and (ii) quantities of drug product reasonably required for use by Shionogi in Phase 1 clinical trials of zuranolone in the Shionogi territory under the collaboration and license agreement, in the quantities agreed to by the parties. Collaboration revenue from the clinical supply agreement, which excludes the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_531e1f69-2c30-4e63-8ee8-fe6e3029fc1f" contextRef="C_2204d339-5d64-45be-917c-4696379675ab" name="sage:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5">90.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront payment, pertains to the clinical material sold under the terms of the clinical supply agreement. The Company records the costs related to the clinical supply agreement in research and development expense on its condensed consolidated statements of operations and comprehensive loss. For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recognized </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_361c405a-7051-4d14-8245-4510ae6cb9ca" contextRef="C_a27e3064-3e8b-4d7c-97fd-d2f5bdd6bd44" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c07eef4c-f77d-4e34-a9a5-cd90d0ae59c8" contextRef="C_fe878ea5-22df-4ead-ab1d-48438facdfb4" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> collaboration revenue from the Company&#x2019;s agreement with Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company completed the evaluation of the standalone selling prices of each of the performance obligations and determined that the standalone selling price of the license performance obligation was $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7942b082-3d5b-4fc6-a3d4-f3139a91d417" contextRef="C_94d81f85-dbf8-4abd-8cc2-b5a8a0cbec84" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5">90.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company recognized the transaction price allocated to the license performance obligation of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c908e395-6f3f-4f82-9d83-49644f73ac68" contextRef="C_150eb2ee-5e12-4af8-9658-d633a3fc51a6" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5">90.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as revenue during the quarter upon delivery of the license to Shionogi and resulting ability of Shionogi to use and benefit from the license, which was in the three months ended June 30, 2018. The remaining transaction price related to the performance obligation for the supply of certain clinical material is not significant. The potential milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biogen</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company entered into the Biogen Collaboration Agreement to jointly develop and commercialize SAGE-217 products for MDD, PPD and other disorders and SAGE-324 products for essential tremor and other disorders. Concurrently, the Company also entered into a stock purchase agreement with BIMA (the &#x201c;Biogen Stock Purchase Agreement&#x201d;) under which BIMA purchased shares of the Company&#x2019;s common stock. The Biogen Collaboration Agreement became effective on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7420604d-86cf-418b-aafe-3794c1e76ff8" contextRef="C_4ea38295-87e6-4099-8ab6-a32ad999eac8" name="sage:CollaborationAgreementEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 28, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;Effective Date&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Biogen Collaboration Agreement, the Company granted Biogen co-exclusive licenses to develop and commercialize SAGE-217 products and SAGE-324 products (each, a &#x201c;Product Class&#x201d; and together, the &#x201c;Licensed Products&#x201d;) in the U.S., an exclusive license to develop and commercialize SAGE-217 products in all countries of the world other than the U.S. and the Shionogi Territory, and an exclusive license to develop and commercialize SAGE-324 products in all countries of the world other than the U.S. The Company refers to the territories outside the U.S. to which Biogen has rights under the Biogen Collaboration Agreement with respect to the applicable Licensed Product as the &#x201c;Biogen Territory&#x201d;.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the effectiveness of the Biogen Collaboration Agreement and the closing of the sale of shares to BIMA in December 2020, the Company received $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df67e45e-28a9-4640-bb74-8aa24bb80970" contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="9" decimals="-8">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in consideration, comprised of an upfront payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e10cddb5-778e-4e89-a071-6f8d7a457e1c" contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4" name="sage:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5">875.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e8e6d61-6333-4823-9de0-70e8184f4364" contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4" name="sage:PurchasePriceForNewShareIssued" unitRef="U_USD" scale="6" decimals="-5">650.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million purchase price for </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c019db9-5564-49c3-ae46-3e96da1705e1" contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,241,473</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> newly issued shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;). As a result of the purchase of the Biogen Shares, Biogen has become a related party of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is eligible to receive additional payments of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44114d58-bb44-4bb3-9bc6-e096aa74fe0e" contextRef="C_159c0b2e-4b20-4fe8-842e-d19291806674" name="sage:CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" unitRef="U_USD" scale="9" decimals="INF">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion if certain regulatory and commercial milestones are achieved. The potential future milestone payments for SAGE-217 products include up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04c25bc1-a04b-4d05-ae02-f60cf62ac023" contextRef="C_3bb6c209-64a4-4fa9-9e19-b14c178a0c67" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">475.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified regulatory and commercial milestones, including milestones totaling $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f80ee7a7-1045-4d91-879d-afdd60dd02cb" contextRef="C_6f864b66-2233-436e-9a55-3a656e209f1c" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the first commercial sale of zuranolone for the treatment of MDD and PPD, and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e92b9179-7809-4ab4-8c74-b33006611c4d" contextRef="C_218b8633-84a1-4518-ac04-a09bb4743a05" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified net sales milestones. The potential future milestone payments for SAGE-324 products include up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfbf2712-35cc-4035-8cff-a51a5938e89b" contextRef="C_e166f395-27e9-4ed3-b61a-0efed3d9f77f" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">520.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified regulatory and commercial milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33152f17-8006-412e-b155-717ebb212072" contextRef="C_699a6647-c36c-4a33-a3f4-ae8e7184b152" name="sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" unitRef="U_USD" scale="6" decimals="INF">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified net sales milestones. The Company is also eligible to receive tiered royalties on net sales of SAGE-217 products and SAGE-324 products in the Biogen Territory at percentage rates ranging from the high teens to low twenties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may never receive any milestone payments or any royalty payments under the Biogen Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and commercialization activities in the U.S. are conducted pursuant to plans agreed to by the Company and Biogen and overseen by a joint steering committee that will consist at all times of an equal number of representatives of each party. The Company and Biogen will share equally in the costs for development and commercialization, as well as the profits and losses upon FDA approval and commencement of product sales, in the U.S., subject to the Company&#x2019;s opt-out right described below. Biogen will be solely responsible for all development activities and costs related to any development and commercialization of SAGE-217 products and SAGE-324 products for the Biogen Territory, and the Company will receive royalties on any sales in the Biogen Territory, as mentioned above. Biogen will be the principal and record sales of SAGE-217 products globally. The Company will be the principal and record sales of SAGE-324 products in the U.S. and Biogen will be the principal and record sales of SAGE-324 products in the Biogen Territory.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will supply API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to support development and commercialization activities. Biogen has the right to assume manufacturing responsibilities for API for the Biogen Territory at any time during the term of the agreement and will, within a reasonable period of time after the Effective Date, assume manufacturing responsibility for bulk drug product for the Biogen Territory.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless terminated earlier, the Biogen Collaboration Agreement will continue on a Licensed Product-by-Licensed Product and country-by-country basis until the date on which (a) in any country in the Biogen Territory, the royalty term has expired for all Licensed Products in a Product Class in such country, and (b) for the U.S., the parties agree to permanently cease to commercialize all Licensed Products in a Product Class. Biogen also has the right to terminate the Biogen Collaboration Agreement for convenience in its entirety, on a Product Class-by-Product Class basis or as to a particular region, upon advance written notice. The Company has an opt-out right to convert the co-exclusive licenses in the U.S. to an exclusive license to Biogen on a Product Class-by-Product Class basis. Following the exercise of the opt-out right, the Company would no longer share equally in the profits and losses in the U.S. and would be entitled to receive certain royalty payments at percentage rates ranging from the high teens to low twenties and additional sales milestones.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the Biogen Collaboration Agreement and the Biogen Stock Purchase Agreement should be combined and treated as a single arrangement for accounting purposes as the agreements were entered into contemporaneously and in contemplation of one another. The Company determined that the combined agreements had elements that were within the scope of Topic 606 and Topic 808.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of the Effective Date, the Company identified the following promises in the Biogen Collaboration Agreement that were evaluated under the scope of Topic 606: delivery of (i) a co-exclusive license for SAGE-217 products in the U.S.; (ii) an exclusive license for SAGE-217 products in the Biogen Territory; (iii) a co-exclusive license for SAGE-324 products in the U.S.; (iv) an exclusive license for SAGE-324 products in the Biogen Territory; (v) the clinical manufacturing supply of API and bulk drug product for SAGE-217 products in the Biogen Territory; and (vi) the clinical manufacturing supply of API and bulk drug product for SAGE-324 products in the Biogen Territory.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also evaluated whether certain options outlined within the Biogen Collaboration Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Biogen and therefore are not considered separate performance obligations within the Biogen Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the above promises and determined that the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. are reflective of a vendor-customer relationship and therefore represent performance obligations within the scope of Topic 606. The co-exclusive license for SAGE-217 products and SAGE-324 products in the U.S. are considered functional intellectual property and distinct from other promises under the contract. The exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory are considered functional licenses that are distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the licenses on its own or together with other readily available resources. As the co-exclusive licenses in the U.S. and the exclusive licenses in the Biogen Territory are delivered at the same time, they are considered one performance obligation at contract inception. The clinical manufacturing supply of API and bulk drug product for SAGE-217 products and SAGE-324 products for the Biogen Territory are considered distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the manufacturing services together with the licenses transferred by the Company at the inception of the agreement. Therefore, each represents a separate performance obligation within a contract with a customer under the scope of Topic 606 at contract inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers the collaborative activities associated with the co-development, co-commercialization, and co-manufacturing of SAGE-217 products and SAGE-324 products in the U.S. to be separate units of account within the scope of Topic 808 as the Company and Biogen are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on the development and commercial success of the activities in the arrangement. The Company has determined that the supply of API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to Biogen will be classified as collaboration revenue &#x2013; related party in the condensed consolidated statements of operations and comprehensive loss. During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49ba9a56-fdfc-4330-863d-bc161574b91c" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="us-gaap:Revenues" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bd72a7fa-076c-40ca-a876-5aada297dd68" contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07" name="us-gaap:Revenues" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> collaboration revenue &#x2013; related party was recognized related to the Biogen Collaboration Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments to or reimbursements from Biogen related to the co-development, co-commercialization, and co-manufacturing activities and the agreement of the parties to share equally the cost of these activities will be accounted for as an increase to or reduction of research and development expenses or selling, general and administrative expenses, depending on the nature of the activity.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, the Company recorded a net reimbursement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa4416ae-9ef7-4c19-84e0-5187e621ca74" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="sage:ReimbursementReductionsOrAdditionToOperatingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, for the amounts due from Biogen as a reduction of or an addition to the related operating expense categories in the condensed consolidated statement of operations and comprehensive loss. During the three months ended March 31, 2022, the Company recorded a net reimbursement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22abd350-eb63-4c59-b0d4-ce986601b2c6" contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07" name="sage:ReimbursementReductionsOrAdditionToOperatingExpenses" unitRef="U_USD" scale="6" decimals="-5">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the amounts due from Biogen as a reduction of the related operating expense categories in the condensed consolidated statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, the Company recorded a Collaboration Receivable &#x2013; Related Party of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d1d7190-ce92-4533-9aa2-b61909b70e94" contextRef="C_b2aeaf62-e210-498e-b523-527707b39cfa" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the condensed consolidated balance sheet for the amounts due for the three months ended March 31, 2023. During the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company made </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e271f16-f99b-4c2b-9911-2d30ad172f6d" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="sage:PaymentsToRelatedParties" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments to Biogen and the Company received </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faefb30d-f18d-4a47-9238-dc3c3edbf241" contextRef="C_0ac1b81a-4423-47d2-b61e-3baceb754609" name="sage:ProceedsFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from Biogen for the amounts due for the three months ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_90ed762a-f8df-4340-b9f5-8a6d1311132e" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes expenses related to the Biogen Collaboration Agreement that were incurred by the Company and the related reimbursement from Biogen or to Biogen, reflected by category of operating expenses:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.701%;"></td>
        <td style="width:1.585%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.064%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.585%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.064%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses related to the Biogen Collaboration Agreement<br />&#160;&#160;&#160;incurred by Sage</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aab5417d-ad30-4708-a3f2-786969a5d5fb" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,136</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32cee6c2-64d5-4fbc-9a0a-9e16ab23b684" contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net reimbursement to (from) Biogen reflected in the<br />&#160;&#160;&#160;condensed consolidated statements of operations and <br />&#160;&#160;&#160;comprehensive loss:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96e1d71a-4a0c-4410-b48e-7558ded2c78d" contextRef="C_df2b4db8-ae1e-400c-96db-0a5ee962f62b" name="sage:ReimbursementReductionsToExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ae5f91a-dfa3-4e05-abfe-0e7135e50109" contextRef="C_b379d84e-292f-4ec3-8309-f2e399adad4c" name="sage:ReimbursementReductionsToExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,514</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7816cb50-1b02-40d1-9152-4827dcc03db9" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="sage:ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,034</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cadc95b2-699a-46bf-8904-8a1f3473c053" contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07" name="sage:ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_738b8de3-86c6-4ae7-9618-586d61809bdb" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="sage:ReimbursementReductionsToOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b05b055f-3624-4aca-8532-62e218eb7191" contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07" name="sage:ReimbursementReductionsToOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,988</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net expenses related to the Biogen Collaboration <br />&#160;&#160;&#160;Agreement in the condensed consolidated statements of <br />&#160;&#160;&#160;operations and comprehensive loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f041b488-efb0-4f6b-8e6e-505c038c9b83" contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,888</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7485ccf-1fc9-485d-be51-0e7bcafba4ba" contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined the transaction price under Topic 606 at the inception of the Biogen Collaboration Agreement to be $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b271029-03d5-4336-a12e-4f1a4427db44" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:CollaborativeAgreementTransactionPrice" unitRef="U_USD" scale="9" decimals="-8">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion, consisting of the upfront payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c203be7-dd90-4eb1-bdc2-4e41a0150512" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5">875.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million plus $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89906e6d-0368-4e71-853c-3c01acbfe331" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:PremiumAmountOnEquityInvestment" unitRef="U_USD" scale="6" decimals="-5">232.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in excess proceeds from the equity investment under the Biogen Stock Purchase Agreement, when measured at fair value, plus future variable consideration for manufacturing supply of clinical API and bulk drug product for the Biogen Territory. The amount of variable consideration related to the future manufacturing services was not material. The Company determined that any variable consideration related to clinical development and regulatory milestones is deemed to be fully constrained and therefore excluded from the transaction price due to the high degree of uncertainty and risk associated with these potential payments, as the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company also determined that royalties and sales milestones relate solely to the licenses of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of Topic 606. Revenue related to these royalties and sales milestones will only be recognized when the associated sales occur, and relevant thresholds are met.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As noted above, the Company identified three performance obligations in the Biogen Collaboration Agreement: (i) the delivery of the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. and the exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory; (ii) the clinical manufacturing supply of API and bulk drug product for SAGE-217 products in the Biogen Territory; and (iii) the clinical manufacturing supply of the API and bulk drug product for SAGE-324 products in the Biogen Territory. The selling price of each performance obligation in the Biogen Collaboration Agreement was determined based on the Company&#x2019;s SSP with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the variable consideration related to the manufacturing obligations to the future clinical supply of SAGE-217 products and SAGE 324 products in the Biogen Territory and the remaining fixed consideration to the license obligation. The variable consideration related to the manufacturing obligations was not material. As such, the entirety of the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbe6b463-75fb-48cc-b020-8423066b0cf9" contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4" name="us-gaap:Revenues" unitRef="U_USD" scale="9" decimals="-8">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion fixed consideration of the transaction price has been allocated to the transfer of the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. and the exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory. The Company recognizes revenue for the license performance obligations at a point in time, that is upon transfer of the licenses to Biogen. As control of these licenses was transferred on the Effective Date and Biogen could begin to use and benefit from the licenses, the Company recognized $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13bb1d5d-8668-48c1-95e6-a2e5bcf6498c" contextRef="C_7cc6f749-3572-4a07-9837-a838d91c9606" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="9" decimals="-8">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion of license revenue during the year ended December 31, 2020 under the Biogen Collaboration Agreement. The Company will recognize revenue for the clinical manufacturing supply obligations at a point in time, that is upon the delivery of the supply to Biogen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for the Biogen Stock Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">connection with the execution of the Biogen Collaboration Agreement, the Company and BIMA entered into the Biogen Stock Purchase Agreement. Pursuant to the Biogen Stock Purchase Agreement, the Company sold the Biogen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to BIMA at a price of approximately $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4340a50d-ef79-4743-b85a-efd86842d38a" contextRef="C_04077a28-e57f-48bf-be52-866b6f516e9c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">104.14</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which represented a </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e31d6f9-8e9c-42c4-89de-4b99f5d2d999" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:PremiumOnPerSharePricePercentage" unitRef="U_pure" scale="-2" decimals="2">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent premium over the 30-day volume-weighted average share price as of the last trading day prior to the date the Biogen Collaboration Agreement and Biogen Stock Purchase Agreement were executed in November 2020, for aggregate consideration of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_829298c5-33de-4806-9f5b-f523e1686552" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:PurchasePriceForNewShareIssued" unitRef="U_USD" scale="6" decimals="-5">650.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The sale of the shares to BIMA closed on December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biogen Stock Purchase Agreement includes certain standstill provisions, lock-up restrictions, and a voting agreement with respect to the Biogen Shares. Pursuant to the terms of the Biogen Stock Purchase Agreement, BIMA has agreed not to, and to cause its affiliates not to, directly or indirectly acquire the Company&#x2019;s securities, seek or propose a tender or exchange offer or merger between the Company and Biogen, solicit proxies or consents with respect to any matter, or undertake other specified actions, in each case subject to specified conditions. </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c38bb6a-fc7d-4ba9-8a6b-42bbd579226c" contextRef="C_d08e78d2-6122-4a68-a2fa-efacb6e5afb6" name="sage:StockPurchaseAgreementDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The standstill restrictions terminate on the earliest of (i) a specified regulatory milestone under the Biogen Collaboration Agreement, (ii) the date one year following the termination of the Biogen Collaboration Agreement and (iii) the seventh anniversary of the Effective Date. BIMA also agreed not to, and to cause its affiliates not to, sell or transfer any of the Biogen Shares for a period of eighteen months from the closing of the sale of the Biogen Shares, which period expired on June 30, 2022, and to limit sales and transfers of the Biogen Shares for an additional eighteen-month period, in each case subject to specified conditions and exceptions.</span></ix:nonNumeric></span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined the fair value of the common shares issued using an option pricing valuation model to take into consideration the holding period restrictions. The fair value of the Company&#x2019;s common stock was considered a Level 2 fair value measurement within the fair value hierarchy. The most significant assumptions within the model are the Company&#x2019;s stock price, the term of the restrictions and the stock price volatility, which is based upon a blend of historical and implied volatility of the Company&#x2019;s stock. Based on the fair value adjustments made by management, the fair value of the shares issued was determined to be $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25d46547-2082-487e-90b0-08f35f658690" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="us-gaap:StockIssued1" unitRef="U_USD" scale="6" decimals="-5">417.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f44b825e-e752-471b-9d2c-c65fa427d0b1" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:PremiumAmountOnEquityInvestment" unitRef="U_USD" scale="6" decimals="-5">232.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million less than the proceeds received from BIMA for the issuance of the Company&#x2019;s common stock under the Biogen Stock Purchase Agreement. As such, the $232.5 million in excess proceeds has been included in the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5418a2cb-ca90-40d8-a4f4-17c28b448a7d" contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1" name="sage:CollaborativeAgreementTransactionPrice" unitRef="U_USD" scale="9" decimals="-8">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion transaction price of the Biogen Collaboration Agreement determined above.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_001cc99c-8c98-4bd5-9114-6b15ea35fb0c" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-Based Compensation</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 2, 2014, the stockholders of the Company approved the 2014 Stock Option and Incentive Plan (the &#x201c;2014 Plan&#x201d;), which became effective immediately prior to the completion of the Company&#x2019;s IPO. The 2014 Plan provides for the grant of restricted stock awards, restricted stock units, incentive stock options and non-statutory stock options. The 2014 Plan replaced the Company&#x2019;s 2011 Stock Option and Grant Plan (the &#x201c;2011 Plan&#x201d;). The Company </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aa3aad9-96d9-4651-a347-c3ed963d4327" contextRef="C_7a300dcf-c0cb-47b1-a0fc-9cd53edc84b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> longer grants stock options or other awards under its 2011 Plan, but any stock options outstanding under the 2011 Plan remain outstanding and effective in accordance with their terms.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2014 Plan provides for an annual increase, to be added on the first day of each year, by up to 4% of the Company&#x2019;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03d7b47e-4045-4cc9-a269-74c9f25402e3" contextRef="C_f717451a-6a70-4aef-9347-14e48ca9154e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,380,365</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, representing </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b27931a9-e8ef-4441-a4ba-2890ad1f9adc" contextRef="C_e7f34c5e-d698-4850-9998-3b9d55aa69dc" name="sage:CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#x2019;s outstanding shares of common stock as of December 31, 2022, were added to the 2014 Plan.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 15, 2016, the Board of Directors of the Company (the &#x201c;Board&#x201d;) approved the 2016 Inducement Equity Plan (as amended and restated, the &#x201c;2016 Plan&#x201d;). The 2016 Plan provides for the grant of equity awards to individuals who have not previously been an employee or a non-employee director of the Company to induce them to accept employment and to provide them with a proprietary interest in the Company. On September 20, 2018, the Board amended the 2016 Plan to increase the total number of shares reserved for issuance by </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b56d7be0-9bd0-43eb-9327-0e23a6f66b6d" contextRef="C_2d205233-d11d-421a-9604-3d24b788eaa7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terms </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of equity grants, including vesting requirements, are determined by the Board or the Compensation Committee of the Board, subject to the provisions of the applicable plan. Stock options granted by the Company that are not performance-based are considered time-based because they vest based on the continued service of the grantee with the Company during a specified period following grant. These awards, when granted to employees, generally vest ratably</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">over </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a4847a82-a8bb-4531-9cd4-63a35e0116e8" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b51c01c-2cba-413b-96a7-b0db328cc354" contextRef="C_ee76c540-63b2-44a9-af22-8b7f35a27ba7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vesting at the </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5942acff-294a-4c68-b2b2-61a24f9cbf24" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> anniversary. All stock option awards expire </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0bc083d-2287-472c-afe6-18f3ed9ac9e9" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the date of grant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, the total number of shares underlying outstanding awards under all equity plans was </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8fcb889-5df2-429e-96c2-9027aa43f69b" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,793,166</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the total number of shares available for future issuance under all equity plans was </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7be6e008-514d-4862-9c6e-bce5bbc5bc69" contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,616,709</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 16, 2022, the Company&#x2019;s stockholders approved an amendment to the amended 2014 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which had been previously approved by the Board, to add </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb40fe10-cb8b-4759-aec0-30b0f4e910cf" contextRef="C_1781ce27-35bc-4e2c-9a64-0b8ce5fdfda1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6bcac53-4515-487c-bb96-06a7641aaed1" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes activity relating to time-based restricted stock units and performance restricted stock units:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.084%;"></td>
        <td style="width:1.534%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.159%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.223%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_029fc205-de64-4047-95e6-02191415cfae" contextRef="C_ad149366-134a-4672-9147-ddac23ada4ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,415,481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00942f88-f84a-4796-85f1-d0c7580b4035" contextRef="C_ad149366-134a-4672-9147-ddac23ada4ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">48.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74209132-53f4-4dfa-a4dc-353791637b71" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,153,335</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63e7dff4-104a-4ecb-bcd8-7bbda5da5adf" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">42.78</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a71fc054-e5ea-4261-b0b6-0d6db5ac0073" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">138,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a7722b3-c5c8-48b3-b26f-d4ee0c067407" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">67.47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f13f9c0-509d-432e-a889-c9be7fd26f11" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,037</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3297cb8-b2e0-4381-b635-75c84683fa1d" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">48.18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_202c41ec-3446-46c1-9ad0-9414d75a213f" contextRef="C_f39072ec-f2ce-4670-be4f-b0f1f4bcf30f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,409,856</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87b68229-f1a3-433a-9309-328ba143d120" contextRef="C_f39072ec-f2ce-4670-be4f-b0f1f4bcf30f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">44.81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Time-based restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ee906b5-0d6f-4837-b500-6c0a3c1cecf3" contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">268,119</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units to certain employees of the Company that vest over </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ffa33efb-9d59-46ed-a970-c5f17d165650" contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In September 2022, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da803c78-8eb2-4ed1-8ff0-f5fe19d289e4" contextRef="C_7bd63346-2edc-4d25-8792-a77d046eb774" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vested on the one-year anniversary of the vesting start date and the remaining </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cb01310-546b-483b-af9a-dd4140ba49b1" contextRef="C_7cfbb3fe-a778-45b0-a709-a4a4a1292a25" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vest ratably in </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_28d8b448-77c1-4cdf-894c-2d65966e9692" contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f" name="sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">quarterly</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> increments over the remaining </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c048911c-c3f6-44f7-9b63-b2674d31b1e0" contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f" name="sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the three months ended March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83a7ce15-8f50-48fb-9886-415f8cb23c2c" contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,494</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of these time-based restricted stock units vested, with a fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4161a683-39a7-41b7-8e3b-dee9cb45daad" contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the date of vesting.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2022, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e9219ec-4a73-43c3-b655-c75b6da7852f" contextRef="C_34e9c797-7ce4-4b4b-b51e-18629a1f9429" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units vested.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00000868-6137-49f6-af06-84fa6a8a2bb0" contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">330,617</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units to certain employees and consultants of the Company. These time-based restricted stock units vest over </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c57e853d-4ca5-41c5-9ec7-662b9b504326" contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a6478ad-defc-4ee5-b5ef-25d7a80ebbd7" contextRef="C_fe000172-bb4d-4a08-9a7f-f806a292fa6c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vesting at the one-year anniversary of the vesting start date and the remaining </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70c10bb2-1573-446c-9934-54a4fd280d73" contextRef="C_59e5900f-8174-4b14-bfc1-b7d19f8176e3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% will vest in equal installments on each anniversary of the vesting start date for the following </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f0cb9f46-7d44-49e2-83bc-520cb1c621a1" contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2" name="sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cba5538b-3bd5-436f-9cdf-b676f22e27ac" contextRef="C_34e9c797-7ce4-4b4b-b51e-18629a1f9429" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_913f8f06-d2bf-4c39-9497-42f49cceb53c" contextRef="C_1377c2db-8563-423b-b496-c6079553d1b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">470,891</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units were both outstanding and unvested, and the total unrecognized stock-based compensation expense related to these awards was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1dacae7-e46f-48f2-9d4b-ef800c049970" contextRef="C_1377c2db-8563-423b-b496-c6079553d1b6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Performance restricted stock units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd5b7c46-8333-4b2f-8286-0bf5ebe0b74a" contextRef="C_4eb33dd9-e498-40d6-b3ab-aed72488e0a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">822,718</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c5afc0b-4c6c-4028-b13e-2ac569631ba3" contextRef="C_b41ee00a-05a1-4445-a768-1bb17e0a6c84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">415,565</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance restricted stock units, respectively, to its employees and consultants. The majority of the performance restricted stock units granted during the three months ended March 31, 2023 and 2022 vest upon the achievement of certain clinical and regulatory development milestones related to product candidates and certain commercial milestones. Certain performance restricted stock units granted in the three months ended March 31, 2023 vest upon the Company reaching specified measures of total stockholder return.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recognition of stock-based compensation expense associated with performance restricted stock units, except for those with milestones that are measures of total stockholder return, commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. Recognition of stock-based compensation associated with performance restricted stock units with milestones that are measures of total stockholder return commences on the grant date and is recorded independently of the vesting outcomes of the grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for performance restricted stock units that were outstanding, except for those with milestones that are measures of total stockhholder return, the achievement of the milestones that had not been met was considered not probable, and therefore </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e89d211-ecce-4a43-9177-60ea6dc182b1" contextRef="C_263ee25c-c855-4e19-8a9f-8283bd620ab3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7fd6a5e0-3fbf-41f0-ba1f-fb3a88638e65" contextRef="C_c31a15fe-00ba-4870-b61b-89dd2a4980ce" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expense has been recognized related to these awards during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022, respectively.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af01def5-118c-4892-bd4f-677ea27fc1e8" contextRef="C_d9a17952-5137-4cb5-9321-ceda02cb88c1" name="sage:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> milestone for outstanding performance restricted stock units was achieved. The fair value of the performance restricted stock units that vested upon achievement was $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de8b507e-9401-434f-8b16-5a0affcfe2fb" contextRef="C_d9a17952-5137-4cb5-9321-ceda02cb88c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the Company recognized stock-based compensation expense related to this milestone of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e863747-4ff0-487e-9374-c573ded2eb0e" contextRef="C_d9a17952-5137-4cb5-9321-ceda02cb88c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db4a3e08-1dad-40d6-89f5-51823e4a4e7a" contextRef="C_0e328e10-72d6-410f-80ac-3d76258027a9" name="sage:MilestonePerformanceRestrictedStockPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">27</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the performance restricted stock units that were granted during the year ended December 31, 2021 included this milestone as a vesting condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d1933b6-1509-4c26-947f-3fa8c9493716" contextRef="C_b41ee00a-05a1-4445-a768-1bb17e0a6c84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance restricted stock units vested during the three months ended March 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e5c4bb6-a515-4510-b4ad-f02681d3ac85" contextRef="C_ca2e20ac-ec64-49a3-90db-a61de00d3168" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,938,965</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance restricted stock units were both outstanding and unvested, and the total unrecognized stock-based compensation expense related to these awards was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d089893-5ee8-4878-a3be-fb1ffa76ca26" contextRef="C_ca2e20ac-ec64-49a3-90db-a61de00d3168" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">87.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Rollforward</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c251ffa-ca0c-4ca6-8c0d-a34dc1189e9b" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes activity related to time-based and performance-based stock options:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.001%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.182%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.459%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.182%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.6%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br />Remaining Life<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12b964cd-8395-4ea3-b1fb-5e9fb20f30b6" contextRef="C_9558178b-ee96-4bb9-98b8-32cd20923e46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,788,350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e6e9834-dd52-4487-8098-adb5d02d8dcd" contextRef="C_9558178b-ee96-4bb9-98b8-32cd20923e46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">77.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c658c0e6-8357-4280-8068-0b7858c7fe3a" contextRef="C_328aba2f-fb20-4a39-964e-4eee7f038c9f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.36</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b4d608a-5d7b-4cd4-99db-a6d400015582" contextRef="C_9558178b-ee96-4bb9-98b8-32cd20923e46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44186f04-452f-4bd6-8663-925d7c8c80c5" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">712,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a8a4252-394f-447e-abd0-371794cc865d" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">44.58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b8cef42-e259-41a4-bb9a-3d8cea39560f" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,908</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c82db89c-5442-4111-985a-5289b496fd37" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ec22779-b042-4896-9870-73fbcb32f61f" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">71,173</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26b4854a-4f21-421e-b6e9-b7a1fae0b6cf" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">96.42</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2660d69-9bb5-4e32-8197-e7e599a42f8a" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,383,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cfb8127-187b-462f-bd69-807d05ec8bfd" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">75.36</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4fb01675-478f-4871-9934-56eacc55a67c" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.46</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90226d77-ec64-425a-b882-5ff6031db6c4" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93532bd5-1136-4595-8b20-f9a76a167a40" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,318,637</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75b2147b-0252-45d2-b4bd-e496fdaefa1c" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">84.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dd76bb00-b28c-4d64-a3c1-9fb31a347d5c" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.19</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6711c893-6469-46d4-95fe-2ae788813595" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,365</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, the Company had unrecognized stock-based compensation expense related to its outstanding and unvested time-based stock option awards of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c35046c2-afb4-4748-bebb-43cb56395d8a" contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">68.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted average vesting period of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b74f50c3-7540-48a2-b33b-59c06969ffe9" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.07</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9c8f2bf-f321-4d25-b948-a0b51238616a" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_915f751d-b0d3-4900-ae32-264716b4db33" contextRef="C_378410ff-522b-42f9-9391-4818fc9692a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Performance-Based Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recognition of stock-based compensation expense associated with performance-based stock options commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for performance-based stock option grants that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb514f02-2d9e-46f6-9ba1-a5246494f336" contextRef="C_263ee25c-c855-4e19-8a9f-8283bd620ab3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0e247629-625f-42f9-bb73-800a02ecd361" contextRef="C_c31a15fe-00ba-4870-b61b-89dd2a4980ce" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expense has been recognized related to these awards during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e92521d-3755-4572-8d46-0dfc72f052d6" contextRef="C_fbb07196-2b75-47c6-80e5-725f729861d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dfb6d028-5b2d-4985-aba3-0dcfbf2c6184" contextRef="C_d6308113-5edd-45dc-ae2f-49266a225055" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options to purchase shares of common stock that contain performance-based vesting criteria.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b187c36b-8f90-45cb-9a16-f43795206f6e" contextRef="C_9c3096d1-dec2-4b13-9d67-bef02783497c" name="sage:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b65376fb-82b0-4ed1-a537-857668380fae" contextRef="C_c1eaf741-1b2c-4c28-bfe7-5c8db9a38dfe" name="sage:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> milestones were achieved under performance-based stock options.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afada9d5-d77b-4044-adba-73090b4863fc" contextRef="C_ef9f0eeb-8bd0-48d2-8cef-1b949dcabefb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">650,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance-based stock options were both outstanding and unvested, the total unrecognized stock-based compensation expense related to these awards was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4e61b9e-b15c-4d45-8f88-75f3708f5938" contextRef="C_ef9f0eeb-8bd0-48d2-8cef-1b949dcabefb" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the timing of recognition of this stock-based compensation expense is subject to judgment of the Company as to when the performance conditions are considered probable of being achieved.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_528ce464-a3a3-4c7e-89e3-e6f15a6e0692" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock-based compensation expense recognized during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"></td>
        <td style="width:2.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.181%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.181%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfd08d71-0ed0-432b-a7ca-03db0c58feec" contextRef="C_c9010a77-202b-457f-a93d-645d7cf2ae6f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,773</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d304534b-58c4-4807-96c4-304eb2a459a3" contextRef="C_0a812fff-cfeb-4da1-8230-6cd1569cea05" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,615</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a795a44-50f0-4e40-bc60-8da58c175804" contextRef="C_d9d6d818-4da5-4eb9-903b-f6a198d8f733" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1f30d60-a47e-4ea5-803e-0aa6b960ba85" contextRef="C_f9308d0f-6e5f-4493-9625-38e3eaaea53c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3047fd0c-5a92-4baf-b407-acacf774ee06" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,038</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00c80c60-367e-4cd0-8796-f641e6222547" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,553</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f908417c-b6df-4cad-a017-c2c33cf32a85" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock-based compensation expense by award type recognized during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"></td>
        <td style="width:2.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.181%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.181%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63087b24-a0ad-4e0b-889b-ff808ce42142" contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,015</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3b44790-e180-4b35-9db1-70dd7e4d6daf" contextRef="C_378410ff-522b-42f9-9391-4818fc9692a8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,465</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7d2c5cf-42f5-4d81-b346-c5b3262585fb" contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,553</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44f3a30c-640d-4011-87be-d1be4fdd2aaf" contextRef="C_041cce77-afef-4aed-92c7-1df0dfbc91eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddfed516-71e8-45ac-9dc7-5a4fb3a66a04" contextRef="C_fbed26d2-cc37-4226-abd6-049e70ee76cc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3">470</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb1879fb-a0af-4a97-b4f8-c071daca0905" contextRef="C_053c255f-d2dc-471e-bb1d-70b5c18befc9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3">285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06e06f79-dc1c-496b-b80f-49dbdcaa9146" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,038</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_484a4fb3-1b76-49f0-b26b-a4be520f9c2e" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,553</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For stock option awards, the fair value is estimated at the grant date using the Black-Scholes option-pricing model, taking into account the terms and conditions upon which stock options are granted. The fair value of the stock options is amortized on a straight-line basis for stock option awards to employees, non-employee directors and non-employee consultants over the requisite service period of the awards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value per share of stock options granted under the Company&#x2019;s stock option plans during the three months ended March 31, 2023 and 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93c96d9a-0ced-4e2b-9d3a-b73b4a58c6a1" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">29.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24e5ac5d-4c95-425f-ae5c-74268e5086be" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.93</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c5df69d-9666-4969-bf47-546df06a7a0d" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:7.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_688602ce-4c27-462a-96ca-7cf01440b2ef" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the calculation of basic and diluted net loss per share for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"></td>
        <td style="width:2.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.181%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.181%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3c798e2-8538-4c4b-b3c2-534537a92f8a" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,828</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_307c0497-773e-4163-88f4-486606380874" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,055</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common stock outstanding<br />&#160;&#160;&#160;&#x2014;basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfb5b046-a7c0-4cce-b85a-7a9fd4bd8c23" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,674,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fdf3dc9-87a8-4a7c-ad96-ded0d4b43d77" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,028,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of shares of common stock<br />&#160;&#160;&#160;equivalents resulting from common stock<br />&#160;&#160;&#160;options and restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce8fa454-5305-4d72-b135-4601981ae103" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c37fdbc0-f4f8-471b-923f-9b81ed13aae3" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common stock outstanding<br />&#160;&#160;&#160;&#x2014;diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_380a4928-9e5f-4f36-b5b6-ed0d485c019c" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,674,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90b34047-bcff-4f79-b370-2c9704907fa1" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">59,028,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#x2014;basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad213076-113f-4700-aa8e-0477210b6ad6" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_d47a81cd-a3b6-418b-826d-571ca8d2e838" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.46</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d212cdc-2bc5-4793-8e0f-7cff7340e090" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_6c0f64dc-8d59-4c1f-8750-32a0bb4ed6af" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.07</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c0d6591-0ced-4eec-a528-4d0f4682809f" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes common stock equivalents outstanding that were excluded from the calculation of diluted net loss per share because including them would have been anti-dilutive as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.24%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.7%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.7%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3b1ecab-257a-4bbd-af5d-9be1ca00834b" contextRef="C_96f30eb5-acb2-4f40-a8d3-bcc1575d5f47" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,733,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9bc0848-c7c8-48d7-af37-e3618bea41e1" contextRef="C_4abf962a-8014-45c8-8864-72250359e195" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,932,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b6f891f-a6d4-49b7-9de9-3243531847c8" contextRef="C_a2ae6c1e-1913-47c9-8778-3d00309c407f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">470,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b99f40fd-c1f7-488f-88ef-2afef7a7b99e" contextRef="C_a954ef97-2d5d-474e-85f1-993cfd4ef26c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">541,913</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c6c3785-99a9-4613-bbe0-3e959857de27" contextRef="C_414c6759-f1c6-41b9-b865-55fecfa38284" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">46,846</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f10409d2-8764-4eaf-a785-0627626ff126" contextRef="C_b7010b40-0dcd-4f49-8b91-0d384171fed0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36e487ce-c857-41b0-9457-0ecdd33854ad" contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,251,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3246cbd-0a16-4a8e-a42d-ef76e8904328" contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,500,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options and restricted stock units that are outstanding and contain performance-based vesting criteria for which the performance conditions have not been met are excluded from the calculation of common stock equivalents outstanding.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f Financial Condition and Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q, or Quarterly Report, and the audited financial statements and related notes contained in our Annual Report on Form 10-K, for the year ended December 31, 2022, or Annual Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. We caution you that forward-looking statements are not guarantees of future performance, and that our actual results of operations, financial condition and liquidity, and the developments in our business and the industry in which we operate, may differ materially from the results discussed or projected in the forward-looking statements contained in this Quarterly Report. We discuss risks and other factors that we believe could cause or contribute to these potential differences elsewhere in this Quarterly Report, including under Part II, Item 1A, &#x201c;Risk Factors&#x201d; and under &#x201c;Cautionary Note Regarding Forward-Looking Statements&#x201d; in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the developments in our business and the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods. We caution readers not to place undue reliance on any forward-looking statements made by us, as such statements speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, or SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a biopharmaceutical company with a mission to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. We are currently targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry. Our focus as a company is on brain health, and we are currently targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the status of our product and product candidate portfolio as of the filing date of this Quarterly Report.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img93198881_0.jpg" alt="img93198881_0.jpg" style="width:720px;height:333px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our first product, ZULRESSO&#174; (brexanolone) CIV injection, is approved in the U.S. for the treatment of postpartum depression, or PPD, in adults. We launched ZULRESSO commercially in the U.S. for the treatment of PPD in June 2019. ZULRESSO may only be administered in qualified, medically-supervised healthcare settings. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also are developing a portfolio of other novel compounds that target GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors including our most advanced product candidate, zuranolone (SAGE-217). Zuranolone is a novel oral compound for the treatment of major depressive disorder, or MDD, and PPD. In December 2022, we, and our collaboration partner, Biogen (as defined below), completed submission of a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, seeking approval of zuranolone for the treatment of both MDD and PPD. The NDA was accepted for filing and granted priority review by the FDA in February 2023, with a Prescription Drug User Fee Act, as amended, or PDUFA, target action date of August 5, 2023. In March 2023, the FDA notified Sage and Biogen that the agency does not currently plan to convene an advisory committee meeting to discuss the NDA for zuranolone for the treatment of MDD and PPD. The FDA granted Fast Track designation to zuranolone for the treatment of PPD in early 2022 and previously granted zuranolone Breakthrough Therapy designation and Fast Track designation to zuranolone for the treatment of MDD. Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors, targeting both synaptic and extrasynaptic GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors. We may in the future develop zuranolone for other affective disorders.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have completed six pivotal clinical trials of zuranolone, four in MDD and two in PPD. The completed pivotal trials evaluating zuranolone for the treatment of PPD and three of the four completed pivotal trials evaluating zuranolone for the treatment of MDD met their primary endpoints. We are currently conducting an open-label Phase 3 clinical trial of zuranolone for the treatment of MDD, known as the SHORELINE Study, which is designed to evaluate the safety, tolerability, and need for repeat dosing of zuranolone in adults for up to one year. Enrollment in a 50 mg cohort of the SHORELINE Study has been completed and the study is ongoing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are jointly developing zuranolone and another of our late-stage compounds, SAGE-324, in the U.S. with Biogen MA Inc., or BIMA, and Biogen International GmbH, or, together with BIMA, Biogen, under a collaboration and license agreement, or the Biogen Collaboration Agreement, that became effective in December 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Biogen Collaboration Agreement, we will also jointly commercialize products containing zuranolone, which we refer to as Licensed 217 Products, and products containing SAGE-324, which we refer to as Licensed 324</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products, with Biogen in the U.S. if our development efforts are successful. We refer to the Licensed 217 Products and Licensed 324 Products collectively as the Licensed Products. In addition, we have granted Biogen sole rights to develop and commercialize the Licensed Products outside the U.S., other than in Japan, Taiwan and South Korea, or the Shionogi Territory, with respect to zuranolone, where we have granted such rights to Shionogi &amp; Co., Ltd., or Shionogi. We refer to the territories outside the U.S. to which Biogen has rights under the Biogen Collaboration Agreement with respect to the applicable Licensed Product as the Biogen Territory. For so long as a Licensed Product is being sold in the U.S., we and Biogen will equally share in all operating profits and losses arising from such Licensed Product. The Biogen Collaboration Agreement provides that Biogen will record sales of Licensed 217 Products globally, if approved. We will record sales of Licensed 324 Products in the U.S., and Biogen will record sales of Licensed 324 Products outside of the U.S., in each case if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have a collaboration agreement with Shionogi for the development of zuranolone in the Shionogi Territory. In September 2021, Shionogi reported completion of a Phase 2 clinical trial of zuranolone for the treatment of patients with moderate to severe MDD in Japan, which Shionogi reported achieved its primary endpoints. Shionogi has also reported that it is conducting two Phase 3 trials of zuranolone for the treatment of patients with moderate to severe MDD as a monotherapy and as an add-on to other antidepressants, and announced that, pending results from these trials, it is aiming to submit an NDA to the Pharmaceuticals and Medical Devices Agency in Japan in the first quarter of 2024 seeking approval of zuranolone for the treatment of MDD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE-324 is a novel GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptor positive allosteric modulator intended for chronic oral dosing. We are currently enrolling patients with essential tremor in a Phase 2b dose-ranging clinical trial of SAGE-324, known as the KINETIC 2 Study. In May 2022, we also initiated an open-label Phase 2 clinical trial designed to evaluate the long-term safety and tolerability of SAGE-324 in patients with essential tremor, with incidence of treatment-emergent adverse events as the primary endpoint. This is intended to be a multi-year clinical trial, and will initially be open to rollover patients from other SAGE-324 clinical trials in patients with essential tremor, including the KINETIC 2 Study. We believe SAGE-324 also has potential for the treatment of a number of other neurological conditions, including epilepsy and Parkinson&#x2019;s disease. Additional development plans for SAGE-324 will be determined as part of our strategic collaboration with Biogen.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our second area of focus for development is novel compounds that target the NMDA receptor. Our lead product candidate selected in this area is SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which we are exploring in certain cognition-related disorders associated with NMDA receptor dysfunction, including cognition dysfunction associated with diseases such as Huntington&#x2019;s disease, Parkinson&#x2019;s disease and Alzheimer&#x2019;s disease.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has granted SAGE-718 Fast Track designation as a potential treatment for patients with Huntington&#x2019;s disease. In addition, in February 2023, the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington&#x2019;s disease. SAGE-718 is currently being studied in three ongoing clinical trials in patients with Huntington&#x2019;s disease cognitive impairment:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DIMENSION Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, dosing commenced in the DIMENSION Study, a double-blind placebo-controlled Phase 2 clinical trial of SAGE-718 in patients with Huntington&#x2019;s disease cognitive impairment. The DIMENSION Study is designed to evaluate the efficacy of once-daily dosed SAGE-718 over three months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SURVEYOR Study</span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we initiated the SURVEYOR Study, a placebo-controlled Phase 2 clinical trial of SAGE-718 in patients with Huntington&#x2019;s disease cognitive impairment, with a healthy volunteer component, with the goal of generating evidence linking efficacy signals on cognitive performance to domains of real-world functioning.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURVIEW Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we initiated the PURVIEW Study, a Phase 3 open-label study to evaluate the long-term safety and tolerability of SAGE-718 in patients with Huntington&#x2019;s disease cognitive impairment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also evaluating SAGE-718 for the treatment of cognitive issues associated with Parkinson&#x2019;s disease and Alzheimer&#x2019;s disease. In March 2022, we initiated a double-blind, placebo-controlled Phase 2 clinical trial of SAGE-718 in patients with mild cognitive impairment due to Parkinson&#x2019;s disease, known as the PRECEDENT Study. The PRECEDENT Study is designed to evaluate the safety and efficacy of SAGE-718 in patients with mild cognitive impairment due to Parkinson&#x2019;s disease over 42 days, followed by a controlled follow-up period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we initiated the LIGHTWAVE Study, a randomized placebo-controlled Phase 2 clinical trial of SAGE-718 in patients with mild cognitive impairment and mild dementia due to Alzheimer&#x2019;s disease. The LIGHTWAVE Study is designed to evaluate the safety and efficacy of SAGE-718 dosed over an 84-day period, followed by a controlled follow-up period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have other programs at earlier stages of development with a focus on both acute and chronic brain health disorders. Our earlier stage product candidates include SAGE-689, a balanced GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receptor positive allosteric modulator in Phase 1 clinical development intended for intramuscular administration, and SAGE-319, an extrasynaptic GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receptor-preferring positive allosteric modulator in Phase 1 clinical development for its potential use as an oral therapy in treating disorders of social interaction. We also have earlier stage compounds focused on NMDA receptor modulation, including SAGE-421, an NMDA receptor positive allosteric modulator that we plan to study for potential use in neurodevelopmental disorders and cognitive recovery and rehabilitation. We expect to continue our work on allosteric modulation of the GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and NMDA receptor systems in the brain. The GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and NMDA receptor systems are broadly accepted as impacting many psychiatric and neurological disorders, spanning disorders of mood, seizure, cognition, anxiety, sleep, pain, and movement, among others. We believe that we may have the opportunity to develop molecules from our internal portfolio with the goal of addressing a number of these disorders in the future. We also believe that we may have the opportunity to use our scientific approach to explore targets beyond the GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and NMDA receptor systems and to develop compounds in areas of unmet need outside of brain health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We began to generate revenue from product sales in the second quarter of 2019 in conjunction with the launch of our first product, ZULRESSO, in June 2019. In the fourth quarter of 2020, we recorded revenue from the strategic collaboration with and stock purchase by Biogen.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses in each year since our inception, except for net income of $606.1 million for the year ended December 31, 2020, reflecting revenue recognized under the Biogen Collaboration Agreement, and we had an accumulated deficit of $2.2 billion as of March 31, 2023. Our net loss was $146.8 million for the three months ended March 31, 2023. These losses have resulted principally from costs incurred in connection with research and development activities and selling, general and administrative costs associated with our operations and our commercial build. We expect to incur significant expenses and increasing operating losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our expenses will increase in the foreseeable future in connection with our ongoing activities, including if and as we:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue our development efforts for zuranolone, including work to complete the open-label SHORELINE Study of zuranolone in MDD; advance our permitted pre-launch and launch-readiness activities with respect to zuranolone, and commercialize zuranolone for the treatment of MDD and PPD, if approved; and potentially advance the development of zuranolone in additional indications as part of our strategic collaboration with Biogen;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue our commercialization efforts with respect to ZULRESSO for the treatment of PPD in the U.S., with a primary focus on geographies that have existing, active ZULRESSO treating sites;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complete the ongoing and planned clinical trials of SAGE-324 as part of our strategic collaboration with Biogen;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complete ongoing and planned clinical trials of SAGE-718; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">support our collaboration with Biogen with respect to zuranolone and SAGE-324 in the U.S., and support Biogen&#x2019;s development of zuranolone and SAGE-324 in Biogen&#x2019;s licensed territories outside the U.S. and Shionogi&#x2019;s development of zuranolone in the Shionogi Territory;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance our earlier-stage compounds;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue our research and development efforts to evaluate the potential for our existing product candidates for the treatment of additional indications or in new formulations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identify new targets, and generate and test new compounds and product candidates, with a focus on indications where we believe we can make well-informed, rapid go/no-go decisions, with the goal of developing a diversified portfolio of assets with differentiated features;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prepare and file NDAs with the FDA and conduct permitted pre-launch activities with respect to any of our other product candidates that we believe have been successfully developed;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialize any product candidates for which we obtain regulatory approval, including the manufacture of commercial supplies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to add personnel at the appropriate time, as our efforts and activities progress, including personnel to support ongoing zuranolone commercialization efforts, such as launch planning, permitted payor engagements, scientific exchange, disease awareness education, and ongoing product development, and to support launch of zuranolone for the treatment of MDD and PPD, if approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">evaluate the market potential and regulatory pathways for our product candidates beyond zuranolone and SAGE-324 in the European Union and other jurisdictions outside the U.S., and determine how best to move forward where and when it may make business and strategic sense;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to build, maintain, defend, leverage, and expand our intellectual property portfolio, including by utilizing the strengths of our proprietary chemistry platform and scientific know-how to expand our portfolio of new chemical entities to lessen our long-term reliance on the success of any one program and to facilitate long-term growth; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to explore opportunities to establish licenses, collaborations or other agreements or alliances with other biotechnology and pharmaceutical companies, at the appropriate time, where we believe a collaboration will add significant value to our efforts, including through capabilities, infrastructure, speed or financial contributions, or to acquire new compounds, product candidates or products if we believe such opportunities will help us achieve our goals or meet other strategic objectives.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time that we can generate significant revenue on a sustained basis from product sales and/or from collaborations, if ever, we expect to finance our operations primarily through a combination of revenue, equity or debt financings and other sources, including our collaborations with Biogen and Shionogi and potential future collaborations. We may not be successful in our commercialization of ZULRESSO, zuranolone, if approved, or any other product, and may not generate meaningful revenue or revenue at the levels or on the timing necessary to support our investment and goals. We may never successfully complete development of any of our current or future product candidates, successfully file for or obtain necessary regulatory approval for such product candidates, or achieve commercial viability for any resulting approved product. We may not obtain or maintain adequate patent protection or other exclusivity for our products or product candidates. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital if and when needed would have a negative impact on our financial condition and on our ability to pursue our business strategy. Arrangements with our existing collaborators have required us to relinquish rights to certain of our technologies or product candidates, and any future collaborations may require us to relinquish additional rights. We will need to generate significant revenue to achieve profitability, and we may never do so.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our existing cash, cash equivalents and marketable securities as of March 31, 2023, in addition to anticipated funding from our ongoing collaborations, excluding revenues and milestones, will enable us to fund our operating expenses and capital expenditure requirements through 2024. See &#x201c;&#x2014;Liquidity and Capital Resources&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We began to generate revenue from product sales in the second quarter of 2019 in conjunction with the launch of our first product, ZULRESSO as a treatment for PPD, in June 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZULRESSO is administered as a continuous infusion given over two and a half days. Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness during the ZULRESSO infusion, ZULRESSO must be administered only in a medically-supervised healthcare setting that has been certified under a Risk Evaluation and Mitigation Strategies, or REMS, program and meets the other requirements of the REMS program, including requirements related to monitoring of the patient during the infusion. The actions required for a healthcare setting to be ready and willing to treat women with PPD are complex and time-consuming. These actions include: becoming REMS-certified; achieving formulary approvals; establishing protocols for administering ZULRESSO; and securing satisfactory reimbursement. Sites must often negotiate reimbursement on a payor-by-payor basis under commercial coverage. These requirements are expected to continue to limit future ZULRESSO revenue growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These barriers were compounded by the COVID-19 pandemic and continue to be impacted by its related disruptive effects on the U.S. healthcare system, and other changes to the macroeconomic environment. The spread of COVID-19 in the U.S. resulted in a significant number of sites of care pausing, limiting or delaying treatment of new patients with ZULRESSO and potential new sites of care pausing site activation activities for a period of time. We believe that, at certain points during the pandemic, concerns about exposure to the virus or its variants caused a significant and sustained reduction in the number of women with PPD seeking treatment with ZULRESSO and in the number of physicians willing to prescribe it, and that difficulties in accessing treatment with ZULRESSO have since been compounded by healthcare staffing shortages and other changes to the macroeconomic environment. Given the ongoing disruption to the healthcare system in the U.S., including as a result of staffing shortages, we cannot predict for how long and to what extent ZULRESSO sales will be adversely impacted by these factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ZULRESSO commercial operations, including our account management field-based team and sales representatives, are primarily focused on geographies that have existing, active ZULRESSO treating sites. We expect that this approach to our commercial efforts will continue to substantially limit the revenue opportunity for ZULRESSO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that ZULRESSO revenues are likely to fluctuate quarter to quarter. We will not generate revenue from other products unless and until we or any of our collaborators successfully develop, obtain regulatory approval of, and commercialize one of our current or future product candidates. If we enter into additional collaboration agreements with third parties for our product candidates, we may generate revenue from those collaborations. We expect that revenue, if any, that we may generate under our existing or future collaboration agreements will fluctuate from quarter to quarter as a result of the timing and amount of license fees, payments for clinical materials or manufacturing services, milestone payments, royalties paid to us and our share of collaboration profits or losses resulting from sales of any commercialized products, and other payments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, we entered into a strategic collaboration with Shionogi for the clinical development and commercialization of zuranolone for the treatment of MDD and other potential indications in the Shionogi Territory. Under the terms of the agreement, Shionogi is responsible for all clinical development, regulatory filings and commercialization and manufacturing of zuranolone for MDD, and potentially other indications, in the Shionogi Territory. In October 2018, we also entered into a supply agreement with Shionogi under which we supply Shionogi with zuranolone clinical material. To date, revenue from our collaboration with Shionogi has come from an initial, upfront license fee upon execution of the collaboration agreement of $90.0 million, which was recorded as collaboration revenue in the year ended December 31, 2018, and for the supply of active pharmaceutical agreement, or API, for Shionogi&#x2019;s clinical trials.</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we entered into the Biogen Collaboration Agreement with Biogen for the development, manufacture and commercialization of the Licensed Products. In connection with the execution of the Biogen Collaboration Agreement, we also entered into a stock purchase agreement for the sale and issuance to BIMA of 6,241,473 shares of our common stock for aggregate consideration of $650.0 million. The Biogen Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement became effective in December 2020, and the sale of the common stock under the stock purchase agreement closed on December 31, 2020. As a result of the purchase of common stock by BIMA, Biogen has become a related party of ours. Under the terms of the Biogen Collaboration Agreement, we will jointly develop and, if successful, jointly commercialize the Licensed Products in the U.S., and Biogen solely will develop and commercialize the Licensed Products in the Biogen Territory. We and Biogen have agreed to share equally all costs for activities, as well as the profits and losses, upon FDA approval of the Licensed Products, under the Biogen Collaboration Agreement solely for the U.S. Biogen is solely responsible for all costs for activities under the Biogen Collaboration Agreement in the Biogen Territory. Biogen will be the principal and record sales of SAGE-217 products globally. We will be the principal and record sales of SAGE-324 products in the U.S. and Biogen will be the principal and record sales of SAGE-324 Products in the Biogen Territory. In the year ended December 31, 2020, we recorded collaboration revenue &#x2013; related party of $1.1 billion, consisting of an upfront payment of $875.0 million plus $232.5 million in excess proceeds from the equity investment under the stock purchase agreement, when measured at fair value. For further discussion regarding the accounting for the Biogen Collaboration Agreement, refer to Note 6, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the accompanying Notes to Condensed Consolidated Financial Statements appearing in Part I, Item 1 of this Quarterly Report.</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborative Arrangements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification, or ASC, Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or Topic 808. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, we apply the five-step revenue recognition model and present the arrangement as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration arrangements that are within the scope of Topic 808, we evaluate the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship, instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as research and development expense or selling, general and administrative expense in the event of a payment to the collaborative partner in a period, or a reduction to these expense line items in the event of a reimbursement from the collaboration partner in a period, as appropriate. For further discussion regarding the accounting for collaborative arrangements, refer to Note 6, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the accompanying Notes to Condensed Consolidated Financial Statements appearing in Part I, Item 1 of this Quarterly Report.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that revenue, if any, that we may generate under our collaboration agreements will fluctuate from quarter to quarter as a result of the timing and amount of license fees, payments for clinical materials or manufacturing services, milestone payments, royalties paid to us and our share of collaboration profits or losses resulting from sales of any commercialized products, and other payments. We have the potential to receive milestone payments totaling $225.0 million related to the first commercial sale of zuranolone for the treatment of MDD and PPD in the U.S., if zuranolone is approved for marketing. For further discussion regarding our collaboration agreements with Shionogi and Biogen and the accounting for revenue from collaboration agreements, refer to Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Note 6, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the accompanying Notes to Condensed Consolidated Financial Statements appearing in Part I, Item 1 of this Quarterly Report.</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of Goods Sold</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of goods sold includes direct and indirect costs related to the manufacturing and distribution of ZULRESSO, including third-party manufacturing costs, packaging services, freight, third-party royalties payable on our net product revenue and amortization of intangible assets associated with ZULRESSO. Cost of goods sold may also include period costs related to certain inventory manufacturing services, inventory adjustment charges, as well as manufacturing variances. We estimate that our cost of goods sold as a percentage of net product revenue will remain in the high-single digit to low-double digits percentage range for the foreseeable future. We expect to utilize zero-cost inventory with respect to ZULRESSO for an extended period of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating expenses consist primarily of costs associated with research and development activities and selling, general and administrative activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses, which consist primarily of costs associated with our product research and development efforts, are expensed as incurred. Research and development expenses consist primarily of:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">personnel costs, including salaries, benefits, stock-based compensation and travel expenses, for employees engaged in research and development functions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with contract research organizations, or CROs, and sites that conduct our non-clinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses associated with manufacturing materials for use in non-clinical studies and clinical trials and developing external manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs of outside consultants engaged in research and development activities, including their fees and travel expenses;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other expenses related to our non-clinical studies and clinical trials and expenses related to our regulatory activities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments made under our third-party license agreements; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a portion of our information technology, facilities and other related expenses, including rent, depreciation, maintenance of facilities, insurance and supplies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider the collaborative activities associated with the co-development, co-commercialization, and co-manufacturing of SAGE-217 products and SAGE-324 products in the U.S. to be separate units of account within the scope of Topic 808 as we and Biogen are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on the development and commercial success of the activities in the arrangement. Payments to or reimbursements from Biogen related to the co-development and co-manufacturing activities are accounted for as an increase to or reduction of research and development expense. During the three months ended March 31, 2023 and 2022, we recorded net reimbursement of $17.3 million and $18.5 million, respectively, from Biogen that was deducted from our research and development expenses because we incurred a greater amount of these expenses than Biogen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have been developing our product candidates and focusing on other research and development programs, including exploratory efforts to identify new compounds, target validation for identified compounds and lead optimization for our earlier-validated programs. Our direct research and development expenses are tracked on a program-by-program basis, and consist primarily of external costs, such as fees paid to investigators, central laboratories, CROs and contract manufacturing organizations, in connection with our non-clinical studies and clinical trials; third-party license fees related to our product candidates; and fees paid to outside consultants who perform work on our programs. We do not allocate employee-related costs and other indirect costs to specific research and development programs because these costs are deployed across multiple product programs under research and development and, as such, are separately classified as unallocated or stock-based compensation in research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development activities are central to our business. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase in the foreseeable future as we continue or initiate clinical trials and non-clinical studies for certain product candidates and pursue later stages of clinical development of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot determine with certainty the duration and costs of the current or future clinical trials of our product candidates. The duration, costs, and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, size, rate of progress, and expense of our ongoing as well as any additional clinical trials, non-clinical studies, and other research and development activities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future results of ongoing, planned or future clinical trials and non-clinical studies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decisions by regulatory authorities related to our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">uncertainties in clinical trial enrollment rate or design;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant and changing government regulation; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the receipt and timing of regulatory approvals, if any.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the COVID-19 pandemic and its downstream effects, such as healthcare and vendor staffing shortages and disruption to the U.S. healthcare system, and/or the impact of other macroeconomic and geopolitical conditions, may also negatively impact our ongoing and planned development activities and increase our research and development costs. Concerns, precautions and restrictions, staffing shortages, or other changes to the macroeconomic environment, or from continuing concerns about the COVID-19 pandemic, may substantially slow clinical site identification and activation and enrollment in our clinical trials, may impair or delay the conduct, auditing, monitoring, or completion of our trials, may impair or impede the timeliness and completion of our data collection and analysis efforts or the integrity of our data, or may cause us to pause trials, in each case which may significantly impact our ability to meet our expected timelines or cause us to change our plans and may significantly increase our research and development costs. For example, we have experienced slower than anticipated recruitment in certain clinical trials, including our ongoing KINETIC 2 Study of SAGE-324 in patients with essential tremor, for which we now expect to complete enrollment in late 2023, rather than in late 2022 as we had initially projected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate or for regulatory approval, or if we experience significant delays in enrollment in any of our clinical trials or need to enroll additional patients, we could be required to expend significant additional financial resources and time on the completion of clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure to complete any stage of the development of any potential product candidates in a timely manner could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with not completing our programs on schedule, or at all, and the potential consequences of failing to do so, are set forth in Part II, Item 1A of this Quarterly Report under the heading &#x201c;Risk Factors&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses consist primarily of personnel costs, including salaries, benefits and travel expenses for our executive, finance, business, commercial, corporate development and other administrative functions, and stock-based compensation expense. Selling, general and administrative expenses also include professional fees for expenses incurred under agreements with third parties relating to the commercialization of ZULRESSO; permitted pre-launch and launch-readiness activities related to zuranolone; public relations, audit, tax and legal services, including legal expenses to pursue patent protection of our intellectual property; and a portion of our information technology, facilities and other related expenses, including rent, depreciation, maintenance of facilities, insurance and supplies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing commercial efforts with respect to ZULRESSO, including our account management field-based team and sales representatives, are primarily focused on geographies that have existing, active ZULRESSO treating sites. We expect to continue to incur significant commercialization expenses, including payroll and related expenses, to support our ongoing commercial activities associated with ZULRESSO. We expect that selling, general and administrative expenses will increase significantly in the future as we prepare for potential commercialization of zuranolone, engage in permitted pre-approval activities, recruit, train and retain a direct sales force and commercialize zuranolone, if approved, and as we progress development efforts of our other current or future product candidates and commercialize those products, if successfully developed and approved. We expect to continue to incur significant expenses associated with general operations, including costs related to accounting and legal services, director and officer insurance premiums, facilities and other corporate infrastructure and office-related costs, such as information technology costs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider the collaborative activities associated with the co-development, co-commercialization, and co-manufacturing of SAGE-217 products and SAGE-324 products in the U.S. to be separate units of account within the scope of Topic 808 as we and Biogen are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on the development and commercial success of the activities in the arrangement. Payments to or reimbursements from Biogen related to the co-commercialization activities are accounted for as an increase to or reduction of selling, general and administrative expense. During the three months ended March 31, 2023, we recorded net reimbursement from us to Biogen of $3.0 million that was added to our selling, general and administrative expenses. During the three months ended March 31, 2022, we recorded net reimbursement from Biogen to us of $1.5 million that was deducted from our selling, general and administrative expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Three Months Ended March 31, 2023 and 2022</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022:</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.034%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.638%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.738%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.738%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product revenue, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,294</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,582</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,712</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating costs and expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of goods sold</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">230</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">286</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(56</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,826</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,018</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,808</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,708</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,477</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating costs and expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,764</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124,781</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,983</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(155,470</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(123,199</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(32,271</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,830</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,168</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,662</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(188</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(164</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(146,828</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(122,055</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24,773</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Revenue, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022, we recognized $3.3 million and $1.6 million, respectively, of net product revenue related to sales of ZULRESSO. Sales allowances and accruals consisted of chargebacks, discounts, distribution fees, rebates and patient financial assistance, and were not significant during either period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cost of Goods Sold</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022, cost of goods sold was $0.2 million and $0.3 million, respectively, and is made up of direct and indirect costs related to the manufacturing and distribution of ZULRESSO, including third-party manufacturing costs, packaging services, freight, third-party royalties payable on our net product revenue and amortization of intangible assets associated with ZULRESSO. Cost of goods sold may also include period costs related to certain inventory manufacturing services, inventory adjustment charges, as well as manufacturing variances. Prior to receiving initial FDA approval for ZULRESSO in March 2019, we manufactured ZULRESSO inventory to be sold upon commercialization and recorded $8.9 million related to this inventory build-up as research and development expense. As a result, the manufacturing costs related to the ZULRESSO inventory build-up incurred before FDA approval were already expensed in a prior period and are therefore excluded from the cost of goods sold for the three months ended March 31, 2023 and 2022. We estimate that our cost of goods sold as a percentage of net product revenue will remain in the high-single digit to low-double digits percentage range for the foreseeable future. We expect to utilize zero-cost inventory with respect to ZULRESSO for an extended period of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses for the three months ended March 31, 2023 and 2022:</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.972%;"></td>
    <td style="width:1.316%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.946%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.316%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.067%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.316%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.067%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zuranolone (SAGE-217)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,139</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,282</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">857</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE-324</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,256</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,035</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,779</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE-718</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,064</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,421</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,643</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other research and development programs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,906</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,655</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(749</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unallocated expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,970</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,524</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,446</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,773</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,615</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net reimbursement from Biogen</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(17,282</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(18,514</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,232</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,826</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,018</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,808</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the three months ended March 31, 2023 were $92.8 million, compared to $78.0 million for the three months ended March 31, 2022. The increase of $14.8 million was primarily due to the following:</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase of $0.9 million in expenses for development of zuranolone, primarily due an increase in manufacturing-related costs in anticipation of potential commercialization of zuranolone, if approved, and partially offset by decreases due to the completion of studies after the three months ended March 31, 2022;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a decrease of $3.8 million in expenses for development of SAGE-324, primarily due to the completion of clinical pharmacology studies after the three months ended March 31, 2022;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase of $3.6 million in expenses for development of SAGE-718, primarily due to activities directed towards the conduct of Phase 2 clinical trials which were initiated during 2021 and 2022;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase of $13.4 million in unallocated expenses, primarily due to an increase in the hiring of employees and corporate infrastructure costs, such as information technology costs, to support the growth in our research and development operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase of $0.2 million in non-cash stock-based compensation expense, primarily due to the recognition of $4.2 million of expense related to performance-based vesting criteria during the three months ended March 31, 2023. No expense was recognized related to the achievement of performance-based vesting criteria during the three months ended March 31, 2022. The increase in expenses was partially offset by decreases due to grants of stock options with high exercise prices that became fully vested before or during the three months ended March 31, 2023, resulting in less expense than in the three months ended March 31, 2022; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the net reimbursement from Biogen pursuant to the Biogen Collaboration Agreement decreased by $1.2 million. For the three months ended March 31, 2023, the amount of net reimbursement was $11.4 million for zuranolone, $3.1 million for SAGE-324 and $2.7 million for costs that are reimbursable and included in unallocated expenses. For the three months ended March 31, 2022, the amount of net reimbursement was $10.9 million for zuranolone, $5.0 million for SAGE-324 and $2.6 million for costs that are reimbursable and included in unallocated expenses. The primary reason for the decrease in net reimbursement was the decrease in spending for SAGE-324, primarily due to the completion of clinical pharmacology studies after the three months ended March 31, 2022.</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selling, General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our selling, general and administrative expenses for the three months ended March 31, 2023 and 2022:</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.419%;"></td>
    <td style="width:1.297%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.815%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.297%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.957%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.297%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.917%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,887</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,267</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,620</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,265</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,938</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,327</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,561</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,509</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,052</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,961</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,237</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,724</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net reimbursement to (from) Biogen</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,034</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,474</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,508</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,708</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,477</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,231</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses for the three months ended March 31, 2023 were $65.7 million, compared to $46.5 million for the three months ended March 31, 2022. The increase of $19.2 million was primarily due to the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase of $10.6 million in personnel-related costs, primarily due to hiring employees to support ongoing permitted pre-launch and launch-readiness activities with respect to zuranolone and in anticipation of a potential commercialization of zuranolone, if approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase of $1.3 million in non-cash stock-based compensation expense, primarily due to the recognition of $4.3 million of expense related to performance-based vesting criteria during the three months ended March 31, 2023. No expense was recognized related to the achievement of performance-based vesting criteria during the three months ended March 31, 2022. The increase in expenses was partially offset by decreases due to grants of stock options with high exercise prices that became fully vested before or during the three months ended March 31, 2023, resulting in less expense than in the three months ended March 31, 2022; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the net reimbursement from Biogen pursuant to the Biogen Collaboration Agreement decreased by $4.5 million. For the three months ended March 31, 2023, the amount of net reimbursement from us to Biogen was $0.1 million for personnel-related costs and $2.9 million for external costs. For the three months ended March 31, 2022, the amount of net reimbursement from Biogen to us was $1.5 million for external costs. The primary reason for the decrease in net reimbursement was an increase in the collaboration costs incurred by Biogen in anticipation of a potential commercialization of zuranolone, if approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income, Net and Other Income, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net, and other income, net, for the three months ended March 31, 2023 and 2022 were $8.6 million and $1.1 million, respectively. The primary reason for the increase was the increase in interest rates from the three months ended March 31, 2022 to the three months ended March 31, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We began to generate revenue from product sales in the second quarter of 2019 in conjunction with the launch of our first product, ZULRESSO, in June 2019. We have incurred net losses in each year since our inception, except for net income of $606.1 million for the year ended December 31, 2020, reflecting revenue recognized under the Biogen Collaboration Agreement. As of March 31, 2023, we had an accumulated deficit of $2.2 billion. On December 31, 2020, we completed the sale of 6,241,473 shares of our common stock in a private placement to BIMA at a price of approximately $104.14 per share, resulting in aggregate gross proceeds of $650.0 million. From our inception through March 31, 2023, we have received aggregate net proceeds of $2.8 billion from the sales of redeemable convertible preferred stock prior to our initial public offering, the issuance of convertible notes, and the sales of common stock in our initial public offering in July 2014, follow-on offerings and in the sale of shares of our common stock to Biogen in connection with the Biogen Collaboration Agreement, which we refer to as the Biogen Equity Purchase. We also received $1.0 billion in upfront payments under our collaborations with Biogen and Shionogi.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, our primary sources of liquidity were our cash, cash equivalents and marketable securities, which totaled $1.1 billion. We invest our cash in money market funds, U.S. government securities, corporate bonds, commercial paper, certificates of deposit and municipal securities, and our primary objectives are to preserve principal, provide liquidity and maximize income without significantly increasing risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the primary sources and uses of cash for the three months ended March 31, 2023 and 2022:</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.482%;"></td>
    <td style="width:2.365%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.024%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.124%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(153,682</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(107,800</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194,867</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,558</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,672</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,799</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,857</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(115,559</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, net cash used in operating activities primarily resulted from our net loss of $146.8 million, which was primarily attributable to our research and development activities and our selling, general and administrative expenses, along with changes in our operating assets and liabilities of $24.0 million, partially offset by $17.2 million of non-cash items.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2022, net cash used in operating activities primarily resulted from our net loss of $122.1 million, which was primarily attributable to our research and development activities and our selling, general and administrative expenses, along with changes in our operating assets and liabilities of $6.9 million, partially offset by $21.2 million of non-cash items.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022, net cash provided by investing activities was $194.9 million and net cash used by investing activities was $9.6 million, respectively. During the three months ended March 31, 2023 and 2022, we purchased marketable securities and had sales and maturities of our marketable securities as part of managing our cash and investments portfolio.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022, net cash provided by financing activities was $2.7 million and $1.8 million, respectively. The increase was mainly due to an increase of proceeds from the purchase of shares under the Employee Stock Purchase Plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Capital Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of our current and future product candidates, and seek regulatory approvals for zuranolone and those other product candidates that are successfully developed; prepare for potential future commercialization of zuranolone and other product candidates beyond ZULRESSO that are successfully developed and approved, including engaging in pre-launch and launch-readiness activities; begin to commercialize any such products, if approved; and continue our efforts to identify and develop new product candidates beyond our current portfolio. We also expect to incur significant costs associated with general operations. In addition, we expect to incur significant commercialization expenses for product sales, marketing and outsourced manufacturing with respect to ZULRESSO, zuranolone, if approved and any other future products that are successfully developed and approved. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our existing cash, cash equivalents and marketable securities as of March 31, 2023, in addition to anticipated funding from our ongoing collaborations, excluding revenues and milestones, will enable us to fund our operating expenses and capital expenditure requirements through 2024. During that time, we expect research and development and selling, general and administrative expenses to increase as we advance planned and ongoing clinical trials for SAGE-718 and SAGE-324; advance regulatory, engage in permitted pre-launch and launch-planning activities for zuranolone; prepare for the potential commercial launch of zuranolone; expand our research activities; and pursue our strategic plan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current operating plan does not contemplate other activities that we may pursue or that all of our currently planned activities will proceed at the same pace, or that all of these activities will be fully initiated or completed during that time. We have based our estimates on assumptions that could change, and we may use our available capital resources sooner than we currently expect. We may also choose to change or increase our development, commercialization or other efforts. Because of the numerous risks and uncertainties associated with the development and commercialization of any product or product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete development of our current or future product candidates or to commercialize any approved product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully receive FDA approval of our NDA to market zuranolone for the treatment of both MDD and PPD, on the timelines we expect, and without significant limitations and restrictions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of regulatory, permitted pre-launch and launch-readiness activities associated with zuranolone;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if zuranolone is approved for one or more indications, the costs associated with its commercial launch and the timing and amount of any revenues;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of revenues from sales of ZULRESSO, which we expect will continue to be impacted by a number of factors, including: the rate, degree and level of market acceptance for ZULRESSO for the treatment of PPD in the U.S.; our decision to focus our efforts primarily on geographies that have existing, active ZULRESSO treating sites; the continued availability of healthcare settings in those geographies to administer ZULRESSO and the ability and willingness of such healthcare settings to make sufficient capacity available, particularly in light of the ongoing disruption to the U.S. healthcare system and related healthcare staffing shortages stemming from the downstream effects of the COVID-19 pandemic; the level of reimbursement for both ZULRESSO and the infusion in the healthcare setting both by commercial and government payors, and the nature of limitations on coverage and reimbursement; the number of healthcare professionals willing to prescribe ZULRESSO and women with PPD who agree to be treated with ZULRESSO; and the downstream effects of the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of costs associated with our commercialization of ZULRESSO;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, progress, completion, timing, costs, and results of ongoing, planned and future non-clinical studies and clinical trials for our other existing and future product candidates; the number and length of clinical trials required by regulatory authorities to support regulatory approval; and the costs of preparing, submitting and supporting regulatory filings for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general macroeconomic and geopolitical conditions, including any capacity </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and resource </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">constraints at our vendors and clinical trial sites on initiation and conduct of our clinical trials or on our supply chain; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of SAGE-324, SAGE-718 and our other clinical-stage product candidates to progress through clinical development successfully and on the timelines we expect; the outcome of discussions with regulatory authorities on regulatory pathways with respect to our product candidates; the timing, scope and outcome of regulatory filings and reviews and approvals of such product candidates, if we are successful in our development efforts; the scope and cost of any clinical trials or other commitments required post-approval for any approved products resulting from such development efforts, if successful; and the level, timing and amount of costs associated with permitted prelaunch activities and preparing for a potential future commercial launch of any such product candidate that is successfully developed and approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amounts we are entitled to receive, if any, from Biogen and Shionogi under our collaborations for profit-sharing, cost-sharing, development, regulatory, and sales milestones, and royalty payments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the markets for which zuranolone and our other product candidates may be approved in the future, if successfully developed; the portion of the population in the approved indications for which zuranolone, if approved, and our future products are actually prescribed; and the rate and degree of market acceptance, pricing, and availability and level of reimbursement for zuranolone, if approved, and for our future products, if successfully developed and approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and characteristics of the product candidates we pursue in development and the nature and scope of our discovery and development programs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we acquire or in-license other products and technologies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish any future collaboration arrangements on favorable terms, if at all.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, we expect to also finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or in light of other strategic considerations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute the ownership interest of our stockholders. If we raise additional funds through collaborations, strategic alliances, licensing arrangements or other agreements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. Raising funds may present challenges. Markets may experience volatility or become disrupted in the future for any number of reasons, including as a result of any long-term negative effects of the COVID-19 pandemic, or other macroeconomic or geopolitical conditions, result in an economic recession, a decrease in corporate and consumer expenditures, prolonged unemployment, or other circumstances that could negatively impact general economic conditions. If we are unable to raise additional funds through equity or debt financings or other means when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been no material changes to our contractual obligations and commitments as included in our Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Application of Critical Accounting Policies</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have prepared our condensed consolidated financial statements in accordance with accounting principles generally accepted in the U.S. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures at the date of the condensed consolidated financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in the notes to our consolidated financial statements to our Annual Report, we believe that our most critical accounting policies are those relating to revenue recognition, collaborative arrangements, accrued research and development expenses, and stock-based compensation.</span></p>
  <p style="text-indent:4.52%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been no material changes to our critical accounting policies from those described in &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Critical Accounting Policies and Significant Judgments and Estimates&#x201d; included in our Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.987%;padding-left:9.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.	Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ive Disclosures about Market Risk</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had cash, cash equivalents and marketable securities of $1.1 billion as of March 31, 2023. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk relates to fluctuations in interest rates, which are affected by changes in the general level of U.S. interest rates. Given the short-term nature of our cash, cash equivalents and marketable securities, we do not expect that a sudden change in market interest rates would have a material impact on our financial condition and/or results of operations. We do not own any derivative financial instruments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We contract with vendors in foreign countries and have subsidiaries in Europe. As such, we have exposure to adverse changes in exchange rates of foreign currencies associated with our foreign transactions. We believe this exposure to be immaterial. We do not hedge against this exposure to fluctuations in exchange rates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not believe that our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash, cash equivalents and marketable securities that are in excess of federally insured limits at one or more financial institutions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our results of operations during the three months ended March 31, 2023 and 2022.</span></p>
  <p style="text-indent:-9.987%;padding-left:9.08%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.	Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Securities Exchange Act of 1934) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC&#x2019;s rules and forms and (2) accumulated and communicated to our management, including our President and Chief Executive Officer, who is our principal executive officer, and our Chief Financial Officer, who is also our principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, our management, with the participation of our principal executive officer and principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial and accounting officer have concluded, based upon the evaluation described above, that, as of March 31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="part_ii_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II &#x2014; OTHE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R INFORMATION</span></p>
  <p style="text-indent:-9.987%;padding-left:9.08%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.	Legal</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may from time to time become involved in legal proceedings relating to claims arising from our ordinary course of business,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including claims related to contracts, employment arrangements, operating activities, intellectual property or other matters. We are not currently subject to any legal proceeding that we believe would have a material adverse impact on our financial position, results of operations or cash flows or other material legal proceeding.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.	Ri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, or Quarterly Report, and in our other public filings before making an investment decision. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that we currently consider immaterial. If any such risks or uncertainties actually occur, our business, financial condition or operating results could differ materially from the plans, projections and other forward-looking statements included in this Quarterly Report, including in the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this report and in our other public filings and public statements. The trading price of our common stock could decline due to any of these risks, and as a result, our stockholders may lose all or part of their investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Product Development, Regulatory Approval and Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future business prospects depend heavily on our ability, with our collaboration partner, Biogen MA Inc., and Biogen International GmbH, or together, Biogen, to gain regulatory approval of zuranolone (SAGE-217) in the U.S. as a treatment for major depressive disorder, or MDD, and postpartum depression, or PPD, and to successfully commercialize zuranolone in those indications, if approved. While our new drug application, or NDA, for zuranolone is currently under review, we cannot be certain that the design and results of our development program for zuranolone will be sufficient to obtain regulatory approval of zuranolone for the treatment of MDD or PPD on the timelines we expect or at all. Even if we receive regulatory approval of zuranolone for the treatment of MDD and PPD, our commercialization efforts with respect to zuranolone may not be successful.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future business prospects depend heavily on our ability, along with our collaboration partner, Biogen, to gain regulatory approval of zuranolone in the U.S. as a treatment for MDD and PPD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our NDA seeking approval of zuranolone for the treatment of both MDD and PPD was accepted for filing by the U.S. Food and Drug Administration, or FDA, and granted priority review in February 2023, with a Prescription Drug User Fee Act, as amended, or PDUFA, target action date for the NDA of August 5, 2023. The FDA may not approve zuranolone as a treatment for MDD and/or PPD on the timelines we expect, or at all. The FDA may require additional trials or data to approve zuranolone as a treatment for MDD and/or PPD, any of which may significantly delay and put at risk our efforts to obtain approval and may not be successful. The FDA may determine that the manufacturing processes or facilities of third-party contract manufacturers with which we contract for the manufacture of zuranolone do not conform to applicable requirements, including current Good Manufacturing Practices, or cGMPs. The FDA may find deficiencies in the conduct of clinical trials or nonclinical studies or in the preparation, collection or analysis of data from clinical and non-clinical studies submitted in our NDA. Although the FDA notified us in March 2023 that the agency does not currently plan to convene an advisory committee meeting to discuss the NDA for zuranolone NDA for the treatment of MDD and PPD, the FDA may change that decision, and if our NDA for zuranolone is reviewed by an advisory committee of the FDA, the advisory committee may recommend against approval of the application or may recommend that the FDA require, as a condition of approval, additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, and the FDA may ultimately agree with the recommendations of the advisory committee. The FDA may also approve zuranolone, but only for one of the indications described in our NDA or for only a specific subset of patients with MDD or PPD, or may impose other restrictions, such as limitations or restrictions in the approved label such as a boxed warning, contraindications or a Risk Evaluation and Mitigation Strategy, or REMS, program requirement. The FDA may not meet expected review timelines or may elect to extend the timeframe for their</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review, or there may be delays at any point in the regulatory review cycle that negatively impact our plans and expectations, including anticipated launch timelines and plans in MDD or PPD. Other decisions or actions of the FDA or other regulatory agencies may also adversely affect the zuranolone program, our plans, progress or results and the potential product profile and success of zuranolone. Even if zuranolone is approved for marketing, it may not have the profile or market acceptance we expect in clinical practice after launch or the unmet need for new treatment options in MDD may not be as significant as we expect or we may encounter reimbursement-related or other market-related issues in the commercialization of zuranolone. We and our collaborator may never be able to successfully commercialize zuranolone in the approved indications or to meet our expectations with respect to timing and revenues or profits from sales of such product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future business prospects depend heavily on our ability, alone or through our collaborations, to successfully develop, gain regulatory approval of and commercialize our current and future product candidates beyond zuranolone. We cannot be certain that we will be able to initiate planned clinical trials, to complete ongoing clinical trials or to announce results of such trials with respect to any of our other product candidates, on the timelines we expect or at all, or that the results of our clinical trials or other activities under our development programs will be positive. We cannot be certain that we or our collaborators will be able to advance such product candidates into additional trials or to successfully develop, obtain regulatory approval for, or successfully commercialize any of our such product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future business prospects depend heavily on our ability, alone or through our collaborations, to successfully develop and gain regulatory approval of our current and future product candidates beyond zuranolone. Drug development and obtaining regulatory approval for a product involves a long, expensive and uncertain process, involving a high degree of risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any product candidate, non-clinical studies and clinical trials must demonstrate that the product candidate is safe and effective for use in each target indication. We or our collaborators, as applicable, may not be able to demonstrate the efficacy and safety of any of our other current product candidates or any future product candidate at each stage of clinical development or we may encounter other issues with any clinical trials or non-clinical studies required for regulatory submissions. Success in non-clinical studies or in earlier clinical trials or interim results of clinical trials may not be repeated or observed in ongoing, future or completed studies or trials involving the same compound or other product candidates. Some or all of our or our collaborators&#x2019; clinical trials may fail to meet their primary or key secondary endpoints, raise safety issues or generate mixed results. For example, in December 2019, we announced that the MOUNTAIN Study, a Phase 3 clinical trial of zuranolone for the treatment of MDD, did not meet its primary endpoint. We may find that studying alternate formulations of our product candidates or doses that achieve higher or lower patient exposure may result in unexpected adverse events or raise other safety issues or may otherwise generate negative results. For example, in our ongoing dose-ranging study of SAGE-324, the KINETIC 2 Study, we are evaluating multiple doses, including the same maximum dose of SAGE-324 that we evaluated in prior studies. We might decide to evaluate different doses, formulations, and durations of dosing for any of our product candidates with other studies or programs in the future. The results of clinical trials or non-clinical studies of our product candidates at any stage may not support further development or may not be sufficient to file for and obtain regulatory approval on the timelines we expect or at all. Other decisions or actions of the FDA or other regulatory agencies may affect our plans, progress or results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in formulation or the need to refine or scale-up the manufacturing process as we do for any of our product candidates could also delay development or require us to conduct additional clinical trials or non-clinical studies or conduct post-approval analyses, or could lead to different results than achieved with the earlier formulation or processes. We or our collaborators may not be able to initiate or complete our clinical trials or announce results from our clinical trials on the timelines we expect. We or our collaborators may experience slower than expected activation of sites or enrollment and randomization of patients in our clinical trials, particularly in clinical trials where an in-patient stay or frequent site visits are required, the patient population is small, enrollment criteria are more selective than historically used, there are existing therapies, where other companies are running large clinical trials, or where relevant clinical sites or our vendors are experiencing healthcare staffing shortages or significant turnover. There is also the potential for slower than expected clinical site initiation, delays or problems in analyzing data, the potential need for additional analysis or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">data or the need to enroll additional patients, or other unexpected issues such as adverse events in any of our clinical trials. These types of delays or issues could lead to delays in the completion of a trial and announcement of results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing and planned development activities may be negatively impacted by a number of factors, including the downstream effects of the COVID-19 pandemic. Widespread healthcare and vendor staffing shortages and increased competition for patients and clinical sites may make it difficult to enroll patients in our clinical trials and/or identify and activate participating clinical sites for our trials, may cause other delays at clinical trial sites and/or vendors, and may increase the rates of patients withdrawing from our clinical trials following enrollment. Some clinical sites may decline or delay participation in our trials due to capacity </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and resource </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">constraints, given the increase in the number of clinical trials being conducted as pandemic-related restrictions have lifted. These factors may substantially slow clinical site identification and activation and enrollment in our clinical trials, or cause us to pause trials, which may, in each case, significantly impact our ability to meet our expected timelines, budgets, or other plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to these challenges during the COVID-19 pandemic, we or our clinical sites implemented measures to help minimize the number of visits a clinical trial participant is required to make to a site, including by limiting or modifying clinical trial procedures and visits for data collection, and some clinical sites imposed other restrictions or limitations on key clinical trial activities such as restrictions related to monitoring of the sites by clinical research organizations. Some of these restrictions and limitations could be implemented again in the future, including in connection with the emergence of new COVID-19 strains. Limitations or modifications to study procedures, study visits or data collection, restrictions on key clinical trial activities such as monitoring or auditing, or other restrictions that may affect data analysis activities may require additional assessment and evaluation from institutional review boards; negatively impact the integrity or completeness of our trial data, the powering of a trial, the integrity or relevance of clinical study endpoints; or impact the timing of availability of results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The drug development process can take many years, and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized. Accordingly, even if we have the requisite financial resources, when needed, to continue to fund our development efforts, we cannot assure you that any of our current or future product candidates will be successfully developed or commercialized either in the U.S. or in any country outside the U.S. Even if we or our collaborators conduct the trials required by or discussed with the FDA, the FDA may ultimately decide that the design, number and type of trials, number of patients studied or results, even if positive, are not sufficient to file for or gain regulatory approval of any of our product candidates in the indications we study, or do not support the safety or efficacy or our intended profile for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we or a collaborator of ours gains approval of any of our current or future product candidates, we and our collaborator may never be able to successfully commercialize such new product in the approved indications or meet our expectations with respect to timing and revenues or profits from sales of such product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may never be able to generate meaningful revenues from sales of ZULRESSO&#174; (brexanolone) CIV injection at levels or on timing necessary to support our investment and goals.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our first product, ZULRESSO, was approved by the FDA in March 2019 as a treatment for PPD in adults, and was made commercially available in June 2019. Our revenues from sales of ZULRESSO have been negatively impacted by significant barriers arising from the complex requirements for treatment and by the direct and indirect impacts of the COVID-19 pandemic. Some or all of these factors are expected to continue to impact revenues negatively in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZULRESSO is administered as a continuous infusion given over two and a half days. Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness during the ZULRESSO infusion, ZULRESSO is approved for administration only in a medically-supervised healthcare setting that has been certified under a REMS program and meets the other requirements of the REMS program, including requirements related to monitoring of the patient during the infusion. The actions required for a healthcare setting to be ready and willing to treat women with PPD are complex and time-consuming. These actions include becoming REMS-certified; achieving formulary approvals; establishing protocols for administering ZULRESSO; and securing satisfactory reimbursement. Sites must often negotiate reimbursement on a payor-by-payor basis under commercial coverage. These requirements have created significant barriers to treatment for women with PPD. We expect these barriers will continue to negatively impact ZULRESSO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revenue growth, but we do not know the extent of the anticipated impact. These barriers were compounded by the COVID-19 pandemic and continue to be impacted by its related disruptive effects on the U.S. healthcare system, and other changes to the macroeconomic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The spread of COVID-19 in the U.S. resulted in a significant number of sites of care pausing, limiting or delaying treatment of new patients with ZULRESSO and potential new sites of care pausing site activation activities for a period of time. We believe that, at certain points during the COVID-19 pandemic, concerns about exposure to the virus or its variants caused a significant and sustained reduction in the number of women with PPD seeking treatment with ZULRESSO and in the number of physicians willing to prescribe it, and that difficulties in accessing treatment with ZULRESSO have now been compounded by healthcare staffing shortages and other changes to the macroeconomic environment. Given the ongoing disruption to the healthcare system in the U.S., including as a result of staffing shortages, we cannot predict for how long and to what extent ZULRESSO sales will be adversely impacted by these factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial efforts for ZULRESSO, including our account management field-based team and sales representatives, are primarily focused on geographies that have existing, active ZULRESSO treating sites. We expect that this approach will continue to substantially limit the revenue opportunity for ZULRESSO, and may make it difficult for us to achieve revenue growth and meet our revenue goals. Given this approach, the number of new healthcare settings that become treating sites for ZULRESSO, if any, is also expected to be limited. We may also find that certain healthcare settings that have in the past been active treating sites may not be willing to remain infusion-ready as a result of the complex requirements related to administration of ZULRESSO and compliance with the REMS, related limitations and restrictions, or because of actual or perceived difficulties obtaining satisfactory reimbursement or limitations on coverage and reimbursement or for other reasons, including staffing shortages. Healthcare settings that are active treating sites may also limit capacity used for ZULRESSO infusions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to encounter other issues and challenges in commercializing ZULRESSO and generating revenues, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some women with PPD who need treatment find it too onerous to undergo an infusion or to be treated at a certified healthcare setting overnight for the length of stay required for treatment, or to be enrolled in the registry that is part of the REMS process or may be concerned about the risk of excessive sedation and sudden loss of consciousness. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More healthcare providers than we expected have been unwilling to accept ZULRESSO as a treatment paradigm for women with PPD and this may continue; we believe this unwillingness is due primarily to the product profile and reimbursement challenges associated with ZULRESSO.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We compete with lower cost antidepressants.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the mode of administration, the nature of the REMS and the current limitation on the administration of ZULRESSO to a medically-supervised healthcare setting certified under the REMS, use of ZULRESSO in the U.S. has been focused primarily on women with more severe symptoms of PPD, and we expect that to continue.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to fully comply with our obligations under the ZULRESSO REMS, which include auditing of healthcare settings, collection and analysis of required data, and other requirements, to the satisfaction of the FDA, or the FDA may require modifications to or additional restrictions under the ZULRESSO REMS. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If zuranolone is successfully approved for PPD and commercialized, it could further limit our commercial opportunity for ZULRESSO.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also expect to continue to encounter challenges related to coverage and reimbursement of ZULRESSO. These include restrictions related to the severity of PPD cases for which ZULRESSO will be reimbursed, requirements that other treatments be used prior to ZULRESSO, or other limitations in the scope, breadth, availability or amount of reimbursement covering ZULRESSO or the infusion. For example, the availability, terms and timing of coverage for ZULRESSO by state Medicaid systems is expected to continue to vary significantly by state, and we encounter states that impose significant coverage restrictions or lengthy delays on reimbursement of ZULRESSO. Similarly, certain healthcare</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">settings or patients may determine that the financial burdens of treatment are not acceptable. A number of healthcare settings that are willing to administer ZULRESSO to women with PPD who have commercial insurance do not currently treat Medicaid patients, which adversely affects our ability to generate revenue from ZULRESSO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these issues could impair our ability to generate revenues or to meet our expectations with respect to the amount or timing of revenues. Any issues or hurdles related to our commercialization efforts may materially adversely affect our business, results of operations, financial condition and prospects and could lead us to make significant further changes to the scope and nature of our efforts. There is no guarantee that we will be successful in our commercialization efforts with respect to ZULRESSO, or that we will be able to generate meaningful revenues or revenues at the levels or on the timing necessary to support our investment and goals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZULRESSO, zuranolone, and our other current or future product candidates and any future products, if successfully developed and approved, may cause undesirable side effects that limit their commercial profile; delay or prevent further development or regulatory approval; cause regulatory authorities to require labeling statements, such as boxed warnings or a REMS; or result in other negative consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may observe undesirable side effects or other potential safety issues in nonclinical studies, in clinical trials at any stage of development of our product candidates, as part of an expanded access program, if initiated for any of our products or product candidates, in commercial use or in post-approval studies of any approved product. Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, certain side effects of ZULRESSO, zuranolone, any other current or future product candidates, or any future products, if successfully developed and approved, may only be uncovered with a larger number of patients exposed to the product. Those side effects could be serious or life-threatening. If we or others identify undesirable side effects caused by ZULRESSO, zuranolone, any other existing or future product candidate or any future approved product:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw, withhold or limit their approval of such products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or regulatory authorities outside the U.S. may impose a clinical hold or partial clinical hold prior to the initiation of development or during development of our product candidates which could cause us or our collaborators to have to stop, delay or restrict further development; or we or our collaborators may, even without a clinical hold, decide to interrupt, delay or halt existing non-clinical studies and clinical trials or stop development;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may have difficulty enrolling patients in our clinical trials and completing such trials on the timelines we expect or at all, or we may have to conduct additional non-clinical studies or clinical trials as part of a development program; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if an NDA for any of our product candidates is reviewed by an advisory committee of the FDA, the advisory committee may recommend against approval of the application or may recommend that the FDA require, as a condition of approval, additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, and the FDA may ultimately agree with the recommendations of the advisory committee;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our collaborators may not be able ultimately to demonstrate, to the satisfaction of the FDA or other regulatory authorities, that our product candidates are safe and that the benefits outweigh the safety risks, and the FDA or applicable foreign regulatory authorities may not approve the product candidate;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a boxed warning or additions to an existing boxed warning, or a contraindication, including as a result of inclusion in a class of drugs for a particular disease, or may require a REMS, or modifications to an existing REMS;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our collaborators may be required to change the way such products are distributed or administered, conduct post-approval studies or change the labeling of the products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our collaborators may be subject to regulatory investigations and government enforcement actions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our collaborators may decide to remove such products from the marketplace;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our collaborators could be sued and held liable for injury caused to individuals exposed to or taking our products or product candidates; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected products, could substantially increase the risks and costs of developing our product candidates or commercializing our products, and could significantly adversely impact our ability and that of our collaborators to successfully develop, gain regulatory approval for, and commercialize our current product candidates or future products and generate revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining regulatory approval to market any of our product candidates is a complex, lengthy, expensive and uncertain process, and the FDA and regulatory authorities outside of the U.S. may delay, limit or deny approval of zuranolone or any of our other product candidates for many reasons. Any setback or delay in obtaining regulatory approval for zuranolone or any of our other product candidates or in our ability to commence marketing of our products, if approved, may have a material adverse effect on our business and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are not permitted to market any of our product candidates in the U.S. until we or our collaborators receive approval of an NDA from the FDA or in any foreign countries until we or our collaborators receive the requisite marketing approval from such countries. Obtaining approval of an NDA in the U.S. or marketing approval in any country outside the U.S. is a complex, lengthy, expensive and uncertain process. The FDA and regulatory authorities outside the U.S. may delay, limit or deny approval of zuranolone or any of our other product candidates for many reasons, including, among others:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our collaborators may not be able to demonstrate, to the satisfaction of the FDA or other regulatory authorities, that our product candidates are safe and effective in any indication and that the benefits outweigh the safety risks;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our non-clinical studies and clinical trials may be negative, or may not meet the level of statistical or clinical significance or other criteria required by the FDA or regulatory authorities outside the U.S. for marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or regulatory authorities outside the U.S. may impose a clinical hold or partial clinical hold prior to the initiation of development or during development of our product candidates which could cause us to have to stop, delay or restrict further development;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or regulatory authorities outside the U.S. may disagree with our interpretation of data from our non-clinical studies and clinical trials, or may not accept data generated at one or more of our sites conducting non-clinical studies or clinical trials which may cause the study or trial to fail;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or regulatory authorities outside the U.S. may determine that the number, design, size, conduct, implementation or result of our non-clinical studies or clinical trials is inadequate for regulatory approval or that changes in dosing or drug formulation used in our non-clinical studies or clinical trials require additional trials or studies, even if the regulatory authorities have previously reviewed and commented on the design and details of our plans;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or regulatory or other government authorities outside the U.S. may require that we or our collaborators conduct additional non-clinical studies and clinical trials prior to approval or post-approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or applicable foreign regulatory authorities may not approve the formulation, labeling or specifications of any of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if an NDA for any of our product candidates is reviewed by an advisory committee of the FDA, the advisory committee may recommend against approval of the application or may recommend that the FDA require, as a condition of approval, additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, and the FDA may ultimately agree with the recommendations of the advisory committee;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or applicable foreign regulatory authorities may approve a product candidate for which we or our collaborators are seeking regulatory approval for a more limited patient population than expected or with substantial use restrictions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as was the case with ZULRESSO, the FDA may require a REMS as a condition of approval or post-approval for our product candidates, or may modify an existing REMS or may impose other limitations or restrictions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or applicable foreign regulatory authorities may determine that the manufacturing processes or facilities of third-party contract manufacturers with which we contract do not conform to applicable requirements, including cGMPs; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or applicable foreign regulatory agencies may change their approval policies or adopt new regulations.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these factors, many of which are beyond our control, could jeopardize or delay our or our collaborators&#x2019; ability to obtain regulatory approval for and successfully market zuranolone or our other product candidates. Even if we or our collaborators receive marketing approval for zuranolone or any of our other product candidates, regulatory or other governmental authorities may still impose significant restrictions, including restrictions on the indicated use or marketing, or may impose ongoing requirements for potentially costly post-approval studies. For example, the FDA has imposed post-approval obligations in connection with approval of ZULRESSO. We may not be able to fulfill these obligations in accordance with the FDA&#x2019;s timelines, or at all. We expect the FDA to recommend scheduling with respect to zuranolone, and the FDA may also recommend scheduling with respect to any of our other current or future product candidates. In such event, as was the case with ZULRESSO, prior to a product launch, the U.S. Drug Enforcement Administration, or DEA, will need to determine the controlled substance schedule of the product, taking into account the recommendation of the FDA. The timing of the scheduling process would delay our ability to market any product candidate that is successfully developed and approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have been granted priority review of our NDA seeking approval of zuranolone for the treatment of MDD and PPD. We may seek priority review of future NDA submissions with the FDA, if our development efforts with respect to other product candidates are successful, but the FDA may not grant such priority review. Even if the FDA grants priority review for an NDA, the FDA may not meet the applicable review timelines or may elect to extend the timeframe for their review. Delays, resource constraints, and other disruptions at the FDA and other agencies may slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, the U.S. government has shut down several times in recent history and certain regulatory agencies, including the FDA, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs in the future, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast Track and Breakthrough Therapy designations from the FDA or PRIority Medicines, or PRIME, designation from the European Medicines Agency, or EMA, do not necessarily lead to a faster development pathway or regulatory review process, and do not increase the likelihood of regulatory approval. The FDA may withdraw Fast Track designation or Breakthrough Therapy designation, and the EMA may withdraw PRIME designation, if the relevant agency believes that the designation is no longer supported by data from our clinical development programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The COVID-19 pandemic, its related downstream effects, and changes to the macroeconomic environment have adversely impacted and may continue to adversely impact our business, including our sales of ZULRESSO and our initiation, conduct and completion of non-clinical studies and clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic in the U.S. resulted in a significant number of sites of care pausing treatment of new patients with ZULRESSO and potential new sites of care pausing site activation activities for a period of time. We believe, at certain points during the pandemic, concerns about exposure to the virus or its variants caused a significant and sustained reduction in the number of women with PPD seeking treatment with ZULRESSO and in physicians willing to prescribe it, and that difficulties in accessing treatment with ZULRESSO have since been compounded by healthcare staffing shortages and other changes to the macroeconomic environment. Given the ongoing disruption to the healthcare system in the U.S., including as a result of staffing shortages, we cannot predict for how long and to what extent ZULRESSO sales will be adversely impacted by these factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the COVID-19 pandemic, its downstream effects, and changes to the macroeconomic environment we could observe delays or other disruptions that may negatively impact our ongoing and planned development activities, including the timing of initiation and completion of non-clinical studies and clinical trials or the integrity, completeness or usefulness of the data we collect in those studies or trials. These delays and disruptions may include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in qualifying clinical sites and in clinical site activation, or the diversion of other healthcare resources and personnel, due to healthcare and vendor staffing shortages or as a result of recommended or required precautions or limitations that could be implemented in the future;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in enrolling patients in our clinical trials, including, for example, with respect to recruiting older patients as we saw in certain clinical trials at certain times during the pandemic, or an increase in the number of patients withdrawing from our clinical trials prior to completion as a result of concerns about potential future variants of COVID-19 or as a result of recommended or required precautions or limitations intended to curb the spread of the virus, or the potential that patients in our trials may have or contract COVID-19 or potential future variants of the virus which may impact the trial results;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or disruptions in non-clinical studies due to precautions taken by contract research organizations, or CROs, or other vendors in response to potential future restrictions recommended or imposed by federal, state or local authorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or modifications to study procedures, the number and type of study visits or data collection or data analysis activities, or other restrictions on other key clinical trial activities such as monitoring and auditing, in response to potential variants of COVID-19 or as a result of future restrictions imposed or recommended by federal, state or local governments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays in the operations of the FDA and foreign regulatory agencies, including as a result of staffing shortages or other resource constraints, which may impact timelines for initiation of clinical trials, amendments of protocols, inspections of manufacturing facilities and review of regulatory submissions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of, or delays in, availability of supplies of our product candidates if the COVID-19 pandemic continues in surges or recurs in waves for an extended period, including the potential for shortages of raw materials, other drugs or materials used in our clinical trials, or staff available to our contract manufacturing organizations or other vendors in the supply chain or as the result of restrictions or limitations in their businesses or activities; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations on employee resources that would otherwise be focused on the conduct of our non-clinical studies and clinical trials, including due to illness as a result of potential future waves of variants of COVID-19.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, future surges of COVID-19 may cause economic disruptions and may in the future adversely impact the capital markets and make additional capital unavailable to us on acceptable terms, or at all if we were to seek it. There may also be other long-term negative effects of the COVID-19 pandemic that may negatively affect general economic conditions and adversely impact our ability to access the capital markets in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The number of people with the diseases and disorders for which our products and product candidates are targeted may be smaller than we expect or our other assumptions with respect to the potential markets for our products and product candidates may not be correct and the markets may be significantly smaller than we expect.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our first product, ZULRESSO, has been approved in the U.S. for the treatment of PPD in adults. We completed a rolling submission of an NDA to the FDA seeking approval of zuranolone for the treatment of MDD and PPD in December 2022. We are developing SAGE-324 as a potential oral therapy for neurological conditions, such as essential tremor, epilepsy and Parkinson&#x2019;s disease. We are developing SAGE-718 as a potential treatment for cognitive dysfunction associated with Huntington&#x2019;s disease, Parkinson&#x2019;s disease and Alzheimer&#x2019;s disease. There is no precise method of establishing the actual number of patients with any of these disorders in any geography over any time period. With respect to PPD, MDD, essential tremor and the other indications for which we are developing, or plan to develop, our product candidates, we estimate the prevalence of the disease or disorder, and our estimates as to prevalence, including the assumptions we apply in determining our estimate, may not be accurate. In each case, there is a range of estimates in the published literature and in marketing studies, which include estimates within the range that are lower than our estimates. For example, our estimates of the prevalence of PPD are higher than estimates reported in some of the published literature and results obtained from certain studies analyzing claims databases. We believe these differences may be the result of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in analytical methodologies and possibly under-diagnosis of PPD as a result of lack of screening and under-reporting and some patients being reluctant to seek treatment in clinical practice. The actual number of patients with PPD, MDD, essential tremor, Huntington&#x2019;s disease, Parkinson&#x2019;s disease, Alzheimer&#x2019;s disease, or any other indication for which we elect to pursue development of our product candidates may, however, be significantly lower than we believe. Even if our prevalence estimates are correct, any approved product that we develop may only be indicated for or used by a subset of patients with the relevant disease or disorder. Our assumptions and estimates about the market for ZULRESSO and the potential market for zuranolone and our other current and future product candidates may not be accurate. In the event the number of patients with the diseases and disorders we are studying is significantly lower than we expect, we or our collaborators may have difficulties in enrolling patients in our clinical trials which may delay or prevent development of our product candidates. If our prevalence estimates with respect to any indication or our other market assumptions are not accurate, the markets for any approved product for these indications may be smaller than we anticipate, which could limit our revenues and our ability to achieve profitability or to meet our expectations with respect to the level and timing of revenues or profits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Positive results from non-clinical studies and clinical trials of our product candidates are not necessarily predictive of the results of later non-clinical studies and clinical trials of our product candidates in the same indications or other indications. Interim results from non-clinical studies and clinical trials may not be predictive of results of such non-clinical studies or clinical trials once completed. If we cannot replicate the positive results from our earlier non-clinical studies and clinical trials of our product candidates in our later non-clinical studies and clinical trials in the same indications or other indications, or we cannot replicate our interim results in our completed non-clinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Positive results from non-clinical studies and clinical trials of our product candidates may not necessarily be predictive of the results we or our collaborators may obtain from subsequent non-clinical studies or clinical trials using the same product candidate or other product candidates. For example, unlike earlier trials of zuranolone for the treatment of MDD and PPD, the Phase 3 MOUNTAIN Study evaluating zuranolone in patients with MDD did not meet its primary endpoint. We or our collaborators may find that ongoing or future clinical trials of zuranolone or any of our other product candidates may also fail to meet their primary endpoints. Similarly, interim results from non-clinical studies and clinical trials may not be predictive of results of a non-clinical study or clinical trial once completed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our collaborators may also observe safety issues in clinical trials or non-clinical studies of our product candidates that we or they did not observe or appreciate in earlier stage clinical studies or non-clinical studies, or a different rate or severity of events, including as a result of an increase in dosing or in frequency or duration of dosing, studying a different patient population or different indication than previously studied, or administering a product candidate with a concomitant medication. For example, in our ongoing dose-ranging study of SAGE-324, we are evaluating multiple doses, including the same maximum dose of SAGE-324 that we evaluated in prior studies. Any of these studies may result in unexpected adverse events or raise other safety issues or may otherwise generate negative results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results from non-clinical animal models may not be replicated in clinical trials. Many product candidates, including many targeting central nervous system disorders, with promising non-clinical profiles have failed to demonstrate similar safety, non-toxicity and efficacy in humans.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials after achieving positive results in earlier-stage development, and we cannot be certain that we will not face similar setbacks. Many drugs have failed to replicate efficacy and safety results in larger or more complex later stage trials. Moreover, non-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in non-clinical studies and clinical trials nonetheless failed to obtain FDA approval. If we or our collaborators fail to produce positive results in our ongoing and planned non-clinical studies or clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failures or delays in the commencement, enrollment or completion of our ongoing and planned clinical trials of our current and future product candidates could cause us not to meet our expected timelines or result in increased costs to us, and could delay, prevent or limit our ability to gain regulatory approval of any such product candidate and to generate revenue from resulting products, if any.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successful completion of clinical trials at each applicable stage of development is a prerequisite to submitting an NDA to the FDA or equivalent filings outside the U.S. and, consequently, the ultimate approval and commercial marketing of any of our product candidates for the indications in which we develop them. We do not know whether any of our ongoing clinical trials will be completed, and results announced, or whether future trials will begin, as planned or expected, if at all, as the commencement, enrollment and completion of clinical trials and announcement of results can be delayed or prevented for a number of reasons, including, among others:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">denial by the FDA or other regulatory authority of permission to proceed with our planned clinical trials or any other clinical trials we may initiate, or placement of one or more clinical trials on full or partial clinical hold;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or inability to satisfy the requirements of the FDA to commence clinical trials, including chemistry, manufacturing and control, or CMC, requirements, or to file or receive approvals of additional investigational new drug applications, or INDs, that may be required;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or inability to satisfy the requirements for clinical trials conducted in the EU, if applicable, pursuant to Regulation (EU) No 536/2014, or the EU Clinical Trials Regulation;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or inconclusive results from our ongoing non-clinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges in qualifying and activating clinical trial sites, including due to capacity </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and resource </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">constraints and attrition at sites, and potential delays at clinical trial sites;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general political and economic conditions, including as a result of bank failures,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the continuing downstream effects of the COVID-19 pandemic on the healthcare system;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching or failing to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties obtaining Institutional Review Board, or IRB, approval, and equivalent approval for sites outside the U.S., to conduct a clinical trial at a prospective site or sites;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the occurrence of serious adverse events or unexpected drug-related side effects experienced by patients in a clinical trial or unexpected results in ongoing non-clinical studies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in validating endpoints utilized in a clinical trial;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or applicable regulatory authorities outside the U.S. disagreeing with our clinical trial design and our interpretation of data from clinical trials, or changing the requirements for approval even after the regulatory authority has reviewed and commented on the design for our clinical trials; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reports from non-clinical or clinical testing of other therapies that raise safety or efficacy concerns.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a clinical trial may be suspended or terminated by us, the FDA or other regulatory authorities, the IRB or Ethics Committee, or EC, at the sites where the IRBs or ECs are overseeing a clinical trial, or recommended for termination or suspension by a data and safety monitoring board overseeing the clinical trial at issue or other regulatory authorities due to a number of factors, including, among others:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities that reveals deficiencies or violations that require us to undertake corrective action, including the imposition of a partial or full clinical hold;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unforeseen safety issues, including any that could be identified in our ongoing non-clinical studies, or adverse side effects or lack of effectiveness identified in ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in government regulations or administrative actions; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">problems with clinical supply materials.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, changes in regulatory requirements or guidance or unanticipated events during our non-clinical studies and clinical trials may force us or our collaborators to amend non-clinical studies and clinical trial protocols or the applicable regulatory authorities may impose additional non-clinical studies and clinical trial requirements. Amendments or changes to clinical trial protocols would require resubmission to the FDA and IRBs for review and approval, which may adversely impact the cost, timing or successful completion of clinical trials. If we or our collaborators experience delays completing, or if we or our collaborators terminate, any of our non-clinical studies or clinical trials, or if we or our collaborators are required to conduct additional non-clinical studies or clinical trials, the development pathway, and ultimately the commercial prospects, for our product candidates may be harmed and our ability to generate product revenue from resulting products, if any, will be delayed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of Food and Drug Omnibus Reform Act, Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#x201c;pivotal study&#x201d; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Similarly, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate clinical trial application to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. If we are not able to fulfill these new requirements, our ability to conduct clinical trials may be delayed or halted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We or our collaborators may never seek or receive regulatory approval to market any of our products or product candidates outside of the U.S., or receive pricing and reimbursement outside the U.S. at acceptable levels</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our collaborators may not seek, or may seek but never receive, regulatory approval to market our products or product candidates outside of the U.S. or in any particular country or region. In order to market any product outside of the U.S., we or our collaborators must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other countries. Approval procedures vary among countries and can involve additional non-clinical studies or clinical trials, additional work related to manufacturing and analytical testing on controls, and additional administrative review periods. The time required to obtain approvals in other countries might differ from that required to obtain FDA approval. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory process in other countries. The marketing approval processes in other countries may implicate all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. In particular, in many countries outside of the U.S., products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval may require additional studies and data, and can result in substantial delays in bringing products to market in such countries and such investment may not be justified from a business standpoint given the market opportunity or level of required investment. Even if we or our collaborators generate the data and information which we believe may be sufficient to file an application for regulatory approval of any of our products or product candidates in a region or country outside the U.S., the relevant regulatory agency may find that we did not meet the requirements for approval, or even if our application is approved, we may have significant post-approval obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we or our collaborators are able to successfully develop our product candidates and obtain marketing approval in a country outside the U.S., we or they may not be able to obtain pricing and reimbursement approvals in such country at acceptable levels or at all, and any pricing and reimbursement approval we or they may obtain may be subject to onerous restrictions such as caps, rebates or other hurdles or restrictions on reimbursement. Failure to obtain marketing and pricing approval in countries outside the U.S. without onerous restrictions or limitations related to pricing, or any delay or other setback in obtaining such approval, would impair our ability or that of our collaborators to market our product candidates successfully or at all in such foreign markets. Any such impairment would reduce the size of our potential market or revenue potential, which could have a material adverse impact on our business, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any setback or delay in obtaining regulatory approval or commencing marketing, if approved, for our product candidates in a country or region outside the U.S. where we or our collaborators have decided it makes business sense to proceed may have a material adverse effect on our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely completely on third-party suppliers to manufacture commercial supplies of ZULRESSO and clinical drug supplies for our product candidates, and we intend to rely on third parties to produce commercial supplies of zuranolone, if approved, and non-clinical, clinical and commercial supplies of our approved products and product candidates in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have, nor do we plan to acquire or develop, the infrastructure or capability internally to manufacture supplies of ZULRESSO for commercial use, or of zuranolone or any of our other existing or future product candidates, for use in the conduct of our clinical trials and non-clinical studies or for future commercial use, and we rely completely on third-party suppliers for both active drug substances and finished drug products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on our contract manufacturers for commercial supplies of active drug substance, finished drug product and packaged and labeled product with respect to ZULRESSO. We also rely on our contract manufacturers to manufacture sufficient quantities of zuranolone to produce validation batches, and, if zuranolone is approved by the FDA, to manufacture commercial supplies of active drug substance, finished drug product and packaged and labeled product. We also rely on our contract manufacturers to manufacture sufficient quantities of SAGE-324, SAGE-718, SAGE-689 and our other product candidates for ongoing and planned clinical trials and non-clinical studies and expect to rely on them to scale our manufacturing processes for future clinical trials, if our development efforts are successful. We expect our contract manufacturers to comply with cGMPs in the manufacture of our products. The facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must typically complete a pre-approval inspection by the FDA and other comparable foreign regulatory agencies to assess compliance with applicable requirements, including cGMPs, after we submit the relevant NDA or equivalent foreign regulatory submission to the applicable regulatory agency, which we expect to occur in connection with our NDA for zuranolone for the treatment of MDD and PPD, which is under review by the FDA. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, and pass regulatory inspections, on the timelines we expect or at all, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities with respect to our products. For example, if the FDA were to find deficiencies in connection with a pre-approval inspection related to our zuranolone NDA submission, the FDA could issue a Form 483 documenting one or more deficiencies, require we provide and comply with a corrective action plan, or determine that our NDA is not approvable in its then-current form.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we have no direct control over our contract manufacturers&#x2019; ability to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our third-party contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our third-party contract manufacturers to regulatory risks for the production of such materials and products. As a result, failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#x2019; facilities generally. If the FDA or an applicable foreign regulatory agency determines now or in the future that these facilities for the manufacture of our products and product candidates are noncompliant, we may need to find alternative manufacturing facilities, which would significantly adversely delay or impact our commercialization efforts for any approved product and our ability to develop and obtain regulatory approval for our product candidates. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary information. Also, if a natural</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disaster were to interrupt or halt production of our drug substance or drug product at one of our third-party contract manufacturers, or cause the loss of batches, we could encounter a supply shortage or face significant costs to rebuild our supply.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have long-term supply agreements with our contract manufacturers with respect to ZULRESSO drug substance and drug product. We have an inventory of ZULRESSO drug product and drug substance in place to help mitigate any potential supply risks, but there is no guarantee that this inventory will be adequate. We have a long-term supply agreement with our contract manufacturer for zuranolone drug product, but we do not have a long-term supply agreement with any of our contract manufacturing organizations, or CMOs, for zuranolone drug substance and do not have arrangements in place for either long-term supply or redundant supply of drug substance or drug product for SAGE-324 or SAGE-718. Each batch of drug substance and drug product for our product candidates, with the exception of zuranolone drug product, is individually contracted through a purchase order governed by master service and quality agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our existing CMOs for our other product candidates are not willing to enter into long-term supply agreements, or are not willing or are unable to supply drug substance or drug product to us, we could be required to engage new contract manufacturers who would need to scale up the manufacturing process before we would be able to use the drug product or drug substance they manufacture for clinical trials or for future commercialization, if we are successful and gain approval. In addition, any contract manufacturer will need to complete validation batches, pass an inspection by the FDA and other applicable foreign regulatory agencies, and be approved by regulatory authorities as our manufacturer before we would be able to use drug product or drug substance they manufacture for commercial purposes, which could result in significant delays or gaps in product availability. We plan to continue to rely upon contract manufacturers to manufacture commercial quantities of our products, if approved. If we are unable to maintain arrangements for third-party manufacturing, or are unable to do so on commercially reasonable terms, or are unable to obtain timely regulatory approvals in connection with our contract manufacturers, we may not be able to successfully commercialize any approved product or successfully complete development of our current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Zuranolone, if approved, or any other future products, if our ongoing development efforts are successful, may not achieve broad market acceptance or reimbursement at sufficient levels, which would limit the revenue that we generate from its sales.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commercial success of zuranolone, if approved by the FDA, or any of our other current or future product candidates, if successfully developed and approved by the FDA or other applicable regulatory authorities, will depend upon the awareness and acceptance among healthcare professionals, patients, policy-makers and healthcare payors, and reimbursement at sufficient levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The availability of coverage and adequacy of reimbursement is essential for most patients to be able to access and afford treatments. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Government authorities, including the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the Department of Health and Human Services, or HHS, in the U.S., and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels for those medications. Cost containment is a primary concern in the U.S. healthcare industry and elsewhere. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Payors may adopt restrictions on coverage for any of our products, including zuranolone, if approved, such as requiring patients to try other lower cost therapies prior to reimbursing our product, requiring patients to meet severity or other criteria more restrictive than the approved label for our product, or requiring onerous and time-consuming prior authorization procedures, or they may limit the amount of reimbursement. These restrictions or limitations might impede appropriate use of our product for the approved indication. Restrictions and limitations on reimbursement or delays in obtaining coverage may vary significantly among payors and payor types. As a result, there is significant uncertainty related to third-party payor coverage and reimbursement of zuranolone, if approved, or any of our other future product candidates, if successfully developed and approved. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. Regulatory approvals, pricing and reimbursement for drug products vary widely from country to country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The inability of us or our collaborators to promptly obtain and maintain coverage and adequate reimbursement rates from both government-funded and private payors for zuranolone, if approved, and any other approved products that we develop could have a material adverse effect on our operating results, our ability to successfully commercialize our products, our ability to raise capital and our overall financial condition. Even if coverage is provided, we may not be able to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor can be an expensive and time-consuming process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. The industry competition to be included in third-party payors&#x2019; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement, often leads to downward pricing pressures on pharmaceutical products. In addition, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply when such metrics are not submitted accurately and on a timely basis. Before granting reimbursement approval, payors may require us to demonstrate that our product candidates, in addition to treating the target indications, also provide incremental health benefits to patients or healthcare costs savings. If zuranolone receives regulatory approval, we plan to pursue a value-based agreement strategy with payors. Payors may not be receptive to the use of value-based agreements or may not agree with our approach and such a strategy may not increase market acceptance or access. Even if payors agree to our value-based agreement approach, they may still impose restrictions such as requiring patients to try other lower cost therapies prior to reimbursing zuranolone, requiring patients to meet severity or other criteria more restrictive than the approved label for our product, or requiring prior authorizations, and such restrictions or requirements may be more onerous than we expect. If we believe a value-based agreement strategy will not be successful we may change our approach. We cannot be sure that adequate coverage or reimbursement will be available for zuranolone or any other product candidate that we or our collaborators commercialize or that coverage will be available on reasonable terms.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market acceptance with respect to zuranolone, if approved, or any of our other product candidates that we successfully develop will depend on a number of factors, including, among others:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety of our products as demonstrated in clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages and limitations of our products over current or future alternative treatment options, including in the case of zuranolone, if approved, the availability of lower cost antidepressants;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the incidence and severity of any side effects of the products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the labeling approved for our products by the FDA or other applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications and size of patient populations for which our products are approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience, benefit, ease and availability of alternative treatments already approved or expected to be commercially launched in the near future;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies, and our ability to increase awareness of our approved products through marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength and effectiveness of our sales, marketing and distribution strategies and support or that of our collaborators;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publicity concerning our products or competing products and treatments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pricing and cost effectiveness; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of sufficient third-party coverage or reimbursement, and the willingness of patients to pay out-of-pocket in the absence of such coverage or reimbursement, including in the case of ZULRESSO for both the product and the cost of the infusion.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our efforts to change the treatment paradigm for a given disorder or to educate the medical community and third-party payors about the benefits of any current or future products, to the extent permitted, including zuranolone for the treatment of MDD and PPD, if approved in those indications, may require significant resources and may never be successful. If zuranolone, if approved, or any other product candidates that may be approved in the future, do not achieve an adequate level of acceptance by patients, physicians, healthcare settings and payors, or reimbursement at reasonable levels, or if the patient population for which any such product is approved is smaller than we expect, we may not generate sufficient revenue from our products to become or remain profitable or to adequately fund operations or may not do so to the degree or on the timelines we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if marketing approval is granted for a product, we may face significant post-marketing obligations and future development and regulatory difficulties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities may impose significant and potentially costly post-marketing obligations with respect to approval of any product, including post-marketing studies, additional CMC work and additional pediatric studies. For example, the FDA has imposed post-marketing commitments with respect to approval of ZULRESSO, and we may encounter issues or delays in the conduct of these post-marketing commitments or we may generate unexpected results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event we or our collaborators elect, or are required, to proceed with pediatric studies of any of our product candidates in any indication, regulatory authorities may also require additional non-clinical studies or clinical trials be completed prior to commencement of such pediatric studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As was the case with brexanolone, the FDA may recommend controlled substance scheduling for our current or future product candidates, including zuranolone, if approved. In such event, the DEA will need to determine the controlled substance schedule taking into account the recommendation of the FDA. If products are determined to be controlled substances, the manufacturing, shipping, storing, selling and using of the products will be subject to an additional regulation. Distribution, prescribing and dispensing of these drugs are also regulated. Because of their restrictive nature, these laws and regulations could limit commercialization of our product candidates containing controlled substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Brexanolone is currently regulated as a Schedule IV controlled substance. Other Schedule IV controlled substances include sedative hypnotics such as benzodiazepines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZULRESSO is, and any future approved products will also be, subject to ongoing FDA requirements governing the labeling, packaging, storage and promotion of the product and record-keeping and submission of safety and other post-market information. The FDA has significant post-marketing authority, including, for example, the authority to require labeling changes based on new safety information and to require post-marketing studies or clinical trials to evaluate serious safety risks, safety and efficacy in pediatric populations or alternate doses or dose regimens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also has the authority to require, as part of an NDA or post-approval, the submission of a REMS. For example, the FDA has required a REMS for ZULRESSO. Any REMS required by the FDA may lead to increased costs to assure compliance with the REMS and with additional post-approval regulatory requirements and potential requirements or restrictions on the sale of approved products, all of which could lead to lower sales volume and revenue. In addition, if we are unable to comply with the ZULRESSO REMS or any REMS imposed for a future product, we may face additional restrictions, limitations or substantial penalties, any of which may materially adversely affect our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, our collaborators and the third-party manufacturers of our drug substance and drug products and our respective facilities are subject to extensive regulations in the manufacture of our products and product candidates, including GMP, and are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMPs and other regulations. If we, our collaborators or a regulatory agency discover problems with our approved products or product candidates such as poor control of production processes or other problems with the facility where our products are manufactured or in the manufacturing process, introduction of contaminants, or adverse events of unanticipated severity or frequency, a regulatory agency may impose restrictions on our products, the manufacturer or us or our collaborators, including requiring withdrawal of such products from the market or suspension of manufacturing. If we, our collaborators, our approved products, our product candidates, or the manufacturers for our products or product candidates fail to comply with applicable regulatory requirements, a regulatory agency may, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issue warning letters or untitled letters;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or withdraw marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend any ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to approve pending applications or supplements to applications submitted by us;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seize or detain products, refuse to permit the import or export of products, or require that we initiate a product recall.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of ZULRESSO, zuranolone, if approved, or any of our other current or future product candidates, if successfully developed and approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceuticals industry is highly competitive. There are many public and private companies, universities, governmental agencies and other research organizations actively engaged in the research and development of products that may be similar to our products or product candidates or address similar markets. It is probable that the number of companies seeking to develop products and therapies similar to our products or targeting similar indications will increase. Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. We expect competition in the indications we are pursuing will focus on efficacy, safety, convenience, availability, and price. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are perceived to be safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, there are no pharmacological therapies specifically approved for the treatment of PPD other than ZULRESSO. Current standard of care for PPD commonly consists of psychotherapy; however, patients with moderate or severe PPD are often prescribed antidepressant medications such as selective serotonin reuptake inhibitors, or SSRIs, and serotonin and norepinephrine reuptake inhibitors, or SNRIs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced product candidate is zuranolone, for which we filed an NDA with the FDA seeking approval for the treatment of MDD and PPD. Patients with MDD are typically treated with a variety of low-cost antidepressant medications, including SSRIs, SNRIs and atypical antipsychotics. If approved, zuranolone may also face competition for the treatment of MDD from AXS-05, a combination formulation of an NMDA receptor antagonist, dextromethorphan, with bupropion, an FDA-approved antidepressant affecting norepinephrine and dopamine, which such combination formulation was approved in August 2022 by the FDA for the treatment of MDD in adults. Zuranolone, if approved, may also face competition from esketamine, which is approved for the treatment of treatment-resistant depression and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">depressive symptoms in adults with MDD with acute suicidal ideation or behavior, and from cariprazine, which was recently approved for the adjunctive treatment of MDD in patients who are receiving ongoing antidepressant therapy. A number of other companies are developing product candidates intended for the treatment of MDD. Furthermore, if zuranolone is successfully approved for PPD and commercialized, it could further limit our commercial opportunity for ZULRESSO.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the field of neuroactive steroids focused specifically on modulation of GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors, we also face competition from a number of companies, including Marinus Pharmaceuticals, Inc., or Marinus. In March 2022, Marinus announced that the FDA had approved ganaxolone, a known GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> positive allosteric modulator neuroactive steroid, to treat seizures associated with CDKL5 deficiency disorder, a rare, genetic epilepsy. Other GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> competitors include darigabat, which is being developed by Cerevel Therapeutics, Inc. for the treatment of epilepsy and panic disorder.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE-324, a novel GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptor positive allosteric modulator, is in Phase 2 development for essential tremor. If successfully developed and approved as a treatment for essential tremor, SAGE-324 will face competition from current first-line treatments which include &#x3b2;-adrenergic blocker propranolol and anticonvulsant primidone. Other companies are also developing potential treatments for essential tremor, including a T-type calcium channel modulator that Jazz Pharmaceuticals, Inc. is currently evaluating in Phase 2b development and a Phase 2 T-type calcium channel modulator being developed by Praxis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A number of companies are working to develop products designed to modulate the NMDA receptor. Novartis AG, following its acquisition of Cadent Therapeutics, Inc., is developing its own NMDA receptor positive allosteric modulator, CAD-9303, which is currently being investigated in cognitive impairment associated with schizophrenia. In addition, Vaccinex, Inc. is evaluating VX15/2503, a monoclonal antibody against the protein semaphorin 4D (SEMA4D), as a treatment for cognitive impairment in Huntington's disease. Prilenia Therapeutics, B.V. is also assessing pridopidine, a sigma-1 receptor (S1R) agonist, in a Phase 3 clinical trial as a treatment for Huntington&#x2019;s disease. Several companies have developed or are developing products for the treatment of Alzheimer's disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our existing collaborations with Biogen and Shionogi, and any future collaborations, may not lead to the successful development or regulatory approval of product candidates or commercialization of products. Our collaborators may have competing priorities, conflicting incentives, or different views than us on key decisions, including appropriate program spending, that may hamper or delay our development and commercialization efforts or increase our costs. Our business may be adversely affected if any of our collaborators fails to perform its obligations or terminates our collaboration, or if we are not able to establish future collaborations that we believe to be important to our business on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates in some or all markets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our existing and future collaborations, if any, may not lead to the successful development and commercialization of any products. Our collaborators face both the same challenges and hurdles that we would face in the development and commercialization of product candidates if we were engaged in the activities solely ourselves, as well as additional challenges related to operating under a collaboration. For example, we have entered into a collaboration and license agreement with Biogen MA Inc., or BIMA, and Biogen International GmbH, or, collectively with BIMA, Biogen, to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. and granting Biogen rights to develop and commercialize those product candidates in the rest of the world other than Japan, Taiwan and South Korea, or the Shionogi Territory, in the case of zuranolone. We have a separate collaboration with Shionogi &amp; Co., Ltd., or Shionogi, under which we granted rights to Shionogi for the development and commercialization of zuranolone in the Shionogi Territory. The efforts under these collaborations may not be successful and we may never receive any additional milestone payments, profit-share revenue or royalty payments from Biogen or Shionogi. In addition, under most collaborations, including our existing collaborations, a certain degree of control in decision-making is transferred to or shared with our collaborators. Our collaborators may use their decision-making authority to make decisions that could delay, decrease the potential of, or otherwise adversely impact, development and commercialization of our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidates. Similarly, where we share decision-making authority, the need to gain alignment on decisions may slow or impede advancement of our programs and cause us not to be able to meet our timelines or achieve our goals. Our collaborators may have competing priorities or different incentives that cause them to divert resources away from our collaboration, or we may not agree on appropriate spending levels, which could hamper our overall development and commercialization efforts or increase our overall spending. Our collaborators may independently develop, or develop with a competitor, competitive products or may believe that product candidates being evaluated in the collaboration could be competitive with the collaborator&#x2019;s own products. In the case of the collaboration with Biogen, both companies have agreed to certain exclusivity provisions for certain products in specified indications which may limit certain development opportunities outside the collaboration. In addition, if we depend on collaborators for capabilities and funding for major product development efforts globally or in key territories then our business may be adversely affected if our collaborator fails to perform its obligations under the agreement or the collaboration terminates. Disputes may also arise with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and commercialize any affected product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify or discover additional product candidates beyond our existing product candidates or to file investigational new drug, or IND, applications for clinical development of new compounds at the rate we expect, or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our business depends upon our and our collaborators&#x2019; ability to successfully develop, gain approval of and commercialize products based on our current product candidates and on our ability to generate new compounds for development in the future and to successfully complete the non-clinical work necessary to file INDs to pursue clinical development of such new compounds. Our research programs may fail to generate new compounds that meet the standards for non-clinical development, and, if even we are successful in generating such compounds, we may not be able to produce the non-clinical and other data necessary to support IND applications for clinical development, in each case in the number or at the rate we expect or at all for a number of reasons. For example, we may not be able to identify a sufficient number of new targets in areas of interest to us. Our research methodology may be unsuccessful in generating a sufficient number of new compounds appropriate for non-clinical testing in the target areas we identify. Even if we generate new compounds in areas of interest to us, we may determine that those compounds are not appropriate for non-clinical development, or we may generate data in non-clinical development that do not support IND filings for clinical development. We may not have, or devote, sufficient technical, financial, and human resources to our research efforts at the various stages needed to identify targets, generate compounds, conduct non-clinical studies and prepare INDs. Additional potential product candidates may be shown to have harmful side effects or may not have a positive risk/benefit profile or may have other characteristics that may make the product candidates not appropriate for further development or unlikely to receive marketing approval. Further, even if we generate new compounds in areas of interest, we may determine that those compounds are not worth pursuing for strategic reasons, including new legislation that may impact the viability of commercializing such compounds, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited financial and management resources, we focus on a limited number of clinical and research programs and product candidates and are currently focused on certain brain health disorders. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful and may not yield any commercially viable drugs. Our resource allocation decisions may cause us to fail to capitalize on other viable opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights through future collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain such sole</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development and commercialization rights. If any of these events occur, it may have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely, and expect that we will continue to rely, on third parties to conduct any clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties, comply with applicable standards and meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our products, if approved, and our business could be substantially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have the ability to independently conduct clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct clinical trials of our product candidates. We enter into agreements with third-party CROs to provide monitors for and to manage data for our ongoing clinical trials. We rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have staffing difficulties and shortages, attrition of experienced staff, and other resource constraints;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fail to comply with contractual obligations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fail to comply with current Good Clinical Practices, or GCPs, or experience other regulatory compliance issues;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undergo changes in priorities or become financially distressed; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">form relationships with other entities, some of which may be our competitors; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be impacted by changes to the macroeconomic and geopolitical environment, and the downstream effects of these changes.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials, and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements, and scientific standards, and our reliance on CROs does not relieve us of our regulatory responsibilities. We, clinical investigators, and our CROs are required to comply with regulations and guidelines, including GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for any product candidates in clinical development or where clinical trials are being conducted. If we or our CROs or contract manufacturers fail to comply with these regulations or if the quality or accuracy of the clinical data obtained is compromised due to the failure to adhere to our clinical protocols or other regulatory requirements or for other reasons, and we are unable to rely on clinical data collected, we may be required to repeat clinical trials or extend the duration of, or increase the size of our clinical trials. This would delay the regulatory approval process, and could also subject us to enforcement action up to and including civil and criminal penalties. If any of our relationships with third-party CROs terminate or if a CRO needs to be replaced, we may not be able to enter into arrangements with alternative CROs in a timely manner or at all. Any of these issues could significantly delay or prevent regulatory approval of our product candidates and require significantly greater expenditures. In such an event, we believe that our financial results might be harmed, our costs could increase and our ability to generate revenue from products beyond ZULRESSO could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">As our development and commercialization efforts advance, we expect to continue to significantly develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the complexity and level of activities and resources that are necessary to develop and commercialize pharmaceutical products, we have been growing and expanding our company and, if our planned development and regulatory efforts are successful, we expect to continue to need to significantly increase our number of employees and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scope of our operations. For example, to commercialize any future products, we will need to recruit and train additional qualified sales personnel, and continue to implement and improve our managerial, operational and financial systems. We may not be able to effectively manage any expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure and give rise to operational mistakes or delays, loss of business opportunities, loss of employees and reduced productivity among remaining employees. If our management is unable to effectively manage any potential significant expansion, our expenses may increase more than expected, and our ability to successfully develop and gain regulatory approval of our product candidates and generate or increase our revenue, if such product candidates are approved, could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize any future products that we successfully develop, and to compete effectively will depend, in part, on our ability to effectively manage the potential future expansion of our company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to attract, retain and motivate qualified personnel.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To accomplish our objectives, we require a strong management team with expertise in research and development, clinical development and commercialization. Although we have entered into employment agreements with each of our executive officers, each of them is employed &#x201c;at will&#x201d; and may terminate his or her employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. Recruiting and retaining qualified personnel is critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. Failure to succeed in clinical trials or in obtaining regulatory approval may make it more challenging to recruit and retain qualified personnel. If we are unable to continue to attract and retain high quality personnel, our development efforts, commercialization activities, business, financial condition, results of operations and growth prospects could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The sale of ZULRESSO and any future approved products and use of our product candidates in clinical trials will expose us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers or others using, prescribing, selling or otherwise coming into contact with our products and product candidates. For example, we may be sued if any product or product candidate allegedly causes injury or is found to be otherwise unsuitable during clinical trials, manufacturing, marketing, sale or commercial use. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, knowledge of risks, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection laws. If we become subject to product liability claims and cannot successfully defend ourselves against them, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of patients from our clinical trials, or difficulty in enrolling clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our approved products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">damage to our reputation and exposure to adverse publicity;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased FDA warnings on product labels;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">litigation costs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">distraction of management&#x2019;s attention from our primary business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of products from the market or our inability to successfully gain approval of product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain product liability insurance coverage with a $20.0 million annual aggregate coverage limit. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or losses we may suffer. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to protect us against losses, including if insurance coverage becomes increasingly expensive. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting judgments exceed our insurance coverage, our financial condition, business and prospects could be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Medicaid Drug Rebate Program, which we participate in, and other governmental programs impose obligations to report pricing figures to the federal government, require us to pay rebates and participate in discount programs. Other programs impose limits on the price we are permitted to charge certain entities for ZULRESSO or for any future products for which we receive regulatory approval. Statutory and regulatory changes or binding guidance regarding these programs and their requirements could negatively affect the coverage and reimbursement by these programs of ZULRESSO or any future products for which we receive regulatory approval and could negatively impact our results of operations. Our failure to comply with these price reporting and rebate payment obligations could negatively impact our financial results. The Patient Protection and Affordable Care Act, as amended, referred to herein as the ACA, and regulations promulgated thereunder could affect our obligations in ways we cannot anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies and the courts. If we become obligated to restate or recalculate the amounts we report under these programs, our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and our price discounts and rebates could be increased. Additionally, we could be held liable for errors associated with our submission of pricing data under the Medicaid Drug Rebate Program and other federal or state drug pricing programs, including retroactive rebates and program refunds, and if we are found to have knowingly submitted false average manufacturer price or best price information to the government, civil monetary penalties per item of false information. Certain failures to submit required data could result in a civil monetary penalty for each day the information is late beyond the due date and be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program, or, if we fail to comply with 340B program requirements, the Health Resources and Services Administration, or HRSA, could decide to terminate our 340B program participation agreement. In the event that CMS terminates our rebate agreement or HRSA terminates our 340B program participation agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. We are also subject to civil monetary and other penalties applicable to the drug pricing negotiation program and Part B and Part D inflation rebate programs, as discussed further below under the risk factor entitled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare regulations aimed at reducing healthcare costs may have a material adverse effect on our business or results of operation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to a number of healthcare and other statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we currently or may in the future conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current or future interactions and arrangements with third-party payors, healthcare providers, patients, healthcare settings, and others who play a role in the recommendation, prescription, reimbursement and administration of ZULRESSO and will play a similar role with respect to zuranolone, if approved and any of our other future product candidates, if successfully developed and approved, are governed in part by broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we market, sell and distribute ZULRESSO or expect to market, sell and distribute any future approved products. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly (including any kickback, bribe or certain rebates), in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical companies on the one hand, and prescribers, purchasers and formulary managers, among others, on the other. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal False Claims Act imposes criminal and civil penalties, including those from civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties. Pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product, among other activities. In addition, the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes privacy, security and breach reporting obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information upon covered entities subject to the rule.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal transparency requirements, sometimes referred to as the &#x201c;Sunshine Act&#x201d;, under the ACA require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program to report to HHS information related to physician payments and other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations were extended to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state laws and regulations, such as state anti-kickback and false claims laws and transparency laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various federal and state health information and data protection laws and regulations, and similar types of laws outside the U.S., govern the collection, use, disclosure and protection of health-related and other personal information by us and our collaborators.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our future practices and business arrangements comply with applicable healthcare laws and regulations is costly. It is possible that governmental authorities will conclude that our business practices and arrangements do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our practices or operations, including activities conducted by our commercial team or other of our employees, consultants or vendors, were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines and exclusion from government funded healthcare programs, such as Medicare and Medicaid, any of which could substantially disrupt our operations and materially adversely affect our business and financial condition. We may also be substantially negatively impacted if governmental authorities conclude that the business practices of one of our collaborators does not comply with applicable laws. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our employees are also subject to other statutes and regulations related to our business, including: regulations imposed by the FDA and applicable non-U.S. regulators, as previously discussed; anti-bribery and anti-corruption laws and regulations applicable to activities outside the U.S.; rules on reporting financial and other information or data timely and accurately; and rules related to insider trading.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we have adopted a code of conduct and have an active compliance program, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure by our employees to comply with these laws or regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We must comply with numerous federal, state and non-U.S. laws which govern the privacy and security of health and other personal information. As described above, to the extent applicable to our business activities, HIPAA imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. In addition, when we conduct clinical trials in the U.S., any personal information that is collected in connection with these trials also is regulated by the Federal Policy for the Protection of Human Subjects (the Common Rule) which creates obligations for our company when conducting these trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to enroll subjects in our ongoing or future clinical trials in the European Union, or EU, or other countries. When we do so, we may be subject to additional privacy restrictions, including restrictions relating to the collection, use, storage, transfer, and other processing of personal data, including personal health data, regarding these individuals. Clinical trial activities in the EEA, for example, are governed by the General Data Protection Regulation, or GDPR, in relation to the processing of personal data. The GDPR imposes several requirements on companies that process personal data, strict rules on the transfer of personal data out of the EEA, including to the U.S., and fines and penalties for failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR in some situations. The obligations under the GDPR may be onerous and adversely affect our business, financial condition, results of operations and prospects. Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any European activities. The issues related to the transfer of personal data are subject to substantial uncertainty at this time, and there can be no reasonable level of confidence that any such data transfers will be found to be consistent with EU law if they are challenged. The United Kingdom&#x2019;s, or UK&#x2019;s, exit from the EU, often referred to as Brexit, has created uncertainty with regard to future data protection regulation in the United Kingdom. The European Commission has adopted an adequacy decision concerning the level of data protection in the UK. Personal data may now flow freely from the EEA to the UK; however, the European Commission may suspend the adequacy decision if it decides that the UK no longer provides for an adequate level of data protection. Similar laws exist in many other countries around the world, and these laws (which are evolving and expanding) create complicated and potentially inconsistent obligations that may impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to the California Consumer Privacy Act, or CCPA, which creates individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our business activities. The CCPA also has been amended through a recent referendum in California that creates additional obligations that went into</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effect on January 1, 2023. In November 2020, California voters approved the California Privacy Rights Act, or CPRA, ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency, or the CPPA. New implementing regulations will be issued under the CPRA that may lead to new or additional obligations for us. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and damages. At least four states have passed similar general privacy legislation that may impact our business activities in the future, and additional states are evaluating similar kinds of general privacy legislation. In addition, there are substantial efforts at the federal level to pass a national data privacy law that may impact our business activities. The uncertainty, ambiguity, complexity and potential inconsistency surrounding the implementation and interpretation of CCPA and other enacted or potential laws in other states and at the federal level exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal data and protected health information. We may be subject to fines, penalties, or private actions in the event of non-compliance with such laws. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. We have implemented processes to manage compliance with the CCPA and continue to assess the impact of the CPRA, and other federal and state legislation, on our business as additional information and guidance becomes available.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the foregoing, any breach of privacy laws or data security laws, particularly resulting in a significant security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, could have a material adverse effect on our business, reputation and financial condition. As a data controller, we will be accountable for any third-party service providers we engage to process personal data on our behalf, including our CROs. There is no assurance that privacy and security-related safeguards we implement will protect us from all risks associated with the third-party processing, storage and transmission of such information. In certain situations, both in the U.S. and in other countries, we also may be obligated as a result of a security breach to notify individuals and/or government entities about these breaches.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, in October 2022, President Joe Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court. The uncertainty around this issue may impact our activities with companies in the EU, and any potential future business operations in the EU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FDA and other regulatory and enforcement agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other regulatory and enforcement agencies strictly regulate the promotional claims that may be made about prescription products, and enforce laws and regulations prohibiting the promotion of unapproved, or &#34;off-label&#34; uses. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the approved labeling of the product. If we are found to have promoted off-label uses for any product, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has taken steps to restrict promotional activities of those companies. Pharmaceutical companies have also been prosecuted and incurred significant civil, criminal and administrative penalties, damages, fines under the False Claims Act in connection with their alleged off-label promotion of drugs. Any promotion of the off-label use of ZULRESSO, zuranolone, if approved, or any of our other future approved products by us or any of our employees could subject us to significant liability, which would materially adversely affect our business and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens, price controls, reimbursement issues and other risks and uncertainties, and could negatively impact our U.S. business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future profitability may depend, in part, on our ability, ourselves or through our collaborators, to commercialize our products and product candidates in foreign markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pricing of prescription pharmaceuticals in foreign markets is subject to foreign governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some countries, including Member States of the EU, the pricing of prescription drugs is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. In the U.S., recent legislative and administrative policies and proposals signal a desire to lower drug prices in the U.S. As a result, we or our collaborators outside the U.S. in the future may be limited in the prices we are able to charge for our products in the U.S. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our collaborators and the potential profitability of our products in those countries would be negatively affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercializing our products and product candidates in foreign markets would subject us to additional risks and uncertainties, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to directly control commercial activities to the extent we are relying on third parties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, including the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">import or export licensing requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">longer accounts receivable collection times;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced protection of intellectual property rights, and the existence of additional potentially relevant third-party intellectual property rights, in some foreign countries; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency exchange rate fluctuations.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. For example, Brexit has already and may continue to adversely affect European and/or worldwide regulatory conditions. Brexit could continue to lead to legal uncertainty and potentially divergent national laws and regulations in the EU and the United Kingdom, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom determines which EU laws to replicate or replace, which could impair our ability to transact business in the EU and the United Kingdom in the future, if we elect to seek to commercialize any of our products there.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property Rights</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our products and compositions, their methods of use and any other inventions that are important to the development of our business. We may also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents, should they issue; preserve the confidentiality of our trade secrets; and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the proprietary position of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot provide any assurances that any of our pending patent applications will mature into issued patents. For example, the U.S. Patent and Trademark Office, or U.S. PTO, has issued a final rejection against one of our patent applications claiming one of our proprietary GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> positive allosteric modulator compounds, asserting a lack of novelty and non-obviousness. We are in the process of challenging the rejection, and may not be successful in overturning the rejection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to obtain issued patents covering our proprietary compounds. We cannot provide any assurances that any of our issued patents will be enforceable, or include claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. For example, the issued patent and patent applications that provide coverage for ZULRESSO only cover particular formulations and particular methods of using such formulations to treat depressive disorders such as PPD and MDD. As a result, such issued patent and any patent that may issue from such patent applications, would not prevent third-party competitors from creating, making and marketing alternative formulations of brexanolone that fall outside the scope of the patent claims or from practicing alternative methods. Moreover, other parties have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent position. Such third-party patent positions may limit or even eliminate our ability to obtain patent protection for certain inventions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, derivation proceedings, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex parte</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reexamination, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review proceedings, post-grant review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. For example, our granted European patent covering brexanolone i.v. has been opposed by a third party, and the opposition proceedings are ongoing. Thus, any patents, should they issue, that we may own or exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding or a derivation proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our product candidates. Furthermore, though a patent, if it were to issue, is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability, and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Even if a patent issues, and is held to be valid and enforceable, competitors may be able to design around our patents, such as using pre-existing or newly developed technology. Other parties may develop and obtain patent protection for more effective technologies, designs or methods.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors, former employees and current employees. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries. If these developments were to occur, they could have a material adverse effect on our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales if any of our product candidates are approved in those countries. Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#x2019;s or potential competitor&#x2019;s product. Any litigation to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming, and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, proceedings to enforce or defend our patents, if and when issued, could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents, if and when issued, covering our product or product candidates is invalidated or found unenforceable, our financial position and results of operations may be materially and adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered our product candidates, our financial position and results of operations may also be materially and adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any of our pending patent applications, if issued as a patent, will include claims having a scope sufficient to protect our current product candidates or any other products or product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any of our pending patent applications will issue as patents at all;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will be able to generate significant revenue from sales of ZULRESSO or any of our product candidates, if successfully developed and approved, before our relevant patents expire;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we were the first to make the inventions covered by each of our pending patent applications and any patents that may issue in the future;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we were the first to file patent applications for these inventions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others will not develop similar or alternative technologies that do not infringe any patents that may be issued to us;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others will not use pre-existing technology to effectively compete against us;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any of our patents, if issued or as issued, will provide us with a competitive advantage and be found ultimately to be valid and enforceable;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will develop additional proprietary technologies or product candidates that are separately patentable; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that our commercial activities or products will not infringe upon the patents or proprietary rights of others.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may rely upon unpatented trade secrets and depend on unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by confidentiality agreements with our employees and our CROs, collaborators and consultants. It is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise become known or be independently discovered by our competitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing ZULRESSO, zuranolone, if approved, and our other product candidates, if successfully developed and approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. We cannot assure you that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties. The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may allege that our products or product candidates or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. As we continue to develop our current product candidates and commercialize ZULRESSO and any future products, competitors may claim that our technology infringes their intellectual property rights as part of business strategies designed to impede our successful commercialization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that our product or product candidates may infringe, or which such third parties claim are infringed by our technologies. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. Patent litigation is costly and time-consuming. Any claim relating to intellectual property infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorney&#x2019;s fees if we are found to be willfully infringing another party&#x2019;s patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we are forced to take a license. In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing our product or product candidates. In the case of trademark claims, if we are found to be infringing, we may be required to redesign, or rename, some or all of our product candidates to avoid infringing the intellectual property rights of third parties, which may not be possible and, even if possible, could be costly and time-consuming. Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into confidentiality and intellectual property assignment agreements with our employees, consultants, CROs, outside scientific collaborators, and other advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign to us any inventions developed in connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution or another party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most of our employees have also been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We also engage advisors and consultants who are concurrently</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employed at universities or who perform services for other entities. We may be subject to claims that an employee, advisor or consultant performed work for us that conflicts with that person&#x2019;s obligations to a third party, such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out of work performed for us.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees which could have a materially adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other formalities and provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the patent applications we own or license are issued, competitors may infringe these patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents should be interpreted narrowly and do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interference proceedings or derivation proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued patents covering our product or any of our product candidates could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or one of our collaborators or licensors initiated legal proceedings against a third party to enforce a patent, if and when issued, covering our product or any of our product candidates, the defendant could counterclaim that the patent covering our product or any of our product candidates is invalid and/or unenforceable. In patent litigation in the U.S.,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description, or non-enablement. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex parte</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, derivation proceedings or interferences and equivalent proceedings in foreign jurisdictions, e.g., opposition or revocation proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. For example, our granted European patent covering brexanolone i.v. has been opposed by a third party, and the opposition proceedings are ongoing. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the applicable product or product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing patent applications and prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. could be less extensive than those in the U.S., assuming that rights are obtained in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may use our technologies in jurisdictions where we do not pursue patent protection. They may pursue and obtain their own patent protection to develop their own products. Further, they may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology and pharmaceuticals. For example, a 2022 report from the Office of the U.S. Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights in such jurisdictions. Many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, proceedings to enforce our patent rights in foreign jurisdictions could, among other things, result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">For ZULRESSO and certain of our product candidates, we are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing certain of our products or product candidates, if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our products, product candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business and we expect that we may need to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we have done previously, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we fail to obtain a license, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties under licenses or collaborative development relationships;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully commercialize the relevant product or to successfully develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into several licenses to support our various programs. We may enter into additional licenses to third-party intellectual property that are necessary or useful to our business. Our current licenses and any future licenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that we may enter into impose various royalty payment, milestone, and other obligations on us. For example, the licensor may retain control over patent prosecution and maintenance under a license agreement, in which case, we may not be able to adequately influence patent prosecution or prevent inadvertent lapses of coverage due to failure to pay maintenance fees. If we fail to comply with any of our obligations under a current or future license agreement, the licensor may allege that we have breached our license agreement, and may accordingly seek to terminate our license. In addition, future licensors may decide to terminate their licenses with us at will. Termination of any of our current or future licenses could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop a product candidate or commercialize a product, as well as harm our competitive business position and our business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if our licensors fail to abide by the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms, our business could materially suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Some intellectual property which we have licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of the intellectual property rights we have licensed may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the intellectual property rights licensed to us under the license agreement with The Regents of the University of California may have been generated using U.S. government funds. As a result, the U.S. government may have certain rights to intellectual property embodied in our current product or current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if the government determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#x201c;march-in rights&#x201d;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor fails, to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we enter into future arrangements involving government funding, and we discover compounds or product candidates as a result of such funding, intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not obtain new chemical entity or other types of marketing and data exclusivity for our product candidates and if we do not obtain additional protection under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments, and similar foreign legislation by extending the patent terms of our product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketing exclusivity provisions under the Federal Food, Drug, and Cosmetic Act, or FDCA, can delay the submission or the approval of certain marketing applications by other companies for a product with the same active moiety as a product we sell or may in the future sell. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to obtain approval of an NDA for a new chemical entity, or NCE. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for a full NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. We have obtained NCE exclusivity for brexanolone and plan to seek NCE exclusivity for our current and future product candidates. There is no guarantee that our product candidates will qualify for marketing or data exclusivity under these provisions or that such exclusivity for any of our products will alone be sufficient for our business. The applicable five-year and three-year exclusivity periods of NCE or data exclusivity under the FDCA will not delay the submission or approval of a full NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of the U.S. patents we own or license may be eligible for limited patent term restoration in the future under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Even if, at the relevant time, we have a valid issued patent covering our product, we may not be granted an extension if we were to fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, and we do not have any other exclusivity, our competitors may obtain approval of competing products following our patent expiration and our business, financial condition or results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted wide-ranging patent reform legislation: the Leahy-Smith America Invents Act, referred to as the America Invents Act. The America Invents Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. It is not yet clear what, if any, impact the America Invents Act will have on the operation of our business. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents that may issue from our patent applications, all of which could have a material adverse effect on our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, in March 2012, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mayo Collaborative Services, DBA Mayo Medical Laboratories, et al. v. Prometheus Laboratories, Inc.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the U.S. Supreme Court held that several claims drawn to measuring drug metabolite levels from patient samples and correlating them to drug doses were not patentable subject matter. The decision appears to impact diagnostics patents that merely apply a law of nature via a series of routine steps and it has created uncertainty around the ability to obtain patent protection for certain inventions. Additionally, in June 2013, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the U.S. Supreme Court held that claims to isolated genomic DNA are not patentable, but claims to complementary DNA molecules are patent eligible because they are not a natural product. In June 2014, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Alice Corporation Pty. Ltd. v. CLS Bank International, et al.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a case involving patent claims directed to a method for mitigating settlement risk, the U.S. Supreme Court held that the patent eligibility of claims directed to abstract ideas, products of nature, and laws of nature</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">should be determined using the same framework set forth in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prometheus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The U.S. PTO has issued a set of guidelines setting forth procedures for determining subject matter eligibility of claims directed to abstract ideas, products of nature, and laws of nature in line with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prometheus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Myriad</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Alice</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> decisions. The guidance does not limit the application of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Myriad</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to DNA but, rather, applies the decision to other natural products. The full impact of these decisions on our business is not yet known.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">With passage of the CREATES Act, we are exposed to possible litigation and damages by competitors. In addition, existing statutes, including the CREATES Act, and proposed legislation in Congress, if passed into law, could limit the patent exclusivity on our products or facilitate earlier entry of generic competition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the CREATES Act, legislation intended to facilitate the development of generic and biosimilar products, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications. Such litigation would subject us to additional litigation costs, damages and reputational harm, which could lead to lower revenues. Increased risk of generic competition with ZULRESSO, zuranolone, if approved, and any of our other product candidates, if approved, including as a result of the CREATES Act, could impact our ability to maximize product revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, members of Congress have proposed numerous legislative initiatives aimed at limiting the patent exclusivity on drug products or facilitating earlier entry of generic versions of approved drugs. Examples of bills that have been proposed include a bill that, if passed, would create a presumption of invalidity for patents beyond the first patent covering a drug product thus shifting the burden to the innovator to prove that these subsequent patents are separately patentable inventions, distinct from the first patent; a bill that, if passed, would empower the Federal Trade Commission to investigate whether large patent portfolios covering a drug product constitute an anti-competitive practice and to file antitrust lawsuits in such instances; and a bill that, if passed, would limit the availability of a 30-month stay on approval by the FDA of a generic version of a drug to only those instances where the ANDA litigation involves a composition of matter patent claiming the drug substance. Such legislation, if passed into law, could adversely affect ZULRESSO or any future products or result in earlier entry into the market of generic versions of our drugs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Industry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare regulations aimed at reducing healthcare costs may have a material adverse effect on our business or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been, and likely will continue to be, legislation and legislative, administrative and regulatory proposals in the U.S., both at the federal and state level, and in many foreign jurisdictions, aimed at reducing healthcare costs. The implementation of cost containment measures, drug pricing controls or other reforms could have an adverse effect on our revenue from ZULRESSO, zuranolone, if approved, or from the sales of any other products that are successfully developed and approved, and may limit our ability to achieve profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, provided a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (pursuant to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D (subsequently modified by the IRA, as discussed below).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the Coronavirus Aid, Relief and Economic Security Act and subsequent legislation, these Medicare sequester reductions were reduced and suspended, with the full 2% cut resuming in July 2022. These and other laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products or product candidates for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. For example, the Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 (PAYGO) sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Act&#x2019;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain provisions of the ACA have been subject to judicial challenges as well as efforts to modify them or to alter their interpretation or implementation. For example, the U.S. Tax Cuts and Jobs Act of 2017, signed into law in December 2017, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; We expect that the ACA, its implementation, efforts to challenge or modify the ACA or its implementing regulations, or portions thereof, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to commercialize our product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices. Specifically, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs, including under Medicare and Medicaid, which may potentially impact negotiations on pricing and discounts with commercial payers, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. There have been multiple Congressional and administrative efforts to address drug pricing, including the Inflation Reduction Act of 2022, or IRA. It is unclear whether any other legislation or public policy will come to pass, and if so, what effect it could have on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The IRA was signed into law by President Biden in August 2022. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for certain outpatient prescription drug coverage, as well as Medicare Part B. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with negotiated prices subject to a cap and first set to take effect in 2026; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (the first Part B inflation rebate period is in first quarter 2023; the first Part D inflation rebate period is fourth quarter 2022 through third quarter 2023); and replaces the Part D coverage gap discount program with a new Part D discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years of these programs. Manufacturers may be subject to civil monetary penalties for certain violations of the negotiation and inflation rebate provisions and an excise tax during a noncompliance period under the negotiation program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized CMS to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. Drugs may be selected for negotiation only once they are at least seven years post-approval (such that they will be nine years post approval when first subject to the maximum negotiated price) and biologics may be selected for negotiation 11 years post approval (such that they will be 13 years post-approval when first subject to the maximum negotiated price). It does not apply to drugs and biologics that have been approved for a single rare disease or condition. We could be at risk of government action if, in the future, any of our products are the subject of Medicare price negotiations. In that event, the outcome of the Medicare price negotiations, which will be made publicly available, may also impact negotiations on pricing and discounts with commercial payers. These risks as to pricing may further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if the pricing of any of our products are the subject of Medicare price negotiations. As a result, these risks may also impact the development decisions we make with respect to our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the IRA subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the IRA by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law or for taking price increases that exceed inflation. The IRA also requires manufacturers to pay rebates for drugs reimbursed under Medicare Part D whose price increases exceed inflation and caps Medicare out-of-pocket drug costs beginning in 2025, at $2,000 a year, subject to an adjustment for inflation thereafter. Drug manufacturers may also be subject to civil monetary penalties with respect to their compliance with these programs. In addition, the IRA potentially raises risks related to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#x201c;catastrophic period&#x201d; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by eliminating the coverage gap starting in 2025, reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and imposing price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is unclear how the IRA will be implemented. We further cannot predict with certainty what impact the IRA or any other federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition. There may be additional Congressional and administrative efforts to address drug pricing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and agencies have implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and price transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare or limiting exclusivity periods for pharmaceutical products. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the demand for ZULRESSO and for zuranolone, if approved, or any of our other product candidates, if approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to receive or set a price that we believe is fair for our products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amount of taxes that we are required to pay; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that the measures discussed above, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue from sales of ZULRESSO, successfully commercialize zuranolone or any other products if approved in the future, and achieve profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems or networks, or cloud platforms or those of our collaborators, our third-party CROs or our other contractors, consultants or service providers, may fail or suffer security breaches, which could result in a material disruption of our development programs, compromise personal or sensitive information related to our business, or cause us to incur significant liabilities which could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business, and despite the implementation of security measures, our internal computer systems and those of our collaborators, our third-party CROs and our other contractors, consultants and service providers are vulnerable to cyber security threats, including damage from unauthorized access, theft, natural disasters, terrorism, war, telecommunication and electrical failures, and system malfunction, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, viruses, worms, denial-of-service attacks, supply chain attacks, social engineering schemes and other means to affect service reliability and threaten the confidentiality, integrity and availability of information). If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs or cause us to have liability for disclosure of personal information of our customers. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory submission and approval efforts and significantly increase our costs to recover or reproduce the data, if possible. To the extent that any disruption, disaster or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed or prevented.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could be required to expend significant amounts of money and other resources to respond to these threats or breaches and to repair or replace information systems or networks or cloud platforms. We also could suffer financial loss or the loss of valuable confidential information. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive acts or practices in violation of Section 5(a) of the Federal Trade Commission Act, or the FTC Act. The Federal Trade Commission, or the FTC, expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The guidance of the FTC for appropriately securing consumers&#x2019; personal information is similar to what is required by the HIPAA Security Rule, which establishes national standards for covered entities to protect individuals&#x2019; electronic personal health information. The HIPAA Security Rule requires covered entities to have appropriate administrative, physical and technical safeguards to help ensure the confidentiality, integrity, and security of electronic protected health information. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#x2019; personal information. Any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Although we develop and maintain systems and controls designed to prevent these events from occurring and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes are costly and require ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, we cannot guarantee that our, or our third-party CROs&#x2019; or our other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contractors&#x2019;, consultants&#x2019; or service providers&#x2019; security measures will be sufficient to prevent data loss and other security breaches. Despite our efforts, the possibility of these events occurring cannot be eliminated entirely and there can be no assurance that any measures we take will prevent cyber-attacks or security breaches that could adversely affect our business, including security breaches that may remain undetected for extended periods of time, which can substantially increase the potential for a material adverse impact resulting from the breach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a biopharmaceutical company that has not generated significant revenue to date. We have incurred significant operating losses since our inception, and anticipate that we will incur losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a biopharmaceutical company with only one approved product, and only began generating revenue from product sales in the second quarter of 2019. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have funded our operations to date primarily through proceeds from sales of common stock, including the sale of stock to BIMA; redeemable convertible preferred stock prior to our initial public offering and, to a lesser extent, the issuance of convertible notes. From our inception through March 31, 2023, we had received aggregate net proceeds of $2.8 billion from such transactions. We also received $1.0 billion in upfront payments under our collaborations with Biogen and Shionogi. As of March 31, 2023, our cash, cash equivalents and marketable securities were $1.1 billion. We have incurred net losses in each year since our inception, except for net income of $606.1 million for the year ended December 31, 2020, reflecting revenue recognized under a collaboration and license agreement with Biogen. Our net loss was $146.8 million for the three months ended March 31, 2023, and our accumulated deficit was $2.2 billion as of March 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital. We expect our research and development expenses and selling, general and administrative expenses to increase, particularly as we advance planned and ongoing clinical trials for SAGE-718 and SAGE-324 and prepare for the potential commercial launch of zuranolone, including in support of permitted pre-launch and launch-readiness activities associated with zuranolone. In addition, if we obtain marketing approval for zuranolone or any of our other current or future product candidates beyond ZULRESSO, we would expect to incur significant sales, marketing and outsourced-manufacturing expenses. We incur significant legal and accounting costs associated with operating as a public company. We expect to continue to incur additional significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to become profitable depends upon our ability to generate product revenue and/or revenue from our collaborations on a sustained basis. We began to generate revenue from product sales in the second quarter of 2019 in conjunction with launch of our first product, ZULRESSO, which commenced in June 2019. We expect that our revenue opportunity for ZULRESSO will continue to be limited. Our ability to generate significant product revenue from any future approved product depends on a number of factors, including, but not limited to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully obtain marketing approval of zuranolone in the U.S. for the indications and on the timelines we expect;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to initiate and successfully complete all efficacy and safety clinical trials and non-clinical studies required to file for, and obtain, U.S. and foreign marketing approval for our other product candidates; and our ability to file for and receive marketing approval to commercialize our product candidates, if successfully developed; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with respect to zuranolone, if approved, and any other approved product, our ability, alone or with collaborators, to commercialize the product by developing and effectively deploying a sales force, and to achieve market acceptance and satisfactory reimbursement of such product in the medical community, with patients and with third-party payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to generate significant product revenue and/or revenue from our collaborations on a sustained basis, we will not become profitable, and may be unable to continue operations without continued funding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to raise additional funding at some point in the future, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or in light of other strategic considerations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our stockholders in our company will be diluted.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently commercializing ZULRESSO, have filed for marketing approval of zuranolone in the U.S. for the treatment of adults with MDD and PPD, have begun our permitted pre-launch and launch-readiness activities associated with the potential approval of zuranolone, and are advancing our other product candidates through non-clinical and clinical development. Commercializing a product and developing additional small molecule products are expensive. We expect our research and development expenses and selling, general and administrative expenses to increase, particularly as we advance planned and ongoing clinical trials for SAGE-718 and SAGE-324 and prepare for the potential commercial launch of zuranolone, including in support of permitted pre-launch and launch-readiness activities associated with zuranolone. We expect we will require additional capital in the future to fund operating needs. We may need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our product candidates, conduct additional clinical trials for indications we are already pursuing beyond the anticipated trials, identify new potential opportunities or otherwise expand our activities more rapidly than we presently anticipate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, our cash, cash equivalents and marketable securities were $1.1 billion. We expect that our existing cash, cash equivalents and marketable securities, in addition to anticipated funding from our ongoing collaborations, excluding revenues and milestones, will be sufficient to fund our anticipated level of operations through 2024. Our current operating plan does not contemplate other development activities we may pursue or that all of the currently planned activities will proceed at the same pace, or that all of the activities will be fully initiated or completed during that time. We may not achieve milestones tied to cash payments to us from our collaboration partners on the timelines we expect or at all, or generate revenues from zuranolone, if approved, or any other of our products that may be successfully developed, at the levels we expect. We may use available capital resources sooner than we expect under our current operating plan, including as a result of unexpected events or changes in plans. In addition, our operating plan may change. We may need or choose to seek additional funds sooner than planned, through equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances, licensing arrangements and arrangements involving other rights or a combination of these or other approaches. In any event, we anticipate we will require additional capital to expand future development efforts for, obtain regulatory approval for, and to commercialize our product candidates. If current or future economic conditions impact capital markets for an extended period, or if our business prospects are impaired or the capital markets disrupted for any other reason, additional capital may not be available to us on acceptable terms, or at all. Failure to obtain capital if and when needed may force us to delay, limit or terminate our product development efforts or other operations. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or in light of other strategic considerations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. In the event we receive negative data from our key clinical programs or encounter other major setbacks in our development or regulatory activities or in our commercialization efforts, our stock price is likely to decline which would make a future financing more difficult and potentially more dilutive to our existing stockholders. For example, after the announcement of the topline results of the Phase 3 MOUNTAIN Study of zuranolone on December 5, 2019, our stock price declined significantly. In addition, future global economic uncertainty, reduced liquidity, capital market disruptions, and other macroeconomic or geopolitical conditions may potentially make it more difficult for us to raise additional funds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on favorable terms. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The incurrence of indebtedness would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our stockholders in our company will be diluted. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic partnerships and licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, our intellectual property, future revenue streams or grant licenses on terms that are not favorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved product, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Market volatility may affect our stock price and the value of an investment in our stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price for our common stock, similar to that of other biopharmaceutical companies, is volatile. The market price of our common stock may fluctuate significantly in response to a number of factors, most of which we cannot control, including, among others:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success or failure of our efforts to: receive FDA approval of our NDA for zuranolone for the treatment of both MDD and PPD on a timely basis, without significant restrictions or limitations, or at all;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our commercialization efforts with respect to zuranolone, if approved, and our ability to attain commercial success;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">plans for, progress of, timing of, changes to, delays in or results from clinical trials or non-clinical studies of any of our product candidates, including positive or negative key data from such studies or clinical trials, serious adverse events arising in the course of development, or any delays or major announcements related to such studies or trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success or failure of any regulatory activities with respect to our other existing or future product candidates beyond zuranolone;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of new products, technologies, commercial relationships, acquisitions, collaborations or other events by us or our competitors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success or failure of our therapies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse developments with respect to our intellectual property portfolio or failure to obtain or loss of exclusivity;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of our future product candidates, if successfully developed and approved, to achieve commercial success;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fluctuations in stock market prices and trading volumes of similar companies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the state of the U.S. and world economies, general market conditions and overall fluctuations in U.S. equity markets, including as a result of U.S. or world events;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in healthcare laws affecting pricing, reimbursement or access;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in our quarterly operating results;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in our financial guidance or securities analysts&#x2019; estimates of our financial performance;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting principles;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to raise additional capital and the terms on which we can raise it;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of macroeconomic and geopolitical conditions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions or departures of key personnel;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">discussion of us or our stock price by the press and by online investor communities; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties described in these risk factors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have broad discretion in how we use our existing cash and the proceeds from potential future follow-on public offerings, and may not use such cash and proceeds effectively, which could affect our results of operations and cause our stock price to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have considerable discretion in the use of our cash and the application of the net proceeds from potential future follow-on public offerings. We may use cash and net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from any potential future follow-on offerings in a manner that does not produce income or that loses value.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, even one that may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales of our common stock may cause our stock price to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock, and impair our ability to raise adequate capital through the sale of additional equity securities. For example, the 6,241,473 shares of our common stock purchased by BIMA were subject to an 18-month lockup period, which expired on June 30, 2022, after which BIMA is able to sell a certain amount of its shares, subject to certain sales and volume limitations, or, if BIMA requests registration of its shares pursuant to its registration rights, without such sales and volume limitations. Following a second 18-month period, which expires December 31, 2023, BIMA will be able to sell shares without limitation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.987%;padding-left:9.08%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="part_ii_item_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Unregistered Sales </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Equity Securities and Use of Proceeds</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, we issued 4,683 shares of our common stock to a former consultant upon the exercise of an option granted in January 2014 in consideration for services provided to us by the consultant. The option vested upon the achievement of a specified milestone and had an exercise price of $1.36 per share of our common stock. The aggregate consideration received by us upon the exercise by the consultant of the option was $6,369. We issued the shares of our common stock pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. Except as stated in this Quarterly Report on Form 10-Q, we did not sell any securities that were not registered under the Securities Act during the three months ended March 31, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.987%;padding-left:9.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.	E</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">xhibits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sage-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy, dated March 23, 2023</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sage-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Performance-Based Restricted Stock Unit Award Agreement Under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sage-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sage-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;32.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sage-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information and contained in Exhibits 101.*)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*      Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+      The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-K and will not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.92%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Barry E. Greene</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Barry E. Greene</span></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer, President and Director</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kimi Iguchi</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kimi Iguchi</span></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Financial Officer</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>sage-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 10.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) of Sage Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company.  In furtherance of this purpose, all non-employee directors shall be paid compensation for services provided to the Company as set forth below:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Retainers</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash retainers to be paid to non-employee directors for their participation on the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and committees of the Board are as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Retainer for Board Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:  $50,000 for general availability and participation in meetings and conference calls of our Board.  No additional compensation for attending individual Board meetings.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Annual Retainer for Non-Executive Chairman of the Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: 	            $35,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Annual Retainers for Committee Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Audit Committee Chairperson:						                        $20,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Audit Committee member:							                        $10,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Compensation Committee Chairperson:				   	                $15,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Compensation Committee member:						                $  7,500</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Nominating and Corporate Governance Committee Chairperson:		$10,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Nominating and Corporate Governance Committee member:		        $  5,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">        Science and Technology Committee Chairperson:				                $15,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">        Science and Technology Committee member:				                $  7,500</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No additional compensation for attending individual committee meetings.									</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee director.  Cash retainers shall be annualized, meaning that, with respect to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">non-employee directors who join the Board during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director. Notwithstanding anything to the contrary in this Policy, the cash retainers paid to non-employee directors will not exceed the 75th percentile paid by the Company&#x2019;s peer group, as then-approved by the Compensation Committee of the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Peer Group</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), to non-employee directors in the prior calendar year.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Election to Receive Options In Lieu of Cash Retainers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each non-employee director may elect to receive a stock option to purchase the Company&#x2019;s common stock, par value $0.0001 per share (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in lieu of payment of all (but not a portion) of the cash retainers specified above that would have otherwise been paid for service on the Board and committees of the Board in a given calendar year.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Election</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  To elect to receive an option to purchase shares of Common Stock in lieu of cash retainers for any calendar year, the non-employee director must notify the Company&#x2019;s Corporate Secretary in writing of such election prior to the commencement of the calendar year for which the cash retainers would otherwise have been paid (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment Year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  A newly elected or appointed non-employee director may not make an election for the year in which he or she first becomes a non-employee director.  All elections shall remain in effect for future calendar years unless revoked by written notice to the Corporate Secretary.  A revocation of an election received after the start of a calendar year will not be effective until the next calendar year.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Option Shares and Terms of Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The number of shares underlying each stock option to be granted to a non-employee director who has made an election to receive an option in lieu of cash retainers for any year shall be determined on the first business day of the Payment Year, and shall equal the total amount of the cash retainers the non-employee director would have received in the Payment Year under this Policy divided by the product of (x) the closing trading price of the Common Stock on such first business day of the Payment Year and (y) 70%.  Each stock option granted pursuant to such election shall be granted on the second business day of the Payment Year and shall fully vest on the last business day of such year, subject to the non-employee director&#x2019;s continued service through such date.   If a non-employee director who has elected to receive a stock option in lieu of cash retainers is appointed to one or more additional committees of the Board after the start of the relevant Payment Year (but not where the individual is departing the same number of Board committees), such director may receive a cash retainer for such additional services.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See also </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General Terms Applicable to Option Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Retainers</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Equity Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Each new non-employee director will, on the business day after his/her election to the Board is first effective, be granted a one-time option to purchase shares of Common Stock in such amount and on such terms as authorized by the Board, or by a committee appointed by the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Equity Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Such Initial Equity Grant shall vest in equal monthly installments during the 36 months following the grant date, subject to the director&#x2019;s continued service on the Board.  Notwithstanding anything to the contrary in this Policy, an Initial Equity</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant will not exceed two times the Annual Equity Grant (as defined below) most recently awarded to the Company&#x2019;s incumbent non-employee directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Equity Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:  Each non-employee director serving on the Board immediately following the Company&#x2019;s annual meeting of stockholders for a given year will, on the date of the meeting, be granted an option to purchase shares of Common Stock in such amount and on such terms as authorized by the Board, or by a committee appointed by the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Equity Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Such Annual Equity Grant shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company&#x2019;s next annual meeting of stockholders, subject to the director&#x2019;s continued service on the Board.  Notwithstanding anything to the contrary in this Policy, the Annual Equity Grant in any year will not exceed the lesser of (i) a percent of the Company equal to the 65th percentile of the annual equity compensation awarded to non-employee directors by the Company&#x2019;s Peer Group, calculated as a percent of the company, as reported by the Peer Group in the prior year and (ii) a Black-Scholes value (calculated in accordance with FASB Topic 718) equal to the highest reported value of the annual equity compensation awarded to non-employee directors by any member of the Peer Group in the prior year.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See also </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General Terms Applicable to Option Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Terms Applicable to Option Grants.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted to non-employee directors under this Policy, whether in lieu of cash retainers or as initial or annual equity retainers, will have the following additional terms:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the exercise price will be the closing price of the Common Stock on the Nasdaq Global Market on the date of grant;</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each option will become fully vested and immediately exercisable upon the death or disability of such director or upon a change in control of the Company;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each option will be exercisable as to vested shares during the term of the non-employee director&#x2019;s service on the Board and for a period of six months following cessation of service as a director, provided that the director has not been removed for cause; </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each option will be granted under the Company&#x2019;s 2014 Stock Option and Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and subject to the terms of the Plan; </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each option will be documented on the Company&#x2019;s standard form of non-qualified stock option agreement as modified to reflect the specific terms of this Policy; and  </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each option will expire on the tenth anniversary of the date of grant if not earlier terminated or forfeited under the terms of the Plan or the applicable stock option agreement. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For avoidance of doubt, all equity grants described in this Policy shall be effective by their terms, without additional action or approval from the Board or any committee thereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending Board and committee meetings.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADOPTED: April 30, 2014</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EFFECTIVE: July 17, 2014</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: March 5, 2015</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: December 15, 2016</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: September 19, 2017</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: March 30, 2018</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: September 20, 2018</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: April 8, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: December 16, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED: March 23, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>sage-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:66.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     EXHIBIT 10.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT </font><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNDER THE SAGE THERAPEUTICS, INC. </font><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2014 STOCK OPTION AND INCENTIVE PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Grantee: ###PARTICIPANT_NAME###</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Target No. of Performance-based Restricted Stock Units:  ###TOTAL_AWARDS###</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Date: ###GRANT_DATE###</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Performance Period: [__]]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            Pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Sage Therapeutics, Inc. (the &#x201c;Company&#x201d;) hereby grants an award of the target number of Performance-based Restricted Stock Units (&#x201c;PSUs&#x201d;) listed above (an &#x201c;Award&#x201d;) to the Grantee named above. Each PSU shall relate to one share of common stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company and shall be subject to all of the terms and conditions set forth in this Performance-Based Restricted Stock Unit Award Agreement (the &#x201c;Agreement&#x201d;) and the Plan. Capitalized terms used in this Agreement and not otherwise defined will have the meaning set forth in the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            1.       Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the PSUs have vested as provided in Exhibit A of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            2.       Vesting of PSUs. Subject to the conditions contained herein and in the Plan, the PSUs shall vest as provided in Exhibit A to this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            3.       Termination of Employment. Except as set forth in Exhibit A to this Agreement, if the Grantee&#x2019;s employment with the Company or its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Exhibit A to this Agreement, any PSUs that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested PSUs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            4.       Issuance of Shares of Stock. As soon as practicable following the Administrator&#x2019;s certification of the satisfaction of the vesting conditions set forth in Exhibit A to this Agreement (but in no event later than two and one-half months after the end of the year in which such certification occurs), the Company shall issue to the Grantee the number of shares of Stock determined pursuant to Exhibit A to this Agreement, less the amount [withheld] OR [sold to cover withholding] under Section 6, and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            5.       Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            6.       Tax Withholding. [The minimum tax withholding obligation arising from vesting of the PSUs will be satisfied through withholding by the Company from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due.] OR [The Grantee acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Grantee any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the PSUs. At such time as the Grantee is not aware of any material nonpublic information about the Company or the Stock and is not prohibited from doing so by the Company&#x2019;s insider trading policy or otherwise, the Grantee shall execute the instructions set forth in Exhibit B attached hereto (the &#x201c;Durable Automatic Sell-to-Cover Instruction&#x201d;) as the means of satisfying such tax obligation. If the Grantee is required to but does not execute the Durable Automatic Sell-to-Cover Instruction prior to an applicable vesting date, then the Grantee agrees that if under applicable law the Grantee will owe taxes at such vesting date on the portion of the award then vested the Company shall be entitled to immediate payment from the Grantee of the amount of any tax required to be withheld by the Company. The Company shall not deliver any shares of Stock to the Grantee until it is satisfied that all required withholdings have been made.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            7.       Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#x201c;short-term deferrals&#x201d; as described in Section 409A of the Code. The delivery of shares of Stock on the vesting of the PSUs may not be accelerated or deferred unless permitted or required by Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            8.       No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            9.       Integration. This Agreement constitutes the entire agreement between the parties</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">           10.      Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">            11.       Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGE THERAPEUTICS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:   ###SIGNATURE###</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Dated:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                       </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                         </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">                                                                                                                                                                                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grantee&#x2019;s Signature</font><font style="background-color:rgba(0,0,0,0);color:rgba(77,79,83,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grantee&#x2019;s name and address:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>sage-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Barry E. Greene, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2023 of Sage Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: May 2, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.699%;"></td>
    <td style="width:1.944%;"></td>
    <td style="width:6.389%;"></td>
    <td style="width:2.338%;"></td>
    <td style="width:74.63%;"></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:0.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:0.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:0.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:0.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:0.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:0.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Barry E. Greene</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Barry E. Greene</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer, President and Director (Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>sage-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Kimi Iguchi, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2023 of Sage Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: May 2, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.699%;"></td>
    <td style="width:1.944%;"></td>
    <td style="width:6.389%;"></td>
    <td style="width:2.338%;"></td>
    <td style="width:74.63%;"></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:0.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:0.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:0.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:0.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:0.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:0.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kimi Iguchi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kimi Iguchi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>sage-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with this Quarterly Report on Form 10-Q of Sage Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.0%;"></td>
    <td style="width:85.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Barry E. Greene</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Barry E. Greene</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Chief Executive Officer, President and Director (Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2, 2023</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kimi Iguchi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Kimi Iguchi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Chief Financial Officer (Principal Financial and Accounting Officer)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;May 2, 2023</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img93198881_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img93198881_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ?W$3 # 2(  A$! Q$!_\0
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
M^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H ["BN/_X6/H__ #[7W_?"
M?_%4?\+'T?\ Y]K[_OA/_BJ .PHKC_\ A8^C_P#/M??]\)_\51_PL?1_^?:^
M_P"^$_\ BJ .PHKC_P#A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJ@#
ML**X_P#X6/H__/M??]\)_P#%4?\ "Q]'_P"?:^_[X3_XJ@#L**X__A8^C_\
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M?:^_[X3_ .*H ["BN/\ ^%CZ/_S[7W_?"?\ Q5'_  L?1_\ GVOO^^$_^*H
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M (J@#L**X_\ X6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*H ["BN/\
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M_>*Y7_OH<4 4:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5T'_  A'B+_H'_\ D:/_ .*H_P"$(\1?] __ ,C1_P#Q5 '/T5T'_"$>(O\
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M3E'7.<$'!'%1T %%=%8>"=;OXO-^SK;H>GV@[2?PQD?B*N/\.M91"5FLW/\
M=61LG\U% '(T5:OM.O-,G\B]MY(9.P8<'W!Z$?2JM !116CIF@ZGK"2/86IE
M6,@,VY5 )[<D9H SJ*TM3T#5-'B22_M?*1VVJ=ZMD_@36;0 45L6/A;6=2LX
M[NTL_,@DSM;S4&<$@\$YZ@U8_P"$(\1?] __ ,C1_P#Q5 '/T5T'_"$>(O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8M !1110 44JJ68*H)). !WK9N?"6N6EK)<SV.R&-=SMYJ' ^@.: ,6BBB@
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MW_D9C_UP?^8KE*ZOX>_\C,?^N#_S% '8>//^14N/]]/_ $(5Q_P]_P"1F/\
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MZ_SKQZI+>>6UN(YX'*2QL&5AU!% 'I_C3PU%J%A+J%M$JWD(WN5',J@<@^I
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M+=0D-VI;8.@<?>P/3D'ZDURE:6IZ]J>L1QI?W/G+&25'EJN#^ %9M !1110
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M3B@"/_A-_#O_ $$/_(,G_P 31_PF_AW_ *"'_D&3_P")KS__ (0CQ%_T#_\
MR-'_ /%4V3P9K\43R/881%+,?.CX _X%0!EZG-'<:K>3Q-NCDG=U.,9!8D5W
M_A#PA!#:QZCJ,2RS2J&CB=<B,=02#W_E7"Z':"^URQMF4,DDRAP>ZYR?TS7K
MOB.]?3O#U]<QMMD6/",.S,=H/YF@"EJGC71]+N# [R3RJ<.L"AMI]"20*MZ;
MK.E>([:1(&64;?WD$J<@'U!Z^G&17BM7-+U*?2-0CO;;:9(\X#9VD$8P<$4
M;WC/PTFC7"75H"+2=B-O_/-NN/IU_*IOAQ_R,-Q_UZ-_Z&E9>K^*]2UNU^S7
M7D"+<&VI'T(SW.2.M:GPX_Y&&X_Z]&_]#2@#7^)?_'C8?]=6_D*\XKT?XE_\
M>-A_UU;^0KSB@ KTOX;?\@B\_P"N_P#[**\TKTOX;?\ ((O/^N__ +** ,+X
MB_\ (R1?]>R_^A-7H6@_\B]IG_7I%_Z *\]^(O\ R,D7_7LO_H35Z#H9V^'-
M-)Z"TB/_ (X* /./&V@G2M4-U"F+2Z)9<#A'[K_4?CZ52\(?\C7I_P#OG_T$
MUZE?VEKXCT%HPX,5Q&'BDQ]TXRK8_I^%>9^&[6:R\;6EM.A26*5E8'UVF@#N
MO'G_ "*EQ_OI_P"A"N$\$?\ (WV/_;3_ -%M7=^//^14N/\ ?3_T(5PG@C_D
M;['_ +:?^BVH [?X@?\ (L-_UV3^M<%X:\/R>(-1,._R[>(!II!U ]![G_'Z
M5WOQ _Y%AO\ KLG]:/ %JL'AA)AG=<2NYS[';_[+0!IR2Z/X6TU0?+M8,X"J
M,LYZ?5C[UFV?C[1+J81.T]MD@!ID 7\P3C\:XSQU>RW7B:>)F_=VX6-%R<#@
M$GZY/Z"N:H ]=\3>%K;7+1I846.^4$QR*,;_ /9;USZ]J\C92K%6!!!P0>U=
M'9>-]7L-.ALH?(*1+M5V0EL=N^..G3M7/33/<3R32D&21B[$ #))R>!Q0!)9
M6KWU]!:Q_?FD"#CIDXS7N<4<-G;Q0)A(T C0?H!7FOP]TPW6LO?.H\JU7C/=
MVX'Z9_2MCQ_K#V4NG6\##S$D%T0?]D_+GVSG\J )?B)IOVC28M04_-:MAAZJ
MQ _GC\S7F5>XGR==T(XW+#>6_&>JAA_,9KQ&:)X)I(95VR1L59?0@X(H ZCX
M>_\ (S'_ *X/_,5T?Q(_Y 5K_P!?(_\ 06KG/A[_ ,C,?^N#_P Q71_$C_D!
M6O\ U\C_ -!:@#S&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ][
MMO\ CUA_W%_E7,7'Q!TFVN98'M[TM&Y0D(F,@X_O5T]M_P >L/\ N+_*O#]5
M_P"0O>_]=Y/_ $(T >NZ1XGTO6Y/*M9F$VW=Y4B[6Q_(_@:R_'>BQ7NCO?I&
M/M5J,[AP63/(/TZ__KKE?!>CW[^(;:Z-M+'!#EGD=2HZ$8'J>:]!\32I#X9U
M%G; ,#+GW(P/U(H \_\ A[_R,Q_ZX/\ S%=AX\_Y%2X_WT_]"%<?\/?^1F/_
M %P?^8KN?%NGW6I^'YK6SB\R9F4A=P7H<GDG% 'C==A\./\ D8;C_KT;_P!#
M2L__ (0CQ%_T#_\ R-'_ /%5TG@GP[JND:S-<7UKY436[(&\Q6YW*<<$^AH
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M6*")Y9&X5$4L3] *976_#V6.#7;J2:1(XUM&+,[  #<G4F@#;\*^"6LITO\
M5 IF0YB@&&"GU;W],=,5T?B7_D6=1_ZX-_*L>7QG#=:]9Z9IN)(WF"RS]B,\
MA?\ '_\ 76QXE_Y%G4?^N#?RH \4HHHH **** "BBB@ HHHH **** "BBB@
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MO_Z$:XC7YDMO'LL\G^KCN8W;Z#:30!W&A^%]-T.Q6>ZCA>Y5-TTTN"J'OC/
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ME72!01R.A KSJZTR;1_$*V4W)29=KXP'7/!%>I>+/^16U#_KE_44 >,4444
M%%%% !1110 4444 %=-X%M;>\\0F*Y@BGC\ECLE0,,Y'.#7,UU?P]_Y&8_\
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MQ1__ % __(-8?Q"T^]O;FQ-I9W$X5'#&*(MCD=<"N+_L'6/^@3??^ [_ .%
M'<>*?^$;_P"$<N_L']E?:ODV>1Y>_P"^N<8YZ9K+^'MC:7MS?"[M8)PJ(5$L
M8;')Z9KE;G3;ZRC$EU97,"$X#2Q,H)],D5V/PS_X^M1_W$_F: .LN;'PU9%1
M=VNDP%N5$L<:Y^F:;%IWAG4%*6]MI<WKY"H3^:\UROQ,_P"/K3O]Q_YBN(@G
MEMITFAD:.5#N5E."#0!VWBOP5#96C7^EAA'&,RPDYPO=@2<\>E<+7MVAWPU?
M0+6ZD 8S1XD!'!8?*W'ID&O'-4M19:M=VJ@A8IG1<^@)Q^E %2BBB@ HHHH
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MW_'K#_N+_*@#D?AU?&XTV\MY'+21S^9SV##M^(/YU:T_1_(\?:E>;4$9@5T
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M^M1_W$_F:['6]>M= MHY[J.9UD?8!$ 3G&>Y%<=\,_\ CZU'_<3^9K0^)/\
MR"+/_KO_ .RF@#HM'U_3]<C9K.4EU +QN,,N?;_#-5/%&I:MI>GM<:?:Q2HH
M_>.Q):,>NWN/Q_#%>5Z1JD^CZG%>P9)0_,F<!U[J:]JLKN#4K"*Z@8/#,F1W
M^H/\C0!X9=74][<R7-S(TDTARSMU)J*M_P 6Z$=$U9O+7%I.2\)ST]5_ G\L
M5@4 =7\/?^1F/_7!_P"8KL/'G_(J7'^^G_H0KC_A[_R,Q_ZX/_,5V'CS_D5+
MC_?3_P!"% 'DE=7\/?\ D9C_ -<'_F*Y2NK^'O\ R,Q_ZX/_ #% '3?$9BOA
M^V9201=J01V^1ZTO"FN#6]'1W8&ZAPDXSR3V;\?\?2LSXC_\B];_ /7VO_H#
MUQ'AG6VT/6(YR3]GD^2=<G[OKCU'7].] '>VVA?V9XZ-["A%M=PR-QG"OD$C
MVSU'X^E5_B1_R K7_KY'_H+5U\<D<T22QLKHP#(RG(((X(KD/B1_R K7_KY'
M_H+4 8/PX_Y&&X_Z]&_]#2N^UO6[;0;)+JZ25T>01@1 $Y()[D>E<#\./^1A
MN/\ KT;_ -#2NF\?VES>:%!':V\L[BY5BL2%B!M;G ^M $/_  L?1_\ GVOO
M^^$_^*H_X6/H_P#S[7W_ 'PG_P 57G_]@ZQ_T";[_P !W_PH_L'6/^@3??\
M@._^% $&H7"7>I75S&&"2S/(H;J 23S7J_@C_D4+'_MI_P"C&KR6YM+FSD$=
MU;RP.1N"RH5)'K@_2O6O!'_(H6/_ &T_]&-0 W4?&>F:7JLFGW*7(DCQND5
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MZ/\ \^U]_P!\)_\ %5U%Q##J.GR0L=T-Q&5)'<$=10!X/75_#W_D9C_UP?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.SCK^'<>QH S_'G_ "*EQ_OI_P"A"N$\$?\ (WV/_;3_ -%M7=^//^14N/\
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MKL=>TV&VM8KE'282$RJH&,$=B?6N.J])HNJQ1M))IEXB("S,T#  #J2<51H
M**** -?PO_R,^G?]=A7JGB7_ )%G4?\ K@W\J\K\+_\ (SZ=_P!=A7JGB7_D
M6=1_ZX-_*@#Q2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^/6'_<7^5>/:EHFK2:I=NFEWK*TSD,+=R"-QYZ4 =M_PL?1_^?:^_P"^$_\
MBJYOQ?XHLM?MK:.UBN$,3EF\U5'4=L$UA_V#K'_0)OO_  '?_"F2Z-JD,32R
MZ;>1QJ,L[P, !ZDXH I4444 %=/X5\)2:V_VJZWQ6"G&1P93Z#V]3^'TA\)>
M'?[>ORTV19P$&7'!;T4'^?M7J&H-=6.E[-)L5FF4!(H@RHJ#'4Y(X'H/_KT
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M*Y?X@Z?965E9-:V=O 6D8,8HE7/'? JWX*\+7^E7CW]]LB+1&-80<MR0<G'
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M?[7TD0S.3=VH"/G.67^%L]SQS[CWJYXL_P"16U#_ *Y?U% 'C%%%% !1110
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M!CGH>O\ 2@#B;'PMXFLM2@O5L&:2*02?\?$8+<\@G=W_ *UZ/K>GC5M%NK+
MW2Q_)N. ''*YQ[@5Q_\ PLW_ *A'_DS_ /85TOAKQ$GB*TFE$ @DB?:8_,WG
M!&0>@Z\_E0!XVZ-&[(ZE64X*D8(/I7M^@_\ (O:9_P!>D7_H KR_QIIXT_Q-
M<!0!'/B=0#_>Z_\ CP:O4-!_Y%[3/^O2+_T 4 9FF>-](U.[6V4S02.0J>>H
M 8^@()_7UK6U2>]MK%Y;"U2YF7GRV?;Q[<<GVXKPRO7?!VOC6=*$<S9O+8!9
M>/O#^%OR'/O]10!YAJNKWFLWAN;R0,V,*J\*H] *[+X9?\Q3_ME_[/5/Q]H
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M10![->>+-#LDW/J$,A[+"?,)_+^M>>^)O%L^NG[/"IAL5.0A^\Y]6_PKFZ*
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MFW??#)*61L$9'T-9U% 'I'A;Q3HVF^'+2TN[SRYX]^Y?*<XR[$<@8Z$5L?\
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M?^H1_P"3/_V%>?T4 >@?\+-_ZA'_ ),__855U/X@_P!HZ9<V?]F>7YT93?\
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M+7K*YN'V0QRAG;!.!]!7?ZYXNT.\T.]MH+[?+)"RHOE.,DCU*UY?10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[!_PF_AW_H(?^09/
M_B:\?HH **** "ND\$ZK9:1K,UQ?3>5$UNR!MI;G<IQP#Z&N;HH [SQMXBTK
M5]&AM[&Z\V5;A7*^6R\;6&>0/45P=%% '6>!M9T_1[B\:_N/)$BJ$.QFS@G/
M0&KGC?Q!I>KZ=;16%UYSI-N8>6RX&".X%</10!Z=H'B3PYI.B6MH;\"14S)B
M&0Y<\G^'UKC/%>K1ZSKTMQ"^^W51'$<$94?7W)K$HH *UO#>K?V-KD%TQQ"3
MY<W^X>I_#@_A6310!ZGK'B;PUJVDW-E)J'^M3"GR9/E8<J>G8@5POASQ!/X?
MOC*B^9!( LL6<;@.A'N.?S-8U% 'LECXNT2^B5Q?1P,>J3G81^?'Y&K;:_HR
MC)U6R_"=3_6O$** /3-?\>V<%O)!I3F>X;*^:!A8_<9^\?TKS1W:1V=V+,QR
M6)R2?6DHH ]<@\:^'DMXU;4,$* 1Y,GI_NU)_P )OX=_Z"'_ )!D_P#B:\?H
MH ]@_P"$W\._]!#_ ,@R?_$UGZYXNT.\T.]MH+[?+)"RHOE.,DCU*UY?10 4
M444 >C>%?$6@Z/H$-M->[+ABSRCR7/S$^P] !^%;7_";^'?^@A_Y!D_^)KQ^
MB@#V#_A-_#O_ $$/_(,G_P 37*>.->TS6+2T2PN?.:-V+#RV7 Q[@5Q5% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %6+"5(-1M99#M1)D9CC
M. "":KT4 >N3^-?#SV\BKJ&25( \F3T_W:\CHHH **** .L\#:SI^CW%XU_<
M>2)%4(=C-G!.>@-7/&_B#2]7TZVBL+KSG2;<P\MEP,$=P*X>B@ KL/ NMZ=H
MWV_[?<>3YOE[/D9LXW9Z ^HKCZ* .P\=:WIVL_8/L%QYWE>9O^1EQG;CJ!Z&
MNCTGQ/X:TO2K:R34!^Z0!B()!N;N?N]SDUY910!J>(M3&KZ[=7:,3$6VQ9)^
MX.!UZ9ZX]ZRZ** -WPGK*Z+KB33/MMI%,<QP3@=0<#T('ZUV&O\ B3PYJ^B7
M-I]O!D92T689!\XY'\/K7F5% &[X9\2S>'[ILJTMI+CS(@>A_O#WQ^=>DV?B
MS1+V%9%OXHB>J3ML93Z'/].*\9HH ]N;Q!HR+DZK98]IU/\ (US'B'Q[;I;R
M6ND,TDS#!N,$*G^[GDG]/K7G%% !7L'_  F_AW_H(?\ D&3_ .)KQ^B@#V#_
M (3?P[_T$/\ R#)_\31_PF_AW_H(?^09/_B:\?HH ](\4^*=&U+PY=VEI>>9
M/)LVKY3C.'4GDC'0&O-Z** "MWPSXDE\/WC,5:6UEP)8P<?\"'N.?K6%10![
M3:^*-$NXA(FI6Z9'W9G$9'X'%5]3\8Z-IT!9;I+J0_=C@8-GZD<"O'J* +NK
M:I<:QJ,EY<GYWX"CHBCH!5*BB@ HHHH **** "BBB@ HHHH *Z[0?&_]B:3'
M8_V=YVQF._SMN<G/3::Y&B@"]K&H?VKJUQ?>5Y7G,#LW;L< =<#TJK;SRVMQ
M'/ Y26-@RL.H(J.B@#OO^%E[HMDNCJ^5PW^D<'UXV]*YO1==BT36Y+^"R+1,
MK*L)FY4$C^+'.,>E8M% 'H'_  LW_J$?^3/_ -A1_P +-_ZA'_DS_P#85Y_1
M0!W[?$S<I7^R.HQ_Q\__ &%<!110!T^@^-K[2(DMID%U:KPJL<,@] ?3V/Z5
MTZ?$C2B@,EI>*W<*JD?GN%>8T4 >@7_Q)RI73K'!Q]^X/0_[H_QKBM1U.\U:
MZ-Q>SM*YZ ]%'H!V%5** .NT'QO_ &)I,=C_ &=YVQF._P [;G)STVFN?UC4
M/[5U:XOO*\KSF!V;MV. .N!Z51HH [/1/B!<V4*6^HPFZC48656Q(![YX;MZ
M?C6Y_P +(TC;S:WN?38G_P 57F%% ':ZW\09KRV:WTZ%K97&&E9OG]\8Z?7^
M5<5110 5W4WQ&\ZSDM_[*QOC*;OM'3(QG[M<+10 5K>'M:_L'4S>?9_/_=E-
MF_;UQSG!]*R:* .F\2^+?^$ALX;?[#]G\N3?N\W?G@C'W1ZUS-%% '5Z!XWG
MT73OL<MK]J16S&3+M*#TZ'(_QI\OC*TEUZ#5SHV+B&,IQ<\-G@$_+U )'X^P
MKD:* .H\1^,GU_3TM%LS;*) [$3;MV >,8'KG\*Y>BB@">RNGL;Z"ZC^_#('
M'/7!SBNOU+Q]%J>FW%E-I'R3(5S]IZ'L?N]C@_A7$T4 %='X:\5_\([!/%]B
M^T>:P;/F[,8'T-<Y10!K^(M<_M_4EN_L_D;8A'LW[NA)SG ]:R*** .XO_B)
M]MTZYM/[+V>?$\>[[1G;N!&<;>>M</110!UFB>.[[3(5M[N/[9"N I+8=1Z9
M[_C^==&/B1I.WFUO0WH$3'_H5>844 =QJWQ$GN(GATVW-N&X\Z1LOC'8#@'\
M37$,Q9BS$DDY)/>DHH ZCPWXP_X1_3I+3[!]HWRF3=YVS&0!C&T^E8NL:A_:
MNK7%]Y7E><P.S=NQP!UP/2J-% &AHNKS:)J<=["H;;\KH3@.IZC/;_&NCU;Q
M]_:FE7%E_9GE><NW?Y^['/IM%<910 4444 %%%% !1110 4444 %:WA[6O[!
MU,WGV?S_ -V4V;]O7'.<'TK)HH Z#Q/XG_X2/[+_ *']G\C?_P M=^[=CV&.
ME7- \;OHFE+8M8"<(S%7$VS@\XQ@]\UR=% &EKNKOKFJR7KQ^4&"JL>[=M '
M3.!WR?QKI+KX@_:=)GL?[,V^; T._P"T9QE<9QMKB:* .G\.>+D\/6,ENNG>
M>\DF]I/.V]L 8VG_ ":S/$&M/KVJ&\>+REV!$CW;MH'O@=R3^-9=% !6WX:\
M12>';N:40>?'*FUH]^WD'@YP>G/YUB44 =%XE\3Q>(HH =/^SRPDXD\[=E3U
M&,#VK6L/B)]BTZVM/[+W^1$D>[[1C=M &<;>.E</10 5?T?59M&U.*]@&XIP
MR$X#J>H/^>N*H44 =OJ'C^'4K":SN-&S'*I4_P"D\CT(^3J.M9'ACQ/_ ,(Y
M]J_T/[1Y^S_EKLV[<^QSUKGZ* -CQ)KO_"0:C'=_9OL^R(1[=^_."3G.!ZUC
MT44 =U:?$B6"SBBGT[SY44*TGG[=Q]<;>*YRZUB&;Q)'J\%EY(69)F@$F06!
M!.#M&,X]#R36110!Z!_PLW_J$?\ DS_]A1_PLW_J$?\ DS_]A7G]% 'H'_"S
M?^H1_P"3/_V%<5JE]_:6J7%[Y?E^<Y?9NSC\:J44 3V5Q]DOK>YV[_)E63;G
M&<'.,UUFK>/O[4TJXLO[,\KSEV[_ #]V.?3:*XRB@ K>\,^)/^$=EN'^R?:/
M.51CS-F,9]CZU@T4 >@?\+-_ZA'_ ),__84?\+-_ZA'_ ),__85Y_10!V^H_
M$+[?IMS:?V7Y?GQ-'O\ M&=N1C.-M8WAGQ)_PCLMP_V3[1YRJ,>9LQC/L?6L
M&B@#T#_A9O\ U"/_ "9_^PIK_$UR/DTE0?>XS_[+7 T4 :FL>(-1UR0->3?N
MU.5A0813]/7W.:RZ** "BBB@ HHHH W?^$.U[_GP_P#(T?\ \51_PAVO?\^'
M_D:/_P"*KU:B@#RG_A#M>_Y\/_(T?_Q5'_"':]_SX?\ D:/_ .*KU:B@#RG_
M (0[7O\ GP_\C1__ !5'_"':]_SX?^1H_P#XJO5J* /*?^$.U[_GP_\ (T?_
M ,51_P (=KW_ #X?^1H__BJ]6HH \I_X0[7O^?#_ ,C1_P#Q5'_"':]_SX?^
M1H__ (JO5J* /*?^$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\ XJO5J* /*?\
MA#M>_P"?#_R-'_\ %4?\(=KW_/A_Y&C_ /BJ]6HH \I_X0[7O^?#_P C1_\
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M  AVO?\ /A_Y&C_^*KU:B@#RG_A#M>_Y\/\ R-'_ /%4?\(=KW_/A_Y&C_\
MBJ]6HH \I_X0[7O^?#_R-'_\51_PAVO?\^'_ )&C_P#BJ]6HH \I_P"$.U[_
M )\/_(T?_P 51_PAVO?\^'_D:/\ ^*KU:B@#RG_A#M>_Y\/_ "-'_P#%4?\
M"':]_P ^'_D:/_XJO5J* /*?^$.U[_GP_P#(T?\ \51_PAVO?\^'_D:/_P"*
MKU:B@#RG_A#M>_Y\/_(T?_Q5'_"':]_SX?\ D:/_ .*KU:B@#RG_ (0[7O\
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M #X?^1H__BJ]6HH \I_X0[7O^?#_ ,C1_P#Q5'_"':]_SX?^1H__ (JO5J*
M/*?^$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\ XJO5J* /*?\ A#M>_P"?#_R-
M'_\ %4?\(=KW_/A_Y&C_ /BJ]6HH \I_X0[7O^?#_P C1_\ Q5'_  AVO?\
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M$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\ XJO5J* /*?\ A#M>_P"?#_R-'_\
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M?^1H_P#XJO5J* /*?^$.U[_GP_\ (T?_ ,51_P (=KW_ #X?^1H__BJ]6HH
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MAVO?\^'_ )&C_P#BJ]6HH \I_P"$.U[_ )\/_(T?_P 51_PAVO?\^'_D:/\
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M \I_X0[7O^?#_P C1_\ Q5'_  AVO?\ /A_Y&C_^*KU:B@#RG_A#M>_Y\/\
MR-'_ /%4?\(=KW_/A_Y&C_\ BJ]6HH \I_X0[7O^?#_R-'_\52#P?KIZ60/_
M &U3_&O5STJ*+J: /+O^$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\ XJO5J* /
M*?\ A#M>_P"?#_R-'_\ %4?\(=KW_/A_Y&C_ /BJ]6HH \I_X0[7O^?#_P C
M1_\ Q5'_  AVO?\ /A_Y&C_^*KU:B@#RG_A#M>_Y\/\ R-'_ /%4?\(=KW_/
MA_Y&C_\ BJ]6HH \I_X0[7O^?#_R-'_\51_PAVO?\^'_ )&C_P#BJ]6HH \I
M_P"$.U[_ )\/_(T?_P 51_PAVO?\^'_D:/\ ^*KU:B@#RG_A#M>_Y\/_ "-'
M_P#%4?\ "':]_P ^'_D:/_XJO5J* /*?^$.U[_GP_P#(T?\ \51_PAVO?\^'
M_D:/_P"*KU:B@#RG_A#M>_Y\/_(T?_Q5'_"':]_SX?\ D:/_ .*KU:B@#RG_
M (0[7O\ GP_\C1__ !5'_"':]_SX?^1H_P#XJO5J* /*?^$.U[_GP_\ (T?_
M ,51_P (=KW_ #X?^1H__BJ]6HH \I_X0[7O^?#_ ,C1_P#Q5'_"':]_SX?^
M1H__ (JO5J* /*?^$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\ XJO5J* /*?\
MA#M>_P"?#_R-'_\ %4?\(=KW_/A_Y&C_ /BJ]6HH \I_X0[7O^?#_P C1_\
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M5'_"':]_SX?^1H__ (JO5J* /*?^$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\
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M \I_X0[7O^?#_P C1_\ Q5'_  AVO?\ /A_Y&C_^*KU:B@#RG_A#M>_Y\/\
MR-'_ /%4?\(=KW_/A_Y&C_\ BJ]6HH \I_X0[7O^?#_R-'_\51_PAVO?\^'_
M )&C_P#BJ]6HH \I_P"$.U[_ )\/_(T?_P 51_PAVO?\^'_D:/\ ^*KU:B@#
MRG_A#M>_Y\/_ "-'_P#%4?\ "':]_P ^'_D:/_XJO5J* /*?^$.U[_GP_P#(
MT?\ \51_PAVO?\^'_D:/_P"*KU:B@#RG_A#M>_Y\/_(T?_Q5'_"':]_SX?\
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M_&O5C]T_2F1=Z /+?^$.U[_GP_\ (T?_ ,51_P (=KW_ #X?^1H__BJ]6HH
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MAVO?\^'_ )&C_P#BJ]6HH \I_P"$.U[_ )\/_(T?_P 51_PAVO?\^'_D:/\
M^*KU:B@#RG_A#M>_Y\/_ "-'_P#%4?\ "':]_P ^'_D:/_XJO5J* /*?^$.U
M[_GP_P#(T?\ \51_PAVO?\^'_D:/_P"*KU:B@#RG_A#M>_Y\/_(T?_Q5'_"'
M:\.MC_Y&3_XJO5J1ON'Z4 >4CP?KIZ66?^VJ?XTO_"':]_SX?^1H_P#XJO4H
MNAJ2@#RG_A#M>_Y\/_(T?_Q5'_"':]_SX?\ D:/_ .*KU:B@#RG_ (0[7O\
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M #X?^1H__BJ]6HH \I_X0[7O^?#_ ,C1_P#Q5'_"':]_SX?^1H__ (JO5J*
M/*?^$.U[_GP_\C1__%4?\(=KW_/A_P"1H_\ XJO5J* /*?\ A#M>_P"?#_R-
M'_\ %4?\(=KW_/A_Y&C_ /BJ]6HH \I_X0[7O^?#_P C1_\ Q5'_  AVO?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*BBZFI3TJ*+J: ):*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *BC^^:EJ*/[YH EHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (HNIJ6HHNIJ6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TID7>G
MG[I^E,B[T 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %(WW#]*6D;[A^E #(NAJ2HXNAJ2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH :_W#21?<_&E?[AI(ON?C0 ^BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSZ5L>/"<6 ['S/\ V6I/ H_T6\/?>O\ (U%:*KYBJ<]E_E<JA)X?*W4AN_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ****  ]*BBZFI3TJ*+J: ):*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *BC^^:EJ*/[YH EHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** (HNIJ6HHNIJ6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TID7>GG[I^E,B[T 24
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW
M#]*6D;[A^E #(NAJ2HXNAJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH :_W#21?<_&E?[AI(ON?C0 ^BBB@ HHHH ****
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M##JIX##K]/7\:S_$N@G5H4EM\"ZB&!N. R^GU]*XJ.75=$E.WS[5CR05P&_
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MFPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH #TJ*+J:E/2HHNIH EHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*/[YJ6H
MH_OF@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH BBZFI:BBZFI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!#]T_2F1=Z>?NGZ4R+O0!)1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4C?</TI:1ON'Z4 ,BZ&I*C
MBZ&I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!K_<-)%]S\:5_N&DB^Y^- #Z*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2H
MHNIJ4]*BBZF@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "HH_OFI:BC^^: ):*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*+J:E
MJ*+J:EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $/W3]*9%WIY^Z?I3(N] $E%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !2-]P_2EI&^X?I0 R+H:DJ.+H:DH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O]PTD7W/QI
M7^X:2+[GXT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM
M% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*
MBKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM%
M %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*B
MKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM%
M%*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BK
MM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %
M*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM
M% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*
MBKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM%
M %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*B
MKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM%
M%*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BK
MM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %
M*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM
M% %*BKM% %*BKM% %(]*BBZFM%ONGZ54LOO/]!0 E%7:* *5%7:* *5%7:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TJI9?>?Z"K;?
M=/TJI9?>?Z"@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5*U_X^'^A_G5VJ5K_Q\/\
M0_SH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %!Z44'I0!3LOOO]*N53LOOO\ 2KE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 V3_5M]#5:R_C_"K,G^K;Z&JUE_'^%
M%NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
MDW^I?Z&GTR;_ %+_ $- $-E]QOK5FJUE]QOK5F@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO>Q$@,.<*V#G')&1T!/!Z4 >+:'X1U>]^"LNNZ3K>J8AEE-UI/VEQ;3PJ?F
M12.<9)YY&>AKU*^\=: GP(FU;3XHK2WFLWL8+-<#9.5*>7@'MRWJ5&:H+?\
MQTT[-D=)T35,''VXNBY[9P)$^OW*MZ%\-=>UK7X_$'Q&U.'498&W6NFP\P1G
ML6& #CGC!S@9)Z4 =;\-],GT?X=:%8W,;1SI:AG1NJEB6P?^^JZFBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z?I52R^\_T%6V^
MZ?I52R^\_P!!0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE:_\?#_0_P ZNU2M?^/A
M_H?YT 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "@]**#TH IV7WW^E7*IV7WW^E7* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!LG^K;Z&JUE_'^%69/]6WT-5K+^/\*
M+=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"AKT/_ ,&,/_Q5> ?\,X^,/^@EH?\ W_F_^-4?\,X^,/\ H):'_P!_YO\
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MM=/C)YDN+I& 'TC+'_/:O>/AO\,M/^']G*Z3&[U.Y4">Y(P !_ @[+GGU/Y
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MG/PO*U]J'B>XB984C^RVQ(X=B07(^@ &?]HU]#U5T[3K/2-.@T_3[>.WM+=
MD448P%'^>_>K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 445XM\2/BUXF\*>.E\/Z+IVG
MW8DCB,2RP222N[\;0%<9R<  #- 'M-%?/_\ PM/XO_\ 0A?^4>[_ /BZ:_QS
M\;Z%L?Q+X+6&-VPI:&:TW>P+[LGB@#Z"HK"\)>+-+\9Z%%JNER$QL=LD3XWP
MN.JL!T/\P0:W: "BBB@ HHHH ***R_$7B#3_  OH5SK&J2M':6X!8JI9F)(
M4 =220/3UP,F@#4HK#\(>)8?%_A>TUVWMY+>&Z,FR.0@L LC)SCCG;G\:W*
M"BBB@ HHHH **** "BBB@ HKCM#^(^D>(O'%]X8TV*>22Q@DDGN'7:FY)%0J
MH/)Y;KQT[UV- !1110 4444 %%%% !1110 445R_Q$\27GA'P)J6N6$<$EU:
M^5L2=24.Z5$.0"#T8]Z .HHKYVT_XS?%'5K476G>$+:\MR2HEM]-N9$)'495
MR*L-\7_BA8*;C4O PCME^\QTZYB _P"!,Q [T ?0-%>:?#OXR:5XWN1IEU;_
M -FZMC*1-)N2< <[&XYZG:1TZ$\X]+H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **\K\(?$O6?$'Q7UOPK=VU@EC8O<K%)%&XE/ERA%
MW$L1TZX _"O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 1ONGZ54LOO/]!5MONGZ54LOO/\ 04 7**** "BBB@ H
MHHH **** ,>;Q5HMO/)!+>[9(V*.OE.<$'![5'_PF&@_\_W_ )!?_P")KSG6
MO^0[J'_7S)_Z$:HU\W/.*\9-)+3U_P SZJGD>'E!2<I:KR_R/5/^$PT'_G^_
M\@O_ /$T?\)AH/\ S_?^07_^)KRNBI_MK$=E^/\ F5_8.&_FE]Z_R/5/^$PT
M'_G^_P#(+_\ Q-'_  F&@_\ /]_Y!?\ ^)KRNBC^VL1V7X_YA_8.&_FE]Z_R
M/5/^$PT'_G^_\@O_ /$T?\)AH/\ S_?^07_^)KRNBC^VL1V7X_YA_8.&_FE]
MZ_R/5/\ A,-!_P"?[_R"_P#\31_PF&@_\_W_ )!?_P")KRNBC^VL1V7X_P"8
M?V#AOYI?>O\ (]4_X3#0?^?[_P @O_\ $T?\)AH/_/\ ?^07_P#B:\KHH_MK
M$=E^/^8?V#AOYI?>O\CU3_A,-!_Y_O\ R"__ ,31_P )AH/_ #_?^07_ /B:
M\KHH_MK$=E^/^8?V#AOYI?>O\CU3_A,-!_Y_O_(+_P#Q-'_"8:#_ ,_W_D%_
M_B:\KHH_MK$=E^/^8?V#AOYI?>O\CU3_ (3#0?\ G^_\@O\ _$T?\)AH/_/]
M_P"07_\ B:\KHH_MK$=E^/\ F']@X;^:7WK_ "/5/^$PT'_G^_\ (+__ !-'
M_"8:#_S_ '_D%_\ XFO*Z*/[:Q'9?C_F']@X;^:7WK_(]4_X3#0?^?[_ ,@O
M_P#$T?\ "8:#_P _W_D%_P#XFO*Z*/[:Q'9?C_F']@X;^:7WK_(]4_X3#0?^
M?[_R"_\ \31_PF&@_P#/]_Y!?_XFO*Z*/[:Q'9?C_F']@X;^:7WK_(]4_P"$
MPT'_ )_O_(+_ /Q-'_"8:#_S_?\ D%__ (FO*Z*/[:Q'9?C_ )A_8.&_FE]Z
M_P CU3_A,-!_Y_O_ ""__P 31_PF&@_\_P!_Y!?_ .)KRNBC^VL1V7X_YA_8
M.&_FE]Z_R/5/^$PT'_G^_P#(+_\ Q-'_  F&@_\ /]_Y!?\ ^)KRNBC^VL1V
M7X_YA_8.&_FE]Z_R/5/^$PT'_G^_\@O_ /$T?\)AH/\ S_?^07_^)KRNBC^V
ML1V7X_YA_8.&_FE]Z_R/5/\ A,-!_P"?[_R"_P#\31_PF&@_\_W_ )!?_P")
MKRNBC^VL1V7X_P"8?V#AOYI?>O\ (]4_X3#0?^?[_P @O_\ $T?\)AH/_/\
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M']M8CLOQ_P P_L'#?S2^]?Y'JG_"8:#_ ,_W_D%__B:/^$PT'_G^_P#(+_\
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M^VL1V7X_YA_8.&_FE]Z_R/5/^$PT'_G^_P#(+_\ Q-'_  F&@_\ /]_Y!?\
M^)KRNBC^VL1V7X_YA_8.&_FE]Z_R/5/^$PT'_G^_\@O_ /$T?\)AH/\ S_?^
M07_^)KRNBC^VL1V7X_YA_8.&_FE]Z_R/5/\ A,-!_P"?[_R"_P#\31_PF&@_
M\_W_ )!?_P")KRNBC^VL1V7X_P"8?V#AOYI?>O\ (]4_X3#0?^?[_P @O_\
M$T?\)AH/_/\ ?^07_P#B:\KHH_MK$=E^/^8?V#AOYI?>O\CU3_A,-!_Y_O\
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M?[_R"_\ \37E=%']M8CLOQ_S#^P<-_-+[U_D>J?\)AH/_/\ ?^07_P#B:/\
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M_P")H_X3#0?^?[_R"_\ \37E=%']M8CLOQ_S#^P<-_-+[U_D>J?\)AH/_/\
M?^07_P#B:/\ A,-!_P"?[_R"_P#\37E=%']M8CLOQ_S#^P<-_-+[U_D>J?\
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M?[_R"_\ \37E=%']M8CLOQ_S#^P<-_-+[U_D>J?\)AH/_/\ ?^07_P#B:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MG'XB?\G)>'O^OK3_ /T:*^CJ^8?C#J?]B?'&QU;R?.^PBTN?*W;=^QMVW.#C
M.,9P: /IZJ&N:59ZYH=[IFH(K6ES$R2;NP]?;'7\*\._X::_ZE'_ ,J7_P!J
MK-UWXP^+_'.F3:1X=\,S6T=XIB=[</<2%3D, P4 9 ()QP,].M $W[-=[.-9
MURQRYMFMTF(R=JN&QTZ9(/\ X[7L_C'QWH7@:P2YUBX</*2(;:%=TLN.NT9
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M_P *_P##UOJW]G?;_.NUMO*\_P K&4=MV=K?W,8QWJS\./\ DFWAS_L'P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^E ';45Y5\5_BG<^$[BWT'0(%N-<N@#DH7\D,<+A<?,S<X';'(.17,6_P_\
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M/#8\4?#S5+-(A)=0I]JMN,D2)SA?<KN7_@5>-?'[_DJNB_\ 7A!_Z/EKZ7H
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M<D9!X STH ]P\4Z'_P )+X7U'1?M'V;[9"8O.V;]F>^W(S^=8WPX\"_\*_\
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MT/N*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_K\^[]X&++$&^]@GEF)SEC^'<D ROCQX\U7PU9Z?H^CSR6D]\KR3749VNJ#
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M9_:;U6>])=K6\NVC Z?NR8TS]!C\0*^D:^:?&"WGPN^.">*#:-+IM[,T^53
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M_K!_T[_'_@'A]%>X44?V'_T\_#_@A_K!_P!._P ?^ >'T5[A11_8?_3S\/\
M@A_K!_T[_'_@'A]%>X44?V'_ -//P_X(?ZP?]._Q_P" >'T5[A0>E']A_P#3
MS\/^"'^L'_3O\?\ @'A]%>R67WW^E7*/[#_Z>?A_P0_U@_Z=_C_P#P^BO<**
M/[#_ .GGX?\ !#_6#_IW^/\ P#P^BO<**/[#_P"GGX?\$/\ 6#_IW^/_  #P
M^BO<**/[#_Z>?A_P0_U@_P"G?X_\ \/HKW"BC^P_^GGX?\$/]8/^G?X_\ \/
MHKW"BC^P_P#IY^'_  0_U@_Z=_C_ , \/HKW"BC^P_\ IY^'_!#_ %@_Z=_C
M_P  \/HKW"BC^P_^GGX?\$/]8/\ IW^/_ /#Z*]PHH_L/_IY^'_!#_6#_IW^
M/_ /#Z*]PHH_L/\ Z>?A_P $/]8/^G?X_P# /#Z*]PHH_L/_ *>?A_P0_P!8
M/^G?X_\  /#Z*]PHH_L/_IY^'_!#_6#_ *=_C_P#P^BO<**/[#_Z>?A_P0_U
M@_Z=_C_P#P^BO<**/[#_ .GGX?\ !#_6#_IW^/\ P#P^BO<**/[#_P"GGX?\
M$/\ 6#_IW^/_  #P^BO<**/[#_Z>?A_P0_U@_P"G?X_\ \/HKW"BC^P_^GGX
M?\$/]8/^G?X_\ \/HKW"BC^P_P#IY^'_  0_U@_Z=_C_ , \/HKW"BC^P_\
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MBC^P_P#IY^'_  0_U@_Z=_C_ , \/HKW"BC^P_\ IY^'_!#_ %@_Z=_C_P
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MM]/M$MK:,)&@X'K[GWJQ117MQBHJRV/ E)R=WN%%%%,04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 457::Y#D+:[@#P?, S2>?=?\^?\
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M_ G@*3P;<ZGJ-S(VJ:QJ4K27%ZP6+()W$!02!EB2>>>/2NV\^Z_Y\_\ R**
M+-%5O/NO^?/_ ,BBCS[K_GS_ /(HH S/$G@_0/%UJMOKFFQ703_5R'*R1_[K
MC##H,C.#CFN D_9U\&O<&1;O6$0G/E+<1[1[<QDX_&O4O/NO^?/_ ,BBCS[K
M_GS_ /(HH YOPO\ #3PIX1D6?2],4W:C'VJ=C))^!/"_\! KK:K>?=?\^?\
MY%%'GW7_ #Y_^110!R'B_P"%>A^-?$%KK.I76HQ7-M"D*+;2(J%5=F&0R$YR
MQ[UW%5O/NO\ GS_\BBCS[K_GS_\ (HH LUYQKWP2\*>(O$L^N7CZA'+<2+)-
M!!*BQ.1C.1MW#=CG!'4]*[[S[K_GS_\ (HH\^Z_Y\_\ R** +"J%4*H 4#
MZ"EJMY]U_P ^?_D44>?=?\^?_D44 6:IZMIL.LZ-?:7<-(L%[;R6\C1D!@KJ
M5)&01G!]#3_/NO\ GS_\BBCS[K_GS_\ (HH Y_P1X!TKP#975II5Q>31W,@D
M<W3JQ! QQM5>*IZS\,-$USQO9^++JZU!+^TDADCCBD01$Q-N7(*$]1SS^5=9
MY]U_SY_^111Y]U_SY_\ D44 6:XWQ7\-=&\8:_I^LZA<W\5S8A5B6WD14.U]
MPW J3U/8BNI\^Z_Y\_\ R**//NO^?/\ \BB@#E_BK(D7PN\0M(ZHIM2H+'')
M( 'U)('XUR?[.<;)\.KQF& ^J2,ON/+B'\P:9XM^%?BCQ;J%])<^,KN+3[F8
MR+IXB+0QKQM7'FX.,#G YR<#-=UX0\.KX-\,VFB65L\B0@EY7D4&1R<LQ';G
MMV&* -/7/#VD>)=/:PUFPAO+8G(60<J>F58<J?<$&O.9_P!G?P9+=M,EQJ\,
M9((@CN$*#VRR%OUKU#S[K_GS_P#(HH\^Z_Y\_P#R** ,3PGX#\/>"X&31K$1
MS.NV2YD.Z609S@MZ>PP.!7256\^Z_P"?/_R**//NO^?/_P BB@#C?%/P@\(>
M++N6]NK.6UOICF2YLY-C,?4J05)/<[<GUJEH/P-\%Z%>QW9MKG4)8CE/MTH=
M0<]=JA0?Q!%=_P"?=?\ /G_Y%%'GW7_/G_Y%% %FO,]>^!/@[7M5EU _;[&2
M9B\B6<RJC,3DG#*V/H,#VKT/S[K_ )\__(HH\^Z_Y\__ "** .7U[X;Z1XB\
M&:7X7O+J_6RTTQ>3)$Z"5O+C,:[B4(/#=@*Z#0-%MO#N@V6CVCRO;VD8CC:8
M@N0/4@ 9_"K'GW7_ #Y_^111Y]U_SY_^110!B^*O GAWQG$BZS8+++&-L<Z$
MI(@SG 8=O8^IKBK?]GCP7#=>;)-JUPF?]3)<*$_\=0-^M>G^?=?\^?\ Y%%'
MGW7_ #Y_^110!!HVAZ9X>TV/3M(LHK2TCZ1QCJ<8R3U8\#).2:QO&_@'2O'U
ME:VFJW%Y#';2&1#:NJDDC'.Y6XKH//NO^?/_ ,BBCS[K_GS_ /(HH 9I.FPZ
M-HUCI=NTC065O';QM(06*HH4$X &<#T%97C+P?I_CC0QI.IS745N)EFW6S*K
M;@"!RRD8Y/:MCS[K_GS_ /(HH\^Z_P"?/_R** *^@:+;>'=!LM'M'E>WM(Q'
M&TQ!<@>I  S^%:-5O/NO^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//
MNO\ GS_\BB@"S15;S[K_ )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[
MK_GS_P#(HH LT56\^Z_Y\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z
M_P"?/_R** +-%5O/NO\ GS_\BBCS[K_GS_\ (HH LT56\^Z_Y\__ "**//NO
M^?/_ ,BB@"S15;S[K_GS_P#(HH\^Z_Y\_P#R** +-%5O/NO^?/\ \BBCS[K_
M )\__(HH LT56\^Z_P"?/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y
M\_\ R** +-%5O/NO^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\
MGS_\BB@"S15;S[K_ )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS
M_P#(HH LT56\^Z_Y\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z_P"?
M/_R** +-%5O/NO\ GS_\BBCS[K_GS_\ (HH LT56\^Z_Y\__ "**//NO^?/_
M ,BB@"S15;S[K_GS_P#(HH\^Z_Y\_P#R** +-%5O/NO^?/\ \BBCS[K_ )\_
M_(HH LT56\^Z_P"?/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y\_\
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M LT56\^Z_P"?/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y\_\ R**
M+-%5O/NO^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\ GS_\BB@"
MS15;S[K_ )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS_P#(HH L
MT56\^Z_Y\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z_P"?/_R** +-
M%5O/NO\ GS_\BBCS[K_GS_\ (HH LT56\^Z_Y\__ "**//NO^?/_ ,BB@"S1
M5;S[K_GS_P#(HH\^Z_Y\_P#R** +-%5O/NO^?/\ \BBCS[K_ )\__(HH LT5
M6\^Z_P"?/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y\_\ R** +-%5
MO/NO^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\ GS_\BB@"S15;
MS[K_ )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS_P#(HH LT56\
M^Z_Y\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z_P"?/_R** +-%5O/
MNO\ GS_\BBCS[K_GS_\ (HH LT56\^Z_Y\__ "**//NO^?/_ ,BB@"S15;S[
MK_GS_P#(HH\^Z_Y\_P#R** +-%5O/NO^?/\ \BBCS[K_ )\__(HH LT56\^Z
M_P"?/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y\_\ R** +-%5O/NO
M^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\ GS_\BB@"S15;S[K_
M )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS_P#(HH LT56\^Z_Y
M\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z_P"?/_R** +-%5O/NO\
MGS_\BBCS[K_GS_\ (HH LT56\^Z_Y\__ "**//NO^?/_ ,BB@"S15;S[K_GS
M_P#(HH\^Z_Y\_P#R** +-%5O/NO^?/\ \BBCS[K_ )\__(HH LT56\^Z_P"?
M/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y\_\ R** +-%5O/NO^?/_
M ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\ GS_\BB@"S15;S[K_ )\_
M_(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS_P#(HH LT56\^Z_Y\_\
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MY_\ D44>?=?\^?\ Y%% %FBJWGW7_/G_ .111Y]U_P ^?_D44 6:*K>?=?\
M/G_Y%%'GW7_/G_Y%% %FBJWGW7_/G_Y%%'GW7_/G_P"110!9HJMY]U_SY_\
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MG_Y%% %FBJWGW7_/G_Y%%'GW7_/G_P"110!9HJMY]U_SY_\ D44>?=?\^?\
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M\_\ R** +-%5O/NO^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\
MGS_\BB@"S15;S[K_ )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS
M_P#(HH LT56\^Z_Y\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z_P"?
M/_R** +-%5O/NO\ GS_\BBCS[K_GS_\ (HH LT56\^Z_Y\__ "**//NO^?/_
M ,BB@"S15;S[K_GS_P#(HH\^Z_Y\_P#R** +-%5O/NO^?/\ \BBCS[K_ )\_
M_(HH LT56\^Z_P"?/_R**//NO^?/_P BB@"S15;S[K_GS_\ (HH\^Z_Y\_\
MR** +-%5O/NO^?/_ ,BBCS[K_GS_ /(HH LT56\^Z_Y\_P#R**//NO\ GS_\
MBB@"S15;S[K_ )\__(HH\^Z_Y\__ "** +-%5O/NO^?/_P BBCS[K_GS_P#(
MHH LT56\^Z_Y\_\ R**//NO^?/\ \BB@"S15;S[K_GS_ /(HH\^Z_P"?/_R*
M* +-%5A/=9_X]/\ R(*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M C?=/TJI9?>?Z"K;?=/TJI9?>?Z"@"Y1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5*U_X
M^'^A_G5VJ5K_ ,?#_0_SH NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %!Z44'I0!3LOOO\ 2KE4[+[[_2KE !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z?
MI52R^\_T%6V^Z?I52R^\_P!!0!<HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE:_\?#_0
M_P ZNU2M?^/A_H?YT 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "@]**#TH IV7WW^E7*IV7WW^E7* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^K;Z&JUE_'^%69/]
M6WT-5K+^/\* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3)O\ 4O\ 0T^F3?ZE_H: (;+[C?6K-5K+[C?6K- !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<?\>[TRS_U
M)_WJ?<?\>[TRS_U)_P!Z@"Q1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!\MD[CNSSDYK4H **** "BBB@ HHHH **^4]%;Q]XV\<:OH^C^+]0MGMVFF
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MT/V'R_,^UZI<+G?NQC;N_N'KCM77GX7_ !AB_>+XY+LI!"C5[HY_-<?G0!]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5T'AOQ))HTWDS%GLG/S+W0^H_P *Y^BM*56=*:G!V:,JU&%:
M#IU%=,]MAFCN(4FA=7C<95E/!%/KR_PWXDDT:;R9BSV3GYE[H?4?X5Z;#-'<
M0I-"ZO&XRK*>"*^MP>,AB876C6Z/B\=@9X2=GK%[/^NH^BBBNPX0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M BN/^/=Z99_ZD_[U/N/^/=Z99_ZD_P"]0!8HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MST^8@_SKC/'GB.UM?C]<:GJMM+>6.G3QJ+;(.0D8P!GC&_+?B:[O_AI31?\
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M[IC,3%;3Q3(".AD5@>?^V8X_QH ]RJAK?_( U'_KUE_]!-7ZH:W_ ,@#4?\
MKUE_]!- 'AW[,O\ S-/_ &Z?^UJ^@*^?_P!F7_F:?^W3_P!K5] 4 <)\8?#\
M6O\ PUU7<J^?8QF]A<C[IC!+?FFX?C7.?L\:S)?>!+G39"#_ &==,L>#_ _S
M\_\  B]>@>.)X[;P%XAEF"%%TVXRKD -^[8!>?4\?C7E'[-,;#2/$$A'RM/"
MH/N%;/\ ,4 :.C^.?$=U\?KSPS-J.[1XWE"6WD1C 6/</F"[NOO75?$_XBP_
M#_1(I(H4N-3NRRVL+GY1C&7?!SM&1P.I...H\T\/_P#)U&H?]=)__1-=1\=?
M!NK>(=.TO5M$MI+FZTQWWPQ#<[(VT@JO\1!7H.>>AH R;>7X\:O"NHQ265C$
MX#):ND +#&>C!F&>G)!^E:OP]^*VJZCXID\(^+[".RU=-X24?)O<<["O3)&2
M"#@@#US7.:-^T7<V0BL_$WA^0S1X6>>W?8YX'/E, ,]3]X#V%=SX;UCX;>-_
M%4>MZ>(9/$>P$"X#I,H08X4G:2!W7/'TH Z?QIXQT[P/X?DU74=S\^7! GWI
MI""0H].A)/8#\#Y'I_BGXR>/5.H^'[>VTG3,MY3M%&%D&1@9E#%\?WE 7(/T
MJI^T#.VH^._#>@M)(D)A5S@\ RRE,@>H"5]!6EK!8V<%G:Q+%;P1K%%&O1%4
M8 'L * /#;'XL^,/!6NP:3\1M+!MY3@7L48#8X^<;/DD49&0H!&?7BO:;V]!
MT"YO[.56'V5IH95P0?E)4CU[&N"^/.F6U[\+KR[E0&:PFAFA;N"SK&1],.?R
M'I47PMU"2_\ @7&)6=GM[>Y@W,<Y"EMH'L%('X4 >>^$_BQ\0/$=I-H6FD:A
MK]S+NCNY(8D2UA  +8  )R>K X]#GCU/P$?B+:W5\OCF:Q>QBA#Q7*",,6SS
MRF % !SE>XP>#GS_ /9HM!GQ'>'&?]'B7U_C)_\ 9:]+^+M_+IWPJ\03P_>:
M!8#S_#(ZQM^C&@#SN\^*GC/QSX@GTGX<V*QVL)&;Z6-2VW/WVW_*@.#@$%B/
M?@,UCQ?\1O!VCWEKXZL([_3=0MY;:.^M1&#%(R, #LP.I'! X!P3@BNH_9_T
MR"S^&RWB9,M]=222$]MIV #V^7/U)KNO%^EPZUX.UC3IU+)/:2*,#)#;25(]
MP0#^% 'E?[-?_(MZW_U]I_Z!75?$[XI6_@2*&RL[=+W6[E<Q0,3MC7H&<#DY
M/11C.#R*Y7]FO_D6];_Z^T_] KSW5_%MEIOQ\U+7]6M)KV#3[Z6..#()W1@Q
MH1G@ $!A[@4 =Y#-\>[^)M2C%K:HW*6+QVZG&!T# D?1F!S6_P##KXKW6N:R
M_A?Q78_V;X@CR$'ELBS8&2"IY5L<^A[8X!QO^&E-%_Z %_\ ]_4KS+QM\1;/
MQ%X\TGQ3I-A+87%GY9D+[2TC(^X$XX/''/8 =* /H#XN^(M5\+^ IM3T:Z^S
M7BSQ()/+5^">1A@1^E>=Z+XX^)WC[2[6+PKY4!LH@M]J-Q'$//F[J 5*@8(X
M [9)&<5V/Q\_Y)=<?]?4/_H57O@G:"U^$^C]-TWFRMCWE;'Z 4 ;W@EO%#^'
M$/B]+=-5$K@B #&P'"D[202>3QC@@8R#71444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (W
MW3]*J67WG^@JVWW3]*J67WG^@H N4444 %%%% !1110 4444 >.ZU_R'=0_Z
M^9/_ $(U1J]K7_(=U#_KYD_]"-4:^%J_Q)>K/T.C_#CZ(****@T"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH/#?B231IO)F+/
M9.?F7NA]1_A7/U>TK2KG5[U;>W7W=ST0>IK;#SJ0J)TOB,,3"E.DU6^$]?AF
MCN(4FA=7C<95E/!%/JGI>FPZ381VD&XJO)9CRQ[FKE?:P<G%<VY\%-14FH.Z
MZ!1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% $5Q_Q[O3+/_4G_>I]Q_Q[O3+/_4G_ 'J +%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEDB5P5YZ$C(()/H0<]#7SKXWT'2?#/QGT2Q\&AHK@36\CPH_FK#,9.% )ST
M8J3T;TXKMV_9Z:UED&C>--0L;=F)\LP[C[9*N@)]\5U?@?X/^'_!5VNH(TM_
MJ2@A+F< "/( .U1P#UYY/)YH X;]HC2[NUO] \46V62W/V=\KD(X;>A/U^;\
MAZU['X7\2Z=XLT&UU;3IE>.9 7C# M"^.4;T(.1[]1Q5[4=.L]7TZ?3]0MX[
MBTN$*2Q2#(8?Y[]J\AO/V>[:*]EF\/\ BB_TJ.3'[ORS(0/3<'4GGUH E_:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***O:5I5SJ]ZMO;K[NYZ(/4U4(2G)1BKMDSG&$7*3LD&E:5<ZO>
MK;VZ^[N>B#U->J:5I5MI%DMO;K[NYZN?4T:5I5MI%DMO;K[NYZN?4U>KZK 8
M".'CS2UD_P #X[,<QEBI<L=(+\?-A1117HGEA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<?\>[TRS_ -2?
M]ZGW'_'N],L_]2?]Z@"Q1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 -<LL;%%WL 2%SC)],U\[:QX'^+
MOCZ[M+#Q.;>WT^"3<)2\.Q3T+!8SN8X)P#C\,U]%T4 5[&SAT[3[:QMUVP6T
M2PQK@#"J  ...@JQ110 4444 %%%% !1110 4444 %%%% !1110 5PGQ=\.Z
MKXH\!3:9HUK]IO&GB<1^8J< \G+$#]:[NB@#EOAQI%]H/P^TC2]3@\B]MXV6
M6/>K;278]5)!X(Z&NIHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z?I52R^\_T%6V
M^Z?I52R^\_T% %RBBB@ HHHH **** "BBB@#'F\*Z+<3R3RV6Z21B[MYKC))
MR>]1_P#"'Z#_ ,^/_D9__BJW**P>%H/5P7W(Z%C,0E95)?>S#_X0_0?^?'_R
M,_\ \51_PA^@_P#/C_Y&?_XJMRBE]4P_\B^Y#^N8G_GY+[V8?_"'Z#_SX_\
MD9__ (JC_A#]!_Y\?_(S_P#Q5;E%'U3#_P B^Y!]<Q/_ #\E][,/_A#]!_Y\
M?_(S_P#Q5'_"'Z#_ ,^/_D9__BJW**/JF'_D7W(/KF)_Y^2^]F'_ ,(?H/\
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MW(/KF)_Y^2^]F'_PA^@_\^/_ )&?_P"*H_X0_0?^?'_R,_\ \56Y11]4P_\
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MC_A#]!_Y\?\ R,__ ,56Y11]4P_\B^Y!]<Q/_/R7WLP_^$/T'_GQ_P#(S_\
MQ5'_  A^@_\ /C_Y&?\ ^*K<HH^J8?\ D7W(/KF)_P"?DOO9A_\ "'Z#_P ^
M/_D9_P#XJC_A#]!_Y\?_ ",__P 56Y11]4P_\B^Y!]<Q/_/R7WLP_P#A#]!_
MY\?_ ",__P 556W\*Z*\S*UED '_ ):OZ_6NFJE:_P#'P_T/\Z/JF'_D7W(/
MKF)_Y^2^]E#_ (0_0?\ GQ_\C/\ _%4?\(?H/_/C_P"1G_\ BJW**/JF'_D7
MW(/KF)_Y^2^]F'_PA^@_\^/_ )&?_P"*H_X0_0?^?'_R,_\ \56Y11]4P_\
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MC_A#]!_Y\?\ R,__ ,56Y11]4P_\B^Y!]<Q/_/R7WLP_^$/T'_GQ_P#(S_\
MQ5'_  A^@_\ /C_Y&?\ ^*K<HH^J8?\ D7W(/KF)_P"?DOO9A_\ "'Z#_P ^
M/_D9_P#XJC_A#]!_Y\?_ ",__P 56Y11]4P_\B^Y!]<Q/_/R7WLP_P#A#]!_
MY\?_ ",__P 51_PA^@_\^/\ Y&?_ .*K<HH^J8?^1?<@^N8G_GY+[V8?_"'Z
M#_SX_P#D9_\ XJC_ (0_0?\ GQ_\C/\ _%5N44?5,/\ R+[D'US$_P#/R7WL
MP_\ A#]!_P"?'_R,_P#\51_PA^@_\^/_ )&?_P"*K<HH^J8?^1?<@^N8G_GY
M+[V8?_"'Z#_SX_\ D9__ (JC_A#]!_Y\?_(S_P#Q5;E%'U3#_P B^Y!]<Q/_
M #\E][,/_A#]!_Y\?_(S_P#Q5'_"'Z#_ ,^/_D9__BJW**/JF'_D7W(/KF)_
MY^2^]F'_ ,(?H/\ SX_^1G_^*H_X0_0?^?'_ ,C/_P#%5N44?5,/_(ON0?7,
M3_S\E][,/_A#]!_Y\?\ R,__ ,51_P (?H/_ #X_^1G_ /BJW**/JF'_ )%]
MR#ZYB?\ GY+[V8?_  A^@_\ /C_Y&?\ ^*H_X0_0?^?'_P C/_\ %5N44?5,
M/_(ON0?7,3_S\E][,/\ X0_0?^?'_P C/_\ %4'P?H6/^/'_ ,C/_P#%5N4'
MI1]4P_\ (ON0?7,3_P _)?>SFK7PIHLC,'LLX'_/5_\ &K/_  A^@_\ /C_Y
M&?\ ^*K0LOOO]*N4?5,/_(ON0?7,3_S\E][,/_A#]!_Y\?\ R,__ ,51_P (
M?H/_ #X_^1G_ /BJW**/JF'_ )%]R#ZYB?\ GY+[V8?_  A^@_\ /C_Y&?\
M^*H_X0_0?^?'_P C/_\ %5N44?5,/_(ON0?7,3_S\E][,/\ X0_0?^?'_P C
M/_\ %4?\(?H/_/C_ .1G_P#BJW**/JF'_D7W(/KF)_Y^2^]F'_PA^@_\^/\
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M_P#\51_PA^@_\^/_ )&?_P"*K<HH^J8?^1?<@^N8G_GY+[V8?_"'Z#_SX_\
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MY11]4P_\B^Y!]<Q/_/R7WLP_^$/T'_GQ_P#(S_\ Q5'_  A^@_\ /C_Y&?\
M^*K<HH^J8?\ D7W(/KF)_P"?DOO9A_\ "'Z#_P ^/_D9_P#XJC_A#]!_Y\?_
M ",__P 56Y11]4P_\B^Y!]<Q/_/R7WLP_P#A#]!_Y\?_ ",__P 51_PA^@_\
M^/\ Y&?_ .*K<HH^J8?^1?<@^N8G_GY+[V8?_"'Z#_SX_P#D9_\ XJC_ (0_
M0?\ GQ_\C/\ _%5N44?5,/\ R+[D'US$_P#/R7WLP_\ A#]!_P"?'_R,_P#\
M51_PA^@_\^/_ )&?_P"*K<HH^J8?^1?<@^N8G_GY+[V8?_"'Z#_SX_\ D9__
M (JC_A#]!_Y\?_(S_P#Q5;E%'U3#_P B^Y!]<Q/_ #\E][,/_A#]!_Y\?_(S
M_P#Q5'_"'Z#_ ,^/_D9__BJW**/JF'_D7W(/KF)_Y^2^]F'_ ,(?H/\ SX_^
M1G_^*H_X0_0?^?'_ ,C/_P#%5N44?5,/_(ON0?7,3_S\E][,/_A#]!_Y\?\
MR,__ ,51_P (?H/_ #X_^1G_ /BJW**/JF'_ )%]R#ZYB?\ GY+[V8?_  A^
M@_\ /C_Y&?\ ^*H_X0_0?^?'_P C/_\ %5N44?5,/_(ON0?7,3_S\E][,/\
MX0_0?^?'_P C/_\ %4?\(?H/_/C_ .1G_P#BJW**/JF'_D7W(/KF)_Y^2^]F
M'_PA^@_\^/\ Y&?_ .*H_P"$/T'_ )\?_(S_ /Q5;E%'U3#_ ,B^Y!]<Q/\
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MH_X0_0?^?'_R,_\ \56Y11]4P_\ (ON0?7,3_P _)?>S#_X0_0?^?'_R,_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (WW3]*J67WG^@JVWW3]*J67WG^@
MH N4444 %%%% !1110 4444 %%4WU?38Y&CDU"T1U)#*TR@@CL1FF_VUI7_0
M3L_^_P"O^-9^UI_S+[S3V-3^5_<7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'M:?\R^\/8U/Y7]Q>HJC_;6E?]!.S_[_ *_XT?VUI7_03L_^_P"O
M^-'M:?\ ,OO#V-3^5_<7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-
M'M:?\R^\/8U/Y7]Q>HJC_;6E?]!.S_[_ *_XT?VUI7_03L_^_P"O^-'M:?\
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M *_XT?VUI7_03L_^_P"O^-'M:?\ ,OO#V-3^5_<7J*H_VUI7_03L_P#O^O\
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M_H)V?_?]?\:/:T_YE]X>QJ?RO[B]15'^VM*_Z"=G_P!_U_QH_MK2O^@G9_\
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MZ_XU;_MK2O\ H)V?_?\ 7_&CVM/^9?>'L:G\K^XO451_MK2O^@G9_P#?]?\
M&C^VM*_Z"=G_ -_U_P :/:T_YE]X>QJ?RO[B]15'^VM*_P"@G9_]_P!?\:/[
M:TK_ *"=G_W_ %_QH]K3_F7WA[&I_*_N+U%4?[:TK_H)V?\ W_7_ !H_MK2O
M^@G9_P#?]?\ &CVM/^9?>'L:G\K^XO451_MK2O\ H)V?_?\ 7_&C^VM*_P"@
MG9_]_P!?\:/:T_YE]X>QJ?RO[B]15'^VM*_Z"=G_ -_U_P :/[:TK_H)V?\
MW_7_ !H]K3_F7WA[&I_*_N+U%4?[:TK_ *"=G_W_ %_QH_MK2O\ H)V?_?\
M7_&CVM/^9?>'L:G\K^XO451_MK2O^@G9_P#?]?\ &C^VM*_Z"=G_ -_U_P :
M/:T_YE]X>QJ?RO[B]15'^VM*_P"@G9_]_P!?\:/[:TK_ *"=G_W_ %_QH]K3
M_F7WA[&I_*_N+U%4?[:TK_H)V?\ W_7_ !H_MK2O^@G9_P#?]?\ &CVM/^9?
M>'L:G\K^XO451_MK2O\ H)V?_?\ 7_&C^VM*_P"@G9_]_P!?\:/:T_YE]X>Q
MJ?RO[B]15'^VM*_Z"=G_ -_U_P :/[:TK_H)V?\ W_7_ !H]K3_F7WA[&I_*
M_N+U%4?[:TK_ *"=G_W_ %_QH_MK2O\ H)V?_?\ 7_&CVM/^9?>'L:G\K^XO
M451_MK2O^@G9_P#?]?\ &C^VM*_Z"=G_ -_U_P :/:T_YE]X>QJ?RO[B]15'
M^VM*_P"@G9_]_P!?\:/[:TK_ *"=G_W_ %_QH]K3_F7WA[&I_*_N+U%4?[:T
MK_H)V?\ W_7_ !H_MK2O^@G9_P#?]?\ &CVM/^9?>'L:G\K^XO451_MK2O\
MH)V?_?\ 7_&C^VM*_P"@G9_]_P!?\:/:T_YE]X>QJ?RO[B]15'^VM*_Z"=G_
M -_U_P :/[:TK_H)V?\ W_7_ !H]K3_F7WA[&I_*_N+U%4?[:TK_ *"=G_W_
M %_QH_MK2O\ H)V?_?\ 7_&CVM/^9?>'L:G\K^XO451_MK2O^@G9_P#?]?\
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M*_Z"=G_W_7_&C^VM*_Z"=G_W_7_&CVM/^9?>'L:G\K^XO451_MK2O^@G9_\
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MT_YE]X>QJ?RO[BQ9?<;ZU9K)M-8TQ4;=J-H.>\Z_XU8_MK2O^@G9_P#?]?\
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M% !1110 4444 %%%% $5Q_Q[O3+/_4G_ 'J?<?\ 'N],L_\ 4G_>H L4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGNM,DVA)I',AB4\"2-SRR=BIZ8XP00?HI'26-9(V5T8!E93D$'H0: '4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y7X0^&FL^'_ (KZ
MWXJN[FP>QOGN6BCBD<RCS)0Z[@5 Z=<$_C7JE !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW3]*J67WG^@JVWW3]
M*J67WG^@H N4444 %%%% !1110 4444 >.ZU_P AW4/^OF3_ -"-4:O:U_R'
M=0_Z^9/_ $(U1KX6K_$EZL_0Z/\ #CZ(****@T"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "M;0M=N-$N]Z9>!S^]BSU]Q[UDT5=.I*G)
M3@[-$5:4*L'":NF>T65[;ZA:)<VT@>-QP?3V/O5BO)="UVXT2[WIEX'/[V+/
M7W'O7J5E>V^H6B7-M('C<<'T]C[U]7@<='$QL])+='QF89?/"SNM8O9_HRQ1
M117>><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% $5Q_Q[O3+/_4G_>I]Q_Q[O3+/_4G_ 'J +%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC;Q-XQ6=5/)\R6Z8=>F_;[?G[<@%;]FNQN&U?7-0^86R01P'CAG9MWY@*?\
MOH>M=7\3/BEJNG>((?!_@Z 3:W*RK)-L#^6S8*H@/&[')+< ?F/1_"_AC3/"
M&A0Z/I4;K;QDL6D;<\C'JS'N3^ ] !7A?PG5=5^/OB.^NXOW\0O)XPW)C<S*
MG&?1784 :Z?#7XM2VHOY/'DL>H'$@M?MLWE@\':<?+^ 4C\.:N_#SXH:[%XK
M/@KQU#Y>J!_+BN"JJV_&X*^WY3D$;67KQUSFO::^<_C^JZ;\0/#VK6L.;OR5
M8A>-YCDRO3OSC/T]* /3?BUX_E\!^&HY+*-7U*]=HK<N,K'@99R.^,C ]3Z
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M"KQ3XB\+0:G+H'A*YUHW+1K+-%#*XCV@X7Y <?>)_*O1?^%M?$;_ *)G?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]LA62Y<1KO\ M"MM+'@<*W7TQUKO?CQ FM?"J._L9%N;>"[ANA+"P=60ADW
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M^2>.UNMF]X& <;75Q@D$=5':@#S+X)>*?#VD_#B"UU'7M+L[@7,K&*XO(XW
M)X.&(-=[>?$?P78P--+XHTIE4%B(;I96X]%0DD^P%</_ ,,X^#_^@EKG_?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1
MONGZ54LOO/\ 05;;[I^E5++[S_04 7**** "BBB@ HHHH **** *;Z1ILDC2
M2:?:.[$EF:%223W)Q3?[%TK_ *!EG_WX7_"KU%9^RI_RK[C3VU3^9_>4?[%T
MK_H&6?\ WX7_  H_L72O^@99_P#?A?\ "KU%'LJ?\J^X/;5/YG]Y1_L72O\
MH&6?_?A?\*/[%TK_ *!EG_WX7_"KU%'LJ?\ *ON#VU3^9_>4?[%TK_H&6?\
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M7_"KU%'LJ?\ *ON#VU3^9_>4?[%TK_H&6?\ WX7_  H_L72O^@99_P#?A?\
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M?] RS_[\+_A1_8NE?] RS_[\+_A5ZBCV5/\ E7W![:I_,_O*/]BZ5_T#+/\
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M8NE?] RS_P"_"_X5>HH]E3_E7W![:I_,_O*/]BZ5_P! RS_[\+_A1_8NE?\
M0,L_^_"_X5>HH]E3_E7W![:I_,_O*/\ 8NE?] RS_P"_"_X4?V+I7_0,L_\
MOPO^%7J*/94_Y5]P>VJ?S/[RC_8NE?\ 0,L_^_"_X4?V+I7_ $#+/_OPO^%7
MJ*/94_Y5]P>VJ?S/[RC_ &+I7_0,L_\ OPO^%']BZ5_T#+/_ +\+_A5ZBCV5
M/^5?<'MJG\S^\H_V+I7_ $#+/_OPO^%']BZ5_P! RS_[\+_A5ZBCV5/^5?<'
MMJG\S^\H_P!BZ5_T#+/_ +\+_A1_8NE?] RS_P"_"_X5>HH]E3_E7W![:I_,
M_O*/]BZ5_P! RS_[\+_A1_8NE?\ 0,L_^_"_X5>HH]E3_E7W![:I_,_O*/\
M8NE?] RS_P"_"_X4?V+I7_0,L_\ OPO^%7J*/94_Y5]P>VJ?S/[RC_8NE?\
M0,L_^_"_X4?V+I7_ $#+/_OPO^%7J*/94_Y5]P>VJ?S/[RC_ &+I7_0,L_\
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M?] RS_[\+_A1_8NE?] RS_[\+_A5ZBCV5/\ E7W![:I_,_O*/]BZ5_T#+/\
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M7J*/94_Y5]P>VJ?S/[RC_8NE?] RS_[\+_A1_8NE?] RS_[\+_A5ZBCV5/\
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M_O*/]BZ5_P! RS_[\+_A1_8NE?\ 0,L_^_"_X5>HH]E3_E7W![:I_,_O*/\
M8NE?] RS_P"_"_X4?V+I7_0,L_\ OPO^%7J*/94_Y5]P>VJ?S/[RC_8NE?\
M0,L_^_"_X4?V+I7_ $#+/_OPO^%7J*/94_Y5]P>VJ?S/[RC_ &+I7_0,L_\
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M3=U8;47G''XG\.2\<_!+7?&'BZYUE_$=L8YW 2.2!@8(AP%4 D' ^F22>,T
M:/\ PT9X.\W9]AUK;G&_R(L?7_69Q^%=OX2\?^'?&T<G]C7I>>)0TMO*A21
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MX*/1@V?8KTY)KZ*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLN/Q'H\MJ]PE_'Y:$AMV0WX*1D_@*8?$^D" 3FXD$).!(;>3:?QVXI?6*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM5'3YM+CL;Q+ZVEEN73%NZ'A&P>3R.^.QJ[%!JQ\(33+=1#3 _SPX^8G</\
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MR?/XW?(=V<[>G/ITJ;7HK^UU>R.O3I=IPQ$(QF/=R.B\]:AM/]*\4I_PC_\
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MV0L!YWD<[?D&W&-W7CUJ?0)=0MM4OAH$$=W'D@&8X^3=\IZKS4%UBT\42?\
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M6WT-5K+^/\*LR?ZMOH:K67\?X4 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "F3?ZE_H:?3)O\ 4O\ 0T 0V7W&^M6:K67W
M&^M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"*X_X]WIEG_J3_O4^X_X]WIEG_J3_ +U %BBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ  (F>W&W</;=G_Q[C]*ZGQQ\9]$\'ZD^DV]K-JFJ)@/#"P1(R>BL^#\W(X
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MP;RKJ1<A=C^6\;/_ !'/()R>&YX%>?\ QO\  =IX7U%=:@O)YYM9O;B:2-U
M6,D[\#'7EOTKUSX=?%[3?'MV^G/92:?J:1^8(B_F)(H/)5L#IP<$#KQG!KC_
M -I?_D&>'?\ KM/_ "2@#KOAA\,+'P8W]L6VH7%S+?6:*R2*H5<X;C'TKSXR
M>,/C-XTU.Q@U2YT70;'.$"LH"D[5W)E2[-M8_-P,,..A][T3_D :=_UZQ?\
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ME[R%;O6O%=[+J; ,9$3<$..!EF);!SSQ4'@+5O%G@OXG/X'UFZN=4TY@1'(
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MK^[O_/\ \$IZ79?:K'4I?[0^R^3'N\K/^NX;Y>H],=^M.AOMGAJXL_[-W[Y
MWVS'W.5XZ>WKWJ&PATV6UOFO[B2*X1,VRH.';!X/![[?3K5N";5!X2N88[:(
MZ:909)B?F#97@<^N.W>LJ?PZ?RO;7[UT_IFU3X]?YH[Z?<_M>GR&7MAY/A^T
MN_[3\[S& ^RY_P!7P>>OMZ=ZLZE>?VI>:9#_ &?_ &7B3;YV,9R5&[HO3K^-
M4+J#24T:WEMKJ5]09AYT3#Y5&#G'R^N.]:>N3:C<SZ8FNV\=K;;B \)R=A*[
MCU;H,=JO[,K;6CMJOF^AG]N-][RWT>W2/VOZ8R>/^QO$ELWF_P!LXC+;>N<A
MAC^+IUIMI#_;'B&Z/VC^Q\H7QTQRHV]5^OX40K#9^);4^&G-ZX0E1/QEL-D?
MP_P\TPI;W?B*[/B*1K-BN6$'.'XP.C<8S5:;=.;:^FW\Q&N_7EWM[V_\FWX$
M.G7GV.VU2'[!]L\U-GG8_P!5PPW=#ZYZCI3(++?X<NKS^T=GERA?LF?]9]WY
MNOOZ=JGTB748;+5TTVWCFMFCQ.[GE$PV".1SC/8]*IPPZ8VB3RRW$BZBL@$4
M('RLOR\GCW;OVK)? K]I;Z?<^O\ 2-W\<K=X[:O9;K[/],GNK[S/#MK:?V;Y
M?ER;OM>/]9][CI[^O:I]1L_[.DTN;[?_ &CN._R<YVXVG;U/7..G:FWDVJ-X
M5LHIK:)=.67,4H/S,WS<'G_>[=J;<1:=;W.FOHUQ)<W)<%TE& 'RNT=!QG/>
MJEMKO:.^C^2Z_P!,B.^FUY;:KYO[/](LSR?VSXCM5\G^Q<Q%=W3&-QW?P]>E
M%O+_ &-XCNE\G^V<1A=W7.=IW?Q=.E.U1IKSQ%;#Q*@LD,.&,'.%^8@_Q?Q<
M4FE-/9^(KD>&T6]00X4S\97Y<G^'^+BM?^7E^O-OUV_D_P" 8Z>SMTY=K^[O
M_/O^)7TZS_M#^U)OM_\ 9^SY_)S]_.X[>HZ8QT[U!;WOE^'+JS_L[S/,D#?:
M\?ZO[O'3V]>]/MHM.GDU%]7N)+>Y4DQ)&,AG^;(/![X[TZUFU-?"EY%%;1MI
MS2@RS$_,K?)P.?\ =[=ZQCMIVEMJ_FNG],WEOKM>.^B^3^U_2(I[+9X<M;S^
MT=_F2E?LF?\ 5_>^;K[>G>I=1O/MT>F0_8/L/EC9YV/]9G:-W0=,9Z]ZJS0Z
M8NB02Q7$C:BTA$L)'RJOS<CCV7OWJ]K$NHSVVDIJEO'!;*F(7C/+)A<D\GMC
ML.M+[#MVCMK][Z?TA_;C?O+?1[=%]K^F2747]C^(K5O/_MG$>[;USG<-O5NG
M6E@C_MGQ'=-YW]BYB#;>F,;1M_AZ]:8BV]IXCM#X<=KQ@N5$_&7^;(Z+VP:6
M98;SQ+='Q*YLG,8+"#G#84 ?Q?P\UMIMTYMNFW\W_!,==^O+O;WM_P"3;\!-
M.O/[,N=4A^P?VGN?9YW7;@L-W0]<YZ]JKVECYOAZZN_[3\KRW(^RY_UG"\]?
M?T[5=T274;:354T.WCNK8G#/*<$(-VT]5Y(SVK,MH-*;1KB6XN94U!6Q%$!\
MK#CKQ]>_:H^S&^UI;Z+Y/K_2-%\<K;WCMJ]NJ^S_ $Q\][O\-VUG_9VS9(6^
MUX^_RW'3W]>U.U*S^R6>F3?VA]K\Z/=Y.?\ 4\*=O4^N.W2GW,VIGPG:12VT
M:Z<LI,4P/S,V6X//^]V[57O8=.B@L'T^XDFN77-PCCA'PO X'?/<]*B?PZ]H
M[Z?<NO\ 3+I_%I_-+;7ON^G](O7LW]K^(+0?9_[(RH3/3').[HOKC\*="_\
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M6VJR9Z[N1\W1O3]:?J)DN_$L0\1J+-3'AS!S@8.W^]WI-%>ZM=?NO^$?B6[
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MD$'J"* /D+_A=OQ#_P"AA_\ )*W_ /C='_"[?B'_ -##_P"25O\ _&Z^G_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC%)M/-M.S12/&6$1/WD8*"<$_,&&0=QYQBOHBL+7_!?ASQ3@ZUH]M=N!M$K
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MY_Z4QU]#USNC^!?#>@:[=ZWIFG>1J-V'$\WGR-O#L';Y68@98 \"@#3UO_D
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M]P5'FVUSD-&W<9QAA[C].E>1^*+^R^*/QGTE?"T#2P1"(3W8A:,N%?<TC=&
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MOE=IZGC.>U)=6+1^&[2[.I&59)-HM,\1_>YZ^WIWJ6^O%U&;3(4L!IQ5@GG
M8W9VC=T'3&>O>JEMKO:.^K^3Z?TB(ZNZVO+;1?-?:_IEC55FM/$5L?$KK>IY
M.6%OQE?FP.-O\7-)I*SW?B*Y/AIULD\G*B?G"_+D<[OXN:+N,Z-XCM6DF_MK
M$1;:W.<[AM_BZ=:2SB.L^([IHYO[&S%NVKQC&T;?X>O6M=?:6Z\VWVMOYO\
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MXH/EG^R/,'&WCR\)_P !ZX_6KE?VMNO,M.O_ (%_P2(V]C?IRO6WN_\ @/\
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M>=Y'&[Y/EQC;TX].E&H72ZKK%BL=D-*RRIN7C&6^]T7I_2DD_P")3XI_>?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 17'_ ![O3+/_ %)_WJ?<?\>[TRS_
M -2?]Z@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@DDGH!7-R_$'1?M$4%HMU?R29P+5 <8]<D5Q.M:PU_C5=:C*VO(L--)P9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH R/%.A_\ "2^%]1T7[1]F^V0F+SMF_9GOMR,_G67\//!?_"!^&FT?^T/M
MV;AYO-\GROO #&-S>GK75T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "-]T_2JEE]Y_H*MM]T_2JEE]Y_H* +E%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M4K7_ (^'^A_G5VJ5K_Q\/]#_ #H NT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %!Z44'I0!3LOOO]*N53LOOO]*N4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/\ 5M]#
M5:R_C_"K,G^K;Z&JUE_'^% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDW^I?Z&GTR;_4O]#0!#9?<;ZU9JM9?<;ZU9H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KC
M_CW>F6?^I/\ O4^X_P"/=Z99_P"I/^]0!8HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KX]$!^'/QK2+Y5@T_4UQN8@"W<C&2?
M^F;]_P!:^PJ\._:$\%/?V%OXLLD9IK-!!=HHSF+)*O\ \!)(/LP_NT >XUX%
M\3/@9>W^KSZUX36)_M+[YM/9A'M?'+(Q.,$\X.,$\<<#T?X4>+!XN\ V5U*X
M:]M1]ENQC^- ,-_P)2K<<9)':NVH ^.;;1/BEH,?V.PLO%=I$#GR[-9PG4_W
M./6KVC_"#QYXJOQ<7]G/:+*09;O4G(?L.5)WDX]NW45]<44 <_X/\*6/@GPS
M!H^GAI!'F264@!IY#U8^_  ]  ,\5\Z:E\)/B+XC\47.HW^B_9_M]V9)9&O(
M)!"K-SP'R0H/0=AQ7U710!!96D&GV-O96R"."WB6*- ,!548 _(5/110!\]?
M%OX2^(]<\<S:OX<TQ;JWO(4>;$T46R4#:1AF&<A5.1W)KU#X4Z=KVC> [72O
M$5E]EN[.1XHQYJ2;XL[E.48C^(K_ ,!KM:* /*OBA\';?QG,=7TB2*SUG $F
M\8CN !QNP,AN@W<\#![$>)2>!/B7X/O'^PZ=K,#L=IFTIW<.!G!S$2<?7'6O
ML*B@#X['@'XD^*KQ)+S2M8N)FX\[4F9"![F4@XX_E[5ZAX#^ ']F:C;ZKXHO
M(YY(&66*RM2=@8<C>Y )QZ 8R.I'!]THH YSQ]I=YK7@/6=-T^'SKNYMBD4>
MX+N;CC)( _$U\Q_\*2^(?_0O?^3MO_\ '*^OZ* /D#_A27Q#_P"A>_\ )VW_
M /CE'_"DOB'_ -"]_P"3MO\ _'*^OZ* ./\ A;HFH^'/AQI.DZM;_9[Z#SO,
MBWJ^W=,[#E20>"#P:["BB@#-\0/J,?A[46T>#S]2^SN+6/<%S(1A>20.N#U%
M?*7_  I+XA_]"]_Y.V__ ,<KZ_HH ^0/^%)?$/\ Z%[_ ,G;?_XY6]X(^$?C
MG2/'&BZC?:'Y5I;7D<LLGVN!MJ@\G <D_A7U#10 5RWQ'TB^U[X?:OI>F0>?
M>W$:K%'O5=Q#J>K$ < ]374T4 >!?!KX<>+/"GC>34=;TK[+:&SDB$GVB)_F
M+*0,*Q/8U[[110!Y;\;_  IX@\7:'I=EH-@;MHKEI91YL<84;<#EV'J>E3_!
M/PEK'A#PG?6FN69M+N:^:18_-20%/+0 Y0D=0W?M7I=% !5#6]3CT70M0U27
M'EV=O).0>^U2<?I5^O'_ -H+Q4=*\(PZ%;RA;G5'_>CG(@0Y.".F6VCW&X8H
M \M^!^C3:[\3[>^E:1DL$>[FD.3N8_*H+>I9L^^TU]95YM\%O!3>%/!J7-Y#
MY>I:EB>8,/F1,?(AX!& <D'H2:])H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KB->3^W?&=IHS30M;6B?:YH2H8EQ@*#Z<-FNWKD]+M8&\>^(+LH//5H
M8PW^R84.*F70UI.S;\CSSQKX9U2PN)=3N[M;R @;I<;-G. H7TKCR/\ ZU?0
MGB"..32;I756'E-PPR.E?/2CY5] !S7%B8I.Z/K<CQ$JBY7T%'/?FKFF:7=:
MQ>QV=G&7=_O'L@]2:I]><<]J],^%5G;&"\O&4?:?,\K=G^# .,?6LZ$>9ZGH
M9M7=&BVB[J>@WNC^&;*Y2=[JZTI@\1B'E9BXW*1WX'6NZL+K[=I]O<A=@FC6
M3;G[N1G%5=?_ .1=U'_KUD_]!-5/!L]S<^%;&2[M_(D$879ZJ!@'\1S7HK38
M^#G)S5V>0_M#:_J<5_IOA^&Z\K3[F 32H#MWMO*@,>Z]#C\:L:+\ -+OO!D$
MEQJF=6N LJW=NWF0HIQ\J@'#C&?FR.M=E\4OAG#XZT];JU<1:Q:IM@=B=LB\
MG8WIU)SCK7AMFOQ/^'EA->QV^HV%F0L;M,BR(HS\H .<<GM5&)T'PTTWQ3X(
M^)!M?['U2;2YYVLY)/*>.)ANPLQX(( Y_'K7,_%8 _&/5CC_ )>(?_0$KTWX
M5_&2YUK48M!\2/']JD)$-V1M\UR>$( P#SQ7F'Q<WCXN:R8_]8)HMOUV+B@1
M]>)_JU^@KYT\>@?\-):1_P!=K/\ F*/[7^.__/K??^ L/^%<K!/XDN?C)H4G
MBQ)$U8WEL&61%0[-PV\+Q0!ZQ^T8!_P@EC_V$%_] >M;PQK]OX7^!.F:O<,R
MQP6 VE4W?.20O'IDBLG]HO\ Y$2Q_P"P@G_H#U0U?_DUFV_Z](?_ $:*!GG'
MA/PIK7QA\3:C?W^I^48_FN+AAO*%L[55,_=X/?BNA\3_ +/^HZ-H4]_INJ-J
M<T(W-;+;;69>^W!.3[5U?[.UKID?AW4;B"Y#ZE+*!<PYYC09V'\>:]G?[C$>
MAH \,^ ?C66Z-YX;U2Z=YP?.MY+BXRQZ QJI],$\>]>1_$90?B-X@X_Y?9.?
MQK7^$W_)8M*S_P ]YO\ T!ZC\16L%]\;[FTNH_,MY]9$<J9QN4R $9^E CW?
MX.>-8_$_A*&RN9T.J6"B*6,)L^0<(1Z_*!D^M>$_$D#_ (71JO'_ "_1?R2M
MBY@O/@S\6([A1.FD32$@HH;SK<D$H,]QP,\'BL;XBNLGQDU*12"KWD# @]BJ
M&@#V/XZ>-I- T*#2--NVAU&\<,TD%QLD@12#G YPW([=#7GW@_X(ZAXOT)-;
MU#59-/DNG9ECEMR[N,_?))'7K57]H(?\7*'_ %X1?S:OI#PM_P BCHI_Z<(/
M_18I@?,OCKX<:I\+IM.UFRU<S(9 L=S&/*DCEY. ,GC ZU[KX4^(5KJGPS_X
M26^GC$UK$4NB^(E:=5!VC/')( ^M4?CC'H[_  ZN6U-D%RCAK#<Q!,WMCJ=N
M[K7E>E\_LR:T?^HF/_0HZ0&1##XF^-GC4O(72V1LECDQ641/0=MV/INQ72>(
MOV?Y]&\/WVI6FM27\]O'O2VCM,-)ST&&/UK8_9L_X]O$8[;X./P>KWC?XU:K
MX5\8:AHMMH5O<PVQ4+*[."V5![#WQ3 ;^S[XMO-4L=0T*\::=K3$\<\LI8A6
MPNP ] ,9_&O+H@/^%^1''_,RI_Z4"O9OA)\03XTU34[<Z#I^F_9X4DWVHP7R
MV,'BO&X_^2^1?]C*G_I0*!GUY1112 **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!&^Z?I52R^\_T%6V^Z?I52R^\_T% %RB
MBB@ HHHH **** "BBB@ HK"U#Q;I6G2&-GDFD5BCI$H)4CKG)%-N?%EI97<=
MO>6EY;O)@@R*N "<9.&/'6N=XN@FTY+0Z8X+$22:@]3?HK 7Q=837_V.TAN;
MJ3^$PJN&XR<9840^,-+>YE@G,UJ\1*MYZCJ#@C@FCZW0_F7]>8_J6(_D??S^
M[<WZ*P+?Q9;W5I+=06%^\$6?,<(F%P,G^+TIO_"9Z/\ 8?M/F2;O^>&T>9UQ
MZX]^O2E]<H6OS(/J6(O;D?8Z&BN?N/%EM:VL-S/87R0S &-RB8;(R/XO2EF\
M8:6ES%;P>==/*0%\A1C). .2.:'BZ"WD"P6(>T7_ ,,;]%8#>+["&_\ L=U#
M<VL@^\9E7"\9&<,?\FEMO%EI>W4MO9VEY<M'DDQJN" <9&6'%/ZW0;MS:_C]
MP/!8A*_+IO?I]YO45SL'C72)H)92\L10$B.11N?CM@D?F13QXLMSIYOQ87_V
M4=9=B8ZX_O>M)8R@]5) \#B$[.#70WZ*YZ;QGH\-K',)))6?&8D4;UR,\Y('
MMUJ2Y\4VMC/#%>V=Y;&4\-(J8 SC)PQX%/ZW0_F0?4L1MR/_ (8W:*P!XNT^
M6_6SM8KF[D8?*857!XR>I%)%XQTQKN2VG$]J\>0QF48R#@C@GG_"E];H?S+^
MO,/J6(_D??S^[<Z"BN>M_%UK=P3SP6-\\4"[I&")\HP3_>]C2#QKI!LFN-\H
M8''DE1O//UQ^M'URA:_,A_4<1>W(SHJ*P)_%EO;645Y-87Z6\N-CE$P<C(_B
M]!2S>+M+2:&&!I;J29MJK H.#D  [B.N:?UN@MY"6"Q#VB_^&-ZBL&3Q98V]
M\MI>075HY&=TRK@#WPQ]*(/%EG>7DEM9VMW<N@))B5<$ XR,L..11];HWMS:
M_C]P?4Z]K\NF]^GW[&]17.0>-M(FBF=C-$8QD)(HR_7A<$\\=\=:<OBZU>P>
M^6QOC;(VUI-B8!X'][W%)8R@]I(;P.(3LX,Z&BN=D\:Z1':1SAY79S@Q*HWK
M]<G'Z]ZEN/%-M920+>6=Y;K.<*\BICMDG#'@9%'UNAOS(7U+$;<C_P"&-VBL
M(^+-/DOH[2T2>\E<97R%&.Y(^8CG S2+XNTT7LEK<K/:21CYO/48SQQ\I//-
M/ZW0_F7;R^\7U/$?R/OY_=N;U%<_!XNM+J.XDM[*]ECMQND943"CGG[WL:8O
MC;2&LWN"9E96P(2HWMTY'.,<^O8TOKE#?F17U'$7MR,Z.BN>D\76L5C'>O8W
MRVTC;4DV)@GG_:]C3I?&.E(T"0F6X>8X"0J,J>, Y(]:/KE#K)"^I8CI!_\
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M6-<MYZC'; ^4GG!S3^MT/YEV\OO)^IXC^1]_.WIN;M%85OXJM;QIQ:6=[<+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %,F_P!2_P!#3Z9-_J7^AH ALON-]:LU6LON-]:L
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $
M5Q_Q[O3+/_4G_>I]Q_Q[O3+/_4G_ 'J +%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q%R8=(^)1GEEE5-2M\
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M/F0,I(##U7D],Y[5Z9XN^.'AFTT.5O#\L>I:E+^[17@8*F1]YL@9'L/6NO\
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M4!R/RK0H CGFCMK>2>5ML<:EW;&< #)-<'_PNWX>?]##_P"25Q_\;KL=;_Y
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MFEDNJ;HL<$M][@+R/Z4ZFDFGO[N^K^3Z"I:Q36WO;:+YKJ.O/]&\4M_PD/\
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M*]M%\UU'ZB)+7Q+$?$C"[41Y<0<9&#MZ;>]6_#%S.WB*XCT@*EDP,A@G8CY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KC_CW>
MF6?^I/\ O4^X_P"/=Z99_P"I/^]0!8HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVEFE_M7P\I)\D03%1VW;ES^@6MI/ WQG\M?+\;Z=LP-NVXDQCMC]S0!B>-?
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M8> ?#(FCC(!N+A2[ $\,>0D>?]HGH?P?/I'QPUJWD^WZQ9:5;A"SHK1@XQR
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M-U2[CMX952>)SEH@S<9(P'C)VJ58=<=<\?1B;/+7R]NS V[>F.V*Y#XJ[/\
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M-3:6%M'+L6*-#C/ XYW<?B<DU[3X1\(Z9X*T3^R=*$I@,K3,TQ!=F;U( S@
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M-H=PUY)Y@8*Y#?.&&T< =:6Y+:CXG4:^/L0=<2;/EV@*=O7/4XIMW)IT^K6
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M;@5VC@#J<U)?/+J?B.V'B)!8H8L,8_EPHW$'G/?BHKF339[_ $U= A>WN?-
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MO;M6<OA5_P"7KZ_9_P"#YEQ^)\O\VO+Z?:O^GD7M6N=0O6TN+5[=;6W4[4=
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M_ET_I"V+S:9XCN5\.H+Y!%@&3YLJ=I)XQ_%Q4-G;:??7>IRZU<-:7(<LJ(0
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MP(WM\L@7S23B3=P>2>.E%3XG??W=_B^73^D%/X5;;WMOA^?7^F/E U'Q0_\
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MNX X88(^M.HHKZ<^2"BBB@ HHHH ;)_JV^AJM9?Q_A5F3_5M]#5:R_C_  H
MMT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,
MF_U+_0T^F3?ZE_H: (;+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!%<?\>[TRS_ -2?]ZGW'_'N],L_
M]2?]Z@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5P?Q1^',/C_ $6,12B#5;,,UI(Q^1LXRC^QP.>H/X@]Y10!\Y>'OBIXH^&I
MC\.^--%N)[> ;(9"V)44#HK<K*HX P>,]> *Z>?]I'PRMMNM]'U:2?'W)%C1
M<_[P<G]*]@N;6WO8&@NK>*>%NL<J!E/X&LF#P9X6M9!);^&M'BD'1H[&)3^8
M6@#P&\D\??'.]@A%DNGZ%#)YBLRLL*GIN+'F1P">GKVS7N-UX*M[CX:'P<T^
M^,6"VJ3R(#AU VN5]F ;&>W7O74T4 ?-G@GQOJ'P<O[WPKXMTZY:R,IEBD@^
M;:2 "R9P&1N#P00<\9)%='XQ^/>EW.B3:=X4COIM3NT,4<_E^7Y);C*]RW/&
M!UQSVKV:^TVQU2 P:A96UW">L=Q$LB_D01573_#>A:3*)=-T73K.09P]M:I&
M>>#RH% '#_!?P9JGA7PS)/K3RB\O2I2V=RWV:( [5P?NL222![9Y%<)>?\G;
M+_UUC_\ 2-:^AZSCH&C-J_\ :[:18'4\@_;#;)YWW=OW\;NG'7IQ0!HU\\7G
M_)VR_P#76/\ ](UKZ'K..@:,VK_VNVD6!U/(/VPVR>=]W;]_&[IQUZ<4 <7\
M8_ ESXW\+1?V:L;:G82&:%6X,JD8:,'L3A3Z94#W'&>"/CG9Z/HT&A^+[2^@
MOK%!!YZQ;MRJ,#>I(8-C Z'/7BO>*S=1\/:+K#!M3T?3[UEZ&YMDE(_[Z!H
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MO/6HITYN-K-VB_*W_P EZ%U*L(SNI)7DO[U__D?5&9?ZE;76FVMM%IL5O+"
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M"BBBM3$**** "BBB@!LG^K;Z&JUE_'^%69/]6WT-5K+^/\* +=%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)O\ 4O\ 0T^F
M3?ZE_H: (;+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!%<?\>[TRS_U)_WJ?<?\>[TRS_U)_P!Z@"Q1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'FVI? [PAJWB6XUN\^WN]Q,T\ULLX6)V8DG.%W#)/9A7HEM;06
M=K#:VT2100HL<<:#"HH&  .P %2T4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2JEE]Y_H*MM]
MT_2JEE]Y_H* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %4K7_CX?Z'^=7:I6O\ Q\/]
M#_.@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4'I10>E %.R^^_P!*N53LOOO]*N4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% #9/]6WT-5K+^/\ "K,G^K;Z&JUE_'^%
M %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIDW^I?Z&GTR;_4O]#0!#9?<;ZU9JM9?<;ZU9H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** (KC_CW>F6?^I/^]3[C_CW>F6?
M^I/^]0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7\.U=2OUV?\ D#R[$IV<;7=MTONUU.GHKE9/&]O)=V]OI]JURTS!,N_EX8G
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M7'?FB:.+1?$ELV@/]O81EE&1+EB&!'R8[<TVUA@UCQ#='79/L+%"[#<(\/\
M* /FSVS56_><O][:_E_.9W_=\W7EWMY_R;%.SOK:QBU&"YLTNI9E*1RN!F,_
M,-PR#Z@_A4MM874GA6\OEOI$MHY@KVP)VN<IR><=QV[4FFWE]9VVJ0V%MY]O
M*FR:38S;%PP!R.!P3U]*9!9:>_ARZO)+K;?QRA8X/,4;E^7G;C)ZM^58QUC;
M?27E;Y]?Z1T3TDWM[T?.^W3[/],9<:A:RZ);V26$<=Q&^Y[D ;G'/!XSW'?M
M6AK-C<Z7_94][>/?1/\ .L4A)"@;25Y)ZY _"JEU?:C+X<M;2:TV6,<FZ.;R
MV&X_-QNS@]3^53ZC9V.FRZ9-I5S]JN&.]X]ZOAAM(&%P>235;Q;WTCY6^7VO
MZ9.TXK:[EYWT[_9_I$D<J:]XEM5TR(:4QC*AH>,$!B3\N.HXI'E30?$ETNIQ
M#52$"DS<Y)"D'YL]!Q3KB276O$=JNOI]@0Q%2<&+"C<0?GSWXHMI9M%\1W2Z
M!']O41[0<&7*G:2?DQWXK2_VO[V_R_DV,;?9Z<NU_/\ GW^0S1[&YU*/59[2
M\>RBC&]HHR0'!W$+P1TP1^-4(=0M8]#N+%[&-[F23<ER0-R#Y>!QGL>_>K>G
M6=CJ']IS:G<_9KA/GCCWJFYCN)&&Y/('YU#;WNH1^'+JSBM=UC)(&DG\MCM;
MY>-V<#H/SK+:">VDO._R^S_3-MYM;V<?*WS^U_2'W-A=1^%;.^:^D>VDF*I;
M$G:AR_(YQV/;O3+N^MM0_LZ"ULTM)8L(\J 9<G:-QP!Z$_C23V6GIX<M;R.Z
MW7\DI62#S%.U?FYVXR.B_G4NI7E]?1Z7#J-M]GMXQLBDV,FY3M!.3P> .GK1
M+2-MM(^=_GT_I#CK)/>SEY6^7VOZ99U2&30O$-LVI3'5 (MY$W.02PQ\V>_-
M+IL3Z]XBN6TR4Z4IAW!8>, ;01\N.IYIES%#HWB*U;09/MS"/<!D2Y8[@1\N
M.W-.ACBUKQ'=-K[_ &!S$&(R(L, H ^?/;FMK>_R_P![:_E_.87_ '?-UY=[
M>?\ )L06U];:1>:G!?6::A*TA02R $@@L"W(/7.?PHLM.NYO"]Y>QW\D=O%(
M5>V!.USA>3SCN.W:I--O+[3+C5(=(MOM=NS[&DV-)A06"G*X'()JM:6&FR^'
MKJ[FN]E]&Y$4/F*-PPO.TC)ZG\JS6J2WTEY6^?VOZ1I+1M[7<==[_+[/],AF
MU"UDT*"Q6QC2YCD+-<@#<XRW!XSW'?M5G5[&YLK#29[B]>YCGBWQQ.3B(84X
M&2?4#\*CGO=0?PW;6<EKML$D+1S^6PW-EN-V<'J?RHU*SL+2TTR:RN?.GFCW
M3IO5MC84XP.1R3U]*AZP;WT7E;;IU_IFBTG%;:R\[Z/K]GT^1.]Q%K?B&T&G
M0+IA8",&+ PV2=WRX]<?A3Y9$T+Q-<KJ48U0J@4F;G<2JD'YL]!Q1?3W&K^(
M+0:Y%]A!4(QVF/"9)S\V>Y/-.@>31O$MPN@I]O58PJG'FY!"DGY,=#Q6M]>;
M^]O;R_D,;:<O]W:_G_/N2Z%87.LW>I3:?>R:=&'#>7$2!ABQ X(Z8K,L]3L[
M?1KFSETZ.6XE)*7# ;DR ..,]CW[U>TRRT_5K[4I=:NOL4WF;@GF+'\Q+%AA
M@3P<57L-0U.#P_=VEO9^992,QEF\MCM) !Y!P. /SI;1B]OBUWO\OLCWG);V
M<=-K:?S?:_I#IM.NT\)07[7\C6SR%5M23M4[F&>N.Q/3O534=0M;NRLH8+&.
MWD@CVR2*!F4X R<#V/7UJ:6PTU?#4-ZEWG4&?#P>8O R1G;C/0#\Z35;W4+K
M3].BO+7R888]L#^6R^8N%&<D\\ =/6LZFD>WNKSO\^GI\C6GK.[UM*7E;Y?:
M]?F6M9MIM&UZU.H7#:EM19#YN3E=Q^7G/'!_.BQ1M<\3.=-8Z6'3*B'C: H!
M'RXZ]:9?V]MI.OVG]BS?;2H61?F$F7W'Y?EQZ#CWIR*FL>)I3KK?82ZY<9\O
M:0H ^]GJ,5JU^\Y?[RTO_P"W&*?[KFO]EZV\_P"3;^K"6E];:-JFH1ZA9)J3
M^:4WR@$Y#')Y!ZT_2M+O+KPY?7D.I2P01;]]NI.V3" G.#CD<=*72KR_TG4M
M0CT6V^VQ>9MW;&D^4$[3E<=:@T[3M*N-"N[JZO?*O(]_E0^:J[\*".",G)R.
M*(:V6_Q:;6_[>ZA/2[VORZ[W_P"W?LD#:G9GP^E@-.C%TIR;K W'YB?3/3CK
M5C6-.N[31]-N)[^2XBGC#1Q,3B(;0<#)]\?A37U#4SX7CLC9XT\-E9_+;D[B
M?O9QUR*9JEAIMMI=A/:7?FW$R SQ^8K;#M!Q@#(YSUK.6L'?7W5Y6^7VO4UC
MI426EY/^]?3O]GT^0^ZNH-8UVR^P6R:=N9(AY6!ABWWN .>1^5/N"-$\42#4
M1_:?E !_-YWY08SNSTR/RHU.YN]5URS_ +9@^Q[MD;?*8\1[CEOFSZGGIQ2J
M3I'BAO[#'VX1C]U_RTW93G[N,XR?RJF_>YO[RUM_[:0E[JC_ '7I?S_G_KOT
M)="LKC6=5OGL+M].4DR!8B1A2W"\$=*HV&IV=KI5U:S:=%/-,&"3L!F/*X&,
MC/!YJUIEI9:KJU\VM7'V-RS.1O$?SECD?-GIZ5'IFHZI;:)>VUI9^;:2AO.E
M\IFV97!Y!P..>:(Z*+V^+7?_ ,EZ!+5R6_PZ;6_[>ZDQTN\_X0X:A_:4OV7_
M )],G;_K,>N.O/2J5_J=G=:9:6T&G1P30A1),H&9,+@YP,\GFI_[.TK_ (1<
M7WVW_B8_\^_FK_?Q]W&?N\TFJ:AJ=SH]C;W=GY5K$JB&7RV7> N!R3@\<\4J
MFD--/=7]Z_\ \CZ#I^]/76TG_=M\OM>I8URSGT;5[)K^[?40,2$2DG*AN5Y)
MX-0VW_$Z\4I_9_\ Q+?-SL\KCR\)SC&.N#^=.U.UL]*UBQ;1;C[8P97 WB3+
MAN!\N/;BFG_B;^*?^)W_ *%YO^M_Y9[,)\OWLXS@=?6JFOWG+_>6E_\ V[^O
MP)@_W7-_=>MK?^2?UVZC;6[@T?6[X7]JFHE7>,F7!RP;EN0>3@_G3](TV[N]
M%U&Y@U"2"*%&,D*DXD 4G!P?3BETNZO-*UJ]&C0?; "T:G89,H&X;Y<>@YJ'
M3+#3+G2;Z>[O/*N8E)AC\Q5WG:2.",GGTI0U:6_Q:;?^3=?Z[E5-$WM\.N__
M )+T_KL,&IV8\/MIYTZ(W1.1=8&X?-GTSTXZU<U;2[RU\.V-W-J4L\$NS9 Q
M.(\H2,9..!QTJ%=1U0>%FL19_P#$N)YN/*;^_G[V<=>*-2T[2K;0[.ZM;WS;
MR79YL7FJVS*DG@#(P>.:6\'?6T5_=M_\D'PU%;2\G_>O_P#(CKN]M]9U:PCT
M^S33F,BINB 'S%AAN .E.O5.B>)U.HM_:8C7+"7G?E3C.[/3/Z4[5;R^U;5+
M!-:MOL49<(6V&/Y"PW'YL]*8RKH_B>,Z$?MQ1<Q_\M-Q*G/W<9QDU4G>3E_>
M6MK?^2_U^),%:*C_ '7I>_7^??\ KR%T6UFUC7KO[!<MIVY7E'E9&%W#Y>".
M.1^54M/U"UM+&]@GL([B2=-L<K 9B.",C(]P?PJUIUM:ZKKUY_;,WV/=OD;Y
MA'B3</E^;/J>.O%1:5?:C:Z;J$-G:>=!-&5G?RV;RQ@C.0<#@GKZ5$=.5_XM
M=_\ R7I_78N6O,M_ATV_\FZ_UW)H]-NV\(S7XU"06JO@VN3M)W 9ZXZG/3M5
M>]U.SN=&MK.+3HH;B(J7N% W/@$'/&>2<]>U/CL-,;PS+>M>8U!6PL'F+R-P
M'W<9Z$FGZAJ.J7&@6EK<V?EV497RIO*8;L*0.2<'@GI3EI'33W5YWU_\E"/O
M3UUM)_W;:?\ DQ<UZPN=&O=.EU"]DU)-Y;RY22,*5)')/6H(777?$T"Z:@TL
MNI53#QM(4DGY<=1Q3M4LM/TG4-.ET6Z^VS>9NV>8LGS KM&% ZFDF=]9\2PC
M7E^PJR8<X\O  )!^;/4UI-6J./\ >6E[_P#DW3^NQC3=Z2E_=EK:W_DFS_KN
M117$6B^(+P:A NI%=T9,N#ELCYN<\\'\Z9H]A<WFG:K-!>R6\<$6Z2-2<2C#
M'!P?8_G4UA/<Z1K]V-$B^VA59%^4R93(Y^7'H.:JZ79:?=66HRWEUY,T,>Z!
M/,5?,;#'&".>0.GK6<=9)?XM-O\ R;K_ %W-9:0<O*.N_7^7I_789%J%JFA3
M6+6$;7+ON6Y(&Y1D''3/8]^]6[_3;N#PQ97LFH22V\K@);DG:APW(YQV/;O4
M,-]J*>&KBS2TW6#R!GG\MCM.5XW9QU _.EO;#3(?#]I=P7GF7LC 2P^8IVC!
MSP!D=!^=):Q?7W?2VO\ Y-_78IZ35M+R_P 5]/\ R7^NY-<WUMK%_IL%A9)I
MT@E"&6( $EBH!X Z8S^-3:E$^@^([=M3D.JA8MQ$W.0=P ^;/0\TW4[R_P!5
MN],AUFV^QP"3:'V-'E25#'+9' Q1-'%HOB2V;0'^WL(RRC(ERQ# CY,=N:U>
MK<O-:[?^2]3&*LE'^[+2]_\ R?=?UV#2H)-<\073:=,VF!HRX$.1A<J-ORX[
M\U1L[ZVL8M1@N;-+J692D<K@9C/S#<,@^H/X5<M88-8\0W1UV3["Q0NPW"/#
M_* /FSVS5?3;R^L[;5(;"V\^WE39-)L9MBX8 Y' X)Z^E1M9^<M=_P#R7I_7
M8O>\?*.FW_DW7^NXMM874GA6\OEOI$MHY@KVP)VN<IR><=QV[5!<:A:RZ);V
M26$<=Q&^Y[D ;G'/!XSW'?M3X++3W\.75Y)=;;^.4+'!YBC<OR\[<9/5ORIU
MU?:C+X<M;.6TV6,<FZ.;RV&X_-QNS@]3^59O2/;W?6^OX?UW-%K+76TO2VG_
M )-_78MZS8W.E_V5/>WCWT3_ #K%(20H&TE>2>N0/PHCE37O$MJNF1#2F,94
M-#Q@@,2?EQU'%1ZC9V.FRZ9-I5S]JN&.]X]ZOAAM(&%P>234MQ)+K7B.U77T
M^P(8BI.#%A1N(/SY[\5N])N/G'3?_P FZ?UV,(N]-2\I:[=_L=?Z[C7E30?$
METNIQ#52$"DS<Y)"D'YL]!Q2:/8W.I1ZK/:7CV448WM%&2 X.XA>".F"/QI]
MM+-HOB.Z70(_MZB/:#@RY4[23\F._%0:=9V.H?VG-J=S]FN$^>./>J;F.XD8
M;D\@?G26LU'SEIM_Y-U_KN-Z4W+RCKOV^QT_KL5(=0M8]#N+%[&-[F23<ER0
M-R#Y>!QGL>_>K%S874?A6SOFOI'MI)BJ6Q)VH<OR.<=CV[TRWO=0C\.75G%:
M[K&20-)/Y;':WR\;LX'0?G23V6GIX<M;R.ZW7\DI62#S%.U?FYVXR.B_G6*U
MCW]WTMK^/]=C=Z2TTO+UOI_Y+_7<6[OK;4!IT%K9I:2Q81Y4 RY.T;C@#T)_
M&KNJ0R:%XAMFU*8ZH!%O(FYR"6&/FSWYJMJ5Y?7T6EPZC;?9[>,;(I-C)N4[
M03D\'@#IZU/<Q0Z-XBM6T&3[<PCW 9$N6.X$?+CMS6N[<O..NW_DO7^NYELE
M'REIO_Y-T_KL/TV)]>\17+:9*=*4P[@L/& -H(^7'4\U7MKZVTB\U."^LTU"
M5I"@ED )!!8%N0>N<_A4\,<6M>([IM??[ YB#$9$6& 4 ?/GMS3--O+[3+C5
M(=(MOM=NS[&DV-)A06"G*X'()JEHU+SEKO\ ^2]"&KIQ\HZ;?^3[O^NY'9:=
M=S>%[R]COY([>*0J]L"=KG"\GG'<=NU5)M0M9-"@L5L8TN8Y"S7( W.,MP>,
M]QW[5-:6&FR^'KJ[FN]E]&Y$4/F*-PPO.TC)ZG\J2>]U!_#=M9R6NVP20M'/
MY;#<V6XW9P>I_*L7I%6T]WUOK^']=S=:S=];2_PVT_\ )OZ[$FKV-S96&DSW
M%Z]S'/%OCB<G$0PIP,D^H'X4][B+6_$-H-.@73"P$8,6!ALD[OEQZX_"H-2L
M["TM-,FLKGSIYH]TZ;U;8V%.,#D<D]?2K5]/<:OX@M!KD7V$%0C':8\)DG/S
M9[D\U;TDUYQTW_\ )NG]=B%K!2\I:[=?Y>O]=PED30O$URNI1C5"J!29N=Q*
MJ0?FST'%3Z%87.LW>I3:?>R:=&'#>7$2!ABQ X(Z8J*!Y-&\2W"Z"GV]5C"J
M<>;D$*2?DQT/%&F66GZM?:E+K5U]BF\S<$\Q8_F)8L,,">#BM(*]11\WI>W_
M )-U,JCM2<O[L=;7[?8V7]=BC9ZG9V^C7-G+IT<MQ*24N& W)D <<9['OWJQ
M-IUVGA*"_:_D:V>0JMJ2=JG<PSUQV)Z=Z;8:AJ<'A^[M+>S\RRD9C+-Y;':2
M #R#@< ?G3);#35\-0WJ7>=09\/!YB\#)&=N,] /SK%:Q[^[Z6U_\F-Y>[/3
M2\E_>OI_Y+_7<AU'4+6[LK*&"QCMY((]LDB@9E. ,G ]CU]:OZS;3:-KUK_:
M%PVI;460^;DY7<?EYSQP?SJKJM[J%UI^G17EKY,,,>V!_+9?,7"C.2>> .GK
M4]_;VNDZ_:?V+-]M*A9%^829?<?E^7'H./>AZ\S_ ,.NW_DO7^NXEIRQV^+3
M?_R;I_78?8HVN>)G.FL=+#IE1#QM 4 CY<=>M-M+ZVT;5-0CU"R34G\TIOE
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MB^%ETDI4/+<PI%G'+;MW'OM5NGO7+QV5PO[)AA;=')Y!F^7G*&[W]NQ7^?-
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M\-9?QPDCA^)'@N6;'E(ZL^>F!,N>M '6>%?@IX;T[1T.OV:ZKJTZ;KN>:1F
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MMDJCC./IG=CZFO4M;_Y &H_]>LO_ *":\7_9H_Y!GB+_ *[0?R>@#W>BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 1ONGZ54LOO/]!5MONGZ54LOO/\ 04 7**** "BBB@ HHHH
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MU"2*VB9@]N&;#X4$YYQW'Y5,=;*.Z4KVT?S?4J6EY2V;C:^L?^W5T*TC:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 17'_'N],L_]2?\ >I]Q_P >[TRS_P!2?]Z@"Q1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>\ >*_B=XM3Q+XYAFM-/0+B*2/RVE53D1HAY5.223UR<9))'T6JA5"J % P
M.@I:* /G/4/#OB;X+^,Y]>\/V4FIZ!<AA)&JDA$)SL?;]TJ<8?&/S(K6NOVA
MI[ZU>TT/PK=/J[954D?S%0^NU1N;''''U]?=J* /&_@S\.-3T2\N?%?B,,FJ
M7BLL<$GWT#'+._\ M-Z=AUY.!S'[1T33^)O#T*D!I+=U!/3)<"OHNOGK]H3_
M )''PQ_US/\ Z,% &A:?&37_  5;)I'C?PS>-=VX\I+Q&*BX"\;LL,,3@G<#
M@^@K+T[0?%'QG\8VNN>(K%].\.VA!CA=" Z9!*)G!8L1R_3\@*^B:* ./^*"
MA?A=X@50 HLV  Z#I7,?L]?\DU?_ *_Y?_04KU>B@#'\4^'K?Q5X8O\ 0[IV
MCBNX]N]1DHP(96QWPP!_"O!M \1>+?@E-=:)K.ARZAH[2M+#-&2$SCED?!&#
M@$J>1UXR<_2-% 'SMXG^*NN_$G2I/#GA+PW>!+L".XFSO;;G)7CY5! &23T)
M''6O5?ACX%'@/PJ+&:5)KZX?S[J1/N[B  J^P QGOR>,UVE% 'SIJ>E>*?@_
M\0[_ %[1-*EU#P_>,7D2)"4$;-GRV(!*%2<!NA&.N2*U[K]H:6]MWM-#\*WD
MFJL"JI(^\1MCKM49;!QQQ]17NE% 'DGP1\ :IX4L]0U77$:&_O\ :BP,V61%
M).6]R3GZ >M<?J>E>*?@_P#$._U[1-*EU#P_>,7D2)"4$;-GRV(!*%2<!NA&
M.N2*^BZ* /"[K]H:6]MWM-#\*WDFJL"JI(^\1MCKM49;!QQQ]16S\$? &J>%
M+/4-5UQ&AO[_ &HL#-ED123EO<DY^@'K7K=% 'SUX?\ ^3J-0_ZZ3_\ HFO1
M?BU\/G\>>'(ELG1-4L6:2VW\"0$?-&3VSA>?4#MS7H%% 'S]H?QFUKP5IT6A
M>,?#EXUQ9HL4<X.QV4#Y0V1@G'\0/./7)JCK%YXN^.NI6EE8:4^E^';>42&:
M;E><CS"3C>V,X5>FXY..1]'T4 81TFVT+P+)I5H"+>TT]H4SU("$9/N>M>2_
MLT?\@SQ%_P!=H/Y/7N]% %#6_P#D :C_ ->LO_H)KQ?]FC_D&>(O^NT'\GKW
M>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $;[I^E5++[S_05;;[I^E5++[S_ $% %RBBB@ H
MHHH **** "BBB@#S7Q=J&HW5R8+NT\FWAF<0R>6R[QG&<G@\ =*JZE:VNDZY
M9_V//]MV[)%^829<,<+\OT''7FMC7M(\2ZI=R*T0FM4E<P -&N%)X]#TQUHU
M?PM=PZK;SZ%8F..-5;<95.) Q.?F8^U?,UJ%6<YSY6]5JUK\NG](^LH8BC"$
M(<Z6CT35OGU_IF0 -8\4-_;9^PF0?O/^6>W"<?>Z9P.OK3]+O+W2-6ODT:V^
MVH&* [#)\@8X/R^OK6E:>&]5O=>%SKEIYT3@^8PD49(7 X4CT%-AT/Q'IFI7
M<FDP""%W8(2\;93)V_>)[5,:%9-5.5_$];>]]VQ4L10:=+FC\*TO[OW[_AV,
MG3-.TRYT6]N;J]\JZB#>5%YJKOPN1P>3SQQ3O[2U3_A%18_8O^)?_P _'E-_
M?S][IUXK9TWPBPT:\%]IQ-_AOLY$PX.WCHV.OK57^Q?%?]D?V;Y0^R?\\=\6
M?O;NO7KSUI+#UH05H-7BUHGKZW_0;Q-"I-WFG:2?O-67G&V_S,W4].TVUT>R
MN;6\\VZE53-%YBML)7)X'(YXYJ;5+N\U;6+%=8M_L2EEC)V&/"%N6^;\>:U=
M2\(N=(LA8:<1>[5^T$S#D[>>K8Z^E1S:%XBU/4[235H!/"CJ'(>-<)NY'!';
M-.>&JQ;BH/7ET2=OF*&*HR2FYK3FU;7,O1;&7_R!_%(_L7_3O*_U7_+3?E.?
MN]<9/3TI=-M;35M:O3K%Q]B)+2,-XCPY;E?F^IXZUJ77AO5K+7VN=#M/)A3'
ME,9$.,KAN&)]34FD>%KJ;4[F?7;$R+("VX2@9<MDGY6'O3CAJOM.3D=N9Z6?
M+]^X2Q5'V?.IJ_*M;KF^[;^F8>EZAJ5KI-_;VEGYUM,I$TGELVP%2#R.!QZT
MJZ=IA\,-?&]_XF /%OYJ_P!_'W>O3FM"TT/Q59V=Q;00B.&<$2(7C.X$8ZYX
MXJV/"+?\(RP.G'^UL\'SAC&__>V_=J88>M*-G!NT7NGIZ>953%4(3NII7DOA
M:=_\79>AC:GJ6J7.A6=K=67E6D6SRIO*9=^%(')X.1SQ4FIV=EI&J6#Z-<_;
M9 X<+O63Y@PP/E]:MW6B^*[O3X+.>(26\.W9&'B&W P.?I[U=UCPM/#>VDV@
MV)C,9WLQE!PP((/S,:;H5I*4N5NW+NM?D2L10A*,.=*_-HFN7YO=&,[-K/B=
M!K8^PB1<2?\ +/: IQ][.,X%-TVYNM)UZ[_L>#[;MWQK\IDRFX?-\OT'/3FM
M6W\.ZO?Z]'<ZY:^= 01*PD1<X4X^Z0>N*9'H'B#3=6NI])MQ!&S,L9+HW[O=
MD#YB?04*A63]IROXGK;WONV!XB@U[+FC\*TO[N_??\-C&TNPT^ZT[4)KN[\F
M>&,M GF*OF'!.,'D\@=/6GQZAJ2^&);%;/-@S9:?RVX.X'[W3J *V-,\(3C3
MK\:AIY-T4/V4B8<-@^C8ZXZU NA^*ETI]/$(%JQR8M\>2<@]<YZ@=ZA8>M""
M]QJZ>R=_G_6Q<L50G-KG3M)/5JW_ &[;?_,S]0T[3+?0;2[MKWS;R0KYL/FJ
M=F5)/ Y'('6K.JWU_J]_IT6LVOV*+S-N_P MH_E)7<<MZ"M*_P#"+'0K06>G
M$:CE?//G#IM.>K8ZXZ4R;1O$FJ7UD=6A$]O'(-V'C7"$C=]T@]!6DL/5C>*@
MU?ET2=GZ_P# ,X8FC*TW-.W-JVN9>G3[S-D1-%\30G0F^WLB$H,^;DE2"/DQ
MT'--L;>WUC7[LZU-]A+*TC?,(\/D?+\WU/'M6O?>&]2LM;2YT"T\F-$^5FD4
MX8@@\,3V-&E^&+VYU>>XUZR,L<B$[A*HR^1S\I';--8:K[3DY';FVL^7[]Q/
M%4?9^TYU?EM>ZY]^VWXF!I=]?VECJ4-G:^=#/'MG?RV;RUPPSD<#@GKZ40V&
MGOX;N+U[O;?)(%2#S%&X97G;UZ$_E6E::!XHLX+J&W@$<=PNR52\9WC!&.2<
M=3Z=:LQ>$)_^$<G$FGG^U-X\H^<,;<K_ +6.FZLH8:M*-G!Z)[IV7IY_J;5,
M50C+F4TKRCLU=^OEZ=#'O=0U*;P]:6D]GY=E&P,4WEL-QP<<G@]3T]*L:C96
M.DWFF3:/=?;9S)O*;UDPP*E1A>>3FK,^A^*KC38;&6$/;1$%(]\8VG![YSW/
M>K^K>%IH9;";0K$QS1L7D8R@X8;2I^9CWS5_5ZTHN7*W;EW3O\NYG]9H1E&*
MFE=RV:M_V\^GRZF3<22ZWXDMEUY/[/4QE2<&+"@,0?GSU/%-LYI]&\0W0T.+
M[>H0HIVF3*Y4D_)CO@5J0Z!K.HZY;SZ];>?;JI5RKHO&#@?*0>IIK:#KFFZU
M<SZ);^1"PV(2Z-\O!Q\Q)ZBJ]C6_B<K^+>WO;=MK$^WHV]ES1MR[7]S?OO?Y
M&)IUE8WMOJ<]]<_9[B)-\,>]5WMACC!Y/('3UID%]?Q^&[JSCM=UC)*&DG\M
MCM;Y>-W0=!^=;NF^$KEK746U*P+7+)FV(F'W\-Z-CKMZU5CT#Q1'I<M@D %K
M*^]XM\>6/'.<Y[#OVK)8>M&*?(U=/9._S_K8V>*H2FUSIV<=VK=-N_\ F9MU
M8:?%X=M;R*[WWLDFV2#S%.T?-SMZCH/SJQJ5[?:G)I<&J6WV2!#L238R94[0
M3EN. !6G<^$)_P#A'[40:>?[3W_OCYP^[\WJV/[O2FS:'XDU">R34H1-;PL!
M@/&NU,C/0@G@53P]:*Y5!ZJ.R=GZDQQ5"3YG-.SENU=>G_!Z%.:*+1/$=JV@
MO_:#"(L!D2Y8A@1\F.@YI((HM;\1W3:])_9[&,,1D188;0!\^>W-:VH>'+^R
MUF"Y\/6GDHD?WFD4X<[@>&)[$4FG>&[^]UF>Y\0V?G(\?WED49<;0.%([ UI
M]7J\_L^1VYKVL^7;ON8_6J/)[3G5^6U[KGWVMM^)B:;>WVG?VI!IMM]J@D^2
M238S[5&X Y7@<$_E4%O8Z?)X=NKR2[VWT<@6.#S%&Y?EYV]3U/Y5L0Z%XEL)
M+V/3X!#;SDJ5+QG<O.!R21P:?;^$+C_A'KD3:>?[4\P>2?.'W?E_VL?WNM9+
M#UI+E<'HI;IV7I_6YM+%4(OF4TKN.S5WZ^7IT,2>^OY/#=K9R6NVQCE+1S^6
MPW-\W&[H>I_*I=1LK&PCTR?3[G[3/(-\L>]7V,-I P.1R3U]*O2:!XHDTN*P
M> &UB?>D6^/*GGG.<]SW[U;U/PG<)!ISZ58%;A5S<$RC[^%Q]YL==W2E]7K2
MBWR-V2W3O\OZV']:H1FESI7<MFK?]O=O\S.NYIM:\16JZ[']@4Q["<&+"C<0
M?GSWXI;>671/$=TN@I_:"B(*#@RY4[23\F.AXK030=;U+6K>?7+?SX%78Y5T
M7Y>2!\I!ZFG2Z#K6FZY<3Z#;^1;L@1"SHW&%)'S$GJ*U]C5_B<K^+>WO;=MK
M?,R]O1_A<T;<NU_<W[[W^1E:?96.J7.ISZM<_8[A7+K'O6/+$L6&&YX(%5[3
M4-1A\.W=G#:;[*1R9)O+8[3A>-PX'0?G70:5X6GF>_FUNQ,D\AW1,)0,L=Q8
M_*P[XZU0AT+Q3!ILUC'"%MI6W/%OC.X\=\Y[#O4?5ZT8J7*U=2V3O\^W^1?U
MFA*4HN:=G'=JW_;O?Y]3+GL=/3PY;7L=WNOI)"LD'F*=JY;G;U'0?G3M3O;Z
M\L],AO;7R((8]D#[&7S%PHSD\'@#IZULS^$+C_A';81:>?[4\P^:?.&-N6_V
ML?W>E07.@>)KR*TANH!)#;KLC4/&-B\#'!&> /7I4SPU:,;*#U2V3M\_/]2X
M8JA*7,YIV<MVKKT\O7H5;R"WT;Q!:'1)?MQ50ZC<),ODC'R^P'%.BCCUOQ+<
M-KK_ &!FC#,,^5@@* /GSU'-:NI^&;VUUB"XT"R,21H#N,JG#Y/]XGMBBP\-
MZC>ZW+<^(+3SD=.6611EA@#A2.PK7ZM5Y^3D=N;:SY=N^YC]:H^S]ISJ_+:]
MUS[]MOQ,S2KZ_P!(O=2AT:U^VP^9MW^6TGRJ6"G*\<C-5;'3M-GT"[N[B\\N
M\C9A%#YBC>  1P>3R3T]*V8=&\2:9>WO]DPB"WED.T%XVR@)V_>)/0TFG^%M
M^AW:7-@3J>6\D^;T&!CHV.N>M*.'JRM%P>G-HT[+T_X(Y8FC&\U-*[CJFKOU
MZ?<8TNH:BWAF&R>TQ8*Y*3^6W)W$XW=.I/Y4S5+'3[6PTZ:TN_.FGCW3IYBM
MY;84XP.1R3U]*U'T+Q2^E)I[0@VJ-N6+?'D')/7.>Y[U/JGA"X-AI_\ 9^GD
M7(C_ -*)F'+87U;'7=TK.6'K3@WR-V2W3O\ +^MC6.*H0FESI7;>C5MNO;_,
MS=1N+G5]?M/[9A^Q!@L;?*8\)N/S?-]3STXIT;/HWB:4:&OV\(N$./,W J"?
MN8S@YK0?0-?U+5[:?5[<3Q*560AT7Y,Y(^4CU-/G\/:QI^NRW&A6OD08 C9I
M$;C:,_>)/7-7["M?VG*_B6MO>V[;&:Q%!+V7-'X7I?W=^^_X;&;I=E8ZOJ6H
M2:S=?8I?,+[=ZQ_,2=PPWI46FZEJEMH-Y:VMEYMG+O\ -F\IFV94 \C@8&#S
M6[H_A:::[O)M>L3(TC;U82@98DEC\K#VJC:Z+XKM-/FLH(A';S;M\9>([LC!
MY^@]::H5HQC+E:OS;+7YB>(HSE*'.G;ET;7+_P!NO=F:^G::/#"7PO,Z@6P;
M?S%X&XC[O7I@TFJ:AJ-UI=A!=VGDV\* 0R>6R[QM SD\'@#I6XWA%_\ A&D"
MZ<?[6W?,?.&,;C_M;?NXJI=Z%XIO+2WMYX1)% H6- \8VC '7// J)X>M&-E
M!J\5LGKZ^9I3Q5"4^9S3M)[M*WIY>I2U*UM=)URS_L>?[;MV2+\PDRX8X7Y?
MH..O-* -8\4-_;9^PF0?O/\ EGMPG'WNF<#KZUKZOX6NX=5MY]"L3''&JMN,
MJG$@8G/S,?:FVGAO5;W7A<ZY:>=$X/F,)%&2%P.%(]!5O#5?:<G([<RTL^7[
M]R(XJC[/GYU?E>MUS?=L9NEWE[I&K7R:-;?;4#% =AD^0,<'Y?7UJ'3-.TRY
MT6]N;J]\JZB#>5%YJKOPN1P>3SQQ6M#H?B/3-2NY-)@$$+NP0EXVRF3M^\3V
MJ73?"+#1KP7VG$W^&^SD3#@[>.C8Z^M*&&JR:BX/3FT:=OD$\51BG-32ORZI
MKF?JMC&_M+5/^$5%C]B_XE__ #\>4W]_/WNG7BF:GIVFVNCV5S:WGFW4JJ9H
MO,5MA*Y/ Y'/'-:7]B^*_P"R/[-\H?9/^>.^+/WMW7KUYZU9U+PBYTBR%AIQ
M%[M7[03,.3MYZMCKZ4GAZTX/W&[12U3O\BEB:%.:M-*\F]&K/SE?;Y&5JEW>
M:MK%BNL6_P!B4LL9.PQX0MRWS?CS3/\ D#^*1_8O^G>5_JO^6F_*<_=ZXR>G
MI6I-H7B+4]3M)-6@$\*.H<AXUPF[D<$=LTMUX;U:RU]KG0[3R84QY3&1#C*X
M;AB?4TY4*S?M.5_$M;>]]VQ,<102]ES1^%Z7]W[]_P -KF7IMK::MK5Z=8N/
ML1):1AO$>'+<K\WU/'6H]+U#4K72;^WM+/SK:92)I/+9M@*D'D<#CUK<TCPM
M=3:G<SZ[8F19 6W"4#+ELD_*P]ZJ6FA^*K.SN+:"$1PS@B1"\9W C'7/'%)4
M*T5&7*U\6J6OS'+$T).4.>+MRZ-KE^3W_I&>NG:8?##7QO?^)@#Q;^:O]_'W
M>O3FG:GJ6J7.A6=K=67E6D6SRIO*9=^%(')X.1SQ6R/"+?\ ",L#IQ_M;/!\
MX8QO_P![;]VJMUHOBN[T^"SGB$EO#MV1AXAMP,#GZ>]$L/6A&R@U>*V3U]?/
MT"&)H3G=S3M)_$TK?X;;KU*FIV=EI&J6#Z-<_;9 X<+O63Y@PP/E]:1V;6?$
MZ#6Q]A$BXD_Y9[0%./O9QG K9UCPM/#>VDV@V)C,9WLQE!PP((/S,:AM_#NK
MW^O1W.N6OG0$$2L)$7.%./ND'KBKGAJJJ<B@[<RT2?+]^Y$,51=/VCFK\KU;
M7/\ =M_2,K3;FZTG7KO^QX/MNW?&ORF3*;A\WR_0<].:@TNPT^ZT[4)KN[\F
M>&/= GF*OF'!.,'D\@=/6MF/0/$&FZM=3Z3;B"-F98R71OW>[('S$^@IVF>$
M)QIU^-0T\FZ,?^BD3#AL'T;'7'6HAAJSDHN#TYMT[?+^NQI/%4%%S4UKRZIK
MF^:V_IF/'J&I+X8EL5L\V#-EI_+;@[@?O=.H I=0T[3+?0;2[MKWS;R0KYL/
MFJ=F5)/ Y'('6M!=#\5+I3Z>(0+5CDQ;X\DY!ZYSU [U;O\ PBQT*T%GIQ&H
MY7SSYPZ;3GJV.N.E'U>M.+O!NT>J?X \50A-6FE>3>C6NGVK[?(S=5OK_5[_
M $Z+6;7[%%YFW?Y;1_*2NXY;T%,D1-%\30G0F^WLB$H,^;DE2"/DQT'-:4VC
M>)-4OK(ZM")[>.0;L/&N$)&[[I!Z"GWWAO4K+6TN= M/)C1/E9I%.&((/#$]
MC5RHUI-U.5[K5KWONV,XUZ,4J7-%>Z]$_=^;W_ R+&WM]8U^[.M3?82RM(WS
M"/#Y'R_-]3Q[57TN^O[2QU*&SM?.AGCVSOY;-Y:X89R.!P3U]*W]+\,7MSJ\
M]QKUD98Y$)W"51E\CGY2.V:I6F@>*+."ZAMX!''<+LE4O&=XP1CDG'4^G6L_
MJ]96GRO[6J6OSZ?TS3ZS0ES0YX[1T;7+\GO_ $C-AL-/?PW<7KW>V^20*D'F
M*-PRO.WKT)_*GWNH:E-X>M+2>S\NRC8&*;RV&XX..3P>IZ>E;$/A"?\ X1R<
M2:>?[4\P>4?.&-N5_P!K'3=4$^A^*KC38;&6$/;1$%(]\8VG![YSW/>D\/6C
M&R@U>/1/77J-8JA.5W-.TNK6FGV>_P _,K:C96.DWFF3:/=?;9S)O*;UDPP*
ME1A>>3FG7$DNM^)+9=>3^SU,94G!BPH#$'Y\]3Q6MJWA::&6PFT*Q,<T;%Y&
M,H.&&TJ?F8]\U'#H&LZCKEO/KUMY]NJE7*NB\8.!\I!ZFMI8>JIN"@[-K1)\
MOS>YC#%47351S5TI:MKGZ[+;T^1EV<T^C>(;H:'%]O4(44[3)E<J2?DQWP*K
M:=96-[;ZG/?7/V>XB3?#'O5=[88XP>3R!T]:VVT'7--UJYGT2W\B%AL0ET;Y
M>#CYB3U%)IOA*Y:UU%M2L"URR9MB)A]_#>C8Z[>M0L-5<E#D=DY:-/E^3W_I
M%O%45!SYU=J.J:YOFMO7YF%!?7\?ANZLX[7=8R2AI)_+8[6^7C=T'0?G2W-A
MI\7AVUO(KO?>R2;9(/,4[1\W.WJ.@_.M*/0/%$>ERV"0 6LK[WBWQY8\<YSG
ML._:K-SX0G_X1^U$&GG^T_,_?'SA]WYO5L?W>E0L-6E%W@W:/5/OT_KN:/%4
M(25II7ET:UTZ_P# \C,U*]OM3DTN#5+;[) AV))L9,J=H)RW'  J6:*+1/$=
MJV@O_:#"(L!D2Y8A@1\F.@YJY-H?B34)[)-2A$UO"P& \:[4R,]"">!5G4/#
ME_9:S!<^'K3R42/[S2*<.=P/#$]B*U]A6;=3E>ZU:][Y+8R^L48I4^:.TM$_
M=^;W_ R8(HM;\1W3:])_9[&,,1D188;0!\^>W-0Z;>WVG?VI!IMM]J@D^223
M8S[5&X Y7@<$_E6WIWAN_O=9GN?$-GYR/']Y9%&7&T#A2.P-58="\2V$E['I
M\ AMYR5*EXSN7G Y)(X-+V%9-5.5[O5+WOFM@^L4&G3YX[1T;]W3L]_Z1CV]
MCI\GAVZO)+O;?1R!8X/,4;E^7G;U/4_E1/?7\GANULY+7;8QREHY_+8;F^;C
M=T/4_E6W;^$+C_A'KD3:>?[4\P>2?.'W?E_VL?WNM5Y- \42:7%8/ #:Q/O2
M+?'E3SSG.>Y[]ZR>&K16D&KQZ)]^O]=C58JA.3O-.TNK6FG3_@^91U&SL;"/
M3)]/N?M,\@WRQ[U?8PVD# Y')/7TJQ=S3:UXBM5UV/[ ICV$X,6%&X@_/GOQ
M6CJ?A.X2#3GTNP*W"+FX)E'W\+C[S8Z[NE":#K>I:U;SZY;^? J[7*NB_+R0
M/E(/4UJ\-54W#D=FXZ)/E^;W_IF2Q5%P4^=72EJVN;Y+;T^1GV\LNB>([I=!
M3^T%$04'!ERIVDGY,=#Q3-/LK'5+G4Y]6N?L=PKEUCWK'EB6+##<\$"M)M&U
M:QURXF\/P>3 4"J6=6XPN1\Q)^\*FTKPM/,]_-K=B9)Y#NB82@98[BQ^5AWQ
MUJHX>JYJ#@[)O1I\OR>_H3+%453=135VHZIKFZ;K;U^9S]IJ&HP^';NSAM-]
ME(Y,DWEL=IPO&X<#H/SID]CIZ>'+:]CN]U])(5D@\Q3M7+<[>HZ#\ZU(="\4
MP:;-8QPA;:5MSQ;XSN/'?.>P[U//X0N/^$=MA%IY_M3S#YI\X8VY;_:Q_=Z5
MBL/6E&S@W:/5/OT_KN;O%4(2NII7ET:UTZ_\#R,;4[V^O+/3(;VU\B"&/9 ^
MQE\Q<*,Y/!X Z>M6+R"WT;Q!:'1)?MQ50ZC<),ODC'R^P'%6KG0/$UY%:0W4
M DAMUV1J'C&Q>!C@C/ 'KTJ[J?AF]M=8@N- LC$D: [C*IP^3_>)[8JO85G>
M?*]XZM>]\NG](GZS0CRPYX[2T37+\WO_ $S*BCCUOQ+<-KK_ &!FC#,,^5@@
M* /GSU'-.TJ^O](O=2AT:U^VP^9MW^6TGRJ6"G*\<C-:=AX;U&]UN6Y\06GG
M(Z<LLBC+# '"D=A4<.C>)-,O;W^R81!;RR':"\;90$[?O$GH:N-&M%JIRO=Z
MI>]\UL9RKT9)TN:+T6C?N_)[_@8UCIVFSZ!=W=Q>>7>1LPBA\Q1O  (X/)Y)
MZ>E)+J&HMX9ALGM,6"N2D_EMR=Q.-W3J3^5;ECX1<:#="[TXG4MS>0?.'3 Q
MT;'7/6JCZ%XI?2DT]H0;5&W+%OCR#DGKG/<]ZS>'K0BK0:O'HGWZFJQ5"<W>
M:=I7U:TT^S;?YF7JECI]K8:=-:7?G33Q[IT\Q6\ML*<8'(Y)Z^E6=1N+G5]?
MM/[9A^Q!@L;?*8\)N/S?-]3STXK2U3PA<&PT_P#L_3R+D1_Z43,.6POJV.N[
MI0^@:_J6KVT^KVXGB4JLA#HOR9R1\I'J:<L-64G%0>O+LG;YO^NHHXJ@XJ;F
MKKFU;7-\EM_2,^-GT;Q-*-#7[>$7"''F;@5!/W,9P<TNEV5CJ^I:A)K-U]BE
M\POMWK'\Q)W##>E:4_A[6-/UV6XT*U\B# $;-(C<;1G[Q)ZYJ;1_"TTUW>3:
M]8F1I&WJPE RQ)+'Y6'M5PPU5U%!P=KO1I\OW[F<\515)U%-7Y5JFN?[MOZ9
MA:;J6J6V@WEK:V7FV<N_S9O*9MF5 /(X&!@\TQ].TT>&$OA>9U M@V_F+P-Q
M'W>O3!K2M=%\5VFGS64$0CMYMV^,O$=V1@\_0>M66\(O_P (T@73C_:V[YCY
MPQC<?]K;]W%1'#UIQLX-VB]T]/3S]326)H0G=32O)?"T[_XK[+T,/5-0U&ZT
MNP@N[3R;>% (9/+9=XV@9R>#P!TJ34K6UTG7+/\ L>?[;MV2+\PDRX8X7Y?H
M..O-7;O0O%-Y:6]O/")(H%"QH'C&T8 ZYYX%6]7\+7<.JV\^A6)CCC56W&53
MB0,3GYF/M2>'K2YI<K?PZM:_+^NP1Q-"+C#GBOBT37+\WO\ TS( &L>*&_ML
M_83(/WG_ "SVX3C[W3.!U]:?I=Y>Z1JU\FC6WVU Q0'89/D#'!^7U]:TK3PW
MJM[KPN=<M/.B<'S&$BC)"X'"D>@IL.A^(],U*[DTF 00N[!"7C;*9.W[Q/:J
MC0K)JIROXGK;WONV)EB*#3I<T?A6E_=^_?\ #L9.F:=IESHM[<W5[Y5U$&\J
M+S57?A<C@\GGCBG?VEJG_"*BQ^Q?\2__ )^/*;^_G[W3KQ6SIOA%AHUX+[3B
M;_#?9R)AP=O'1L=?6JO]B^*_[(_LWRA]D_YX[XL_>W=>O7GK26'K0@K0:O%K
M1/7UO^@WB:%2;O-.TD_>:LO.-M_F9NIZ=IMKH]E<VMYYMU*JF:+S%;82N3P.
M1SQS4VJ7=YJVL6*ZQ;_8E++&3L,>$+<M\WX\UJZEX1<Z19"PTXB]VK]H)F')
MV\]6QU]*CFT+Q%J>IVDFK0">%'4.0\:X3=R.".V:<\-5BW%0>O+HD[?,4,51
MDE-S6G-JVN9>BV,O_D#^*1_8O^G>5_JO^6F_*<_=ZXR>GI2Z;:VFK:U>G6+C
M[$26D8;Q'ARW*_-]3QUXK4NO#>K66OM<Z':>3"F/*8R(<97#<,3ZFI-(\+74
MVIW,^NV)D20%MPE RY;)/RL/>G'#5?:<G([<STL^7[]PEBJ/L^=35^5:W7-]
MVW],P]+U#4K72;^WM+/SK:92)I/+9M@*D'D<#CUI5T[3#X8:^-[_ ,3 'BW\
MU?[^/N]>G-:%IH?BJSL[BV@A$<,X(D0O&=P(QUSQQ5L>$6_X1E@=./\ :V>#
MYPQC?_O;?NU,,/6E&S@W:+W3T]/,JIBJ$)W4TKR7PM._^+LO0QM3U+5+G0K.
MUNK+RK2+9Y4WE,N_"D#D\'(YXJ34[.RTC5+!]&N?ML@<.%WK)\P88'R^M6[K
M1?%=WI\%G/$)+>';LC#Q#;@8'/T]ZNZQX6GAO;2;0;$QF,[V8R@X8$$'YF--
MT*TE*7*W;EW6OR)6(H0E&'.E?FT37+\WNC&=FUGQ.@UL?81(N)/^6>T!3C[V
M<9P*;IMS=:3KUW_8\'VW;OC7Y3)E-P^;Y?H.>G-:MOX=U>_UZ.YURU\Z @B5
MA(BYPIQ]T@]<4R/0/$&FZM=3Z3;B"-F98R71OW>[('S$^@H5"LG[3E?Q/6WO
M?=L#Q%!KV7-'X5I?W=^^_P"&QC:78:?=:=J$UW=^3/#'N@3S%7S#@G&#R>0.
MGK3X]0U)?#$MBMGFP9LM/Y;<'<#][IU %;&F>$)QIU^-0T\FZ,?^BD3#AL'T
M;'7'6H%T/Q4NE/IXA M6.3%OCR3D'KG/4#O4+#UH07N-73V3O\_ZV+EBJ$YM
M<Z=I)ZM6_P"W;;_YF?J&G:9;Z#:7=M>^;>2%?-A\U3LRI)X'(Y ZU9U6^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!%<?\ 'N],L_\ 4G_>I]Q_Q[O3+/\ U)_WJ +%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 C?=/TJI9?>?Z"K;?=/TJI9?>?Z"@"Y1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5*U
M_P"/A_H?YU=JE:_\?#_0_P Z +M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !0>E%!Z4 4[+[[_2KE4[+[[_2KE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_ %;?0U6L
MOX_PJS)_JV^AJM9?Q_A0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *9-_J7^AI],F_U+_0T 0V7W&^M6:K67W&^M6: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*X_X]
MWIEG_J3_ +U/N/\ CW>F6?\ J3_O4 6**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"IO;^\?SHWM_>/YTVB@!V]O[Q_.
MC>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]
MX_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3
M:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* '
M;V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O
M'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-
M[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC
M^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-H
MH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O
M;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?
MSHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM
M_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/Y
MTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@
M!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O
M[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.
MC>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]
MX_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3
M:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* '
M;V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O
M'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-
M[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC
M^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-H
MH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O
M;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?
MSHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM
M_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/Y
MTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@
M!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O
M[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.
MC>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]
MX_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3
M:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* '
M;V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O
M'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-
M[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC
M^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-H
MH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O
M;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?
MSHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM
M_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/Y
MTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH 4NV#\Q_.HH203@D?2I
M#TJ*+J: )][?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?S
MIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM%
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MIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HH_OFI:BC^^: ):*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"*+J:EJ*+J:EH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $/W3]*9%WIY^Z?I3(N] $E%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-]P
M_2EI&^X?I0 R+H:DJ.+H:DH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &O]PTD7W/QI7^X:2+[GXT /HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ*+
MJ:E/2HHNIH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*/[YJ6HH_OF@"6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BBZFI:B
MBZFI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!#]T_2F1=Z>?NGZ4R+O0!)1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4C?</TI:1ON'Z4 ,BZ&I*CBZ&I* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_<-)%]S\:5_
MN&DB^Y^- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\:?\B?J7_7(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z5%%U-2GI447
M4T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5%']\U+44?WS0!+1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 11=34M11=34M !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A^Z?
MI3(N]//W3]*9%WH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *1ON'Z4M(WW#]* &1=#4E1Q=#4E !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 U_N&DB^Y^-*_W#21?<_&
M@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 'I4474U*>E11=30!+1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !44?WS4M11_?- $M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!%%U-2U%%U-2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'[I^E,B[T\_=/TID7>
M@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI&^X?I2TC?</TH 9%T-25'%T-24 %%%% !1110 4444 %%%% !1110 4444
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MGT4 ,\E/[OZT>2G]W]:?10 SR4_N_K1Y*?W?UI]% #/)3^[^M'DI_=_6GT4
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MGT4 ,\E/[OZT>2G]W]:?10 SR4_N_K1Y*?W?UI]% #/)3^[^M'DI_=_6GT4
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MGT4 ,\E/[OZT>2G]W]:?10 SR4_N_K1Y*?W?UI]% #/)3^[^M'DI_=_6GT4
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MT>2G]W]:?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCWY]-N[-;"L&4,I!4C((Z&@!:*IZEJVFZ-;K<:IJ%I8P,X19+J98E+8)P"Q
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MKJ%LES97,-S XRDL,@=6'L1P:GH **** "BBB@ HHHH **** "BBB@ HHHH
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M@I_Y+Q?_ !-<O16GU+#?\^X_<A>TGW.H_P"%B>*O^@I_Y+Q?_$T?\+$\5?\
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M5?\ 04_\EXO_ (FN7HH^I8;_ )]Q^Y![2?<ZC_A8GBK_ *"G_DO%_P#$T?\
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M'_"Q/%7_ $%/_)>+_P")KEZ*/J6&_P"?<?N0>TGW.H_X6)XJ_P"@I_Y+Q?\
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M\EXO_B:/^%B>*O\ H*?^2\7_ ,37+T4?4L-_S[C]R#VD^YU'_"Q/%7_04_\
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MK?P07ABCDVE25# 9]LUP_P"T=_R3S3_^PK'_ .BI:[GX<?\ )-O#G_8/A_\
M010!\]_#WP+H?B3XI:_H.H13&PLDN&A6.4JPV3HBY/?AC7H'QYTRVT;X3:)I
MEFK+;6NH0PQ!FR0JPR@9/>L/X/?\EV\6?]<KS_TICKI_VCO^2>:?_P!A6/\
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MF3?LY>'GTN1%U?4SJ14D7+LA0OCNFW.W/.-V?>N>L_\ D[9O^NLG_I&U?0]
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MR?SK0^!"*OPIT\J,%YIRWN?,(_D!0!T_@[P5I'@;3;BQT@3&*><SNT[!FR0
M%R /E '&??UKHJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z?I52R^\_T%
M6V^Z?I52R^\_T% %RBBB@ HHHH **** "BBB@#YT\2_\C5J__7[-_P"AFLNM
M3Q+_ ,C5J_\ U^S?^AFLNOT:C_"CZ(\N6["BBBM1!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5Z?X#\>?ZK1]8E]%M[ES^2L?Y&
MO,*EMK::\N8[>WB:6:1MJ(HR2:Y<7A:>)IN%3[^Q4)N+NCZ:HK)\-6-_IN@V
MUKJ5U]HN47EO[H[+GOCUK6KX&I%1DXIWMU/23N@HHHJ!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 V3_5M]#5:R_C_"K,G^K;Z&
MJUE_'^% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IDW^I?Z&GTR;_ %+_ $- $-E]QOK5FJUE]QOK5F@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN/^/=Z99_ZD_[U
M/N/^/=Z99_ZD_P"]0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY<>$O#5W=?:KGP]I,UQG/FR64;/^97-:=O;06ENEO;0QPPH,)'&H55'L!P*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*
MX_X]WIEG_J3_ +U/N/\ CW>F6?\ J3_O4 6**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPI__ *CO_DI_]G1_PI__ *CO_DI_]G7I]%']L8W^?\%_D'L*?8\P_P"%/_\
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MI_\ ZCO_ )*?_9UZ?11_;&-_G_!?Y!["GV/,/^%/_P#4=_\ )3_[.C_A3_\
MU'?_ "4_^SKT^BC^V,;_ #_@O\@]A3['F'_"G_\ J._^2G_V='_"G_\ J._^
M2G_V=>GT4?VQC?Y_P7^0>PI]CS#_ (4__P!1W_R4_P#LZ/\ A3__ %'?_)3_
M .SKT^BC^V,;_/\ @O\ (/84^QYA_P *?_ZCO_DI_P#9T?\ "G_^H[_Y*?\
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M/L>8?\*?_P"H[_Y*?_9T?\*?_P"H[_Y*?_9UZ?11_;&-_G_!?Y!["GV/,/\
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M>PI]CS#_ (4__P!1W_R4_P#LZ/\ A3__ %'?_)3_ .SKT^BC^V,;_/\ @O\
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MI_\ ZCO_ )*?_9T?\*?_ .H[_P"2G_V=>GT4?VQC?Y_P7^0>PI]CS#_A3_\
MU'?_ "4_^SH_X4__ -1W_P E/_LZ]/HH_MC&_P _X+_(/84^QYA_PI__ *CO
M_DI_]G1_PI__ *CO_DI_]G7I]%']L8W^?\%_D'L*?8\P_P"%/_\ 4=_\E/\
M[.NG\*>";+PQOF\W[5>/QY[)MVKZ*,G'N<UU%%95LRQ5:#A.>C\DOR0XTH1=
MT@HHHKA- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!LG^K;Z&JUE_'^%69/\ 5M]#5:R_C_"@"W1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R;_4O]#3Z9-_J7^A
MH ALON-]:LU6LON-]:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% $5Q_Q[O3+/_4G_ 'J?<?\ 'N],L_\ 4G_>H L4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 45!=WD-E 9IFPHX '4UR%YXONX[P-%&HMPP^0]2._-:4Z4I[&<ZD8
M;G;45Y'K?B_5M21H8;E[0*^Y?(8HV/0D8)K"BUW75<$ZOJ!(/1KER/YUE7<J
M+7,CGEC(IV2/>:*\XT7Q_=HXCU*-94)4;UX*CN<=Z]#@GBN8$FA=7C<95E.0
M:F%2,]CHIU8U%H244459H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "-]T_2JEE]Y_H*MM]T_2JEE]Y_H* +E%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %4K7_CX?Z'^=7:I6O_'P_P!#_.@"[1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4'I10>E %.R^^_TJY5.R^^
M_P!*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS9.YE&,(>_I6AI^O6NI>&(-?ACF6TFM?M2HX <)MW8(!QG'O6'\1_P#A#?\
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M.,_,J E>/4#MZT =117.>'_'WA7Q3+Y.C:W;7$YSB$YCD;&2<(X#$<=A71T
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M !)XR\/>+/ACXG?0]5AO/+TZ8N@!5U&TC)1@& XZXK#_ &<?^2>:A_V%9/\
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MCTJW;PA-J1UR-9D? T[(W/\ ,!G[V>^?N]JNZUJ]Q=>#=-L9-!EM(H6C*WS
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M)H2"39]HE! (8H"_*K]W&>O?M4:PKX<\:6+V4X\2%8F<)#SN)#C;P7Z#YO\
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MC?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!%<?\>[TRS_U)_P!ZGW'_ ![O3+/_ %)_WJ +%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-NKZ97:*VA>9P@!8JH).,]^* /+/B5\&M%U70+F^\.Z=%8ZK;(TJ0VL>U+C
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MQERMGIM%16US#=V\=Q;R+)#(-R.IR"*EKE:L=.X4444 %%%% !1110 4444
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MAZD(PD)'TVCGW]Z $_9^F>7X8JC'B*]F1?I\K?S8UQ?PS_Y.,\5_]=;_ /\
M2@5Z)\$M(DTGX7:<9599+QGNBK*1@,<+U]5"G/O^)\[^&?\ R<9XK_ZZW_\
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MOF4>=/<$E=V!D(O "YSCC/J:\X^)O@8_"W4=-\7>#IY[2'S_ "GB+EQ"^,@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVU>ZT[Q!+H]W%;64<.ZZCDZR1X? 'RGG 8=1UJA;W6BIX7N[:>SE?6'E#07
M^XB97(/S>S]CUK9?Q)6[QVWV7Q7Z>G0GHOG_ $C0U&XUU_ >FP7-E FCK/FW
MN%(WNWS\$;CZMV'05'=P:/:WNC2>&[N:\O3(K2QSC"K("NT#*KP3GOVZBG:A
M::XG@73KFYO87TAYL06X^^C?/R?E]F[GK27USI%]=Z+%X<M);*]60++)-T:0
ME=I'S-P#D].]1#RVO+;;_MZ^OW=1O_+^D7]>>YO_ !A9#QK&NFQFWPQM/F(0
M;RIX+\EN/I^=&@/=6'C"]'@N-=2C%OA3=_*2F4+'DIR&X_SFC6DN=+\863>,
MY%U.,6^YA;]T.\*.B=&Y_P XI-$CN=4\87I\&R+ID9M]RBX[(-@8='ZMS6&G
ML.EN7_MS?_P*_P"A7VOG\S-LX-'N9]8D\07<UI>JQ:". 95I,MN!PK< [>XZ
M]:EL;C6U\ ZC!;V<#Z.UP#/<,1O1\Q\ ;NG"?PGJ?PCL+G2+.768M?M);R]=
MBL,D719!NW$_,O!)4]#TIUC:ZT_@34;F"]B31TG GMS]]WRG(^7W7N.E=$]]
M=KQWV_[=MK?UZD+_ #_IE&XM]$7PS:SP7D[:RTI$]N0=B)EL$';UX3^(]3^&
MMXCGUBXLO#\>NVD-K9)'MMY(3EGCPF2?F;G&WL.O2LNXNM%?PO:6T%G*FL)*
M6GN#]QTRV /F]T[#I6EXAMM7M+30)=<NXKJR>/=;QQ=4CPF0?E'."HZGI3?\
M2-^\M]]G\-M+>O0.C^7],?$EI8>,M//@R5]1<(2HNAMS)A@1R$XVX/\ 6G7*
M6U_XTOSXUD;39#$I86GS .%0*. _!7GZ_E31):ZGXRL!X.B;37,>U3<=I/F)
M/5N-N!3Y7MM+\:7Z^,XVU.01*K&W[N0A4]4Z+Q_G-8Z\W6_)_P!O[_=8KI\_
MD2>&)]8LY==C\+VD-]9%@KR7!PPC&_8>67DC/;MT%8EG;:"_AR[GN[V>/5U<
MBW@53L=<+R3M/JW<=*VO#=MJ]_/KLOAF[BL;(-N>.;J8R7V#[K<@9'7OWK'L
MKO0H_#-Y;75C-)JSN3!<+]U%PO!^8>C=CUJX_P 2=M[QV^+;[5]/NZ"Z+Y_T
MBW>7&MMX T^">S@71EN"8+@$;V?,F01NZ9+?PCH/QI:C!HT%KI4FD7<UQ>.@
M-Y'*"%CDPO"_*.,ENYZ=:MWEKK2> K"YFO8FT=YR(+<??5\ODGY?4-W/6JNI
MW6CW-II,6DVDMO>11A;N23I))A>1\QXR&[#K6E+XM/YI;;=?BOU].HG^B_I&
MMXDDO;[Q;8CQA"FGJ855S:G=B+<WS<%^<Y_PIVB-/8>,KD>#$74D$&(S=?+E
M2%+$Y*=&XIOB"*]TWQ;8GQ=,FHJ(E9Q;]XMS?+T7G.?SZTND)/JGC.Y/@UQI
MJ&',8N.R@*&'\?5N:Y]/8=+<O_;F_P!__ *^U\_F06=OHM[K.LOXLO)K"[^T
M,0EL"PWEFWCA7X!QCG\Z?HMSXAC\#ZG#8V-O+I+._P!HG=AO0[5S@;AVV]CU
MINGW6C:=K&LQ^*[.74+O[05$D'3>&;>?O+U..WY4:/9Z_+X*U.XLK^&+2D=Q
M<0-]YSM7./E/;'<=*JIMKM>._P /_;MM?OZ@O\_7YF;+;:"/"\$\5[.VM%R)
M;<J?+5=QY!V^FW^+O5WQ+<:W-H>@IJEG!!:1V^+)XR"9$VIRWS'G 7L.M5);
MO0F\*06L=C,NLJY,ER?N,NYN!\WH5[=JL^([76K?1="DU.]BGM)8,V<:=8DV
MIP?E'8KW/2ME_%C?^:7Q;[?9MT]>A/1_U]XLT6GV7BS3?^$2GDOR&1D^TC;F
M;<?EY"<?=_/K4UZ([[QQ='QBQTYF53,+7YMK!%V@8W]1CUJ*ZFL-1\6:=_PB
MD#Z>241//[2[C\W5N.5_+I4URT>F>-[D>,%.I,J 3&W_ (F*+M(^[T&*SUNM
M[\K_ ,>_W?\ !'_G\BUX2GUFRU75E\)VD-_;[P-]R=I\L,VP\LG)'7C\!6-I
MEKX<E\/WDVHZA<PZJF_[- BDH^%!7)V'JV1U%;'A6UUC4=6U=_"EW%I]OYF[
M9/U\LLVP?=;D#_)K)TN]\.P^';VWU#3YYM4??]GG3[J94!<_,.C9/0TO^7D[
M;^[\/Q;?:OI]P=%\_3Y%Z6Y\0GX<PV[V-N-$#_)<AAYA/F$]-W][(^[67JMM
MH,.E:?)IE[//?.@-W'(I"QMM&0ORCOD=36E)9Z^/AY#=-?PG12^$MOXP?,(_
MN_WLGK6?J]WH4^D:=%IMC-!>QH!=ROTD;: 2/F/?)Z"KH_&^7^:7P[?]O7Z^
MG44MOEU_0T_%4NI7GBBP_P"$KMXK %(U?[,<XAWG+<%N?O?ETJ/2RUCXY'_"
M(#^T JG[/]J^7>#'\V<[.GS>G3O3O$\&I:?XHT__ (2FXCOP%C=_([P[SE>B
M\\-^?6FZ>&U+QS_Q2)_LX.I^S_:/X (_FS][KAO7K6<;>PZ6Y7_@_P _^!<I
M_%\_F1V<&DWOB+53XLNIK"7SG9EMAD"4N=R\*W Y_P :L^'KKQ%%X1U>+3;"
MWFTUUD^U32, R#R\-CYAT7GH:@L+G2=.\0ZJOBJUDU"42NK-!T,H<[FZKP>?
M\*E\/V7B&?PGJT^G:A!#IL:R?:87^](!'EL?*>J\=13J_"[[>[O\/_;MM?O\
MA1W^_P!3/^R^'/\ A$Q<?VA<_P!N_P#/MM/E_?QUV?W.?O=?RK0\17/B&7PI
MH\6I6-O#IR(GV66-@6D&SC/S'^'GH*HF]\._\(@+3^SY_P"W/^?K^#_69_O?
MW./N_P"-7/$-GK\'A;2)M2OX9]/D1#:PI]Z,;,C/RC^'CJ:K_EY'F_F?Q;[?
M9MT]0Z.W;I^I#=PZ59>)-+/A2YEOY!+&RBY&,R[QM7E5X/'^-2:EF]\=/_PE
MW_$OW@?:?LWS;,1_)C&_KA?7KVIM_<:7J/B32QX5M9+"0RHBF?M*7&UNK<#C
M_"G7V=-\=/\ \);_ ,3'RP/M/D?QYC^7'W>F5].E*-]+WORO?X]_N_X-@?Z_
M(F\*3:I9^)-1'A2VBOU"NJ&Y.,P[QM;DKST_/I65I5MH$ND7\FIWUQ#?HC&T
MBC4E9&VG /RGO@=16IX8M]3U#Q)J)\+7,=@I#N@G[1;QA>C<]/RZUFZ3>:#!
MHVH0ZE8S3W\B,+65/NQMM(!/S#O@]#3?Q3MO[NWQ?.^GW>8=%\_0TTNO$7_"
MN)+=;"W.A[OFN=P\P'S0>F[^]@?=_P :S=4M?#D6@V4VFZA<S:H^S[3#(I")
ME26Q\@Z-@=36@EEXA/P[DNAJ$ T0-\UM_&3YH']W^]@_>JCJM[X=G\/V,&G:
M?/#J<>S[3._W7PA#8^8]6P>@HI?&^7^=_#M_V]?KZ!+;7MU_0UO%L^L7NLZ4
MOBRUAL(-VTM;'<?++#>>&;D#_P#4:J6(2Q\<6_\ PAY.HLJGR/M7R[B8SNSG
M9T&?3IWJSXIMM7T[6M*;Q5=Q:A#NW%8.OEAAO7HO)%5[4IJ7CBW'A '3BZD0
M&X_A(C.[/WNHSZ]:SI6^KZ6MRRV^#Y]?Z8W\7S^9!;1:=>^*M2_X2NXDL,O(
MTGV89Q-O&5X#<<M^76I/#=QKL.@:Y'I=E!/9R0$7DDA :-=C<K\P[;NQZ4RS
MGT[3_%6I?\)5;O?X:1'\CO-O&6ZKQPWY]*7PY::Y/H.MRZ9>PP6<4)-Y&_61
M=K<#Y3V#=QUK2K_#=]O=W^'?I;7[_(2W^_U*<=MH!\+2W$E]<#6P^([8*?+*
M[ASG;_=R?O=JU=<NO$4G@G2X;^PMXM*1H_L\Z,"[G8VW(W'J,GH*S([S01X3
MFM7L9CK1?,=R/N!=P./O?W<CIWK1UNR\0P^"],N+_4()=*=H_L\"_>0E&*Y^
M4=!D=3UIR_B1YOYG\7I]FWZ^8+9^G3]1E[;Z+9:WH[^$KR:_NOM"G9<@J-X9
M=@Y5."<YY_*IM9::_P#&D \9(-.0Q8E-K\VU0&VD8W]6P*BU"ZT;4=:T>/PI
M9RZ?<_: N^?IO++L/WFZ'/;\ZDU59M,\:0'QBXU)%BS*+?\ B4JP4#[O0X-9
MQO=7O?EEO\>_3I_2&_U^0>&9+^R\67W_  B,,>H*(F5/M)VYBW+\W)3G./SZ
M5CZ5;Z+-8ZF^JWDT%W''FS2,$B1\-PWRGC(7N.IK8\.PWVI>++X^$ITT\&)G
M03]HMR_+T;G./RZUDZ3=:-;V&J1ZI9RSW<L6VSD3I$^&Y/S#N5['I6G65M[1
MV^+Y]/N\R>WS]"_:W&NK\/KZ"&R@;16G!FN"1O5MR< ;O4+_  GK5&^MM C\
M.VDUG?7$FKLX%Q RG8BX;)!VCOM[GK5RUM-<;P#>W45["NC+,!-;'[[-N3D?
M+ZE>_:JM_>:#+X:L[>SL9H]61P;BX;[KKAL@?,>Y7L.E.'QOE_F^SZ?:O^GD
M#V^77]#:\4SZS>76AQ^*K2&QLPY"R6QRQC)3>>&;D#&./P-06JV]AXUL3X*D
M;4I!$Q07?R@N5<,.0G 7G_.*F\36NL:?=Z'+XINXK^S,A98X.HC!3>/NKR1C
MO^50PO;ZIXTL1X,C;3)#$P0W'9PKECU?JO%<].WL%:UN66WP==^O],I_%]WJ
M1M'9WWC#4#XQE?3G*[G%J-V)/EP. _&W)_K3?#L^L0:9XACT:TAN;)X=MU)*
M<-''A\$?,.<;NQZ=*<LMGIGC#4!XOA;4G"E7-OWD^4ANJ\8R*C\/VVKW6G>(
M)='NXK:RCAW74<G62/#X ^4\X##J.M:2_A:[6CO\&ZVZ_?Y"6_W^IG6]OHC>
M&;J>>\G765E @MP#L=,KDD[>O+_Q#H/QTM1N-=?P'IL%S90)HZSYM[A2-[M\
M_!&X^K=AT%9]O=:*GA>[MI[.5]8>4-!<#[B)E<@_-[/V/6KVH6FN1^!=.N;F
M]A?2'FQ!;C[Z-\_)^7V;N>M:S^)<W\WVO3[-OU\Q+;Y?U<;=P:/:WNC2>&[N
M:\O3(K2QSC"K("NT#*KP3GOVZBM#7GN;_P 860\:QKIL9M\,;3YB$&\J>"_)
M;CZ?G5"^N=(OKO18O#EI+97JR!99)NC2$KM(^9N <GIWJ_K27.E^,+)O&<BZ
MG&+?<PM^Z'>%'1.C<_YQ6.MXWO>TM_C^73^D5_P/0- >ZL/&%Z/!<:ZE&+?"
MF[^4E,H6/)3D-Q_G-9EG!H]S/K$GB"[FM+U6+01P#*M)EMP.%;@';W'7K6EH
MD=SJGC"]/@V1=,C-ON47'9!L##H_5N:SK"YTBSEUF+7[26\O78K#)%T60;MQ
M/S+P25/0]*:WE:][1V^/Y]/Z8NWS]"2QN-;7P#J,%O9P/H[7 ,]PQ&]'S'P!
MNZ<)_">I_#/N+?1%\,VL\%Y.VLM*1/;D'8B9;!!V]>$_B/4_A>L;76G\":C<
MP7L2:.DX$]N?ON^4Y'R^Z]QTJG<76BOX7M+:"SE36$E+3W!^XZ9; 'S>Z=AT
MK:'Q.W\WV?3[5_T\A/;Y?U8U/$<^L7%EX?CUVTAM;)(]MO)"<L\>$R3\S<XV
M]AUZ4L26EAXRT\^#)7U%PA*BZ&W,F&!'(3C;@_UIGB&VU>TM- EUR[BNK)X]
MUO'%U2/"9!^4<X*CJ>E/$EKJ?C*P'@Z)M-<Q[5-QVD^8D]6XVX%81_@Z;6EM
M\&[WZ_TRG\7W>H^?R+SQO>R>,IGTN81JQ^Q\[9 $V@8#_P //U_*O0_!7B8Z
MZ+ZT.^9;*3;'=-@&6,D["PX.["\\?E7GDKVVE^-+]?&<;:G((E5C;]W(0J>J
M=%X_SFG^&K?6+ZXUR;PQ>1V%FK!GCF^\8R7*#HW(&>_YURXO#PK4/>TLHV?V
M5MMU^_R*A)QE]_J>V45P?@7QU'JT4>F:G+MU$<)(PP)AVY_O=?K7>5\UB,/4
MP]1TZBU.N,E)704445@4%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 V3_5M]#5:R_C_  JS)_JV^AJM9?Q_A0!;HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *9-_J7^AI],F_U+_0T 0V7W
M&^M6:K67W&^M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"*X_X]WIEG_J3_O4^X_X]WIEG_J3_O4 6**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:UJL6A:)>ZM<132P6<
M+3R)" 7*J,G ) Z9/6O-_"WQTTKQ3XML]#ATFZMA=EE2XFE7A@I(!4>N,=>I
MKU26))X7BE4-&ZE64]"#P17QYX\^'>M?#[6VFB6X?35EWV>H1]1@@C<5^XX)
M [9(R* /K/5O#FBZ[&8]5TJSO <<SPJQ&.A!(R#R>E?-7QL^'FC>";O3+K1"
MT-O?"16M7D+[&3;RI))(.[OTQ[\)8?M">-+.U2&6/2[UE&/-N+=M[>YV.H_2
MN4U'4O%OQ0\11M(D^I7I&R*&%,)$OL.BCN2?Q- 'MG[-]W/+X0U6U=RT4%[N
MC!/W=R#('MQGZD^M<G^T9XD2]\16'A^"0,NGQF:X !XDD (!^B 'C^_^7L7P
M_P#"T/P\\!I9W<R>8@>[OI1RH? W8XS@*H'X5\HW<UYXY\=R2(O^E:O?X1?[
MN]\*/H 0/H* )/#7CSQ+X/@N(=!U$6B7#!Y1]GBD+$# Y=2:N:Y\4/&/B32)
MM*U?5Q<V4Q4O&;6%<[6##E4!'('0U]CZ?8P:9IMK86RE;>UA2&('LJ@ ?H*L
MT ?&?PI\0'PY\1])NF<K!/+]EGQCE)/EY]@VUO\ @-?2_P 6M&EUSX8ZS:V\
M7F7$<:W$:@9/[M@YP/4J&'XU\T?%;P^?#GQ'U:U5"L$\OVJ#..4D^;CV#;E_
MX#7U!\-/$!\3?#W2-0=RTXA$,Y.,F1/E)./7&[\: /FOX,^(XO#?Q'LY;F5(
MK2\C>TFD<@!0V"I)/0;U3)],U];ZA91ZEIMU8S,ZQ7,+PN4(#!6!!QGOS7S7
M\4_@W?:)?S:OX;LY+K296+O;0*7>V/4_*!DIUQC. .?6L/P]\:_&?AFR33Q-
M;7L$"^5''?PEC&!VW*58XZ<DXZ>E 'J&H_L\^$K33+NYCU'6R\,+R*&GBP2%
M)&?W=>$^!/\ DH?AK_L*VO\ Z-6MKQ)\5_&7C%&L)[SR;:?]V;.QCV+)GC:>
MK-G.,$D'TKI/A;\)/$=YXCTW7=2MI-+L+&YCN1]I0K+,4;< J'D#(')QP>,T
M >P_&W_DD.N_]N__ *41UXC\ /\ DI\7_7I-_(5[=\;?^20Z[_V[_P#I1'7R
MIX?\1ZKX6U0:EHUU]ENPA02>6K_*>HPP(_2@#[KHKY _X7;\0_\ H8?_ "2M
M_P#XW1_PNWXA_P#0P_\ DE;_ /QN@#Z<\?:7>:UX#UG3=/A\Z[N;8I%'N"[F
MXXR2 /Q-?,?_  I+XA_]"]_Y.V__ ,<KZ<\ ZI>:UX#T;4M0F\Z[N;8/+)M"
M[FYYP  /P%='0!XS\&/">N_#^Q\37GB73GM(GBAE39(DS.L8E+X$98Y (X[Y
MXKIO#_QC\*^)O$5MHFG->FYN2PC>2$(API8\DYZ CIUKOV4,I5@"I&"#T-?*
M/Q ^$VN^#M<-]H5O>7>EF3S;>>U5FDMB#D!MO(([-T/'0\4 ?2OB^*QG\&ZS
M'J2QM9FSE,HDZ !2<^Q! (/4'&*^5/@Y<W=M\5-$%HT@,LCQRJF?FC*-N! Z
M@8S[8![57O/'/CSQA8KHLNHW^HP.0IMX(06DYR VQ<MR.^>E>R?!7X5WGAN5
MO$>O1>3?R1E+6U)^:%3U9L'AB.,=AUY.  >J^(?$&G>%]$N-7U2;RK6 9.!E
MF)Z*H[DG_.*^6=:UGQ1\:O&:6ME;MY29-O:AOW=M%D NY]>1EOH .@KH?VB/
M$LE[XJMO#T4I^S:?$LLJ=O.<9S^"%?\ OHUY1IFN:MHK2-I6J7M@TH D-K</
M$7QTSM(SU- 'U[\/?AQI?@#3F2W/VG49P/M%XZX9O]E1_"N>W?OGC"?%G5+S
M1OA?KE[83-!<K''&LB]5#R(C8/8[6.#U'6OE3_A._&'_ $->N?\ @QF_^*KZ
M9^$S'Q/\)K,>("=6$\DHE^W_ +_S-LIV[M^<XP,9Z8% 'S1X-\8WG@C6&U73
M[&QN;LQF-&NT=A&#U*A67D],G/%:GC?XHZWX^LK6TU6UT^&.VD,B&UC=221C
MG<[<5]4_\()X/_Z%30__  70_P#Q->/_ +0/A[1-%T#1Y-*T?3[&22Z97:UM
MDB+#9T)4#(H \^^'WQ0UOP3;MI6FVNGRP7=TLCM<QNS D!>"K@=!Z5]@UX-^
MS]X>T35O"NHW.I:/I][/'?[4EN;9)&0;$. 6!(YYKWF@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""6TBE#9!!/<&H!I<08$
MNQQ]*O45FZ4&[M 1QPQQ$E%P3U/6I***M)+1 <G\1_\ D2[G_KI'_P"A"O)O
M#NO3^'=3-[!#'*YC,>U\XP<>GTKUGXC_ /(EW/\ UTC_ /0A7GGP[L+34O$I
M@O;>.>+[.[;)!D9RO->S@W%863DKK7]#R<6I/$Q479Z&K_PMC4_^@?:?^/?X
MU@7^MWGBS4D34KZ*V@!9HPZG9'GMP">PKU__ (1'P]_T![3_ +]BN7\9^!;#
M^RY]0TNV\J>)03%&0J;1]XX]<>]31Q&&Y[1C9]RJU#$<EY2NNQO^#M L=#TS
M_1;A;EY@KO*._';T%<)\5O\ D8;7_KV'_H352^'>LRZ=XCCM"7:&[_=E V &
MR,,1[<_G5WXK?\C#:_\ 7L/_ $)JJG2E3Q?O.]T34J1GA?=5K,Z7P#=K8^ 9
M;MU+) \LA5>I  ->:3RWOBCQ'@NTD]S+M3>>@[#\!7<Z 9U^$][Y ^;,N[_=
MP,UQO@W_ )''3/\ KN*THI1E5J+?4SJMRC2ATLCU:T\ ^'K>TBBDL1.ZKAI'
M9@6/J<'%>;^.O"\?AW4HY+9_]&N=S1H3RF,9'TYXKV^O/?BLML=+M&<C[0'/
ME_3O_2N/!XBHZR4FW<[,70IJBVE:Q;^'>L3ZAX:FAF*[K0E$;/S$8SS].E>5
M;Y-5UM&O)B7N)E$DG /)P3Z5UWPJQ_;]V#T^RG/_ 'TM9WBO3=-G\2F'0)#/
M)+)M>!$.%?/.T]"/Y8-=M)1IXB<5UU]#BJ.52A"3Z:>I[!I^D6.GV$-K!!&8
MXU #%02WN?K7EOQ1LK:TUVWD@A6-IH=\A7^(Y(SCZ 4ZS\3>,=$MQIHL6E%N
M2@:2W=S@<8R#R/2H+?P[XE\8WR76H>8D6[8TDW&P=>%/.*PH4I4:CJ3DK>NY
MM6JJM3]G"+OZ;'6^ [^2#P%<7+L'-LTA0-TPJ@@5YS;M-XJ\5QB^F8&YF =U
MQ\BY[9]!7H_B_3+;0_AY-9V*E(U>/)[L=P!)]S7EFCZ3>ZS??9;!0T^PM@N%
MX'7D_6M<-RR4ZRTN_N,\3S1<*3ULOO/=[/3='L+,6EO%;+$!@@D$GUR37EOQ
M"\/V.D7=M<:=Y<<$RE?*1LX*XY_'/Z5!_P *^\4?\^W_ )'7_&D/P[\3-]ZU
M!^LR_P"-30A"E/F]JG_7J76G.I#E]E;^O0[[X?:W)J_ATQ3L[SVGR,[8Y!SM
MQCT Q7C<JLUZRIG>7P,>N:]A\ :!J.@V5]'J$(C:5E*8<-G .>A]Z\EM_P#D
M-Q?]=Q_.KPO*JM3DVT,\3S>RI\^^IZCX8^'UG'8?:-;B^TW<X#%&8@1]\<=^
M>:X_X@>'[/0=5A^Q!EBN$+^6>0F..*]LKRGXM?\ (2T[_KBW\ZY<)7J5,1[S
MW.G%4*<*'NK8Z#X77$L_A642N7$5TR)G^%=B''YDUVU<+\*/^16N?^OU_P#T
M!*[JN7%?QI>IU87^#$****YS<**** "BBB@ HHHH *^8?C#J?]B?'&QU;R?.
M^PBTN?*W;=^QMVW.#C.,9P:^GJ* /G__ (::_P"I1_\ *E_]JH_X::_ZE'_R
MI?\ VJOH"B@#SSX9_%+_ (6+<:C%_8W]G_8DC;/VKS=^XM_L+C&WWZUXY\0;
M?5[G]H>^30"1JJO!+;8;;EDMD;&?<*1@\'.#7U-7SQ>?\G;+_P!=8_\ TC6@
M#4/[0&H6%J;+5O!UW;ZZ$XA)9$8X^]M8;E&0>.>G6CX;^"/$/B'QH_C_ ,9Q
M-#-NWVMK+'M8MC"MM_A51]T'DD9[9/N=% 'C_P"T=_R3S3_^PK'_ .BI:ZKP
MI_R1?3?^P*/_ $57;44 >$?LT?\ (,\1?]=H/Y/5OXL?#[7%\30>//"8DFU&
M!HWGMXUW2;D "NH_C& %*]3[@G'ME% 'A4'[19@MQ!J7A2Y340N/+CEVJ[\C
MHRY49^O?K6?X6\(^)/B7\0E\9>*;)]/TZ!T>*"1&7S A^2- >=N1DL>I)QUX
M^A:* /,?CY_R2ZX_Z^H?_0J\W\!>.O$_PZ\+6AU#09]2\,W2M/;W,1;]QEB&
M7=@J.58[3@Y).<5Z1\?/^277'_7U#_Z%6O\ "#_DE&@?]<7_ /1C4 >4:]XG
M\5?&R>'0O#^D366A^8K3SR@E21WD?&  <D*,DX[XX]V\+>'K7PIX:L=%LSNB
MM8]I?&#(QY9B/4DDUL44 ?,?B2_U7X6?&V_\13:9]KM;MY)(B6*)*D@R0KX.
M&4\'(/3I@@UV'Q)\2KXP^ $&O);?9A=W"'R=^_85D9"-V!GE?2O;** .(^$'
M_)*- _ZXO_Z,:O+[/_D[9O\ KK)_Z1M7T/10!RWQ"\&Q>.O"4^D-*L-P'$UM
M*PR$E7.,^Q!(/UKQ[PU\1?$OPJL5\-^+/#US-:VV[[/,K8*J6Z!N5=<YP<\9
MQTP!]%44 ?.?B/QEXJ^,L2>'O#&@S6NE2.K7$\S\/M(/SO@*J@\[1DG:,>E>
MV^"O"T'@WPI9:)!)YIA4F67&/,=CEFQVY/ ] *WZ* /GKX&_\E4\5_\ 7.7_
M -'BOH6BB@#YZ^!O_)5/%?\ USE_]'BO;O%?_(GZW_UX3_\ HMJUZ* /$?V:
M_P#D6];_ .OM/_0*Z[XV_P#)(==_[=__ $HCKT"B@#SCX%?\DGTW_KK/_P"C
M&KT>BB@#D/BE_P DP\0_]>C?S%?/_P ./C!_PK_P]<:3_87V_P Z[:Y\W[7Y
M6,HB[<;&_N9SGO7U?10!\_-^TA?WBF'3?" -R?NYNVE'_?*Q@GMWK/TWP9XS
M^+OBB'6?&$,VG:3&HP#&8ODZ[(D;GG/WSGZG %?2-% $<$$5M;QV\$:QPQ($
M1%& J@8 'X5\^?#/_DXSQ7_UUO\ _P!*!7T/10!XG\7_  7K\?BG3O''A.WD
MGOK<*L\4$>^0,N=KA>=P(.T@#L.N3B"+]HM8+98=0\*W::GMP8DEVJ[].,KN
M )[8./>O<Z* /!/ GAKQ'XS^*#?$#7]/?3;-&\R"%\J7(78BJ#S@ 9).,GH.
M>.N^,GPYG\;Z-!>:9M_M73PQCC;@3H<$IGL>,C/TXSD>FT4 >":9\==4\,V:
MZ5XR\.7AU&W'E^>IV&;'!+!AUZ<@D'/:LN_A\7?'77;/=ISZ1X<M'8>9)DA<
M_>;G&]\   # ]LDGZ/HH XGXB64&F_!_6+&U39;VVG"&)?[J*  /R%<]^SU_
MR35_^O\ E_\ 04KU>B@#.U[1K;Q#H-]I%X#]GO(6B8@#*Y'##/<'!'N*^?M$
MUCQ=\#=0O-,U72)M1\/R2>8LT8*Q@D@;T?! ) Y1L<XZ=3])44 ?-_C/X@^)
M/B;X>O+/P[H5S::';0/<ZA<R$'>D8W;=W 'W<[026QZ UV'[./\ R3S4/^PK
M)_Z*BKV"B@#P/QSX,\1^"/'S>/O"4$E[#+*TUU;HA8H6_P!8&4<LC9)R/NGG
MC -6/^&C ]N;>+PI='52 $A\[*EB!_L[O4XQS[9X]THH \)^&'@/7M8\9S>/
M_%L+6TS2-+;VTB%69V& VT\JB@X4'G@>G-C]I3_D6]$_Z^W_ /0*]NHH R/"
MG_(GZ)_UX0?^BUKSWXV>!-2\1V>GZ[H,32ZKIC$&)/OR1D@@KZE6&0.^X^@!
M]9HH \(L/V@KK2;..S\4^&;R/4HALD=?W?F,.I*,!M/3(Y_#I698Z7XE^,'Q
M&T[Q'J&D2:5HEEL"[V/*HV_:I(&YF+?>  Q[CGZ*HH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[I^E5++[S_ $%6V^Z?
MI52R^\_T% %RBBB@ HHHH **** "BBB@#QCXAZI)>W?V9M$:R6WN95%R1Q<<
MXS]T>F>IZUG:M9+H7BC3O*U :[M,<OR'.XAS^[ZMUQ_X]TK7^)%SKTTT<>IV
M4$%BEQ(+22-@6D7/!;YCVP>@K$NHM-L_%.F?\(I<2WY$D3)]I&,S;^%Y"\?=
M_/K7VF$TH02VM+;5?.73^NQP3^)D[C_A(/',AF;_ (1[S@"0_'DXC'KMZX]N
MM2>'[]]!U[5$BTMM> =H]Z#.0&/S]&Z_Y-17X6^\<S_\)>?[/+ ?:/LOS;"(
MQMQC?U^7UZ]JM>$Y]6LM=U0>$[6&_BR55KDX)B#':W++R>/\*=2WL;/;E6E[
M1_\  _\ @_F"^+Y_UH9^C:1'>>'=1O&UY;-H Y%F3S/A,_WAUZ=#4YUB3_A
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M\A>/N_GUJ:_"WWCF?_A+S_9Y8#[1]E^;81&-N,;^OR^O7M4J]D^O*];>]O\
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M(P#1KL.2/F';)Z&JJ:Q:>WN[Z+Y2Z_UW$M_O*ZZ1&?!3ZG_;RAP<?V;GD_O
MO][_ (%]W_&I]<UB2\\*:;9-H#6:P^7B](XFPA']T=>O4]*HK:^'?^$4:X:_
MN!KF?EMMI\LC?CKM_NY/WO\ "M7Q#=>(Y?!NE0ZEI]M#I:"+[--&P+OB,A<_
M.>JY/04WK47-K[SM?W>G3^8.FG;^O0BUC3TT'7=)DBU5=>(E63RT.<E6'R?>
M;[W^0:+EO^$A\;QB9/\ A'O-3!+\>5A"<\[.N,=NM1WD&CV7B#26\)W4U_/Y
MZ,%N1M'F!QL'*KP3_P#K%2:L7OO&Z_\ "8 :<K(//^R_-M 0[<8W]3CUZ]JF
M-[)O?E>MK2W_ )/^!^8/]?E]XW0;QM"\5:AY5@=>VB2+Y1G<-X_>=&]/_'NM
M4]$TN.]TC5;AM96R-O$6%N3_ ,?'RL=OWAZ8Z'K5_P +2ZC9>*K_ /X12WCO
M\1R+']I.,P[UPW)7GA?SZ5E:3;Z%-IFHR:I>SP7D<9-G'&"5D;:>&^4]]O<=
M:MZ.36_N[:OYQZ?\/V%V^9=AU61? L^F_P!ALR/(#_:..$^=3C[OMC[W>FZK
MI$=KX7L+Y=>6[>8H#8@\PY4G^\>F,=!UJQ!<Z^/AW<V\=C;G1#(#)<EAY@;>
MO&-W][ ^[WJAJ-KX=C\/6<UA?W$NJN5^T0.I"(-IW8.T=#@=31#2;Y=/>=[>
M]TZ_R@]M>W]>IK^(M2?7M5T>&72&T >=L\YQC[S*-WW5^[UZ]^U1&,>'?&UL
MT,O_  D>R,L%3G?E6&.-_3K5KQ=<:U>ZCHZ>+;.&PM?,8;[8ACL)3>>&?D#&
M./SJI9K#8>-[0^#7.HN$8Q"Z^7<Q1MP.=G1<FL*5O8I+;EEHG>/7[>Z^_P#(
MI_%\UZ_<,L+5=?\ %NH&:]'A_<K2X?C:=RC9R5]<_ATJMH&I/8Z5K<"Z0U\+
MF#89P/\ CV^5QN^Z?7/4?=J9(["]\6ZC_P )=-)I['<S_9ANQ+N'R\!^,9_+
MK2>&[C6H=&U]-*LX9[22WQ>/(0#&FU^5^8<X+=CT%;2_AM/:T=]%OTEU_P"&
M[B6_W_U8KV^EQR>#[K43K*QO'*%&GYYDY4;OO>^>G\-3ZGJLEQX.T^P.AM;I
M#(I%^1Q-@,,?='7.>IZ52AM]";PQ<3S7LZZTL@$-N =C+E>2=OH6_B'2M/5[
MG7Y/ VF0WEC;QZ0LBFWG5AO=MKX!&X]MW8=*J6LUS:^]I?W>G3^;^NPEM\A^
MJZ<FA:EHEQ%JRZZQF#_9U.<;2AV?>;[V<=.W>I+^8^)/&5DDT!\-AH"F]^-N
M YW<A.OW?\XJM=0:-9ZOHLGA6[FOKPSJ6CN1A1(&78.57@G.>?Q%6M=:XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 V3_5M]#5:R_C_"K,G^K;Z&
MJUE_'^% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IDW^I?Z&GTR;_ %+_ $- $-E]QOK5FJUE]QOK5F@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN/^/=Z99_ZD_[U
M/N/^/=Z99_ZD_P"]0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ I&4,I5@"I&"#T-+10!A3>"O"EQ*TLWAG1I)&.6=["(DGW
M)6M6SL;33X/(LK6"VASN\N&,(N?7 JQ10 4444 %%%% !1110 5EZAX;T+5I
M3+J6BZ=>2'&7N;5)#QP.6!K4HH H:?H6D:2 --TJQLP,X^S6Z1XSU^Z!5^BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4K8J%W-^\&5'OZ5Q_C'Q_P#8I;>'0KR*5\%I755=<'& #Z]:QA\*]: (%Y:
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MD-V'6O9CX%\.M;"W-E*8%.1$;N;:#]-^*ENO!GAZ\M[>";3(S';KMCV,R'&
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M.BW<P#?4;^:<\XH235GTW2:T[*]D"H2/'UN_#H\)M;&PN#KA/RW.?W8&_/\
M>_NY'W?\:T_$%IXCA\&Z5-J6H6\VEN(OLT*#YDS&2N?E'1<CJ:]4'A#0!IAT
M[^S(OLQYQEMW7/W\[NOO4,G@?P]-"D,MG,\28VHUW,57 P,#?QQ1_;%#F4K/
M=O6S^Z[T^0>PE8\IO;C2+[7])7PG:2V$WG(H:X.1YA8;#]YN ?\ ]1J350]A
MXW7_ (3 C455!Y_V;C<"AVX^YT./3I7K-[X2T*_FBFGTZ,21?<:%FB([Y^0C
MFF0^#= AOEO18&2X7H\TTDO;'(9B#P>]*.;T$EI+9KN]?[U[_@'L)?U_D>5>
M%X=1OO%5_P#\(I<1V&4D=/M SB'>N%Z-SROY=:RM)N=#ATS48]3LIY[R2,BS
MDC/RQMM/+?,.^WL>E>T#P5X?6[ENH[%XII22[0W,L><G)X5@ ,]AQ3K7P;X>
ML[:XMX=,B$=PNV3>S.<8(X+$E>IZ8JGG%#71ZV[)Z=W>[_KN'L)'E$-KKY^'
MES<)?0#1!(!);$?.6WKS]W^]@_>[51U&[\.R^'K."PL+B+54*_:)W/R.-IW8
M^8]3@]!TKV >!?#HMC;"RE$!.3%]KFVGOTWXJ>X\(:!<V$5E+ID1@BP4"EE;
M@8&6!#'KW-$<XH*5[/XKZ67WZZ_,/82L>9^+;?6K'4M'?Q9>0W]KYI.RW&#L
M!3>/NKR1C'/Y54M&AU#QO:#P:ATYV1A$;KG:P1MQ/W^HR*]4/@S07GAFELY)
MGA8-'YUS+( <@]&8CL.*=<>$-!N;T7CV 2X4;0\$KQ8'T0@=ZSAFU&-/EL]F
MMDHZ_P!V]ANC*]_Z^\\CCEL+#Q;J/_"70/J##<K_ &8XS+N'S=4XQG\^E-\-
MV^M3Z-K[Z5>0P6D=OF\CD',B;7X7Y3S@-W'6O7[3PAH-E=O=1:>K32*59II'
MESD@_P 9//'7K5>/P)X<A21(K&2-)1B14NI@&'H0'YZFM'G%!Q:L^G1-:>5[
M+^NPO82N>-PW.AKX7N+>:RG;66D!AN ?D5<KP?F] W\)ZUIZM:Z_'X&TR>\O
MH)-)>11;P*/G1MK8)^4=MW<]:]73P;X>339-/73(OL\C;F!9BV<@\/G<.@Z&
MHG\"^'9(%@>RE:%#E8VNYBJ_0;\4WG-!R3L][ZV?3IKH'L)6/*[NXT:]U;18
M_"MI-87@G56DN#E3(678?O-P#G/'YU:UQ+C3O&-F?&DBZE&+?+BUX)0[PHX"
M<AN?\XKU.\\)Z%?- TVG1AH#F-HF:(@\<Y0C/0=:9%X/T*.]CO#9&6>,$*T\
M\DN!@C&&8CN:S6;4=-'LUW>O]Z]U]P_8R_K_ "/+?#T=YJ'BZ^/@Z5-.0PED
M%SSB/*9'1^<X/]:RK"XT>WAU>/6;2:YO74K:R1'"QR?-DGYAQDKV/3I7LS^#
M=!:\DNULFBGD^\T,\D>?;"L !P*+;P;X?M(KF*'38]MRNV7>[.2.>A8DKU/(
MQ5?VQ0UT>J79/3O*]W_7<7L)'D5E;:VW@'4;B"\A71UN )[<CYW?,>"/EZ<I
MW'0_C2NKG0W\-6D%M93IK"R9GN&/R.OS<#YCZKV'2O9%\">'%MVMUL9! QRT
M8NIMI/J1OQV'Y5-+X-\/3:?%8OID7V>)MR@,P;//5@=QZGJ:M9S03O9_%?2R
MZ===?Z["]A(\N\2V^L6G]@R>)+N&\LF^:*. 898QLW _*O)&._;K3;=[;4?&
ME@/!<;:;(8F"FZY <*Y8\E^"O'^<UZ@?!6@/)"\EE)*82#&);F5PO3L6([#B
MIKKPEH5W>)=R6 2=%V*\$CPX'/\ <(]3S62S:BH<MGLULDM?[M[,KV,KW_K[
MSRF=[;3O&E^/&D;:E((E#&UX!?"%3P4X"\?YS2>&[?6+J'7Y/#]W#:62KNGC
MF&6:,[]H'RMR!N[CKUKU:U\(Z%:7CW<=@KSNNUGGD>7(X_OD^@YJ)?!'A]&F
M:.RDC\XYD$=U*@;KU ;'<\4/-J#ARV>R6R:T_NWL@]C*]_Z^\\7MKG1%\,W=
MO<6<SZPTH,%P#\B)\O!^;KPW8]1^%Z]MM;7P#IUQ/>0MH[7!$%N!\Z/F3)/R
M].'[GJ/P]=C\&>'HM.EL%TR/[/*VY@68MGCHQ.X=!P#_ #J%O GAQK=;=K&0
MP*<K&;J;:#Z@;\=S^=:O.:#=[/XKZV?3IKI_7<GV$CR*^N-'N?['CT.TFM;U
M,+<22G*O)\N"/F;C.[L.O2M/7TN]/\7V1\92IJ2" ,PM>,QY< <!.=V37J-U
MX.\/WD=NDVFQXMQB(QNR$=.I4@GH.3FD3P=H*7D=X;)I9XQA6GGDEP.>,,Q!
MZFH_M>AIH]$^S>O:5[K^NP_82_K_ ".4\%Z*DWB2XUS2DGT_2'C"0P2 %Y1A
M=V<EL+N7.<YKTBJ5B I8      5=KQ,3B)8B?-+T^7F^K\SHA%15@HHHKG*"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R?ZMOH:K
M67\?X59D_P!6WT-5K+^/\* +=%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3)O]2_T-/IDW^I?Z&@"&R^XWUJS5:R^XWUJS0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17'
M_'N],L_]2?\ >I]Q_P >[TRS_P!2?]Z@"Q1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $;[I^E5++[S_ $%6V^Z?I52R^\_T% %RBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J5K_ ,?#_0_SJ[5*U_X^'^A_G0!=HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THH/2@"G9???Z
M5<JG9???Z5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &R?ZMOH:K67\?X59D_U;?0U6LOX_PH MT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %,F_U+_0T^F3?ZE_H: (;
M+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!%<?\ 'N],L_\ 4G_>I]Q_Q[O3+/\ U)_WJ +%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117BWQ(^+7B;PIX
MZ7P_HNG:?=B2.(Q++!))*[OQM 5QG)P  ,T >TT5\_\ _"T_B_\ ]"%_Y1[O
M_P"+IK_'/QOH6Q_$O@M88W;"EH9K3=[ ONR>* /H*BL+PEXLTOQGH46JZ7(3
M&QVR1/C?"XZJP'0_S!!K=H **** "BBB@ HK@_BSXUU+P'X5M=4TN"TFGEO4
MMV6Z1F4*4=LC:RG.4'?UKH_">K3Z]X1TG5KI(TGO+6.:18@0H9ADX!)./QH
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MOZ-8:9;6$L5ZI:0W,;LP^8#C:P]?>O4Z "BBB@ HHHH **** "BBB@ HHHH
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MDW^I?Z&@"&R^XWUJS5:R^XWUJS0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 17'_'N],L_]2?\ >I]Q_P >[TRS_P!2?]Z@
M"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDUK[#]MV2I'Y/G>7G<<9W;3_ "KCM6^/.AZ7I6G2+837>JWMJEP;*WD!6 N
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MU><I"IVI&@!DE;LJ#(R?T'4X%>"_"EK"/X]ZHNB2#^S'%T(/+)"&+<"H'JO
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M;.=TBDHQ_%E)QVH Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $;[I^E5++[S_05;;[I^E5++[S_04 7****
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M\)[#[WYIJ6H0ZFNC6T&DII;P@1M<H #,3M&\X4=,9ZGK3AJ[K;FEMHOFNO\
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MU2;3M0MH=*0R_:8'4%WQ&"V#L/5<#J*BTS48=!US5XKO28]?;SF3S90"<JS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KYQ^(G_)R7A[_KZT_P#]&BOHZO%/&?@+Q-JWQNT?Q#9:;YNE6\]F\L_G
MQKM"2 N=I8,<#T% 'M=%%% !7S3>7GB'XR_$V^\/1ZK+I^BVAE)A4_*L2,$W
M%00'<DCJ>-QQP*^EJ\*\4?"KQ9HGC6X\4_#^\5)+@O(\#2JKJ[<NOS_(ZD\X
M;H?H#0!O:?\ L]^#+38;I]1OF&"PEG"*QXSP@! _'//6O.O"=MI.G?M,PV>C
M(D.G6\\\$2ARP!6V=2,DDGY@>]=>VF_&[Q/ ;#4;JST.UD.V6:)X_,*XSP8R
MQ'3'!!Y]*R]+^$6N>"_BGHVHZ-9S:EH]N4,US)-$C LI60[2P.!DL!@\8&2:
M .A_:._Y)YI__85C_P#14M=S\./^2;>'/^P?#_Z"*Y[XU^%M9\7>#;.PT.S^
MUW4>H),R>:D>$$<@)RY ZL/SKJO!6G76D>"-$TZ^B\J[MK..*6/<&VL% (R"
M0?PH \]_:._Y)YI__85C_P#14M8EK\(=,UCX(6<VEVRG7IH%U!;A@-\KE<^5
MGLI!P!TS@GO79_&OPMK/B[P;9V&AV?VNZCU!)F3S4CP@CD!.7('5A^==5X*T
MZZTCP1HFG7T7E7=M9QQ2Q[@VU@H!&02#^% 'G7P(\=MJ^CMX6U%F&H:9'^X+
M\%X 0 OU3@?3'H:?^T=_R3S3_P#L*Q_^BI:S?'OPV\36/Q'M?&'@6S26>1S/
M/$)4B"2CAB=S+N60$Y _VL]:Z3XO^'-?\:^ --MM+TESJ O8[B:T>>(&(>5(
M""Q;:<%@.": .G^''_)-O#G_ &#X?_017C_[-'_(0\1_]<H/YO7M/@K3KK2/
M!&B:=?1>5=VUG'%+'N#;6"@$9!(/X5YQ\#O OB3P?>:U)KVG?9%N8XA$?/CD
MW%2V?N,<=1UH ]EKYX_9H_Y"'B/_ *Y0?S>OH>O&O@=X%\2>#[S6I->T[[(M
MS'$(CY\<FXJ6S]QCCJ.M '37GB3P7XT\5S>!]2TUKR\@\PD7, "(R==C9W D
M<@CMWKG];_9W\+WR,VDW=YI<V20-WGQ@>FUOF_\ 'JD^)7PEO_$/B&+Q3X8O
MX[+64"F02.R"1D'R.K ':V !Z' Z<YR6?X^RQ?8C#91[@%-Z&MLCWQG\.%^G
MK0!D_!C4]8\/?$G4O!-U>F\LHA,A57S''+&0-RYY P"I ]1Z5#J#IX8_:EAO
M+\"*VN9PT;D\$30F,-[#>2#GT/:O0_AA\+F\%S76KZM>B^UN\7$D@R5C!PS
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M= =H3(R1G#,3C/3!Q0!:^)$]]XO_ &?-(UR>,_:(G@NKG&.3AHF; [$OG Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD,'&U0K%3SNZG I- GOM*\67X\*0+J($;(AF&<Q;E^;@KSD#\^E.UA9K'QI
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MY PY#\[N?\XK'3V/3EY?^W-_OO\ H5]KY_,SM.M-(OI-:FUZ[DL[Q"6ABC(
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M@G\&Z9;7VGQ0Z7&T?V>=0=SD(P7/S'J,GH.E9T=SX?'A66"2RG.ME\QW 8[
MNX<8W8^[D?=K3URV\11^"=+FO[ZWETEFC^SPHHWH=C;<G:.V1U-.7\2/-_,[
M<WI]FWZ^8+;3MT_4;J=GHVEZSH\GA6\DU"Y\\-LF((WAEV#@+U.?_K4_4WEU
M?QI /%Z#34:+$A@XVJ%8J>=W4X%17T^B7FMZ.GA*TFL;K[0!ON"2-Y9=AY9N
M <YX_.IM86:Q\:0'QFPU!!%F46OR[E*MM QLZ-@UE&^E[\W++?X]^G3^D-_K
M\AN@3WVE>++\>%(%U$"-D0S#.8MR_-P5YR!^?2LO1[/1KG3]5EU2\DM[J&+=
M9QH0!*^&X/![A>XZUJ^&X[^]\67W_"(3)8*8F9/M(SB+<OR\AN<X_+K61I4^
MB0V.J)JMI-/=O%BR>,D"-\-RWS#C)7L>E:]96WM';XOGT_ID]OGZ%VUO=;7P
M'>VD5C$VCO,#+<D'<K;DX!W>H7MWJO?V.A1>&+*ZL[^6359' GMV(VH,-DCY
M1W"]SUJU:V^NM\/[V>&\@715F FMR!O9]R<@[<]=O?M5.^N?#[^'+.&SLIX]
M75P;B=F.QUPV0!N/?;V'2G#XWR_S:\OI]J_Z>0/;7MU_0V?$EWJ^IWFB1>*+
M..PLQ(562($$QDH'/);H,=OSJ-([?2/&EBW@Z0ZG((F91/SERKAAQMZ+S4WB
MB#6;.ZT-_%=U#?61<E8[< ,(P4WCA5Y(QW_*H+=K>^\:V(\%(VG2&)@ANOF
M?:Y8\E^"O'^<UST[>Q5K6Y9;?!UWZ_TRG\7W>HR.*TU;QAJ!\73-IKE"[B$X
MQ)\H"\AN,9-0Z#=ZO::?K\.CVD=S9RQ;;J5P28X\. 1R.Q8]#TJ4O9V7C#4!
MXRB?4'"[7-L=N9/EP>"G&W(_I3/#T&L3Z;X@DT6ZAM[)(<W4<H!9X\/@#*GG
M&[N.O6M)?PG?:T=_AW6W7^D);_?ZE"VL]&?PK>7<][(FKI,%@MP1M=,IDGCW
M;N.E7-0O=;D\#Z=:W-C$FDI-F"X .YV^?@_-[MV'2J-O/HB^&;N">TF;66E!
M@G!.Q4RN01NZ\/V/4?AH:C;ZZG@/39KF\@?1VFQ;P*!O5_GY)V^S=SUK6?Q+
MF_F^UZ?9M^OF);?+^KB:A::1I]UHLWAV[DO;QG#2Q2D$+("A4<!>I)'7M5W5
MY+C6/&-DOC*,:9&;<JQ@XP@WE3SNZMQ5"\GT:ZO-%C\-VLUG>B11+).25:0E
M=I&6;@'/;OTK0UU;FQ\861\;2+J,8M\L+7Y24^<*. G(;G_.*QUO&][VEO\
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MC\]K7\O(ZZ7-RKF"BBBN T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ;)_JV^AJM9?Q_A5F3_5M]#5:R_C_"@"W1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4R;_4O]#3Z9-_J7^AH ALO
MN-]:LU6LON-]:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $5Q_P >[TRS_P!2?]ZGW'_'N],L_P#4G_>H L4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+O/);H,5E'>-]7>6NS7I'[7],I_Y?U?H0ZK&WAOQI VHRGQ$(XMS+<<[P58
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M$>#H[Y=0D.LEL-:[QM WD=-N?NX/6IO$%_K=UX?T>#4K"."RAB46LJJ09%V
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M3@5V%>!CLP4U[.EU23>U_ELOD=-.E;5A1117CFX4444 %%%% !1110 4444
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M^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_P ]H_\
MOH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,'_/:
M/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\ /:/_
M +Z%'VF#_GM'_P!]"@"6BHOM,'_/:/\ [Z%'VF#_ )[1_P#?0H EHJ+[3!_S
MVC_[Z%'VF#_GM'_WT* ):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_ #VC
M_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\ WT* ):*B^TP?
M\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_P ]
MH_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,
M'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\
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MM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\ WT*
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M6BHOM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\
MWT* ):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H
M EHJ+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_
M -]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT
M* ):*B^TP?\ /:/_ +Z%'VF#_GM'_P!]"@"6BHOM,'_/:/\ [Z%'VF#_ )[1
M_P#?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\]H_^^A1]I@_Y[1_]
M]"@"6BHOM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">
MT?\ WT* ):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?
M_?0H EHJ+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\
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M%'VF#_GM'_WT* ):*B^TP?\ /:/_ +Z%'VF#_GM'_P!]"@"6BHOM,'_/:/\
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M!+147VF#_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\
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M^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_P ]H_\
MOH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,'_/:
M/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\ /:/_
M +Z%'VF#_GM'_P!]"@"6BHOM,'_/:/\ [Z%'VF#_ )[1_P#?0H EHJ+[3!_S
MVC_[Z%'VF#_GM'_WT* ):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_ #VC
M_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\ WT* ):*B^TP?
M\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_P ]
MH_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,
M'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\
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M%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147VF#_GM'_WT*/M,'_/:/\ [Z%
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M 2T5%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147VF#_GM'_WT*/M,'_/:/\
M[Z% $M%,26.0X21&/L<T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I&574JRA@>Q&:6B@"+[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH
MB^S0?\\8_P#OD4?9H/\ GC'_ -\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@
M"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\ /&/_ +Y%'V:#_GC'_P!\BI:*
M (OLT'_/&/\ [Y%'V:#_ )XQ_P#?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EH
MH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6
MB@"+[-!_SQC_ .^11]F@_P">,?\ WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI
M:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_P \8_\ OD4?9H/^>,?_ 'R*
MEHH B^S0?\\8_P#OD4?9H/\ GC'_ -\BI:* (OLT'_/&/_OD4?9H/^>,?_?(
MJ6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\ /&/_ +Y%'V:#_GC'_P!\
MBI:* (OLT'_/&/\ [Y%'V:#_ )XQ_P#?(J6B@"+[-!_SQC_[Y%'V:#_GC'_W
MR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_ #QC_P"^11]F@_YXQ_\
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M^^11]F@_YXQ_]\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_P \8_\
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M'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\
M/&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/&/\ [Y%'V:#_ )XQ_P#?(J6B@"+[
M-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_
M #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\ WR*EHH B
M^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!
M_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0?\\8_P#OD4?9H/\ GC'_ -\BI:*
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M* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\
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M]\BC[-!_SQC_ .^14M% $7V:#_GC'_WR*/LT'_/&/_OD5+10!%]F@_YXQ_\
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MR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_ #QC_P"^11]F@_YXQ_\
M?(J6B@"+[-!_SQC_ .^11]F@_P">,?\ WR*EHH B^S0?\\8_^^11]F@_YXQ_
M]\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"%[> 1L1#'T/\(JO9PQ-OW1(>
MG515R3_5M]#5:R_C_"@";[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0?\\8
M_P#OD4?9H/\ GC'_ -\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_SQ
MC_[Y%'V:#_GC'_WR*EHH B^S0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/
M&/\ [Y%'V:#_ )XQ_P#?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\
M\8_^^11]F@_YXQ_]\BI:* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_
MSQC_ .^11]F@_P">,?\ WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'
M_/&/_OD4?9H/^>,?_?(J6B@"+[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0
M?\\8_P#OD4?9H/\ GC'_ -\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-
M!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OL
MT'_/&/\ [Y%'V:#_ )XQ_P#?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^
MS0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+
M[-!_SQC_ .^11]F@_P">,?\ WR*EHH B^S0?\\8_^^13);>$0N1#&#C^Z*L4
MR;_4O]#0!5M((F1MT2'GNHJQ]F@_YXQ_]\BH[+[C?6K- $7V:#_GC'_WR*/L
MT'_/&/\ [Y%2T4 1?9H/^>,?_?(H^S0?\\8_^^14M% $7V:#_GC'_P!\BC[-
M!_SQC_[Y%2T4 1?9H/\ GC'_ -\BC[-!_P \8_\ OD5+10!%]F@_YXQ_]\BC
M[-!_SQC_ .^14M% $7V:#_GC'_WR*/LT'_/&/_OD5+10!%]F@_YXQ_\ ?(H^
MS0?\\8_^^14M% $7V:#_ )XQ_P#?(H^S0?\ /&/_ +Y%2T4 1?9H/^>,?_?(
MH^S0?\\8_P#OD5+10!%]F@_YXQ_]\BC[-!_SQC_[Y%2T4 1?9H/^>,?_ 'R*
M/LT'_/&/_OD5+10!%]F@_P">,?\ WR*/LT'_ #QC_P"^14M% $7V:#_GC'_W
MR*/LT'_/&/\ [Y%2T4 1?9H/^>,?_?(H^S0?\\8_^^14M% $7V:#_GC'_P!\
MBC[-!_SQC_[Y%2T4 1?9H/\ GC'_ -\BC[-!_P \8_\ OD5+10!%]F@_YXQ_
M]\BC[-!_SQC_ .^14M% $7V:#_GC'_WR*/LT'_/&/_OD5+10!%]F@_YXQ_\
M?(H^S0?\\8_^^14M% $7V:#_ )XQ_P#?(H^S0?\ /&/_ +Y%2T4 1?9H/^>,
M?_?(H^S0?\\8_P#OD5+10!%]F@_YXQ_]\BC[-!_SQC_[Y%2T4 5I[>$0,1#&
M#ZA13+6"%HB6B0G/=14]Q_Q[O3+/_4G_ 'J '_9H/^>,?_?(H^S0?\\8_P#O
MD5+10!%]F@_YXQ_]\BC[-!_SQC_[Y%2T4 1?9H/^>,?_ 'R*/LT'_/&/_OD5
M+10!%]F@_P">,?\ WR*/LT'_ #QC_P"^14M% $7V:#_GC'_WR*/LT'_/&/\
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M\*P/!WQ\US6?&&EZ9K%GI4-C=SB!Y((I%=68$)@ER!\Q7.1TSTZT ?0=%%%
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MGKGM0!ZA15;3KA[O3+2YD"AYH4D8+T!*@G%6: "BBB@ HHHH **** "BBB@
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M/8_^%LZ#_P ^FI?]^T_^+H_X6SH/_/IJ7_?M/_BZ\<HH_L/"=G]X?6)GL?\
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ME:M*=*;A-6:.Q--704445F,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"@]**#TH IV7WW^E7*IV7WW^E7* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!LG^K;Z&JUE_'^%69/]6WT-5K+^/\* +=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)O\
M4O\ 0T^F3?ZE_H: (;+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!%<?\>[TRS_U)_WJ?<?\>[TRS_U)
M_P!Z@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(5\1::(@NT(&^4#IC&.E>(OK&@^&/CQIVH^$;F"32;UXTGCMB%B02ML=0,8
M'#X]<=!0!]/T444 ?/OQ[UZ]U?Q+I7@?37W>88WEC4D;YI&VQH?8#!_X$/3C
MUSP3X'TGP1HD5E80JUQMS<73 >9,QQG)[#C@=!CUR:\0E7[1^U4!=8XOE(R?
M[L(V=?HM?2M !7BOQ)^$>H:EXKTW7_!<-M9WF_S+IMXB1)58,DH&/O$YSCN
M<9)-:_Q#^,O_  @7B5-'_L'[=NMUG\W[9Y7WBPQC8W]WKGO7)?\ #37_ %*/
M_E2_^U4 >^Q>9Y*><%$NT;PARN>^,]JXKXN>(QX;^'&J2I*$NKI/LEN ^UBS
M\$COD+N;CTKI/#FL?\)!X:TW6/(^S_;;=)_*W[]FX9QG S]<"O"_C=>R^+/B
M+H7@VPEW>65638=P665@#N4?W4 //9CTH S[3P#++^SC=:C)!_IOVHZK%\GS
M>2H"$9]-F]_R^M>J_!;Q.WB3X=VBSNINM./V*3GDJH&PD?[I SW(-=Q'IEG'
MHZZ2L"_85MQ;"+H/+V[=O';'%?.WPKN9OAY\8=1\)Z@[".[/V4,,X+CYXG/U
M4D#C^,=J /I2OG']FK_D/Z[_ ->L?_H1KZ.KXX^&O_">?;[[_A!/^/GRE^T_
MZC[F>/\ 6\=?2@#['KYQ_:'AMX/&6A3Z>JKJTD)9_*7]XV' B) Y)R& _P!W
M':KS#]H9E*G.",<&P!KD/#VHGPK\2H]4^)VF:I+?$K+#<W+%A$1G$FS!\P X
M VG"X/!(& #ZLB+F%#* LA4;@.@/>N*^+GB,>&_AQJDJ2A+JZ3[);@/M8L_!
M([Y"[FX]*[2">*YMX[B"19(94#HZG(92,@C\*^>_C=>R^+/B+H7@VPEW>656
M38=P665@#N4?W4 //9CTH S[3P#++^SC=:C)!_IOVHZK%\GS>2H"$9]-F]_R
M^M>J_!;Q.WB3X=VBSNINM./V*3GDJH&PD?[I SW(-=Q'IEG'HZZ2L"_85MQ;
M"+H/+V[=O';'%?.WPKN9OAY\8=1\)Z@[".[/V4,,X+CYXG/U4D#C^,=J /I2
MBBB@#S'X^?\ )+KC_KZA_P#0JG^!7_))]-_ZZS_^C&J#X^?\DNN/^OJ'_P!"
MKRKP+X#^(NN^$[:_\/>+/[/TV1W$=O\ VC<1;2&(;Y44J,D$T ?4=?/_ .TU
M_P RM_V]_P#M&C_A5GQ?_P"A]_\ *Q=__$5P'Q-\*^,/#/\ 9?\ PE>O?VK]
MH\W[-_IDT_E;=F[_ %@&,[EZ=<>U 'T;KWB>?P=\-K;7(=,_M!;>"#S8O/\
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ML****U$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!;TS4[O2+^*]LI3'-&>".A'<$=P:]U\*^*K3Q-8>9'B.[C
M\Z GE3ZCU!KY_JWIFIW>D7\5[92F.:,\$=".X([@UYN8Y=#%PNM)+9_HS6E5
M<'Y'TI165X<UAM=T.WU![9[=I!RC#@D=U]0>U:M?$3A*$G"6Z.].ZN@HHHJ1
MA1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 4[+[[_2KE4[+[[_ $JY
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZG9R6=_:>,KNUDQOAGCNI$;!!&5/!P0#^%?85M;Q6EK#;6Z".&%!'&@Z*H&
M/RJ6@#XK^'VNOX2^(>EWTY:&.*X\BZ5SLVHWR/NSZ9S@]U[5]4?$G0IO%'PZ
MU?3;-1)<20B6 +R79&#@#W.W'XU\^_%+X=:[;_$/5)M'T+4;RQNW^U1R6EK)
M*H+\N"0" =V[CT(KZ#^&MWJ5U\/])&KV5W:7\$7V>6.ZC9'.P[0Q# $Y4 Y]
MS0!\O?"OQ3%X1\?V.H74IBL9 UO=-S@1L.IQV#!6_"OL.6*UU737B8I/9W<)
M4E'^62-AV(/0@]17A7Q3^"-U=W\VN^$X$D:9B]QIZD*0W4M'DX.3DE>/;/2O
M-+/Q=\0O *G3DO=3TU(_E%M=P[E3//RK(I SUX]Z />]:^#WP[T_0[^\.B)#
MY%O)()'OIP%(4D$YDQ^=?-W@3_DH?AK_ +"MK_Z-6M"\U+Q]\0YHTF?5M65V
MPL<43>2"#UVJ @QGDXXKTKX:? W5K36['7O$KK9"SF2>&SC</([J<J7(RJC(
M!P"2>0<4 >B_&W_DD.N_]N__ *41UXC\ /\ DI\7_7I-_(5[M\7["\U/X6ZS
M9V%I/=W4GD;(8(S([8GC)PHY. "?PKYBT_POX_TFZ%UINA>);.X *B6VM)XW
MP>HRH!Q0!]JT5\@?\7?_ .IY_P#)NC_B[_\ U//_ )-T ?47C/1;GQ%X-U71
M[1XDN+N QQM,2$!/J0"<?A7S[_PSCXP_Z"6A_P#?^;_XU7OG@'^T?^$#T;^U
M_M7]H?9AY_VO=YN[G[V[G/UKHZ /)?AE\+-7\'Z3XFL=7NK"4:M!'#&;61V"
MX60'=N5?[XZ>]?/?A<Q:+\0=(_M=%BCL]3B%R)#Q'MD&XG'88)_"OMZO"/BQ
M\%KS5M5G\0^%XXY)[@[[JQ+!"S]W0G R>202.<D9)Q0![?>2VJZ;<373)]C$
M+-*QY7R\9)X[8S7Q;\.XI9OB/X;6$D,-2@8XS]T."W3V!K2_X1CXF3VW]BMI
MGB4V:':+9UF$ QQQGY,?3M[5[+\(?A#<^$[S^W]?\HZF8RMO;H=WV;.0Q+ X
M+$<<9 !/)S0!QO[24UTWBW1X'W?8TL2\7IYC2,'_ $6/]*]+^ [6A^%5B+;9
MYHGG%SM;)\S><9]#LV?ABM#XG_#J'X@:)%'%,EOJ=H6:UF<?*<XRCX&=IP.1
MT(SST/@]AX>^+'PYNYQI&GZE%YQVN;.%;N.3&<': P^A(!YH VOVD%M/^$PT
MIHMGVLV.)L'G;O.S(_%O\XKTWX'320_"*QEN RPQR7#(<$Y02,20![[NE>.Z
M1\+?'GCS7_MOB".[M$=E^T7FH K)MQT5#R2 ,8X ]J^GM%TBST#1;/2;!"EK
M:1"*,'J0.Y]23DD^IH \RD^('PT^(VM66@7NFR7LUPS1037-L$"$J3@/N#KD
M@#COCZU9\7>&/!WPX\!:WJ>EZ1;6MW):/:P2L[/)OE!0;2Y8_P 1) Z@'L*\
MT^(GP5UO2=<N-2\+V4E[I<K-,L5OCS+8YSL"]6 _AV@GL>>3S:>"?B7XMN8(
M+W3]<FV_(CZHTB)&![RG@#/;\,T 7/@5I$FI_%"RN @:&PBDN9<]!\I1?QW.
MI_"OK:N&^&7PXMOA_HTD;R)<ZI<MNN;E5P,#HBY_A'7U))/H!W- !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\>#SR>M &-'J%OJ?[5@N+5]\0NO)W?[4=ML;_P >4UZ5\=?^23ZE_P!=8/\
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M]C0S+\R<<CL2.>W2OJ^N6^(OA8>,? ^H:4BYNBGFVIR!^^7E1D\ '[I/HQH
MT?"NO0>)_"VFZU;E2MW '8*" K]'7GT8,/PK8KR[X*:%XK\+Z+?:-XBTO[+;
MK*)[23SXY,EAAU.QCC& 1QW;GI7J- 'F/Q\_Y)=<?]?4/_H53_ K_DD^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3)O]2_T-/IDW^I?Z&@"&R^XWUJS5:R^XWUJS0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17'
M_'N],L_]2?\ >I]Q_P >[TRS_P!2?]Z@"Q1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% "-]T_2JEE]Y_H*MM]T_2JEE]Y_H* +E%%%
M!1110 4444 %%%% '@OB#P_K4WB35)8M(OY(WO)61TMG(8%S@@XY%9W_  C6
MO?\ 0$U+_P !7_PKZ+HKWX9_4C%1Y%H<SPR;O<^=/^$:U[_H":E_X"O_ (4?
M\(UKW_0$U+_P%?\ PKZ+HJO]8:O\B#ZLNY\Z?\(UKW_0$U+_ ,!7_P */^$:
MU[_H":E_X"O_ (5]%T4?ZPU?Y$'U9=SYT_X1K7O^@)J7_@*_^%'_  C6O?\
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MO^@)J7_@*_\ A1_PC6O?] 34O_ 5_P#"OHNBC_6&K_(@^K+N?.G_  C6O?\
M0$U+_P !7_PH_P"$:U[_ * FI?\ @*_^%?1=%'^L-7^1!]67<^=/^$:U[_H"
M:E_X"O\ X4?\(UKW_0$U+_P%?_"OHNBC_6&K_(@^K+N?.G_"-:]_T!-2_P#
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M"O\ X5]%T4?ZPU?Y$'U9=SYT_P"$:U[_ * FI?\ @*_^%'_"-:]_T!-2_P#
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MK+^/\*LR?ZMOH:K67\?X4 6Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "F3?ZE_H:?3)O]2_T- $-E]QOK5FJUE]QOK5F@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN/^
M/=Z99_ZD_P"]3[C_ (]WIEG_ *D_[U %BBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 1ONGZ54LOO/\ 05;;[I^E5++[S_04 7**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I
M6O\ Q\/]#_.KM4K7_CX?Z'^= %VBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ H/2B@]* *=E]]_I5RJ=E]]_I5R@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JV^AJM9?
MQ_A5F3_5M]#5:R_C_"@"W1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4R;_4O]#3Z9-_J7^AH ALON-]:LU6LON-]:LT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5Q_P >
M[TRS_P!2?]ZGW'_'N],L_P#4G_>H L4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %3>W]X_G1O;^\?SIM% #M[?WC^=&
M]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q
M_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT
M4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .W
MM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/
MYT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V
M_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\
MZ;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10
M [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W
M]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G
M1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^
M\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SI
MM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #
MM[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?W
MC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&
M]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q
M_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT
M4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .W
MM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/
MYT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V
M_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\
MZ;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10
M [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W
M]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G
M1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^
M\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SI
MM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #
MM[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?W
MC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&
M]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q
M_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT
M4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .W
MM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/
MYT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V
M_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\
MZ;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10
M [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W
M]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G
M1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^
M\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SI
MM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 I=L'YC^=10D@G!(^E2'
MI4474T 3[V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3
M:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* '
M;V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O
M'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-
M[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC
M^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-H
MH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O
M;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?
MSHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\ZAB)$A()!Q4E11_?- $^]O
M[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.
MC>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]
MX_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3
M:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* '
M;V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O
M'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-
M[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z3>W]X
M_G244 1PD@G!(^E3;V_O'\Z@BZFI: ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_
M>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YT
MVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!
MV]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[
MQ_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C
M>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X
M_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G3:
M* ';V_O'\Z-[?WC^=-HH 5G;:?F/3UJ*%B-V"1]*>?NGZ4R+O0!-O;^\?SHW
MM_>/YTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/
MYTVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB
M@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]
MO[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_
M.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W
M]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G
M3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!V]O[Q_.FN[%#ECT]:*
M1ON'Z4 -A8A3@D<]JEWM_>/YU#%T-24 .WM_>/YT;V_O'\Z;10 [>W]X_G1O
M;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?
MSIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM%
M #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[
M?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^
M=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O
M[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.
MFT4 .WM_>/YT;V_O'\Z;10 DC,8R"Q/XTD+,$X)'/K0_W#21?<_&@"7>W]X_
MG1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;
M^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?S
MIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM%
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M_(1MO^NB_P ZSH48U(R;Z&>'H1J0E)]#M:@N;R"S53/)L#<#@G^53UA^)/\
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MY3G]Y$ /JO:BK0BH*I#8*V'BJ:J4W=&E)(D4;2.VU5&23VJFNL6#NJ+.2S'
M 1N3^59WB"]Z6:-_M28_0?UI- L,DWDB\#B//ZFB-"*I>TF$</!4?:5/D=!1
M117*<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 'I4474U*>E11=30!+1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44?WS4M11_?-
M$M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!%%U-2U%%U-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "'[I^E,B[T\_=/TID7>@"2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ I&^X?I2TC?</TH 9%T-25'%T-24
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC;6<4)@CV%B0?F)_G3HRH.:Y8N_]>8Z$\,ZB4(M/^O,F\-?\O7_ /ZT>)?\
MEU_X'_2CPU_R]?\  /ZT>)?^77_@?]*/^8O^NP?\QO\ 78E\-_\ 'K-_O_TJ
M[JUS]ET^1A]YOD7ZG_ZV:I>&_P#CUF_W_P"E5O$=QNGBMP>$&X_4_P"?UJ'#
MGQ-C-T^?%M%?0K?SM1#D?+$-WX]!_GVJ3Q!;"&]691A91D_[PZ_TJ'3=473H
MW7[/YC.<EM^./3I]:=J.KKJ$"QFWV%6W!M^?Z5T.-3V_-;38ZG&K]8Y[>[L;
M&AW(GT]4)R\7RGGMV_S[5IURV@7'E7_ED_+*N.O<<C^OYUU-<.)AR5'YGGXN
MGR57YZD-Y_QY7'_7-OY5R6F?\A.W_P!\5UMY_P >5Q_US;^5<EIG_(3M_P#?
M%=&%_AS.C!_PI_UT.SK+\0?\@S_@8K4K+\0?\@S_ (&*Y:'\2)R8?^+'U,32
M;Z*PN'DE5R&3:-H'J*USXCM,<13Y^@_QK(TFQBO[AXY6<!4W#:1ZBI=3T@V*
M"6-R\1.#D<@UWU(49U+2W/2JPH3J\L]RMJ%Z;^Z\W9M &U5SGBNFTFV:UT^-
M'!#G+,#VS6-H=Q:I.(Y8E$I.$D]_2NFK#%3LE32LD<V,GRI4DK)%>^M%O;1X
M6X)Y4^A[5R5O/-IU[N (="593W]J[6N9\1(JWL;@8+)S[TL).[=-[,,%.[=*
M6S*5K!)J5^%))+G<[>@[FNQC18HU1%"JHP .U9/AV-!922!1O9R"?8 5L5.*
MJ<T^7HB,95<I\BV04445RG&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 !Z5%%U-2GI4474T 2T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5%']\U+44?WS0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 11=34M11=34M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 A^Z?I3(N]//W3]*9%WH DHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1ON'Z4M(W
MW#]* &1=#4E1Q=#4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 U_N&DB^Y^-*_W#21?<_&@!]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!2U;_D%W'^[_ %K"T#_D)_\  #73S1)/$T4B[D;@C.*@M]-M
M+67S(8MKXQG<3_,UTTZT8TI0>[.JE7C"C*#W9+<VZ75N\,@^5AU]#ZUQ4\+V
M\[PR##*<&NZJK<:=:7<@DFAW,!C.XC^5&'K^RNGL/"XGV+:EL4O#G_(/D_ZZ
MG^0K/\1_\A"/_KD/YFNAMK6&TC,<";%)W$9)Y_&H[G3K6[D$D\6]@-H.XCC\
M#3C7BJSJ=!PQ$8UW4>Q@:?K/V&V\G[/O^8G._']*M?\ "2_].G_D3_ZU:']B
MZ?\ \^__ (^W^-']BZ?_ ,^__C[?XU<JN'D[N+_KYFDJV%D^9Q=_Z\RI;:_]
MIN8X?LVW>V,^9G'Z5>U2V-WI\D:#+CYE^HI(M)L895DC@PZG(.]N/UJ[6$YP
M4E*FK6.>I4IJ:E25K'%V5Y)I]UY@7/\ "ZGN/2MH^)+?R\B"0OZ'&/S_ /K5
M=NM*M+MM\D>U^[(<$_6JO_".V>?]9/\ ]]#_  KHE5H5/>FM3IE6P]7WIIW.
M?E>:_O"^W=+(W 7^5=E;PBWMHX1_ H%16NGVUGS#& W=CR:M5E7K*I:,5HC#
M$XA5+1BK)'&:G_R$[C_?-=;9_P#'E;_]<U_E4$NDV,TK2209=CDG>W/ZU;1%
MC144850 ![45JT9PC%=!UZ\:D(Q70R==L//A^TQK^\C'S8[K_P#6K)TB^^Q7
M8#']U)\K9[>AKKB 1@C(J@=%T\DDVXY]'8?UJJ6(BJ;ISV*I8F*ING45T6[B
M%;BWDA?[KKCZ5QTL-QIMX ?ED0Y5AT/N*[.-%CC5%SM48&3FF3VT-S'LFC5U
M]^U10K^S;3U3(P^(]DVGJF9$'B./8//A<-W,>"#^=4-2UB2]7RHU,<7<9Y;Z
MUJMX>LV.0TR^P8?U%2P:)90,&\LR$=/,.?TZ5LJF'B^9+4VC5PL'SQ3N4-!T
M]@_VR0$ #$8]<]ZN>(/^09_P,5J5%<6T5U%Y<R;DSG&2/Y5@ZW-54Y&#Q#E6
M521SOAS_ )"$G_7(_P Q73U5MM.M;20R01;&(VD[B>/Q-6J5>HJD^9$XFJJL
M^:(54U.U-Y8R1* 7^\N3W%6Z*RC)Q::,HR<9*2Z'%V5Y)I]UYBKG^%D/&1Z>
MU;?_  D=MLSY,N_TXQ^>:O76F6MX2TL?SD8WJ<&J?_".V>?]9/\ ]]#_  KM
ME5H5-9K4[Y5L/5]Z:=S!NKB74+PR%/G?"JJ\_A76V-N;6RBA/55Y^IY--M=.
MM;,[HH@'_O$Y-6JRKUU-*,5HC'$8A5$H05D@KD]>_P"0H_\ NK_*NLJI/IEG
M<RF6:'<YXSN(_D:G#U53GS,C#58TI\TAFC_\@F#Z'^9J]4<,,=O$L42[47H,
MYJ2LIOFDVC*I)2FY+J8VMZ:URHN(%W2KPRCJP_QK)L=4N+ &-0&3/*-V^GI7
M7U6GL+6Y.98$8^N,'\Q713Q"4>2HKHZ:6)2A[.HKHP;O7YKB(QQ1B$,,$ALG
M\ZCT?3WN;E)G4^0AR2?XCZ>];J:/8(V1;*3_ +1)_F:N@!0   !P *J6(A&/
M+25BI8J$8.-&-KD=S_QZS?[C?RKC]._Y"-M_UT7^==HRAT*L,@C!%4X](L8I
M%D2##J<@[VX/YU%"M&G&2?4C#UXTX2B^I=K#\2?ZFW_WC6Y4%S9P7BJ)X]X7
MD<D?RK*C-0FI,QH5%3J*3Z&/X:_Y>O\ @']:/$O_ "Z_\#_I6O;65O9[O(CV
M;\;OF)SCZ_6BYLK>\V^?'OV9V_,1C/T^E;>WC[?VG3_@&_UB/UCVO3_@6,SP
MZP6SG9C@!\D_A6'*[WEZS ?-*_ ^IX%==%86T,$D,<>V.3[PW'G]:CBTFRAE
M62.##J<@[B<?K5QQ,(SE.VYI#%4XSE.SN]ABZ)8!0#!D@<G>W/ZTO]BZ?_S[
M_P#C[?XU?HKF]M4_F?WG)[>K_,_O.'=9+.\(!P\3\'W!KM()EGMXY5Z.H;KT
MJ"?2[.YF:66'<[=3N(_D:GAACMX5BB7:B]!DG^=:UZT:L5W-L17A6BM-4-O/
M^/*X_P"N;?RKDM,_Y"=O_OBNQ=%D1D895@01[54BTFQAE62.##J<@[VX_6BC
M6C"$HOJ%"O&G"47U+M9?B#_D&?\  Q6I45Q;1747ES)N3.<9(_E6-.2C-29A
M2FH34GT.?\.?\?LO_7/^HKHY(TEC:-UW*PP0>]06VGVMHY>"+8Q&"=Q/'XFK
M-77J*<^:)>(JJI4YXG%7UH]C=-$V<=4;U'8UTVDWWVVT&X_O8_E?W]#^-3W-
ME;WFWSX@^WH<D']*;;Z?:VDA>",HQ&#\Q/\ ,UK4KQJ4TI+4VJXB%6FE)>\B
MU7-^)/\ CZA_W/ZUTE5KFPMKMU:>+>5& =Q'\C65"HJ<^9F.'JJG44F4O#W_
M "#F_P"NA_D*UJBM[:&TC\N!-J9SC)//XU+459*<W)$59J<W)=0HHHJ#,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ
M*+J:E/2HHNIH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*/[YJ6HH_OF@"6BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BBZFI
M:BBZFI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!#]T_2F1=Z>?NGZ4R+O0!)1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4C?</TI:1ON'Z4 ,BZ&I*CBZ&I* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_ '#21?<_
M&E?[AI(ON?C0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ*+J:E/2HHNIH
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ J*/[YJ6HH_OF@"6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BBZFI:BBZFI: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#]T_2F1
M=Z>?NGZ4R+O0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/(7U-2T4 1>0OJ:/(7U-2T4 5IH56%B">*;;1*\623UJ:X_X]WIEG_J3_O4
M/\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH
MB\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH
MB\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH
MB\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH
MB\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH
MB\A?4T>0OJ:EHH B\A?4T>0OJ:EHH B\A?4T>0OJ:EHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME=O0;?[U 'H-%>)ZI^T9IT5S(NB^';S4;>(G?/++Y P.A "L<'!/.#[>G8^
MOBMH7CR1[2W26SU)$WM:SX.Y1U*,.& R/0^V.: .[HIDLL<$+S32)'%&I9W=
M@%51R22>@KQW5?V@]/CU22R\/:!=ZUL)'FK(8@X'4J-K,1]0* /9:*\>C_:#
MT.3P[J%Y_9TT.K6FTKIT\NSSP7"G;(%/(!R01G@]@2.F@^(LUU\)U\;V^A23
M2MG;IT<Y9C^_\KAPG_ ON^WO0!<M_B)I-]\0&\'V22SWD*.UQ-C;'&5ZH,\L
M?7M[GI77U\BZ#XZO=*^+&H^)T\.W%Q<W+3,VG+(0\>_GD[">/]T5]0>'-?;6
MO"EKKE]9G2_-B:66&=_]2 3RS$+Q@9R0* -JBO'=9_:#TB#438^'M&O-;D#8
MWJWE*X R2GRLQQ[J._XR^'_C_H=_J*Z?KVFW.ASL^S?*WF1(?]LX5E[?PX&>
M2!S0!Z[12*P90RD%2,@CH:\JTWXY:3*-?DU>P.GPZ3((DV7 EDNF+, J+M7G
MY,]<>I &: /5J*\+D_:1MTN Z^%+HZ>S86X:Z"L?^ [",YSQN[5ZMX2\8Z/X
MUT?^TM'F=D5MDL4J[9(FZX8<_F"1[T <-\6_B7KW@/4-/ATBRL9X9X6DE>YB
M=MI#8'*LN/QKU>N'\?>&M7\876DZ*B6\>@"=;G49V?,CA#Q$JX[_ -[_  PW
M97=W;V-I-=W<T<%O"A>261MJHHY))H FHKQ>]_:&L9+U[?P]X:U#5MA.6+^5
ME0<;@ KG'3J!U[=*U?"WQRT37-7CTG5+"YT:_E=8T28[T,A.-N0 1VY( Y[4
M >IT444 >7_&#XCZQ\/_ .QO[)MK&;[=Y_F?:T=L;/+QC:R_WSUSVKCD^*_Q
M<EC62/P*KHP#*RZ1=D$'H0=]+^TU_P RM_V]_P#M&O<=$_Y &G?]>L7_ *"*
M /"Y/CAX[T3;)XB\%I!"2.6MY[7(ST!?=[UZSX&\?:1X]THW>G,T5Q%@7-I*
M1YD1/TZJ><-W]CD#IIX(;F!X+B))87&UXY%#*P]"#UKYDUFU7X0_'"TN+$M!
MI%PR2;0<@6\AVR)SUVD,1GT7ZT ?07C/6KGP[X-U76+1(GN+2 R1K,"4)'J
M0<?C6-\+/&&H>./"+:MJ<-K%<"Z>';;*RKM 4CAF)SR>];_BG7/^$:\+ZCK7
MV?[3]CA,OD[]F_';=@X_*LOX>>-/^$\\--K']G_8<7#P^5YWF_= .<[5]?2@
M#JZ*\[\<_&+0/!-__9K13:AJ(7<\-N5"Q>@=B>">N "<=<9&>8B_:$^SS)_;
M?@[4-.MW8*)1*7^O#(N<#GK0![716=H>N:=XDT>#5=*N!<6<X.QPI7H<$$'D
M$$&L7QK\1-!\"6T;ZI-))<RC,-I  TKC.,\D #W)'0XR>* .KHKPY?VBF"?:
MI/!EXNG%B$N1<Y##./\ GF!GKQNZ\5ZEX1\9Z-XVTG^T-'G9E4[989!MDA;T
M89/Y@D'L>* -^BLW7=>TWPUI$VJ:M=+;VD.-SD$DDG   Y)/H*\DD_:&2ZG<
M:'X.U'4(4^\S3;&7/3(17QG![]J /;:*\D\,?'W0M;U2+3=4L)](GE<(LDL@
M>)6]&;@KSQG&/7%>M,P52S$!0,DGH* %HKR#6_C_ *1::I)IV@Z/=ZW,CE \
M;A(Y,=2A 8L!SSMYQZ<TFC_'_29M02R\0Z->:&[#[\A,JKZ9^4-@\\XH ]@H
MI%8,H92"I&01T->;^-OC3X=\'WLNFQQRZGJ461)# 0J1M_==ST/T#8P<XZ4
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M[1M[IWC:3[5Y7EN "!C8V<C=_P!\FNOTK4H-8TBSU.U;=!=P)/&?]E@"/YT
M7**Y;X@>-(/ ?A=M8EM3=N9DAB@\SR][-D_>P<84,>AZ?C5_PGK=QXD\+V&L
MW-A]@:\C\U;?S?,VH?NG=M7J,'IWH VJ*\H\4?'G0=%U%]-T>RGUN\5Q&?(<
M)$7SC:'P2Q^BD'C!]*>E?M!:9)J4=EXAT*]T4OC]XS>8J9/!8;58#W /T[T
M>QT4R*6.>%)H9$DBD4,CHP*LIY!!'44^@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!&^Z?I52R^\_P!!5MONGZ54LOO/]!0!<HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ JE:_P#'P_T/\ZNU2M?^/A_H?YT 7:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@]**#TH IV7WW^E7*
MIV7WW^E7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!LG^K;Z&JUE_'^%69/]6WT-5K+^/\* +=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3)O]2_T-/IDW^I?Z&@"&R^X
MWUJS5:R^XWUJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 17'_ ![O3+/_ %)_WJ?<?\>[TRS_ -2?]Z@"Q1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\N_&BWN;OXTVUM93>
M3=3):QPR[BNQR<*V1R,'!R.:^HJ^:?BE_P G!:/_ -=;+_T,4 :W_"K/B_\
M]#[_ .5B[_\ B*/^%6?%_P#Z'W_RL7?_ ,17T!10!\P_!ZUO+'XXWUGJ-Q]H
MOH!=Q7$V\OYDBMAFW'DY()R>378?M*?\BWHG_7V__H%<_P##O_DY+Q#_ -?6
MH?\ HTUT/[2:,?"^BN!\HO6!/N4./Y&@#U;PI_R)^B?]>$'_ *+6O*/VE/\
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M_H)H X;]G'_DGFH?]A63_P!%15S7[0G_ "./AC_KF?\ T8*Z7]G'_DGFH?\
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MVYLX7=([DSLYW,H8J!N=N@8GC^\/P]$H **** "BBB@ HHHH **** "BBB@
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M[&Q16/\ \))9_P#/.?\ [Y'^-'_"26?_ #SG_P"^1_C1[&IV#V%3L;%%8_\
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M_P#/.?\ [Y'^-'_"26?_ #SG_P"^1_C1[&IV#V%3L;%%8_\ PDEG_P \Y_\
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M_P"><_\ WR/\:/8U.P>PJ=C8HK'_ .$DL_\ GG/_ -\C_&C_ (22S_YYS_\
M?(_QH]C4[!["IV-BBL?_ (22S_YYS_\ ?(_QH_X22S_YYS_]\C_&CV-3L'L*
MG8V**Q_^$DL_^><__?(_QH_X22S_ .><_P#WR/\ &CV-3L'L*G8V**Q_^$DL
M_P#GG/\ ]\C_ !H_X22S_P"><_\ WR/\:/8U.P>PJ=C8HK'_ .$DL_\ GG/_
M -\C_&C_ (22S_YYS_\ ?(_QH]C4[!["IV-BBL?_ (22S_YYS_\ ?(_QH_X2
M2S_YYS_]\C_&CV-3L'L*G8V**Q_^$DL_^><__?(_QH_X22S_ .><_P#WR/\
M&CV-3L'L*G8V**Q_^$DL_P#GG/\ ]\C_ !H_X22S_P"><_\ WR/\:/8U.P>P
MJ=C8HK'_ .$DL_\ GG/_ -\C_&C_ (22S_YYS_\ ?(_QH]C4[!["IV-BBL?_
M (22S_YYS_\ ?(_QH_X22S_YYS_]\C_&CV-3L'L*G8V**Q_^$DL_^><__?(_
MQH_X22S_ .><_P#WR/\ &CV-3L'L*G8V**Q_^$DL_P#GG/\ ]\C_ !H_X22S
M_P"><_\ WR/\:/8U.P>PJ=C8HK'_ .$DL_\ GG/_ -\C_&C_ (22S_YYS_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3?ZE_H:?3)O]2_T-
M $-E]QOK5FJUE]QOK5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH BN/^/=Z99_ZD_[U/N/^/=Z99_ZD_[U %BBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW*48D ,#GJ1G/48YW/AC_P + 6#44\>*=RF+[&Y: DC#;Q^Z^B\MZ_6N^HH
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M&5AR<#[P//YD@&/\0O"'BZ?PI=^+/'>J*U["8XK&Q@*E(M[C<&VC:,#/0DG
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MPM=4T^XL+Z!)[6X0QRQ/T93U%6:* /!'^&/C_P  ZS<W/@#4DN-/N"3]GE=
MPQG =7^5B,X# @^PINI>#_B]\01'8>);FUTK3 P+QJZ%6QSN*QDECTP"0..W
M6O?:* ,7PKX7T[P?H$&CZ8C""+YF=SEI'/5F/J?_ *PK:HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ54LOO/]!5MONGZ54LO
MO/\ 04 7**** "BBB@ HHHH **** .'O_P#D(W/_ %U?^9JO5B__ .0C<_\
M75_YFJ]>Q'X4>W#X4%%%%44%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !T.173:/K'GA;:Y;][T5S_%['WKF:.AR*SJ4U45F9U:4
M:D;,] HK%T?6//"VURW[WHKG^+V/O6U7F3@X.S/)J4Y0E9A1114$!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_5M]#5:R_C_"
MK,G^K;Z&JUE_'^% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IDW^I?Z&GTR;_ %+_ $- $-E]QOK5FJUE]QOK5F@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN/^/=Z
M99_ZD_[U/N/^/=Z99_ZD_P"]0!8HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *R=0\4>'M)NC:ZEKNF6=P &,5S=QQO@]#AB#BM:O
MF7XM:;#K/QYTW2[AI%@O6L[>1HR P5WVDC((S@^AH ]Z_P"$[\'_ /0UZ'_X
M,8?_ (JM'3]=TC5@#INJV-X#G'V:X23..OW2:\N_X9Q\'_\ 02US_O\ P_\
MQJN?\2_L\OIUH=0\):O=27MN?,2WN"H=B#D;)%QM88XR.3W% 'T!17D?P7^)
M=SXI@F\/ZVQ;5[*+>DS9W3Q@A3N_VU)&?7.>Q->N4 %%%% !1110 445R?Q-
MU*[TCX;ZY>V,IBN4M]J2#JNY@I(]\$T :EUXL\.6-X;2[\0:5;W(.TPRWD:.
M#TQM)S6LCI+&LD;*Z, RLIR"#T(-?-GPO^#NC^-O"K:YK&H:@LLMPZ(EJZ+@
M+U+%E;))SZ5]&V-G%I^GVUE!N\FWB6)-QR=J@ 9_ 4 6**** "BBB@ HHHH
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MO_\ D(W/_75_YFJ]6+__ )"-S_UU?^9JO7L1^%'MP^%!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '0Y%=9HE[/=V
MQ$R$[.!)_>_^O6)I>EO?R;FRL"GYF]?85UL<:0QK'&H5%& !7%BIQMR]3AQ=
M2-N7J.HHHKB. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &R?ZMOH:K67\?X59D_U;?0U6LOX_PH MT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %,F_U+_0T^F3?ZE_H: (;+[C?
M6K-5K+[C?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!%<?\ 'N],L_\ 4G_>I]Q_Q[O3+/\ U)_WJ +%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SC\1/^3DO#W_7UI_\
MZ-%?1U?./Q$_Y.2\/?\ 7UI__HT4 ?1U%%% 'S48QX7_ &H_*L]\<-Q>KN49
MPPGC!8>XW.?ICVK1^.]A<>'?&^@>-+!-K%E#L.GFQ-N7/^\IQ]$-4;\R:]^U
M/&+;<RV]Y%G@?*(8@7[^JM^?X5[!\5/#_P#PDGPYU>T5 UQ#%]J@]=\?S8'N
M0&7_ (%0!U.GWT&IZ;:W]LQ:WNH4FB)[JP!'Z&O!_C'-)XP^*/AWP3:NQCC*
MF?8X^5I""Q(]5C4,,_WCQZ]1\$/%<%Q\+I5O9E7^PS(LK'C$.#(K'MC!8?\
M *P_@O%+XJ\?^*/'-RK[7<PV^['&\YQQW5%1?^!=Z .D^,_C*\\$>$K.ST8>
M1<WS&!)E_P"6$:J,[?1N0 >W/?%<QIWP GUJPAO_ !)XHO9K^X02NH&_86&2
M"[$EC[\5Z+\3/ :^/_#26"7(MKRWE$UO*RY7.""K=\$'MW Z]#Y!!'\:?A[
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M\6_%?0[:\U36Y='\/10);6=G""PF6,;-Y7<!U!^8Y)Y  &*Z7]H[_DGFG_\
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MX.?M+\_H* /H>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ*T/[$U'_GW_ /'U_P :/[$U'_GW_P#'U_QH]I#N@]K3_F7WF?16A_8FH_\
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MT?V)J/\ S[_^/K_C1[2'=![6G_,OO,^BM#^Q-1_Y]_\ Q]?\:/[$U'_GW_\
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M[$U'_GW_ /'U_P :/[$U'_GW_P#'U_QH]I#N@]K3_F7WF?16A_8FH_\ /O\
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M6WLYW$B7"H65" 0)  "65Q@9&<%0,=<>B>+_ (V>%]'T.=M'U&/4=3="MO%
M"55C_$S$8 '7'4^G<=UKGAG1/$D"PZSIEM>HOW3*F67Z-U'X&L+2_A1X&T:\
M6[L_#UOYR'*F>1Y@I[$"1F /O0!S'P%\,ZCHWA*?4M3\Y)-1=6MX92<I"H^4
MX/W=Q)_ *?IYUX+\2Z;X&^-OB:X\0R26<$K74&_RF?:QF5P2%!."%X(!ZCMS
M7T]7+>(?ASX2\57ZWVLZ-'<707;YJRO$S#MN*,-V/?.* //_ (^ZC:ZO\*M'
MU&QE\VTN=1AEBDVE=RF&4@X(!'XUVW@[38-8^#^D:9=+N@N](2"0?[+1X/\
M.K]_X"\,ZGX:L_#UYIOFZ59,'MX//D780& .X,&/#-U)ZUM:;IUKI&FVVG6,
M7E6EM&(HH]Q;:H& ,DDG\: /G3X?>*)O@]XIU/PQXLBE@L9W$BSJA8(PR!(
M.61AZ9(*@8ZUZIKGQG\%Z1ILES!JL>HW !\JVM<EG;' )QA1[G]:ZW6_#>B^
M)+86^LZ;;WL8.5\U<E3['J.IZ5SMC\(? >G7*7%OX=A,B,&7SII90".G#L10
M!YY\#_#FIZMXEU/Q_K,)4W1D^S,PP))';+NH_N@94=OF/I5'XP_\EV\)_P#7
M*S_]*9*^AE4*H50 H& !T%<]K'@7PWK^NVFMZGIWGZC:!!!-Y\B[ C%U^56
M.&)/(H Z*OGCXP_\EV\)_P#7*S_]*9*^AZYW6/ OAO7]=M-;U/3O/U&T""";
MSY%V!&+K\JL <,2>10!T5%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (WW3]*J67WG^@JVWW3]*J67WG^@H
M N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 52M?\ CX?Z'^=7:I6O_'P_T/\ .@"[1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I10>E
M %.R^^_TJY5.R^^_TJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 -D_P!6WT-5K+^/\*LR?ZMOH:K67\?X4 6Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3?ZE_H:?3)
MO]2_T- $-E]QOK5FJUE]QOK5F@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH BN/^/=Z99_ZD_P"]3[C_ (]WIEG_ *D_[U %
MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N$^)?PTA^(MOIZMJ;6$MD9"CB'S00^W((W+_='>N[HH XOX>_#72_A[
M9SK:SRW=[=!?M%U*H7(7. JC[J\DXR3ZDX&.THHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ON
MGZ54LOO/]!5MONGZ54LOO/\ 04 7**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I6O_'P_
MT/\ .KM4K7_CX?Z'^= %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ H/2B@]* *=E]]_I5RJ=E]]_I5R@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JV^AJM9?Q_A5F3
M_5M]#5:R_C_"@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4R;_ %+_ $-/IDW^I?Z&@"&R^XWUJS5:R^XWUJS0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17'_'N],L_
M]2?]ZGW'_'N],L_]2?\ >H L4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/=#,*>1(^X9QU52!SZUT- !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4'I10>E %.R^^_P!*N53LOOO]*N4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #9/]6WT-5K+^/\ "K,G^K;Z
M&JUE_'^% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ IDW^I?Z&GTR;_4O]#0!#9?<;ZU9JM9?<;ZU9H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KC_CW>F6?^I/^]3[
MC_CW>F6?^I/^]0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD\N.*#H&(SY<6<A<#:6)!)R.N<CKO$O[/6BR::\WAJZNK/4H@6B267?'(1R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MH/2B@]* *=E]]_I5RJ=E]]_I5R@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ;)_JV^AJM9?Q_A5F3_5M]#5:R_C_"@"W111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R;_4O
M]#3Z9-_J7^AH ALON-]:LU6LON-]:LT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $5Q_P >[TRS_P!2?]ZGW'_'N],L_P#4
MG_>H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4UW2*-I)&5$4%F9C@ #J2:=7R+\1?'^K_$'Q.VFZ?).=+\\065E"3^_;=A
M68 _,Q.,>G&.Y(!]/3^,_"UK(8[CQ+H\4@ZK)?1*?R+5K6UU;WL"SVMQ%/"W
M22)PRG\17R_!^SQXTFMO->?28'QGR9+ARW_CJ$?K7'^;XI^%_BN2%)I=/U&W
M(+!3NCE7!P<?==2"<9_0B@#[6HK"\'>)8?%WA/3]<A01BY0EXP<^6X)5ES@=
M"#6[0 45\G?'?Q$=:^(DUE')NMM+C%LH'3?]YS]<G:?]P5R7A?5[GP1XZL=1
MN()$ETZZ*W,)7#A>4D7!(^;!8<]Z /MZBF12I/"DL3!HW4,K#H0>0:<S!5+,
M0% R2>@H 6LF_P#%'A_2I_(U'7=,LYO^>=Q=QQM^3$5\Y_%'XQZEKNHW.CZ!
M=&UT:%]GGP,1)=$=]W9,] .O4YS@9>A? SQIKEC'=FWM=/CD&4%]*4<C&<[5
M5B/H0#[4 ?4VG:[I&L$C3-5L;W W'[-<))@9QGY2>]:%?&OBSX;^*O 'E7U[
M&OD;\)>64C,J-VR< KG/&0,UZ]\$OBC?>(9Y/#FO7!GO40R6ERP^:51]Y6]2
M!R#W&<T >V45Y_\ &W_DD.N_]N__ *41U\J>'_#FJ^*=4&FZ-:_:KLH7$?F*
MGRCJ<L0/UH ^ZZ*^0/\ A27Q#_Z%[_R=M_\ XY1_PI+XA_\ 0O?^3MO_ /'*
M /K^BL[P_:S6/AO2[2X39/!9Q12+D':RH 1D<'D5HT %%8?C2":Z\"^(;>WB
MDFGETRY2..-2S.QB8  #DDGC%?'G_"">,/\ H5-<_P#!=-_\30!]OT5\,WGA
M'Q+I]I)=WOAW5K:VC&7FFLI$11TY8K@5T_P:T;4-4^).F7-I;/)!8R>=<R]%
MC7! R?4G@#J?P- 'U_117A'QD^+=@VDW/ACP[=K<SW ,=Y=0G,:(?O1J>C$C
M@D< 9'7H >[T5\T?LV_\CAJ__7A_[46OI>@ HKY-\;?$;Q)X]\5OI6BW-S%I
M\L_V:TL[:4IY_P V%9R",EN#@\#CTR6Z[\(_&_@S27\1?:(7\H;YVL+ES-"#
MU9OE&0#U*DXZ] 30!]:45XU\#_B7?^*!<>'];E\^^M8O.AN6/SRQY (;L2,C
MGJ0?8D^RT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,OQ:TV'6?CSINEW#
M2+!>M9V\C1D!@KOM)&01G!]#7TU7SC\1/^3DO#W_ %]:?_Z-% '7?\,X^#_^
M@EKG_?\ A_\ C5:&G? +P/8RH\T-]?;3G;<W/!Z]=@7_ "/K7J%% $5M;06=
MM';6L$<$$2A(XHD"JBCH !P!7DOC/XT3Z=XE?PSX3T?^UM5CD,3NP9E$@ZHJ
M+RV.<G(Q@_6O7Z^7;'4)/@_\9-2N]=TR6>UN1,(GBP6\N1PRR)G )XVGD=6H
M [-1\>-;4 FPT>.4=3Y((!_[[8=?J,>O7C_!5CJNF_M(VEIKEZM[J<;2_:+A
M22'8VKG@D X ('0=*]%U+]H#PTEJ5T6SU#4]0?B&W$.P$^YY./H#_6O,/"3:
MY9?'_2[OQ- ;/4KV=II$8 8$T3!0!DX^\%P>1T/(H ])_:._Y)YI_P#V%8__
M $5+7;_#5%C^&GAP*, V$1_$KD_J:XC]H[_DGFG_ /85C_\ 14M=S\./^2;>
M'/\ L'P_^@B@#AOVCO\ DGFG_P#85C_]%2UY#-\/?$MIX L_'C7<C-&T;0P@
MEI(8!PDF[/ ! PO88/'0>O?M'?\ )/-/_P"PK'_Z*EKM/ -M!>?"S0;6YB26
M";2XXY(W&5=2F"".X(- !\.O&D'CCPE;ZD"BWD8$5Y$O&R4#D@=E/4>Q]JXO
M]H[_ ))YI_\ V%8__14M<+:2S_ SXM26\IDD\/7X +LI),!/#<=7C/!]1G@;
MACN?VBW27X<:;)&RNC:I$RLIR"##+@@T =U\./\ DFWAS_L'P_\ H(KQ_P#9
MH_Y"'B/_ *Y0?S>O8/AQ_P DV\.?]@^'_P!!%>/_ +-'_(0\1_\ 7*#^;T ?
M0]?/'[-'_(0\1_\ 7*#^;U]#U\\?LT?\A#Q'_P!<H/YO0!VWQ)^#T'C745UG
M3M0^P:LJ*K%U+1R[?NDXY4CU&>@X[UP7]D_&SP-^]MKJZU6U3Y-D<OVQ<#H
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M/EM=&MG61'E48.Q=B*#T+$KN.,[>>>E 'T51110!\X_#O_DY+Q#_ -?6H?\
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MBMC]I'3KJ?PYH]_%$SV]K<.LSJ,[-X&TGT&5(SZD#O0!Z]HG_( T[_KUB_\
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MX22\_P"><'_?)_QK'HH]C3[!["GV-C_A)+S_ )YP?]\G_&C_ (22\_YYP?\
M?)_QK'HH]C3[!["GV-C_ (22\_YYP?\ ?)_QH_X22\_YYP?]\G_&L>BCV-/L
M'L*?8V/^$DO/^><'_?)_QH_X22\_YYP?]\G_ !K'HH]C3[!["GV-C_A)+S_G
MG!_WR?\ &C_A)+S_ )YP?]\G_&L>BCV-/L'L*?8V/^$DO/\ GG!_WR?\:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!%<?\>[TRS_U)_P!ZGW'_ ![O3+/_
M %)_WJ +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6^F:SY^I6MPDT$8M9DW@_*PRR =&SU'W1]* ._\ @KX@&O?#33T=P9]/S92
M9X"8V?\ CA3\<_2KWQ8UN30/AIK-U"2)Y8A;1D-M(,A"$@^H!)X]/QKQ+]GK
MQ$=-\;3Z-+)B#4X"$4Y_UJ?,/;[N_P#2O5_CQ \WPJOW3&V&>!WR>V\+_-A0
M!X=\$O#\6O\ Q*M/M"JT&GQM>NC#[Q4@+^3LI_"OKNOEO]G:XBA^(]S'(X5Y
M]-ECC!_B;?&V/R5C^%?2?B#[3_PC>J?8_-^U?8Y?)\G._?L.W;CG.<8Q0 _6
M=)M-=T:\TJ^3?:W<312#C(!'49Z$=0>Q -<?X9^#OA/PKJ=KJ=C'>O?6V3'/
M-<G.2"#D+@'()&,8KY\=_BY%&TDC>-T1069F-V  .I)IO@OQIXJNO'7AZWN/
M$NLS02ZG;))')?RLKJ95!!!;!!'&* /H/XV_\DAUW_MW_P#2B.OGWX0>(]*\
M+>/(]2UFZ^RV@MI$,GEL_P QQ@84$_I7T%\;?^20Z[_V[_\ I1'7S1X \'?\
M)SXH71?M_P!BW0O+YWD^;]W'&W</7UH ^E_^%V_#S_H8?_)*X_\ C=36GQC\
M!7U[!9VVO;YYY%BC3['.-S,< 9*8')KSG_AF7_J;O_*;_P#;:NZ1^SI_9>LV
M.H?\)5YOV6XCG\O^S]N[:P;&?-.,XZT >YT5D>*=<_X1KPOJ.M?9_M/V.$R^
M3OV;\=MV#C\J\6_X::_ZE'_RI?\ VJ@#Z HKS_X9?$W_ (6-_:G_ !*/[/\
ML'E?\O/F[]^__87&-GOUKI/&'B!?"WA#5-;959K2 M&K=&D/RH#[%BHH \&^
M//C>;6=?3PCICL]K:.OVA8P<RW!_@X/(4$<8^]GT%>S?#;P5#X'\(V]@4C.H
M2@2WLJ@9:0_PY[A<X'Y\9KP#X):(_B;XG+J5]^_6Q#WTK2<[Y2<(?KN;=_P&
MOJZ@#SCXUZ/KVO>"[73?#\%S/<3ZA&)HH7VAHMDF=Y) V[MG7C.*\@U_X./X
M0^&E]KVM7(DU8-$L5O V8X0SJ#N./F;!QQP.>O!'U-7G'QU_Y)/J7_76#_T8
MM 'E_P"S;_R.&K_]>'_M1:^E719(VC<95@01Z@U\U?LV_P#(X:O_ ->'_M1:
M^DKFXBM+6:YN'$<,*&21ST50,D_E0!\A)I]]\(_B?93ZO923P6=P7C<+@7$7
M(WIVS@YQG@\'%>L>//C5X3U#P+J5AI$\EY?7]L]NL+V[H(P_REF+ #(!)&,\
M@5Y3J6O>(?C!XZM-->Y:.&YN"MK;#/EVZ8Y; ZD*"2?KT%>@>+OV?=-TOPK=
M:AHFI7\M]9PM,\5P%=9@JY95"J"I[C[WIWS0!6_9W\)ZDFLW?B:YMY(+#[,;
M>W9U*^>S,"2OJH"D$^I&,X./HFOG'X&_$G4QKUOX3U2>6ZL[E6%H[_,T#J"V
MW/780",<X.,8&:^CJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2RMH;:VC&$AAC"(HZ\*.!4]% &=8Z!HVEW<MUI^DV%I<S9$LUO;)&[Y.3N(
M)YYYJ[/!#<P/!<1)+"XVO'(H96'H0>M244 9>F^&M!T:X:XTO1--L9V0HTEK
M:I$Q7(."5 .,@''L*?8Z!HVEW<MUI^DV%I<S9$LUO;)&[Y.3N( )YYYK1HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_!VB^"],:QT:V,:NV^65SNDE/8LWMV'0?B:WJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ54LOO/]!5MONGZ54LOO/\
M04 7**** "BBB@ HHHH **** .'O_P#D(W/_ %U?^9JO5B__ .0C<_\ 75_Y
MFJ]>Q'X4>W#X4%%%%44%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !116]H^C[]MU=+\O5$/?W-14J*"NR*E2-.-V&CZ/OVW5TOR]
M40]_<UT5%%>74J.;NSR:E2525V%%%%09A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 V3_5M]#5:R_C_"K,G^K;Z&JUE_'^% %NBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDW^I
M?Z&GTR;_ %+_ $- $-E]QOK5FJUE]QOK5F@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH BN/^/=Z99_ZD_[U/N/^/=Z99_ZD
M_P"]0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^GS_ ,A?_7H_X1C_ *?/_(7_ ->N@HH^L5.X?6:O?\CG_P#A&/\ I\_\A?\
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M$8_Z?/\ R%_]>N@HH^L5.X?6:O?\CG_^$8_Z?/\ R%_]>C_A&/\ I\_\A?\
MUZZ"BCZQ4[A]9J]_R.?_ .$8_P"GS_R%_P#7H_X1C_I\_P#(7_UZZ"BCZQ4[
MA]9J]_R.?_X1C_I\_P#(7_UZ/^$8_P"GS_R%_P#7KH**/K%3N'UFKW_(Y_\
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MX1C_ *?/_(7_ ->N@HH^L5.X?6:O?\CG_P#A&/\ I\_\A?\ UZ/^$8_Z?/\
MR%_]>N@HH^L5.X?6:O?\CG_^$8_Z?/\ R%_]>C_A&/\ I\_\A?\ UZZ"BCZQ
M4[A]9J]_R.?_ .$8_P"GS_R%_P#7H_X1G_I\_P#(7_UZZ"@]*/K%3N'UFKW_
M ".9AT#SB1]IQC_IG_\ 7J;_ (1C_I\_\A?_ %ZU++[[_2KE'UBIW#ZS5[_D
M<_\ \(Q_T^?^0O\ Z]'_  C'_3Y_Y"_^O7044?6*G</K-7O^1S__  C'_3Y_
MY"_^O1_PC'_3Y_Y"_P#KUT%%'UBIW#ZS5[_D<_\ \(Q_T^?^0O\ Z]'_  C'
M_3Y_Y"_^O7044?6*G</K-7O^1S__  C'_3Y_Y"_^O1_PC'_3Y_Y"_P#KUT%%
M'UBIW#ZS5[_D<_\ \(Q_T^?^0O\ Z]'_  C'_3Y_Y"_^O7044?6*G</K-7O^
M1S__  C'_3Y_Y"_^O1_PC'_3Y_Y"_P#KUT%%'UBIW#ZS5[_D<_\ \(Q_T^?^
M0O\ Z]'_  C'_3Y_Y"_^O7044?6*G</K-7O^1S__  C'_3Y_Y"_^O1_PC'_3
MY_Y"_P#KUT%%'UBIW#ZS5[_D<_\ \(Q_T^?^0O\ Z]'_  C'_3Y_Y"_^O704
M4?6*G</K-7O^1C6GAZ*"<22R^<%Y"[,#/OS6S1143G*;O)F<ZDIN\F%%%%00
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V
M3_5M]#5:R_C_  JS)_JV^AJM9?Q_A0!;HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *9-_J7^AI],F_U+_0T 0V7W&^M6:K67
MW&^M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"*X_X]WIEG_J3_O4^X_X]WIEG_J3_O4 6**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;".SL$@65)Y'$AV3,YV@*1T88R1S7JE% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2JEE]Y_H*M
MM]T_2JEE]Y_H* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4K7_ (^'^A_G5VJ5K_Q\
M/]#_ #H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %!Z44'I0!3LOOO]*N53LOOO]*N4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% #9/\ 5M]#5:R_C_"K,G^K;Z&JUE_'
M^% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ IDW^I?Z&GTR;_4O]#0!#9?<;ZU9JM9?<;ZU9H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (KC_CW>F6?^I/\ O4^X_P"/
M=Z99_P"I/^]0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[I^E5++[S_ $%6
MV^Z?I52R^\_T% %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5K_ ,?#_0_SJ[5*U_X^
M'^A_G0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *#THH/2@"G9???Z5<JG9???Z5<H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** &R?ZMOH:K67\?X59D_U;?0U6LOX_PH
M MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M,F_U+_0T^F3?ZE_H: (;+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!%<?\ 'N],L_\ 4G_>I]Q_Q[O3
M+/\ U)_WJ +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (KC_ (]WIEG_ *D_[U/N/^/=Z99_
MZD_[U %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J"]O+?3[&XO;N016UO$TLLA!(5%&2>/0 U/7E?Q\\2)H_@ Z8D@%UJT@A5<
M'/EJ0SGT_NK_ ,#_ " .,^#=C-XR^(OB+QA?1@VQ$JA#_>E/W?H$R/Q'--^$
MEY-X'^+.L^"[N8K:W#O'")#]Z1/FC;/0;HR?3/R^@%=A\(M6\*>%_AU86USX
MDT:&]N2UU<QR7\2LK/T!&[((4("#SD'Z5YY\:+K2H?'&D^+O#>LZ9>SDHTJ6
MMPDA2:(@H[;6S@C ]MG7D4 ?3E?/%Y_R=LO_ %UC_P#2-:]VT'5X-?T"PU>W
M4K%>0),JDY*[ADJ?<'C\*\)O/^3ME_ZZQ_\ I&M 'HOC_P 1>/M'U:V@\)>'
MK;4K1X-\TDL3L5?<1@$.O8"N3_X3GXU?]"18?^ \G_QZO;J\S^+OQ)_X0[2E
MTS2G#:]?+B';AOLZ9QO(]3R%'KD]L$ X*W^-?Q"D\41>'WT'2#J#3B%[>."5
MG4]QQ*0,#.?3!ST-=3^T=_R3S3_^PK'_ .BI:N?![X;OX8L&U[6HR^O7R[CY
MF2UNC<[3G^,]6/7MZYI_M'?\D\T__L*Q_P#HJ6@#G]#^+FIP^&='\.>#/#LN
ML:A9Z?$+B9D=DC8+@C8H!(!P-Q(&>!G@U9TWX\:SI&LIIWCKPY]@WD$R0Q21
M-&A.-QC<DL.#R#] :]!^$ND6>D_#31OLL*(]U;K<SN%P9'<9R3WP,#Z 5QW[
M2%E;OX,TN_,2_:8]0$*R8Y"-&Y(SZ91?RH ]E1TEC62-E=& 964Y!!Z$&O(O
M%OQN-IK<N@^$-&DUO48RR-(H9D#CLJ(-SX.<\CIQGK6A=Z[<:5^SG!JB3-'<
M+HL$22KR0S*L8/URPY_&O-/@[XX\&>!](O)M6:8:O=2X+QP%]L( VJ#VYW$X
MZ\9Z"@#II_B_X^\,O%<>+?!216#OM:6!)(\9Z#<6=<]3@XS[=:]?\.^(M,\4
MZ+!JVDW FMI1]&1NZL.S#T_H0:\^OOC?\/-3L+BQO)+N:UN(VBEC:U;#*1@B
MN-_9RU=H]?UW0HY"]I)$+N(-G(*,$)_$.N?H* .U\1?$K6=(^,&F>$;>VL&T
M^Z:!7DDC<RC>><$,!^E=%\3O%E_X+\&2ZQIT5M+<)-'&%N%9DPQP>%(/ZUY7
MXV_Y.:T'_KI:?S-=O\?/^277'_7U#_Z%0!STOQQU74;#3K/POH']KZY):I+>
MF*&1H8)".5"CYB >IW #U/.(]$^.FK67B2+2/'.@II8D(5IDC>(Q9)PS(Y.5
MZ<@^IYZ5UGP.TBUT[X8:==10QK<WQDFGD4<OB1@N3[*!Q]?6N)_:7M8?)\.W
M@11/NGB+@#++\A )ZG!SCZGUH UM9^,>O:EJ5Q:^ /#$NKVUN_EO?/;R21LX
MSG 0C ( ()()]*M> /C-/X@\2+X:\2:2--U5BR(R[D4R*,E&1^4/!QDG)X^O
MH7@_2[31O!^DV-E$L<,=K'T !9BH)8XZDG))]37B/Q41;#]H'PQ=6XVRR_8I
M7/\ >83LO_H*@4 ?0&H7]KI>GW%_?3I!:VZ&265^BJ.IKQ:?XV>)O$6HR6W@
M3PD]Y#&V#/<QO)D8S\P0@)[98Y^IP)_VD-7EM?#.DZ5'*R+?7#R2*!PZQ@<$
M_5U./;VIG@GXK_#[PEX0T[2(9;I)(HE-PR6K?O)B,NV>^3G'H,#H!0!)IGQN
MU72==BTKQ[X<;2?.QBYC1U"CINVMG<N>ZDXQT->SQ2QSPI-#(DD4BAD=&!5E
M/(((ZBO _B=\3_ WC/P3=Z; ]S)?HRRVC/;LNR0'GGW4L/Q_&NT^!&L3:M\,
MK>.9M[6%Q):!CG.T8=0?H' ^@% '(6GQ\U2/4=:L;W2K>ZNH93!IMM912!YG
MWD?.2S< #/ R3T]NN\$^+OB%J?B--.\4>$HK&U>)Y/M<22(J8Z#DN"2>,9'&
M3VP?-O@SIT=Y\:-:N98D<6:7,B%@#M<RA01Z'#-S7TK0!R/A;PE>:7XAUGQ%
MK5_'>ZKJ+"-3"A2."!?NHH)SSP3[CUR34^(WQ,L? -M;Q?9FOM4NO]1:*VWY
M<X+,V#@9X QDG\2.YKY^^.-CJ.A^/-$\:6]B+JTMTC5O,3=&LL;E@&QT!##'
MN#0!H+\2OBRT7]H#P%'_ &?@OL-M,)=H_P"!Y_\ '>E=K\-_B?8?$&WGB6V>
MSU*U16G@9@58'C<AZD9ZY'&1UK#T3]H/PAJ+1Q:A'>Z7(P^9IH_,B!] R$G\
M2HK;\)^$?!A\3WGC#P]?B\NKIF=S#<(\<?F<L JCC)R<'G.: .]HHHH ^<?A
MW_R<EXA_Z^M0_P#1IKZ.KYQ^'?\ R<EXA_Z^M0_]&FOHZ@#$\7>&[7Q;X8O=
M'NHT;SHSY3N/]5)CY7'H0?TR.]>,_LYZU<6^HZWX7NMX*+]J1&/$;*P208]R
MR?E7T#7S;\' K_'+7FA1A&([L@?W5\Y<9_2@#O\ XI_$K6?!&OZ-8:9;6$L5
MZI:0W,;LP^8#C:P]?>O1M6U6RT/2;G5-1F$-I;(9)7(S@?0=3VQ7@_[0G_(X
M^&/^N9_]&"O4_BKH-WXC^'&K:?8QM+=[4EBC09+E'#%0.Y(!Q[XH \]C^,?C
MCQ--(_@[P4)K-&(\ZX1Y0P![E2JANAVY/X]:O:+\;-1LO$4.A>./#[:5<S%$
M6:,%54L<;F5C]SW!/0]>W+?#CXTZ=X0\.P^'=<TBYC^R.ZK+:(,\MD^8K$<@
MELD>W%=]J3?#CXQ'3EDUD//:L3' L@@F;=C*%7&YAD#[O?OS0!Z>[I%&TDC*
MB*"S,QP !U)->+:O\<=1U/6)-*\!>'9-6D0@?:94=E;YL$A%P0O^TS#KR!CG
M;^-VH'0/A0]G:R/$+F2*Q4CDE,$D$^ZH1_\ KKB_A;\2/ O@CP;#97+W"ZG.
M[2WLB6S-N;)VC/H%P,=,Y/<T ::_&GQ5X;U"WB\<^$39VLQP)[='3'J5W%@^
M!C(# _RKV?3M1L]7TZ#4-/N([BTN$#Q2QG(8?Y[=J\@\7?%[X?\ B?PGJ>D3
M27<AN(&$0:V8;9 ,HV>V& --_9OUB:Z\,ZMI,C;DL;A)(\YRJR@\>F,H3]2:
M -[Q]\8+;PIJZZ#I.FR:OK+;=T2-A8R1P#@$LW0[0.AZ]JYB;XD_%VUM_MMQ
MX%@%IC>0MI-O5<9Y D)&.^5_*NZ_X0WPCX3\67?C>^OC;W<WF%I+ZY7RT9R,
ME-PR#C*C!Z,1CI1J/QC\!Z:"'U^*=\$A;:-Y<_BHQ^9H K_#3XJV7Q!$]H]H
M;'5+=/,>#?O5TX!=6P.Y (/3(Y-;'CSQWIW@+0O[0O4:>>4E+:U0X:9_K@[0
M.Y[>YP*\2^%=[8ZE\?=2OM,0I97'VJ6%2NWY6.1QVZ]*ZG]HC0+Z[L-'UVTM
MFN(=/:1;E0NX(K;2&8?W?E()]Q0!'#\3OBIJL8OM+\"1?V>>5$L$I9AUR#N7
M(QT(6NG^'GQ<M_&6J2:'J&G2:;K40=C$3\C;3@J,X8,.X(['Z5B^'OVA_#=S
M;V\.LV5WIUQM"R211B2!>!R,'<!UXVG [FNATOPYX$\5>-5\:Z5J:WFHKM?R
MX+A=JE1MW-'C<#C ^;VH [#Q#X@T[POHEQJ^J3>5:P#)P,LQ/15'<D_YQ7CR
M?&/QSXFN'?P=X+66RC+#S;F.27< 1CYE**I_V<G],UE_M'ZJTFN:'H;7#1VZ
M0FZD7;D LQ0-[X"MQ[GUKK]*^-'PYT32K73-/>[AM+:,1Q1K:MP!Z^I/4GJ2
M2: (?#'QLDD\0C0/&FCG0KUV"I*VY$!/0.K<J#V;)!SV'->P5\U?&'Q_X-\<
M>'K1=,:=]5M9\QO)"4_=D$.N?J%/X?G[5\,]8FU[X<:'J%PV^9K?RY'YRS1L
M8R3GN=N3[T =77C_ .T=_P D\T__ +"L?_HJ6O8*\?\ VCO^2>:?_P!A6/\
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M_/U/_P!_#1]NN_\ GZG_ ._AH^JON'U.7<[6BN*^W7?_ #]3_P#?PT?;KO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5\U^.C_P ++^.UGX=@9C96;?9)&7C 3+S'Z\%?^ BOH^Y\
M\6LWV41FXV'RA*2$+8XW8YQGKBO*?A7\*=5\'>(]1UO7KNQNKJ>+RX3;,SX+
M-N=CN5<'@#C/4].X!)_PSUX*_P">FJ?^!*__ !-9/B?]G_P];^&=1N-$DO\
M^TH8&E@66575V7G;C Z@$ YX)!KVVB@#Q#]G3Q0+K1+WPS/*S36;FYMU8CB)
MB-P'?AR3_P #K'O/^3ME_P"NL?\ Z1K70Z%\)->\*_%-_$&B76F1Z(\[;K9Y
M'$@@?ED \LCY3]WG^$9(YK2G^&FLR_'(>-EN;#^S Z-Y1D?SN+<1]-NWJ/[W
M3\J .H^(7CJR\!^''OI\27DP:.SM\9\R3'?T4<$GT]R*\Q^$G@.\\1ZO+\0/
M%J&>6XE,MG%.OWVX(FQT"CH@Z<9& %SH?%+X1^)?''B[^U+#4-.2T6W2*..Z
MFD#*1G. $( )/K5+_A7/QD[>.+51V"WTX ^@$7% 'N]>/_M'?\D\T_\ ["L?
M_HJ6LC_A77QE_P"AZM__  /G_P#C==I\2_ NK^-? VFZ-9W5HM[;7$4TLMU(
MX5ML3JV"%)))8'D>M &Y\./^2;>'/^P?#_Z"*X;]H[_DGFG_ /85C_\ 14M>
MC^$])GT'PCI.DW3QO/9VL<,C1$E2RC!P2 <?A7.?%GP5J7CSPK:Z7I<]I#/%
M>I<,UT[*I4(ZX&U6.<N.WK0!CSZ1)KG[-L-C" 93HT4J*<_,8PL@'U.S%<Q\
M!K7PIX@\-WFFZEHFE76JV<Y<M<VD<CO"V,'+ DX.X>WR^M>Q>$])GT'PCI.D
MW3QO/9VL<,C1$E2RC!P2 <?A7G'BGX(M-X@.O>#=7_L2]9][PKN5 QZE&7E?
M]W!'/8<4 =OJ'A/P/I>G7-_>>&-"CMK:)I97.G0\*HR?X:Y?X5>*/#OBG4-1
MFT+P;:Z*;:,(]U##&I<,<A,HHZ[<D9["N:G^$7Q$\1I'9>*/&L4FGH03'%))
M+N^JE4!/'!)->M>%/"FE^#=#BTK2H=L:_-)(W+S/W=CW)_3H.* /%O&W_)S6
M@_\ 72T_F:[?X^?\DNN/^OJ'_P!"J+Q%\-=9U?XP:9XNM[FP73[5H&>.21Q*
M=AYP I'ZUT7Q.\)W_C3P9+H^G2VT5P\T<@:X9E3"G)Y4$_I0!#\(/^24:!_U
MQ?\ ]&-7G_[2_P#R#/#O_7:?^25ZKX$T"Z\+^"=,T6]DADN;6-E=H22A)8G@
MD ]_2N7^+WP]U;Q_9Z5#I5Q90M:22-(;IW4$,% QM5O2@#N]$_Y &G?]>L7_
M *"*\'^,/_)=O"?_ %RL_P#TIDKW[3K=[33+2VD*EX84C8KT)"@'%>:>/?AI
MK/BGXE:'XCL;FPCL[!(%E2>1Q(=DS.=H"D=&&,D<T 8_[2.D27/AK2-60 K9
M7+Q/UR!(!S],Q@?B*ZGP'HW@CQ3X*TO5(?#.A22- J7 -A$6691AP?ESUYYZ
M@@]Z[G4=.L]7TZ?3]0MX[BTN$*2Q2#(8?Y[]J\6D^"?BCP[J,\_@?Q:;.WE.
M?)N)'C(YZ,4!#_4@>F* .N\=0> O OAUM6O/"&BSL9%BA@2PA5I7/;)7C !/
MX5L_#G4=-UCPC#J>E:!#HEI<R,ZVT4:(&(PI?"@ YVXSZ 5YW:_!'7M?U>&_
M\>^*#J*Q'_CW@=V#+Q\H9@NP''.U?UYKVJTM+>QM(;2TAC@MX4"1Q1KM5%'
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MQS/)%Z]54,I/OWZ\4 =%\1+SP!\/;&TEN/!>C7ES=.5CMTLH4.T#YF)*G@9
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M4 %':BCM0!##U-35##U-34 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQOK5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH BN/^/=Z99_ZD_P"]3[C_ (]WIEG_ *D_[U %BBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIQ0!N45Y_P#\+M^'G_0P_P#DE<?_ !NK-G\8/ -](4B\1VZD8YFBDB'YNH%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%0Q?ZP_2IJAB_P!8?I0!-1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4=J*.U $,/4U-4,/4U-0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444J(SN$12S$X '>@ 1&=PB*68G  [UUF
MDZ<;&$EV)E?&X \#VIFE:4MDGFR@-.1_WS["M.N"O6YO=CL>=B,1S^['8***
M*YCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG
M^K;Z&JUE_'^%69/]6WT-5K+^/\* +=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !3)O\ 4O\ 0T^F3?ZE_H: (;+[C?6K-5K+
M[C?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!%<?\>[TRS_U)_WJ?<?\>[TRS_U)_P!Z@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\X_M*_\A_0O^O63_P!"%?1U?./[
M2O\ R']"_P"O63_T(4 ?14\\-K;RW%Q+'#!$A>221@JHH&223P !SFJEKK>D
MWVGR:A::I97%E&2'N8KA'C7'7+ X&,UG>._^2>>)?^P5=?\ HIJ^=?A=X/U7
MXAZ;)H]WJ<MKX8T^X\^6.$ /+,X P.,<!<Y.<9X'/ !]+6/B30M4NFM=/UK3
MKNX7.8K>Z21QCV!)[&KEY?6FGP>?>W4%M#G;YDT@1<^F37SG\4?A%8>"-#C\
M1>'KZ]4V\Z"1)I 63)^5D95!!#8Z^O7M6KX3\&ZK\8M/@\1>--8N_L$8$%G:
MVIV!R@VO(<@@%F!R0,DY^Z !0![AINMZ3K*.VEZI97RH<,;6X24*??:3CJ*M
MSSPVMO+<7$L<,$2%Y))&"JB@9))/  '.:^8/B-X)/PCUW1==\-7UV8I)&*^>
M03'(A#;25QN5@<8(Z*<DYKWSQ;=)?_"W7;R/A)]%N)5YSPT#$?SH U[?7=(O
M-.?4;;5;&>QC)5[F*X1HU(QP6!P.H_.H].\2:%J\IBTS6M.O9!U2VNDD(ZGH
MI/H?R-?-'PM\'ZI\0K0Z3>:A-;^%].G,\L41 ,LS@?+[G"]3G;DX^]7:^,_@
M-8Z?HKZKX1N;V'4K%1,(I)=WF[,DE2 "LG<=N ,#.: /=J:[I%&TDC*B*"S,
MQP !U)-><?!;QM<^,/"$D>I3>;J6G2"&60MEI$(RCM[G#+[[<]S7+>/O#WB[
MXA?$R'098KZP\*PX(G$9\I]HRSG'!<DE5SVYQR<@'JK>-?"BS>2WB;1A+D#8
M;^+.3TXW5M12QSQ++%(LD;#*NAR#]#7E;_L]>"VL3 CZFDV,"X^T OGUQMV_
MI7#_  ODU/P-\:;KP1]K:>PGDE1ESA25C,B28[,5 ! ]>^!0!Z_\1] \-^(_
M#UO9^*-7_LNQ2[65)OM,<&Z0(X"[I 0>"QQUX]JW/#EE8:=X:TVRTNY^U6$%
MND=O/YBOYB <-N7@Y'<<5YG^T=_R3S3_ /L*Q_\ HJ6NY^''_)-O#G_8/A_]
M!% &G9^)="U&"XGL=;TVZAM@&GD@ND=8@<X+$'Y<X/7T-2Z;K>DZRCMI>J65
M\J'#&UN$E"GWVDXZBOD_X3^&+GQIK5UH#W\MMHS(EWJ$<38:81DA%''K(3SQ
MWZ@5]$^%?A7X:\&ZZ^KZ2ER)V@,&V:4.J@D$L,C(;@#KT^IH Z;3M=T?6(Y9
M-,U6QO8X<>:UM<)($S_>*DXZ'K4-OXI\/7=ZMG;:]I<UTW @CO(V<_\  0<]
MZ^5_AAH.M^,I[WPQ9ZBUEH\VRYU)U'+*A(51ZY+=#QQGM@]W\0/@5HVA>$+S
M6-$O+XSV4?F21W+JZR(/O'Y5!!QSZ<=J /?KBY@M+=[BYFCAA09>21@JJ/<G
M@52T_P 0Z+JT\D&G:QI]Y-']^.WN4D9?J%)QT/Y5X!X&T/Q#\8M*AB\1ZY=I
MH&D 6ZK"<27,OW@6)R"RJP&X@G&.,EB8/BG\*;/P#I-IXA\.7U^NRY6*19)
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M3YED([=#^'U5\4O^28>(?^O1OYBO#/#?A\:]^SCK[H@,^GZL][&3G@)#%O\
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M(*F&<@CH>4KZ(KX\^*7AW5_"&KVF@7FHS7VEP1M+ICR#E(V."A..H*C@<="
M-V*^PZ "O$?VE/\ D6]$_P"OM_\ T"O;J\1_:4_Y%O1/^OM__0* -;PG\(/
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M^AH ALON-]:LU6LON-]:LT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $5Q_Q[O3+/\ U)_WJ?<?\>[TRS_U)_WJ +%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SC^TK_R']"_
MZ]9/_0A7T=7SC^TK_P A_0O^O63_ -"% 'MWCO\ Y)YXE_[!5U_Z*:O-_P!F
MY1_PAVK-@;CJ&">_^K7_ !KTCQW_ ,D\\2_]@JZ_]%-7G'[-W_(F:K_V$#_Z
M+2@#H/CK_P DGU+_ *ZP?^C%J?X)?\DAT+_MX_\ 2B2H/CK_ ,DGU+_KK!_Z
M,6I_@E_R2'0O^WC_ -*)* .1_:4_Y%O1/^OM_P#T"NWU#_DAEU_V+3_^DQKB
M/VE/^1;T3_K[?_T"NWU#_DAEU_V+3_\ I,: .;_9U\K_ (5S<^7][^TI?,Z_
M>\N/^F*];KY0^%7Q#N_A_;7$U]IUS=>'KR?RVDA S%.J@\9X)*D<$C@9'0BN
M[\:_'.QU/1I-'\'VMU=ZA?(T/F/"1Y888.U>K,1G'IUYZ4 9G[.2C_A(O$C6
MX;[*(HP",[?OMMS[X!Z^]=1XS^-$^G>)7\,^$]'_ +6U6.0Q.[!F42#JBHO+
M8YR<C&#]:VO@[X#G\$>%Y6U!%75-0=9;A5;/EJ!\B$^HRQ/NQZXKR*QU"3X/
M_&34KO7=,EGM;D3")XL%O+D<,LB9P">-IY'5J .S4?'C6U )L-'CE'4^2" ?
M^^V'7ZC'KUX_P58ZKIO[2-I::Y>K>ZG&TOVBX4DAV-JYX) . "!T'2O1=2_:
M \-):E=%L]0U/4'XAMQ#L!/N>3CZ _UKS#PDVN67Q_TN[\30&SU*]G::1& &
M!-$P4 9./O!<'D=#R* /2?VCO^2>:?\ ]A6/_P!%2UW/PX_Y)MX<_P"P?#_Z
M"*X;]H[_ ))YI_\ V%8__14M=S\./^2;>'/^P?#_ .@B@#QW]FA%.J>(7(^8
M0P@'V+/G^0KZ)KYX_9H_Y"'B/_KE!_-Z^AZ /G?]FA1_:7B)L#<(8 #WZO7L
M/Q'_ .2;>(_^P?-_Z":\?_9H_P"0AXC_ .N4'\WKV#XC_P#)-O$?_8/F_P#0
M30!PW[./_)/-0_["LG_HJ*M+X^?\DNN/^OJ'_P!"K-_9Q_Y)YJ'_ &%9/_14
M5:7Q\_Y)=<?]?4/_ *%0!F:6TJ_LNR&$D-_9<X./[N]]WZ9KSKX7>'/'^L>'
M;JX\)>(K33;-;LI+#+*RLTFQ3NP(VXP0.O8U[1\+;2#4/@UI%E<H)(+BUEBD
M0C(96=P1^1KR30-3UGX#>+;S3M:LYKS1+W!$T X?&=LB9.-V"0RDCMS@ D Z
MO_A!OC5_T.]A_P"!$G_QFK'PW^%7BCPIX[F\0:QJ&F7"SQ2K-]GD=G=W(;.#
M&HZC/6GZY^T-X;@TF1M&@O+J_="(TEB\M$;'!8D\@'L,Y_6D^!_A'7K+[;XG
M\0RW*R7X8P6\[MN.]MSRLIZ,Q P>N">QH YSXP_\EV\)_P#7*S_]*9*^AZ^>
M/C#_ ,EV\)_]<K/_ -*9*^AZ /GCXP_\EV\)_P#7*S_]*9*]@^(__)-O$?\
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M3K0!T\^D?'#6K>3[?K%EI5N$+.BM&#C'(!C5B3@GC=CC\:H_LR_\S3_VZ?\
MM:M7Q%\87\5VLGAWP#I-[?ZA>H86N)(PBPJPP2.>N,\MM Z\UB_LW.UKK/B;
M3YCLFV0EHCURC.I_(MC\: &_&'_DNWA/_KE9_P#I3)7T/7SQ\8?^2[>$_P#K
ME9_^E,E?0] 'SQ\8?^2[>$_^N5G_ .E,E;7[2>__ (1?1<;MGVUL^F=AQ_7]
M:Q?C#_R7;PG_ -<K/_TIDKUGXE^#SXV\%76E0E%O$99[5GZ"1>Q^H++GMNSV
MH U/!S1MX(T!H<>4=-MRF!@8\M<<5S/QL5&^$>N%_P"'R"#C.#Y\?_ZOQKSK
MX?\ Q>_X0JQ/A/QI8WD$NGGRH95CRR+R=CJ3GCC:1G(([#)R/BK\39?'FERV
M'A^PNO["LF2>]NY(B"6)VH#CA5R>,\D^F.0#USX)?\DAT+_MX_\ 2B2O0*\_
M^"7_ "2'0O\ MX_]*)*] H Y#XI?\DP\0_\ 7HW\Q7&?L[1)/\-]3BE4-&^I
MRJRGH088@179_%+_ ))AXA_Z]&_F*X[]G'_DGFH?]A63_P!%14 <]\')I/!_
MQ1\1>";IV$<A8P;W'S-&25('JT;%CC^Z./32\.JOCK]H75]9<"73] C\B D;
MUWC*+CMRWFN#Z@8]:S/C0MYX+^)&C>-M+11+/$T;DIQYBJ4.3ZF-P!G^[WZ5
MV/P&T$Z7\/AJ,PS<ZK.UPS$DML'RJ#^3-_P*@#B?C#_R7;PG_P!<K/\ ]*9*
M]'^-O_)(==_[=_\ THCKSCXP_P#)=O"?_7*S_P#2F2O1_C;_ ,DAUW_MW_\
M2B.@"#X%?\DGTW_KK/\ ^C&KS_X9_P#)QGBO_KK?_P#I0*] ^!7_ "2?3?\
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M^N5Y_P"E,=>P?#C_ ))MX<_[!\/_ *"*\"T;Q*GPO^-/B*[URPNGBG:XBVP
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M???Z5<JG9???Z5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &R?ZMOH:K67\?X59D_U;?0U6LOX_PH MT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,F_U+_0T^F3?ZE_H
M: (;+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!%<?\ 'N],L_\ 4G_>I]Q_Q[O3+/\ U)_WJ +%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z44'I0!3LOOO]*N
M53LOOO\ 2KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 V3_5M]#5:R_C_"K,G^K;Z&JUE_'^% %NBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDW^I?Z&GTR;_ %+_ $-
M$-E]QOK5FJUE]QOK5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH BN/^/=Z99_ZD_[U/N/^/=Z99_ZD_P"]0!8HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &><G][]
M*/.3^]^E5:* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/
M.3^]^E5:* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3
M^]^E5:* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]
M^E5:* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E
M5:* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:
M* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:*
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M* +7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:*
M+7G)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:* +7
MG)_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:* +7G)
M_>_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:* +7G)_>
M_2CSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:* +7G)_>_2
MCSD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:* +7G)_>_2CS
MD_O?I56B@"UYR?WOTH\Y/[WZ55HH M><G][]*/.3^]^E5:* +7G)_>_2CSD_
MO?I56B@"UYR?WOTH\Y/[WZ55HH LF5-I^;MZ56M'56;<<<4'I4474T 7_.3^
M]^E'G)_>_2JM% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^
ME'G)_>_2JM% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^E'
MG)_>_2JM% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^E'G)
M_>_2JM% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^E'G)_>
M_2JM% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^E'G)_>_2
MJM% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^E'G)_>_2JM
M% %KSD_O?I1YR?WOTJK10!:\Y/[WZ4><G][]*JT4 6O.3^]^E'G)_>_2JM%
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M[]*/.3^]^E5:* +7G)_>_2CSD_O?I56B@ HHHH **** "BBB@ HHHH ****
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M_P 4>(CH<$2P+&]U*<A7Y 4=2<$'Z?CZ53\,^(=6UR]998+5+6,9D=$8'/8
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MXEO-<O)X;F*!%CCW Q*0<YQW)H ZJBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ****  ]*BBZFI3TJ*+J: ):*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BC^^:E
MJ*/[YH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (HNIJ6HHNIJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 0_=/TID7>GG[I^E,B[T 24444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW#]*6D;[A^E #(NAJ2
MHXNAJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH :_W#21?<_&E?[AI(ON?C0 ^BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH R/%/\ R+-]_P!<Q_,5YYX4@BN?$MI%/$DL;;\HZA@?D8]#7H?BG_D6;[_K
MF/YBO*K/[7]K3[#YWVGG9Y&=_3G&.>F: /7O[$TK_H&67_@.O^%']B:5_P!
MRR_\!U_PKS?_ (JO_J-?^1:='_PE7F+G^V<9&<^;0!ZC%%'#&L<2+'&HPJJ,
M #V%9_B"_P#[-T*ZN V)-FR/G!W'@8^F<_A6G7 _$&_WW%K8*W"*97 /<\#(
M]0,_G0!B>&='&LZC)"^-B0NQ)/<C"_D2#^%4],NGTK68+A@5,$OSCVZ,/RS7
M=> [$V^C27; AKE^/]U>!^NZN;\;6/V37VF482Y42#Z]#_+/XT >G AE#*00
M1D$=ZY7X@?\ (!@_Z^E_]!:KWA'4CJ.@1;SF6#]RW/)P.#^6*H_$#_D P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z5%%U-
M2GI4474T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5%']\U+44?WS0!+1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 11=34M11=
M34M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 A^Z?I3(N]//W3]*9%WH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *1ON'Z4M(WW#]* &1=#4E1Q=#4E !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_N&DB^Y^-*_W#
M21?<_&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>*?^19OO^N8_F*X#
MP=_R-=E_P/\ ] :O0?$D4D_AZ]BAC>21DPJ(I)/(Z 5YG#I>MVTJRP6.H12+
MT=(74CMU H ]AHKRG_BJ_P#J-?\ D6C_ (JO_J-?^1: /56944LS!5 R23@
M5X[JMX^L:W/<1J[F:3$2[?F(Z*,#OC%=N9-33P"$>&\EOY0T15D9I "YR3GG
M[O\ 2L+PGH-X=>BFN[.>&* &3,L;*"W0 9'7)S^% &?%%XG@B6*&/5XXUX5$
M60 ?0"H+ZWUR6+S;^'47CBR=]PKD)GW/3M7L%0W=LEY9S6TGW)4*'\10!Y_X
M"U 6^J2V;MA+A,KD_P 8Z?H36W\0/^0#!_U]+_Z"U<;;Z7K-A?QS1Z=>%X)
MP*PL02#ZXZ5VOC6"XO\ 0;<6UM-*YG5RBQDL!M;J!TZT 9'P\_X_;[_KFO\
M,UH>,/#D=Q9F_LH42>$$R*BX\Q?7CN/Y?A5;P)87EG=WC7-I/ &C4 RQE<\^
M]=Q0!Y5X9\12Z-=B*1BUE(W[Q/[I_O#_ #S7JBLKJ&5@RD9!!R"*\U\2^%[J
MTU-I+"TFFMIOF C0OL/<<=!Z5TW@ZYOO[/-C?VMS$T&/*>6-E#)Z9([?R^E
M''>,?^1KO?\ @'_H"UZ%X;_Y%RP_ZXBN(\5Z7J%SXENY8+&ZEC;9ATA9@?D4
M=0*HQ1>)X8UCB35XXU&%51* !["@#UFBO*?^*K_ZC7_D6NV\'_VA_9$O]I?:
MO.\\[?M.[=MVKTW<XSF@#H*\I\8_\C7>_P# /_0%KU:O-/%>EZA<^);N6"QN
MI8VV8=(68'Y%'4"@#M_#?_(N6'_7$5J5F^'XI(= LHY4:.18@&5A@@^XK2H
M**** /$;7_C[A_ZZ+_.O;J\;&C:LI!&FWH(Y!$#_ .%7O^*K_P"HU_Y%H ['
MQMJ$=KH3VVX>=<D*J@\@ Y)^G&/QKF/ MF\^O_: OR6\9);T)& /U/Y&JEKX
M7UK49_GMI(MW+27&5_GS7HVB:/#HFGK;1'>Q.Z20C!<^OM0!B_$#_D P?]?2
M_P#H+5C_  ]_Y"=W_P!<1_Z$*W?'%K<7>BPQVT$LSBX5BL:%B!M;G KAK>PU
M^T8M;6FI0LPP3%'(I(_ 4 >OT5Y3_P 57_U&O_(M'_%5_P#4:_\ (M 'JU>?
M?$"Q\N]MKY1Q*OEO]1T_0_I7=66_[#;^;N\SREW;NN<<Y]ZS?%.G-J6@3QQH
M7ECQ+&JC))'8#Z9% 'G,FKN_AN+2NR3F3/\ LXX'YEC77^ -/\K3Y[YU^:9]
MB$K_  KZ'W/_ *#7%C0]6) &F7G/K P_I7K.F62Z=IEM:+C]U&%)'0GN?Q.:
M +=>(W7_ !]S?]=&_G7MU>/W.C:HUU*1IMX07)!$#>OTH ]@HKRG_BJ_^HU_
MY%H_XJO_ *C7_D6@#U:O+O&__(S3?]<T_E73>"_[5_T[^T_MO_+/R_M.[_:S
MC=^'Z5A^,-,O[GQ#++;V-S+&40!XXF8=/4"@#K?"7_(KV/\ NM_Z$:VJ\EAA
M\36\2Q0QZO'&O1$60 ?@*D_XJO\ ZC7_ )%H ]4D198VC<95@5(]0:\9GBET
MO57CS^\MIL!@<<J>"*]!\&?VI]GN_P"T_MF[>NS[3NSC!SC=2>*/"O\ :Q^V
M695;P##*QP) .GT- &_I]]#J5C%=P,"D@SC^Z>X/N*FFFCMX7FF=4C099F.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*BBZ
MFI3TJ*+J: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *BC^^:EJ*/[YH EHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (HNIJ6HH
MNIJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 0_=/TID7>GG[I^E,B[T 24444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %(WW#]*6D;[A^E #(NAJ2HXNAJ2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_P!PTD7W/QI7
M^X:2+[GXT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*BBZFI3TJ*+J: ):*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *BC^^:EJ*/[YH EHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (HNIJ6HHNIJ6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TID7>G
MG[I^E,B[T 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %(WW#]*6D;[A^E #(NAJ2HXNAJ2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH :_W#21?<_&E?[AI(ON?C0 ^BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4
M 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*
MNT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4
M4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*N
MT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4
MJ*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT
M4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J
M*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4
M 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*
MNT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4
M4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*N
MT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4
MJ*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT
M4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J
M*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4
M 4CTJ*+J:T6^Z?I52R^\_P!!0 E%7:* *5%7:* *5%7:* *5%7:* *5%7:*
M*5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7
M:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *
M5%7:* *5%7:* *5%7:* *5%7:* *5%7:* *511_?-:54K7_CX?Z'^= !15VB
M@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E1
M5VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@"E15VB@
M"E15VB@"E15VB@"E15VB@"E15VB@"E15V@]* ,V+J:EI;+[[_2KE %*BKM%
M%*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BK
MM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %*BKM% %
M*BKM% %*BKM% %*BKM% %*BKM% %$_=/TID7>K\G^K;Z&JUE_'^% #:*NT4
M4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*N
MT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4
MJ*NT4 4J*NT4 4J*NT4 4J*NT4 4J1ON'Z5>IDW^I?Z&@"C%T-25)9?<;ZU9
MH I45=HH I45=HH I45=HH I45=HH I45=HH I45=HH I45=HH I45=HH I4
M5=HH I45=HH I45=HH I45=HH I45=HH I45=HH I45=HH I45=HH I45=HH
M I45=HH I45=HH I45=HH I45=HH I45=HH H/\ <-)%]S\:MW'_ ![O3+/_
M %)_WJ (J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*N
MT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4
MJ*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 4J*NT4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117FOQ#^,>D^"+AM-M
MH#J.KA<M"CA8X<]-[<G/?:!G'4C(H ]*HKYDG_:0\4M(3;Z3H\<?99$E<_F'
M'\JZOPM^T587UW':^(]-&GASC[7 Y>,'!^\N-P'3H3U[8H ]PHI%8,H92"I&
M01T-+0 45YE\1_C#;^ =:M]*CTG^TIY(/.EQ=>4(@20H^ZV2<$]N,>M8WA/X
M_P 'B3Q3I^C7&@"P2\E\H7!OM^UB#M&WRQG+87KWH ]FHHHH **X_P <?$G0
M? ENOV^4SWT@S'90$&0C^\?[J^YZX.,UXU?_ +27B"2?.G:)IEO#_=N#),WY
MJR?RH ^E:*^<](_:3U))@-9T*TFB(Y:S=HV'OABV?ID?6O<?"WBW1_&.E#4=
M&N?-B!VR(PVO$WHR]C^A[4 ;=%<_XV\3_P#"'>$+[7_L?VS[+Y?[CS?+W;I%
M3[V#C&[/3M7C_P#PTU_U*/\ Y4O_ +50!] 45\__ /#37_4H_P#E2_\ M5'_
M  TU_P!2C_Y4O_M5 'T!1532K[^T]'L=0\OROM5O'-LW;MNY0V,\9QFK= !1
M17!^//BQH/@246<XEO=390PM("/D!Z%V/W<_B>G&.: .\HKPJS_:6L'N]M]X
M:N8;;G]Y!=+*_P#WR54?^/5[%H/B#2_$VDQ:GI%VES:2$@,N05(ZJP/(/L:
M-.BBL'QCXJL_!OAB[UJ\&\1+B*'=@S2'[J X.,GO@X&3VH WJ*\T^&WQ;_X6
M%K%WI_\ 8GV#[/;^=O\ M?F[OF"XQL7'6O2Z "BO/O''Q@\.^";IM/<2W^IJ
M,M;6^,1^F]CPN1V&3Z@9%<9IW[2NGS7(34O#EQ:PD@>9!="8C_@)5?YT >Z4
M50T;6=/\0:3;ZII=REQ:3KN1U_4$=B.A!Y!J_0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 (WW3]*J67WG^@JVWW3]*J67WG^@H N4444 %%%% !1110
M 4444 %%>5ZMXPUZVUF^MX;[;%%<2(B^2AP Q '*U3_X3?Q%_P!!#_R#'_\
M$T >P45X_P#\)OXB_P"@A_Y!C_\ B:/^$W\1?]!#_P @Q_\ Q- 'L%%>/_\
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M^(O^@A_Y!C_^)H_X3?Q%_P!!#_R#'_\ $T >P45X_P#\)OXB_P"@A_Y!C_\
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M=>1BRW^"?^F,?_Q- 'L=%>/_ /";^(O^@A_Y!C_^)H_X3?Q%_P!!#_R#'_\
M$T >P45X_P#\)OXB_P"@A_Y!C_\ B:/^$W\1?]!#_P @Q_\ Q- 'L%%>/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6>TN$W(PZCU!'8@\$=C7*?&'Q$WASX;:C-#(T=S=XLX&4X(9\[L'L=@<_44
M?-?B>^N/B#\4KI[1BYU"^6VM<_W,A$/H/E )_'ZU6\<>'I/!'CR_TRVDF1;6
M82VDV2K[#AD(8=QG&1W!Z5V/[/WA[^U?'KZI(FZ#2H#("5R/-?*H/RWD>ZUU
M_P"TAX<$ECI7B.&(;XG-I<,J<E6&Y"3Z AAS_>'X@'K_ (2UU/$WA+2]90KF
M[MU=PIR%?HZ_@P8?A4_B#5XM \/:CJ\PS'9V[S%?[Q49 _$X'XUY!^SGXG%S
MH]_X:F?,MH_VJW!(_P!6Q 8 >S<_\#KIOCS,\7PJO44\2SPHWTWAOY@4 ?.%
MA;:K\2?'\4,TX.H:K<DR2E>$&,L0/15!P/08KZDT+X2^"]"L8X!H=K?2*/GG
MOHQ,[G&,_-P/H !7B?[.D22?$6\9U!:/3)&0GL?,B&?R)'XU],ZA>QZ;IMU?
M3*[16T+S.$ +%5!)QGOQ0!Y9\2O@UHNJZ!<WWAW3HK'5;9&E2&UCVI<8&2FP
M#[W'RXQR>?;C?@MX:\;^&O&$5S<:'>VVD7D9CN_."QX&"48JQ!R&'IG!-==_
MPT=X/_Z!NN?]^(?_ ([5S2?C[X5UG6;'2[?3]96>]N([>-I(8@H9V"@G$A.,
MGT- &I\;?^20Z[_V[_\ I1'7S[\(/#FE>*?'D>FZS:_:K0VTCF/S&3YAC!RI
M!_6OH+XV_P#)(==_[=__ $HCKY4\/^(]5\+:H-2T:Z^RW80H)/+5_E/488$?
MI0!]5_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..5X!_PNWXA_P#0
MP_\ DE;_ /QNM+P[\8_'M]XFTJSN=>WP3WD,4B?8X!N5G (R$R.#0!]3VEK#
M8V<%I;IL@@C6*-<D[548 R>3P*FHHH *^:;GX)>,]<\:_;==:#[+?7;2WES;
M7"L8U.6. V#_ +(P#CCC KZ6HH \ ^+/PF\*^&_ LFLZ-%)9W5H\:D-.SBX#
M,%/#$_-SNXP, \51_9KO;H:WK=@'8V;6R3,O82!L ^Q()^N!Z5P_C[6?'.O;
M;KQ'#JJ:4LK-:>?9F&'!)VD?*H8X/4\XKV[X&7'@Y?#DUIX>EE;4OE>_^U($
MGD(X#8!(V#)  )QGGD\@'6?$'QQ;^ /#:ZM/92WC23K;Q0HX0%R&;YF.<#"G
MD \XX[CY<\6^*?%/Q":XUC4(Y&TZPP-D*$06VX@ 9[L3ZDD_0<?6/BGPCI/C
M+3[>PUF*26U@N%N1&DA3<P5EP2.<88]"/K7$?&#2-/T/X+WUAI=G#:6L<D 6
M*%=H_P!8O)]2>Y/)[T >>?LV_P#(X:O_ ->'_M1:^@/%>J2:)X1UC5(1F:TL
MY9H^/X@I(_7%?/\ ^S;_ ,CAJ_\ UX?^U%KZ"\2Z0=?\+ZII"RB)KRUD@60C
M(4LI )]LT ?(OP_\-'Q]X_M["_N9!'.TEQ=R@_.P&6.,]R<#/;.>U>N_$WX+
M^&[#P;>ZOX>MFL+JP3SF0SO(DJ#[P.\D@@9(QZ8[Y'C/AG6M0^'7CR&]GM7%
MS83/#=6I;;N'*NI(X]P>1D UZ=X_^.^G>(?"5SHVBZ;>Q2WJ>5/-=;%$:Y&0
MH5FW9&1SC'O0!F?L\^)9K#QA-H$DK&TU*)GCC.2!,@W9'890/GUPOH*^G:^-
M/A+(8OBIX?90,FX*\^Z,/ZU]ET %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYI__ &%8_P#T5+7L%>/_ +1W_)/-/_["L?\ Z*EH ZGX0?\ )*- _P"N+_\
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M6WT-5K+^/\*LR?ZMOH:K67\?X4 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "F3?ZE_H:?3)O\ 4O\ 0T 0V7W&^M6:K67W
M&^M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3UY^J=6E2?PU?2Q,&C>SD96'0@H2#7GWQZ\,-KG@/^T8$4W.DR?:.1R8B,2
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M %ZR?^A"OHZ@#Y\OO^+?_M*1763'I^MD%R6P")CALGT$HW<]L?6I/',I\?\
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M#P=H X[_ #'&.ON._P#A+\/6\!^'I/MIC?5;XK)<E.1& /EC![XR23ZGV!H
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M_:$_Y''PQ_US/_HP4 ?0M?/7[0G_ "./AC_KF?\ T8*^A:^>OVA/^1Q\,?\
M7,_^C!0!]"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (WW3]*J67WG^@JVWW3]*J67WG^@H N4444 %%
M%% !1110 4444 >'Z]_R,.I_]?<O_H9K/K0U[_D8=3_Z^Y?_ $,UGT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %3V5E<:A=QVMK&9)I#A5'\_8465E<:A=QVMK&9)I#A5'\_85Z[X;\
M-V^@6F!B2[D'[V;'Z#T'\_Y %W1;&;3=)M[2XN6N)(UP7/\ (>PZ<U?HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "@]**#TH IV7WW^E7*IV7WW^
ME7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!LG^K;Z&JUE_'^%69/]6WT-5K+^/\* +=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !3)O\ 4O\ 0T^F3?ZE_H: (;+[C?6K
M-5K+[C?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!%<?\>[TRS_U)_WJ?<?\>[TRS_U)_P!Z@"Q1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2,H92K %2,$'H:6B@#"F\
M%>%+B5I9O#.C22,<L[V$1)/N2M:MG8VFGP>196L%M#G=Y<,81<^N!5BB@ HH
MHH **** "BBB@ K+U#PWH6K2F74M%TZ\D.,O<VJ2'C@<L#6I10!0T_0M(TD
M:;I5C9@9Q]FMTCQGK]T"K]%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[^^M],TZYO[R3R
M[6UB>:9]I.U%!+' Y. #TJQ45S;Q7=K-;7""2&9#'(AZ,I&"/RH \'^*7Q5T
MSQ7H47A?P?<3WMUJ5Q'%(RPM&&7/"#=@Y9MHZ8QD=Z]@\&>'(O"?A#3=%BY-
MO$/-;^](WS.?Q8G'H,"J6A?#?PAX;U$ZAI6AP0W?\,K,\A3_ '-Y.WJ1\N..
M*ZJ@"AK?_( U'_KUE_\ 037B_P"S1_R#/$7_ %V@_D]>YSPQW-O)!*NZ.12C
MKG&01@BL7PSX,T#P?%<1Z#8?9$N2K2CSI)-Q&<??8XZGI0!O4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_PKC1_^?F^_[[3_ .)H \OHKU#_ (5QH_\ S\WW_?:?_$T?\*XT?_GYOO\
MOM/_ (F@#R^BO4/^%<:/_P _-]_WVG_Q-'_"N-'_ .?F^_[[3_XF@#R^BO4/
M^%<:/_S\WW_?:?\ Q-'_  KC1_\ GYOO^^T_^)H \OHKU#_A7&C_ //S??\
M?:?_ !-'_"N-'_Y^;[_OM/\ XF@#R^BO4/\ A7&C_P#/S??]]I_\31_PKC1_
M^?F^_P"^T_\ B: /+Z*]0_X5QH__ #\WW_?:?_$T?\*XT?\ Y^;[_OM/_B:
M/+Z*]0_X5QH__/S??]]I_P#$T?\ "N-'_P"?F^_[[3_XF@#R^BO4/^%<:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW3]*J67WG^@JV
MWW3]*J67WG^@H N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 52M?^/A_H?YU=JE:_\?#_
M $/\Z +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !0>E%!Z4 4[+[[_2KE4[+[[_ $JY0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 -D_U;?0U6LOX_PJS)_JV^AJM9?Q_A
M0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*9-_J7^AI],F_P!2_P!#0!#9?<;ZU9JM9?<;ZU9H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (KC_CW>F6?^I/^]3[C_CW>
MF6?^I/\ O4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY=2K%;P1M++(W1%49)/L *Y?0?B=X/\ $VK1Z7I&K_:;V0,R1_9IDR ,GED
MZ#UH ZZBLO7_ !%I7A?2VU/6;K[-9JRH9/+9^3T&%!/Z5R?_  NWX>?]##_Y
M)7'_ ,;H ] HKA;?XR?#^ZE\J/Q%$K8SF6WFC'YL@%=AI^I6.K627NG7D%W:
MR9VS02!U..#R* +5%%% !17)W_Q,\'Z9XA;0;O65CU)94A,(@E8!VQ@;@I7N
M._'?&*ZR@ HHHH **R]?\1:5X7TMM3UFZ^S6:LJ&3RV?D]!A03^E.T+7M,\2
MZ3%JFD7/VFRE+!)/+9,E3@\, >H]* -*BBN?\3^-O#O@[[+_ &_J'V/[5O\
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M** "BBB@ HHHH 1ONGZ54LOO/]!5MONGZ54LOO/]!0!<HHHH **** "BBB@
MHHHH HR:UI44C1R:G9HZ$JRM.H((Z@C--_M[1_\ H+6/_@0G^->/Z]_R,.I_
M]?<O_H9K/H ]P_M[1_\ H+6/_@0G^-']O:/_ -!:Q_\  A/\:\/HH ]P_M[1
M_P#H+6/_ ($)_C1_;VC_ /06L?\ P(3_ !KP^B@#W#^WM'_Z"UC_ .!"?XT?
MV]H__06L?_ A/\:\/HH ]P_M[1_^@M8_^!"?XT?V]H__ $%K'_P(3_&O#Z*
M/</[>T?_ *"UC_X$)_C1_;VC_P#06L?_  (3_&O#Z* /</[>T?\ Z"UC_P"!
M"?XT?V]H_P#T%K'_ ,"$_P :\/HH ]P_M[1_^@M8_P#@0G^-']O:/_T%K'_P
M(3_&O#Z* /</[>T?_H+6/_@0G^-']O:/_P!!:Q_\"$_QKP^B@#W#^WM'_P"@
MM8_^!"?XT?V]H_\ T%K'_P "$_QKP^B@#W#^WM'_ .@M8_\ @0G^-']O:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MV3_5M]#5:R_C_"K,G^K;Z&JUE_'^% %NBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ IDW^I?Z&GTR;_4O]#0!#9?<;ZU9JM9?
M<;ZU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;DN]Y%J,;OL0[2&R90![&2,^P4]C7TO\,O$Z^+/ .FZ@TQENXT%O=EOO><@
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MAUR.Q( ![KXQ\1Z=H>@WZW&L6=C?/9S-;++<)'(S!3@H"<DYQT[U\\?"30/
M>L6NIW?C6^LQ,)52"*[U#[/D8RS\.I;GCTKVKXC^"=!\7:!/K-Z)I)K/3Y9+
M62*4J/NE@<=^0*\C^#/PX\/>-M&U.YUF*=Y+>X6./RIB@P5SVH ]]L[OPOX4
MM[#P_#J.G:>H11:6DMVH=E9B!M#-N;)SSSDUO5\[?%Y%C^.7A&-!A5ALP!Z
M7,E?1- &=>:_HVG7\-A?:O86MY, 8K>>Y1)'R<#:I.3D@@8[BK-]?V>F6<EY
M?W<%I:QXWS3R"-%R0!ECP,D@?C7@'QA_Y+MX3_ZY6?\ Z4R5Z/\ &W_DD.N_
M]N__ *41T =I'JNG2Z:-2CU"U>P(W"Z693$1G&=^<8SQUJ#3?$>AZQ*T6EZS
MIU](@RR6MTDI'U"D^AKY^^''@"^^)6@V<_B'4IX?#^F;K:RM;8A6=L[G;)!
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M_P ?#_0_SH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTEX@*PZ1X<B<@N3>SK[#*1_KYGY#\.S^"7A2Y\,>! ]_$T5[J$IN7C?(9$P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP\/?]>B_S-?/OQ&^W> O'GBK3K ".SUZW#?=P/+D<.VT=/O+(GT)Z'H >D?
MNREUJ_\ $GCB_B_TC4;MHX2XR47.]PK'J/F5>,?<Q],/P_\ \G4:A_UTG_\
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M=BQ ..V!T.0,OXQ^#]:L?%%EX_\ #4+2W%L8S<I$I9PZ'"N5'+*1A6]@.V<
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MP0%H8U1D+^BON!Q[D#Z&@#GOC#_R7;PG_P!<K/\ ]*9*]'^-O_)(==_[=_\
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MD\<<KC(ZUWOQ \4V'C+X ZOK.G1SQV\K1($G"AP5N8P<A21^M %KX-F4?!2
MPOLE NMC>C;WP?SKC_V9MGF>)\[=^+7'KC][G^GZ5W7P*_Y)/IO_ %UG_P#1
MC5YK?6FL?!#XD7&M6U@]UX;OBP(BX58V8'8>,*ZG&,\$< \G !](U\Z^-RP_
M::T/[,ZI)Y]GO(],C<#[E>/Q%=A=_M#>#XM.,]K#J%Q<E05MC"$.3V+9(&.Y
M&?;-<_\ "SPMKGBCQ]<_$3Q);- C.SVT<JD%W*[5VJ>=B)P">X&,X- $/[37
M_,K?]O?_ +1KWFQ_Y!]M_P!<E_D*\&_::_YE;_M[_P#:->\V/_(/MO\ KDO\
MA0!X-^TU_P RM_V]_P#M&O>;'_D'VW_7)?Y"O!OVFO\ F5O^WO\ ]HU[S8_\
M@^V_ZY+_ "% $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!LG^K;Z&JUE_'^%69/]6WT-5K+^/\* +=%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)O\ 4O\
M0T^F3?ZE_H: (;+[C?6K-5K+[C?6K- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!%<?\>[TRS_U)_WJ?<?\>[TRS_U)_P!Z
M@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ* (;2UAL;."TMTV001K%&N2=JJ, 9/)X%3444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_C5BB@ I&4,I5@"I&"#T-+10!EZ;X:T'1KAKC2]$TVQG9"C26MJD3%<@X)4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M;)_JV^AJM9?Q_A5F3_5M]#5:R_C_  H MT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %,F_U+_0T^F3?ZE_H: (;+[C?6K-5K
M+[C?6K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!%<?\>[TRS_ -2?]ZGW'_'N],L_]2?]Z@"Q1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 (WW3]*J67WG^@JX>1BHHH%A)().?6@"6BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J5K_Q\/]#_ #J[44<"QR%P2<^M $M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !0>E%% %.R^^_TJY444"PDD$G/K4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V
M3_5M]#5:R_C_  JT1N4@]QBF10B'."3GUH DHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *9-_J7^AI](R[T*GN,4 5[+[C?6
MK-1Q1")2 2<^M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $5Q_P >[TRS_P!2?]ZIG02(5/0TD48B3:"3SGF@!]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*AB=J*.!W^M 'TE15#1M9L/$&D0:KI<YGLK@$Q2&-DW $J>& /4'M5^@ HK
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MC[#'(T.&>3+C<3L4%@-Q."1V]J /1J*R=!\3:+XGM#=:+J4%[$N-_EM\R9Y
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M#U_79O\ 7:A?[&XP#L7=D>V96_*@#V&UM+:QM8[6TMXK>WB&V.*% B(/0 <
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MC;?,WNR $G@X"' QC+<YXQUMK\'OA[HMH99])BD6)<R7%[<,PQSRV2%'7T%
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MX;R6CB*S2A=IP'DRP^NV('GL1QZ[?[0D6HR?#N(V8D:V6\0W8C&?W>UL%O\
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MGUJM^T)-)J#>%_#5NY,M]>%]@7//RQH<#_KHWZU[5!#';6\<$2[8XU"(N<X
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MO$EYKVE>*+#[5K%E-D*US(A* E7QM89PP&21_$/6@#T6]T;X-WFB2:8+KPI
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MOA_^T9;Z/H[21:7JENQ> G< I1V 'L'08/4#(YSS[S)/#%;M<22HD"(7:1F
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M&/ -]=QP[ <?(N7Z=P"JC'N*T/$0;PC^S_-;[]LD&D1VK,H_CD"QDC'NYYH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD9/4XSUJI\/?!4?@+PS_ &.EX+QFG>=YQ#Y>XM@?=W'H% Z]JZJB@#AOB/\
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M1]YB<ENOL*;X[^%>B>.9H[V:2:QU2)0J7=OC) Z!E/7'8\'WQQ7=44 >._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sage-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-01T11:19:10.2690+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" xlink:href="sage-20230331.xsd#Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="sage_CostOfSales" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CostOfSales" xlink:label="sage_CostOfSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sage_PremiumOnMarketableSecurities" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="6" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="12" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumOnMarketableSecurities" xlink:label="sage_PremiumOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sage_AccruedResearchAndDevelopmentCosts" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AccruedResearchAndDevelopmentCosts" xlink:label="sage_AccruedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="sage_ReimbursementReductionsToOperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToOperatingExpenses" xlink:label="sage_ReimbursementReductionsToOperatingExpenses"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sage-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-01T11:19:09.7502+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail" xlink:href="sage-20230331.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail" xlink:href="sage-20230331.xsd#Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CostOfSales" xlink:label="sage_CostOfSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="sage_CostOfSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShionogiCollaborationAgreementMember" xlink:label="sage_ShionogiCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ShionogiCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NatureOfBusinessLineItems" xlink:label="sage_NatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NatureOfBusinessTable" xlink:label="sage_NatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ConvertibleNotesMember" xlink:label="sage_ConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" xlink:label="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="sage_NatureOfBusinessTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="sage_ConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sage_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCorporateBondsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:label="sage_DebtInstrumentFairValueCarryingValueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueTable" xlink:label="sage_DebtInstrumentFairValueCarryingValueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:label="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:label="us-gaap_EquitySecuritiesInvestmentObjectiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:label="us-gaap_EquitySecuritiesInvestmentObjectiveMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" xlink:label="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CorporateBondsAndMunicipalSecuritiesMember" xlink:label="sage_CorporateBondsAndMunicipalSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesRemainingContractualMaturities" xlink:label="sage_MarketableSecuritiesRemainingContractualMaturities"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" xlink:label="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesHeldToMaturityFairValue" xlink:label="sage_MarketableSecuritiesHeldToMaturityFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesMaturityPeriod" xlink:label="sage_MarketableSecuritiesMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_DebtInstrumentFairValueCarryingValueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:to="us-gaap_EquitySecuritiesInvestmentObjectiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:to="us-gaap_EquitySecuritiesInvestmentObjectiveMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_CorporateBondsAndMunicipalSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_MarketableSecuritiesRemainingContractualMaturities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_MarketableSecuritiesHeldToMaturityFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_MarketableSecuritiesMaturityPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sage_InternationalCorporateBondsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sage_InternationalCommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCorporateBondsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseOneMember" xlink:label="sage_OperatingLeaseOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AreaOfOfficeSpace" xlink:label="sage_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseTwoMember" xlink:label="sage_OperatingLeaseTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseThreeMember" xlink:label="sage_OperatingLeaseThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LessorOperatingLeaseRemainingLeaseTerms" xlink:label="sage_LessorOperatingLeaseRemainingLeaseTerms"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseFiveMember" xlink:label="sage_OperatingLeaseFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AreaOfOfficeSpace" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LessorOperatingLeaseRemainingLeaseTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseFiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseOneMember" xlink:label="sage_LicenseOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CydexLicenseAgreementMember" xlink:label="sage_CydexLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseTwoMember" xlink:label="sage_LicenseTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstAndSecondRegulatoryMilestonesMember" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalClinicalDevelopmentMilestoneMember" xlink:label="sage_AdditionalClinicalDevelopmentMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IntangibleAssetRelatedToMilestone" xlink:label="sage_IntangibleAssetRelatedToMilestone"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePaymentsRelatedToIntangibleAssets" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_LicenseOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_CydexLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_LicenseTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_AdditionalClinicalDevelopmentMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_IntangibleAssetRelatedToMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePaymentsRelatedToIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ScenarioOneMember" xlink:label="sage_ScenarioOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UniversityOfCaliforniaLicenseAgreementsMember" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PaymentForClinicalDevelopmentMilestones" xlink:label="sage_PaymentForClinicalDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ScenarioTwoMember" xlink:label="sage_ScenarioTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestoneOutstandingLicenseAgreement" xlink:label="sage_MilestoneOutstandingLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryAndSalesMilestonesMember" xlink:label="sage_RegulatoryAndSalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseAgreementMaximumTerm" xlink:label="sage_LicenseAgreementMaximumTerm"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IntangibleAssetRelatedToMilestone" xlink:label="sage_IntangibleAssetRelatedToMilestone"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePaymentsRelatedToIntangibleAssets" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_UniversityOfCaliforniaLicenseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_PaymentForClinicalDevelopmentMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestoneOutstandingLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_SalesMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryAndSalesMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseAgreementMaximumTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_UpFrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseMaintenanceCostAnnual" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_IntangibleAssetRelatedToMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePaymentsRelatedToIntangibleAssets" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementEffectiveDate" xlink:label="sage_CollaborationAgreementEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseThreeMember" xlink:label="sage_LicenseThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShionogiCollaborationAgreementMember" xlink:label="sage_ShionogiCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationRevenueMember" xlink:label="sage_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SAGE324Member" xlink:label="sage_SAGE324Member"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommercialMilestonesMember" xlink:label="sage_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenCollaborationAgreementMember" xlink:label="sage_BiogenCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" xlink:label="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstCommercialSaleOfZuranoloneMember" xlink:label="sage_FirstCommercialSaleOfZuranoloneMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenStockPurchaseAgreementMember" xlink:label="sage_BiogenStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AveragePercentageOnTieredRoyalties" xlink:label="sage_AveragePercentageOnTieredRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryAndCommercialMilestonesMember" xlink:label="sage_RegulatoryAndCommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PurchasePriceForNewShareIssued" xlink:label="sage_PurchasePriceForNewShareIssued"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsOrAdditionToOperatingExpenses" xlink:label="sage_ReimbursementReductionsOrAdditionToOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PaymentsToRelatedParties" xlink:label="sage_PaymentsToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ProceedsFromRelatedParties" xlink:label="sage_ProceedsFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborativeAgreementTransactionPrice" xlink:label="sage_CollaborativeAgreementTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumAmountOnEquityInvestment" xlink:label="sage_PremiumAmountOnEquityInvestment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumOnPerSharePricePercentage" xlink:label="sage_PremiumOnPerSharePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_StockPurchaseAgreementDescription" xlink:label="sage_StockPurchaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_CollaborationAgreementEffectiveDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_LicenseThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_RegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ShionogiCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sage_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_UpFrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_SAGE324Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_BiogenCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_FirstCommercialSaleOfZuranoloneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_BiogenStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_SalesMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_AveragePercentageOnTieredRoyalties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_RegulatoryAndCommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PurchasePriceForNewShareIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_ReimbursementReductionsOrAdditionToOperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PaymentsToRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_ProceedsFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_CollaborativeAgreementTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PremiumAmountOnEquityInvestment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PremiumOnPerSharePricePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_StockPurchaseAgreementDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssued1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementFromCollaborationAbstract" xlink:label="sage_ReimbursementFromCollaborationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToExpense" xlink:label="sage_ReimbursementReductionsToExpense"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenCollaborationAgreementMember" xlink:label="sage_BiogenCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" xlink:label="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToOperatingExpenses" xlink:label="sage_ReimbursementReductionsToOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementReductionsToExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_BiogenCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_ReimbursementFromCollaborationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementReductionsToOperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandElevenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestoneOneMember" xlink:label="sage_MilestoneOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TimeBasedRestrictedStockUnitsMember" xlink:label="sage_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandFourteenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PerformanceRestrictedStockUnitsMember" xlink:label="sage_PerformanceRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandSixteenStockOptionPlanMember" xlink:label="sage_TwoThousandSixteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PerformanceBasedStockOptionsMember" xlink:label="sage_PerformanceBasedStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePerformanceRestrictedStockPercentage" xlink:label="sage_MilestonePerformanceRestrictedStockPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NumberOfMilestonesAchieved" xlink:label="sage_NumberOfMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandElevenStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_MilestoneOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_TimeBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_PerformanceRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandSixteenStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_MilestonePerformanceRestrictedStockPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_NumberOfMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sage_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>sage-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-01T11:19:10.1126+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.sagerx.com/20230331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:sage="http://www.sagerx.com/20230331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sage-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sage-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sage-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sage-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100060 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100080 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100090 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingencies" id="Role_DisclosureLeasesCommitmentsAndContingencies">
        <link:definition>100100 - Disclosure - Leases, Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100110 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100120 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100130 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100140 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100150 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100160 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsTables" id="Role_DisclosureCollaborationAgreementsTables">
        <link:definition>100170 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100180 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100190 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100200 - Disclosure - Nature of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail">
        <link:definition>100220 - Disclosure - Fair Value Measurements - Summary of Company's Cash Equivalents and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100230 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail">
        <link:definition>100240 - Disclosure - Fair Value Measurements - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail">
        <link:definition>100250 - Disclosure - Fair Value Measurements - Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail">
        <link:definition>100260 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Leases, Commitments and Contingencies - Operating Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail" id="Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Leases, Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" id="Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail">
        <link:definition>100310 - Disclosure - Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" id="Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail">
        <link:definition>100330 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail" id="Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail">
        <link:definition>100340 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Time Based and Performance Based Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail">
        <link:definition>100350 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail">
        <link:definition>100360 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100370 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail" id="Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail">
        <link:definition>100380 - Disclosure - Net Loss Per Share - Summary of Anti-Dilutive Common Stock Equivalents Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sage_CollaborationAgreementAbstract" name="CollaborationAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_DebtInstrumentFairValueCarryingValueAbstract" name="DebtInstrumentFairValueCarryingValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ReimbursementFromCollaborationAbstract" name="ReimbursementFromCollaborationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" name="AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" name="AdditionalPaymentsBasedOnAchievementOfCertainMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_AreaOfOfficeSpace" name="AreaOfOfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_AveragePercentageOnTieredRoyalties" name="AveragePercentageOnTieredRoyalties" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_CollaborationAgreementEffectiveDate" name="CollaborationAgreementEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" name="CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_CollaborativeAgreementTransactionPrice" name="CollaborativeAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" name="CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_CostOfSales" name="CostOfSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" name="FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" name="IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" name="IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_IntangibleAssetRelatedToMilestone" name="IntangibleAssetRelatedToMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_LeaseAssetDeRecognizedUponLeaseCancellation" name="LeaseAssetDeRecognizedUponLeaseCancellation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_LessorOperatingLeaseRemainingLeaseTerms" name="LessorOperatingLeaseRemainingLeaseTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_LicenseAgreementMaximumTerm" name="LicenseAgreementMaximumTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_LicenseMaintenanceCostAnnual" name="LicenseMaintenanceCostAnnual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_MarketableSecuritiesHeldToMaturityFairValue" name="MarketableSecuritiesHeldToMaturityFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_MarketableSecuritiesMaturityPeriod" name="MarketableSecuritiesMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_MarketableSecuritiesRemainingContractualMaturities" name="MarketableSecuritiesRemainingContractualMaturities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_MilestoneOutstandingLicenseAgreement" name="MilestoneOutstandingLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_MilestonePaymentsRelatedToIntangibleAssets" name="MilestonePaymentsRelatedToIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_MilestonePerformanceRestrictedStockPercentage" name="MilestonePerformanceRestrictedStockPercentage" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" name="NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_PaymentForClinicalDevelopmentMilestones" name="PaymentForClinicalDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_PaymentsToRelatedParties" name="PaymentsToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" name="PercentageOfNetSalesRequiredForRoyaltyEntitlement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_PremiumAmountOnEquityInvestment" name="PremiumAmountOnEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_PremiumOnMarketableSecurities" name="PremiumOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_PremiumOnPerSharePricePercentage" name="PremiumOnPerSharePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" name="ProceedsFromIssuanceOrSaleOfEquityAndNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_ProceedsFromRelatedParties" name="ProceedsFromRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_PurchasePriceForNewShareIssued" name="PurchasePriceForNewShareIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_ReimbursementReductionsOrAdditionToOperatingExpenses" name="ReimbursementReductionsOrAdditionToOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_ReimbursementReductionsToExpense" name="ReimbursementReductionsToExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_ReimbursementReductionsToOperatingExpenses" name="ReimbursementReductionsToOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" name="ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" name="ResearchAndDevelopmentExpenseRelatedToMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_StockPurchaseAgreementDescription" name="StockPurchaseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_UpFrontPayment" name="UpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sage_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_DebtInstrumentFairValueCarryingValueLineItems" name="DebtInstrumentFairValueCarryingValueLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_NatureOfBusinessLineItems" name="NatureOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_AdditionalClinicalDevelopmentMilestoneMember" name="AdditionalClinicalDevelopmentMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_BiogenCollaborationAgreementMember" name="BiogenCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_BiogenStockPurchaseAgreementMember" name="BiogenStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" name="ClinicalDevelopmentAndRegulatoryMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ClinicalDevelopmentMilestonesMember" name="ClinicalDevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ConvertibleNotesMember" name="ConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_CorporateBondsAndMunicipalSecuritiesMember" name="CorporateBondsAndMunicipalSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_CydexLicenseAgreementMember" name="CydexLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" name="FirstAndSecondClinicalDevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_FirstAndSecondRegulatoryMilestonesMember" name="FirstAndSecondRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_FirstCommercialSaleOfZuranoloneMember" name="FirstCommercialSaleOfZuranoloneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_InternationalCommercialPaperMember" name="InternationalCommercialPaperMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_InternationalCorporateBondsMember" name="InternationalCorporateBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_LicenseOneMember" name="LicenseOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_LicenseThreeMember" name="LicenseThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_LicenseTwoMember" name="LicenseTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_MilestoneOneMember" name="MilestoneOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_OperatingLeaseFiveMember" name="OperatingLeaseFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_OperatingLeaseOneMember" name="OperatingLeaseOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_OperatingLeaseThreeMember" name="OperatingLeaseThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_OperatingLeaseTwoMember" name="OperatingLeaseTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_PerformanceBasedStockOptionsMember" name="PerformanceBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_PerformanceRestrictedStockUnitsMember" name="PerformanceRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_RegulatoryAndCommercialMilestonesMember" name="RegulatoryAndCommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_RegulatoryAndSalesMilestonesMember" name="RegulatoryAndSalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_SAGE324Member" name="SAGE324Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_SalesMilestonesMember" name="SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ScenarioOneMember" name="ScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ScenarioTwoMember" name="ScenarioTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ShionogiCollaborationAgreementMember" name="ShionogiCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" name="ThirdAndFourthClinicalDevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_ThirdAndFourthRegulatoryMilestonesMember" name="ThirdAndFourthRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_TimeBasedRestrictedStockUnitsMember" name="TimeBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_TwoThousandElevenStockOptionPlanMember" name="TwoThousandElevenStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" name="TwoThousandFourteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_TwoThousandFourteenStockOptionPlanMember" name="TwoThousandFourteenStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_TwoThousandSixteenStockOptionPlanMember" name="TwoThousandSixteenStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_UniversityOfCaliforniaLicenseAgreementsMember" name="UniversityOfCaliforniaLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_DebtInstrumentFairValueCarryingValueTable" name="DebtInstrumentFairValueCarryingValueTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_NatureOfBusinessTable" name="NatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sage_BusinessRisksAndUncertaintiesPolicyTextBlock" name="BusinessRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" name="SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sage-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-01T11:19:11.7454+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:label="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementEffectiveDate" xlink:label="sage_CollaborationAgreementEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ProceedsFromRelatedParties" xlink:label="sage_ProceedsFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryAndCommercialMilestonesMember" xlink:label="sage_RegulatoryAndCommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestoneOutstandingLicenseAgreement" xlink:label="sage_MilestoneOutstandingLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseOneMember" xlink:label="sage_LicenseOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_StockPurchaseAgreementDescription" xlink:label="sage_StockPurchaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesMaturityPeriod" xlink:label="sage_MarketableSecuritiesMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenStockPurchaseAgreementMember" xlink:label="sage_BiogenStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PaymentForClinicalDevelopmentMilestones" xlink:label="sage_PaymentForClinicalDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumOnPerSharePricePercentage" xlink:label="sage_PremiumOnPerSharePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PerformanceRestrictedStockUnitsMember" xlink:label="sage_PerformanceRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AccruedResearchAndDevelopmentCosts" xlink:label="sage_AccruedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CydexLicenseAgreementMember" xlink:label="sage_CydexLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:label="sage_DebtInstrumentFairValueCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseThreeMember" xlink:label="sage_LicenseThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SAGE324Member" xlink:label="sage_SAGE324Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseTwoMember" xlink:label="sage_OperatingLeaseTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborativeAgreementTransactionPrice" xlink:label="sage_CollaborativeAgreementTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueTable" xlink:label="sage_DebtInstrumentFairValueCarryingValueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesRemainingContractualMaturities" xlink:label="sage_MarketableSecuritiesRemainingContractualMaturities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" xlink:label="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:label="us-gaap_EquitySecuritiesInvestmentObjectiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandFourteenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NatureOfBusinessTable" xlink:label="sage_NatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PaymentsToRelatedParties" xlink:label="sage_PaymentsToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UniversityOfCaliforniaLicenseAgreementsMember" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandElevenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalClinicalDevelopmentMilestoneMember" xlink:label="sage_AdditionalClinicalDevelopmentMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstAndSecondRegulatoryMilestonesMember" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LeaseAssetDeRecognizedUponLeaseCancellation" xlink:label="sage_LeaseAssetDeRecognizedUponLeaseCancellation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandSixteenStockOptionPlanMember" xlink:label="sage_TwoThousandSixteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseFiveMember" xlink:label="sage_OperatingLeaseFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AveragePercentageOnTieredRoyalties" xlink:label="sage_AveragePercentageOnTieredRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseAgreementMaximumTerm" xlink:label="sage_LicenseAgreementMaximumTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TimeBasedRestrictedStockUnitsMember" xlink:label="sage_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PerformanceBasedStockOptionsMember" xlink:label="sage_PerformanceBasedStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementFromCollaborationAbstract" xlink:label="sage_ReimbursementFromCollaborationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumOnMarketableSecurities" xlink:label="sage_PremiumOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstCommercialSaleOfZuranoloneMember" xlink:label="sage_FirstCommercialSaleOfZuranoloneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryAndSalesMilestonesMember" xlink:label="sage_RegulatoryAndSalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NatureOfBusinessLineItems" xlink:label="sage_NatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ConvertibleNotesMember" xlink:label="sage_ConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ScenarioTwoMember" xlink:label="sage_ScenarioTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseThreeMember" xlink:label="sage_OperatingLeaseThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToExpense" xlink:label="sage_ReimbursementReductionsToExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestoneOneMember" xlink:label="sage_MilestoneOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LessorOperatingLeaseRemainingLeaseTerms" xlink:label="sage_LessorOperatingLeaseRemainingLeaseTerms"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PurchasePriceForNewShareIssued" xlink:label="sage_PurchasePriceForNewShareIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" xlink:label="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NumberOfMilestonesAchieved" xlink:label="sage_NumberOfMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IntangibleAssetRelatedToMilestone" xlink:label="sage_IntangibleAssetRelatedToMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" xlink:label="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementAbstract" xlink:label="sage_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsOrAdditionToOperatingExpenses" xlink:label="sage_ReimbursementReductionsOrAdditionToOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenCollaborationAgreementMember" xlink:label="sage_BiogenCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseOneMember" xlink:label="sage_OperatingLeaseOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePaymentsRelatedToIntangibleAssets" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommercialMilestonesMember" xlink:label="sage_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" xlink:label="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseTwoMember" xlink:label="sage_LicenseTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationRevenueMember" xlink:label="sage_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" xlink:label="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_GoingConcernPolicyTextBlock" xlink:label="sage_GoingConcernPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePerformanceRestrictedStockPercentage" xlink:label="sage_MilestonePerformanceRestrictedStockPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BusinessRisksAndUncertaintiesPolicyTextBlock" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToOperatingExpenses" xlink:label="sage_ReimbursementReductionsToOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AreaOfOfficeSpace" xlink:label="sage_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesHeldToMaturityFairValue" xlink:label="sage_MarketableSecuritiesHeldToMaturityFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" xlink:label="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ScenarioOneMember" xlink:label="sage_ScenarioOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CorporateBondsAndMunicipalSecuritiesMember" xlink:label="sage_CorporateBondsAndMunicipalSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:label="sage_DebtInstrumentFairValueCarryingValueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CostOfSales" xlink:label="sage_CostOfSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumAmountOnEquityInvestment" xlink:label="sage_PremiumAmountOnEquityInvestment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShionogiCollaborationAgreementMember" xlink:label="sage_ShionogiCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Objective</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities By Investment Objective [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement effective date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement efective date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental costs incurred expected amortization period of asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Practical Expedient Incremental Cost Of Obtaining Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted stock units vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use operating asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ProceedsFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ProceedsFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ProceedsFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryAndCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory and Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryAndCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory And Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryAndCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory and commercial milestones member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestoneOutstandingLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestoneOutstandingLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Outstanding License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestoneOutstandingLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone outstanding license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the employee stock purchase plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Weighted Average Grant Date Fair Value at ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Weighted Average Grant Date Fair Value at beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income from up-front</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brexanolone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use operating asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right of use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee-related</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_StockPurchaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen stock purchase agreement, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_StockPurchaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_StockPurchaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities held, maturity period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities maturity period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net sales paid as royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Sales Required For Royalty Entitlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty percentage on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Vest Two Year Anniversary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Product and Service [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BiogenStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BiogenStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BiogenStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen Stock Purchase Agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PaymentForClinicalDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PaymentForClinicalDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Clinical Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PaymentForClinicalDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for clinical development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumOnPerSharePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium on per share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumOnPerSharePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium On Per Share Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumOnPerSharePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium on per share price, percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third and Fourth Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third And Fourth Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third and fourth regulatory milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding&#8212; basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PerformanceRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PerformanceRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PerformanceRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Vest One Year Anniversary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrealized Loss On Investments Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 months, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Available For Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued research and development costs, such as clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating costs and expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CydexLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CyDex License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CydexLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cydex License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CydexLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CyDex license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share&#8212;diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fair Value Carrying Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument Fair Value Carrying Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Anti-Dilutive Common Stock Equivalents Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SAGE-217 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued or outstanding at March 31, 2023 and December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SAGE324Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SAGE-324 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SAGE324Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S A G E324 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SAGE324Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SAGE-324 member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborativeAgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price, total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborativeAgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreement Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborativeAgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreement transaction price, total.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseMaintenanceCostAnnual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseMaintenanceCostAnnual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Cost Annual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseMaintenanceCostAnnual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance cost annual.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments And Contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Remaining Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock option exercises and employee stock purchase plan issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average common stock outstanding &#8212;diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding&#8212; diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Fair Value Carrying Value [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fair Value Carrying Value [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument fair value carrying value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesRemainingContractualMaturities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, remaining contractual maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesRemainingContractualMaturities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Remaining Contractual Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesRemainingContractualMaturities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The remaining contractual period for marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Selling, general and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Reductions To Selling General And Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement reductions to selling, general and administrative expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesInvestmentObjectiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Objective</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesInvestmentObjectiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Investment Objective [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium (discount) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen stock option plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by share based payment award award remaining vesting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Award Remaining Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation remaining vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expire date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payments Based On Achievement Of Certain Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payments based on achievement of certain milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Standalone selling price of license performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PaymentsToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PaymentsToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PaymentsToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of California License Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of California License Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of California license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering of common stock, net of offering costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandElevenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2011 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandElevenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eleven Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandElevenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eleven stock option plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalClinicalDevelopmentMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional clinical development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalClinicalDevelopmentMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Clinical Development Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First and Second Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First And Second Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First and second regulatory milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development and Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development And Regulatory Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development and regulatory milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding and unvested stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LeaseAssetDeRecognizedUponLeaseCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease asset de-recognized upon lease cancellation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LeaseAssetDeRecognizedUponLeaseCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Asset De Recognized Upon Lease Cancellation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LeaseAssetDeRecognizedUponLeaseCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease asset de-recognized upon lease cancellation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating costs and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, net of employee tax obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value per share; 120,000,000 shares authorized at March 31, 2023 and December 31, 2022; 59,765,034 and 59,512,158 shares issued at March 31, 2023 and December 31, 2022; 59,762,001 and 59,509,125 shares outstanding at March 31, 2023 and December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized loss on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandSixteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandSixteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TwoThousandSixteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 Stock Option Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease five member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AveragePercentageOnTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average percentage on tiered royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AveragePercentageOnTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average Percentage On Tiered Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AveragePercentageOnTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Average percentage on tiered royalties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Greater than 12 months, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseAgreementMaximumTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses Expiration period, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseAgreementMaximumTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Maximum Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseAgreementMaximumTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement maximum term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time based restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases, Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance-based stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive gain (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementFromCollaborationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net reimbursement to (from) Biogen reflected in the condensed consolidated statements of operations and comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementFromCollaborationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement From Collaboration [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementFromCollaborationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement from collaboration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of employee tax obligations related to vesting of restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Premium on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium On Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium on marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstCommercialSaleOfZuranoloneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Commercial Sale of Zuranolone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstCommercialSaleOfZuranoloneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First commercial sale of Zuranolone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, consideration received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Received On Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, term of plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory and Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory And Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory and sales milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_InternationalCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">International Corporate Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_InternationalCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">International Corporate Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_InternationalCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">International corporate bonds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front payments receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Corporate Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities non current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After The First Sale [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period of unrecognized compensation costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive items:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Reductions To Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of reimbursement from collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Relating to Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Relating to Time Based and Performance Based Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LessorOperatingLeaseRemainingLeaseTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease remaining lease terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LessorOperatingLeaseRemainingLeaseTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Remaining Lease Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LessorOperatingLeaseRemainingLeaseTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor operating lease remaining lease rerms.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PurchasePriceForNewShareIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PurchasePriceForNewShareIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price For New Share Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PurchasePriceForNewShareIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price for new share issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Bond Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Bond Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of marketable securities not part of remaining contractual maturities of one year or less</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Marketable Securities Not Part Of Remaining Contractual Maturities Of One Year Or Less</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of marketable securities not part of remaining contractual maturities of one year or less.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestones achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IntangibleAssetRelatedToMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset related to milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IntangibleAssetRelatedToMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset Related To Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_IntangibleAssetRelatedToMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible asset related to milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers among the Level 1, Level 2 and Level 3 categories</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of transfers of assets measured on a recurring basis among Level 1, Level 2 and Level 3.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, vest period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award award cliff vesting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to the Biogen Collaboration Agreement incurred by Sage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Up front payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsOrAdditionToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsOrAdditionToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Reductions Or Addition To Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsOrAdditionToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement reductions or addition to operating expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BiogenCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BiogenCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BiogenCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen Collaboration Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_OperatingLeaseOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for issuance under stock option plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase on outstanding shares of Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding Reserved For Issuance Increase Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage increase in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments related to intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Related To Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments related to intangible assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Common Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units vesting period month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award award vesting period month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_InternationalCommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">International Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_InternationalCommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">International Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_InternationalCommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">International commercial paper.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock, at cost, 3,033 shares at March 31, 2023 and December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Common Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Greater than 12 months, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation granted under plan vested period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Regulatory And Commercial Event Based Additional Milestone Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement regulatory and commercial event based additional milestone payment receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SAGE-689 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_LicenseTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Municipal Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Expenses Category Related to Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Operating Expenses Category Related To Collaboration Agreement Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of operating expenses category related to collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding and unvested restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Shares at beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Shares at ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePerformanceRestrictedStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone performance restricted stock percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePerformanceRestrictedStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Performance Restricted Stock Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MilestonePerformanceRestrictedStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone performance restricted stock percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third and Fourth Clinical Development Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third And Fourth Clinical Development Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third and fourth clinical development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total number of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Outstanding Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Outstanding Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Collaboration receivable - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share&#8212;basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares annual increase added to plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business risks and uncertainties policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Reductions To Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ReimbursementReductionsToOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement reductions to operating expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Office space rent under operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Office Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space in square feet.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesHeldToMaturityFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities fair value held to maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesHeldToMaturityFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Held To Maturity Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_MarketableSecuritiesHeldToMaturityFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities held to maturity fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Future milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payments Based On Achievement Of Certain Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payments based on achievement of certain milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less than 12 months, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of equity and notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity And Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the issuance of equity and debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After The Effective Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of shares of common stock equivalents resulting from common stock options and restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Conversion Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CorporateBondsAndMunicipalSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds and Municipal Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CorporateBondsAndMunicipalSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bonds And Municipal Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CorporateBondsAndMunicipalSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds and municipal securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Fair Value Carrying Value [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fair Value Carrying Value [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_DebtInstrumentFairValueCarryingValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument fair value carrying value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of goods sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercises of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First and Second Clinical Development Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First And Second Clinical Development Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First and second clinical development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense by Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, net of employee tax obligations, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercises of stock options, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumAmountOnEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium amount on equity investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumAmountOnEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Amount On Equity Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_PremiumAmountOnEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium amount on equity investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense related to milestone expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Related To Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense related to milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Gross Unrealized Gains and Losses of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Accounting Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShionogiCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shionogi Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShionogiCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shionogi Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShionogiCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shionogi collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share based payment award, vesting frequency.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Vesting Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation vesting frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock units granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive common stock equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash operating and investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:to="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CollaborationAgreementEffectiveDate" xlink:to="sage_CollaborationAgreementEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ProceedsFromRelatedParties" xlink:to="sage_ProceedsFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_RegulatoryAndCommercialMilestonesMember" xlink:to="sage_RegulatoryAndCommercialMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestoneOutstandingLicenseAgreement" xlink:to="sage_MilestoneOutstandingLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseOneMember" xlink:to="sage_LicenseOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sage_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_StockPurchaseAgreementDescription" xlink:to="sage_StockPurchaseAgreementDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MarketableSecuritiesMaturityPeriod" xlink:to="sage_MarketableSecuritiesMaturityPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:to="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseOptionToExtend" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_BiogenStockPurchaseAgreementMember" xlink:to="sage_BiogenStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PaymentForClinicalDevelopmentMilestones" xlink:to="sage_PaymentForClinicalDevelopmentMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PremiumOnPerSharePricePercentage" xlink:to="sage_PremiumOnPerSharePricePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:to="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PerformanceRestrictedStockUnitsMember" xlink:to="sage_PerformanceRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AccruedResearchAndDevelopmentCosts" xlink:to="sage_AccruedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CydexLicenseAgreementMember" xlink:to="sage_CydexLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="sage_DebtInstrumentFairValueCarryingValueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseThreeMember" xlink:to="sage_LicenseThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SAGE324Member" xlink:to="sage_SAGE324Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_OperatingLeaseTwoMember" xlink:to="sage_OperatingLeaseTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CollaborativeAgreementTransactionPrice" xlink:to="sage_CollaborativeAgreementTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseMaintenanceCostAnnual" xlink:to="sage_LicenseMaintenanceCostAnnual_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="sage_DebtInstrumentFairValueCarryingValueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MarketableSecuritiesRemainingContractualMaturities" xlink:to="sage_MarketableSecuritiesRemainingContractualMaturities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" xlink:to="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:to="us-gaap_EquitySecuritiesInvestmentObjectiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandFourteenStockOptionPlanMember" xlink:to="sage_TwoThousandFourteenStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:to="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_NatureOfBusinessTable" xlink:to="sage_NatureOfBusinessTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PaymentsToRelatedParties" xlink:to="sage_PaymentsToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_UniversityOfCaliforniaLicenseAgreementsMember" xlink:to="sage_UniversityOfCaliforniaLicenseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandElevenStockOptionPlanMember" xlink:to="sage_TwoThousandElevenStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AdditionalClinicalDevelopmentMilestoneMember" xlink:to="sage_AdditionalClinicalDevelopmentMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstAndSecondRegulatoryMilestonesMember" xlink:to="sage_FirstAndSecondRegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:to="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LeaseAssetDeRecognizedUponLeaseCancellation" xlink:to="sage_LeaseAssetDeRecognizedUponLeaseCancellation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandSixteenStockOptionPlanMember" xlink:to="sage_TwoThousandSixteenStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_OperatingLeaseFiveMember" xlink:to="sage_OperatingLeaseFiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AveragePercentageOnTieredRoyalties" xlink:to="sage_AveragePercentageOnTieredRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseAgreementMaximumTerm" xlink:to="sage_LicenseAgreementMaximumTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TimeBasedRestrictedStockUnitsMember" xlink:to="sage_TimeBasedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PerformanceBasedStockOptionsMember" xlink:to="sage_PerformanceBasedStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementFromCollaborationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PremiumOnMarketableSecurities" xlink:to="sage_PremiumOnMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_EmployeeStockPurchasePlanMember" xlink:to="sage_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstCommercialSaleOfZuranoloneMember" xlink:to="sage_FirstCommercialSaleOfZuranoloneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_RegulatoryAndSalesMilestonesMember" xlink:to="sage_RegulatoryAndSalesMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="sage_NatureOfBusinessLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_InternationalCorporateBondsMember" xlink:to="sage_InternationalCorporateBondsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ConvertibleNotesMember" xlink:to="sage_ConvertibleNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:to="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ScenarioTwoMember" xlink:to="sage_ScenarioTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_OperatingLeaseThreeMember" xlink:to="sage_OperatingLeaseThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ReimbursementReductionsToExpense" xlink:to="sage_ReimbursementReductionsToExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestoneOneMember" xlink:to="sage_MilestoneOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_RegulatoryMilestonesMember" xlink:to="sage_RegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LessorOperatingLeaseRemainingLeaseTerms" xlink:to="sage_LessorOperatingLeaseRemainingLeaseTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PurchasePriceForNewShareIssued" xlink:to="sage_PurchasePriceForNewShareIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBondSecuritiesMember" xlink:to="us-gaap_USTreasuryBondSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" xlink:to="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SalesMilestonesMember" xlink:to="sage_SalesMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_NumberOfMilestonesAchieved" xlink:to="sage_NumberOfMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IntangibleAssetRelatedToMilestone" xlink:to="sage_IntangibleAssetRelatedToMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" xlink:to="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CollaborationAgreementAbstract" xlink:to="sage_CollaborationAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_UpFrontPayment" xlink:to="sage_UpFrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ReimbursementReductionsOrAdditionToOperatingExpenses" xlink:to="sage_ReimbursementReductionsOrAdditionToOperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_BiogenCollaborationAgreementMember" xlink:to="sage_BiogenCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ClinicalDevelopmentMilestonesMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_OperatingLeaseOneMember" xlink:to="sage_OperatingLeaseOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" xlink:to="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestonePaymentsRelatedToIntangibleAssets" xlink:to="sage_MilestonePaymentsRelatedToIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommercialMilestonesMember" xlink:to="sage_CommercialMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_InternationalCommercialPaperMember" xlink:to="sage_InternationalCommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" xlink:to="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseTwoMember" xlink:to="sage_LicenseTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CollaborationRevenueMember" xlink:to="sage_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalBondsMember" xlink:to="us-gaap_MunicipalBondsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" xlink:to="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_GoingConcernPolicyTextBlock" xlink:to="sage_GoingConcernPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestonePayments" xlink:to="sage_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestonePerformanceRestrictedStockPercentage" xlink:to="sage_MilestonePerformanceRestrictedStockPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:to="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_BusinessRisksAndUncertaintiesPolicyTextBlock" xlink:to="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ReimbursementReductionsToOperatingExpenses" xlink:to="sage_ReimbursementReductionsToOperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AreaOfOfficeSpace" xlink:to="sage_AreaOfOfficeSpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MarketableSecuritiesHeldToMaturityFairValue" xlink:to="sage_MarketableSecuritiesHeldToMaturityFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" xlink:to="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseRenewalTerm" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" xlink:to="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ScenarioOneMember" xlink:to="sage_ScenarioOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CorporateBondsAndMunicipalSecuritiesMember" xlink:to="sage_CorporateBondsAndMunicipalSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_DebtInstrumentFairValueCarryingValueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CostOfSales" xlink:to="sage_CostOfSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:to="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PremiumAmountOnEquityInvestment" xlink:to="sage_PremiumAmountOnEquityInvestment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShionogiCollaborationAgreementMember" xlink:to="sage_ShionogiCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sage-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-01T11:19:09.7264+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="sage-20230331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="sage-20230331.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="sage-20230331.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="sage-20230331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="sage-20230331.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingencies" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="sage-20230331.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sage-20230331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="sage-20230331.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsTables" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="sage-20230331.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:href="sage-20230331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="sage-20230331.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:href="sage-20230331.xsd#Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" xlink:href="sage-20230331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail" xlink:href="sage-20230331.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" xlink:href="sage-20230331.xsd#Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail" xlink:href="sage-20230331.xsd#Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CostOfSales" xlink:label="sage_CostOfSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="sage_CostOfSales" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumOnMarketableSecurities" xlink:label="sage_PremiumOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LeaseAssetDeRecognizedUponLeaseCancellation" xlink:label="sage_LeaseAssetDeRecognizedUponLeaseCancellation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" xlink:label="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sage_PremiumOnMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sage_LeaseAssetDeRecognizedUponLeaseCancellation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_12"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShionogiCollaborationAgreementMember" xlink:label="sage_ShionogiCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementAbstract" xlink:label="sage_CollaborationAgreementAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ShionogiCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CollaborationAgreementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BusinessRisksAndUncertaintiesPolicyTextBlock" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_GoingConcernPolicyTextBlock" xlink:label="sage_GoingConcernPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_BusinessRisksAndUncertaintiesPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_GoingConcernPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementAbstract" xlink:label="sage_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" xlink:label="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CollaborationAgreementAbstract" xlink:to="sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NatureOfBusinessTable" xlink:label="sage_NatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NatureOfBusinessLineItems" xlink:label="sage_NatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ConvertibleNotesMember" xlink:label="sage_ConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" xlink:label="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sage_NatureOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="sage_ConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="sage_NatureOfBusinessLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sage_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCorporateBondsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCommercialPaperMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:label="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:label="us-gaap_EquitySecuritiesInvestmentObjectiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:label="sage_DebtInstrumentFairValueCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueTable" xlink:label="sage_DebtInstrumentFairValueCarryingValueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:label="sage_DebtInstrumentFairValueCarryingValueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" xlink:label="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CorporateBondsAndMunicipalSecuritiesMember" xlink:label="sage_CorporateBondsAndMunicipalSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesRemainingContractualMaturities" xlink:label="sage_MarketableSecuritiesRemainingContractualMaturities"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" xlink:label="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesHeldToMaturityFairValue" xlink:label="sage_MarketableSecuritiesHeldToMaturityFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MarketableSecuritiesMaturityPeriod" xlink:label="sage_MarketableSecuritiesMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" xlink:to="us-gaap_EquitySecuritiesInvestmentObjectiveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="sage_DebtInstrumentFairValueCarryingValueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesInvestmentObjectiveMember" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_CorporateBondsAndMunicipalSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="us-gaap_EquitySecuritiesByInvestmentObjectiveAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_MarketableSecuritiesRemainingContractualMaturities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueTable" xlink:to="sage_DebtInstrumentFairValueCarryingValueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_MarketableSecuritiesHeldToMaturityFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="sage_MarketableSecuritiesMaturityPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:label="sage_DebtInstrumentFairValueCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sage_InternationalCorporateBondsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sage_InternationalCommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:label="sage_DebtInstrumentFairValueCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCorporateBondsMember" xlink:label="sage_InternationalCorporateBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_InternationalCommercialPaperMember" xlink:label="sage_InternationalCommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCorporateBondsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sage_InternationalCommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AccruedResearchAndDevelopmentCosts" xlink:label="sage_AccruedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sage_AccruedResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseOneMember" xlink:label="sage_OperatingLeaseOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AreaOfOfficeSpace" xlink:label="sage_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseTwoMember" xlink:label="sage_OperatingLeaseTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseThreeMember" xlink:label="sage_OperatingLeaseThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LessorOperatingLeaseRemainingLeaseTerms" xlink:label="sage_LessorOperatingLeaseRemainingLeaseTerms"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_OperatingLeaseFiveMember" xlink:label="sage_OperatingLeaseFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AreaOfOfficeSpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LessorOperatingLeaseRemainingLeaseTerms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sage_OperatingLeaseFiveMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseOneMember" xlink:label="sage_LicenseOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CydexLicenseAgreementMember" xlink:label="sage_CydexLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseTwoMember" xlink:label="sage_LicenseTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstAndSecondRegulatoryMilestonesMember" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalClinicalDevelopmentMilestoneMember" xlink:label="sage_AdditionalClinicalDevelopmentMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IntangibleAssetRelatedToMilestone" xlink:label="sage_IntangibleAssetRelatedToMilestone"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePaymentsRelatedToIntangibleAssets" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_LicenseOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_CydexLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_LicenseTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondRegulatoryMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_AdditionalClinicalDevelopmentMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthRegulatoryMilestonesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_IntangibleAssetRelatedToMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePaymentsRelatedToIntangibleAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ScenarioOneMember" xlink:label="sage_ScenarioOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UniversityOfCaliforniaLicenseAgreementsMember" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PaymentForClinicalDevelopmentMilestones" xlink:label="sage_PaymentForClinicalDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ScenarioTwoMember" xlink:label="sage_ScenarioTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestoneOutstandingLicenseAgreement" xlink:label="sage_MilestoneOutstandingLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryAndSalesMilestonesMember" xlink:label="sage_RegulatoryAndSalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseAgreementMaximumTerm" xlink:label="sage_LicenseAgreementMaximumTerm"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_IntangibleAssetRelatedToMilestone" xlink:label="sage_IntangibleAssetRelatedToMilestone"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePaymentsRelatedToIntangibleAssets" xlink:label="sage_MilestonePaymentsRelatedToIntangibleAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_UniversityOfCaliforniaLicenseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_PaymentForClinicalDevelopmentMilestones" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestoneOutstandingLicenseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_SalesMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryAndSalesMilestonesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseAgreementMaximumTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_UpFrontPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseMaintenanceCostAnnual" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_IntangibleAssetRelatedToMilestone" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePaymentsRelatedToIntangibleAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementEffectiveDate" xlink:label="sage_CollaborationAgreementEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_LicenseThreeMember" xlink:label="sage_LicenseThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShionogiCollaborationAgreementMember" xlink:label="sage_ShionogiCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementAbstract" xlink:label="sage_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationRevenueMember" xlink:label="sage_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SAGE324Member" xlink:label="sage_SAGE324Member"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommercialMilestonesMember" xlink:label="sage_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenCollaborationAgreementMember" xlink:label="sage_BiogenCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" xlink:label="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_FirstCommercialSaleOfZuranoloneMember" xlink:label="sage_FirstCommercialSaleOfZuranoloneMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenStockPurchaseAgreementMember" xlink:label="sage_BiogenStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" xlink:label="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_AveragePercentageOnTieredRoyalties" xlink:label="sage_AveragePercentageOnTieredRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_RegulatoryAndCommercialMilestonesMember" xlink:label="sage_RegulatoryAndCommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PurchasePriceForNewShareIssued" xlink:label="sage_PurchasePriceForNewShareIssued"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsOrAdditionToOperatingExpenses" xlink:label="sage_ReimbursementReductionsOrAdditionToOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PaymentsToRelatedParties" xlink:label="sage_PaymentsToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ProceedsFromRelatedParties" xlink:label="sage_ProceedsFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborativeAgreementTransactionPrice" xlink:label="sage_CollaborativeAgreementTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumAmountOnEquityInvestment" xlink:label="sage_PremiumAmountOnEquityInvestment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PremiumOnPerSharePricePercentage" xlink:label="sage_PremiumOnPerSharePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_StockPurchaseAgreementDescription" xlink:label="sage_StockPurchaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_CollaborationAgreementEffectiveDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_LicenseThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_RegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ShionogiCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CollaborationAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sage_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_UpFrontPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sage_SAGE324Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_BiogenCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_FirstCommercialSaleOfZuranoloneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_BiogenStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_SalesMilestonesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_AveragePercentageOnTieredRoyalties" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_RegulatoryAndCommercialMilestonesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PurchasePriceForNewShareIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_ReimbursementReductionsOrAdditionToOperatingExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PaymentsToRelatedParties" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_ProceedsFromRelatedParties" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_CollaborativeAgreementTransactionPrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PremiumAmountOnEquityInvestment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_PremiumOnPerSharePricePercentage" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_StockPurchaseAgreementDescription" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssued1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementFromCollaborationAbstract" xlink:label="sage_ReimbursementFromCollaborationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToExpense" xlink:label="sage_ReimbursementReductionsToExpense"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_BiogenCollaborationAgreementMember" xlink:label="sage_BiogenCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CollaborationAgreementAbstract" xlink:label="sage_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" xlink:label="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ReimbursementReductionsToOperatingExpenses" xlink:label="sage_ReimbursementReductionsToOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementReductionsToExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_BiogenCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CollaborationAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sage_ReimbursementFromCollaborationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="sage_ReimbursementReductionsToOperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_ReimbursementFromCollaborationAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandElevenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestoneOneMember" xlink:label="sage_MilestoneOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TimeBasedRestrictedStockUnitsMember" xlink:label="sage_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandFourteenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PerformanceRestrictedStockUnitsMember" xlink:label="sage_PerformanceRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandSixteenStockOptionPlanMember" xlink:label="sage_TwoThousandSixteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_PerformanceBasedStockOptionsMember" xlink:label="sage_PerformanceBasedStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_MilestonePerformanceRestrictedStockPercentage" xlink:label="sage_MilestonePerformanceRestrictedStockPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_NumberOfMilestonesAchieved" xlink:label="sage_NumberOfMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandElevenStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_MilestoneOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_TimeBasedRestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenStockOptionPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_PerformanceRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandSixteenStockOptionPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_PerformanceBasedStockOptionsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_MilestonePerformanceRestrictedStockPercentage" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_NumberOfMilestonesAchieved" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="sage-20230331.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sage_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564246431776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAGE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sage Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001597553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,762,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-4486580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">215 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">299-8380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245081120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 206,557<span></span>
</td>
<td class="nump">$ 162,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">923,028<span></span>
</td>
<td class="nump">1,109,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">58,850<span></span>
</td>
<td class="nump">50,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Collaboration receivable - related party</a></td>
<td class="nump">15,002<span></span>
</td>
<td class="nump">13,660<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,203,437<span></span>
</td>
<td class="nump">1,336,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating asset</a></td>
<td class="nump">9,062<span></span>
</td>
<td class="nump">10,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,255<span></span>
</td>
<td class="nump">4,770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,220,686<span></span>
</td>
<td class="nump">1,356,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,263<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">64,745<span></span>
</td>
<td class="nump">72,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">7,684<span></span>
</td>
<td class="nump">7,643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">84,692<span></span>
</td>
<td class="nump">99,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">4,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">87,557<span></span>
</td>
<td class="nump">103,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued or outstanding at March 31, 2023 and December 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 120,000,000 shares authorized at March 31, 2023 and December 31, 2022; 59,765,034 and 59,512,158 shares issued at March 31, 2023 and December 31, 2022; 59,762,001 and 59,509,125 shares outstanding at March 31, 2023 and December 31, 2022</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 3,033 shares at March 31, 2023 and December 31, 2022</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">3,313,609<span></span>
</td>
<td class="nump">3,291,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,174,998)<span></span>
</td>
<td class="num">(2,028,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,088)<span></span>
</td>
<td class="num">(10,206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,133,129<span></span>
</td>
<td class="nump">1,252,599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,220,686<span></span>
</td>
<td class="nump">$ 1,356,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564246352928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">59,765,034<span></span>
</td>
<td class="nump">59,512,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">59,762,001<span></span>
</td>
<td class="nump">59,509,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">3,033<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245061072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">92,826<span></span>
</td>
<td class="nump">78,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">65,708<span></span>
</td>
<td class="nump">46,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">158,764<span></span>
</td>
<td class="nump">124,781<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(155,470)<span></span>
</td>
<td class="num">(123,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">8,830<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (146,828)<span></span>
</td>
<td class="num">$ (122,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share&#8212;basic</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share&#8212;diluted</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding&#8212; basic</a></td>
<td class="nump">59,674,127<span></span>
</td>
<td class="nump">59,028,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding&#8212; diluted</a></td>
<td class="nump">59,674,127<span></span>
</td>
<td class="nump">59,028,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (146,828)<span></span>
</td>
<td class="num">$ (122,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">5,118<span></span>
</td>
<td class="num">(8,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive gain (loss)</a></td>
<td class="nump">5,118<span></span>
</td>
<td class="num">(8,541)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(141,710)<span></span>
</td>
<td class="num">(130,596)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 3,294<span></span>
</td>
<td class="nump">$ 1,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564241675472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (146,828)<span></span>
</td>
<td class="num">$ (122,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">20,038<span></span>
</td>
<td class="nump">18,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PremiumOnMarketableSecurities', window );">Premium on marketable securities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(1,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="num">(3,179)<span></span>
</td>
<td class="nump">3,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(8,024)<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Collaboration receivable - related party</a></td>
<td class="num">(1,342)<span></span>
</td>
<td class="num">(1,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">515<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Right-of-use operating asset</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="num">(1,728)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(6,550)<span></span>
</td>
<td class="num">(3,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(8,389)<span></span>
</td>
<td class="num">(4,507)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(153,682)<span></span>
</td>
<td class="num">(107,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">351,982<span></span>
</td>
<td class="nump">292,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(156,890)<span></span>
</td>
<td class="num">(301,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">194,867<span></span>
</td>
<td class="num">(9,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock option exercises and employee stock purchase plan issuances</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee tax obligations related to vesting of restricted stock units</a></td>
<td class="num">(629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">43,857<span></span>
</td>
<td class="num">(115,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">163,969<span></span>
</td>
<td class="nump">295,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 207,826<span></span>
</td>
<td class="nump">$ 179,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PremiumOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PremiumOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245127552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 1,729,031<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="nump">$ 3,227,471<span></span>
</td>
<td class="num">$ (2,660)<span></span>
</td>
<td class="num">$ (1,495,386)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,937,050<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercises of stock options, Amount</a></td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercises of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized loss on available-for-sale securities</a></td>
<td class="num">(8,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(122,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,055)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2022</a></td>
<td class="nump">1,618,502<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="nump">3,247,538<span></span>
</td>
<td class="num">(11,201)<span></span>
</td>
<td class="num">(1,617,441)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,066,149<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">1,252,599<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="nump">3,291,369<span></span>
</td>
<td class="num">(10,206)<span></span>
</td>
<td class="num">(2,028,170)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,509,125<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercises of stock options, Amount</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercises of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">19,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized loss on available-for-sale securities</a></td>
<td class="nump">5,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units, net of employee tax obligations</a></td>
<td class="num">(629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units, net of employee tax obligations, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(146,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2023</a></td>
<td class="nump">$ 1,133,129<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="nump">$ 3,313,609<span></span>
</td>
<td class="num">$ (5,088)<span></span>
</td>
<td class="num">$ (2,174,998)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,762,001<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564246397328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of the Business</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sage Therapeutics, Inc. (&#8220;Sage&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company with a mission to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s first product, ZULRESSO&#174; (brexanolone) CIV injection, is approved in the U.S. as a treatment for postpartum depression (&#8220;PPD&#8221;) in adults. The Company launched ZULRESSO commercially in the U.S. in June 2019. The Company's submission of a new drug application (an "NDA") for its lead investigational product candidate, zuranolone, for the treatment of major depressive disorder (&#8220;MDD&#8221;) and PPD was accepted for filing and granted priority review by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2023, with a Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;) target action date of August 5, 2023. The Company has a portfolio of other product candidates with a current focus on modulating two critical central nervous system (&#8220;CNS&#8221;) receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. The Company is currently targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was incorporated under the laws of the State of Delaware on April 16, 2010, and commenced operations on January 19, 2011 as Sterogen Biopharma, Inc. On September 13, 2011, the Company changed its name to Sage Therapeutics, Inc.</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with the marketing and sale of pharmaceutical products; the potential for development by third parties of new technological innovations that may compete with the Company&#8217;s products and product candidates; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; the uncertainty of being able to secure additional capital when needed to fund operations; and the direct or indirect impacts of the macroeconomic environment and geopolitical events on its development activities, operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The product candidates developed by the Company require approvals from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the current and future product candidates of the Company will receive, or that the Company&#8217;s current product, ZULRESSO, will maintain, the necessary approvals. If the Company fails to successfully complete clinical development and generate results sufficient to file for regulatory approval or is denied approval or approval is delayed for any of its product candidates, including zuranolone, such occurrences may have a material adverse impact on the Company&#8217;s business and its financial condition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also subject to additional risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events, including disruption to the U.S. healthcare system that began as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been and continue to be healthcare staffing shortages and other changes to the macroeconomic environment as downstream effects of the COVID-19 pandemic have continued. These factors have had a significant and sustained negative impact on the Company&#8217;s revenue from sales of ZULRESSO. While the Company has seen slower patient recruitment in certain clinical trials due to the COVID-19 pandemic and its downstream effects, and has</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experienced some challenges in qualifying and activating clinical trial sites, including due to capacity and resource constraints and employee attrition at our vendors and at sites, the Company has not experienced other significant impacts to the Company&#8217;s development activities as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, U.S. and global financial markets have experienced volatility and disruption due to other macroeconomic and geopolitical events such as rising inflation, the risk of a recession and the ongoing conflict between Russia and Ukraine. In addition, if equity and credit markets deteriorate, including as a result of recent and potential future bank failures, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to our existing stockholders. The Company cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements&#8212;Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Subtopic 205-40), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The Company has incurred losses and negative cash flows from operations in each year since its inception, except for net income of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">606.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2020, reflecting revenue recognized under a collaboration and license agreement with Biogen MA Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (collectively with BIMA, &#8220;Biogen&#8221;) (the &#8220;Biogen Collaboration Agreement&#8221;). As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. From its inception through March 31, 2023, the Company has received aggregate net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion from the sales of redeemable convertible preferred stock prior to its initial public offering (&#8220;IPO&#8221;), the issuance of convertible notes, and the sales of common stock in its IPO in July 2014, in follow-on public offerings, and to BIMA under a stock purchase agreement executed in connection with the Biogen Collaboration Agreement. The Company has also received $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in upfront payments under its collaborations with Biogen and Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;). Until such time, if ever, as the Company can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding. If the Company is unable to raise additional funds through equity or debt financings or other sources of funding when needed, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects that, based on its current operating plans, the Company&#8217;s existing cash, cash equivalents and marketable securities will be sufficient to fund its currently planned operations for </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements (&#8220;condensed consolidated financial statements&#8221;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At some point after that time, the Company anticipates it will require additional financing to fund its future operations. Even if the Company believes it has sufficient funds for its current or future operating plans, the Company may seek to raise additional capital if market conditions are favorable or in light of other strategic considerations.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247456992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">audited consolidated financial statements as of and for the year ended December 31, 2022, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company&#8217;s management, the accompanying condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, its results of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, its cash flows for the three months ended March 31, 2023 and 2022, and its statements of changes in stockholders&#8217; equity for the three months ended March 31, 2023 and 2022. The consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but does not include all disclosures required by GAAP. The results for the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.</span></p></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as disclosed in Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, within the &#8220;Notes to Consolidated Financial Statements&#8221; accompanying its Annual Report on Form 10-K for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Intercompany accounts and transactions have been eliminated.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full extent to which the COVID-19 pandemic and its downstream effects may directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend in large part on future developments, which cannot be predicted with confidence at this time. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Company has made estimates of the impact of the COVID-19 pandemic within its condensed consolidated financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the evolving nature of the COVID-19 pandemic, its downstream effects, and their impacts,</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> there may be changes to those estimates in future periods, and a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ctual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, overhead costs, depreciation, contract services and other related costs. Research and development costs are expensed to operations as the related obligation is incurred.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside of the U.S. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue from the sale of ZULRESSO, which was approved by the FDA in March 2019 and the Company subsequently began selling in June 2019, and from collaboration and supply agreements with the Company&#8217;s collaborators. To date, revenue from collaboration agreements has come from initial, upfront payments allocated to licenses of intellectual property delivered to the Company&#8217;s collaborators and from the supply of material for clinical trials under a supply agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;Topic 606&#8221;), an entity recognizes revenue when or as performance obligations are satisfied by transferring control of promised goods or services to a customer, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For contracts determined to be within the scope of Topic 606, the Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Revenue</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promised good or service is distinct in the evaluation of a collaboration or license arrangement subject to Topic 606, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the standalone selling price is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its arrangements with Shionogi and Biogen and concluded that a significant financing component does not exist for either arrangement. For arrangements with licenses of intellectual property that include sales-based royalties or milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty or milestone payment has been allocated has been satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Revenue from the Company&#8217;s collaboration agreement with Shionogi has come from initial, upfront consideration upon execution of the agreement and for the supply of drug product for Shionogi&#8217;s clinical trials. Revenue from the Company&#8217;s collaboration agreement with Biogen has come from initial, upfront consideration related to the execution of the Biogen Collaboration Agreement. For additional information, refer to Note 6, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Revenue, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes product revenue, net of variable consideration related to certain allowances and accruals that are determined using the expected value method, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for ZULRESSO is to deliver the product to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within selling, general and administrative expenses on its condensed consolidated statements of operations and comprehensive loss. The Company expenses incremental costs of obtaining a contract as incurred if the expected amortization period of the asset would be </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">less than one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the Company were to incur incremental costs with an amortization period greater than a year, such costs would be capitalized as contract assets, as they are expected to be recovered, and would be expensed by amortizing on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company did not have any contract assets (unbilled receivables) at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, as customer invoicing generally occurs before or at the time of revenue recognition. The Company did not have any contract liabilities at March 31, 2023, as the Company did not receive any payments in advance of satisfying its performance obligations to its customers. Amounts billed or invoiced that are considered trade accounts receivable are included in prepaid expenses and other current assets on the condensed consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and December 31, 2022, the Company had not provided any allowance for bad debts against the trade accounts receivable, and the amount of trade accounts receivable was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records reserves, based on contractual terms, for the following components of variable consideration related to product sold during the reporting period, as well as its estimate of product that remains in the distribution channel inventory of its customers at the end of the reporting period. On a quarterly basis, the Company updates its estimates, if necessary, and records any material adjustments in the period they are identified.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chargebacks</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company estimates chargebacks from its customers who directly purchase the product from the Company for discounts resulting from contractual commitments to sell products to eligible healthcare settings at prices lower than the list prices charged to its customers. Customers charge the Company for the difference between what they pay to the Company for the product and the selling price to the eligible healthcare settings. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at the end of each reporting period that the Company expects will be sold to eligible healthcare settings, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Rebates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company is subject to discount obligations under government programs, including Medicaid. The Company records reserves for rebates in the same period the related product revenue is recognized, resulting in a reduction of ZULRESSO product revenue and a current liability that is included in accrued expenses on its condensed consolidated balance sheets. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trade Discounts and Allowances</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company generally provides customary invoice discounts on ZULRESSO sales to its customers for prompt payment and the Company pays fees for sales order management, data, and distribution services. The Company estimates its customers will earn these discounts and fees and deducts these discounts and fees in full from gross ZULRESSO revenue and accounts receivable at the time the Company recognizes the related revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company provides voluntary financial assistance programs to patients with commercial insurance that have coverage and reside in states that allow financial assistance. The Company estimates the financial assistance amounts for ZULRESSO and records any such amounts within accrued expenses on its condensed consolidated balance sheets. The calculation of the accrual for financial assistance is based on an estimate of claims and the cost per claim that the Company expects to receive using demographics for patients who have registered and been approved for assistance. Any adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the condensed consolidated balance sheets.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Consistent with industry practice, the Company offers product return rights to customers for damaged, defective or expiring product, provided it is within a specified period around the product expiration date as set forth in the Company&#8217;s return goods policy. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reserve within accrued expenses on the condensed consolidated balance sheets. Product returns have not been significant to date and are not expected to be significant in the future.</span></p></div><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above, and presents the arrangement as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as research and development expense or selling, general and administrative expense, in the event of a payment to the collaborative partner in a period, or a reduction to these expense line items in the event of a reimbursement from the collaboration partner in a period, as appropriate.</span></p></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:7.0%;"/>
        <td style="width:2.0%;"/>
        <td style="width:91.0%;"/>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted market prices in active markets for identical assets or liabilities.</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities at March 31, 2023 and December 31, 2022 were carried at fair value, determined according to the fair value hierarchy; see Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts reflected in the condensed consolidated balance sheets for the collaboration receivable &#8211; related party, accounts payable and accrued expenses approximate their fair values due to their short-term maturities at March 31, 2023 and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s condensed consolidated financial statements upon adoption.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247261712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s cash equivalents are classified within Level 1 and Level 2 of the fair value hierarchy. The Company&#8217;s investments in marketable securities are classified within Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of the Company&#8217;s marketable securities are based on prices obtained from independent pricing sources. Consistent with the fair value hierarchy described in Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, marketable securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates. The Company performs validation procedures to ensure the reasonableness of this data. The Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of March 31, 2023 and December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.108%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,965</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,965</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">189,088</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">267,310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">267,310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,428</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,428</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,551</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,551</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,112,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">947,977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.108%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,911</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,911</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,270,979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers among the Level 1, Level 2 and Level 3 categories.</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the gross unrealized gains and losses of the Company&#8217;s marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.75%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.733%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.774%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,149</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,688</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,052</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,808</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">267,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,313</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,180</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,999</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">778</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,551</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">928,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.648%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">307,173</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,262</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358,019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128,374</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,133</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,248</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,163</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114,249</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,250</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,120,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value and the unrealized losses of the Company&#8217;s marketable securities that have been in a loss position for either less than twelve months or greater than twelve months as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.018%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.971%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Greater than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,601</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,525</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,097</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">830</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,762</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,808</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,712</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,712</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,307</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,321</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">778</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">430,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,322</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,251</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">684,391</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.018%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.971%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Greater than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,243</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">297,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,262</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">208,507</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,989</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,541</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">339,140</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,530</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">497</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,133</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">497</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">533</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,717</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">513,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,795</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">399,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,455</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">913,521</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and December 31, 2022, the unrealized losses on the Company&#8217;s investments in U.S. government securities, U.S. corporate bonds, and international corporate bonds were caused by interest rate increases. The Company purchased those investments at a premium relative to their face amount. The current credit ratings are all within the guidelines of the investment policy of the Company and the Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment. The Company does not intend to sell the investments and it is not probable that the Company will be required to sell the investments before recovery of their amortized cost basis.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all marketable securities held by the Company had remaining contractual maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less, except for U.S. government securities, U.S. corporate bonds, international corporate bonds and municipal securities with a fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_15ef7878-1081-4815-8372-c33bbdbbcbd7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all marketable securities held by the Company had remaining contractual maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less, except for U.S. government securities, U.S. corporate bonds, international corporate bonds and municipal securities with a fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and maturities of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9fe7857e-17e4-49cf-93b3-30d78c5acea7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities, including those with remaining contractual maturities of more than one year, are classified as current assets on the balance sheet because they are considered to be &#8220;available for sale&#8221; and the Company can convert them into cash to fund current operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments of the Company&#8217;s assets measured and carried at fair value during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247303376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes accrued expenses as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.507%;"/>
        <td style="width:2.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.201%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.201%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,138</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,565</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee-related</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,872</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,922</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247261712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Leases, Commitments and Contingencies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:7.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases, Commitments and Contingencies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases office space and certain equipment. All of the leases recorded on the condensed consolidated balance sheets are operating leases. The Company&#8217;s leases have remaining lease terms ranging from less than </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to approximately </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.75</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. Some of the leases include </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_02aacb61-99a8-43ba-8bb8-3474e32fbedc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options to extend</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the leases for up to </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These options were not included for the purpose of determining the right-of-use assets and associated lease liabilities as the Company determined that the renewal of these leases is not reasonably certain so only the original lease term was taken into consideration. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of January 1, 2022, the Company leased office space in two multi-tenant buildings in Cambridge, Massachusetts, consisting of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in the first building, under an operating lease that will expire on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,419</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in the second building, under an operating lease that will expire on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; and in a multi-tenant building in Raleigh, North Carolina, consisting of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,525</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet under an operating lease that will expire on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 30, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CyDex License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2015, the Company amended and restated its existing commercial license agreement with CyDex Pharmaceuticals, Inc. (&#8220;CyDex&#8221;), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated. Under the terms of the commercial license agreement as amended and restated, CyDex has granted to the Company an exclusive license to CyDex&#8217;s Captisol drug formulation technology and related intellectual property for the manufacture of pharmaceutical products incorporating brexanolone and the Company&#8217;s compound known as SAGE-689, and the development and commercialization of the resulting products for the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i) the ocular treatment of any disease or condition with a formulation, including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration. The Company is required to pay a royalty to CyDex on sales of brexanolone and will be required to pay a royalty on any sales of SAGE-689, if such product candidate is successfully developed in the future. Royalty rates are in the low single digits based on levels of net sales. From the effective date of the agreement to March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has paid to CyDex $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for licensing fees, which was recorded as research and development expense.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the amended and restated license agreement with CyDex, the Company agreed to make milestone payments on the achievement of clinical development and regulatory milestones in the amount of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in clinical milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in regulatory milestones for each of the first two fields with respect to brexanolone; up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in clinical milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in regulatory milestones for each of the third and fourth fields with respect to brexanolone; and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in clinical milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in regulatory milestones for one field with respect to SAGE-689. From the effective date of the agreement to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has recorded research and development expense and made cash payments of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these clinical development and regulatory milestones and has recorded an intangible asset and made a cash payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these regulatory milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any expense or intangible asset, or make any milestone payments related to clinical development or regulatory milestones for the brexanolone program or SAGE-689 under the license agreement with CyDex.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">University of California License Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2013, the Company entered into a non-exclusive license agreement with the Regents of the University of California ("the Regents&#8221;) under which the Company was granted a non-exclusive license to certain clinical data and clinical material related to brexanolone for use in the development and commercialization of biopharmaceutical products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the licensed field, including status epilepticus and postpartum depression. In May 2014, the license agreement was amended to add the treatment of essential tremor to the licensed field of use, materials and milestone fee provisions of the agreement. The Company paid to the Regents clinical development milestones of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, prior to December 31, 2015; </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> other milestones are outstanding under this non-exclusive license agreement. The Company is required to pay royalties of less than </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on net sales for a period of fifteen years following the sale of the first product developed using the data and materials, and the Company began to pay these royalties in 2019. The license will terminate on the earlier to occur of (i) </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the effective date or (ii) </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the last-derived product is first commercially sold.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2015, the Company entered into an exclusive license agreement with the Regents whereby the Company was granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In exchange for such license, the Company paid an upfront payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was required to make payments of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for annual maintenance fees until the calendar year following the first sale of ZULRESSO. The Company is obligated to make milestone payments following the achievement of specified regulatory and sales milestones of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, respectively. The Company pays royalties at a low single digit percentage of net sales of ZULRESSO, subject to specified minimum annual royalty amounts. Unless terminated by operation of law or by acts of the parties under the terms of the agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire, whichever is later. From the effective date of the agreement to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has recorded research and development expense and made cash payments of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these regulatory and sales milestones; and has recorded an intangible asset and made a cash payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to these regulatory and sales milestones.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any expense or make any milestone payments under the license agreements with the Regents.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564328309520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shionogi</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, the Company entered into a strategic collaboration with Shionogi for the clinical development and commercialization of zuranolone for the treatment of MDD and other potential indications in Japan, Taiwan and South Korea (the &#8220;Shionogi Territory&#8221;). In October 2018, the Company entered into a supply agreement with Shionogi for the Company to supply zuranolone clinical material to Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the collaboration agreement, Shionogi is responsible for all clinical development and regulatory filings for zuranolone in MDD and other indications in the Shionogi Territory and would be responsible for commercialization of zuranolone in the Shionogi Territory, if zuranolone is successfully developed and obtains marketing approval in any of the countries within the Shionogi Territory. Shionogi was required to make an upfront payment to the Company of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and the Company will be eligible to receive additional payments of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">485.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million if certain regulatory and commercial milestones are achieved by Shionogi. The potential future milestone payments include up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified regulatory milestones, up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified commercialization milestones, and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">385.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified net sales milestones. The Company is eligible to receive tiered royalties on sales of zuranolone in the Shionogi Territory, if development efforts are successful, with tiers averaging in the low to mid-</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twenty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent range, subject to other terms of the agreement. Shionogi has also granted to the Company certain rights to co-promote zuranolone in Japan. As between the Company and Shionogi, the Company maintains exclusive rights to develop and commercialize zuranolone outside of the Shionogi Territory. The upfront cash payment and any payments for milestones and royalties are non-refundable and non-creditable. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments from Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that Shionogi meets the definition of a customer because the Company is delivering intellectual property and know-how rights for the zuranolone program in support of territories in which the parties are not jointly sharing the risks and rewards. In addition, the Company determined that the Shionogi collaboration met the requirements to be accounted for as a contract, including that it was probable that the Company will collect the consideration to which the Company was entitled in exchange for the goods or services that will be delivered to Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the performance obligations in the Shionogi collaboration agreement included the license to zuranolone and the supply of certain materials during the clinical development phase, which includes the supply of active pharmaceutical ingredient (&#8220;API&#8221;). The performance obligation related to the license to zuranolone was determined to be distinct from other performance obligations and therefore was a separate performance obligation for which control was transferred upon signing. The obligation to provide certain clinical materials, including API for use during the development period, was determined to be a separate performance obligation. Given that Shionogi is not obligated to purchase any minimum amount or quantities of commercial API, the supply of API to Shionogi for commercial use was determined to be an option for Shionogi, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that there was no separate material right in connection with the supply of API for commercial use as the expected pricing was not at a discount. Given this fact pattern, the Company has concluded the agreement has two performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the clinical supply agreement, the Company is obligated to manufacture and supply to Shionogi (i) clinical quantities of API reasonably required by Shionogi for the development of licensed products in the Shionogi territory under the collaboration and license agreement and (ii) quantities of drug product reasonably required for use by Shionogi in Phase 1 clinical trials of zuranolone in the Shionogi territory under the collaboration and license agreement, in the quantities agreed to by the parties. Collaboration revenue from the clinical supply agreement, which excludes the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront payment, pertains to the clinical material sold under the terms of the clinical supply agreement. The Company records the costs related to the clinical supply agreement in research and development expense on its condensed consolidated statements of operations and comprehensive loss. For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recognized </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> collaboration revenue from the Company&#8217;s agreement with Shionogi.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company completed the evaluation of the standalone selling prices of each of the performance obligations and determined that the standalone selling price of the license performance obligation was $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company recognized the transaction price allocated to the license performance obligation of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as revenue during the quarter upon delivery of the license to Shionogi and resulting ability of Shionogi to use and benefit from the license, which was in the three months ended June 30, 2018. The remaining transaction price related to the performance obligation for the supply of certain clinical material is not significant. The potential milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biogen</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company entered into the Biogen Collaboration Agreement to jointly develop and commercialize SAGE-217 products for MDD, PPD and other disorders and SAGE-324 products for essential tremor and other disorders. Concurrently, the Company also entered into a stock purchase agreement with BIMA (the &#8220;Biogen Stock Purchase Agreement&#8221;) under which BIMA purchased shares of the Company&#8217;s common stock. The Biogen Collaboration Agreement became effective on </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 28, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#8220;Effective Date&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Biogen Collaboration Agreement, the Company granted Biogen co-exclusive licenses to develop and commercialize SAGE-217 products and SAGE-324 products (each, a &#8220;Product Class&#8221; and together, the &#8220;Licensed Products&#8221;) in the U.S., an exclusive license to develop and commercialize SAGE-217 products in all countries of the world other than the U.S. and the Shionogi Territory, and an exclusive license to develop and commercialize SAGE-324 products in all countries of the world other than the U.S. The Company refers to the territories outside the U.S. to which Biogen has rights under the Biogen Collaboration Agreement with respect to the applicable Licensed Product as the &#8220;Biogen Territory&#8221;.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the effectiveness of the Biogen Collaboration Agreement and the closing of the sale of shares to BIMA in December 2020, the Company received $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in consideration, comprised of an upfront payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">875.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million purchase price for </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,241,473</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> newly issued shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;). As a result of the purchase of the Biogen Shares, Biogen has become a related party of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is eligible to receive additional payments of up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion if certain regulatory and commercial milestones are achieved. The potential future milestone payments for SAGE-217 products include up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">475.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified regulatory and commercial milestones, including milestones totaling $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the first commercial sale of zuranolone for the treatment of MDD and PPD, and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified net sales milestones. The potential future milestone payments for SAGE-324 products include up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified regulatory and commercial milestones and up to $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified net sales milestones. The Company is also eligible to receive tiered royalties on net sales of SAGE-217 products and SAGE-324 products in the Biogen Territory at percentage rates ranging from the high teens to low twenties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may never receive any milestone payments or any royalty payments under the Biogen Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and commercialization activities in the U.S. are conducted pursuant to plans agreed to by the Company and Biogen and overseen by a joint steering committee that will consist at all times of an equal number of representatives of each party. The Company and Biogen will share equally in the costs for development and commercialization, as well as the profits and losses upon FDA approval and commencement of product sales, in the U.S., subject to the Company&#8217;s opt-out right described below. Biogen will be solely responsible for all development activities and costs related to any development and commercialization of SAGE-217 products and SAGE-324 products for the Biogen Territory, and the Company will receive royalties on any sales in the Biogen Territory, as mentioned above. Biogen will be the principal and record sales of SAGE-217 products globally. The Company will be the principal and record sales of SAGE-324 products in the U.S. and Biogen will be the principal and record sales of SAGE-324 products in the Biogen Territory.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will supply API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to support development and commercialization activities. Biogen has the right to assume manufacturing responsibilities for API for the Biogen Territory at any time during the term of the agreement and will, within a reasonable period of time after the Effective Date, assume manufacturing responsibility for bulk drug product for the Biogen Territory.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless terminated earlier, the Biogen Collaboration Agreement will continue on a Licensed Product-by-Licensed Product and country-by-country basis until the date on which (a) in any country in the Biogen Territory, the royalty term has expired for all Licensed Products in a Product Class in such country, and (b) for the U.S., the parties agree to permanently cease to commercialize all Licensed Products in a Product Class. Biogen also has the right to terminate the Biogen Collaboration Agreement for convenience in its entirety, on a Product Class-by-Product Class basis or as to a particular region, upon advance written notice. The Company has an opt-out right to convert the co-exclusive licenses in the U.S. to an exclusive license to Biogen on a Product Class-by-Product Class basis. Following the exercise of the opt-out right, the Company would no longer share equally in the profits and losses in the U.S. and would be entitled to receive certain royalty payments at percentage rates ranging from the high teens to low twenties and additional sales milestones.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the Biogen Collaboration Agreement and the Biogen Stock Purchase Agreement should be combined and treated as a single arrangement for accounting purposes as the agreements were entered into contemporaneously and in contemplation of one another. The Company determined that the combined agreements had elements that were within the scope of Topic 606 and Topic 808.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of the Effective Date, the Company identified the following promises in the Biogen Collaboration Agreement that were evaluated under the scope of Topic 606: delivery of (i) a co-exclusive license for SAGE-217 products in the U.S.; (ii) an exclusive license for SAGE-217 products in the Biogen Territory; (iii) a co-exclusive license for SAGE-324 products in the U.S.; (iv) an exclusive license for SAGE-324 products in the Biogen Territory; (v) the clinical manufacturing supply of API and bulk drug product for SAGE-217 products in the Biogen Territory; and (vi) the clinical manufacturing supply of API and bulk drug product for SAGE-324 products in the Biogen Territory.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also evaluated whether certain options outlined within the Biogen Collaboration Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Biogen and therefore are not considered separate performance obligations within the Biogen Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the above promises and determined that the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. are reflective of a vendor-customer relationship and therefore represent performance obligations within the scope of Topic 606. The co-exclusive license for SAGE-217 products and SAGE-324 products in the U.S. are considered functional intellectual property and distinct from other promises under the contract. The exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory are considered functional licenses that are distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the licenses on its own or together with other readily available resources. As the co-exclusive licenses in the U.S. and the exclusive licenses in the Biogen Territory are delivered at the same time, they are considered one performance obligation at contract inception. The clinical manufacturing supply of API and bulk drug product for SAGE-217 products and SAGE-324 products for the Biogen Territory are considered distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the manufacturing services together with the licenses transferred by the Company at the inception of the agreement. Therefore, each represents a separate performance obligation within a contract with a customer under the scope of Topic 606 at contract inception.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers the collaborative activities associated with the co-development, co-commercialization, and co-manufacturing of SAGE-217 products and SAGE-324 products in the U.S. to be separate units of account within the scope of Topic 808 as the Company and Biogen are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on the development and commercial success of the activities in the arrangement. The Company has determined that the supply of API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to Biogen will be classified as collaboration revenue &#8211; related party in the condensed consolidated statements of operations and comprehensive loss. During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> collaboration revenue &#8211; related party was recognized related to the Biogen Collaboration Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments to or reimbursements from Biogen related to the co-development, co-commercialization, and co-manufacturing activities and the agreement of the parties to share equally the cost of these activities will be accounted for as an increase to or reduction of research and development expenses or selling, general and administrative expenses, depending on the nature of the activity.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, the Company recorded a net reimbursement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, for the amounts due from Biogen as a reduction of or an addition to the related operating expense categories in the condensed consolidated statement of operations and comprehensive loss. During the three months ended March 31, 2022, the Company recorded a net reimbursement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the amounts due from Biogen as a reduction of the related operating expense categories in the condensed consolidated statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, the Company recorded a Collaboration Receivable &#8211; Related Party of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the condensed consolidated balance sheet for the amounts due for the three months ended March 31, 2023. During the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company made </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments to Biogen and the Company received </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from Biogen for the amounts due for the three months ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes expenses related to the Biogen Collaboration Agreement that were incurred by the Company and the related reimbursement from Biogen or to Biogen, reflected by category of operating expenses:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.701%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.064%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses related to the Biogen Collaboration Agreement<br/>&#160;&#160;&#160;incurred by Sage</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,136</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,754</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net reimbursement to (from) Biogen reflected in the<br/>&#160;&#160;&#160;condensed consolidated statements of operations and <br/>&#160;&#160;&#160;comprehensive loss:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,514</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,034</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,988</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net expenses related to the Biogen Collaboration <br/>&#160;&#160;&#160;Agreement in the condensed consolidated statements of <br/>&#160;&#160;&#160;operations and comprehensive loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,888</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined the transaction price under Topic 606 at the inception of the Biogen Collaboration Agreement to be $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion, consisting of the upfront payment of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">875.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million plus $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in excess proceeds from the equity investment under the Biogen Stock Purchase Agreement, when measured at fair value, plus future variable consideration for manufacturing supply of clinical API and bulk drug product for the Biogen Territory. The amount of variable consideration related to the future manufacturing services was not material. The Company determined that any variable consideration related to clinical development and regulatory milestones is deemed to be fully constrained and therefore excluded from the transaction price due to the high degree of uncertainty and risk associated with these potential payments, as the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company also determined that royalties and sales milestones relate solely to the licenses of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of Topic 606. Revenue related to these royalties and sales milestones will only be recognized when the associated sales occur, and relevant thresholds are met.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As noted above, the Company identified three performance obligations in the Biogen Collaboration Agreement: (i) the delivery of the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. and the exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory; (ii) the clinical manufacturing supply of API and bulk drug product for SAGE-217 products in the Biogen Territory; and (iii) the clinical manufacturing supply of the API and bulk drug product for SAGE-324 products in the Biogen Territory. The selling price of each performance obligation in the Biogen Collaboration Agreement was determined based on the Company&#8217;s SSP with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the variable consideration related to the manufacturing obligations to the future clinical supply of SAGE-217 products and SAGE 324 products in the Biogen Territory and the remaining fixed consideration to the license obligation. The variable consideration related to the manufacturing obligations was not material. As such, the entirety of the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion fixed consideration of the transaction price has been allocated to the transfer of the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. and the exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory. The Company recognizes revenue for the license performance obligations at a point in time, that is upon transfer of the licenses to Biogen. As control of these licenses was transferred on the Effective Date and Biogen could begin to use and benefit from the licenses, the Company recognized $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion of license revenue during the year ended December 31, 2020 under the Biogen Collaboration Agreement. The Company will recognize revenue for the clinical manufacturing supply obligations at a point in time, that is upon the delivery of the supply to Biogen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for the Biogen Stock Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">connection with the execution of the Biogen Collaboration Agreement, the Company and BIMA entered into the Biogen Stock Purchase Agreement. Pursuant to the Biogen Stock Purchase Agreement, the Company sold the Biogen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to BIMA at a price of approximately $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which represented a </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent premium over the 30-day volume-weighted average share price as of the last trading day prior to the date the Biogen Collaboration Agreement and Biogen Stock Purchase Agreement were executed in November 2020, for aggregate consideration of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The sale of the shares to BIMA closed on December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biogen Stock Purchase Agreement includes certain standstill provisions, lock-up restrictions, and a voting agreement with respect to the Biogen Shares. Pursuant to the terms of the Biogen Stock Purchase Agreement, BIMA has agreed not to, and to cause its affiliates not to, directly or indirectly acquire the Company&#8217;s securities, seek or propose a tender or exchange offer or merger between the Company and Biogen, solicit proxies or consents with respect to any matter, or undertake other specified actions, in each case subject to specified conditions. </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The standstill restrictions terminate on the earliest of (i) a specified regulatory milestone under the Biogen Collaboration Agreement, (ii) the date one year following the termination of the Biogen Collaboration Agreement and (iii) the seventh anniversary of the Effective Date. BIMA also agreed not to, and to cause its affiliates not to, sell or transfer any of the Biogen Shares for a period of eighteen months from the closing of the sale of the Biogen Shares, which period expired on June 30, 2022, and to limit sales and transfers of the Biogen Shares for an additional eighteen-month period, in each case subject to specified conditions and exceptions.</span></span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined the fair value of the common shares issued using an option pricing valuation model to take into consideration the holding period restrictions. The fair value of the Company&#8217;s common stock was considered a Level 2 fair value measurement within the fair value hierarchy. The most significant assumptions within the model are the Company&#8217;s stock price, the term of the restrictions and the stock price volatility, which is based upon a blend of historical and implied volatility of the Company&#8217;s stock. Based on the fair value adjustments made by management, the fair value of the shares issued was determined to be $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">417.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million less than the proceeds received from BIMA for the issuance of the Company&#8217;s common stock under the Biogen Stock Purchase Agreement. As such, the $232.5 million in excess proceeds has been included in the $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion transaction price of the Biogen Collaboration Agreement determined above.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564244131728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-Based Compensation</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 2, 2014, the stockholders of the Company approved the 2014 Stock Option and Incentive Plan (the &#8220;2014 Plan&#8221;), which became effective immediately prior to the completion of the Company&#8217;s IPO. The 2014 Plan provides for the grant of restricted stock awards, restricted stock units, incentive stock options and non-statutory stock options. The 2014 Plan replaced the Company&#8217;s 2011 Stock Option and Grant Plan (the &#8220;2011 Plan&#8221;). The Company </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> longer grants stock options or other awards under its 2011 Plan, but any stock options outstanding under the 2011 Plan remain outstanding and effective in accordance with their terms.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2014 Plan provides for an annual increase, to be added on the first day of each year, by up to 4% of the Company&#8217;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,380,365</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, representing </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#8217;s outstanding shares of common stock as of December 31, 2022, were added to the 2014 Plan.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 15, 2016, the Board of Directors of the Company (the &#8220;Board&#8221;) approved the 2016 Inducement Equity Plan (as amended and restated, the &#8220;2016 Plan&#8221;). The 2016 Plan provides for the grant of equity awards to individuals who have not previously been an employee or a non-employee director of the Company to induce them to accept employment and to provide them with a proprietary interest in the Company. On September 20, 2018, the Board amended the 2016 Plan to increase the total number of shares reserved for issuance by </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,200,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terms </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of equity grants, including vesting requirements, are determined by the Board or the Compensation Committee of the Board, subject to the provisions of the applicable plan. Stock options granted by the Company that are not performance-based are considered time-based because they vest based on the continued service of the grantee with the Company during a specified period following grant. These awards, when granted to employees, generally vest ratably</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">over </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vesting at the </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> anniversary. All stock option awards expire </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the date of grant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, the total number of shares underlying outstanding awards under all equity plans was </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,793,166</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the total number of shares available for future issuance under all equity plans was </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,616,709</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 16, 2022, the Company&#8217;s stockholders approved an amendment to the amended 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which had been previously approved by the Board, to add </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes activity relating to time-based restricted stock units and performance restricted stock units:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.084%;"/>
        <td style="width:1.534%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.223%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,415,481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,153,335</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.78</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.18</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,409,856</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Time-based restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,119</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units to certain employees of the Company that vest over </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In September 2022, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vested on the one-year anniversary of the vesting start date and the remaining </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vest ratably in </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">quarterly</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> increments over the remaining </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the three months ended March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,494</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of these time-based restricted stock units vested, with a fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the date of vesting.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2022, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units vested.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">330,617</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units to certain employees and consultants of the Company. These time-based restricted stock units vest over </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vesting at the one-year anniversary of the vesting start date and the remaining </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% will vest in equal installments on each anniversary of the vesting start date for the following </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470,891</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> time-based restricted stock units were both outstanding and unvested, and the total unrecognized stock-based compensation expense related to these awards was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Performance restricted stock units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">822,718</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">415,565</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance restricted stock units, respectively, to its employees and consultants. The majority of the performance restricted stock units granted during the three months ended March 31, 2023 and 2022 vest upon the achievement of certain clinical and regulatory development milestones related to product candidates and certain commercial milestones. Certain performance restricted stock units granted in the three months ended March 31, 2023 vest upon the Company reaching specified measures of total stockholder return.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recognition of stock-based compensation expense associated with performance restricted stock units, except for those with milestones that are measures of total stockholder return, commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. Recognition of stock-based compensation associated with performance restricted stock units with milestones that are measures of total stockholder return commences on the grant date and is recorded independently of the vesting outcomes of the grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for performance restricted stock units that were outstanding, except for those with milestones that are measures of total stockhholder return, the achievement of the milestones that had not been met was considered not probable, and therefore </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expense has been recognized related to these awards during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022, respectively.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> milestone for outstanding performance restricted stock units was achieved. The fair value of the performance restricted stock units that vested upon achievement was $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the Company recognized stock-based compensation expense related to this milestone of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the performance restricted stock units that were granted during the year ended December 31, 2021 included this milestone as a vesting condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance restricted stock units vested during the three months ended March 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,938,965</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance restricted stock units were both outstanding and unvested, and the total unrecognized stock-based compensation expense related to these awards was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Rollforward</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes activity related to time-based and performance-based stock options:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.001%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.182%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.284%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.459%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.182%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.284%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.6%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Remaining Life<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,788,350</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.36</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">712,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.58</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,173</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.42</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,383,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.46</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,318,637</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.19</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,365</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, the Company had unrecognized stock-based compensation expense related to its outstanding and unvested time-based stock option awards of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted average vesting period of </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.07</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Performance-Based Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recognition of stock-based compensation expense associated with performance-based stock options commences when the performance condition is considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for performance-based stock option grants that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expense has been recognized related to these awards during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company granted </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options to purchase shares of common stock that contain performance-based vesting criteria.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> milestones were achieved under performance-based stock options.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023, </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance-based stock options were both outstanding and unvested, the total unrecognized stock-based compensation expense related to these awards was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the timing of recognition of this stock-based compensation expense is subject to judgment of the Company as to when the performance conditions are considered probable of being achieved.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock-based compensation expense recognized during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,773</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,615</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,265</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,938</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,553</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock-based compensation expense by award type recognized during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,465</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,553</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,803</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,038</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,553</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For stock option awards, the fair value is estimated at the grant date using the Black-Scholes option-pricing model, taking into account the terms and conditions upon which stock options are granted. The fair value of the stock options is amortized on a straight-line basis for stock option awards to employees, non-employee directors and non-employee consultants over the requisite service period of the awards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value per share of stock options granted under the Company&#8217;s stock option plans during the three months ended March 31, 2023 and 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.93</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247311472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:7.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the calculation of basic and diluted net loss per share for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146,828</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common stock outstanding<br/>&#160;&#160;&#160;&#8212;basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,674,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,028,858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of shares of common stock<br/>&#160;&#160;&#160;equivalents resulting from common stock<br/>&#160;&#160;&#160;options and restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common stock outstanding<br/>&#160;&#160;&#160;&#8212;diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,674,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,028,858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes common stock equivalents outstanding that were excluded from the calculation of diluted net loss per share because including them would have been anti-dilutive as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.24%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.7%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.7%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,733,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,932,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">541,913</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,846</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,323</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,251,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options and restricted stock units that are outstanding and contain performance-based vesting criteria for which the performance conditions have not been met are excluded from the calculation of common stock equivalents outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564246331072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_BusinessRisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with the marketing and sale of pharmaceutical products; the potential for development by third parties of new technological innovations that may compete with the Company&#8217;s products and product candidates; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; the uncertainty of being able to secure additional capital when needed to fund operations; and the direct or indirect impacts of the macroeconomic environment and geopolitical events on its development activities, operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The product candidates developed by the Company require approvals from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the current and future product candidates of the Company will receive, or that the Company&#8217;s current product, ZULRESSO, will maintain, the necessary approvals. If the Company fails to successfully complete clinical development and generate results sufficient to file for regulatory approval or is denied approval or approval is delayed for any of its product candidates, including zuranolone, such occurrences may have a material adverse impact on the Company&#8217;s business and its financial condition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also subject to additional risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events, including disruption to the U.S. healthcare system that began as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been and continue to be healthcare staffing shortages and other changes to the macroeconomic environment as downstream effects of the COVID-19 pandemic have continued. These factors have had a significant and sustained negative impact on the Company&#8217;s revenue from sales of ZULRESSO. While the Company has seen slower patient recruitment in certain clinical trials due to the COVID-19 pandemic and its downstream effects, and has</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experienced some challenges in qualifying and activating clinical trial sites, including due to capacity and resource constraints and employee attrition at our vendors and at sites, the Company has not experienced other significant impacts to the Company&#8217;s development activities as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, U.S. and global financial markets have experienced volatility and disruption due to other macroeconomic and geopolitical events such as rising inflation, the risk of a recession and the ongoing conflict between Russia and Ukraine. In addition, if equity and credit markets deteriorate, including as a result of recent and potential future bank failures, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to our existing stockholders. The Company cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements&#8212;Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Subtopic 205-40), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The Company has incurred losses and negative cash flows from operations in each year since its inception, except for net income of $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">606.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2020, reflecting revenue recognized under a collaboration and license agreement with Biogen MA Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (collectively with BIMA, &#8220;Biogen&#8221;) (the &#8220;Biogen Collaboration Agreement&#8221;). As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. From its inception through March 31, 2023, the Company has received aggregate net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion from the sales of redeemable convertible preferred stock prior to its initial public offering (&#8220;IPO&#8221;), the issuance of convertible notes, and the sales of common stock in its IPO in July 2014, in follow-on public offerings, and to BIMA under a stock purchase agreement executed in connection with the Biogen Collaboration Agreement. The Company has also received $</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in upfront payments under its collaborations with Biogen and Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;). Until such time, if ever, as the Company can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding. If the Company is unable to raise additional funds through equity or debt financings or other sources of funding when needed, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects that, based on its current operating plans, the Company&#8217;s existing cash, cash equivalents and marketable securities will be sufficient to fund its currently planned operations for </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements (&#8220;condensed consolidated financial statements&#8221;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At some point after that time, the Company anticipates it will require additional financing to fund its future operations. Even if the Company believes it has sufficient funds for its current or future operating plans, the Company may seek to raise additional capital if market conditions are favorable or in light of other strategic considerations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">audited consolidated financial statements as of and for the year ended December 31, 2022, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company&#8217;s management, the accompanying condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, its results of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, its cash flows for the three months ended March 31, 2023 and 2022, and its statements of changes in stockholders&#8217; equity for the three months ended March 31, 2023 and 2022. The consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but does not include all disclosures required by GAAP. The results for the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as disclosed in Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, within the &#8220;Notes to Consolidated Financial Statements&#8221; accompanying its Annual Report on Form 10-K for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Intercompany accounts and transactions have been eliminated.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full extent to which the COVID-19 pandemic and its downstream effects may directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend in large part on future developments, which cannot be predicted with confidence at this time. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Company has made estimates of the impact of the COVID-19 pandemic within its condensed consolidated financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the evolving nature of the COVID-19 pandemic, its downstream effects, and their impacts,</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> there may be changes to those estimates in future periods, and a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ctual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Accruals</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, overhead costs, depreciation, contract services and other related costs. Research and development costs are expensed to operations as the related obligation is incurred.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside of the U.S. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue from the sale of ZULRESSO, which was approved by the FDA in March 2019 and the Company subsequently began selling in June 2019, and from collaboration and supply agreements with the Company&#8217;s collaborators. To date, revenue from collaboration agreements has come from initial, upfront payments allocated to licenses of intellectual property delivered to the Company&#8217;s collaborators and from the supply of material for clinical trials under a supply agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;Topic 606&#8221;), an entity recognizes revenue when or as performance obligations are satisfied by transferring control of promised goods or services to a customer, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For contracts determined to be within the scope of Topic 606, the Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Revenue</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promised good or service is distinct in the evaluation of a collaboration or license arrangement subject to Topic 606, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the standalone selling price is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its arrangements with Shionogi and Biogen and concluded that a significant financing component does not exist for either arrangement. For arrangements with licenses of intellectual property that include sales-based royalties or milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty or milestone payment has been allocated has been satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Revenue from the Company&#8217;s collaboration agreement with Shionogi has come from initial, upfront consideration upon execution of the agreement and for the supply of drug product for Shionogi&#8217;s clinical trials. Revenue from the Company&#8217;s collaboration agreement with Biogen has come from initial, upfront consideration related to the execution of the Biogen Collaboration Agreement. For additional information, refer to Note 6, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Revenue, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes product revenue, net of variable consideration related to certain allowances and accruals that are determined using the expected value method, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for ZULRESSO is to deliver the product to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within selling, general and administrative expenses on its condensed consolidated statements of operations and comprehensive loss. The Company expenses incremental costs of obtaining a contract as incurred if the expected amortization period of the asset would be </span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">less than one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the Company were to incur incremental costs with an amortization period greater than a year, such costs would be capitalized as contract assets, as they are expected to be recovered, and would be expensed by amortizing on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company did not have any contract assets (unbilled receivables) at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023, as customer invoicing generally occurs before or at the time of revenue recognition. The Company did not have any contract liabilities at March 31, 2023, as the Company did not receive any payments in advance of satisfying its performance obligations to its customers. Amounts billed or invoiced that are considered trade accounts receivable are included in prepaid expenses and other current assets on the condensed consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 31, 2023 and December 31, 2022, the Company had not provided any allowance for bad debts against the trade accounts receivable, and the amount of trade accounts receivable was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records reserves, based on contractual terms, for the following components of variable consideration related to product sold during the reporting period, as well as its estimate of product that remains in the distribution channel inventory of its customers at the end of the reporting period. On a quarterly basis, the Company updates its estimates, if necessary, and records any material adjustments in the period they are identified.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chargebacks</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company estimates chargebacks from its customers who directly purchase the product from the Company for discounts resulting from contractual commitments to sell products to eligible healthcare settings at prices lower than the list prices charged to its customers. Customers charge the Company for the difference between what they pay to the Company for the product and the selling price to the eligible healthcare settings. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at the end of each reporting period that the Company expects will be sold to eligible healthcare settings, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Rebates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company is subject to discount obligations under government programs, including Medicaid. The Company records reserves for rebates in the same period the related product revenue is recognized, resulting in a reduction of ZULRESSO product revenue and a current liability that is included in accrued expenses on its condensed consolidated balance sheets. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trade Discounts and Allowances</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company generally provides customary invoice discounts on ZULRESSO sales to its customers for prompt payment and the Company pays fees for sales order management, data, and distribution services. The Company estimates its customers will earn these discounts and fees and deducts these discounts and fees in full from gross ZULRESSO revenue and accounts receivable at the time the Company recognizes the related revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company provides voluntary financial assistance programs to patients with commercial insurance that have coverage and reside in states that allow financial assistance. The Company estimates the financial assistance amounts for ZULRESSO and records any such amounts within accrued expenses on its condensed consolidated balance sheets. The calculation of the accrual for financial assistance is based on an estimate of claims and the cost per claim that the Company expects to receive using demographics for patients who have registered and been approved for assistance. Any adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the condensed consolidated balance sheets.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Consistent with industry practice, the Company offers product return rights to customers for damaged, defective or expiring product, provided it is within a specified period around the product expiration date as set forth in the Company&#8217;s return goods policy. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reserve within accrued expenses on the condensed consolidated balance sheets. Product returns have not been significant to date and are not expected to be significant in the future.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above, and presents the arrangement as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaboration arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as research and development expense or selling, general and administrative expense, in the event of a payment to the collaborative partner in a period, or a reduction to these expense line items in the event of a reimbursement from the collaboration partner in a period, as appropriate.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:7.0%;"/>
        <td style="width:2.0%;"/>
        <td style="width:91.0%;"/>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted market prices in active markets for identical assets or liabilities.</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities at March 31, 2023 and December 31, 2022 were carried at fair value, determined according to the fair value hierarchy; see Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts reflected in the condensed consolidated balance sheets for the collaboration receivable &#8211; related party, accounts payable and accrued expenses approximate their fair values due to their short-term maturities at March 31, 2023 and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s condensed consolidated financial statements upon adoption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_BusinessRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business risks and uncertainties policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_BusinessRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245022672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Company's Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.108%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,965</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,965</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">189,088</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">267,310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">267,310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,428</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,428</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,551</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,551</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,112,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,139</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">947,977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.108%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.128%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.096%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,911</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,911</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,270,979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Gross Unrealized Gains and Losses of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the gross unrealized gains and losses of the Company&#8217;s marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.75%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.733%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.153%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.774%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,149</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,688</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,052</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,808</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">267,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,313</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,180</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,999</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">778</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,551</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">928,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">923,028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.648%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.22%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">307,173</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,262</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358,019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128,374</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,133</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,248</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,163</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114,249</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,250</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,120,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,109,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value and the unrealized losses of the Company&#8217;s marketable securities that have been in a loss position for either less than twelve months or greater than twelve months as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.018%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.971%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Greater than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,601</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,525</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,097</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">830</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,762</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,808</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,712</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,712</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,307</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,321</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">778</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">430,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,322</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,251</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">684,391</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.018%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.971%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Greater than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,243</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">297,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,262</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">208,507</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,989</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,541</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">339,140</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,530</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">497</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,133</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. municipal securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">497</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">533</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,717</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">513,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,795</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">399,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,455</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">913,521</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564244124368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes accrued expenses as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.507%;"/>
        <td style="width:2.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.201%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.201%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,138</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,565</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee-related</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,872</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,922</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">557</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247303376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CollaborationAgreementAbstract', window );"><strong>Collaboration Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock', window );">Summary of Operating Expenses Category Related to Collaboration Agreement</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes expenses related to the Biogen Collaboration Agreement that were incurred by the Company and the related reimbursement from Biogen or to Biogen, reflected by category of operating expenses:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.701%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.064%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.585%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.064%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses related to the Biogen Collaboration Agreement<br/>&#160;&#160;&#160;incurred by Sage</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,136</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,754</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net reimbursement to (from) Biogen reflected in the<br/>&#160;&#160;&#160;condensed consolidated statements of operations and <br/>&#160;&#160;&#160;comprehensive loss:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,514</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,034</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,988</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net expenses related to the Biogen Collaboration <br/>&#160;&#160;&#160;Agreement in the condensed consolidated statements of <br/>&#160;&#160;&#160;operations and comprehensive loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,888</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of operating expenses category related to collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564238507312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Activity Relating to Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes activity relating to time-based restricted stock units and performance restricted stock units:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.084%;"/>
        <td style="width:1.534%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.223%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,415,481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,153,335</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.78</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.18</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,409,856</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Relating to Time Based and Performance Based Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes activity related to time-based and performance-based stock options:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.001%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.182%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.284%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.459%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.182%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.284%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.6%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Remaining Life<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,788,350</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.36</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">712,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.58</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,173</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.42</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,383,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.46</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of March 31, 2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,318,637</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.19</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,365</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock-based compensation expense recognized during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,773</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,615</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,265</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,938</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,553</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense by Award Type</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock-based compensation expense by award type recognized during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,465</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,553</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,803</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,038</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,553</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247321552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the calculation of basic and diluted net loss per share for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months ended March 31, 2023 and 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.424%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.181%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146,828</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common stock outstanding<br/>&#160;&#160;&#160;&#8212;basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,674,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,028,858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of shares of common stock<br/>&#160;&#160;&#160;equivalents resulting from common stock<br/>&#160;&#160;&#160;options and restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common stock outstanding<br/>&#160;&#160;&#160;&#8212;diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,674,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,028,858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Anti-Dilutive Common Stock Equivalents Outstanding</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes common stock equivalents outstanding that were excluded from the calculation of diluted net loss per share because including them would have been anti-dilutive as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023 and 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.24%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.7%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.7%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,733,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,932,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">541,913</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,846</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,323</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,251,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564246334000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">156 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 2,174,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,174,998<span></span>
</td>
<td class="nump">$ 2,028,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Net income from up-front</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 606,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Up-front payments receive</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member] | Convertible Notes [Member] | Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes', window );">Net proceeds from sale of equity and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of equity and debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=sage_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=sage_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564247321552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract', window );">Incremental costs incurred expected amortization period of asset</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL51790836-203054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130569-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564242026352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Company's Cash Equivalents and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 189,088<span></span>
</td>
<td class="nump">$ 161,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">923,028<span></span>
</td>
<td class="nump">1,109,794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">1,112,116<span></span>
</td>
<td class="nump">1,270,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">164,139<span></span>
</td>
<td class="nump">161,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">164,139<span></span>
</td>
<td class="nump">161,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">24,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">923,028<span></span>
</td>
<td class="nump">1,109,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">947,977<span></span>
</td>
<td class="nump">1,109,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">164,139<span></span>
</td>
<td class="nump">161,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">164,139<span></span>
</td>
<td class="nump">161,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember', window );">International Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">75,766<span></span>
</td>
<td class="nump">127,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember', window );">International Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">75,766<span></span>
</td>
<td class="nump">127,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">232,688<span></span>
</td>
<td class="nump">302,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">232,688<span></span>
</td>
<td class="nump">302,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">U.S. Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">19,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">267,310<span></span>
</td>
<td class="nump">354,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">U.S. Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">19,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">267,310<span></span>
</td>
<td class="nump">354,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">U.S. Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">62,428<span></span>
</td>
<td class="nump">63,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">U.S. Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">62,428<span></span>
</td>
<td class="nump">63,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember', window );">International Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">108,999<span></span>
</td>
<td class="nump">133,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember', window );">International Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">108,999<span></span>
</td>
<td class="nump">133,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">U.S. Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">15,286<span></span>
</td>
<td class="nump">15,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">U.S. Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">15,286<span></span>
</td>
<td class="nump">15,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">U.S. Municipal Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">160,551<span></span>
</td>
<td class="nump">113,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">U.S. Municipal Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">$ 160,551<span></span>
</td>
<td class="nump">$ 113,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564240635824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_DebtInstrumentFairValueCarryingValueLineItems', window );"><strong>Debt Instrument Fair Value Carrying Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount', window );">Transfers among the Level 1, Level 2 and Level 3 categories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByInvestmentObjectiveAxis=us-gaap_USTreasuryBondSecuritiesMember', window );">US Treasury Bond Securities | Corporate Bonds and Municipal Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_DebtInstrumentFairValueCarryingValueLineItems', window );"><strong>Debt Instrument Fair Value Carrying Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MarketableSecuritiesHeldToMaturityFairValue', window );">Marketable securities fair value held to maturity</a></td>
<td class="nump">$ 186,300,000<span></span>
</td>
<td class="nump">$ 211,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | US Treasury Bond Securities | U.S. Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_DebtInstrumentFairValueCarryingValueLineItems', window );"><strong>Debt Instrument Fair Value Carrying Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MarketableSecuritiesRemainingContractualMaturities', window );">Marketable securities, remaining contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | US Treasury Bond Securities | Corporate Bonds and Municipal Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_DebtInstrumentFairValueCarryingValueLineItems', window );"><strong>Debt Instrument Fair Value Carrying Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MarketableSecuritiesMaturityPeriod', window );">Marketable securities held, maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | US Treasury Bond Securities | Corporate Bonds and Municipal Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_DebtInstrumentFairValueCarryingValueLineItems', window );"><strong>Debt Instrument Fair Value Carrying Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MarketableSecuritiesMaturityPeriod', window );">Marketable securities held, maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DebtInstrumentFairValueCarryingValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument fair value carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DebtInstrumentFairValueCarryingValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis among Level 1, Level 2 and Level 3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MarketableSecuritiesHeldToMaturityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities held to maturity fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MarketableSecuritiesHeldToMaturityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MarketableSecuritiesRemainingContractualMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining contractual period for marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MarketableSecuritiesRemainingContractualMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByInvestmentObjectiveAxis=us-gaap_USTreasuryBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByInvestmentObjectiveAxis=us-gaap_USTreasuryBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=sage_CorporateBondsAndMunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=sage_CorporateBondsAndMunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564237950704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 928,106<span></span>
</td>
<td class="nump">$ 1,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5,573)<span></span>
</td>
<td class="num">(10,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">923,028<span></span>
</td>
<td class="nump">1,109,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">234,555<span></span>
</td>
<td class="nump">307,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,149)<span></span>
</td>
<td class="num">(4,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">232,688<span></span>
</td>
<td class="nump">302,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">U.S. Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">269,052<span></span>
</td>
<td class="nump">358,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,808)<span></span>
</td>
<td class="num">(3,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">267,310<span></span>
</td>
<td class="nump">354,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sage_InternationalCorporateBondsMember', window );">International Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">76,313<span></span>
</td>
<td class="nump">128,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(554)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">75,766<span></span>
</td>
<td class="nump">127,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">U.S. Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">62,529<span></span>
</td>
<td class="nump">63,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">62,428<span></span>
</td>
<td class="nump">63,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sage_InternationalCommercialPaperMember', window );">International Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">109,180<span></span>
</td>
<td class="nump">133,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">108,999<span></span>
</td>
<td class="nump">133,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">U.S. Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,286<span></span>
</td>
<td class="nump">15,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">15,286<span></span>
</td>
<td class="nump">15,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">U.S. Municipal Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">161,191<span></span>
</td>
<td class="nump">114,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(778)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 160,551<span></span>
</td>
<td class="nump">$ 113,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sage_InternationalCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sage_InternationalCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sage_InternationalCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sage_InternationalCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564238086896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">$ 430,420<span></span>
</td>
<td class="nump">$ 513,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(2,322)<span></span>
</td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Greater than 12 months, Fair Value</a></td>
<td class="nump">253,971<span></span>
</td>
<td class="nump">399,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Greater than 12 months, Unrealized Losses</a></td>
<td class="num">(3,251)<span></span>
</td>
<td class="num">(5,455)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">684,391<span></span>
</td>
<td class="nump">913,521<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(5,573)<span></span>
</td>
<td class="num">(10,250)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">59,680<span></span>
</td>
<td class="nump">112,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(548)<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Greater than 12 months, Fair Value</a></td>
<td class="nump">108,845<span></span>
</td>
<td class="nump">185,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Greater than 12 months, Unrealized Losses</a></td>
<td class="num">(1,601)<span></span>
</td>
<td class="num">(2,745)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">168,525<span></span>
</td>
<td class="nump">297,934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(2,149)<span></span>
</td>
<td class="num">(4,262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">U.S. Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">144,665<span></span>
</td>
<td class="nump">208,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(978)<span></span>
</td>
<td class="num">(1,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Greater than 12 months, Fair Value</a></td>
<td class="nump">88,097<span></span>
</td>
<td class="nump">130,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Greater than 12 months, Unrealized Losses</a></td>
<td class="num">(830)<span></span>
</td>
<td class="num">(1,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">232,762<span></span>
</td>
<td class="nump">339,140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(1,808)<span></span>
</td>
<td class="num">(3,530)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember', window );">International Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">36,432<span></span>
</td>
<td class="nump">50,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Greater than 12 months, Fair Value</a></td>
<td class="nump">35,015<span></span>
</td>
<td class="nump">68,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Greater than 12 months, Unrealized Losses</a></td>
<td class="num">(341)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">71,447<span></span>
</td>
<td class="nump">119,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(554)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">U.S. Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">36,712<span></span>
</td>
<td class="nump">24,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">36,712<span></span>
</td>
<td class="nump">24,768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember', window );">International Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">95,624<span></span>
</td>
<td class="nump">30,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">95,624<span></span>
</td>
<td class="nump">30,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">U.S. Municipal Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">57,307<span></span>
</td>
<td class="nump">86,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Greater than 12 months, Fair Value</a></td>
<td class="nump">22,014<span></span>
</td>
<td class="nump">14,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Greater than 12 months, Unrealized Losses</a></td>
<td class="num">(479)<span></span>
</td>
<td class="num">(533)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">79,321<span></span>
</td>
<td class="nump">100,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (778)<span></span>
</td>
<td class="num">$ (1,030)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=sage_InternationalCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=sage_InternationalCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564238105280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">$ 40,138<span></span>
</td>
<td class="nump">$ 32,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related</a></td>
<td class="nump">9,872<span></span>
</td>
<td class="nump">29,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">13,922<span></span>
</td>
<td class="nump">10,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 64,745<span></span>
</td>
<td class="nump">$ 72,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued research and development costs, such as clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245188512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies - Operating Leases - Additional Information (Detail) - ft&#178;<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Operating lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseOneMember', window );">Operating Lease One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AreaOfOfficeSpace', window );">Office space rent under operating lease</a></td>
<td class="nump">63,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expire date</a></td>
<td class="text">Aug. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseTwoMember', window );">Operating Lease Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AreaOfOfficeSpace', window );">Office space rent under operating lease</a></td>
<td class="nump">40,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expire date</a></td>
<td class="text">Aug. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseThreeMember', window );">Operating Lease Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AreaOfOfficeSpace', window );">Office space rent under operating lease</a></td>
<td class="nump">15,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expire date</a></td>
<td class="text">Nov. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_LessorOperatingLeaseRemainingLeaseTerms', window );">Operating lease remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_LessorOperatingLeaseRemainingLeaseTerms', window );">Operating lease remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space in square feet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LessorOperatingLeaseRemainingLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor operating lease remaining lease rerms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LessorOperatingLeaseRemainingLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sage_OperatingLeaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564238196736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 92,826,000<span></span>
</td>
<td class="nump">$ 78,018,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Brexanolone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | First and Second Clinical Development Milestones [Member] | Brexanolone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | First and Second Regulatory Milestones [Member] | Brexanolone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Third and Fourth Clinical Development Milestones [Member] | Brexanolone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Third and Fourth Regulatory Milestones [Member] | Brexanolone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Clinical Development [Member] | Brexanolone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePaymentsRelatedToIntangibleAssets', window );">Milestone payments related to intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Clinical Development [Member] | SAGE-689 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Regulatory Milestones [Member] | Brexanolone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_IntangibleAssetRelatedToMilestone', window );">Intangible asset related to milestone</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePaymentsRelatedToIntangibleAssets', window );">Milestone payments related to intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Regulatory Milestones [Member] | SAGE-689 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Clinical Development and Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_IntangibleAssetRelatedToMilestone', window );">Intangible asset related to milestone</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payments based on achievement of certain milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IntangibleAssetRelatedToMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible asset related to milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IntangibleAssetRelatedToMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePaymentsRelatedToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePaymentsRelatedToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_LicenseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_LicenseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_LicenseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_LicenseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564241600048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies - University of California License Agreements - Additional Information (Detail) - University of California License Agreements [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">94 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_LicenseMaintenanceCostAnnual', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">After The Effective Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_LicenseAgreementMaximumTerm', window );">Licenses Expiration period, maximum</a></td>
<td class="text">27 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">After The First Sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_LicenseAgreementMaximumTerm', window );">Licenses Expiration period, maximum</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">Clinical Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PaymentForClinicalDevelopmentMilestones', window );">Milestone payments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestoneOutstandingLicenseAgreement', window );">Milestone outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">Clinical Development [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement', window );">Percentage of net sales paid as royalties</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">Regulatory Milestones [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">Sales Milestones [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones', window );">Expected milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember', window );">Regulatory and Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_IntangibleAssetRelatedToMilestone', window );">Intangible asset related to milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePaymentsRelatedToIntangibleAssets', window );">Milestone payments related to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payments based on achievement of certain milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IntangibleAssetRelatedToMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible asset related to milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IntangibleAssetRelatedToMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LicenseAgreementMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement maximum term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LicenseAgreementMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LicenseMaintenanceCostAnnual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance cost annual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LicenseMaintenanceCostAnnual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestoneOutstandingLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone outstanding license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestoneOutstandingLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePaymentsRelatedToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePaymentsRelatedToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PaymentForClinicalDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for clinical development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PaymentForClinicalDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up front payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sage_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sage_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sage_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sage_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_RegulatoryAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_RegulatoryAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564237832928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 12, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Collaboration receivable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,002,000<span></span>
</td>
<td class="nump">$ 13,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member] | SAGE-217 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AveragePercentageOnTieredRoyalties', window );">Average percentage on tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Standalone selling price of license performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable', window );">Additional milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember', window );">Shionogi Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CollaborationAgreementEffectiveDate', window );">Collaboration agreement effective date</a></td>
<td class="text">Dec. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Standalone selling price of license performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of offering costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,241,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PurchasePriceForNewShareIssued', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementReductionsOrAdditionToOperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Collaboration receivable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PaymentsToRelatedParties', window );">Payments to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ProceedsFromRelatedParties', window );">Proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable', window );">Additional milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | First Commercial Sale of Zuranolone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member] | SAGE-217 [Member] | Maximum [Member] | Regulatory and Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="nump">475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member] | SAGE-324 [Member] | Maximum [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member] | SAGE-324 [Member] | Maximum [Member] | Regulatory and Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones', window );">Future milestone payments</a></td>
<td class="nump">$ 520,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenStockPurchaseAgreementMember', window );">Biogen Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PurchasePriceForNewShareIssued', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CollaborativeAgreementTransactionPrice', window );">Transaction price, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PremiumAmountOnEquityInvestment', window );">Premium amount on equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_PremiumOnPerSharePricePercentage', window );">Premium on per share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_StockPurchaseAgreementDescription', window );">Biogen stock purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The standstill restrictions terminate on the earliest of (i) a specified regulatory milestone under the Biogen Collaboration Agreement, (ii) the date one year following the termination of the Biogen Collaboration Agreement and (iii) the seventh anniversary of the Effective Date. BIMA also agreed not to, and to cause its affiliates not to, sell or transfer any of the Biogen Shares for a period of eighteen months from the closing of the sale of the Biogen Shares, which period expired on June 30, 2022, and to limit sales and transfers of the Biogen Shares for an additional eighteen-month period, in each case subject to specified conditions and exceptions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments based on achievement of certain milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AveragePercentageOnTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average percentage on tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AveragePercentageOnTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CollaborationAgreementEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement efective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CollaborationAgreementEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement regulatory and commercial event based additional milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement transaction price, total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PaymentsToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PaymentsToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PremiumAmountOnEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium amount on equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PremiumAmountOnEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PremiumOnPerSharePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium on per share price, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PremiumOnPerSharePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ProceedsFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ProceedsFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PurchasePriceForNewShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price for new share issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PurchasePriceForNewShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ReimbursementReductionsOrAdditionToOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement reductions or addition to operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ReimbursementReductionsOrAdditionToOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_StockPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_StockPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up front payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ShionogiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sage_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sage_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_LicenseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_LicenseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_FirstCommercialSaleOfZuranoloneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_FirstCommercialSaleOfZuranoloneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_RegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_RegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_SAGE324Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sage_SAGE324Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_BiogenStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_BiogenStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564237765968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementFromCollaborationAbstract', window );"><strong>Net reimbursement to (from) Biogen reflected in the condensed consolidated statements of operations and comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">$ 158,764<span></span>
</td>
<td class="nump">$ 124,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember', window );">Biogen Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Expenses related to the Biogen Collaboration Agreement incurred by Sage</a></td>
<td class="nump">56,136<span></span>
</td>
<td class="nump">48,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementFromCollaborationAbstract', window );"><strong>Net reimbursement to (from) Biogen reflected in the condensed consolidated statements of operations and comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses', window );">Selling, general and administrative expenses</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="num">(1,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementReductionsToOperatingExpenses', window );">Operating expenses</a></td>
<td class="num">(14,248)<span></span>
</td>
<td class="num">(19,988)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">41,888<span></span>
</td>
<td class="nump">28,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member] | Biogen Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementFromCollaborationAbstract', window );"><strong>Net reimbursement to (from) Biogen reflected in the condensed consolidated statements of operations and comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ReimbursementReductionsToExpense', window );">Research and development expenses</a></td>
<td class="num">$ (17,282)<span></span>
</td>
<td class="num">$ (18,514)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ReimbursementFromCollaborationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement from collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ReimbursementFromCollaborationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ReimbursementReductionsToExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursement from collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ReimbursementReductionsToExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ReimbursementReductionsToOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement reductions to operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ReimbursementReductionsToOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement reductions to selling, general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_BiogenCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564241002832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Milestone </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Milestone </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 16, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation granted under plan vested period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod', window );">Share based compensation, vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,793,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance under stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,616,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,038,000<span></span>
</td>
<td class="nump">$ 18,553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.65<span></span>
</td>
<td class="nump">$ 27.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sage_TimeBasedRestrictedStockUnitsMember', window );">Time Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation granted under plan vested period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod', window );">Share based compensation remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency', window );">Share based compensation vesting frequency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Restricted stock units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,494<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sage_PerformanceRestrictedStockUnitsMember', window );">Performance Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822,718<span></span>
</td>
<td class="nump">415,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,938,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,383,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,015,000<span></span>
</td>
<td class="nump">15,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sage_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares outstanding and unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,553,000<span></span>
</td>
<td class="nump">$ 2,803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,409,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Restricted Stock Units Vest One Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock units vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Restricted Stock Units Vest One Year Anniversary [Member] | Time Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock units vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Restricted Stock Units Vest Two Year Anniversary [Member] | Time Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock units vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandElevenStockOptionPlanMember', window );">2011 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Common stock shares annual increase added to plan</a></td>
<td class="nump">2,380,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Plan [Member] | Performance Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_NumberOfMilestonesAchieved', window );">Milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Plan [Member] | Performance Restricted Stock Units [Member] | Milestone One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_MilestonePerformanceRestrictedStockPercentage', window );">Milestone performance restricted stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Plan [Member] | Performance-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_NumberOfMilestonesAchieved', window );">Milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage', window );">Percentage of increase on outstanding shares of Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandSixteenStockOptionPlanMember', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage increase in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePerformanceRestrictedStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone performance restricted stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePerformanceRestrictedStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award award cliff vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by share based payment award award remaining vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share based payment award, vesting frequency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sage_TimeBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sage_TimeBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sage_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sage_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sage_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sage_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandElevenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandElevenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandSixteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandSixteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245575936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail) - Restricted Stock Units [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Shares at beginning balance | shares</a></td>
<td class="nump">1,415,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares | shares</a></td>
<td class="nump">1,153,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares | shares</a></td>
<td class="num">(138,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Shares | shares</a></td>
<td class="num">(20,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Shares at ending balance | shares</a></td>
<td class="nump">2,409,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted Average Grant Date Fair Value at beginning balance | $ / shares</a></td>
<td class="nump">$ 48.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">42.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">67.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">48.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted Average Grant Date Fair Value at ending balance | $ / shares</a></td>
<td class="nump">$ 44.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564245007424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Relating to Time Based and Performance Based Stock Options (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, Outstanding Shares</a></td>
<td class="nump">10,793,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, Outstanding Shares</a></td>
<td class="nump">7,788,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Shares</a></td>
<td class="nump">712,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Shares</a></td>
<td class="num">(45,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, Shares</a></td>
<td class="num">(71,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, Outstanding Shares</a></td>
<td class="nump">8,383,310<span></span>
</td>
<td class="nump">7,788,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Shares</a></td>
<td class="nump">5,318,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, Outstanding Weighted Average Exercise Price</a></td>
<td class="nump">$ 77.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price</a></td>
<td class="nump">44.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price</a></td>
<td class="nump">5.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price</a></td>
<td class="nump">96.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, Outstanding Weighted Average Exercise Price</a></td>
<td class="nump">75.36<span></span>
</td>
<td class="nump">$ 77.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 84.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Life</a></td>
<td class="text">6 years 5 months 15 days<span></span>
</td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Life</a></td>
<td class="text">5 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 12,177<span></span>
</td>
<td class="nump">$ 7,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 8,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564241969360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 20,038<span></span>
</td>
<td class="nump">$ 18,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">8,773<span></span>
</td>
<td class="nump">8,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 11,265<span></span>
</td>
<td class="nump">$ 9,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564241601328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 20,038<span></span>
</td>
<td class="nump">$ 18,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">10,015<span></span>
</td>
<td class="nump">15,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">9,553<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sage_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sage_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sage_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564246258016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (146,828)<span></span>
</td>
<td class="num">$ (122,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding&#8212; basic</a></td>
<td class="nump">59,674,127<span></span>
</td>
<td class="nump">59,028,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Dilutive effect of shares of common stock equivalents resulting from common stock options and restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding &#8212;diluted</a></td>
<td class="nump">59,674,127<span></span>
</td>
<td class="nump">59,028,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share&#8212;basic</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share&#8212;diluted</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140564244878048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Anti-Dilutive Common Stock Equivalents Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">8,251,047<span></span>
</td>
<td class="nump">7,500,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">7,733,310<span></span>
</td>
<td class="nump">6,932,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">470,891<span></span>
</td>
<td class="nump">541,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sage_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">46,846<span></span>
</td>
<td class="nump">26,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sage_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sage_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>sage-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sage="http://www.sagerx.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sage-20230331.xsd" xlink:type="simple"/>
    <context id="C_afad7b91-c063-484c-8b27-af3fdd038f98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_5b7a5ab4-63f6-4561-8f6d-b3de184d3551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fae74238-7ce3-4af5-9f76-7ddc34eb01f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ad149366-134a-4672-9147-ddac23ada4ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1260202e-e0d1-44c6-91a1-7328082cd6ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_694b1751-ca21-4b1a-8ae0-231f74098b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_66eb2bc3-a6d2-4d81-939a-2ee9abc0d88c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="C_e45cbb2e-3c5f-498a-a209-b241cd20689d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_053c255f-d2dc-471e-bb1d-70b5c18befc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_631cae3a-ac3e-456e-a8b7-57e54ff8a7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_cc0e2088-ed2f-4615-ae09-35dc9db057e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b41ee00a-05a1-4445-a768-1bb17e0a6c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_96f30eb5-acb2-4f40-a8d3-bcc1575d5f47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ef9f0eeb-8bd0-48d2-8cef-1b949dcabefb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_b2914001-6eb8-4b83-a2c2-bd94ddbe5fe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_041cce77-afef-4aed-92c7-1df0dfbc91eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_1978be30-cc7c-4cc4-a992-11e42d4bd0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34e9c797-7ce4-4b4b-b51e-18629a1f9429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_473be90c-b2bd-4a46-8157-218452e72424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_51b62e2e-6e5b-43f1-9a64-7a9fc0694111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_d9d6d818-4da5-4eb9-903b-f6a198d8f733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dbfc6e76-8aca-485a-914b-f8d69d2c7389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59e5900f-8174-4b14-bfc1-b7d19f8176e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_96c58346-5075-4864-bc24-0ddf5e57105c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fbb07196-2b75-47c6-80e5-725f729861d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_f9308d0f-6e5f-4493-9625-38e3eaaea53c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_1377c2db-8563-423b-b496-c6079553d1b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_22abec7d-1872-4be4-b3da-b134f50ffb38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2eed04fd-66bf-403b-b097-ca6cfcbcd5d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_80624434-96c6-446e-ada9-fe739d3d9e5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_d9a17952-5137-4cb5-9321-ceda02cb88c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_90273a42-5bc2-4c8a-b365-81b8b3294dbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_75423cb0-1c5c-451b-8f34-441ea3df08c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sage:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_0417f1bf-3a90-4585-8698-483b60daf578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ThirdAndFourthRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_3bb6c209-64a4-4fa9-9e19-b14c178a0c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:RegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2b34f602-7812-4da1-a117-ccb5aabeb0c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0a4f411b-755b-4edb-9b9a-1c815418b4e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_73403fc5-d8c9-42ee-a01a-11d2ee5fe21a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_859555c6-3449-4a1e-829a-27a34b936e07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_27bf7966-adaf-4a98-8cd4-cf044ac22be7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_08b2b642-fbe6-4621-9e25-1ad7325fb6fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_41166faf-b133-46b7-89f9-98cc0e4a309b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_872fc801-16d0-407b-a188-71e78a10b66e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0a812fff-cfeb-4da1-8230-6cd1569cea05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b0558d4b-6d1c-4376-8c22-956a113e11fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_df2b4db8-ae1e-400c-96db-0a5ee962f62b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_90692949-732e-4bb8-962a-750c256e3415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e7f34c5e-d698-4850-9998-3b9d55aa69dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ff1b2d86-e176-4930-a80e-46e442e30f10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9558178b-ee96-4bb9-98b8-32cd20923e46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_159c0b2e-4b20-4fe8-842e-d19291806674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-12</instant>
        </period>
    </context>
    <context id="C_1a4476f1-f818-43ff-b2be-89e56448a77d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20237446-69f4-4551-93d5-fee5a4bf888c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c8fdbb15-6c4b-4e31-80ed-4104897dd692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cd88a57a-5b9d-49be-a744-23e0bf41890a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9077cfbe-fe30-4100-87f2-a75b18e864fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_4abf962a-8014-45c8-8864-72250359e195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_2204d339-5d64-45be-917c-4696379675ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_78cc9303-1878-4bf1-bcb6-79233994a9c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_8fafe567-6ae5-44ee-8496-6f5bb08d136a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f39072ec-f2ce-4670-be4f-b0f1f4bcf30f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_184f14a5-c851-40db-a3ad-edc0666d719c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c148acc4-eb89-4bb9-b863-bbc6f10137ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sage:OperatingLeaseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_c188b130-04d4-4adb-80ea-ddd9b3454d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_378410ff-522b-42f9-9391-4818fc9692a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_699a6647-c36c-4a33-a3f4-ae8e7184b152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:SAGE324Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_1a762d75-188f-4244-ab8c-58366e1a3a7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e166f395-27e9-4ed3-b61a-0efed3d9f77f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:SAGE324Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:RegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_3319e980-82fb-4d89-a8c2-15e306377f32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7cfbb3fe-a778-45b0-a709-a4a4a1292a25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a27e3064-3e8b-4d7c-97fd-d2f5bdd6bd44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sage:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0a046e3a-d734-4572-ba58-9c70fe1e9fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_7a300dcf-c0cb-47b1-a0fc-9cd53edc84b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandElevenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_04077a28-e57f-48bf-be52-866b6f516e9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1dfde7f5-0e05-4477-b311-a6bafe7de036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_d4873c8c-5811-4fbb-bbcc-4e44f6387941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ThirdAndFourthClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_6f864b66-2233-436e-9a55-3a656e209f1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:FirstCommercialSaleOfZuranoloneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_f717451a-6a70-4aef-9347-14e48ca9154e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_0ac07274-fc3a-4894-82ec-ea46b3499663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b95b663e-2b75-4278-99c2-2c62b7b11486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_f08fa5ab-3d5a-498f-8805-b37168240ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sage:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-30</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_a87f9c6e-2ef9-466a-ae7a-ee5de7690022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="C_1781ce27-35bc-4e2c-9a64-0b8ce5fdfda1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="C_59765745-97e9-4396-b431-ab2d3335cfad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_758d45bc-86ac-4f04-b85e-741bffc1d6f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_e663c40a-15ae-4907-b98c-552196067f88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_c1eaf741-1b2c-4c28-bfe7-5c8db9a38dfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_8d91e179-f711-4e4d-aaa6-c27f609457e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b2aeaf62-e210-498e-b523-527707b39cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_150eb2ee-5e12-4af8-9658-d633a3fc51a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_b7010b40-0dcd-4f49-8b91-0d384171fed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d696c64-4852-4448-9e18-cca9af20998a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6e880326-ed6e-48e7-a99c-374dfaae0004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_fe878ea5-22df-4ead-ab1d-48438facdfb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sage:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_e922eff6-ae97-4689-ab0c-b231d4614194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a2ae6c1e-1913-47c9-8778-3d00309c407f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ee76c540-63b2-44a9-af22-8b7f35a27ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_cec5550d-a16c-4e00-9894-1a8d869e5bae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_9b6f49c8-d774-48fb-b187-986662265c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eaf26748-7cbb-49a2-a010-8177fc4192d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_f8c25304-e6ec-4215-ad71-34b22a23bf68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_8d3496d1-3be0-413b-9f3a-0b624246add1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_985df593-5059-41c1-979c-cfad810abdef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_110148da-fe96-4b69-87ce-8a98365c120f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f338a222-b449-4bcc-a112-e91bc99cd864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c9010a77-202b-457f-a93d-645d7cf2ae6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_be15177a-d746-4e38-b283-8b06ad56dd5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e009878c-16d0-44dd-938b-4ab63e464396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sage:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-30</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_27dd408f-5b77-4383-b146-868c9ccf1126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_b5072417-0f0f-44a9-8e76-a71228d6ebf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_398f2f38-b40a-44f3-b42a-adb45a79772b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_deab43ad-3c90-4a47-ae84-57cc9e11dfaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1249121-8d96-4038-9762-31833df70a85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_c31a15fe-00ba-4870-b61b-89dd2a4980ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_328aba2f-fb20-4a39-964e-4eee7f038c9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b2b10c3e-e417-48ea-a3c8-37953b52b9c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_43b0053b-716b-4f02-839f-ad6443d25548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_fbed26d2-cc37-4226-abd6-049e70ee76cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0f48cc31-4e82-4c5a-8987-efbee611a07b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_415d3116-954c-4e68-b279-376d06d7f3f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_d4fdb95a-3eb7-454b-aa35-9c3868eab086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9b20c727-7972-478a-9e8f-c96192d5a8c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_3733b62f-9978-46fa-ae1f-0ca914403f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_281fc868-2fdb-4949-a787-87a97e7468c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_32d6c0d5-c8be-40ce-8635-6583447c427f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_cb341859-3071-42f6-bc53-4b0e98b5f8a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstAndSecondClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_ec5cbc69-f530-4cf4-94cc-314aa3b6a25a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_3499aa63-1335-4278-afe4-3af8c03e1236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_94d7d66d-d764-476a-bdb7-7e62dfec2d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ebde5ad9-f57b-4a0d-a856-31c668cee290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_62a04c01-c554-489b-94ff-f68796238daf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7bd63346-2edc-4d25-8792-a77d046eb774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0e328e10-72d6-410f-80ac-3d76258027a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_94d81f85-dbf8-4abd-8cc2-b5a8a0cbec84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ShionogiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_ce43f41b-b49a-4a4d-ac4f-591e551f6206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_850361db-7291-43d8-8579-6031f3718f59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_4ea38295-87e6-4099-8ab6-a32ad999eac8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_c7472141-c913-4194-b3cf-9b99dbf32ab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a954ef97-2d5d-474e-85f1-993cfd4ef26c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_d275e93b-4da3-49de-a49e-a35ac74b5238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d6308113-5edd-45dc-ae2f-49266a225055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_8b581abc-0b6e-4877-a6fd-ea611d7c0a1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstAndSecondRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_9c3096d1-dec2-4b13-9d67-bef02783497c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_2ae85a8f-70ca-4220-93dc-e4da3306dc78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sage:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_263ee25c-c855-4e19-8a9f-8283bd620ab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_23999eda-d8e5-4c17-ae2e-ed2f30bd77ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_34f017d3-fc3a-40f4-a32a-6e68c12be396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c8887f83-2b64-4c67-9ed6-bf1f704f02eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_d3351468-5ac6-43c1-8075-f9f598ae56b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByInvestmentObjectiveAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:CorporateBondsAndMunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d205233-d11d-421a-9604-3d24b788eaa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandSixteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="C_0ac1b81a-4423-47d2-b61e-3baceb754609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_88622809-97e6-415e-84af-28e0cecdedb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a7db4793-3d03-4e12-aff2-9ea90996fb1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sage:OperatingLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_414c6759-f1c6-41b9-b865-55fecfa38284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_b379d84e-292f-4ec3-8309-f2e399adad4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_5fb3fbe9-a1c0-46ce-b650-af5e52d18ce1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-30</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_bdd95323-8fa2-447a-b407-594cf62cbf26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ff91b6cd-d80c-40f0-b294-2711aab14ffb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_a131c6ed-00ee-4297-b3ee-b15e20f02a2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ed9cf729-5356-4b5d-ad2b-e3ed67efc846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sage:OperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_39f2ebec-0b4d-4975-8d61-08994c517086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_5673061c-1475-40d8-a68f-d13874d6120e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-30</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_fe4b519c-5caf-4568-8a3a-2efeec719a51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_c36d2239-87f1-407c-91da-2330c526026f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="C_fe000172-bb4d-4a08-9a7f-f806a292fa6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_95a6685d-c914-4c9f-b57b-5ca39c0070ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_cd11ff6a-3076-4878-b379-411eea2932d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_27a73613-5f17-4ab4-b5a6-643c79010992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_ca2e20ac-ec64-49a3-90db-a61de00d3168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e8b28052-9239-40b1-9476-79d5174ad674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0418523-3fbf-4353-b5fc-b74fa6275d25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dfcf2c3b-ff61-431f-b715-71fc37e86066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sage:InternationalCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4eb33dd9-e498-40d6-b3ab-aed72488e0a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_24252855-7fbc-49c5-993c-ccdb3e3e73e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7cc6f749-3572-4a07-9837-a838d91c9606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c9b8b2ef-3e7c-4781-829b-f175d048affc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d08e78d2-6122-4a68-a2fa-efacb6e5afb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_b2824d78-7fd0-4324-bd17-8138321ed536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_fe2f65bc-c1a3-4823-84d8-2de25bace4b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_c906b10e-a37d-4bef-9c1a-2f9273872ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7d098601-3538-45a4-aa05-ee4216c06e54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_565d202e-3bb5-4101-a291-f12dafc51a69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_218b8633-84a1-4518-ac04-a09bb4743a05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sage:LicenseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:BiogenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_25ec2f51-a9c3-49be-9f2a-0f5e21581ba9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Milestone">
        <measure>sage:Milestone</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_21484654-1747-43a0-a65e-1ae6c9c7e6e4">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_02aacb61-99a8-43ba-8bb8-3474e32fbedc">true</us-gaap:LessorOperatingLeaseOptionToExtend>
    <dei:AmendmentFlag
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_f626faa3-d234-4588-bb64-a0e2e90343a1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      id="F_722165e9-8516-4f03-ba84-faf866355366"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_0bb4eff4-2c78-4ed6-a5dc-d2873b5f55dc">0001597553</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      id="F_4c74dc23-2f32-4cdf-9616-71a40e398db1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sage:MarketableSecuritiesMaturityPeriod
      contextRef="C_90692949-732e-4bb8-962a-750c256e3415"
      id="F_9fe7857e-17e4-49cf-93b3-30d78c5acea7">P1Y</sage:MarketableSecuritiesMaturityPeriod>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_daac0f6d-a17b-45b7-8238-999b9f5345f2">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockValue
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      id="F_bc779985-800d-437e-b177-c597d5bba68a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sage:MarketableSecuritiesMaturityPeriod
      contextRef="C_f8c25304-e6ec-4215-ad71-34b22a23bf68"
      id="F_15ef7878-1081-4815-8372-c33bbdbbcbd7">P1Y</sage:MarketableSecuritiesMaturityPeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      id="F_894d0bec-ae52-4ca9-a5f4-73ac643e9e66"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_71f37d5b-ed46-4c11-9134-1ce927638453">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_19e5434c-21f1-4209-98b4-7353ee7996b9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b282236d-bc49-4ebc-bfbf-14af552b1ca1">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_16d4f0d6-c627-4de8-b96c-eaa7ce09e3b1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b71f5023-1843-409f-a0bc-5df6e2c04aef">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_0c7d8053-6cf8-401e-b42c-ada6c1aa5bae">001-36544</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_cc468799-099d-41d1-8c27-2dc72c754f1b">Sage Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_db2e891d-ddf3-44bc-9cd8-1da91695f233">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_17606b56-fc7e-4200-90c2-98f08d630de9">27-4486580</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_005ab3d0-298b-46c4-9f66-c8d3e43009a7">215 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_af025a85-5aa5-40f2-9698-6210b9ca7508">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_c3d1198f-cea1-4c9e-972a-e271da48840a">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_0e52e542-a1d5-4898-9b70-7795671399d7">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_01742252-d6f5-472c-b3c5-57625bde8a8c">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_e240f7d1-0ef5-4253-a684-442465ba379a">299-8380</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b9c817db-88b6-4bc3-b405-d7acb972180a">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b964c55f-7112-4659-8ce6-aed5cdf1c715">SAGE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_11096860-8cc7-4d50-bdd2-ec00e1dc43d9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_d0a10b9d-d438-471f-b1f4-743c955c7bf0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_4f114027-91fc-452b-8b8b-6889edaf8f9e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_2a6709f9-3126-4cd1-a9d7-6f114e009cde">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_9e3e191b-0e03-4843-82d5-49e2ee8318d4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_4085be57-efb1-40be-b723-30b9424bc504">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_4d736a1d-2c80-414b-a53b-ddc026659640">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_c36d2239-87f1-407c-91da-2330c526026f"
      decimals="INF"
      id="F_2dabec0c-7b0d-47d1-a5ca-b52cc16d0681"
      unitRef="U_shares">59762106</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_cbfd8acf-8921-4c62-a3b4-59a4e954f5f3"
      unitRef="U_USD">206557000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_bb89847c-5829-4bd7-8ba5-46be95d53878"
      unitRef="U_USD">162700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_546e4af9-e48d-4198-bb8a-f7e6fff811b7"
      unitRef="U_USD">923028000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_eef32bb5-4b4b-4d09-b50a-804fa1900452"
      unitRef="U_USD">1109794000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_ea5e6078-f5df-4cf5-a86e-dd46b32f46d2"
      unitRef="U_USD">58850000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_82535d17-622e-49ea-9b9c-d9e5c13e8789"
      unitRef="U_USD">50826000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_a91738f3-8cc5-4f8a-a389-3d6539ed4e53"
      unitRef="U_USD">15002000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_b4f762f0-5f8a-4993-9e03-bfc21325f1f0"
      unitRef="U_USD">13660000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_08d17728-b15c-4a9e-a4b9-a3ded913ab28"
      unitRef="U_USD">1203437000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_6caa4499-ae5e-4d62-817b-f13a2c822b1a"
      unitRef="U_USD">1336980000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_25695f94-54a6-4a54-9799-9f3f3b130c0f"
      unitRef="U_USD">2663000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_dc74cbbf-2146-4f5e-98b4-1d62809fe405"
      unitRef="U_USD">2898000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_d499316e-844e-4754-ae5e-860b7e10a34e"
      unitRef="U_USD">1269000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_64c4a448-18bb-4d7b-9bb4-09207000f23e"
      unitRef="U_USD">1269000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_24d3d60d-6914-4138-af67-4d027e56c0cd"
      unitRef="U_USD">9062000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_4b99fb7a-d9e5-4725-a2d8-f684b9576e7a"
      unitRef="U_USD">10532000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_5fbe74e7-aaf6-4226-98c2-a5b2e31960ca"
      unitRef="U_USD">4255000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_864a5971-0131-48d1-8a7d-43ce3569b292"
      unitRef="U_USD">4770000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_651fa7a4-497e-43f6-82ab-65bb3cad009c"
      unitRef="U_USD">1220686000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_95f5674f-90fc-4c82-8347-13003f8da707"
      unitRef="U_USD">1356449000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_2788b2e7-31f7-4a82-a9f8-7f1384ebf74a"
      unitRef="U_USD">12263000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_91add304-8efb-4a0d-adf9-504e73969b07"
      unitRef="U_USD">18950000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_dcd1cbbb-df7f-4116-ba15-cf86e024b256"
      unitRef="U_USD">64745000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_a79de10f-6c1f-4dcf-a3dd-4e0eebdd0864"
      unitRef="U_USD">72666000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_e9585b93-6294-4407-bafd-e0ec2526523b"
      unitRef="U_USD">7684000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_229ba4d4-be2f-4667-9db9-55f81d2e45bd"
      unitRef="U_USD">7643000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_0e0d2767-730f-459c-aec6-5ea28ebda3c2"
      unitRef="U_USD">84692000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_75928d44-6f58-4be7-a3dc-638ecc79d059"
      unitRef="U_USD">99259000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_9b3a864d-12bb-432c-8f2f-768eb64631bd"
      unitRef="U_USD">2763000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_83d108c5-2172-46fd-ae08-67acd5bca57a"
      unitRef="U_USD">4491000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_83d7e8af-00d5-4df1-bf93-06e0c0b74f54"
      unitRef="U_USD">102000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_8edac4f3-2203-4866-862e-ec6eb6faa1c2"
      unitRef="U_USD">100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_b9800d1d-b21b-4358-a537-5aade448e004"
      unitRef="U_USD">87557000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_186dd8fe-82e7-4cf6-be7e-4a887be47b12"
      unitRef="U_USD">103850000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_a5fc754e-52ad-4948-b501-88032ecf9e9f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_c1c00af1-1aec-42fc-b396-4debea59e366"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_944b38de-b384-4d10-978b-6fb743e6b071"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_68bf4643-1428-4556-943a-71ee7d6011dc"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_f6663014-056a-46ab-97e5-594f2aedf4d6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_a5d98363-e71d-43e8-a598-cff9cbf3ee65"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_c1146a9a-8abf-4144-b839-bff3dae17336"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_418cde14-e922-4da2-9f0f-d1ad300f04a6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_ad534995-a1de-498b-9a64-4fce93188441"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_762fc7be-cc55-4de5-a938-e152f08b236d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_20b7b99f-3dd3-4a41-8738-09154b2345db"
      unitRef="U_shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_d974f708-3462-4822-93c5-f85bf448065e"
      unitRef="U_shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_02d159b2-3358-4885-98dd-207b2c2c3d0d"
      unitRef="U_shares">59765034</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_3e88ffd8-99c7-494f-bbc6-0f57b093d470"
      unitRef="U_shares">59512158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_65c68aa6-7c1a-4b10-ab21-98a69b7919e9"
      unitRef="U_shares">59762001</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_1cedc339-d384-4c59-90fb-1bdaa78220fd"
      unitRef="U_shares">59509125</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_684e4715-1b9b-4b11-80b1-93000d4d34e2"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_be764312-eced-4e12-a19f-5c2a11857aca"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_674e8374-1c34-49f5-b036-5ed75a45e1e5"
      unitRef="U_shares">3033</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="INF"
      id="F_8fb34b4e-4278-414a-ba7e-7e65bd998f21"
      unitRef="U_shares">3033</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_e38c8649-5d09-4645-ae17-dd48b47da797"
      unitRef="U_USD">400000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_00a18c46-fd1f-4276-a9e7-2434dea2c00f"
      unitRef="U_USD">400000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_013fee83-8079-4fb6-898c-8ba3831f34cb"
      unitRef="U_USD">3313609000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_f94da8c2-58fa-4ba2-845c-82dad994c329"
      unitRef="U_USD">3291369000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_afd6205d-0f72-456e-a01f-48ba521e88f6"
      unitRef="U_USD">-2174998000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_79aa99b1-3789-4c1d-8cde-d66e763b9572"
      unitRef="U_USD">-2028170000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_3876fa93-329c-4f75-8294-c242b3363ee5"
      unitRef="U_USD">-5088000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_d19ebe28-0e24-46fb-bfa7-255edd8a8c34"
      unitRef="U_USD">-10206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_9c763134-ef31-4840-9172-3409d5e80330"
      unitRef="U_USD">1133129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_31c2d073-9fe4-40e9-8fbf-0849fc812539"
      unitRef="U_USD">1252599000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_b16a65ef-0d6d-4def-88f4-3f9340689337"
      unitRef="U_USD">1220686000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_c072a33e-cdd0-4a8e-a5fd-e71914f456b5"
      unitRef="U_USD">1356449000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_80624434-96c6-446e-ada9-fe739d3d9e5b"
      decimals="-3"
      id="F_fa630da6-e5a3-4858-ac26-0985420e47fd"
      unitRef="U_USD">3294000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_8d91e179-f711-4e4d-aaa6-c27f609457e6"
      decimals="-3"
      id="F_f42886ba-91ee-452b-9331-a837a53b73e1"
      unitRef="U_USD">1582000</us-gaap:Revenues>
    <sage:CostOfSales
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_42bedce7-692a-4e50-9b55-b0cbfc21fad1"
      unitRef="U_USD">230000</sage:CostOfSales>
    <sage:CostOfSales
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_e0d59703-8ece-400e-b3dd-039a0415f98e"
      unitRef="U_USD">286000</sage:CostOfSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_6424e6e9-d292-43f8-9c6b-a9e495b198d5"
      unitRef="U_USD">92826000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_34f69b42-4e08-4daa-a437-a50267c3c1d4"
      unitRef="U_USD">78018000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_c1e9381c-91a7-42ee-af5f-22e55d949c1b"
      unitRef="U_USD">65708000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_46144922-dd4e-426d-ab12-8ea64d3c94d8"
      unitRef="U_USD">46477000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_ffb84a50-c190-4bd4-907d-f23551a3534d"
      unitRef="U_USD">158764000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_23cd9bad-4fb6-4d6d-a3a7-4379caf74c01"
      unitRef="U_USD">124781000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_bf373a36-56d4-4eb6-b44b-cbf376a361d7"
      unitRef="U_USD">-155470000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_84bba483-7039-427d-b1c6-a28984cc5d0c"
      unitRef="U_USD">-123199000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_5591b326-d146-4a51-a27e-18cc0a637755"
      unitRef="U_USD">8830000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_fca15b90-3e6d-478a-a916-5f0f0743f8f0"
      unitRef="U_USD">1168000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_e0acbd2b-d553-4e90-a364-cb0663873df0"
      unitRef="U_USD">-188000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_6fd89a63-eddc-42a5-9c0c-34b526c67bdc"
      unitRef="U_USD">-24000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_41dc41d9-e31b-42fd-a556-a7919c020ac9"
      unitRef="U_USD">-146828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_bda99b6b-5498-486e-9e67-1db1c9fba7ce"
      unitRef="U_USD">-122055000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="2"
      id="F_79829790-f07f-446b-a362-5366fc1f2f95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="2"
      id="F_1f9ddbf9-7864-4c86-ad67-4dac785afb30"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="2"
      id="F_23990e9a-b355-4636-a145-bb2907ed6128"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="2"
      id="F_aeb3ed48-ba16-4a94-8492-b23f77577d93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="0"
      id="F_78ec86f8-170a-499b-a2f7-001e63a5435d"
      unitRef="U_shares">59674127</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="0"
      id="F_d2f952f7-8871-4e8a-948a-182eadc7aca9"
      unitRef="U_shares">59674127</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="0"
      id="F_13ddb1b3-d2ef-44b7-8fe1-0ab20f65ba27"
      unitRef="U_shares">59028858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="0"
      id="F_417f36d1-6d49-4fcd-8923-87a8b46f658a"
      unitRef="U_shares">59028858</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_2d371ae8-7749-41fe-9a0d-4cfcf1f25c4f"
      unitRef="U_USD">-146828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_977b212b-a918-415d-b9f5-901c81db5c68"
      unitRef="U_USD">-122055000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_55215690-aa32-4627-8396-ec3af808473d"
      unitRef="U_USD">5118000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_cdf411ca-a7e9-4f46-96c7-b38c6ebec541"
      unitRef="U_USD">-8541000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_f6a2ef44-1fbe-46d7-bf1d-43fcafbc3799"
      unitRef="U_USD">5118000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_756dd892-2500-419a-8e29-fe91c81a97f8"
      unitRef="U_USD">-8541000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_3dde52d3-7ddd-4a68-93e9-9ad147f823d0"
      unitRef="U_USD">-141710000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_219042c2-bde3-463b-af72-9935458e543c"
      unitRef="U_USD">-130596000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_9f3d5cfb-4803-47f7-827b-dba59057b4ce"
      unitRef="U_USD">-146828000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_d49b5133-d2ee-4f71-acb0-2fb623911c49"
      unitRef="U_USD">-122055000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_9c110ce9-a3cc-4431-bb1c-a71ab2dc73e2"
      unitRef="U_USD">20038000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_0c79e5bb-ccf1-423e-b2e4-3646002934cf"
      unitRef="U_USD">18553000</us-gaap:ShareBasedCompensation>
    <sage:PremiumOnMarketableSecurities
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_daa12745-ac11-49f0-87cb-e596ade7cef7"
      unitRef="U_USD">29000</sage:PremiumOnMarketableSecurities>
    <sage:PremiumOnMarketableSecurities
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_7d36f27d-bd5e-4058-81f1-644b25b9775c"
      unitRef="U_USD">1189000</sage:PremiumOnMarketableSecurities>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_244a86ea-365a-470a-9ce4-cafe80ed8420"
      unitRef="U_USD">3179000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_bebccf8b-5d93-41de-8c8e-570a8dbcebc4"
      unitRef="U_USD">-3533000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:Depreciation
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_55382147-74e2-4fda-bd18-48cbb1946af8"
      unitRef="U_USD">323000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_dbf1e1d0-71a6-444b-8936-66e4c80658b9"
      unitRef="U_USD">275000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_df7f0e8b-f86b-4190-8495-a9cf6dc8008e"
      unitRef="U_USD">8024000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_eeb903a3-87e4-4a4e-bc04-73f8e2895910"
      unitRef="U_USD">-2635000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_0b74389f-6f7e-4dc0-9e85-398185788acf"
      unitRef="U_USD">1342000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_0d71e6d4-05d2-460d-beb9-cd5fc405d131"
      unitRef="U_USD">1291000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_be42cd24-6a48-4322-b299-350073e735a5"
      unitRef="U_USD">-515000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_2694a18e-8c4b-4d13-bdf4-ed82bbc0c731"
      unitRef="U_USD">340000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <sage:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_c29585e2-d647-4491-9b56-fdc92e3b4ce8"
      unitRef="U_USD">-1470000</sage:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <sage:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_de4d0682-96b5-48c6-b478-2dd67d9ee266"
      unitRef="U_USD">-1350000</sage:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <sage:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_caf406c7-2053-42e1-a16a-19ebdb73ebdc"
      unitRef="U_USD">41000</sage:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <sage:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_49317ce2-b49d-4af5-8761-cae73b3b79b9"
      unitRef="U_USD">55000</sage:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <sage:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_27922e86-bd6b-46b3-8a7b-f785b1ded523"
      unitRef="U_USD">-1728000</sage:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent>
    <sage:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_45224de2-adf0-4a97-bfbd-44371ce20e7a"
      unitRef="U_USD">-1568000</sage:IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_40a996a2-cbdf-46d8-b5e9-4d9de4c712d9"
      unitRef="U_USD">-6550000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_0beead26-1772-4149-a6ed-744867591920"
      unitRef="U_USD">-3251000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_2d8a47db-23f4-494f-95ad-06accc8f4c29"
      unitRef="U_USD">-8389000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_702973d0-4acb-4414-ad7f-9792e412a89e"
      unitRef="U_USD">-4507000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_cd6680cd-2bed-429c-864c-d0b5997e79f3"
      unitRef="U_USD">-153682000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_52505438-9841-4008-bba7-0c96612bffd7"
      unitRef="U_USD">-107800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_21738257-376b-455f-893f-a4ce709e0076"
      unitRef="U_USD">351982000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_2d6a61d5-004d-432f-8444-756ae19b5a62"
      unitRef="U_USD">292539000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_82c9af42-b1e8-450f-a7ae-a13e8983dd51"
      unitRef="U_USD">156890000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_c3423a3e-ec59-4dbb-a2e2-afbf78bf0cc4"
      unitRef="U_USD">301928000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_3c1b8f98-40db-4ccc-9357-6d68de041929"
      unitRef="U_USD">225000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_0bfb8fc9-82e6-4efa-a6ec-7cb29dd326bf"
      unitRef="U_USD">169000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_91c584b1-b7f7-44d2-8c31-80a69296ec12"
      unitRef="U_USD">194867000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_1cf40bac-cebe-41a4-85a0-367d6070275d"
      unitRef="U_USD">-9558000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_cd299e73-f7d5-49e1-bc23-6f4fafb1a19e"
      unitRef="U_USD">3301000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_6a2ebaac-3ddf-45b3-a5f0-5bdfa46d1d61"
      unitRef="U_USD">1799000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_b9314d92-34a0-4149-a3f7-d08dad8930f6"
      unitRef="U_USD">629000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_eb35ce5f-a87f-4703-9ed4-3a76ffe3106b"
      unitRef="U_USD">2672000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_692d9939-044c-4db5-a337-deb9bdeacfa0"
      unitRef="U_USD">1799000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_b941e980-0668-4d15-ae8c-8be6be5ff5ea"
      unitRef="U_USD">43857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_65511ed4-9369-43ad-bd74-5f6543e6395d"
      unitRef="U_USD">-115559000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_04414ec2-8442-46f6-bd79-ad142efd196c"
      unitRef="U_USD">163969000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cd11ff6a-3076-4878-b379-411eea2932d1"
      decimals="-3"
      id="F_b0dcdef5-77ee-44a5-8e32-8e1fa9451b93"
      unitRef="U_USD">295502000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_e3f02daa-c99c-4fc1-80b0-2d66f0a736eb"
      unitRef="U_USD">207826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e"
      decimals="-3"
      id="F_3c65a197-7442-4bd1-9617-b7f32ca90cca"
      unitRef="U_USD">179943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:SharesIssued
      contextRef="C_34f017d3-fc3a-40f4-a32a-6e68c12be396"
      decimals="INF"
      id="F_e831a684-67a4-4f89-998c-87417b58b4d9"
      unitRef="U_shares">58937050</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_34f017d3-fc3a-40f4-a32a-6e68c12be396"
      decimals="-3"
      id="F_2dfe5ff2-2e3f-4c75-8b06-ffca168a4251"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="C_9d696c64-4852-4448-9e18-cca9af20998a"
      decimals="INF"
      id="F_895d283a-d03d-4106-af24-66ae01171add"
      unitRef="U_shares">3033</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_9d696c64-4852-4448-9e18-cca9af20998a"
      decimals="-3"
      id="F_a324e7b3-3482-4f3a-8e48-6bf5d5feed31"
      unitRef="U_USD">-400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_25ec2f51-a9c3-49be-9f2a-0f5e21581ba9"
      decimals="-3"
      id="F_04b99004-80fd-45ed-9083-b123fc2edc18"
      unitRef="U_USD">3227471000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3499aa63-1335-4278-afe4-3af8c03e1236"
      decimals="-3"
      id="F_c14ab140-1271-4dad-b1ae-05fbc9844283"
      unitRef="U_USD">-2660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_96c58346-5075-4864-bc24-0ddf5e57105c"
      decimals="-3"
      id="F_e65df97a-1396-4147-a503-ad85886f0ad7"
      unitRef="U_USD">-1495386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cd11ff6a-3076-4878-b379-411eea2932d1"
      decimals="-3"
      id="F_ae46ccd3-41fc-41bf-b093-24adc5787269"
      unitRef="U_USD">1729031000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_cc0e2088-ed2f-4615-ae09-35dc9db057e2"
      decimals="INF"
      id="F_be5d0270-dd44-4b6c-87b5-bdcc2e926b4e"
      unitRef="U_shares">105474</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b2824d78-7fd0-4324-bd17-8138321ed536"
      decimals="-3"
      id="F_5c8bee7c-76e7-4816-b9b8-89eed4890aad"
      unitRef="U_USD">646000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_cbf87b5b-7697-4274-91e5-94055ef83787"
      unitRef="U_USD">646000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_cc0e2088-ed2f-4615-ae09-35dc9db057e2"
      decimals="INF"
      id="F_fde71233-2573-4147-80f2-46f6edc4422a"
      unitRef="U_shares">23625</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b2824d78-7fd0-4324-bd17-8138321ed536"
      decimals="-3"
      id="F_16c4cb5f-ee6b-4fa2-9a4d-00de160f4d21"
      unitRef="U_USD">1153000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_abe3d7bf-989d-48e1-b0c6-3b695d22235d"
      unitRef="U_USD">1153000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b2824d78-7fd0-4324-bd17-8138321ed536"
      decimals="-3"
      id="F_caa50524-97ce-484a-b458-bfa620f1ea32"
      unitRef="U_USD">18268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_52310b8c-8b72-4362-9f01-6a1a5f1f8b97"
      unitRef="U_USD">18268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_cec5550d-a16c-4e00-9894-1a8d869e5bae"
      decimals="-3"
      id="F_5f95849a-6440-482c-848a-5f9e3474d91e"
      unitRef="U_USD">-8541000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_e295facf-03a2-4989-87d7-70b84eeaf3c0"
      unitRef="U_USD">-8541000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_e45cbb2e-3c5f-498a-a209-b241cd20689d"
      decimals="-3"
      id="F_5aa3fc90-2d57-487c-86a5-6b26f237316f"
      unitRef="U_USD">-122055000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_39dcf672-3750-4722-abd3-8cff61674a7f"
      unitRef="U_USD">-122055000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_758d45bc-86ac-4f04-b85e-741bffc1d6f8"
      decimals="INF"
      id="F_94605b6e-242e-4d2d-b199-54b8ac50cda1"
      unitRef="U_shares">59066149</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_758d45bc-86ac-4f04-b85e-741bffc1d6f8"
      decimals="-3"
      id="F_80544610-6184-41d4-ac23-4757911815a5"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="C_110148da-fe96-4b69-87ce-8a98365c120f"
      decimals="INF"
      id="F_3396722a-634b-498c-a866-d85807fa6886"
      unitRef="U_shares">3033</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_110148da-fe96-4b69-87ce-8a98365c120f"
      decimals="-3"
      id="F_4ea097e1-cefb-4892-94f3-edda1df7f8d4"
      unitRef="U_USD">-400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e663c40a-15ae-4907-b98c-552196067f88"
      decimals="-3"
      id="F_60334ce8-2fde-4715-b15b-a90cb85d9b54"
      unitRef="U_USD">3247538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8fafe567-6ae5-44ee-8496-6f5bb08d136a"
      decimals="-3"
      id="F_64d89467-c8df-4a2e-b5ba-bad4057dec68"
      unitRef="U_USD">-11201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_32d6c0d5-c8be-40ce-8635-6583447c427f"
      decimals="-3"
      id="F_659c7acb-0929-4266-a5c0-dbb7327f652c"
      unitRef="U_USD">-1617441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e"
      decimals="-3"
      id="F_51226b68-892f-4b7f-aada-98cec88a50f8"
      unitRef="U_USD">1618502000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="C_deab43ad-3c90-4a47-ae84-57cc9e11dfaa"
      decimals="INF"
      id="F_f785fad0-4b04-4895-bd69-64c7f84a4302"
      unitRef="U_shares">59509125</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_deab43ad-3c90-4a47-ae84-57cc9e11dfaa"
      decimals="-3"
      id="F_8d350fa1-4552-439b-be7d-a164bc781591"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="C_872fc801-16d0-407b-a188-71e78a10b66e"
      decimals="INF"
      id="F_04008266-d236-4e4e-9e99-e4eba7b04292"
      unitRef="U_shares">3033</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_872fc801-16d0-407b-a188-71e78a10b66e"
      decimals="-3"
      id="F_31f26fa8-2360-4003-bc0a-cd9628e6e4c7"
      unitRef="U_USD">-400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b6f49c8-d774-48fb-b187-986662265c23"
      decimals="-3"
      id="F_0b181a9d-d62c-4dd7-9d1a-5d390fdfd22b"
      unitRef="U_USD">3291369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dbfc6e76-8aca-485a-914b-f8d69d2c7389"
      decimals="-3"
      id="F_733650aa-0cc6-4214-ac0a-b8148b885154"
      unitRef="U_USD">-10206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_94d7d66d-d764-476a-bdb7-7e62dfec2d61"
      decimals="-3"
      id="F_60ca7794-6f11-4630-921e-03467182aa3a"
      unitRef="U_USD">-2028170000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_9b8c6f16-b039-45a9-9225-6a64fa83d998"
      unitRef="U_USD">1252599000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_473be90c-b2bd-4a46-8157-218452e72424"
      decimals="INF"
      id="F_f01e539b-a0be-4fd7-ba89-2392d954d5c0"
      unitRef="U_shares">52058</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9"
      decimals="-3"
      id="F_fdf0a91f-6cf8-424d-8c1e-68f8e06153e8"
      unitRef="U_USD">438000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_976e1cc8-8250-4295-9b8f-855f9e5511f7"
      unitRef="U_USD">438000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_473be90c-b2bd-4a46-8157-218452e72424"
      decimals="INF"
      id="F_1bcac7c9-472c-45e4-8a78-e0133123724d"
      unitRef="U_shares">76105</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9"
      decimals="-3"
      id="F_e47009e0-ae6d-4c02-98a9-62f949046f6d"
      unitRef="U_USD">2863000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_9a61a975-7fce-4874-895d-683260c80253"
      unitRef="U_USD">2863000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9"
      decimals="-3"
      id="F_0b02edac-104e-46d6-ad0b-46d3061bc2c5"
      unitRef="U_USD">19568000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_1e0ee895-d699-48b5-84f8-6cdee9c6cc7e"
      unitRef="U_USD">19568000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0a046e3a-d734-4572-ba58-9c70fe1e9fda"
      decimals="-3"
      id="F_9af0c02e-f496-44c9-8132-19dff9514ae6"
      unitRef="U_USD">5118000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_07c58864-e5db-408c-bb2d-f28c88f16e3d"
      unitRef="U_USD">5118000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_473be90c-b2bd-4a46-8157-218452e72424"
      decimals="INF"
      id="F_20e5baee-9a80-435f-8c83-f4e8d8689b7b"
      unitRef="U_shares">124713</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_4ef809cc-20e5-4b58-ac5f-aec22d1205d9"
      decimals="-3"
      id="F_85d2842c-7e07-4dd9-a834-49b650a2ea06"
      unitRef="U_USD">-629000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_5736363d-e0a2-4b68-81fd-760fec33f5e5"
      unitRef="U_USD">-629000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:NetIncomeLoss
      contextRef="C_90273a42-5bc2-4c8a-b365-81b8b3294dbe"
      decimals="-3"
      id="F_ec2ffedb-3b24-4d9b-8147-10c3b174aa07"
      unitRef="U_USD">-146828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_aa356daf-ef1e-40ae-ba8a-ade88f878f64"
      unitRef="U_USD">-146828000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_f1249121-8d96-4038-9762-31833df70a85"
      decimals="INF"
      id="F_87b6f5bf-42ee-4658-9f8d-9756c2d3dfb2"
      unitRef="U_shares">59762001</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_f1249121-8d96-4038-9762-31833df70a85"
      decimals="-3"
      id="F_3311b078-a29d-4cf3-8c14-9e74ecab3f91"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="C_24252855-7fbc-49c5-993c-ccdb3e3e73e2"
      decimals="INF"
      id="F_b3a220ae-39f2-4240-9168-7bee108f614f"
      unitRef="U_shares">3033</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_24252855-7fbc-49c5-993c-ccdb3e3e73e2"
      decimals="-3"
      id="F_8986040c-f505-4ac3-a17e-831ab159ea25"
      unitRef="U_USD">-400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_41166faf-b133-46b7-89f9-98cc0e4a309b"
      decimals="-3"
      id="F_928cca8f-70a5-4e6f-8a23-d8432293a9d8"
      unitRef="U_USD">3313609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ff91b6cd-d80c-40f0-b294-2711aab14ffb"
      decimals="-3"
      id="F_b6577923-170e-416f-b471-dcc6a88f382a"
      unitRef="U_USD">-5088000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d098601-3538-45a4-aa05-ee4216c06e54"
      decimals="-3"
      id="F_fa8cd971-885c-4a96-8bb1-73fe53a286d0"
      unitRef="U_USD">-2174998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_d01bb5c5-edde-4985-9a7f-63c42d4ce633"
      unitRef="U_USD">1133129000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_75978d56-69ab-4ddd-85d1-ad26919562c7">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Nature of the Business&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sage Therapeutics, Inc. (&#x201c;Sage&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company with a mission to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s first product, ZULRESSO&#xae; (brexanolone) CIV injection, is approved in the U.S. as a treatment for postpartum depression (&#x201c;PPD&#x201d;) in adults. The Company launched ZULRESSO commercially in the U.S. in June 2019. The Company's submission of a new drug application (an "NDA") for its lead investigational product candidate, zuranolone, for the treatment of major depressive disorder (&#x201c;MDD&#x201d;) and PPD was accepted for filing and granted priority review by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in February 2023, with a Prescription Drug User Fee Act, as amended (&#x201c;PDUFA&#x201d;) target action date of August 5, 2023. The Company has a portfolio of other product candidates with a current focus on modulating two critical central nervous system (&#x201c;CNS&#x201d;) receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:7.37pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. The Company is currently targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company was incorporated under the laws of the State of Delaware on April 16, 2010, and commenced operations on January 19, 2011 as Sterogen Biopharma, Inc. On September 13, 2011, the Company changed its name to Sage Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with the marketing and sale of pharmaceutical products; the potential for development by third parties of new technological innovations that may compete with the Company&#x2019;s products and product candidates; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; the uncertainty of being able to secure additional capital when needed to fund operations; and the direct or indirect impacts of the macroeconomic environment and geopolitical events on its development activities, operations and financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The product candidates developed by the Company require approvals from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the current and future product candidates of the Company will receive, or that the Company&#x2019;s current product, ZULRESSO, will maintain, the necessary approvals. If the Company fails to successfully complete clinical development and generate results sufficient to file for regulatory approval or is denied approval or approval is delayed for any of its product candidates, including zuranolone, such occurrences may have a material adverse impact on the Company&#x2019;s business and its financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also subject to additional risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events, including disruption to the U.S. healthcare system that began as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There have been and continue to be healthcare staffing shortages and other changes to the macroeconomic environment as downstream effects of the COVID-19 pandemic have continued. These factors have had a significant and sustained negative impact on the Company&#x2019;s revenue from sales of ZULRESSO. While the Company has seen slower patient recruitment in certain clinical trials due to the COVID-19 pandemic and its downstream effects, and has&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;experienced some challenges in qualifying and activating clinical trial sites, including due to capacity and resource constraints and employee attrition at our vendors and at sites, the Company has not experienced other significant impacts to the Company&#x2019;s development activities as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Moreover, U.S. and global financial markets have experienced volatility and disruption due to other macroeconomic and geopolitical events such as rising inflation, the risk of a recession and the ongoing conflict between Russia and Ukraine. In addition, if equity and credit markets deteriorate, including as a result of recent and potential future bank failures, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to our existing stockholders. The Company cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements&#x2014;Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (Subtopic 205-40), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The Company has incurred losses and negative cash flows from operations in each year since its inception, except for net income of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;606.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2020, reflecting revenue recognized under a collaboration and license agreement with Biogen MA Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (collectively with BIMA, &#x201c;Biogen&#x201d;) (the &#x201c;Biogen Collaboration Agreement&#x201d;). As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion. From its inception through March 31, 2023, the Company has received aggregate net proceeds of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion from the sales of redeemable convertible preferred stock prior to its initial public offering (&#x201c;IPO&#x201d;), the issuance of convertible notes, and the sales of common stock in its IPO in July 2014, in follow-on public offerings, and to BIMA under a stock purchase agreement executed in connection with the Biogen Collaboration Agreement. The Company has also received $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion in upfront payments under its collaborations with Biogen and Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). Until such time, if ever, as the Company can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding. If the Company is unable to raise additional funds through equity or debt financings or other sources of funding when needed, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expects that, based on its current operating plans, the Company&#x2019;s existing cash, cash equivalents and marketable securities will be sufficient to fund its currently planned operations for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements (&#x201c;condensed consolidated financial statements&#x201d;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At some point after that time, the Company anticipates it will require additional financing to fund its future operations. Even if the Company believes it has sufficient funds for its current or future operating plans, the Company may seek to raise additional capital if market conditions are favorable or in light of other strategic considerations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <sage:BusinessRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_df460751-9ea7-4c80-a896-4e8934a6db18">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with the marketing and sale of pharmaceutical products; the potential for development by third parties of new technological innovations that may compete with the Company&#x2019;s products and product candidates; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; the uncertainty of being able to secure additional capital when needed to fund operations; and the direct or indirect impacts of the macroeconomic environment and geopolitical events on its development activities, operations and financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The product candidates developed by the Company require approvals from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the current and future product candidates of the Company will receive, or that the Company&#x2019;s current product, ZULRESSO, will maintain, the necessary approvals. If the Company fails to successfully complete clinical development and generate results sufficient to file for regulatory approval or is denied approval or approval is delayed for any of its product candidates, including zuranolone, such occurrences may have a material adverse impact on the Company&#x2019;s business and its financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also subject to additional risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events, including disruption to the U.S. healthcare system that began as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There have been and continue to be healthcare staffing shortages and other changes to the macroeconomic environment as downstream effects of the COVID-19 pandemic have continued. These factors have had a significant and sustained negative impact on the Company&#x2019;s revenue from sales of ZULRESSO. While the Company has seen slower patient recruitment in certain clinical trials due to the COVID-19 pandemic and its downstream effects, and has&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;experienced some challenges in qualifying and activating clinical trial sites, including due to capacity and resource constraints and employee attrition at our vendors and at sites, the Company has not experienced other significant impacts to the Company&#x2019;s development activities as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Moreover, U.S. and global financial markets have experienced volatility and disruption due to other macroeconomic and geopolitical events such as rising inflation, the risk of a recession and the ongoing conflict between Russia and Ukraine. In addition, if equity and credit markets deteriorate, including as a result of recent and potential future bank failures, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to our existing stockholders. The Company cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events.&lt;/span&gt;&lt;/p&gt;</sage:BusinessRisksAndUncertaintiesPolicyTextBlock>
    <sage:GoingConcernPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_6ee38989-5882-46fd-980a-56c0a8d17ccb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements&#x2014;Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (Subtopic 205-40), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The Company has incurred losses and negative cash flows from operations in each year since its inception, except for net income of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;606.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2020, reflecting revenue recognized under a collaboration and license agreement with Biogen MA Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (collectively with BIMA, &#x201c;Biogen&#x201d;) (the &#x201c;Biogen Collaboration Agreement&#x201d;). As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion. From its inception through March 31, 2023, the Company has received aggregate net proceeds of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion from the sales of redeemable convertible preferred stock prior to its initial public offering (&#x201c;IPO&#x201d;), the issuance of convertible notes, and the sales of common stock in its IPO in July 2014, in follow-on public offerings, and to BIMA under a stock purchase agreement executed in connection with the Biogen Collaboration Agreement. The Company has also received $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion in upfront payments under its collaborations with Biogen and Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). Until such time, if ever, as the Company can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding. If the Company is unable to raise additional funds through equity or debt financings or other sources of funding when needed, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expects that, based on its current operating plans, the Company&#x2019;s existing cash, cash equivalents and marketable securities will be sufficient to fund its currently planned operations for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements (&#x201c;condensed consolidated financial statements&#x201d;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At some point after that time, the Company anticipates it will require additional financing to fund its future operations. Even if the Company believes it has sufficient funds for its current or future operating plans, the Company may seek to raise additional capital if market conditions are favorable or in light of other strategic considerations.&lt;/span&gt;&lt;/p&gt;</sage:GoingConcernPolicyTextBlock>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_23999eda-d8e5-4c17-ae2e-ed2f30bd77ac"
      decimals="-5"
      id="F_9012ca6d-bc36-4ea9-8ec4-066c07abbf64"
      unitRef="U_USD">606100000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_75423cb0-1c5c-451b-8f34-441ea3df08c3"
      decimals="-8"
      id="F_b6a98866-8044-4a14-82d7-ae59c84e99b8"
      unitRef="U_USD">-2200000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <sage:ProceedsFromIssuanceOrSaleOfEquityAndNotes
      contextRef="C_2ae85a8f-70ca-4220-93dc-e4da3306dc78"
      decimals="-8"
      id="F_46ff96fb-ac08-4924-9105-89c8f0fb8ea5"
      unitRef="U_USD">2800000000</sage:ProceedsFromIssuanceOrSaleOfEquityAndNotes>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-8"
      id="F_10290745-3ac3-4e80-8e90-27a4b8c2948f"
      unitRef="U_USD">1000000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_01be12b7-4988-4eb4-b9e2-b87271cdb94f">&lt;div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;audited consolidated financial statements as of and for the year ended December 31, 2022, included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company&#x2019;s management, the accompanying condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, its results of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, its cash flows for the three months ended March 31, 2023 and 2022, and its statements of changes in stockholders&#x2019; equity for the three months ended March 31, 2023 and 2022. The consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but does not include all disclosures required by GAAP. The results for the three months ended March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as disclosed in Note 2, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, within the &#x201c;Notes to Consolidated Financial Statements&#x201d; accompanying its Annual Report on Form 10-K for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The full extent to which the COVID-19 pandemic and its downstream effects may directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition will depend in large part on future developments, which cannot be predicted with confidence at this time. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Company has made estimates of the impact of the COVID-19 pandemic within its condensed consolidated financial statements. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due to the evolving nature of the COVID-19 pandemic, its downstream effects, and their impacts,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; there may be changes to those estimates in future periods, and a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ctual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, overhead costs, depreciation, contract services and other related costs. Research and development costs are expensed to operations as the related obligation is incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with research institutions and other companies both inside and outside of the U.S. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company generates revenue from the sale of ZULRESSO, which was approved by the FDA in March 2019 and the Company subsequently began selling in June 2019, and from collaboration and supply agreements with the Company&#x2019;s collaborators. To date, revenue from collaboration agreements has come from initial, upfront payments allocated to licenses of intellectual property delivered to the Company&#x2019;s collaborators and from the supply of material for clinical trials under a supply agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when or as performance obligations are satisfied by transferring control of promised goods or services to a customer, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For contracts determined to be within the scope of Topic 606, the Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration and License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing whether a promised good or service is distinct in the evaluation of a collaboration or license arrangement subject to Topic 606, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the standalone selling price is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its arrangements with Shionogi and Biogen and concluded that a significant financing component does not exist for either arrangement. For arrangements with licenses of intellectual property that include sales-based royalties or milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty or milestone payment has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Revenue from the Company&#x2019;s collaboration agreement with Shionogi has come from initial, upfront consideration upon execution of the agreement and for the supply of drug product for Shionogi&#x2019;s clinical trials. Revenue from the Company&#x2019;s collaboration agreement with Biogen has come from initial, upfront consideration related to the execution of the Biogen Collaboration Agreement. For additional information, refer to Note 6, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Revenue, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes product revenue, net of variable consideration related to certain allowances and accruals that are determined using the expected value method, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for ZULRESSO is to deliver the product to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within selling, general and administrative expenses on its condensed consolidated statements of operations and comprehensive loss. The Company expenses incremental costs of obtaining a contract as incurred if the expected amortization period of the asset would be &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;less than one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. If the Company were to incur incremental costs with an amortization period greater than a year, such costs would be capitalized as contract assets, as they are expected to be recovered, and would be expensed by amortizing on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company did not have any contract assets (unbilled receivables) at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023, as customer invoicing generally occurs before or at the time of revenue recognition. The Company did not have any contract liabilities at March 31, 2023, as the Company did not receive any payments in advance of satisfying its performance obligations to its customers. Amounts billed or invoiced that are considered trade accounts receivable are included in prepaid expenses and other current assets on the condensed consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023 and December 31, 2022, the Company had not provided any allowance for bad debts against the trade accounts receivable, and the amount of trade accounts receivable was not significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records reserves, based on contractual terms, for the following components of variable consideration related to product sold during the reporting period, as well as its estimate of product that remains in the distribution channel inventory of its customers at the end of the reporting period. On a quarterly basis, the Company updates its estimates, if necessary, and records any material adjustments in the period they are identified.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Chargebacks&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company estimates chargebacks from its customers who directly purchase the product from the Company for discounts resulting from contractual commitments to sell products to eligible healthcare settings at prices lower than the list prices charged to its customers. Customers charge the Company for the difference between what they pay to the Company for the product and the selling price to the eligible healthcare settings. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at the end of each reporting period that the Company expects will be sold to eligible healthcare settings, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Government Rebates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company is subject to discount obligations under government programs, including Medicaid. The Company records reserves for rebates in the same period the related product revenue is recognized, resulting in a reduction of ZULRESSO product revenue and a current liability that is included in accrued expenses on its condensed consolidated balance sheets. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Trade Discounts and Allowances&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company generally provides customary invoice discounts on ZULRESSO sales to its customers for prompt payment and the Company pays fees for sales order management, data, and distribution services. The Company estimates its customers will earn these discounts and fees and deducts these discounts and fees in full from gross ZULRESSO revenue and accounts receivable at the time the Company recognizes the related revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Assistance&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company provides voluntary financial assistance programs to patients with commercial insurance that have coverage and reside in states that allow financial assistance. The Company estimates the financial assistance amounts for ZULRESSO and records any such amounts within accrued expenses on its condensed consolidated balance sheets. The calculation of the accrual for financial assistance is based on an estimate of claims and the cost per claim that the Company expects to receive using demographics for patients who have registered and been approved for assistance. Any adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Returns&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: Consistent with industry practice, the Company offers product return rights to customers for damaged, defective or expiring product, provided it is within a specified period around the product expiration date as set forth in the Company&#x2019;s return goods policy. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reserve within accrued expenses on the condensed consolidated balance sheets. Product returns have not been significant to date and are not expected to be significant in the future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above, and presents the arrangement as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For collaboration arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as research and development expense or selling, general and administrative expense, in the event of a payment to the collaborative partner in a period, or a reduction to these expense line items in the event of a reimbursement from the collaboration partner in a period, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:7.0%;"/&gt;
        &lt;td style="width:2.0%;"/&gt;
        &lt;td style="width:91.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents and marketable securities at March 31, 2023 and December 31, 2022 were carried at fair value, determined according to the fair value hierarchy; see Note 3, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts reflected in the condensed consolidated balance sheets for the collaboration receivable &#x2013; related party, accounts payable and accrued expenses approximate their fair values due to their short-term maturities at March 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_912a5728-d7fa-4ec0-a5aa-9a097750aee8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;audited consolidated financial statements as of and for the year ended December 31, 2022, included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company&#x2019;s management, the accompanying condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, its results of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, its cash flows for the three months ended March 31, 2023 and 2022, and its statements of changes in stockholders&#x2019; equity for the three months ended March 31, 2023 and 2022. The consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but does not include all disclosures required by GAAP. The results for the three months ended March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b546dd33-bcee-4648-b70b-ab2850a89099">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries as disclosed in Note 2, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, within the &#x201c;Notes to Consolidated Financial Statements&#x201d; accompanying its Annual Report on Form 10-K for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_03750040-9d83-49a1-a5f8-3d74b294a078">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The full extent to which the COVID-19 pandemic and its downstream effects may directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition will depend in large part on future developments, which cannot be predicted with confidence at this time. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Company has made estimates of the impact of the COVID-19 pandemic within its condensed consolidated financial statements. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due to the evolving nature of the COVID-19 pandemic, its downstream effects, and their impacts,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; there may be changes to those estimates in future periods, and a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ctual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_9b7825f0-59e4-4159-a021-072c837b97c7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, overhead costs, depreciation, contract services and other related costs. Research and development costs are expensed to operations as the related obligation is incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with research institutions and other companies both inside and outside of the U.S. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_914fd5eb-06d4-44f4-960f-b6ebcb79e30e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company generates revenue from the sale of ZULRESSO, which was approved by the FDA in March 2019 and the Company subsequently began selling in June 2019, and from collaboration and supply agreements with the Company&#x2019;s collaborators. To date, revenue from collaboration agreements has come from initial, upfront payments allocated to licenses of intellectual property delivered to the Company&#x2019;s collaborators and from the supply of material for clinical trials under a supply agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when or as performance obligations are satisfied by transferring control of promised goods or services to a customer, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For contracts determined to be within the scope of Topic 606, the Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration and License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing whether a promised good or service is distinct in the evaluation of a collaboration or license arrangement subject to Topic 606, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the standalone selling price is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its arrangements with Shionogi and Biogen and concluded that a significant financing component does not exist for either arrangement. For arrangements with licenses of intellectual property that include sales-based royalties or milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty or milestone payment has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Revenue from the Company&#x2019;s collaboration agreement with Shionogi has come from initial, upfront consideration upon execution of the agreement and for the supply of drug product for Shionogi&#x2019;s clinical trials. Revenue from the Company&#x2019;s collaboration agreement with Biogen has come from initial, upfront consideration related to the execution of the Biogen Collaboration Agreement. For additional information, refer to Note 6, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Revenue, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes product revenue, net of variable consideration related to certain allowances and accruals that are determined using the expected value method, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for ZULRESSO is to deliver the product to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within selling, general and administrative expenses on its condensed consolidated statements of operations and comprehensive loss. The Company expenses incremental costs of obtaining a contract as incurred if the expected amortization period of the asset would be &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;less than one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. If the Company were to incur incremental costs with an amortization period greater than a year, such costs would be capitalized as contract assets, as they are expected to be recovered, and would be expensed by amortizing on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company did not have any contract assets (unbilled receivables) at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023, as customer invoicing generally occurs before or at the time of revenue recognition. The Company did not have any contract liabilities at March 31, 2023, as the Company did not receive any payments in advance of satisfying its performance obligations to its customers. Amounts billed or invoiced that are considered trade accounts receivable are included in prepaid expenses and other current assets on the condensed consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023 and December 31, 2022, the Company had not provided any allowance for bad debts against the trade accounts receivable, and the amount of trade accounts receivable was not significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records reserves, based on contractual terms, for the following components of variable consideration related to product sold during the reporting period, as well as its estimate of product that remains in the distribution channel inventory of its customers at the end of the reporting period. On a quarterly basis, the Company updates its estimates, if necessary, and records any material adjustments in the period they are identified.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Chargebacks&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company estimates chargebacks from its customers who directly purchase the product from the Company for discounts resulting from contractual commitments to sell products to eligible healthcare settings at prices lower than the list prices charged to its customers. Customers charge the Company for the difference between what they pay to the Company for the product and the selling price to the eligible healthcare settings. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at the end of each reporting period that the Company expects will be sold to eligible healthcare settings, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Government Rebates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company is subject to discount obligations under government programs, including Medicaid. The Company records reserves for rebates in the same period the related product revenue is recognized, resulting in a reduction of ZULRESSO product revenue and a current liability that is included in accrued expenses on its condensed consolidated balance sheets. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Trade Discounts and Allowances&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company generally provides customary invoice discounts on ZULRESSO sales to its customers for prompt payment and the Company pays fees for sales order management, data, and distribution services. The Company estimates its customers will earn these discounts and fees and deducts these discounts and fees in full from gross ZULRESSO revenue and accounts receivable at the time the Company recognizes the related revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Assistance&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company provides voluntary financial assistance programs to patients with commercial insurance that have coverage and reside in states that allow financial assistance. The Company estimates the financial assistance amounts for ZULRESSO and records any such amounts within accrued expenses on its condensed consolidated balance sheets. The calculation of the accrual for financial assistance is based on an estimate of claims and the cost per claim that the Company expects to receive using demographics for patients who have registered and been approved for assistance. Any adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Returns&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: Consistent with industry practice, the Company offers product return rights to customers for damaged, defective or expiring product, provided it is within a specified period around the product expiration date as set forth in the Company&#x2019;s return goods policy. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reserve within accrued expenses on the condensed consolidated balance sheets. Product returns have not been significant to date and are not expected to be significant in the future.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract
      contextRef="C_80624434-96c6-446e-ada9-fe739d3d9e5b"
      id="F_58a63175-343d-4fb3-bb83-f45c55500446">true</us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_e60d3dfe-9396-488c-8c34-019d083a4fb0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above, and presents the arrangement as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For collaboration arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as research and development expense or selling, general and administrative expense, in the event of a payment to the collaborative partner in a period, or a reduction to these expense line items in the event of a reimbursement from the collaboration partner in a period, as appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_32ec00ae-8c7c-48c5-a994-01eeea6a1930">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:7.0%;"/&gt;
        &lt;td style="width:2.0%;"/&gt;
        &lt;td style="width:91.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents and marketable securities at March 31, 2023 and December 31, 2022 were carried at fair value, determined according to the fair value hierarchy; see Note 3, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts reflected in the condensed consolidated balance sheets for the collaboration receivable &#x2013; related party, accounts payable and accrued expenses approximate their fair values due to their short-term maturities at March 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_bac2d237-e6ec-4345-94de-a30d4c239edd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b94add1b-84f7-4d11-84fc-5376911e67a7">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;3.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents are classified within Level 1 and Level 2 of the fair value hierarchy. The Company&#x2019;s investments in marketable securities are classified within Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values of the Company&#x2019;s marketable securities are based on prices obtained from independent pricing sources. Consistent with the fair value hierarchy described in Note 2, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, marketable securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates. The Company performs validation procedures to ensure the reasonableness of this data. The Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.108%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;189,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;267,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;267,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,112,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;947,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.108%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,270,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers among the Level 1, Level 2 and Level 3 categories.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the gross unrealized gains and losses of the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.75%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.733%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;269,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;267,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;928,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.648%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;307,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the fair value and the unrealized losses of the Company&#x2019;s marketable securities that have been in a loss position for either less than twelve months or greater than twelve months as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.018%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.971%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Greater than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;430,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;684,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.018%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.971%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Greater than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;297,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;208,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;339,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;513,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;399,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;913,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023 and December 31, 2022, the unrealized losses on the Company&#x2019;s investments in U.S. government securities, U.S. corporate bonds, and international corporate bonds were caused by interest rate increases. The Company purchased those investments at a premium relative to their face amount. The current credit ratings are all within the guidelines of the investment policy of the Company and the Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment. The Company does not intend to sell the investments and it is not probable that the Company will be required to sell the investments before recovery of their amortized cost basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, all marketable securities held by the Company had remaining contractual maturities of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or less, except for U.S. government securities, U.S. corporate bonds, international corporate bonds and municipal securities with a fair value of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and maturities of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_15ef7878-1081-4815-8372-c33bbdbbcbd7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, all marketable securities held by the Company had remaining contractual maturities of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or less, except for U.S. government securities, U.S. corporate bonds, international corporate bonds and municipal securities with a fair value of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;211.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and maturities of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9fe7857e-17e4-49cf-93b3-30d78c5acea7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All marketable securities, including those with remaining contractual maturities of more than one year, are classified as current assets on the balance sheet because they are considered to be &#x201c;available for sale&#x201d; and the Company can convert them into cash to fund current operations&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There have been &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairments of the Company&#x2019;s assets measured and carried at fair value during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023 and the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_65e861b7-f231-4b71-ac67-e60b947d8580">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.108%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;189,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;267,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;267,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,112,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;947,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.108%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,270,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_fe4b519c-5caf-4568-8a3a-2efeec719a51"
      decimals="-3"
      id="F_586eb026-1f58-44fa-ac82-bde3a9a89315"
      unitRef="U_USD">164139000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_59765745-97e9-4396-b431-ab2d3335cfad"
      decimals="-3"
      id="F_b3d88fd8-ff54-498b-aab1-79b5ac4dd598"
      unitRef="U_USD">164139000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_e0232fd3-6bd9-4932-a310-6a8a5f23de98"
      unitRef="U_USD">19965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_415d3116-954c-4e68-b279-376d06d7f3f7"
      decimals="-3"
      id="F_6ead5c66-cd07-4c7a-b03e-0b674df41120"
      unitRef="U_USD">19965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194"
      decimals="-3"
      id="F_680d4b82-8247-4a10-8fe0-a3a80ed32419"
      unitRef="U_USD">4984000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_27a73613-5f17-4ab4-b5a6-643c79010992"
      decimals="-3"
      id="F_ca92690d-3221-4c9d-b4df-2f8fe82517be"
      unitRef="U_USD">4984000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_735b6cb7-d837-46e2-82a9-6bb93da7e0a4"
      unitRef="U_USD">189088000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1dfde7f5-0e05-4477-b311-a6bafe7de036"
      decimals="-3"
      id="F_d8d67e4a-9513-4698-96bc-ccf32429042e"
      unitRef="U_USD">164139000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff"
      decimals="-3"
      id="F_cb8c3f21-68d2-482e-a9c3-3328cb25a0b9"
      unitRef="U_USD">24949000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_e185e9cf-234a-48c2-834a-d67972dd9975"
      unitRef="U_USD">232688000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_88622809-97e6-415e-84af-28e0cecdedb9"
      decimals="-3"
      id="F_98c4537d-b961-4d0c-9be8-4c5aba6cee2c"
      unitRef="U_USD">232688000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_aa191f9a-08d1-45c7-b0ab-e40051915fe5"
      unitRef="U_USD">267310000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_415d3116-954c-4e68-b279-376d06d7f3f7"
      decimals="-3"
      id="F_5011eb58-fb85-46ea-b806-4df0538f7260"
      unitRef="U_USD">267310000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_4b3dffe6-6f67-450f-8a6a-e0bbde8152cb"
      unitRef="U_USD">75766000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3733b62f-9978-46fa-ae1f-0ca914403f18"
      decimals="-3"
      id="F_ae474802-9b6a-4777-b6e5-e83fec002344"
      unitRef="U_USD">75766000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_850361db-7291-43d8-8579-6031f3718f59"
      decimals="-3"
      id="F_7258c1e5-f052-43c3-b3db-1524ae2533eb"
      unitRef="U_USD">62428000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_2eed04fd-66bf-403b-b097-ca6cfcbcd5d0"
      decimals="-3"
      id="F_045b2f7b-6ba0-4e20-9f45-311580eba982"
      unitRef="U_USD">62428000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194"
      decimals="-3"
      id="F_813fd7a9-6824-475e-8738-b6a7ba8ee7c6"
      unitRef="U_USD">108999000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_27a73613-5f17-4ab4-b5a6-643c79010992"
      decimals="-3"
      id="F_a5cd5020-7dc5-494e-8e88-356e28049664"
      unitRef="U_USD">108999000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_cd88a57a-5b9d-49be-a744-23e0bf41890a"
      decimals="-3"
      id="F_021450c3-a6c1-4993-9880-3c3da9a86b1a"
      unitRef="U_USD">15286000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b95b663e-2b75-4278-99c2-2c62b7b11486"
      decimals="-3"
      id="F_2448303f-fbee-4ddb-94b2-e5c86b10e216"
      unitRef="U_USD">15286000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_cf7b6bb7-85cb-4535-9609-7f5dc53c18f1"
      unitRef="U_USD">160551000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_6e880326-ed6e-48e7-a99c-374dfaae0004"
      decimals="-3"
      id="F_49d0368f-1548-465a-b714-e8cc5ff9e015"
      unitRef="U_USD">160551000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_b49f5547-0786-4371-b5f0-1649f433c2a7"
      unitRef="U_USD">923028000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff"
      decimals="-3"
      id="F_bdae5f1c-966c-4e38-9cc4-0243db81a1b1"
      unitRef="U_USD">923028000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_960bcc94-93fa-4824-a07b-fe559c624cc5"
      unitRef="U_USD">1112116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1dfde7f5-0e05-4477-b311-a6bafe7de036"
      decimals="-3"
      id="F_c04416a3-db70-4dd5-95c1-fc0c84c83898"
      unitRef="U_USD">164139000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d1cefce8-d07a-497f-a9d8-07957b10f7ff"
      decimals="-3"
      id="F_30de32cb-1b1e-445f-8465-e7fb4db41633"
      unitRef="U_USD">947977000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b2b10c3e-e417-48ea-a3c8-37953b52b9c3"
      decimals="-3"
      id="F_279e9e8b-dd8b-40df-aea1-13be36db09a0"
      unitRef="U_USD">161185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1978be30-cc7c-4cc4-a992-11e42d4bd0b9"
      decimals="-3"
      id="F_71a7bade-37e9-4a34-b3c8-0ad16cf9b165"
      unitRef="U_USD">161185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_0143ebd4-c256-492b-a403-b82dd1621d22"
      unitRef="U_USD">161185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c9b8b2ef-3e7c-4781-829b-f175d048affc"
      decimals="-3"
      id="F_2ed4612d-b080-4bc6-b6b1-e1b3eeec12be"
      unitRef="U_USD">161185000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_2f169f8e-5558-47da-b91f-d822b695e00f"
      unitRef="U_USD">302911000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_73403fc5-d8c9-42ee-a01a-11d2ee5fe21a"
      decimals="-3"
      id="F_a1f62023-fce1-42f8-a27e-c7b8d8939972"
      unitRef="U_USD">302911000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_2635002b-b630-46e8-b4a3-1b73eab5490d"
      unitRef="U_USD">354495000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d4fdb95a-3eb7-454b-aa35-9c3868eab086"
      decimals="-3"
      id="F_0269ad44-ad56-4bf0-8429-ffe7cb945a5a"
      unitRef="U_USD">354495000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_2fe2aeb8-5b4a-4058-82b3-592116698df0"
      unitRef="U_USD">127248000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_fae74238-7ce3-4af5-9f76-7ddc34eb01f4"
      decimals="-3"
      id="F_69f67274-d851-4866-9310-bd95de4dbb5b"
      unitRef="U_USD">127248000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_62a04c01-c554-489b-94ff-f68796238daf"
      decimals="-3"
      id="F_a23837dd-01ab-4e8d-a315-bd9cd5f15def"
      unitRef="U_USD">63114000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8d3496d1-3be0-413b-9f3a-0b624246add1"
      decimals="-3"
      id="F_eec797c1-d7e7-4740-990a-53ce36283624"
      unitRef="U_USD">63114000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066"
      decimals="-3"
      id="F_fe61c817-c854-45f1-b334-7ebf47183168"
      unitRef="U_USD">133163000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c7472141-c913-4194-b3cf-9b99dbf32ab2"
      decimals="-3"
      id="F_c78294d1-1dd8-498d-ab99-b823a924917b"
      unitRef="U_USD">133163000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b2914001-6eb8-4b83-a2c2-bd94ddbe5fe5"
      decimals="-3"
      id="F_e955b1bb-56d7-42e5-9340-09b3934622c4"
      unitRef="U_USD">15613000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_ff1b2d86-e176-4930-a80e-46e442e30f10"
      decimals="-3"
      id="F_e3834c9d-dc35-40f1-b43e-b084ab182e01"
      unitRef="U_USD">15613000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_51341176-7b94-481d-958f-12e14896a653"
      unitRef="U_USD">113250000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_22abec7d-1872-4be4-b3da-b134f50ffb38"
      decimals="-3"
      id="F_9f0834fd-cfdd-497e-b0e6-d64204d1962f"
      unitRef="U_USD">113250000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_67ff7ca5-690b-4e8d-8efb-b0acf79e6e3b"
      unitRef="U_USD">1109794000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c8fdbb15-6c4b-4e31-80ed-4104897dd692"
      decimals="-3"
      id="F_550fce5d-472b-4d63-83d2-8500a34b5a76"
      unitRef="U_USD">1109794000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_aee4740d-b071-485c-a97d-8442ae2256a4"
      unitRef="U_USD">1270979000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c9b8b2ef-3e7c-4781-829b-f175d048affc"
      decimals="-3"
      id="F_193aa368-431c-42b8-8e7f-3d658196c6ab"
      unitRef="U_USD">161185000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c8fdbb15-6c4b-4e31-80ed-4104897dd692"
      decimals="-3"
      id="F_7fec24da-b6dd-4637-801f-38d9eba3db36"
      unitRef="U_USD">1109794000</us-gaap:AssetsFairValueDisclosure>
    <sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_5e87aec2-150a-4ff3-80dc-278fcf0e97f3"
      unitRef="U_USD">0</sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount>
    <sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
      contextRef="C_7601ff9d-3322-4299-aef3-b6935a9a3a9e"
      decimals="INF"
      id="F_5da26f48-7329-4839-b634-aa77aa3c044f"
      unitRef="U_USD">0</sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_db5719e8-49f2-4359-ae9e-405c17a51295">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the gross unrealized gains and losses of the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.75%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.733%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.153%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;269,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;267,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;928,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;923,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.648%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;307,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,109,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d"
      decimals="-3"
      id="F_ab1c0f7d-c821-41a9-8ed3-2b86161283d1"
      unitRef="U_USD">234555000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d"
      decimals="-3"
      id="F_f054ea82-8dfe-4ccd-81d0-5faeaeb39190"
      unitRef="U_USD">282000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d"
      decimals="-3"
      id="F_c058ef66-c37a-411f-ad46-50dfdf87f8e2"
      unitRef="U_USD">2149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a20341ba-ddc3-4c5c-b736-828406ee9c6d"
      decimals="-3"
      id="F_a6468b33-3e9e-4e65-a9df-502bee74c17b"
      unitRef="U_USD">232688000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29"
      decimals="-3"
      id="F_47f8b441-2235-4f86-99fa-b877e3d6bdd7"
      unitRef="U_USD">269052000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29"
      decimals="-3"
      id="F_36589725-3b33-4cca-b39e-f198ded54ec0"
      unitRef="U_USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29"
      decimals="-3"
      id="F_f4e1d02e-f9e7-4bb5-8255-d7947d7bbb17"
      unitRef="U_USD">1808000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e54b565e-399f-41a1-ad9b-c491fc4ccd29"
      decimals="-3"
      id="F_8ce14fea-a9cd-476d-b08b-804a75fbd56d"
      unitRef="U_USD">267310000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4"
      decimals="-3"
      id="F_4a5b8db3-99f1-4887-8207-50921e939909"
      unitRef="U_USD">76313000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4"
      decimals="-3"
      id="F_14198963-471e-49b0-b3f9-5121707dfd66"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4"
      decimals="-3"
      id="F_72fa2572-2a96-4c66-ac46-4edcd11c262f"
      unitRef="U_USD">554000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7cf0aab4-0b69-4707-a217-6482aa0dfaa4"
      decimals="-3"
      id="F_2187b49b-6409-40b2-a18a-863e446723ec"
      unitRef="U_USD">75766000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_985df593-5059-41c1-979c-cfad810abdef"
      decimals="-3"
      id="F_3c50f96e-4d28-4fcd-bd93-20308e766e76"
      unitRef="U_USD">62529000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_985df593-5059-41c1-979c-cfad810abdef"
      decimals="-3"
      id="F_154e85ad-b16f-4c5c-ad05-72c8e86f4068"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_985df593-5059-41c1-979c-cfad810abdef"
      decimals="-3"
      id="F_6b9534bd-4928-4d87-a9d3-709f003522e2"
      unitRef="U_USD">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_985df593-5059-41c1-979c-cfad810abdef"
      decimals="-3"
      id="F_09280513-d699-4285-a471-a10dc7bbaf97"
      unitRef="U_USD">62428000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb"
      decimals="-3"
      id="F_36d8d4f7-2ade-4793-99b8-f8f2869f63c4"
      unitRef="U_USD">109180000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb"
      decimals="-3"
      id="F_51a7533f-fa0f-495b-aced-cf5bcd0d5d83"
      unitRef="U_USD">181000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7819dddc-836a-48e0-98f0-4c388dc7c2fb"
      decimals="-3"
      id="F_3aa36695-40fb-4d6f-a900-a802cca71585"
      unitRef="U_USD">108999000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_95a6685d-c914-4c9f-b57b-5ca39c0070ef"
      decimals="-3"
      id="F_ac9fbc0c-5ed6-47ee-ba5e-e18eac748b45"
      unitRef="U_USD">15286000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_95a6685d-c914-4c9f-b57b-5ca39c0070ef"
      decimals="-3"
      id="F_4ca9eda8-911f-4705-922e-d1fd6999cf6d"
      unitRef="U_USD">15286000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9"
      decimals="-3"
      id="F_53102e3f-49fc-4215-a955-4acf29974b50"
      unitRef="U_USD">161191000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9"
      decimals="-3"
      id="F_53f6ae60-117e-471b-beb2-74a88b438fa1"
      unitRef="U_USD">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9"
      decimals="-3"
      id="F_dcd1b6f6-f313-4703-a29d-5792a6425eb1"
      unitRef="U_USD">778000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_eaf26748-7cbb-49a2-a010-8177fc4192d9"
      decimals="-3"
      id="F_19d8e82d-0b65-45ef-a2fb-3359c32d6e49"
      unitRef="U_USD">160551000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_175f8023-634f-460f-9b4a-50d9442b38ad"
      unitRef="U_USD">928106000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_46e99310-285a-4846-af8a-442c436bfbaf"
      unitRef="U_USD">495000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_15e0ffe4-b1e8-4393-9877-18a2508d7b37"
      unitRef="U_USD">5573000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_2aaa02f3-7e75-4a55-9e21-4c4a9950c025"
      unitRef="U_USD">923028000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53"
      decimals="-3"
      id="F_7ebdb27e-8283-413b-a1ae-184134a9b8fa"
      unitRef="U_USD">307173000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53"
      decimals="-3"
      id="F_34b07709-6fca-4eff-be90-bedb472ff992"
      unitRef="U_USD">4262000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_d7bf3e61-e4c2-4a70-ae60-d3833232cd53"
      decimals="-3"
      id="F_c85211c8-9786-4ce3-ace5-849f2b2ed72d"
      unitRef="U_USD">302911000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663"
      decimals="-3"
      id="F_cbe31e63-1e96-46b6-94f7-0abe8443a810"
      unitRef="U_USD">358019000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663"
      decimals="-3"
      id="F_3643e03a-c82a-4640-b9e7-516fe9564ddd"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663"
      decimals="-3"
      id="F_32aa49cd-650d-4045-ad76-daac434f0d05"
      unitRef="U_USD">3530000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0ac07274-fc3a-4894-82ec-ea46b3499663"
      decimals="-3"
      id="F_1b774b4d-4b46-4fa1-a433-0c5cf8f7bb4b"
      unitRef="U_USD">354495000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3"
      decimals="-3"
      id="F_55e33d18-3129-4d07-a8ec-e0f5ec2fbf59"
      unitRef="U_USD">128374000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3"
      decimals="-3"
      id="F_ac04af6c-1ab0-44fc-b7ab-c076c9d6844c"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3"
      decimals="-3"
      id="F_3c4f4692-042e-4d69-b992-aceff932f2fd"
      unitRef="U_USD">1133000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_281fc868-2fdb-4949-a787-87a97e7468c3"
      decimals="-3"
      id="F_d4a5198c-b9c4-480c-8581-95fe0cfa6659"
      unitRef="U_USD">127248000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1"
      decimals="-3"
      id="F_122ec467-0441-420a-a9a1-a0cb0f0d47e8"
      unitRef="U_USD">63234000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1"
      decimals="-3"
      id="F_66fab008-1398-4d89-a8fd-1dc56fc3b386"
      unitRef="U_USD">120000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_328b3320-8cec-4e84-af8e-6dde99f1a3d1"
      decimals="-3"
      id="F_794592bf-3e37-4a1c-8a59-6053df73c417"
      unitRef="U_USD">63114000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e0418523-3fbf-4353-b5fc-b74fa6275d25"
      decimals="-3"
      id="F_c62a7a96-1302-4199-b0a4-75017251e9bd"
      unitRef="U_USD">133338000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e0418523-3fbf-4353-b5fc-b74fa6275d25"
      decimals="-3"
      id="F_83904f6a-1e49-4de4-b910-35bdda2ed108"
      unitRef="U_USD">175000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e0418523-3fbf-4353-b5fc-b74fa6275d25"
      decimals="-3"
      id="F_120b09e3-ba8d-4c79-a63a-8f21bbcedf2f"
      unitRef="U_USD">133163000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5b7a5ab4-63f6-4561-8f6d-b3de184d3551"
      decimals="-3"
      id="F_b233b15d-49cb-46b5-b0a8-363057a5cdd2"
      unitRef="U_USD">15613000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_5b7a5ab4-63f6-4561-8f6d-b3de184d3551"
      decimals="-3"
      id="F_04a56f16-e64f-49ab-8725-059658cf5ce7"
      unitRef="U_USD">15613000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0"
      decimals="-3"
      id="F_a5504c3b-6aa7-4053-b3e4-36acaec08d8c"
      unitRef="U_USD">114249000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0"
      decimals="-3"
      id="F_8e1cadda-f5a7-4456-b500-d22f836c7bc8"
      unitRef="U_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0"
      decimals="-3"
      id="F_dcdac7d5-65c2-44a6-af63-9c01f4de0a8f"
      unitRef="U_USD">1030000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_cb685137-7b3d-49bd-8d05-e9ea92f9dff0"
      decimals="-3"
      id="F_73c3b8ab-9654-4a22-bebc-0b16417dc6db"
      unitRef="U_USD">113250000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_ea9bfd9c-88b3-4a6d-805d-4f8fe27eba7f"
      unitRef="U_USD">1120000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_12c80133-c0c3-4615-bcf7-b1972a490c4b"
      unitRef="U_USD">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_7a3eb231-c3ba-42c2-a5bf-a080272163ec"
      unitRef="U_USD">10250000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_a4434ce5-a269-4696-af98-083e9fbe82d5"
      unitRef="U_USD">1109794000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_80b0c7ce-880e-4b1c-953f-fa9162fc6209">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the fair value and the unrealized losses of the Company&#x2019;s marketable securities that have been in a loss position for either less than twelve months or greater than twelve months as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.018%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.971%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Greater than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;430,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;684,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.018%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.971%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Greater than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;297,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;208,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;339,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;International commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;513,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;399,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;913,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_3c0d8aaf-74ad-4b2f-8143-c9a58bd1542e"
      unitRef="U_USD">59680000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_580c4d21-0735-4c71-a9ec-4523a8f7169f"
      unitRef="U_USD">548000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_692b1d10-e2b1-4407-b8cf-f7817b9d35f3"
      unitRef="U_USD">108845000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_289596d2-cbfe-4702-b2a9-a32966c3a553"
      unitRef="U_USD">1601000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_6a3aff6d-44cf-439c-b3cb-b45095687405"
      unitRef="U_USD">168525000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_aebb90d1-6d9d-4fbe-9dab-669dc7886382"
      decimals="-3"
      id="F_dac0ebe6-55c4-42b2-9abc-a57c7f02c0bb"
      unitRef="U_USD">2149000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_19fddbbd-a6b6-4995-bee0-d87c06379407"
      unitRef="U_USD">144665000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_3c479a9e-4d49-4de2-8d04-61527d48431f"
      unitRef="U_USD">978000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_b06763a3-a718-4343-a2ca-4595c933309d"
      unitRef="U_USD">88097000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_e3d02fdc-0de3-4b0d-8df3-b6f9e9a7f302"
      unitRef="U_USD">830000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_61d5e0b2-21a0-40a8-91f7-88690c104e7b"
      unitRef="U_USD">232762000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_3319e980-82fb-4d89-a8c2-15e306377f32"
      decimals="-3"
      id="F_0e299cb7-9895-4a73-924c-b04867aa3a0a"
      unitRef="U_USD">1808000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_65266708-7b30-46ea-8430-8b86ace77bb3"
      unitRef="U_USD">36432000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_da3c294d-7dd1-4118-848c-1529a2fcc0df"
      unitRef="U_USD">213000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_de0c96f4-d877-4f0a-a400-eb93ad1e0204"
      unitRef="U_USD">35015000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_1dd2e660-f362-4744-8174-f2c54cabe2cc"
      unitRef="U_USD">341000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_527ce713-043d-4d03-9bbc-a7dbf783a442"
      unitRef="U_USD">71447000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_ed7c9b34-48d1-4ac8-99a0-634bf4e0e2bf"
      decimals="-3"
      id="F_eef28081-f165-4398-ba11-8ebb3cd6417d"
      unitRef="U_USD">554000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_850361db-7291-43d8-8579-6031f3718f59"
      decimals="-3"
      id="F_432ee8b4-965c-4c3f-bf65-67bbf20205ab"
      unitRef="U_USD">36712000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_850361db-7291-43d8-8579-6031f3718f59"
      decimals="-3"
      id="F_c1afbbf2-5bcb-4d48-a5b0-2d749f372017"
      unitRef="U_USD">103000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_850361db-7291-43d8-8579-6031f3718f59"
      decimals="-3"
      id="F_5046a3ec-8e1f-4620-ae77-1e59166624df"
      unitRef="U_USD">36712000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_850361db-7291-43d8-8579-6031f3718f59"
      decimals="-3"
      id="F_7deffe1d-c5b0-48ec-8426-6db71df664dd"
      unitRef="U_USD">103000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194"
      decimals="-3"
      id="F_7c0f51ac-9eed-4297-860b-e368e212eef2"
      unitRef="U_USD">95624000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194"
      decimals="-3"
      id="F_41bde811-fa53-48f0-897a-dfc977814a53"
      unitRef="U_USD">181000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194"
      decimals="-3"
      id="F_7c86bb63-4a01-4665-88a4-5253b701f0af"
      unitRef="U_USD">95624000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_e922eff6-ae97-4689-ab0c-b231d4614194"
      decimals="-3"
      id="F_e9852182-9665-41ea-af26-6f81109880db"
      unitRef="U_USD">181000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_9538cd44-b3d8-46ae-8952-7f0b01aff05c"
      unitRef="U_USD">57307000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_20984a72-ac98-475c-b279-8d2dec9db752"
      unitRef="U_USD">299000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_6a660259-ccd0-464d-bf52-7b24c370e8fb"
      unitRef="U_USD">22014000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_79a8bc14-a3f9-4f92-b7a4-447e0f96f3f0"
      unitRef="U_USD">479000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_789c7343-124e-4900-a6f6-b8198f2443fb"
      unitRef="U_USD">79321000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_b3ef2d5d-3081-43d7-85c5-1c599cc35927"
      decimals="-3"
      id="F_e6ed8545-6333-4eed-9e17-ab9e2a66d0ef"
      unitRef="U_USD">778000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_baf05272-9fe6-46a1-880d-e131fd33583f"
      unitRef="U_USD">430420000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_68a0a9e0-4df6-4b8d-9d77-6f2f5062b4d0"
      unitRef="U_USD">2322000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_a83bd9a1-171d-46d2-b528-ca922a32f6c5"
      unitRef="U_USD">253971000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_b2ee059d-de17-4e4d-be1f-e557d5f0c44e"
      unitRef="U_USD">3251000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_6b9d4929-aabd-467e-89f2-221f6beb2055"
      unitRef="U_USD">684391000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_c5eb978b-de93-4f7c-acdb-07708b8054fa"
      unitRef="U_USD">5573000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_dd1c08cb-75ff-4ca3-b1a8-ddcfa461cfd2"
      unitRef="U_USD">112243000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_f6b98129-c21d-4f53-ae1e-66a2b803970f"
      unitRef="U_USD">1517000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_be16eabc-d13a-4a6f-980e-f4d9737d702a"
      unitRef="U_USD">185691000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_f3737c0e-5851-4d1d-9e28-53f6346011d8"
      unitRef="U_USD">2745000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_83e1edbd-5754-4720-a2b7-f3e628780f01"
      unitRef="U_USD">297934000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_e8b28052-9239-40b1-9476-79d5174ad674"
      decimals="-3"
      id="F_2ad464a6-274e-43f8-a4e3-86f6d988ac60"
      unitRef="U_USD">4262000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_1480137c-e104-41a9-8712-6c94b8033b6c"
      unitRef="U_USD">208507000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_074ccf6c-6bda-401c-af95-2da92fb98a02"
      unitRef="U_USD">1989000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_c891f590-63fe-480e-b0b6-d8716e0c0057"
      unitRef="U_USD">130633000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_d72edc67-51da-425d-8919-3cda9bb52f63"
      unitRef="U_USD">1541000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_b84b4d50-a9d8-4a8c-b655-31a4d2927746"
      unitRef="U_USD">339140000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_4d2d01f0-5a7a-4f0a-84ac-4ea7301c0c1d"
      decimals="-3"
      id="F_25d366bf-1715-4815-a494-e1c15d2f6153"
      unitRef="U_USD">3530000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_06183ec1-e4f8-49f5-a5e2-8c43283632b0"
      unitRef="U_USD">50982000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_55f4f954-9f2c-4239-902c-d5710f4769f0"
      unitRef="U_USD">497000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_48f73e4c-99ba-4325-b30a-247015ffff32"
      unitRef="U_USD">68993000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_b50350d0-2a7e-47d6-be9a-7f714f18a4b7"
      unitRef="U_USD">636000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_7b599587-8f15-40ab-9a99-4e7777a2982c"
      unitRef="U_USD">119975000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_0f48cc31-4e82-4c5a-8987-efbee611a07b"
      decimals="-3"
      id="F_f1bf37cc-5f55-4881-933a-8ca6a7a466e2"
      unitRef="U_USD">1133000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_62a04c01-c554-489b-94ff-f68796238daf"
      decimals="-3"
      id="F_53ec2bec-b8eb-4a9e-943b-7e12d1f757c2"
      unitRef="U_USD">24768000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_62a04c01-c554-489b-94ff-f68796238daf"
      decimals="-3"
      id="F_3db38295-95e8-4333-866d-9cc1c13eed1b"
      unitRef="U_USD">120000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_62a04c01-c554-489b-94ff-f68796238daf"
      decimals="-3"
      id="F_f2cccc47-58c7-46c4-b3b7-0d9b00fc2d4f"
      unitRef="U_USD">24768000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_62a04c01-c554-489b-94ff-f68796238daf"
      decimals="-3"
      id="F_95616d1c-fda1-491f-a4c8-f815acfb5388"
      unitRef="U_USD">120000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066"
      decimals="-3"
      id="F_42c826b4-45ac-4c7d-9c79-4a2a8dcdea0a"
      unitRef="U_USD">30987000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066"
      decimals="-3"
      id="F_6d643b1b-a345-45d3-a2a6-f275f8e5c57e"
      unitRef="U_USD">175000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066"
      decimals="-3"
      id="F_ed7248a4-8045-44af-97eb-f10209350523"
      unitRef="U_USD">30987000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_dfcf2c3b-ff61-431f-b715-71fc37e86066"
      decimals="-3"
      id="F_bd8d54de-2561-4363-80ce-f824eace0f93"
      unitRef="U_USD">175000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_686dab8c-50e3-4ecf-a10d-ed0c0949de42"
      unitRef="U_USD">86251000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_6132f2f7-2c34-4d82-a134-adb25b13bba2"
      unitRef="U_USD">497000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_6f4bbe7f-da45-4416-bf5d-490f5e8710e1"
      unitRef="U_USD">14466000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_8526477a-ed82-445e-bd3e-a1750d2f9551"
      unitRef="U_USD">533000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_4c7f17ab-7a75-4084-97da-d78d6fdc8e02"
      unitRef="U_USD">100717000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_694b1751-ca21-4b1a-8ae0-231f74098b27"
      decimals="-3"
      id="F_a6d4bf8e-fa08-4747-88aa-17a3340370e4"
      unitRef="U_USD">1030000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_93318e19-f491-4353-a8ab-3c83927f3659"
      unitRef="U_USD">513738000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_05d2f70e-afeb-44ce-b5cd-bd320a567a41"
      unitRef="U_USD">4795000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_6fb77cdf-bd53-4047-acad-741dddaac987"
      unitRef="U_USD">399783000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_8dff6bad-a730-44ac-af11-4b54f0bfd5d8"
      unitRef="U_USD">5455000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_faf2e7b8-e3ae-4a81-a543-b52c82412bc9"
      unitRef="U_USD">913521000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_a6e2d7f9-77de-4016-bce6-33b02d0dbe8d"
      unitRef="U_USD">10250000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <sage:MarketableSecuritiesRemainingContractualMaturities
      contextRef="C_2b34f602-7812-4da1-a117-ccb5aabeb0c5"
      id="F_3dfde8cd-a7bf-4543-8f2c-16f711c8ee9e">P1Y</sage:MarketableSecuritiesRemainingContractualMaturities>
    <sage:MarketableSecuritiesHeldToMaturityFairValue
      contextRef="C_ebde5ad9-f57b-4a0d-a856-31c668cee290"
      decimals="-5"
      id="F_7a1a6771-aad4-4fce-8c97-b8eec44a5620"
      unitRef="U_USD">186300000</sage:MarketableSecuritiesHeldToMaturityFairValue>
    <sage:MarketableSecuritiesMaturityPeriod
      contextRef="C_08b2b642-fbe6-4621-9e25-1ad7325fb6fa"
      id="F_f9fdad20-5734-4289-8542-74525f0a170f">P2Y</sage:MarketableSecuritiesMaturityPeriod>
    <sage:MarketableSecuritiesRemainingContractualMaturities
      contextRef="C_1a762d75-188f-4244-ab8c-58366e1a3a7d"
      id="F_437ebd50-c191-44d5-844a-bd5ebe581bc8">P1Y</sage:MarketableSecuritiesRemainingContractualMaturities>
    <sage:MarketableSecuritiesHeldToMaturityFairValue
      contextRef="C_d3351468-5ac6-43c1-8075-f9f598ae56b3"
      decimals="-5"
      id="F_3f677a04-1400-457f-b507-bbe6e0a50034"
      unitRef="U_USD">211200000</sage:MarketableSecuritiesHeldToMaturityFairValue>
    <sage:MarketableSecuritiesMaturityPeriod
      contextRef="C_b5072417-0f0f-44a9-8e76-a71228d6ebf1"
      id="F_0dd1067d-8ae0-4606-a93d-f860fd89e510">P2Y</sage:MarketableSecuritiesMaturityPeriod>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="INF"
      id="F_adcf5107-f909-44dc-9954-a79bee3d38ed"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_398f2f38-b40a-44f3-b42a-adb45a79772b"
      decimals="INF"
      id="F_00b979e1-f39c-4e1f-8d42-db2070575fc5"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_ec453388-35c8-432b-84b9-303a20f7165a">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;4.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes accrued expenses as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.507%;"/&gt;
        &lt;td style="width:2.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.201%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.201%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee-related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_c70e19c7-5707-4177-83ce-a7e04417e058">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes accrued expenses as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.507%;"/&gt;
        &lt;td style="width:2.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.201%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.201%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee-related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sage:AccruedResearchAndDevelopmentCosts
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_189bf619-7752-4985-8150-0e62e4c44de6"
      unitRef="U_USD">40138000</sage:AccruedResearchAndDevelopmentCosts>
    <sage:AccruedResearchAndDevelopmentCosts
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_19928e69-226b-43c7-acee-1ab3391fdab9"
      unitRef="U_USD">32565000</sage:AccruedResearchAndDevelopmentCosts>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_3c96d8cc-6bdf-4e51-8f33-c20c187db315"
      unitRef="U_USD">9872000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_fdab7f8d-78d4-4577-ba88-bee1efa3217f"
      unitRef="U_USD">29372000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_d8b548dd-5481-49fd-822a-1482469c6f3b"
      unitRef="U_USD">13922000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_8ae0b4be-58f5-44eb-aa38-42cf900fa7f3"
      unitRef="U_USD">10172000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_26202bf3-320c-42b4-bf16-ca99e80d4858"
      unitRef="U_USD">813000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_7f890585-3d63-4242-a787-a27d89150b4a"
      unitRef="U_USD">557000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="-3"
      id="F_0d0d82bf-abfd-45cf-bd9b-b31b189b1890"
      unitRef="U_USD">64745000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d275e93b-4da3-49de-a49e-a35ac74b5238"
      decimals="-3"
      id="F_0171d638-943d-4daa-84a8-cc0813fa0be7"
      unitRef="U_USD">72666000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_1a25712b-e1e3-4d7d-808d-202af862c0b4">&lt;div style="text-indent:0.0%;display:flex;margin-top:7.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;5.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases, Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company leases office space and certain equipment. All of the leases recorded on the condensed consolidated balance sheets are operating leases. The Company&#x2019;s leases have remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to approximately &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. Some of the leases include &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_02aacb61-99a8-43ba-8bb8-3474e32fbedc;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;options to extend&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the leases for up to &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These options were not included for the purpose of determining the right-of-use assets and associated lease liabilities as the Company determined that the renewal of these leases is not reasonably certain so only the original lease term was taken into consideration. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of January 1, 2022, the Company leased office space in two multi-tenant buildings in Cambridge, Massachusetts, consisting of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,017&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet in the first building, under an operating lease that will expire on &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,419&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet in the second building, under an operating lease that will expire on &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;; and in a multi-tenant building in Raleigh, North Carolina, consisting of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,525&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet under an operating lease that will expire on &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;CyDex License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2015, the Company amended and restated its existing commercial license agreement with CyDex Pharmaceuticals, Inc. (&#x201c;CyDex&#x201d;), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated. Under the terms of the commercial license agreement as amended and restated, CyDex has granted to the Company an exclusive license to CyDex&#x2019;s Captisol drug formulation technology and related intellectual property for the manufacture of pharmaceutical products incorporating brexanolone and the Company&#x2019;s compound known as SAGE-689, and the development and commercialization of the resulting products for the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i) the ocular treatment of any disease or condition with a formulation, including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration. The Company is required to pay a royalty to CyDex on sales of brexanolone and will be required to pay a royalty on any sales of SAGE-689, if such product candidate is successfully developed in the future. Royalty rates are in the low single digits based on levels of net sales. From the effective date of the agreement to March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has paid to CyDex $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for licensing fees, which was recorded as research and development expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the amended and restated license agreement with CyDex, the Company agreed to make milestone payments on the achievement of clinical development and regulatory milestones in the amount of up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in clinical milestones and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in regulatory milestones for each of the first two fields with respect to brexanolone; up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in clinical milestones and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in regulatory milestones for each of the third and fourth fields with respect to brexanolone; and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in clinical milestones and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in regulatory milestones for one field with respect to SAGE-689. From the effective date of the agreement to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has recorded research and development expense and made cash payments of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to these clinical development and regulatory milestones and has recorded an intangible asset and made a cash payment of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to these regulatory milestones.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record any expense or intangible asset, or make any milestone payments related to clinical development or regulatory milestones for the brexanolone program or SAGE-689 under the license agreement with CyDex.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;University of California License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 2013, the Company entered into a non-exclusive license agreement with the Regents of the University of California ("the Regents&#x201d;) under which the Company was granted a non-exclusive license to certain clinical data and clinical material related to brexanolone for use in the development and commercialization of biopharmaceutical products&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the licensed field, including status epilepticus and postpartum depression. In May 2014, the license agreement was amended to add the treatment of essential tremor to the licensed field of use, materials and milestone fee provisions of the agreement. The Company paid to the Regents clinical development milestones of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, prior to December 31, 2015; &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; other milestones are outstanding under this non-exclusive license agreement. The Company is required to pay royalties of less than &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on net sales for a period of fifteen years following the sale of the first product developed using the data and materials, and the Company began to pay these royalties in 2019. The license will terminate on the earlier to occur of (i) &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years after the effective date or (ii) &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years after the last-derived product is first commercially sold.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2015, the Company entered into an exclusive license agreement with the Regents whereby the Company was granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In exchange for such license, the Company paid an upfront payment of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and was required to make payments of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for annual maintenance fees until the calendar year following the first sale of ZULRESSO. The Company is obligated to make milestone payments following the achievement of specified regulatory and sales milestones of up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate, respectively. The Company pays royalties at a low single digit percentage of net sales of ZULRESSO, subject to specified minimum annual royalty amounts. Unless terminated by operation of law or by acts of the parties under the terms of the agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire, whichever is later. From the effective date of the agreement to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has recorded research and development expense and made cash payments of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to these regulatory and sales milestones; and has recorded an intangible asset and made a cash payment of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to these regulatory and sales milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record any expense or make any milestone payments under the license agreements with the Regents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sage:LessorOperatingLeaseRemainingLeaseTerms
      contextRef="C_27bf7966-adaf-4a98-8cd4-cf044ac22be7"
      id="F_425efdcb-7c15-4b93-83b4-aabb1cd09840">P1Y</sage:LessorOperatingLeaseRemainingLeaseTerms>
    <sage:LessorOperatingLeaseRemainingLeaseTerms
      contextRef="C_a131c6ed-00ee-4297-b3ee-b15e20f02a2b"
      id="F_b0488177-629a-4c0a-a4bc-d77e8296387e">P1Y9M</sage:LessorOperatingLeaseRemainingLeaseTerms>
    <us-gaap:LessorOperatingLeaseRenewalTerm
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      id="F_0d841126-b24d-47ab-ad6d-cd80c62cdbbd">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <sage:AreaOfOfficeSpace
      contextRef="C_ed9cf729-5356-4b5d-ad2b-e3ed67efc846"
      decimals="INF"
      id="F_dcea16a4-0a4e-42a7-b8d3-b9258b8ff7f8"
      unitRef="U_sqft">63017</sage:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_ed9cf729-5356-4b5d-ad2b-e3ed67efc846"
      id="F_f8170116-5e0d-4273-aed4-9bd7c87b336b">2024-08-31</us-gaap:LeaseExpirationDate1>
    <sage:AreaOfOfficeSpace
      contextRef="C_a7db4793-3d03-4e12-aff2-9ea90996fb1c"
      decimals="INF"
      id="F_3c0daf09-48e6-480f-98c0-5b15e2d981a2"
      unitRef="U_sqft">40419</sage:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_a7db4793-3d03-4e12-aff2-9ea90996fb1c"
      id="F_a6313fdd-e37a-4532-9327-fe8fe7196cd8">2024-08-31</us-gaap:LeaseExpirationDate1>
    <sage:AreaOfOfficeSpace
      contextRef="C_c148acc4-eb89-4bb9-b863-bbc6f10137ff"
      decimals="INF"
      id="F_e0fbeafc-68ce-4ec4-98fc-cc19ad247b46"
      unitRef="U_sqft">15525</sage:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_c148acc4-eb89-4bb9-b863-bbc6f10137ff"
      id="F_76d1da3b-4f75-4559-9519-71e31ae7ca5e">2024-11-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_184f14a5-c851-40db-a3ad-edc0666d719c"
      decimals="-5"
      id="F_ccd23f16-59ca-4f11-b5e0-cb928659d0af"
      unitRef="U_USD">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_cb341859-3071-42f6-bc53-4b0e98b5f8a5"
      decimals="INF"
      id="F_61912f19-92f0-407c-a9b1-383e5425390f"
      unitRef="U_USD">800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_8b581abc-0b6e-4877-a6fd-ea611d7c0a1d"
      decimals="INF"
      id="F_a5ed912e-1ec6-40bb-9771-c1eb20a220a9"
      unitRef="U_USD">3800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_d4873c8c-5811-4fbb-bbcc-4e44f6387941"
      decimals="INF"
      id="F_be3c1640-4032-440f-8a4c-4a92213b6d78"
      unitRef="U_USD">1300000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_0417f1bf-3a90-4585-8698-483b60daf578"
      decimals="INF"
      id="F_416e7e6a-0cdd-4e99-846a-bc57a8cc42c8"
      unitRef="U_USD">8500000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_631cae3a-ac3e-456e-a8b7-57e54ff8a7ca"
      decimals="INF"
      id="F_6ad81739-d3a3-4dc3-abe5-9296979b7a5f"
      unitRef="U_USD">800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_39f2ebec-0b4d-4975-8d61-08994c517086"
      decimals="INF"
      id="F_2fd5a5c6-7350-4ba9-8715-7fb983467bfe"
      unitRef="U_USD">1800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:MilestonePayments
      contextRef="C_ce43f41b-b49a-4a4d-ac4f-591e551f6206"
      decimals="-5"
      id="F_375304d0-f9c8-4737-8eac-2d0b4f3ff424"
      unitRef="U_USD">3600000</sage:MilestonePayments>
    <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment
      contextRef="C_ce43f41b-b49a-4a4d-ac4f-591e551f6206"
      decimals="-5"
      id="F_58591aba-c71f-4b2e-8206-7d6a2c81b33f"
      unitRef="U_USD">3600000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
    <sage:IntangibleAssetRelatedToMilestone
      contextRef="C_27dd408f-5b77-4383-b146-868c9ccf1126"
      decimals="-5"
      id="F_347e5d30-4a22-4bee-896e-c3024ae27db0"
      unitRef="U_USD">3000000.0</sage:IntangibleAssetRelatedToMilestone>
    <sage:IntangibleAssetRelatedToMilestone
      contextRef="C_c906b10e-a37d-4bef-9c1a-2f9273872ad0"
      decimals="INF"
      id="F_a0390cfc-a8a5-4734-ba23-b74fefc2a0c8"
      unitRef="U_USD">0</sage:IntangibleAssetRelatedToMilestone>
    <sage:MilestonePayments
      contextRef="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f"
      decimals="INF"
      id="F_141e63ee-7a3c-4514-8dd5-16ae1c561926"
      unitRef="U_USD">0</sage:MilestonePayments>
    <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment
      contextRef="C_bdd95323-8fa2-447a-b407-594cf62cbf26"
      decimals="INF"
      id="F_fa58103f-d792-4bd0-bec2-990487bc1a56"
      unitRef="U_USD">0</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
    <sage:MilestonePayments
      contextRef="C_bdd95323-8fa2-447a-b407-594cf62cbf26"
      decimals="INF"
      id="F_7821cc0f-60ef-43eb-b056-07db2241bf34"
      unitRef="U_USD">0</sage:MilestonePayments>
    <sage:MilestonePaymentsRelatedToIntangibleAssets
      contextRef="C_0a4f411b-755b-4edb-9b9a-1c815418b4e7"
      decimals="INF"
      id="F_de25007e-60db-497f-8fea-ef074ee74650"
      unitRef="U_USD">0</sage:MilestonePaymentsRelatedToIntangibleAssets>
    <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment
      contextRef="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f"
      decimals="INF"
      id="F_363677fa-55e6-4a65-ac99-24f276ec8b68"
      unitRef="U_USD">0</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
    <sage:MilestonePaymentsRelatedToIntangibleAssets
      contextRef="C_df9dd421-d53a-45e0-8f9a-3020ead17d1f"
      decimals="INF"
      id="F_f256d26a-e537-4503-8c87-56df28ab086a"
      unitRef="U_USD">0</sage:MilestonePaymentsRelatedToIntangibleAssets>
    <sage:PaymentForClinicalDevelopmentMilestones
      contextRef="C_5fb3fbe9-a1c0-46ce-b650-af5e52d18ce1"
      decimals="INF"
      id="F_c23dede2-c45e-4921-b2cd-12ec3f504a15"
      unitRef="U_USD">100000</sage:PaymentForClinicalDevelopmentMilestones>
    <sage:MilestoneOutstandingLicenseAgreement
      contextRef="C_5fb3fbe9-a1c0-46ce-b650-af5e52d18ce1"
      decimals="INF"
      id="F_bf596add-b722-4ad3-80fc-1a7b5bdd2482"
      unitRef="U_USD">0</sage:MilestoneOutstandingLicenseAgreement>
    <sage:PercentageOfNetSalesRequiredForRoyaltyEntitlement
      contextRef="C_5673061c-1475-40d8-a68f-d13874d6120e"
      decimals="INF"
      id="F_97a2b18a-51cb-4563-ad3e-fb02b63e857f"
      unitRef="U_pure">0.01</sage:PercentageOfNetSalesRequiredForRoyaltyEntitlement>
    <sage:LicenseAgreementMaximumTerm
      contextRef="C_f08fa5ab-3d5a-498f-8805-b37168240ab1"
      id="F_dafea361-5c63-4dbc-866e-0830bf6049e4">P27Y</sage:LicenseAgreementMaximumTerm>
    <sage:LicenseAgreementMaximumTerm
      contextRef="C_e009878c-16d0-44dd-938b-4ab63e464396"
      id="F_135246e4-e124-43b1-a0ca-37d3ca40b638">P15Y</sage:LicenseAgreementMaximumTerm>
    <sage:UpFrontPayment
      contextRef="C_9b20c727-7972-478a-9e8f-c96192d5a8c6"
      decimals="0"
      id="F_9f758504-0318-468a-b068-023398dce961"
      unitRef="U_USD">50000</sage:UpFrontPayment>
    <sage:LicenseMaintenanceCostAnnual
      contextRef="C_c8887f83-2b64-4c67-9ed6-bf1f704f02eb"
      decimals="0"
      id="F_eff87e28-3067-4254-8584-2271b50f7b69"
      unitRef="U_USD">15000</sage:LicenseMaintenanceCostAnnual>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_a87f9c6e-2ef9-466a-ae7a-ee5de7690022"
      decimals="INF"
      id="F_b1b31237-739f-4a35-82b9-2571ffa846cb"
      unitRef="U_USD">700000</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_66eb2bc3-a6d2-4d81-939a-2ee9abc0d88c"
      decimals="INF"
      id="F_6059072c-da97-41bf-a170-23ffbad3f976"
      unitRef="U_USD">2000000.0</sage:AdditionalPaymentsBasedOnAchievementOfCertainMilestones>
    <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment
      contextRef="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd"
      decimals="-5"
      id="F_7735ee36-07de-4b33-a861-bab7342374bd"
      unitRef="U_USD">300000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
    <sage:MilestonePayments
      contextRef="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd"
      decimals="-5"
      id="F_d0e82fd3-8526-4d8d-aa97-3c2c4f7ddf1f"
      unitRef="U_USD">300000</sage:MilestonePayments>
    <sage:IntangibleAssetRelatedToMilestone
      contextRef="C_fe2f65bc-c1a3-4823-84d8-2de25bace4b8"
      decimals="-5"
      id="F_7926c4ed-a72c-470d-ac1a-9ebef4aa8318"
      unitRef="U_USD">500000</sage:IntangibleAssetRelatedToMilestone>
    <sage:MilestonePaymentsRelatedToIntangibleAssets
      contextRef="C_963a4540-f1e7-4f20-b5b4-0f456d5adbfd"
      decimals="-5"
      id="F_72d96474-69a2-48ef-bc41-7ae4f42bb23e"
      unitRef="U_USD">500000</sage:MilestonePaymentsRelatedToIntangibleAssets>
    <sage:MilestonePayments
      contextRef="C_ec5cbc69-f530-4cf4-94cc-314aa3b6a25a"
      decimals="INF"
      id="F_00c626f7-025b-48c3-9637-641a7ee5f497"
      unitRef="U_USD">0</sage:MilestonePayments>
    <sage:MilestonePayments
      contextRef="C_51b62e2e-6e5b-43f1-9a64-7a9fc0694111"
      decimals="INF"
      id="F_9fef8a8c-3d4a-421e-8756-71330aa2240b"
      unitRef="U_USD">0</sage:MilestonePayments>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_20237446-69f4-4551-93d5-fee5a4bf888c"
      id="F_b7902285-e186-4a13-b638-26aaf7d0f3b6">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;6.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Shionogi&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2018, the Company entered into a strategic collaboration with Shionogi for the clinical development and commercialization of zuranolone for the treatment of MDD and other potential indications in Japan, Taiwan and South Korea (the &#x201c;Shionogi Territory&#x201d;). In October 2018, the Company entered into a supply agreement with Shionogi for the Company to supply zuranolone clinical material to Shionogi.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the collaboration agreement, Shionogi is responsible for all clinical development and regulatory filings for zuranolone in MDD and other indications in the Shionogi Territory and would be responsible for commercialization of zuranolone in the Shionogi Territory, if zuranolone is successfully developed and obtains marketing approval in any of the countries within the Shionogi Territory. Shionogi was required to make an upfront payment to the Company of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and the Company will be eligible to receive additional payments of up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;485.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million if certain regulatory and commercial milestones are achieved by Shionogi. The potential future milestone payments include up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified regulatory milestones, up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified commercialization milestones, and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;385.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified net sales milestones. The Company is eligible to receive tiered royalties on sales of zuranolone in the Shionogi Territory, if development efforts are successful, with tiers averaging in the low to mid-&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;twenty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; percent range, subject to other terms of the agreement. Shionogi has also granted to the Company certain rights to co-promote zuranolone in Japan. As between the Company and Shionogi, the Company maintains exclusive rights to develop and commercialize zuranolone outside of the Shionogi Territory. The upfront cash payment and any payments for milestones and royalties are non-refundable and non-creditable. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments from Shionogi.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that Shionogi meets the definition of a customer because the Company is delivering intellectual property and know-how rights for the zuranolone program in support of territories in which the parties are not jointly sharing the risks and rewards. In addition, the Company determined that the Shionogi collaboration met the requirements to be accounted for as a contract, including that it was probable that the Company will collect the consideration to which the Company was entitled in exchange for the goods or services that will be delivered to Shionogi.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the performance obligations in the Shionogi collaboration agreement included the license to zuranolone and the supply of certain materials during the clinical development phase, which includes the supply of active pharmaceutical ingredient (&#x201c;API&#x201d;). The performance obligation related to the license to zuranolone was determined to be distinct from other performance obligations and therefore was a separate performance obligation for which control was transferred upon signing. The obligation to provide certain clinical materials, including API for use during the development period, was determined to be a separate performance obligation. Given that Shionogi is not obligated to purchase any minimum amount or quantities of commercial API, the supply of API to Shionogi for commercial use was determined to be an option for Shionogi, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that there was no separate material right in connection with the supply of API for commercial use as the expected pricing was not at a discount. Given this fact pattern, the Company has concluded the agreement has two performance obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the clinical supply agreement, the Company is obligated to manufacture and supply to Shionogi (i) clinical quantities of API reasonably required by Shionogi for the development of licensed products in the Shionogi territory under the collaboration and license agreement and (ii) quantities of drug product reasonably required for use by Shionogi in Phase 1 clinical trials of zuranolone in the Shionogi territory under the collaboration and license agreement, in the quantities agreed to by the parties. Collaboration revenue from the clinical supply agreement, which excludes the $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upfront payment, pertains to the clinical material sold under the terms of the clinical supply agreement. The Company records the costs related to the clinical supply agreement in research and development expense on its condensed consolidated statements of operations and comprehensive loss. For the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recognized &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; collaboration revenue from the Company&#x2019;s agreement with Shionogi.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company completed the evaluation of the standalone selling prices of each of the performance obligations and determined that the standalone selling price of the license performance obligation was $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company recognized the transaction price allocated to the license performance obligation of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as revenue during the quarter upon delivery of the license to Shionogi and resulting ability of Shionogi to use and benefit from the license, which was in the three months ended June 30, 2018. The remaining transaction price related to the performance obligation for the supply of certain clinical material is not significant. The potential milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Biogen&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2020, the Company entered into the Biogen Collaboration Agreement to jointly develop and commercialize SAGE-217 products for MDD, PPD and other disorders and SAGE-324 products for essential tremor and other disorders. Concurrently, the Company also entered into a stock purchase agreement with BIMA (the &#x201c;Biogen Stock Purchase Agreement&#x201d;) under which BIMA purchased shares of the Company&#x2019;s common stock. The Biogen Collaboration Agreement became effective on &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 28, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the &#x201c;Effective Date&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the Biogen Collaboration Agreement, the Company granted Biogen co-exclusive licenses to develop and commercialize SAGE-217 products and SAGE-324 products (each, a &#x201c;Product Class&#x201d; and together, the &#x201c;Licensed Products&#x201d;) in the U.S., an exclusive license to develop and commercialize SAGE-217 products in all countries of the world other than the U.S. and the Shionogi Territory, and an exclusive license to develop and commercialize SAGE-324 products in all countries of the world other than the U.S. The Company refers to the territories outside the U.S. to which Biogen has rights under the Biogen Collaboration Agreement with respect to the applicable Licensed Product as the &#x201c;Biogen Territory&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the effectiveness of the Biogen Collaboration Agreement and the closing of the sale of shares to BIMA in December 2020, the Company received $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion in consideration, comprised of an upfront payment of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;875.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million purchase price for &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,241,473&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; newly issued shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;). As a result of the purchase of the Biogen Shares, Biogen has become a related party of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is eligible to receive additional payments of up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion if certain regulatory and commercial milestones are achieved. The potential future milestone payments for SAGE-217 products include up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;475.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified regulatory and commercial milestones, including milestones totaling $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the first commercial sale of zuranolone for the treatment of MDD and PPD, and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified net sales milestones. The potential future milestone payments for SAGE-324 products include up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;520.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified regulatory and commercial milestones and up to $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified net sales milestones. The Company is also eligible to receive tiered royalties on net sales of SAGE-217 products and SAGE-324 products in the Biogen Territory at percentage rates ranging from the high teens to low twenties.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may never receive any milestone payments or any royalty payments under the Biogen Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development and commercialization activities in the U.S. are conducted pursuant to plans agreed to by the Company and Biogen and overseen by a joint steering committee that will consist at all times of an equal number of representatives of each party. The Company and Biogen will share equally in the costs for development and commercialization, as well as the profits and losses upon FDA approval and commencement of product sales, in the U.S., subject to the Company&#x2019;s opt-out right described below. Biogen will be solely responsible for all development activities and costs related to any development and commercialization of SAGE-217 products and SAGE-324 products for the Biogen Territory, and the Company will receive royalties on any sales in the Biogen Territory, as mentioned above. Biogen will be the principal and record sales of SAGE-217 products globally. The Company will be the principal and record sales of SAGE-324 products in the U.S. and Biogen will be the principal and record sales of SAGE-324 products in the Biogen Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will supply API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to support development and commercialization activities. Biogen has the right to assume manufacturing responsibilities for API for the Biogen Territory at any time during the term of the agreement and will, within a reasonable period of time after the Effective Date, assume manufacturing responsibility for bulk drug product for the Biogen Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unless terminated earlier, the Biogen Collaboration Agreement will continue on a Licensed Product-by-Licensed Product and country-by-country basis until the date on which (a) in any country in the Biogen Territory, the royalty term has expired for all Licensed Products in a Product Class in such country, and (b) for the U.S., the parties agree to permanently cease to commercialize all Licensed Products in a Product Class. Biogen also has the right to terminate the Biogen Collaboration Agreement for convenience in its entirety, on a Product Class-by-Product Class basis or as to a particular region, upon advance written notice. The Company has an opt-out right to convert the co-exclusive licenses in the U.S. to an exclusive license to Biogen on a Product Class-by-Product Class basis. Following the exercise of the opt-out right, the Company would no longer share equally in the profits and losses in the U.S. and would be entitled to receive certain royalty payments at percentage rates ranging from the high teens to low twenties and additional sales milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that the Biogen Collaboration Agreement and the Biogen Stock Purchase Agreement should be combined and treated as a single arrangement for accounting purposes as the agreements were entered into contemporaneously and in contemplation of one another. The Company determined that the combined agreements had elements that were within the scope of Topic 606 and Topic 808.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of the Effective Date, the Company identified the following promises in the Biogen Collaboration Agreement that were evaluated under the scope of Topic 606: delivery of (i) a co-exclusive license for SAGE-217 products in the U.S.; (ii) an exclusive license for SAGE-217 products in the Biogen Territory; (iii) a co-exclusive license for SAGE-324 products in the U.S.; (iv) an exclusive license for SAGE-324 products in the Biogen Territory; (v) the clinical manufacturing supply of API and bulk drug product for SAGE-217 products in the Biogen Territory; and (vi) the clinical manufacturing supply of API and bulk drug product for SAGE-324 products in the Biogen Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also evaluated whether certain options outlined within the Biogen Collaboration Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Biogen and therefore are not considered separate performance obligations within the Biogen Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the above promises and determined that the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. are reflective of a vendor-customer relationship and therefore represent performance obligations within the scope of Topic 606. The co-exclusive license for SAGE-217 products and SAGE-324 products in the U.S. are considered functional intellectual property and distinct from other promises under the contract. The exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory are considered functional licenses that are distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the licenses on its own or together with other readily available resources. As the co-exclusive licenses in the U.S. and the exclusive licenses in the Biogen Territory are delivered at the same time, they are considered one performance obligation at contract inception. The clinical manufacturing supply of API and bulk drug product for SAGE-217 products and SAGE-324 products for the Biogen Territory are considered distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the manufacturing services together with the licenses transferred by the Company at the inception of the agreement. Therefore, each represents a separate performance obligation within a contract with a customer under the scope of Topic 606 at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers the collaborative activities associated with the co-development, co-commercialization, and co-manufacturing of SAGE-217 products and SAGE-324 products in the U.S. to be separate units of account within the scope of Topic 808 as the Company and Biogen are both active participants in the development and commercialization activities and are exposed to significant risks and rewards that are dependent on the development and commercial success of the activities in the arrangement. The Company has determined that the supply of API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to Biogen will be classified as collaboration revenue &#x2013; related party in the condensed consolidated statements of operations and comprehensive loss. During the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; collaboration revenue &#x2013; related party was recognized related to the Biogen Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments to or reimbursements from Biogen related to the co-development, co-commercialization, and co-manufacturing activities and the agreement of the parties to share equally the cost of these activities will be accounted for as an increase to or reduction of research and development expenses or selling, general and administrative expenses, depending on the nature of the activity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023, the Company recorded a net reimbursement of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, for the amounts due from Biogen as a reduction of or an addition to the related operating expense categories in the condensed consolidated statement of operations and comprehensive loss. During the three months ended March 31, 2022, the Company recorded a net reimbursement of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the amounts due from Biogen as a reduction of the related operating expense categories in the condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023, the Company recorded a Collaboration Receivable &#x2013; Related Party of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the condensed consolidated balance sheet for the amounts due for the three months ended March 31, 2023. During the three months ended March 31, 2023&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company made &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; payments to Biogen and the Company received &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from Biogen for the amounts due for the three months ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes expenses related to the Biogen Collaboration Agreement that were incurred by the Company and the related reimbursement from Biogen or to Biogen, reflected by category of operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.701%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expenses related to the Biogen Collaboration Agreement&lt;br/&gt;&#160;&#160;&#160;incurred by Sage&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net reimbursement to (from) Biogen reflected in the&lt;br/&gt;&#160;&#160;&#160;condensed consolidated statements of operations and &lt;br/&gt;&#160;&#160;&#160;comprehensive loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net expenses related to the Biogen Collaboration &lt;br/&gt;&#160;&#160;&#160;Agreement in the condensed consolidated statements of &lt;br/&gt;&#160;&#160;&#160;operations and comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined the transaction price under Topic 606 at the inception of the Biogen Collaboration Agreement to be $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion, consisting of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;875.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million plus $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in excess proceeds from the equity investment under the Biogen Stock Purchase Agreement, when measured at fair value, plus future variable consideration for manufacturing supply of clinical API and bulk drug product for the Biogen Territory. The amount of variable consideration related to the future manufacturing services was not material. The Company determined that any variable consideration related to clinical development and regulatory milestones is deemed to be fully constrained and therefore excluded from the transaction price due to the high degree of uncertainty and risk associated with these potential payments, as the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company also determined that royalties and sales milestones relate solely to the licenses of intellectual property and are therefore excluded from the transaction price under the sales- or usage-based royalty exception of Topic 606. Revenue related to these royalties and sales milestones will only be recognized when the associated sales occur, and relevant thresholds are met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As noted above, the Company identified three performance obligations in the Biogen Collaboration Agreement: (i) the delivery of the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. and the exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory; (ii) the clinical manufacturing supply of API and bulk drug product for SAGE-217 products in the Biogen Territory; and (iii) the clinical manufacturing supply of the API and bulk drug product for SAGE-324 products in the Biogen Territory. The selling price of each performance obligation in the Biogen Collaboration Agreement was determined based on the Company&#x2019;s SSP with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the variable consideration related to the manufacturing obligations to the future clinical supply of SAGE-217 products and SAGE 324 products in the Biogen Territory and the remaining fixed consideration to the license obligation. The variable consideration related to the manufacturing obligations was not material. As such, the entirety of the $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion fixed consideration of the transaction price has been allocated to the transfer of the co-exclusive licenses for SAGE-217 products and SAGE-324 products in the U.S. and the exclusive licenses for SAGE-217 products and SAGE-324 products in the Biogen Territory. The Company recognizes revenue for the license performance obligations at a point in time, that is upon transfer of the licenses to Biogen. As control of these licenses was transferred on the Effective Date and Biogen could begin to use and benefit from the licenses, the Company recognized $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion of license revenue during the year ended December 31, 2020 under the Biogen Collaboration Agreement. The Company will recognize revenue for the clinical manufacturing supply obligations at a point in time, that is upon the delivery of the supply to Biogen.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for the Biogen Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;connection with the execution of the Biogen Collaboration Agreement, the Company and BIMA entered into the Biogen Stock Purchase Agreement. Pursuant to the Biogen Stock Purchase Agreement, the Company sold the Biogen&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to BIMA at a price of approximately $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104.14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, which represented a &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; percent premium over the 30-day volume-weighted average share price as of the last trading day prior to the date the Biogen Collaboration Agreement and Biogen Stock Purchase Agreement were executed in November 2020, for aggregate consideration of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The sale of the shares to BIMA closed on December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Biogen Stock Purchase Agreement includes certain standstill provisions, lock-up restrictions, and a voting agreement with respect to the Biogen Shares. Pursuant to the terms of the Biogen Stock Purchase Agreement, BIMA has agreed not to, and to cause its affiliates not to, directly or indirectly acquire the Company&#x2019;s securities, seek or propose a tender or exchange offer or merger between the Company and Biogen, solicit proxies or consents with respect to any matter, or undertake other specified actions, in each case subject to specified conditions. &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The standstill restrictions terminate on the earliest of (i) a specified regulatory milestone under the Biogen Collaboration Agreement, (ii) the date one year following the termination of the Biogen Collaboration Agreement and (iii) the seventh anniversary of the Effective Date. BIMA also agreed not to, and to cause its affiliates not to, sell or transfer any of the Biogen Shares for a period of eighteen months from the closing of the sale of the Biogen Shares, which period expired on June 30, 2022, and to limit sales and transfers of the Biogen Shares for an additional eighteen-month period, in each case subject to specified conditions and exceptions.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined the fair value of the common shares issued using an option pricing valuation model to take into consideration the holding period restrictions. The fair value of the Company&#x2019;s common stock was considered a Level 2 fair value measurement within the fair value hierarchy. The most significant assumptions within the model are the Company&#x2019;s stock price, the term of the restrictions and the stock price volatility, which is based upon a blend of historical and implied volatility of the Company&#x2019;s stock. Based on the fair value adjustments made by management, the fair value of the shares issued was determined to be $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;417.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which was $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million less than the proceeds received from BIMA for the issuance of the Company&#x2019;s common stock under the Biogen Stock Purchase Agreement. As such, the $232.5 million in excess proceeds has been included in the $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion transaction price of the Biogen Collaboration Agreement determined above.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <sage:UpFrontPayment
      contextRef="C_2204d339-5d64-45be-917c-4696379675ab"
      decimals="-5"
      id="F_38ba8ce1-509a-48de-afc9-b6a6c03a6881"
      unitRef="U_USD">90000000.0</sage:UpFrontPayment>
    <sage:CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable
      contextRef="C_afad7b91-c063-484c-8b27-af3fdd038f98"
      decimals="INF"
      id="F_988b2707-b627-42bb-a72a-48e3041a6d3c"
      unitRef="U_USD">485000000.0</sage:CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_1260202e-e0d1-44c6-91a1-7328082cd6ac"
      decimals="INF"
      id="F_366e2003-805d-4403-8fb9-c7f2cad2e359"
      unitRef="U_USD">70000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_9077cfbe-fe30-4100-87f2-a75b18e864fe"
      decimals="INF"
      id="F_47b4855b-a4f5-43be-9a02-9238c79f0516"
      unitRef="U_USD">30000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_b0558d4b-6d1c-4376-8c22-956a113e11fa"
      decimals="INF"
      id="F_9e18a29b-346d-41d2-8042-21f168dba8a8"
      unitRef="U_USD">385000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AveragePercentageOnTieredRoyalties
      contextRef="C_2204d339-5d64-45be-917c-4696379675ab"
      decimals="2"
      id="F_1501c989-1ee6-4a3d-8d93-8795138d2c8a"
      unitRef="U_pure">0.20</sage:AveragePercentageOnTieredRoyalties>
    <sage:UpFrontPayment
      contextRef="C_2204d339-5d64-45be-917c-4696379675ab"
      decimals="-5"
      id="F_531e1f69-2c30-4e63-8ee8-fe6e3029fc1f"
      unitRef="U_USD">90000000.0</sage:UpFrontPayment>
    <us-gaap:Revenues
      contextRef="C_a27e3064-3e8b-4d7c-97fd-d2f5bdd6bd44"
      decimals="-3"
      id="F_361c405a-7051-4d14-8245-4510ae6cb9ca"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_fe878ea5-22df-4ead-ab1d-48438facdfb4"
      decimals="-3"
      id="F_c07eef4c-f77d-4e34-a9a5-cd90d0ae59c8"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_94d81f85-dbf8-4abd-8cc2-b5a8a0cbec84"
      decimals="-5"
      id="F_7942b082-3d5b-4fc6-a3d4-f3139a91d417"
      unitRef="U_USD">90000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues
      contextRef="C_150eb2ee-5e12-4af8-9658-d633a3fc51a6"
      decimals="-5"
      id="F_c908e395-6f3f-4f82-9d83-49644f73ac68"
      unitRef="U_USD">90000000.0</us-gaap:Revenues>
    <sage:CollaborationAgreementEffectiveDate
      contextRef="C_4ea38295-87e6-4099-8ab6-a32ad999eac8"
      id="F_7420604d-86cf-418b-aafe-3794c1e76ff8">2020-12-28</sage:CollaborationAgreementEffectiveDate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4"
      decimals="-8"
      id="F_df67e45e-28a9-4640-bb74-8aa24bb80970"
      unitRef="U_USD">1500000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sage:UpFrontPayment
      contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4"
      decimals="-5"
      id="F_e10cddb5-778e-4e89-a071-6f8d7a457e1c"
      unitRef="U_USD">875000000.0</sage:UpFrontPayment>
    <sage:PurchasePriceForNewShareIssued
      contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4"
      decimals="-5"
      id="F_4e8e6d61-6333-4823-9de0-70e8184f4364"
      unitRef="U_USD">650000000.0</sage:PurchasePriceForNewShareIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4"
      decimals="INF"
      id="F_9c019db9-5564-49c3-ae46-3e96da1705e1"
      unitRef="U_shares">6241473</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sage:CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable
      contextRef="C_159c0b2e-4b20-4fe8-842e-d19291806674"
      decimals="INF"
      id="F_44114d58-bb44-4bb3-9bc6-e096aa74fe0e"
      unitRef="U_USD">1600000000</sage:CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_3bb6c209-64a4-4fa9-9e19-b14c178a0c67"
      decimals="INF"
      id="F_04c25bc1-a04b-4d05-ae02-f60cf62ac023"
      unitRef="U_USD">475000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_6f864b66-2233-436e-9a55-3a656e209f1c"
      decimals="-5"
      id="F_f80ee7a7-1045-4d91-879d-afdd60dd02cb"
      unitRef="U_USD">225000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_218b8633-84a1-4518-ac04-a09bb4743a05"
      decimals="INF"
      id="F_e92b9179-7809-4ab4-8c74-b33006611c4d"
      unitRef="U_USD">300000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_e166f395-27e9-4ed3-b61a-0efed3d9f77f"
      decimals="INF"
      id="F_dfbf2712-35cc-4035-8cff-a51a5938e89b"
      unitRef="U_USD">520000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones
      contextRef="C_699a6647-c36c-4a33-a3f4-ae8e7184b152"
      decimals="INF"
      id="F_33152f17-8006-412e-b155-717ebb212072"
      unitRef="U_USD">300000000.0</sage:AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones>
    <us-gaap:Revenues
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="INF"
      id="F_49ba9a56-fdfc-4330-863d-bc161574b91c"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07"
      decimals="INF"
      id="F_bd72a7fa-076c-40ca-a876-5aada297dd68"
      unitRef="U_USD">0</us-gaap:Revenues>
    <sage:ReimbursementReductionsOrAdditionToOperatingExpenses
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="-5"
      id="F_aa4416ae-9ef7-4c19-84e0-5187e621ca74"
      unitRef="U_USD">14200000</sage:ReimbursementReductionsOrAdditionToOperatingExpenses>
    <sage:ReimbursementReductionsOrAdditionToOperatingExpenses
      contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07"
      decimals="-5"
      id="F_22abd350-eb63-4c59-b0d4-ce986601b2c6"
      unitRef="U_USD">20000000.0</sage:ReimbursementReductionsOrAdditionToOperatingExpenses>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_b2aeaf62-e210-498e-b523-527707b39cfa"
      decimals="-5"
      id="F_7d1d7190-ce92-4533-9aa2-b61909b70e94"
      unitRef="U_USD">15000000.0</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <sage:PaymentsToRelatedParties
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="-6"
      id="F_4e271f16-f99b-4c2b-9911-2d30ad172f6d"
      unitRef="U_USD">0</sage:PaymentsToRelatedParties>
    <sage:ProceedsFromRelatedParties
      contextRef="C_0ac1b81a-4423-47d2-b61e-3baceb754609"
      decimals="-5"
      id="F_faefb30d-f18d-4a47-9238-dc3c3edbf241"
      unitRef="U_USD">12900000</sage:ProceedsFromRelatedParties>
    <sage:SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_90ed762a-f8df-4340-b9f5-8a6d1311132e">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes expenses related to the Biogen Collaboration Agreement that were incurred by the Company and the related reimbursement from Biogen or to Biogen, reflected by category of operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.701%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.064%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expenses related to the Biogen Collaboration Agreement&lt;br/&gt;&#160;&#160;&#160;incurred by Sage&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net reimbursement to (from) Biogen reflected in the&lt;br/&gt;&#160;&#160;&#160;condensed consolidated statements of operations and &lt;br/&gt;&#160;&#160;&#160;comprehensive loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net expenses related to the Biogen Collaboration &lt;br/&gt;&#160;&#160;&#160;Agreement in the condensed consolidated statements of &lt;br/&gt;&#160;&#160;&#160;operations and comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sage:SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="-3"
      id="F_aab5417d-ad30-4708-a3f2-786969a5d5fb"
      unitRef="U_USD">56136000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07"
      decimals="-3"
      id="F_32cee6c2-64d5-4fbc-9a0a-9e16ab23b684"
      unitRef="U_USD">48754000</us-gaap:OperatingCostsAndExpenses>
    <sage:ReimbursementReductionsToExpense
      contextRef="C_df2b4db8-ae1e-400c-96db-0a5ee962f62b"
      decimals="-3"
      id="F_96e1d71a-4a0c-4410-b48e-7558ded2c78d"
      unitRef="U_USD">17282000</sage:ReimbursementReductionsToExpense>
    <sage:ReimbursementReductionsToExpense
      contextRef="C_b379d84e-292f-4ec3-8309-f2e399adad4c"
      decimals="-3"
      id="F_9ae5f91a-dfa3-4e05-abfe-0e7135e50109"
      unitRef="U_USD">18514000</sage:ReimbursementReductionsToExpense>
    <sage:ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="-3"
      id="F_7816cb50-1b02-40d1-9152-4827dcc03db9"
      unitRef="U_USD">-3034000</sage:ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses>
    <sage:ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses
      contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07"
      decimals="-3"
      id="F_cadc95b2-699a-46bf-8904-8a1f3473c053"
      unitRef="U_USD">1474000</sage:ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses>
    <sage:ReimbursementReductionsToOperatingExpenses
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="-3"
      id="F_738b8de3-86c6-4ae7-9618-586d61809bdb"
      unitRef="U_USD">14248000</sage:ReimbursementReductionsToOperatingExpenses>
    <sage:ReimbursementReductionsToOperatingExpenses
      contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07"
      decimals="-3"
      id="F_b05b055f-3624-4aca-8532-62e218eb7191"
      unitRef="U_USD">19988000</sage:ReimbursementReductionsToOperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f"
      decimals="-3"
      id="F_f041b488-efb0-4f6b-8e6e-505c038c9b83"
      unitRef="U_USD">41888000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_859555c6-3449-4a1e-829a-27a34b936e07"
      decimals="-3"
      id="F_f7485ccf-1fc9-485d-be51-0e7bcafba4ba"
      unitRef="U_USD">28766000</us-gaap:OperatingExpenses>
    <sage:CollaborativeAgreementTransactionPrice
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-8"
      id="F_5b271029-03d5-4336-a12e-4f1a4427db44"
      unitRef="U_USD">1100000000</sage:CollaborativeAgreementTransactionPrice>
    <sage:UpFrontPayment
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-5"
      id="F_2c203be7-dd90-4eb1-bdc2-4e41a0150512"
      unitRef="U_USD">875000000.0</sage:UpFrontPayment>
    <sage:PremiumAmountOnEquityInvestment
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-5"
      id="F_89906e6d-0368-4e71-853c-3c01acbfe331"
      unitRef="U_USD">232500000</sage:PremiumAmountOnEquityInvestment>
    <us-gaap:Revenues
      contextRef="C_459be31a-3dad-4ea1-b9d7-709c9d0222d4"
      decimals="-8"
      id="F_dbe6b463-75fb-48cc-b020-8423066b0cf9"
      unitRef="U_USD">1100000000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_7cc6f749-3572-4a07-9837-a838d91c9606"
      decimals="-8"
      id="F_13bb1d5d-8668-48c1-95e6-a2e5bcf6498c"
      unitRef="U_USD">1100000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_04077a28-e57f-48bf-be52-866b6f516e9c"
      decimals="2"
      id="F_4340a50d-ef79-4743-b85a-efd86842d38a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">104.14</us-gaap:SaleOfStockPricePerShare>
    <sage:PremiumOnPerSharePricePercentage
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="2"
      id="F_9e31d6f9-8e9c-42c4-89de-4b99f5d2d999"
      unitRef="U_pure">0.40</sage:PremiumOnPerSharePricePercentage>
    <sage:PurchasePriceForNewShareIssued
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-5"
      id="F_829298c5-33de-4806-9f5b-f523e1686552"
      unitRef="U_USD">650000000.0</sage:PurchasePriceForNewShareIssued>
    <sage:StockPurchaseAgreementDescription
      contextRef="C_d08e78d2-6122-4a68-a2fa-efacb6e5afb6"
      id="F_0c38bb6a-fc7d-4ba9-8a6b-42bbd579226c">The standstill restrictions terminate on the earliest of (i) a specified regulatory milestone under the Biogen Collaboration Agreement, (ii) the date one year following the termination of the Biogen Collaboration Agreement and (iii) the seventh anniversary of the Effective Date. BIMA also agreed not to, and to cause its affiliates not to, sell or transfer any of the Biogen Shares for a period of eighteen months from the closing of the sale of the Biogen Shares, which period expired on June 30, 2022, and to limit sales and transfers of the Biogen Shares for an additional eighteen-month period, in each case subject to specified conditions and exceptions.</sage:StockPurchaseAgreementDescription>
    <us-gaap:StockIssued1
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-5"
      id="F_25d46547-2082-487e-90b0-08f35f658690"
      unitRef="U_USD">417500000</us-gaap:StockIssued1>
    <sage:PremiumAmountOnEquityInvestment
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-5"
      id="F_f44b825e-e752-471b-9d2c-c65fa427d0b1"
      unitRef="U_USD">232500000</sage:PremiumAmountOnEquityInvestment>
    <sage:CollaborativeAgreementTransactionPrice
      contextRef="C_e61c3f60-7b9d-42b4-83a0-57ead754c1c1"
      decimals="-8"
      id="F_5418a2cb-ca90-40d8-a4f4-17c28b448a7d"
      unitRef="U_USD">1100000000</sage:CollaborativeAgreementTransactionPrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_001cc99c-8c98-4bd5-9114-6b15ea35fb0c">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;7.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 2, 2014, the stockholders of the Company approved the 2014 Stock Option and Incentive Plan (the &#x201c;2014 Plan&#x201d;), which became effective immediately prior to the completion of the Company&#x2019;s IPO. The 2014 Plan provides for the grant of restricted stock awards, restricted stock units, incentive stock options and non-statutory stock options. The 2014 Plan replaced the Company&#x2019;s 2011 Stock Option and Grant Plan (the &#x201c;2011 Plan&#x201d;). The Company &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; longer grants stock options or other awards under its 2011 Plan, but any stock options outstanding under the 2011 Plan remain outstanding and effective in accordance with their terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2014 Plan provides for an annual increase, to be added on the first day of each year, by up to 4% of the Company&#x2019;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,380,365&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, representing &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Company&#x2019;s outstanding shares of common stock as of December 31, 2022, were added to the 2014 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 15, 2016, the Board of Directors of the Company (the &#x201c;Board&#x201d;) approved the 2016 Inducement Equity Plan (as amended and restated, the &#x201c;2016 Plan&#x201d;). The 2016 Plan provides for the grant of equity awards to individuals who have not previously been an employee or a non-employee director of the Company to induce them to accept employment and to provide them with a proprietary interest in the Company. On September 20, 2018, the Board amended the 2016 Plan to increase the total number of shares reserved for issuance by &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,200,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Terms &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of equity grants, including vesting requirements, are determined by the Board or the Compensation Committee of the Board, subject to the provisions of the applicable plan. Stock options granted by the Company that are not performance-based are considered time-based because they vest based on the continued service of the grantee with the Company during a specified period following grant. These awards, when granted to employees, generally vest ratably&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;over &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% vesting at the &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; anniversary. All stock option awards expire &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years after the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023, the total number of shares underlying outstanding awards under all equity plans was &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,793,166&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and the total number of shares available for future issuance under all equity plans was &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,616,709&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 16, 2022, the Company&#x2019;s stockholders approved an amendment to the amended 2014 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which had been previously approved by the Board, to add &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock to the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes activity relating to time-based restricted stock units and performance restricted stock units:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.084%;"/&gt;
        &lt;td style="width:1.534%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,415,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,153,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;138,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,409,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Time-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2021, the Company granted &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;268,119&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; time-based restricted stock units to certain employees of the Company that vest over &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In September 2022, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% vested on the one-year anniversary of the vesting start date and the remaining &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% vest ratably in &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;quarterly&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; increments over the remaining &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the three months ended March 31, 2023, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,494&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of these time-based restricted stock units vested, with a fair value of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on the date of vesting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2022, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; time-based restricted stock units vested.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023, the Company granted &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;330,617&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; time-based restricted stock units to certain employees and consultants of the Company. These time-based restricted stock units vest over &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% vesting at the one-year anniversary of the vesting start date and the remaining &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% will vest in equal installments on each anniversary of the vesting start date for the following &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; time-based restricted stock units.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;470,891&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; time-based restricted stock units were both outstanding and unvested, and the total unrecognized stock-based compensation expense related to these awards was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Performance restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023 and 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;822,718&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;415,565&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; performance restricted stock units, respectively, to its employees and consultants. The majority of the performance restricted stock units granted during the three months ended March 31, 2023 and 2022 vest upon the achievement of certain clinical and regulatory development milestones related to product candidates and certain commercial milestones. Certain performance restricted stock units granted in the three months ended March 31, 2023 vest upon the Company reaching specified measures of total stockholder return.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recognition of stock-based compensation expense associated with performance restricted stock units, except for those with milestones that are measures of total stockholder return, commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. Recognition of stock-based compensation associated with performance restricted stock units with milestones that are measures of total stockholder return commences on the grant date and is recorded independently of the vesting outcomes of the grants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for performance restricted stock units that were outstanding, except for those with milestones that are measures of total stockhholder return, the achievement of the milestones that had not been met was considered not probable, and therefore &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expense has been recognized related to these awards during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; milestone for outstanding performance restricted stock units was achieved. The fair value of the performance restricted stock units that vested upon achievement was $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the Company recognized stock-based compensation expense related to this milestone of $&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the performance restricted stock units that were granted during the year ended December 31, 2021 included this milestone as a vesting condition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; performance restricted stock units vested during the three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,938,965&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; performance restricted stock units were both outstanding and unvested, and the total unrecognized stock-based compensation expense related to these awards was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Option Rollforward&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes activity related to time-based and performance-based stock options:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.001%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.182%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.459%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.182%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Remaining Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,788,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;712,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,383,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,318,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023, the Company had unrecognized stock-based compensation expense related to its outstanding and unvested time-based stock option awards of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is expected to be recognized over the remaining weighted average vesting period of &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Performance-Based Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recognition of stock-based compensation expense associated with performance-based stock options commences when the performance condition is considered probable of achievement, using management&#x2019;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for performance-based stock option grants that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expense has been recognized related to these awards during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options to purchase shares of common stock that contain performance-based vesting criteria.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; milestones were achieved under performance-based stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of March 31, 2023, &lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; performance-based stock options were both outstanding and unvested, the total unrecognized stock-based compensation expense related to these awards was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the timing of recognition of this stock-based compensation expense is subject to judgment of the Company as to when the performance conditions are considered probable of being achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock-based compensation expense recognized during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.424%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock-based compensation expense by award type recognized during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.424%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For stock option awards, the fair value is estimated at the grant date using the Black-Scholes option-pricing model, taking into account the terms and conditions upon which stock options are granted. The fair value of the stock options is amortized on a straight-line basis for stock option awards to employees, non-employee directors and non-employee consultants over the requisite service period of the awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average grant date fair value per share of stock options granted under the Company&#x2019;s stock option plans during the three months ended March 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.93&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7a300dcf-c0cb-47b1-a0fc-9cd53edc84b6"
      decimals="INF"
      id="F_2aa3aad9-96d9-4651-a347-c3ed963d4327"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_f717451a-6a70-4aef-9347-14e48ca9154e"
      decimals="INF"
      id="F_03d7b47e-4045-4cc9-a269-74c9f25402e3"
      unitRef="U_shares">2380365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <sage:CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage
      contextRef="C_e7f34c5e-d698-4850-9998-3b9d55aa69dc"
      decimals="INF"
      id="F_b27931a9-e8ef-4441-a4ba-2890ad1f9adc"
      unitRef="U_pure">0.04</sage:CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_2d205233-d11d-421a-9604-3d24b788eaa7"
      decimals="INF"
      id="F_b56d7be0-9bd0-43eb-9327-0e23a6f66b6d"
      unitRef="U_shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_a4847a82-a8bb-4531-9cd4-63a35e0116e8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_ee76c540-63b2-44a9-af22-8b7f35a27ba7"
      decimals="INF"
      id="F_7b51c01c-2cba-413b-96a7-b0db328cc354"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_5942acff-294a-4c68-b2b2-61a24f9cbf24">P1Y</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_b0bc083d-2287-472c-afe6-18f3ed9ac9e9">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_b8fcb889-5df2-429e-96c2-9027aa43f69b"
      unitRef="U_shares">10793166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_565d202e-3bb5-4101-a291-f12dafc51a69"
      decimals="INF"
      id="F_7be6e008-514d-4862-9c6e-bce5bbc5bc69"
      unitRef="U_shares">7616709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_1781ce27-35bc-4e2c-9a64-0b8ce5fdfda1"
      decimals="INF"
      id="F_eb40fe10-cb8b-4759-aec0-30b0f4e910cf"
      unitRef="U_shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_a6bcac53-4515-487c-bb96-06a7641aaed1">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes activity relating to time-based restricted stock units and performance restricted stock units:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.084%;"/&gt;
        &lt;td style="width:1.534%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,415,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,153,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;138,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,409,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ad149366-134a-4672-9147-ddac23ada4ed"
      decimals="INF"
      id="F_029fc205-de64-4047-95e6-02191415cfae"
      unitRef="U_shares">1415481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ad149366-134a-4672-9147-ddac23ada4ed"
      decimals="2"
      id="F_00942f88-f84a-4796-85f1-d0c7580b4035"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">48.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="INF"
      id="F_74209132-53f4-4dfa-a4dc-353791637b71"
      unitRef="U_shares">1153335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="2"
      id="F_63e7dff4-104a-4ecb-bcd8-7bbda5da5adf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="INF"
      id="F_a71fc054-e5ea-4261-b0b6-0d6db5ac0073"
      unitRef="U_shares">138923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="2"
      id="F_4a7722b3-c5c8-48b3-b26f-d4ee0c067407"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">67.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="INF"
      id="F_3f13f9c0-509d-432e-a889-c9be7fd26f11"
      unitRef="U_shares">20037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="2"
      id="F_a3297cb8-b2e0-4381-b635-75c84683fa1d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">48.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f39072ec-f2ce-4670-be4f-b0f1f4bcf30f"
      decimals="INF"
      id="F_202c41ec-3446-46c1-9ad0-9414d75a213f"
      unitRef="U_shares">2409856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f39072ec-f2ce-4670-be4f-b0f1f4bcf30f"
      decimals="2"
      id="F_87b68229-f1a3-433a-9309-328ba143d120"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f"
      decimals="INF"
      id="F_8ee906b5-0d6f-4837-b500-6c0a3c1cecf3"
      unitRef="U_shares">268119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f"
      id="F_ffa33efb-9d59-46ed-a970-c5f17d165650">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_7bd63346-2edc-4d25-8792-a77d046eb774"
      decimals="2"
      id="F_da803c78-8eb2-4ed1-8ff0-f5fe19d289e4"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_7cfbb3fe-a778-45b0-a709-a4a4a1292a25"
      decimals="2"
      id="F_4cb01310-546b-483b-af9a-dd4140ba49b1"
      unitRef="U_pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency
      contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f"
      id="F_28d8b448-77c1-4cdf-894c-2d65966e9692">quarterly</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency>
    <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod
      contextRef="C_be15177a-d746-4e38-b283-8b06ad56dd5f"
      id="F_c048911c-c3f6-44f7-9b63-b2674d31b1e0">P3Y</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2"
      decimals="INF"
      id="F_83a7ce15-8f50-48fb-9886-415f8cb23c2c"
      unitRef="U_shares">14494</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2"
      decimals="-5"
      id="F_4161a683-39a7-41b7-8e3b-dee9cb45daad"
      unitRef="U_USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_34e9c797-7ce4-4b4b-b51e-18629a1f9429"
      decimals="INF"
      id="F_7e9219ec-4a73-43c3-b655-c75b6da7852f"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2"
      decimals="INF"
      id="F_00000868-6137-49f6-af06-84fa6a8a2bb0"
      unitRef="U_shares">330617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2"
      id="F_c57e853d-4ca5-41c5-9ec7-662b9b504326">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_fe000172-bb4d-4a08-9a7f-f806a292fa6c"
      decimals="2"
      id="F_8a6478ad-defc-4ee5-b5ef-25d7a80ebbd7"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_59e5900f-8174-4b14-bfc1-b7d19f8176e3"
      decimals="2"
      id="F_70c10bb2-1573-446c-9934-54a4fd280d73"
      unitRef="U_pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod
      contextRef="C_4fb4b0ef-5872-41db-8e6d-745edf401ea2"
      id="F_f0cb9f46-7d44-49e2-83bc-520cb1c621a1">P3Y</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_34e9c797-7ce4-4b4b-b51e-18629a1f9429"
      decimals="INF"
      id="F_cba5538b-3bd5-436f-9cdf-b676f22e27ac"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_1377c2db-8563-423b-b496-c6079553d1b6"
      decimals="INF"
      id="F_913f8f06-d2bf-4c39-9497-42f49cceb53c"
      unitRef="U_shares">470891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_1377c2db-8563-423b-b496-c6079553d1b6"
      decimals="-5"
      id="F_c1dacae7-e46f-48f2-9d4b-ef800c049970"
      unitRef="U_USD">19400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4eb33dd9-e498-40d6-b3ab-aed72488e0a1"
      decimals="INF"
      id="F_cd5b7c46-8333-4b2f-8286-0bf5ebe0b74a"
      unitRef="U_shares">822718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_b41ee00a-05a1-4445-a768-1bb17e0a6c84"
      decimals="INF"
      id="F_8c5afc0b-4c6c-4028-b13e-2ac569631ba3"
      unitRef="U_shares">415565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_263ee25c-c855-4e19-8a9f-8283bd620ab3"
      decimals="INF"
      id="F_3e89d211-ecce-4a43-9177-60ea6dc182b1"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c31a15fe-00ba-4870-b61b-89dd2a4980ce"
      decimals="INF"
      id="F_7fd6a5e0-3fbf-41f0-ba1f-fb3a88638e65"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <sage:NumberOfMilestonesAchieved
      contextRef="C_d9a17952-5137-4cb5-9321-ceda02cb88c1"
      decimals="INF"
      id="F_af01def5-118c-4892-bd4f-677ea27fc1e8"
      unitRef="U_Milestone">1</sage:NumberOfMilestonesAchieved>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_d9a17952-5137-4cb5-9321-ceda02cb88c1"
      decimals="-5"
      id="F_de8b507e-9401-434f-8b16-5a0affcfe2fb"
      unitRef="U_USD">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d9a17952-5137-4cb5-9321-ceda02cb88c1"
      decimals="-5"
      id="F_5e863747-4ff0-487e-9374-c573ded2eb0e"
      unitRef="U_USD">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sage:MilestonePerformanceRestrictedStockPercentage
      contextRef="C_0e328e10-72d6-410f-80ac-3d76258027a9"
      decimals="2"
      id="F_db4a3e08-1dad-40d6-89f5-51823e4a4e7a"
      unitRef="U_pure">0.27</sage:MilestonePerformanceRestrictedStockPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_b41ee00a-05a1-4445-a768-1bb17e0a6c84"
      decimals="-6"
      id="F_8d1933b6-1509-4c26-947f-3fa8c9493716"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ca2e20ac-ec64-49a3-90db-a61de00d3168"
      decimals="INF"
      id="F_7e5c4bb6-a515-4510-b4ad-f02681d3ac85"
      unitRef="U_shares">1938965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_ca2e20ac-ec64-49a3-90db-a61de00d3168"
      decimals="-5"
      id="F_7d089893-5ee8-4878-a3be-fb1ffa76ca26"
      unitRef="U_USD">87300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_6c251ffa-ca0c-4ca6-8c0d-a34dc1189e9b">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes activity related to time-based and performance-based stock options:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.001%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.182%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.459%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.182%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Remaining Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,788,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;712,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,383,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,318,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9558178b-ee96-4bb9-98b8-32cd20923e46"
      decimals="INF"
      id="F_12b964cd-8395-4ea3-b1fb-5e9fb20f30b6"
      unitRef="U_shares">7788350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9558178b-ee96-4bb9-98b8-32cd20923e46"
      decimals="2"
      id="F_2e6e9834-dd52-4487-8098-adb5d02d8dcd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">77.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_328aba2f-fb20-4a39-964e-4eee7f038c9f"
      id="F_c658c0e6-8357-4280-8068-0b7858c7fe3a">P6Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_9558178b-ee96-4bb9-98b8-32cd20923e46"
      decimals="-3"
      id="F_8b4d608a-5d7b-4cd4-99db-a6d400015582"
      unitRef="U_USD">7275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="INF"
      id="F_44186f04-452f-4bd6-8663-925d7c8c80c5"
      unitRef="U_shares">712041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="2"
      id="F_5a8a4252-394f-447e-abd0-371794cc865d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="INF"
      id="F_3b8cef42-e259-41a4-bb9a-3d8cea39560f"
      unitRef="U_shares">45908</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="2"
      id="F_c82db89c-5442-4111-985a-5289b496fd37"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="INF"
      id="F_8ec22779-b042-4896-9870-73fbcb32f61f"
      unitRef="U_shares">71173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="2"
      id="F_26b4854a-4f21-421e-b6e9-b7a1fae0b6cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">96.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="INF"
      id="F_c2660d69-9bb5-4e32-8197-e7e599a42f8a"
      unitRef="U_shares">8383310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="2"
      id="F_5cfb8127-187b-462f-bd69-807d05ec8bfd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">75.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      id="F_4fb01675-478f-4871-9934-56eacc55a67c">P6Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="-3"
      id="F_90226d77-ec64-425a-b882-5ff6031db6c4"
      unitRef="U_USD">12177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="INF"
      id="F_93532bd5-1136-4595-8b20-f9a76a167a40"
      unitRef="U_shares">5318637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="2"
      id="F_75b2147b-0252-45d2-b4bd-e496fdaefa1c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">84.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      id="F_dd76bb00-b28c-4d64-a3c1-9fb31a347d5c">P5Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="-3"
      id="F_6711c893-6469-46d4-95fe-2ae788813595"
      unitRef="U_USD">8365000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_78cc9303-1878-4bf1-bcb6-79233994a9c6"
      decimals="-5"
      id="F_c35046c2-afb4-4748-bebb-43cb56395d8a"
      unitRef="U_USD">68400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      id="F_b74f50c3-7540-48a2-b33b-59c06969ffe9">P3Y25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="-5"
      id="F_a9c8f2bf-f321-4d25-b948-a0b51238616a"
      unitRef="U_USD">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_378410ff-522b-42f9-9391-4818fc9692a8"
      decimals="-5"
      id="F_915f751d-b0d3-4900-ae32-264716b4db33"
      unitRef="U_USD">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_263ee25c-c855-4e19-8a9f-8283bd620ab3"
      decimals="INF"
      id="F_cb514f02-2d9e-46f6-9ba1-a5246494f336"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c31a15fe-00ba-4870-b61b-89dd2a4980ce"
      decimals="INF"
      id="F_0e247629-625f-42f9-bb73-800a02ecd361"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_fbb07196-2b75-47c6-80e5-725f729861d9"
      decimals="INF"
      id="F_5e92521d-3755-4572-8d46-0dfc72f052d6"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_d6308113-5edd-45dc-ae2f-49266a225055"
      decimals="INF"
      id="F_dfb6d028-5b2d-4985-aba3-0dcfbf2c6184"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <sage:NumberOfMilestonesAchieved
      contextRef="C_9c3096d1-dec2-4b13-9d67-bef02783497c"
      decimals="INF"
      id="F_b187c36b-8f90-45cb-9a16-f43795206f6e"
      unitRef="U_Milestone">0</sage:NumberOfMilestonesAchieved>
    <sage:NumberOfMilestonesAchieved
      contextRef="C_c1eaf741-1b2c-4c28-bfe7-5c8db9a38dfe"
      decimals="INF"
      id="F_b65376fb-82b0-4ed1-a537-857668380fae"
      unitRef="U_Milestone">0</sage:NumberOfMilestonesAchieved>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_ef9f0eeb-8bd0-48d2-8cef-1b949dcabefb"
      decimals="INF"
      id="F_afada9d5-d77b-4044-adba-73090b4863fc"
      unitRef="U_shares">650000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_ef9f0eeb-8bd0-48d2-8cef-1b949dcabefb"
      decimals="-5"
      id="F_b4e61b9e-b15c-4d45-8f88-75f3708f5938"
      unitRef="U_USD">8600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_528ce464-a3a3-4c7e-89e3-e6f15a6e0692">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock-based compensation expense recognized during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.424%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9010a77-202b-457f-a93d-645d7cf2ae6f"
      decimals="-3"
      id="F_bfd08d71-0ed0-432b-a7ca-03db0c58feec"
      unitRef="U_USD">8773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0a812fff-cfeb-4da1-8230-6cd1569cea05"
      decimals="-3"
      id="F_d304534b-58c4-4807-96c4-304eb2a459a3"
      unitRef="U_USD">8615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d9d6d818-4da5-4eb9-903b-f6a198d8f733"
      decimals="-3"
      id="F_0a795a44-50f0-4e40-bc60-8da58c175804"
      unitRef="U_USD">11265000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f9308d0f-6e5f-4493-9625-38e3eaaea53c"
      decimals="-3"
      id="F_d1f30d60-a47e-4ea5-803e-0aa6b960ba85"
      unitRef="U_USD">9938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_3047fd0c-5a92-4baf-b407-acacf774ee06"
      unitRef="U_USD">20038000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_00c80c60-367e-4cd0-8796-f641e6222547"
      unitRef="U_USD">18553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_f908417c-b6df-4cad-a017-c2c33cf32a85">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock-based compensation expense by award type recognized during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.424%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f338a222-b449-4bcc-a112-e91bc99cd864"
      decimals="-3"
      id="F_63087b24-a0ad-4e0b-889b-ff808ce42142"
      unitRef="U_USD">10015000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_378410ff-522b-42f9-9391-4818fc9692a8"
      decimals="-3"
      id="F_b3b44790-e180-4b35-9db1-70dd7e4d6daf"
      unitRef="U_USD">15465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a4476f1-f818-43ff-b2be-89e56448a77d"
      decimals="-3"
      id="F_f7d2c5cf-42f5-4d81-b346-c5b3262585fb"
      unitRef="U_USD">9553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_041cce77-afef-4aed-92c7-1df0dfbc91eb"
      decimals="-3"
      id="F_44f3a30c-640d-4011-87be-d1be4fdd2aaf"
      unitRef="U_USD">2803000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fbed26d2-cc37-4226-abd6-049e70ee76cc"
      decimals="-3"
      id="F_ddfed516-71e8-45ac-9dc7-5a4fb3a66a04"
      unitRef="U_USD">470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_053c255f-d2dc-471e-bb1d-70b5c18befc9"
      decimals="-3"
      id="F_bb1879fb-a0af-4a97-b4f8-c071daca0905"
      unitRef="U_USD">285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_06e06f79-dc1c-496b-b80f-49dbdcaa9146"
      unitRef="U_USD">20038000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_484a4fb3-1b76-49f0-b26b-a4be520f9c2e"
      unitRef="U_USD">18553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="2"
      id="F_93c96d9a-0ced-4e2b-9d3a-b73b4a58c6a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="2"
      id="F_24e5ac5d-4c95-425f-ae5c-74268e5086be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_6c5df69d-9666-4969-bf47-546df06a7a0d">&lt;div style="text-indent:0.0%;display:flex;margin-top:7.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;8.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows the calculation of basic and diluted net loss per share for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.424%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;146,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common stock outstanding&lt;br/&gt;&#160;&#160;&#160;&#x2014;basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,674,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,028,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of shares of common stock&lt;br/&gt;&#160;&#160;&#160;equivalents resulting from common stock&lt;br/&gt;&#160;&#160;&#160;options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common stock outstanding&lt;br/&gt;&#160;&#160;&#160;&#x2014;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,674,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,028,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes common stock equivalents outstanding that were excluded from the calculation of diluted net loss per share because including them would have been anti-dilutive as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.24%;"/&gt;
        &lt;td style="width:1.68%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.7%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.68%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.7%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,733,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,932,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;470,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;541,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,251,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,500,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options and restricted stock units that are outstanding and contain performance-based vesting criteria for which the performance conditions have not been met are excluded from the calculation of common stock equivalents outstanding.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_688602ce-4c27-462a-96ca-7cf01440b2ef">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows the calculation of basic and diluted net loss per share for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.424%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.181%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;146,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common stock outstanding&lt;br/&gt;&#160;&#160;&#160;&#x2014;basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,674,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,028,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of shares of common stock&lt;br/&gt;&#160;&#160;&#160;equivalents resulting from common stock&lt;br/&gt;&#160;&#160;&#160;options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common stock outstanding&lt;br/&gt;&#160;&#160;&#160;&#x2014;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,674,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,028,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="-3"
      id="F_d3c798e2-8538-4c4b-b3c2-534537a92f8a"
      unitRef="U_USD">-146828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="-3"
      id="F_307c0497-773e-4163-88f4-486606380874"
      unitRef="U_USD">-122055000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="0"
      id="F_dfb5b046-a7c0-4cce-b85a-7a9fd4bd8c23"
      unitRef="U_shares">59674127</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="0"
      id="F_2fdf3dc9-87a8-4a7c-ad96-ded0d4b43d77"
      unitRef="U_shares">59028858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="INF"
      id="F_ce8fa454-5305-4d72-b135-4601981ae103"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="INF"
      id="F_c37fdbc0-f4f8-471b-923f-9b81ed13aae3"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="0"
      id="F_380a4928-9e5f-4f36-b5b6-ed0d485c019c"
      unitRef="U_shares">59674127</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="0"
      id="F_90b34047-bcff-4f79-b370-2c9704907fa1"
      unitRef="U_shares">59028858</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="2"
      id="F_ad213076-113f-4700-aa8e-0477210b6ad6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="2"
      id="F_d47a81cd-a3b6-418b-826d-571ca8d2e838"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="2"
      id="F_0d212cdc-2bc5-4793-8e0f-7cff7340e090"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="2"
      id="F_6c0f64dc-8d59-4c1f-8750-32a0bb4ed6af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      id="F_8c0d6591-0ced-4eec-a528-4d0f4682809f">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes common stock equivalents outstanding that were excluded from the calculation of diluted net loss per share because including them would have been anti-dilutive as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.24%;"/&gt;
        &lt;td style="width:1.68%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.7%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.68%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.7%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,733,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,932,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;470,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;541,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,251,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,500,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_96f30eb5-acb2-4f40-a8d3-bcc1575d5f47"
      decimals="INF"
      id="F_c3b1ecab-257a-4bbd-af5d-9be1ca00834b"
      unitRef="U_shares">7733310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4abf962a-8014-45c8-8864-72250359e195"
      decimals="INF"
      id="F_f9bc0848-c7c8-48d7-af37-e3618bea41e1"
      unitRef="U_shares">6932438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a2ae6c1e-1913-47c9-8778-3d00309c407f"
      decimals="INF"
      id="F_9b6f891f-a6d4-49b7-9de9-3243531847c8"
      unitRef="U_shares">470891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a954ef97-2d5d-474e-85f1-993cfd4ef26c"
      decimals="INF"
      id="F_b99f40fd-c1f7-488f-88ef-2afef7a7b99e"
      unitRef="U_shares">541913</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_414c6759-f1c6-41b9-b865-55fecfa38284"
      decimals="INF"
      id="F_8c6c3785-99a9-4613-bbe0-3e959857de27"
      unitRef="U_shares">46846</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b7010b40-0dcd-4f49-8b91-0d384171fed0"
      decimals="INF"
      id="F_f10409d2-8764-4eaf-a785-0627626ff126"
      unitRef="U_shares">26323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_43b0053b-716b-4f02-839f-ad6443d25548"
      decimals="INF"
      id="F_36e487ce-c857-41b0-9457-0ecdd33854ad"
      unitRef="U_shares">8251047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c188b130-04d4-4adb-80ea-ddd9b3454d75"
      decimals="INF"
      id="F_c3246cbd-0a16-4a8e-a42d-ef76e8904328"
      unitRef="U_shares">7500674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4EI^+6_'0?=T1]Q\]R%-10U$#&7WT11B:\ 6$J-T5"EL9G$23*5.3W7$S74
M4=:\YSHKQ#%;A7[DCY)[;!9!S9L@-=*S&G'3VN>N2A0<A'V70H_SCC2V0AK.
MLX(?<U84QOX0N\W*]R:@]\Q&7D)M![EO13HFKM@/DU&M&YLE"0VF=FA/;\3-
M;XYI!HI#8OVLV;8P6C1.YK$5E!@R$4%/?,3-?+MJ_<0L6WAMI'.L1A-[C?;<
M1]W<UV;#$_CHF,KB:"S0+68$>_%40: ]Y5$WY5V*LLRUD3:M[DU%99*"5RD
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ME0#\?\68/-RH%W3G=LO_ %!+ P04    " "E.J)6@?$(E6P&   O&P  &
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M<VAE970W+GAM;)U:;7/;-A+^*QBWTTMF%-ERWNLD,W+<M.DTB2<^MS-W<Q]
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M#7XNXS+D?VBPH-.>"S]8T>._4D 2VPX4'T\7*]6BG)UH=:V>E(TT*VU6HG#
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M6)<)']+OZ5]?^NJRZT;8X2-1IP*<T!553\]/__->&YP]6 EFI-PR:EYM-3I
M0Z=\$%G.JO<,P_:F2VJ^=]JMZB 0P"4+W@"X2T^@=#[D%/ $Z1%(<*6:7\&-
MTO<+6FH\23O@8#L0<%8C$ !03X<_% LZ(*GW:-F0WJI:*>/23@C$P'X)B=YZ
MPVI+D@ >"X0WN*P%/0RZ"R$#_0RQE1,K@3*#IW5Z@R$/< 'TW$<N#QNG=;5E
M?\K<+F$3 !$JI(#RFVH%=O;K0. G!%.:1[98'H45 I/Z\\:VC79>^%?IWT8S
M[+YBORBFB:U+U9*-XLA4#?NR7=T"B6%[()48DB"/<R*QJ);C4#66[.80](X$
M)+>I#L_@V.Z@(6/, L<><#*G:9\@/H;,= -V$H/0(/]3N$&540JGYP7A@:=(
M",$YK<8!\$4[:6QS!GXO6FX ?14)^35N,) F*. XXQN#>-R"!+2[4WO; 30_
M+KUI#!Q6DXD0NK)Q^P=Z+Q"L!T09"S+ 8AC%N2 8C^[V*C_']_$<U_$<XH)*
M&X(X_T&36J$Q&[2K RD"B9 F$#AV7M6LT<F4ZM9 Z(ZHGE6?/+'_.S!"6W*A
M/^^'0 ]C%SZ$X0+J'KDL%-P@R;E11;IMU6==Z;@Y(JT\!&\]XSQL0-74:@4Y
MDT@H4@GV5MLH"/"\EO.V1BU-FX(:7)+428Z"7,7=#ZWCG?"(0<P><OZP[1RF
M3M_H;A3<])<>88)<CF3FTR**?423*+0=P2KH+X.0['9C:HX#KG[ZY?V[TZ?_
M7@'G&[TU=52$!E0 T@:MMI4FZB'==T +<"L#Z#X(%JJ__&5 =(3 4Q>X'#V$
MYA[LU6$WD>B A#(2JZ ETW!$4K=6.0@M0:9(PL5:-$".UO9B#_E8H'UHIY8D
M@V"?D((D1"A4!K@ -I@X!&X?A$8SA8(=V"@\9Y-+E+!0CACLQA[A1+4-.^O[
MA_KO1AVB;7UCVQOD'6B62-OL7HL#'%H$V0&/SNAZ"CL %/(.2!+\'6T(EBP[
MINE*&RS05%4/(T43S+R:XLO&P(XN1+L%H#,P1%Z3\\#U[Q*+@,A>Y!NLHP.H
MOGPV8V<2;G0\%$88"K51 3T;=8ANV!0#PF0N@'+N$#PJEI!^AA@5'_?@E%W0
M]26D""N#-+,WVFTP?J:]%BB&(.B&))9"+LJG*\R'32VK+1(:]F\51Y!^F)(B
M1X</@6>3@S;(DUPMO.@SP[/+UJS9G)IT^'W9U6C)B2H [@;.9D=_F"CA))XU
M)#YG0+#,,"8%Y<.QAT!R+>$+?,I@Q(&_CP-]%HG]='9-J(%<J#5$%F+8X+0I
M#:LQ&FK5LM4+R8(RRM&S0')(A=  'CE"DI-#9&$P'OT:RQPZQ2"NF RL[5')
M$5;^$Z+8"FQ\2Z86TCE?C:".+B5I0LK&4J!46XQ@&IV2KL%L)4R_15CX%1;X
M)#U$"=;-HLS8L_AMW]6A'06Z#XKCJR0BF7Z#37(-F4V)881#:%5CS#9U&9<<
M!2"U<L_J*%OB_$E5W4A1! !9P;&M*_1JSA%\[NQMJYMUE)+>61 .C]C>*N00
MRE>KL[+)?=7YQD* A=M:]KJ1,8DMJ+;;[=A1P(H>A$V7GA5ZRN@G(D]9,-*%
MS.'$"&4>F(G(<0<%3"@,.SUPX,2X(I^#FX^0BK0YXGU61)6_CLTZ10DE;\AM
MP?)&HW1"6BH($2=3 A+C$Q$!5I$]$;C;ZN>B2'M#AI'QG940O"S(!B#?SDC4
MS*I$,B(7/N<,V0O>''D?]\]Y@;:68B/X;VV!8C%5")#9] R4$_&3$1"X 9+*
M__[TP\?OKJ]_"K$$)F2J!SF]X00*G_W^W252F=.CBW-PRX&382-,&T!K =46
MG>Y:07*IV6[ PO\8.TWK6 0(AQJ2#K6T+M7'_-CW6*M*UC.:D:E>I<6@A$!U
MUH%%><K)#@DL.@T0<GG,(-U4NZC&'OX&6O=J)_+6MK8F@PE*!OD,&UVL%H#'
M:;$E@:P 4H$$0=C>0(9PH\5NW8EUH@1Q@\\.L /[R6370$$2I &_"M97[9$*
M,A+Z)<O KM%&DHFYL@WI$I$A%/@NKZ]B?>]GVT,P]\WY-XLH4(385>DJKZB1
MH0'U "0N#*"0O^B/,8MQ+)._9\)'/@"3WVC]J3R06W'4:@^?_<J(_&$V!EK@
MI'PT.-LBG8#L6PJ/UA8"-X0:0Q,@OY*VBW8+JI=VDE&PC7)ZU5)X+V8'_;B(
M"?W.IH).@;Z6GK1X((UY/\#3H>[+R29ZG3TT6"S%,.E( Y>I*A4"G$-(+'&<
MN442QM5,ERR3]C4('9(AXUV&M5"7#YB*_"M$WP^Z]R^J1^9QA:G!8%:[POP^
M\H^EJ!QI^!*>GCY^B($38TY+86TB!(4%*<7&@G6M<T>*(1S&2"5GX DRW CP
MYG'4S7EP00/OC20JXR, &X6VE-E')+2/<Q('(<6^R?PVX%'V>!OJ,@[[C"RI
M#2=_H.0SDDSR0!&S=K7Q1!;\*K(F&A?,V!T'$I.@4ZB(04PO%??<1V!&C_]#
M^G)<)X^ABMU0M)N,$N$=J!MPX 1Z57E+0KB3_"5N>X +C(:<C(1Y;R-)X:0\
MH[D@CPXJ)23;W+KEOYINS-M1:07!R!HFH^M!@0&=[]'BII@V2"S9\^6]U&^/
MIB ]%%/AC_OLC39,0&M5;Q*>2,6&ZMPUD3Q3/PYS13:.D)?*_(@*!9 8B+4W
ML"]XZU\U==+C*;/*Q+&B4Q:,+2$0YRH!Q.(@)^(+#QEEA!RH0<T@LO14,4.A
MCIZ08U#EV>Q.>,?QF32.-J;'HFFQ(\41<<M2#",M1:XY8&5+6(@SA)TA,4YX
M(?SL0)4VA*CE\H>])>$;[)I/2 8TI,?>CJ[09NQ383%9W2A#Z>"L1I'-318G
M:KH0F=:(<YS%< H3A('I#<'++DB32=1G= 7ZGHV<& TQO_Z _7U$L2J[7"X@
M9C[6#+E;7<H!6U8T;@)D6.]Y6WU$S!XC"%*C>:T0 8^1":'IO<5"AV[FC?XQ
M<$C3$*T4%(K<"J%_$.5]6E%N7FB^> F*0 ^XPTE-4]@R3]8S^'T:;/_ X6P,
M^-YW8BG0) 8]526E<^$R/NF32(J^46TRN6H2?\-:":'SD">8(L3X@"T-Q_8A
MZ1;S$8I%G,HNT%J-^ 2GI=*)VZ)S4:WYG9&H59]JUM&VY&ABV: 3!23A8!7%
M-;NP(A,8)#ADD5X'(HC?!6S<9SWTK:KU5'.\S<[$!G3@/D4P.E./91[.G#^D
MZ>]7=T#'9#6P_VCY!EBPY* /3-\44&8DCS@.=-,MVHQP#@JYEI *<0)[(&K*
M!)09L*]XALC?Y9Z>RK]YVD?\"1L?#&6H(@MY(%846#>Y(DV%*M7:3L=TF+9.
M*=3U=9JSH!H3NS?PS/ +=^K/Z*,I(A(U%-9"]U&QA3MCWX0C2+83"^%+/=S*
M,,<<@%BHNU>*=E:]F]1>$%DT:8>6Q_#"SQ1Y:,A BEY3@(?B[$/F0D&.#-!1
MZED;4Z<E!#HMV"PLJ)*#/<68 Q&:J^X%VT.R=:LYLACTMN<*+O"_TVL[8+T\
MU*!"<I[*&(5[3^58*>; R6L9':J-J\<M2D^M?7D^#(D59?]B_CCRVH)1L,3N
M,M-"XI$UWM-BMC&')!3E*(N=-A".PY;1%P&@L1-L2_L&3H!Z/_Y>P@ )?G ;
MF6G+1A00R&>]*_J;H[0.]D]*#30JIZE"O+A9%(9@1,&#H\J\4>EB@Z)LQW;
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M^_VT6_VU>(A[V5+$D1>%MQ>%+D5OAL4>XA&SKX .*;!7"J"^LBRNR/=X:UI
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ML4+5HJTW)XX0^>086GB9#AT"YCGT)E2<JE#X/X$D(N4_,:M+M0$T!5@OEVI
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M-T_/GRZ*]RD"7^5&^Q5-'&$/E"X27HS5?2 \=D+UA]CV$9F/K!&F4X(=XB:
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M!F@#;>I.37RG-)=RVI'*DR@YB9.T1 [:$5<%B#QTNB6[*#B."62WRK?BV.U
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M9BC)$;75+?Y%'O'&9/G(50GI3D+>Q?,8FX.ZP$*H9D;!3 2W;1)\DU[^S(F
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MA4JFJG0#H'^FM5T;;H+FORHN_@)02P,$%     @ I3JB5@M,MNZ\ @  W@4
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL?53+;MLP$+S[*Q9J4"2
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M=F%.KQXJNX'6UU*:9F 3M._H[!]02P,$%     @ I3JB5K$D;GBF!   L P
M !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULO5=+;^,V$+[K5PS<H$@
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MT$Z:T-S"N^JUB5PE75+NK:;3BO3L_(;R_ED9 [>HX;[D&N'H@2\$FN-I9,F
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M_=H'X[)SY=Z[<OVMK9ZX0&D-_/GBUK[R/6AN?_?MK6G/J_J/LO JJ+C#9#?
MMN06UDCUC,^Y:%U%+K6J]W7%@5Y88,Y;@U!)A]'A8DU#JA4%E)1EDD :2RY2
MQ392W!?*S_9*%VC5.)8&)N$D3<,TB6$<GJ8L'*;9X [ITJMR1[V+12LKBL)P
M$H?9:0*C81*>)NG@NFZ$^DXF.Z&F)5LT J$17(+K)RHB-@Y3E@ZRD(V2,!Y.
MR-XHCEV)PKZ:BG9F%?7MRD]DEYA6VFYL]5_[H7_>S;H7\>Z/@5Q?5>2@P"6I
MQB<3JA?=3>%N8U7C)]]"69JC?EG2CPMJ)T#G2Z7L=N,,]+]"\Q]02P,$%
M  @ I3JB5BYK36K- P  ,1$  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&ULK5C;;N,V$/T50ET4NT WNOB>V@:22$4#-&F0-.W#8A]H:6P3D4@M2=D;
MH!_?H:0H5J(H:Y1YB$AQSAGRS)CD:+X7\D%M 33YGJ5<+9RMUOFIZZIX"QE5
M)R('CB-K(3.JL2LWKLHET*0$9:D;>-[8S2CCSG)>OKN1R[DH=,HXW$BBBBRC
M\O$<4K%?.+[S].*6;;;:O'"7\YQNX [T?7XCL><V+ G+@"LF.)&P7CAG_FGD
M>P906OS-8*\.VL0L927$@^E<)@O',S."%&)M*"@^=G !:6J8<![?:E*G\6F
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MK@WY=H_+VL]7M,'!GY?&T-X("?J)G?\!4$L#!!0    ( *4ZHE:;5,84A0<
M (!"   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;,V<;6_;-A#'OPKA
M%=L*=+'X(-KJ$@--LFX!FB%HVNY%L1>,3<="]>!*LM,"^_"C9%4T;9J1DC.@
M-XD?CG_Q3G?23R?*IP]I]B5?2%F@;W&4Y&>#15$L7P^'^70A8Y&?I$N9J&_F
M:1:+0KW-[H?Y,I-B5@V*HR'Q/#Z,19@,)J?59S?9Y#1=%5&8R)L,Y:LX%MGW
M<QFE#V<#//CQP?OP?E&4'PPGITMQ+V]E\7%YDZEWPT9E%L8RR<,T09F<GPW>
MX-<7G)<#*HM/H7S(MUZCTI6[-/U2OKF:G0V\<D8RDM.BE!#JWUI>R"@JE=0\
MOM:B@V:;Y<#MUS_4WU;.*V?N1"XOTNB?<%8LS@;C 9K)N5A%Q?OTX2]9.^27
M>M,TRJN_Z*&V]09HNLJ+-*X'JQG$8;+Y+[[5@=@:@-F! :0>0-H.H/4 6CFZ
MF5GEUJ4HQ.0T2Q]05EHKM?)%%9MJM/(F3,K=>%MDZMM0C2LF;T68H4\B6DET
M+46^RJ3:1T6.?D.WFQV+TCFZ2..E2+[_DJ,+D2_0'U]7X5I$E9U(9NA:9%]D
M(>XBB6[E=)6%12AS].NE^BR,7BJIC[>7Z-<7+]$+%";HPR)=Y6I8?CHLE /E
M-(;3>K+GF\F2 Y-5&SI!%+]"Q"/4,OS"/?Q23IOAQ!P^5&%K8D>:V)%*CSX:
MNU?H39[+.ASO0G$71IL@U#&=(96Q[\O89&%R7UG]G299\\&YR,,<?7ZG-H"N
M"AGG_]J"LYD-L\^FK/?7^5),Y=E %70NL[4<3'[^"7/O=UNH@,2,P-$F<-2E
M/OF0%B)"TS*7I,XEF\L;'5[IE$>D]02/ V\\/AVNMYVQF'&,QWYC9DR3-=-D
M+:89Z^S.F^RVS74CYF]-(B#4([MSW3?#V M& ;-/UF\FZS\AIE6JM?; MTP-
M$XSYC@L6.S(J?;"[P!L7N-.%[7JZ2I:K(G^%WLFUC!!&GZ]E?"<S:UTX5;O6
M!9"8$8!1$X!1KPXH(\C  8D9@1LW@1L#'5#&^ZG+&:;!3H;;S X?4()FFL'1
M:S1HYX#-[+ #V-.XX#VQ1HFS1MVR77,-2LT,PA8SX5[5:3T=J. !J9G!T]"$
MG6C1H59KH>TD)BQ@NZGNWMY3_=$L@]O 3.OZK=4>Q02+G9,3L*8:W 9KGG<4
MPA;88:-@--KUHB/M8(T[V,T[UVDBO]>7'NCM2EU/N(\_3K7.)02D9OJN.0GS
M?AU_0 D+2LT,GF8L["21+L>?4;MSK=7.<;+55(/=6./(<?0?>BHNNS?:>6\"
MJ9DATD2%@WZ5@I/P.@</2,UL7VB8(VZ8:U\*M="CI6"U.UP*1",7<5+)Y"HI
M9):(LO6GIGR19LLT$X5$Y^EC1WZW<.>VR3'@B6QUG'K6<H+M.1V#U(@F-0)*
M:F2?P$;^B.\V0RQFF(P(&Q](><UIQ,UI[5+>>2)P7Y.YM]]YYP*IF='2/$C\
M?E4&*%!"J9G!TT!)W)VWKI7!VU7&OIFS,C3"$3?"?3RY/4%_IFM5'N7=BNV[
M#LY\!^UW0:F9,=!L2,;]RG=0:H12,X.GJ9&T:<2US_?];AJAA._=AK#8J2O[
M &-[PE,-:M0-:BT2_AGG ??&N^Y:*#4S5!H4:;]Z<Q04+Z'4S.!IO*1M>G.M
MZX):&G2VNK#8.>MBZSZBF^BJNNAR,>#6Z[RW@-1,[S4@4M:O5 ?E12@U,WB:
M%^E3[I=:W;;<[@P"[N\F^3$0CFJ$HZ (1_?9C/ 1Q=ZN5_MVU&<L.'!!3S7#
MT18,=X2+&O=F.R?I,2"/:LBC_8(\"@IY4&IF\#3DT:?<;;6Z;;E;:JOP8W3K
MF(9 UJ9;UWXYRGXKSEKA%CM7A3--8LS=LJLK/(YE-@W5S&_$4F;.VG4+=DT_
M*#73?<U2K%^M.@;:JH-2,X.GP8Z!MNK8?@^.$[:_],IB1C$^<"^2;:T3<W?J
MW)G^C).9>[N=]^DQB(MIXF+]ZM QT X=E)H9/(UW#!3OV#ZV60O"8N8H" UW
MS UWNZWK+N< 4'Z#4C/CH/F-]8O?&"B_0:F9P=/\QJ#XC>WS&PO&;#?9CX%O
MOL8W'Q3??,N=5&\<!+MW7&UVE&).#RPGUOCF=[OC"G]V<T^@:[9"J9GATKCG
M]POW?%#<@U(S@Z=QSX=Z(,#?1SA+J;LW]U1W- _ZH \.^)9%<M92M]BY2GWK
MT0%W+VS#KS(KPGDX%85*U72.+N4RS</"7<&@B 6E9D9!(Y;?KU5U/NBJ.B@U
M,WB:^/PVJ^K:I[QER9Q/QGL/FMC,.#Z4\)K+?/?"NE8)_YPS&RB'0:F9P=(<
MYO=KB9T/NL0.2LU\HDE3'P>E/FZA.4M=6,T.U@77S,=;M.RN5TDX#9=JVBW7
M5;A%.S^ =0R.XYKC>+\XCH-R')2:&3S-<1RT;<<M2^>XY_MX-]UMST)0XGL'
M\EV#&F_1N'/F^S-. NYM=]ZSQVC><8V(O%_-.PY*EE!J9O"VGFL%;=[5:OS1
MLK#8V<IBN/7S .5O,UR+[#Y,<A3)N1KHG8Q4=++-SQULWA3ILOK%@+NT*-*X
M>KF08B:STD!]/T_3XL>;\D<(FA^=F/P/4$L#!!0    ( *4ZHE;^ZC<!4@0
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M \3[%2'\J2,-U#\G3/X%4$L#!!0    ( *4ZHE845OCC2@8  "XF   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;+U:76_;-A3]*X17#"VPQ.*'OCK'
M0)N@78$&".JE>QCVP-AT+$02/8I.NOWZ4;(J6B)%1XOJ/,26=>_5X15Y[KF4
M9D]</!0;QB3XEJ5Y<3'92+E].YT6RPW+:''.MRQ79]9<9%2J0W$_+;:"T57E
ME*53Y'G!-*-)/IG/JM]NQ'S&=S)-<G8C0+'+,BK^><]2_G0Q@9/O/WQ)[C>R
M_&$ZGVWI/5LP>;N]$>IHVD19)1G+BX3G0+#UQ>0=?'M)_-*ALOB:L*?BX#LH
MAW+'^4-Y\&EU,?%*1"QE2UF&H.KCD5VR-"TC*1Q_UT$GS35+Q\/OWZ-_J :O
M!G-'"W;)TS^2E=Q<3*()6+$UW:7R"W_ZC=4#J@ N>5I4_\%3;>M-P')72)[5
MS@I!EN3[3_JM3L2! R0]#JAV0,]UP+4#K@:Z1U8-ZXI*.I\)_@1$::VBE5^J
MW%3>:C1)7M[&A13J;*+\Y/P#303X2M,= ]>,%CO!U#V2!3@#B_V-!7P-/@I>
M%. V5_,D3?YE*_!1S8\"T'P%/JLSK"B-KJEX8)+>I0PLV'(G$IFH$Z^OU&])
M^D8%O%U<@=>OWH!7(,G![QN^*U2 8C:5:A@EF.FRAOQ^#QGU0%87.@<8_@*0
MA[#%_=+M?L66C3MJNT]5\IH,HB:#J(J'>^(MU,I:[=2H50[>/:JQEBDX4POL
MK*#M7/SY6;F"3Y)EQ5^V8>^O0^S7*=?SVV)+E^QBHA9LP<0CF\Q__@D&WJ^V
M)(P4K)42W*0$NZ+/WV5<R&JB7/)"VH:Z]P\J_Y)I'N<QBJ 7S*:/AX,PS2!4
M!.5YC5T+'VGP$2<^^WRVX=S'\0\ D-CO@+38$#L^O\'G#\.W7V4V@+YQ\3/?
M#W$'HL4*>LCO26/0P R<,#5WV) %QC5CA#T4=:"99A!Z<1CWI#!LL(5.;+?G
MBW/PD3\RD9>$UEJ&URR[8\*Z!)U!AR[!D8*UQA\UXX].Q$K1F"D9*5@K)7&3
MDOB%K!0;<Q%AXOO=!6^:82^$!XNN!0]ZNA1[(]%2':B%-$(=F.ZK_<]DPP-A
M <<BL3I2BY\0)'%W0!8S@@+4DW==P*&S&![AL=JY/2M0$'6)S&*GZ"Z&L >>
M+J;074TK*KOD8LL%E0R\YTHU.4G,'6_HDATK6GOTNE1#<B(B@TY1,#@M(T5K
MIT4K!.B6",?)#)I%'P6QYQLT8=IA/_)@W#-OM3J ;GDP@,Y,$1!TI:#-I@>A
MU@C0+1*&4%1HD5"19Y" Q0S[N$=H05W-H;,R'J.HR'*K0PR]+CK3#OOD4-&V
MX>G*"MVE]5,NE="B96-.TV%<Y0P\>%&.%*W=".H"CKQ3M8(CU>ZZ%_P12@!I
M)8#<2N X5R&SLH<!AMTVQF(&483#GEX!';3P;@7P?*I"9I4/NRA=)FV 6@,@
MMP88P%1UI$Y+2+H@+580XAX-BW2Y1N[6VDU4R.R50S\TN-YB!E&(2-2#3E=-
MY*Z:M93*,B:6B6*J&[IEPLE/[H"#%^)(T=K#UQ49!:?B)V?I'YR6D:*UTZ)E
M '++@&?PDUG6 ^2C;H-B,\.JA>R9MKKZ(W?U'T!/%B70!?DC>G"DI0)R2X4A
M3&8VVF?0,XJ"S0KU*"ZL:SEV-^-N(L-F QX@8FQNV<PPA#T3 NN*BMT5M:NW
M!A":._+0E3M6M'8>=-W&I]I[QZ-NOH\5K9V6@^WW%^^_F^4?>K%J:+H3V&*'
MU5]/)<9:)^"!6_#]-(!--:!:+]A%:K,*>SH;K!4#=BN&(S1@]L[0B^*X6QAL
M=AC#H$=N85W1L;O'W@L:IN[V.EFJCJMZ$G?%MKQ(I)L&1BW@8T5K9T$7<!R>
MB@9&?0 P5K1V6K1LP&[9\ P:,.4"]%%D/(:SF06P;_9J+8#=6N#(XC(+NQ6<
MS:P7'-$"@+@%0+6TKG=YLDRVJK(^\P&2.^C0"316M'8*M,P@\$3KBHRJ.L:*
MUDZ+5AW$O5MP?%T1<PL !A#&W:)ELX,$D9Z]5Z(5 !FX7]#_A-M6X;LZUF*$
M>YYKD(.'\*-) &(I[F%HH+1) *]O\Y5H#4!>H@%JY]9+"H'G^\:]MMA!;#Z$
MGQZ\S%.^275-Q7WYMDW*ULK1.P]5'+%_.6E_(/FV>K_GCDO)L^KKAM$5$Z6!
M.K_F7'X_*%\9:EX1F_\'4$L#!!0    ( *4ZHE;^<H@7VP8  #HK   9
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;+V::V_;-A2&_PKA%4,+-+%XTZ5+
M#+0)V@5(@*!>NP_#/B@V$PO5Q9/DI-NO'R6KHD0=LKXH^9+X<GCT\K7$YQQ*
M9T]9_JU8"5&B[TF<%N>355FNWTVGQ6(EDK XS=8BE=_<9WD2EO)M_C MUKD(
ME_6@))X2QW&G21BED]E9_=EM/CO+-F4<I>(V1\4F2<+\WP\BSI[.)WCRXX//
MT<.JK#Z8SL[6X8.8B_++^C:7[Z9MEF64B+2(LA3EXOY\\AZ_N^"D&E!'?(W$
M4]%YC:JIW&79M^K-U?)\XE2*1"P6994BE/\>Q86(XRJ3U/%/DW32'K,:V'W]
M(_O'>O)R,G=A(2ZR^,]H6:[.)_X$+<5]N(G+S]G3[Z*9$*_R+;*XJ/^BIR;6
MF:#%IBBSI!DL%211NOT??F^,Z S S#" - /(K@-H,X#6$]TJJZ=U&9;A["S/
MGE!>1<MLU8O:FWJTG$V45C_CO,SEMY$<5\X^AE&.OH;Q1J ;$1:;7,C?J"S0
M"9IO?UB4W:-.T/MTB;ZD\H2)H__$$EUG12&**N8FS+^),KR+!9J+Q2:/RDA^
M<976(>@V*Z+Z9WM]*8.B^(T\P)?Y)7K]Z@UZA:(4_;'*-D68+HNS:2FG58F;
M+IHI?-A.@1BF((]\BBA^BXA#*##\PC[\4BS:X:0_?"K-;!TEK:.DSD<-^>;R
M2EMNI W2E/>/<JZ5)R?R@CLIPKXY?UW+H>BJ%$GQ-S3M[7$8?)SJ^GY7K,.%
M.)_("[@0^:.8S'[]!;O.;Y )(R7K64);2Z@M^^Q:R%.@7(4IP@0E65JNBK>=
MDPJ:^S:A6R>LEJ+'&:,.(\[9]+$[JV$8Q]2C?AO6T\M:O6Q_O8.S'I*]S<L[
M>DX(K4ZKGFH@BGD!AT7S5C2WBOXDY94BW]-G/I!". T\K"D>AM$@\'P*2W9;
MR>Y!DG>RVAV:2 G7A0-1G'&#U5ZKV[/JMEOJ#0[I^HP&NK)A6( I)QB6YK?2
M?*NTG:SS 5.X1S6!0!1V"'=@@4$K,+ +/)V?HD_9H\C3BC2]]?!&)'<B!]="
M:])]U\*1DO7FCQU%7.>% -$<:"17QLK6MZ53B."Q(=%D[)ZB/'!]'1) &,:$
M,,/JA17IL96:1W"B2:RM2[XN'(C"''L&W0K'V,[CPU#1).W9Z/@^X[IJ(,[G
M;F!8V;"B,K9C^2A<8 "Z\MS55V4HC'C,  RLX(SM=/Z)M4.^8M?G9& M@.O
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M6:&>65L6$JP3J8N:"DG?;5=;BDNAGDN[%%*?SR%]N&WGC"FU:G(5+$/88_E
MHT!K2JV:"@6T4$N)K<L'U2ENT%@^?< I5' *]7!Z1/DT/G8Z+(/H(VD]'?K
M7ZCP%P[ZK RCL&I*K9H*!:M02X -*P/EY8\P$3A9AH\1 9AS<J!:AN\N&^B#
MZ&I282C48ZB!.GDX_^WJZW T;OU$,42J>1[[X%ZHN!>.^JP;HVQJ2JV:"L6F
M4 M\K9\HX^/6!?2]=G2%%&8B/68>42B=\*OQ[9\A],Q?__4!LDB!+'+[?!%J
M%#M-J553H; 3Z==HC2^OY_WIGB_ZD+I:+KT%U^/E<<OKJ$Z5-1]]\"12/(GT
M/'GSYG'?.%2-UNK+GC5K?2 ?4LB']"N>!C@G[T%KL@^80PKFD![F3-R^NX*.
M/K36][ ^@!$I8$2G?=[.C3*?*;5J*A3S(?U:9TO0R=4J*T^-I*/OMJLMQ6](
MSV]=_R7 [[X):<R*T;5(4VK5O4X*$CVGQ^+PC&*?*;5J*A3V>?KU2^.LX]5?
MP:-A4_GH ^MJ7$&>IX>\XXC'JY/; 3=]\)NG^,W3\UMG[LEURYOS4.-F*'T
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MDSROUK_4"9[SXFO3[)O_ U!+ P04    " "E.J)6^,<$4QD$   ;$   &0
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M0<'H.F>$SC"RP"U-Q8:#/].0A!WV<[T]1!H 0X:WC#$ZQO@::1%O,1L""UX
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M.B#$AZYWT?P7H>PCU*@#Z?2#OI(L2"]9]+E^/@K/P#N%Z^CHNG\V"'JDGN6
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MYR?RWC*?*+XP[=F4*VSVS##&?AR$-L#]&>?J::(/*#O\X!]02P,$%     @
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M3*K!QMRF:O8$K@/4\S5C<K_0+VBFV?E_4$L#!!0    ( *4ZHE8M&HMB(0,
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MK-LUJ579'/Q9]U=@]@502P$"% ,4    " "E.J)6!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *4Z
MHE;'@/LY[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( *4ZHE:97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ I3JB5K?NP4C9
M!0  Y!X  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( *4ZHE86J&J/0P8  $$:   8              "
M@1P.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "E.J)6
M%6V8"PX#  "4"@  &               @(&5%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ I3JB5C;EC D"!0  PQ,  !@
M     ("!V1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M *4ZHE:!\0B5; 8  "\;   8              " @1$=  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "E.J)6<LPHCBD'   /,P  &
M            @(&S(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ I3JB5G3R'>;&#@  'B4  !@              ("!$BL  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *4ZHE9< #\[KQP  ,9A
M   8              " @0XZ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "E.J)6DPQUG.P*  ":(P  &               @('S5@
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ I3JB5NH0-R6U
M @  W@4  !D              ("!%6(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "E.J)6X560--P*  !O'P  &0
M@($!90  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *4Z
MHE9:?&4.BAD  $-B   9              " @11P  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ I3JB5K=89!D;#0  ERT  !D
M         ("!U8D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "E.J)6*AA_D=\#   N"0  &0              @($GEP  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *4ZHE8L*72K-R4  "]_
M   9              " @3V;  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ I3JB5L OZ6<\!P  MA@  !D              ("!J\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "E.J)6"TRV
M[KP"  #>!0  &0              @($>R   >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( *4ZHE; 7\?3*@,  %,'   9
M  " @1'+  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MI3JB5K$D;GBF!   L P  !D              ("!<LX  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "E.J)6(8B<J,@#   6"0  &0
M            @(%/TP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( *4ZHE8N:TUJS0,  #$1   9              " @4[7  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ I3JB5G\1;7%E @
MO04  !D              ("!4ML  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "E.J)6FU3&%(4'  " 0@  &0              @('N
MW0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *4ZHE;^
MZC<!4@0  %H8   9              " @:KE  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ I3JB5A16^.-*!@  +B8  !D
M     ("!,^H  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *4ZHE:SU0E@ @<  &E%   9              "
M@3D% 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ I3JB
M5EMRVBW##@  ?+X  !D              ("!<@P! 'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "E.J)6^,<$4QD$   ;$   &0
M        @(%L&P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( *4ZHE805&0>8!   #CG   9              " @;P? 0!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ I3JB5@++X)EE P  [ H
M !D              ("!4S ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "E.J)6@#XX><L$  !]%@  &0              @('O,P$
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *4ZHE9&2/]+
M-@,  .T+   9              " @?$X 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ I3JB5H86&W1M P  PPX  !D
M ("!7CP! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "E
M.J)6U>&\9V\#  "V"@  &0              @($"0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( *4ZHE8LGACWAP,  -D.   9
M          " @:A# 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#
M%     @ I3JB5BT:BV(A P  #A(   T              ( !9D<! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "E.J)6EXJ[',     3 @  "P
M    @ &R2@$ 7W)E;',O+G)E;'-02P$"% ,4    " "E.J)6\C=%JW(#  "Q
M&@  #P              @ &;2P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ I3JB5D"[PRV' 0  O!<  !H              ( !.D\! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ I3JB5O]Y:I*? 0  '1@
M !,              ( !^5 ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ "\ +P# #   R5(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>204</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Leases, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingencies</Role>
      <ShortName>Leases, Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Nature of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements - Summary of Company's Cash Equivalents and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Company's Cash Equivalents and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Fair Value Measurements - Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Leases, Commitments and Contingencies - Operating Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases, Commitments and Contingencies - Operating Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail</Role>
      <ShortName>Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Leases, Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Leases, Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail</Role>
      <ShortName>Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Time Based and Performance Based Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Relating to Time Based and Performance Based Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sage-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss Per Share - Summary of Anti-Dilutive Common Stock Equivalents Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Anti-Dilutive Common Stock Equivalents Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsReceivableRelatedPartiesCurrent in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. sage-20230331.htm 427, 431, 3789</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. sage-20230331.htm 1440, 1444, 1650, 1654, 1712, 1716, 1957, 1961</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: sage:MarketableSecuritiesMaturityPeriod, us-gaap:LessorOperatingLeaseOptionToExtend -  sage-20230331.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="sage-20230331.htm">sage-20230331.htm</File>
    <File>sage-20230331.xsd</File>
    <File>sage-20230331_cal.xml</File>
    <File>sage-20230331_def.xml</File>
    <File>sage-20230331_lab.xml</File>
    <File>sage-20230331_pre.xml</File>
    <File>sage-ex10_1.htm</File>
    <File>sage-ex10_2.htm</File>
    <File>sage-ex31_1.htm</File>
    <File>sage-ex31_2.htm</File>
    <File>sage-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img93198881_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="552">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sage-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 552,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 204,
   "dts": {
    "calculationLink": {
     "local": [
      "sage-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sage-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sage-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sage-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sage-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sage-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 418,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://www.sagerx.com/20230331": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 11
   },
   "keyCustom": 48,
   "keyStandard": 199,
   "memberCustom": 40,
   "memberStandard": 26,
   "nsprefix": "sage",
   "nsuri": "http://www.sagerx.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Leases, Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingencies",
     "shortName": "Leases, Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_20237446-69f4-4551-93d5-fee5a4bf888c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Collaboration Agreements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_20237446-69f4-4551-93d5-fee5a4bf888c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sage:BusinessRisksAndUncertaintiesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sage:BusinessRisksAndUncertaintiesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sage:SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Collaboration Agreements (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sage:SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Nature of the Business - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail",
     "shortName": "Nature of the Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "sage:GoingConcernPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_23999eda-d8e5-4c17-ae2e-ed2f30bd77ac",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredRevenueAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_80624434-96c6-446e-ada9-fe739d3d9e5b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_80624434-96c6-446e-ada9-fe739d3d9e5b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Fair Value Measurements - Summary of Company's Cash Equivalents and Marketable Securities (Detail)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
     "shortName": "Fair Value Measurements - Summary of Company's Cash Equivalents and Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sage:FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Fair Value Measurements - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail",
     "shortName": "Fair Value Measurements - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Fair Value Measurements - Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position (Detail)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
     "shortName": "Fair Value Measurements - Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sage:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sage:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Leases, Commitments and Contingencies - Operating Leases - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
     "shortName": "Leases, Commitments and Contingencies - Operating Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
     "shortName": "Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_184f14a5-c851-40db-a3ad-edc0666d719c",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_9b20c727-7972-478a-9e8f-c96192d5a8c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sage:UpFrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Leases, Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Leases, Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_9b20c727-7972-478a-9e8f-c96192d5a8c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sage:UpFrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_a27e3064-3e8b-4d7c-97fd-d2f5bdd6bd44",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
     "shortName": "Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sage:SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_c9c37b9f-5e31-49a6-aa0b-e313b7a4ce7f",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_ad149366-134a-4672-9147-ddac23ada4ed",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
     "shortName": "Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_1a4476f1-f818-43ff-b2be-89e56448a77d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_565d202e-3bb5-4101-a291-f12dafc51a69",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Time Based and Performance Based Stock Options (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Summary of Activity Relating to Time Based and Performance Based Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_f338a222-b449-4bcc-a112-e91bc99cd864",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_c9010a77-202b-457f-a93d-645d7cf2ae6f",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_fbed26d2-cc37-4226-abd6-049e70ee76cc",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Net Loss Per Share - Summary of Anti-Dilutive Common Stock Equivalents Outstanding (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail",
     "shortName": "Net Loss Per Share - Summary of Anti-Dilutive Common Stock Equivalents Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sage:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sage:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_cd11ff6a-3076-4878-b379-411eea2932d1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_cd11ff6a-3076-4878-b379-411eea2932d1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Nature of the Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sage-20230331.htm",
      "contextRef": "C_43b0053b-716b-4f02-839f-ad6443d25548",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "verboseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sage_AccruedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued research and development costs, such as clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Costs",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCosts",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_AdditionalClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional clinical development milestone.",
        "label": "Additional Clinical Development Milestone [Member]"
       }
      }
     },
     "localname": "AdditionalClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments based on achievement of certain milestones.",
        "label": "Additional Milestone Payments Based On Achievement Of Certain Milestones",
        "verboseLabel": "Future milestone payments"
       }
      }
     },
     "localname": "AdditionalMilestonePaymentsBasedOnAchievementOfCertainMilestones",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_AdditionalPaymentsBasedOnAchievementOfCertainMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payments based on achievement of certain milestones.",
        "label": "Additional Payments Based On Achievement Of Certain Milestones",
        "terseLabel": "Expected milestone payments"
       }
      }
     },
     "localname": "AdditionalPaymentsBasedOnAchievementOfCertainMilestones",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_AreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office space in square feet.",
        "label": "Area Of Office Space",
        "verboseLabel": "Office space rent under operating lease"
       }
      }
     },
     "localname": "AreaOfOfficeSpace",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sage_AveragePercentageOnTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average percentage on tiered royalties.",
        "label": "Average Percentage On Tiered Royalties",
        "terseLabel": "Average percentage on tiered royalties"
       }
      }
     },
     "localname": "AveragePercentageOnTieredRoyalties",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sage_BiogenCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen Collaboration Agreement.",
        "label": "Biogen Collaboration Agreement [Member]",
        "terseLabel": "Biogen Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "BiogenCollaborationAgreementMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_BiogenStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen Stock Purchase Agreement member.",
        "label": "Biogen Stock Purchase Agreement [Member]",
        "terseLabel": "Biogen Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "BiogenStockPurchaseAgreementMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_BusinessRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business risks and uncertainties policy.",
        "label": "Business Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "BusinessRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sage_ClinicalDevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development and regulatory milestone.",
        "label": "Clinical Development And Regulatory Milestone [Member]",
        "terseLabel": "Clinical Development and Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "ClinicalDevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_ClinicalDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development milestones.",
        "label": "Clinical Development Milestones [Member]",
        "terseLabel": "Clinical Development [Member]"
       }
      }
     },
     "localname": "ClinicalDevelopmentMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_CollaborationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementAbstract",
     "nsuri": "http://www.sagerx.com/20230331",
     "xbrltype": "stringItemType"
    },
    "sage_CollaborationAgreementEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement efective date.",
        "label": "Collaboration Agreement Effective Date",
        "terseLabel": "Collaboration agreement effective date"
       }
      }
     },
     "localname": "CollaborationAgreementEffectiveDate",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "sage_CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement regulatory and commercial event based additional milestone payment receivable.",
        "label": "Collaboration Agreement Regulatory And Commercial Event Based Additional Milestone Payment Receivable",
        "terseLabel": "Additional milestone payment receivable"
       }
      }
     },
     "localname": "CollaborationAgreementRegulatoryAndCommercialEventBasedAdditionalMilestonePaymentReceivable",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreement transaction price, total.",
        "label": "Collaborative Agreement Transaction Price",
        "terseLabel": "Transaction price, total"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones [Member]"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage increase in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Common Stock Shares Outstanding Reserved For Issuance Increase Percentage",
        "terseLabel": "Percentage of increase on outstanding shares of Common stock"
       }
      }
     },
     "localname": "CommonStockSharesOutstandingReservedForIssuanceIncreasePercentage",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sage_ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes.",
        "label": "Convertible Notes [Member]",
        "terseLabel": "Convertible Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_CorporateBondsAndMunicipalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds and municipal securities.",
        "label": "Corporate Bonds And Municipal Securities [Member]",
        "terseLabel": "Corporate Bonds and Municipal Securities [Member]"
       }
      }
     },
     "localname": "CorporateBondsAndMunicipalSecuritiesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_CostOfSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales.",
        "label": "Cost Of Sales",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_CydexLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CyDex license agreement.",
        "label": "Cydex License Agreement [Member]",
        "terseLabel": "CyDex License Agreement [Member]"
       }
      }
     },
     "localname": "CydexLicenseAgreementMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_DebtInstrumentFairValueCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fair Value Carrying Value [Abstract]",
        "label": "Debt Instrument Fair Value Carrying Value [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueCarryingValueAbstract",
     "nsuri": "http://www.sagerx.com/20230331",
     "xbrltype": "stringItemType"
    },
    "sage_DebtInstrumentFairValueCarryingValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument fair value carrying value.",
        "label": "Debt Instrument Fair Value Carrying Value [Line Items]",
        "terseLabel": "Debt Instrument Fair Value Carrying Value [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueCarryingValueLineItems",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_DebtInstrumentFairValueCarryingValueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument fair value carrying value.",
        "label": "Debt Instrument Fair Value Carrying Value [Table]",
        "terseLabel": "Debt Instrument Fair Value Carrying Value [Table]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueCarryingValueTable",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis among Level 1, Level 2 and Level 3.",
        "label": "Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount",
        "terseLabel": "Transfers among the Level 1, Level 2 and Level 3 categories"
       }
      }
     },
     "localname": "FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_FirstAndSecondClinicalDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First and second clinical development milestones.",
        "label": "First And Second Clinical Development Milestones [Member]",
        "terseLabel": "First and Second Clinical Development Milestones [Member]"
       }
      }
     },
     "localname": "FirstAndSecondClinicalDevelopmentMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_FirstAndSecondRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First and second regulatory milestones.",
        "label": "First And Second Regulatory Milestones [Member]",
        "terseLabel": "First and Second Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "FirstAndSecondRegulatoryMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_FirstCommercialSaleOfZuranoloneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First commercial sale of Zuranolone.",
        "label": "First Commercial Sale of Zuranolone [Member]"
       }
      }
     },
     "localname": "FirstCommercialSaleOfZuranoloneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern.",
        "label": "Going Concern Policy [Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sage_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities current.",
        "label": "Increase Decrease In Operating Lease Liabilities Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities non current.",
        "label": "Increase Decrease In Operating Lease Liabilities Non Current",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "negatedLabel": "Right-of-use operating asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_IntangibleAssetRelatedToMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset related to milestone.",
        "label": "Intangible Asset Related To Milestone",
        "terseLabel": "Intangible asset related to milestone"
       }
      }
     },
     "localname": "IntangibleAssetRelatedToMilestone",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_InternationalCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International commercial paper.",
        "label": "International Commercial Paper [Member]",
        "terseLabel": "International Commercial Paper [Member]"
       }
      }
     },
     "localname": "InternationalCommercialPaperMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_InternationalCorporateBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International corporate bonds.",
        "label": "International Corporate Bonds [Member]",
        "terseLabel": "International Corporate Bonds [Member]"
       }
      }
     },
     "localname": "InternationalCorporateBondsMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_LeaseAssetDeRecognizedUponLeaseCancellation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease asset de-recognized upon lease cancellation.",
        "label": "Lease Asset De Recognized Upon Lease Cancellation",
        "terseLabel": "Lease asset de-recognized upon lease cancellation"
       }
      }
     },
     "localname": "LeaseAssetDeRecognizedUponLeaseCancellation",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_LessorOperatingLeaseRemainingLeaseTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor operating lease remaining lease rerms.",
        "label": "Lessor Operating Lease Remaining Lease Terms",
        "terseLabel": "Operating lease remaining lease terms"
       }
      }
     },
     "localname": "LessorOperatingLeaseRemainingLeaseTerms",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sage_LicenseAgreementMaximumTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement maximum term.",
        "label": "License Agreement Maximum Term",
        "terseLabel": "Licenses Expiration period, maximum"
       }
      }
     },
     "localname": "LicenseAgreementMaximumTerm",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sage_LicenseMaintenanceCostAnnual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance cost annual.",
        "label": "License Maintenance Cost Annual",
        "terseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "LicenseMaintenanceCostAnnual",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_LicenseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License one.",
        "label": "License One [Member]",
        "terseLabel": "Brexanolone [Member]"
       }
      }
     },
     "localname": "LicenseOneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_LicenseThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License three.",
        "label": "License Three [Member]",
        "terseLabel": "SAGE-217 [Member]"
       }
      }
     },
     "localname": "LicenseThreeMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_LicenseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License two.",
        "label": "License Two [Member]",
        "terseLabel": "SAGE-689 [Member]"
       }
      }
     },
     "localname": "LicenseTwoMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_MarketableSecuritiesHeldToMaturityFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities held to maturity fair value.",
        "label": "Marketable Securities Held To Maturity Fair Value",
        "terseLabel": "Marketable securities fair value held to maturity"
       }
      }
     },
     "localname": "MarketableSecuritiesHeldToMaturityFairValue",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_MarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities maturity period.",
        "label": "Marketable Securities Maturity Period",
        "terseLabel": "Marketable securities held, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesMaturityPeriod",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sage_MarketableSecuritiesRemainingContractualMaturities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining contractual period for marketable securities.",
        "label": "Marketable Securities Remaining Contractual Maturities",
        "terseLabel": "Marketable securities, remaining contractual maturities"
       }
      }
     },
     "localname": "MarketableSecuritiesRemainingContractualMaturities",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sage_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone one.",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_MilestoneOutstandingLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone outstanding license agreement.",
        "label": "Milestone Outstanding License Agreement",
        "terseLabel": "Milestone outstanding"
       }
      }
     },
     "localname": "MilestoneOutstandingLicenseAgreement",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_MilestonePaymentsRelatedToIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments related to intangible assets.",
        "label": "Milestone Payments Related To Intangible Assets",
        "terseLabel": "Milestone payments related to intangible assets"
       }
      }
     },
     "localname": "MilestonePaymentsRelatedToIntangibleAssets",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_MilestonePerformanceRestrictedStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone performance restricted stock percentage.",
        "label": "Milestone Performance Restricted Stock Percentage",
        "terseLabel": "Milestone performance restricted stock percentage"
       }
      }
     },
     "localname": "MilestonePerformanceRestrictedStockPercentage",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "sage_NatureOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business.",
        "label": "Nature Of Business [Line Items]",
        "terseLabel": "Nature Of Business [Line Items]"
       }
      }
     },
     "localname": "NatureOfBusinessLineItems",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_NatureOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business.",
        "label": "Nature Of Business [Table]",
        "terseLabel": "Nature Of Business [Table]"
       }
      }
     },
     "localname": "NatureOfBusinessTable",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of marketable securities not part of remaining contractual maturities of one year or less.",
        "label": "Number Of Marketable Securities Not Part Of Remaining Contractual Maturities Of One Year Or Less",
        "terseLabel": "Number of marketable securities not part of remaining contractual maturities of one year or less"
       }
      }
     },
     "localname": "NumberOfMarketableSecuritiesNotPartOfRemainingContractualMaturitiesOfOneYearOrLess",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sage_NumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones achieved.",
        "label": "Number Of Milestones Achieved",
        "terseLabel": "Milestones achieved"
       }
      }
     },
     "localname": "NumberOfMilestonesAchieved",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sage_OperatingLeaseFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease five member.",
        "label": "Operating Lease Five [Member]",
        "terseLabel": "Operating Lease Five [Member]"
       }
      }
     },
     "localname": "OperatingLeaseFiveMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_OperatingLeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease one.",
        "label": "Operating Lease One [Member]",
        "terseLabel": "Operating Lease One [Member]"
       }
      }
     },
     "localname": "OperatingLeaseOneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_OperatingLeaseThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease three.",
        "label": "Operating Lease Three [Member]",
        "terseLabel": "Operating Lease Three [Member]"
       }
      }
     },
     "localname": "OperatingLeaseThreeMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_OperatingLeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease two.",
        "label": "Operating Lease Two [Member]",
        "terseLabel": "Operating Lease Two [Member]"
       }
      }
     },
     "localname": "OperatingLeaseTwoMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_PaymentForClinicalDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for clinical development milestones.",
        "label": "Payment For Clinical Development Milestones",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "PaymentForClinicalDevelopmentMilestones",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_PaymentsToRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to related parties.",
        "label": "Payments To Related Parties",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentsToRelatedParties",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage on net sales.",
        "label": "Percentage Of Net Sales Required For Royalty Entitlement",
        "terseLabel": "Percentage of net sales paid as royalties"
       }
      }
     },
     "localname": "PercentageOfNetSalesRequiredForRoyaltyEntitlement",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sage_PerformanceBasedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-based stock options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance-Based Stock Options [Member]"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionsMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_PerformanceRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance restricted stock units.",
        "label": "Performance Restricted Stock Units [Member]",
        "terseLabel": "Performance Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "PerformanceRestrictedStockUnitsMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_PremiumAmountOnEquityInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium amount on equity investment.",
        "label": "Premium Amount On Equity Investment",
        "terseLabel": "Premium amount on equity investment"
       }
      }
     },
     "localname": "PremiumAmountOnEquityInvestment",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_PremiumOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on marketable securities.",
        "label": "Premium On Marketable Securities",
        "negatedLabel": "Premium on marketable securities"
       }
      }
     },
     "localname": "PremiumOnMarketableSecurities",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_PremiumOnPerSharePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on per share price, percentage.",
        "label": "Premium On Per Share Price Percentage",
        "terseLabel": "Premium on per share price"
       }
      }
     },
     "localname": "PremiumOnPerSharePricePercentage",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sage_ProceedsFromIssuanceOrSaleOfEquityAndNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of equity and debt.",
        "label": "Proceeds From Issuance Or Sale Of Equity And Notes",
        "terseLabel": "Net proceeds from sale of equity and notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAndNotes",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_ProceedsFromRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from related parties.",
        "label": "Proceeds From Related Parties",
        "terseLabel": "Proceeds from related parties"
       }
      }
     },
     "localname": "ProceedsFromRelatedParties",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_PurchasePriceForNewShareIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price for new share issued.",
        "label": "Purchase Price For New Share Issued",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "PurchasePriceForNewShareIssued",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_RegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and commercial milestones member.",
        "label": "Regulatory And Commercial Milestones [Member]",
        "terseLabel": "Regulatory and Commercial Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_RegulatoryAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and sales milestones.",
        "label": "Regulatory And Sales Milestones [Member]",
        "terseLabel": "Regulatory and Sales Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryAndSalesMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_ReimbursementFromCollaborationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement from collaboration.",
        "label": "Reimbursement From Collaboration [Abstract]",
        "terseLabel": "Net reimbursement to (from) Biogen reflected in the condensed consolidated statements of operations and comprehensive loss:"
       }
      }
     },
     "localname": "ReimbursementFromCollaborationAbstract",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_ReimbursementReductionsOrAdditionToOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement reductions or addition to operating expenses.",
        "label": "Reimbursement Reductions Or Addition To Operating Expenses",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "ReimbursementReductionsOrAdditionToOperatingExpenses",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_ReimbursementReductionsToExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reimbursement from collaboration agreement.",
        "label": "Reimbursement Reductions To Expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ReimbursementReductionsToExpense",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_ReimbursementReductionsToOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement reductions to operating expenses.",
        "label": "Reimbursement Reductions To Operating Expenses",
        "negatedLabel": "Operating expenses",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "ReimbursementReductionsToOperatingExpenses",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement reductions to selling, general and administrative expenses.",
        "label": "Reimbursement Reductions To Selling General And Administrative Expenses",
        "negatedLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "ReimbursementReductionsToSellingGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense related to milestone payment.",
        "label": "Research And Development Expense Related To Milestone Payment",
        "terseLabel": "Research and development expense related to milestone expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseRelatedToMilestonePayment",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sage_SAGE324Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SAGE-324 member.",
        "label": "S A G E324 [Member]",
        "terseLabel": "SAGE-324 [Member]"
       }
      }
     },
     "localname": "SAGE324Member",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones.",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones [Member]"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_ScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario one.",
        "label": "Scenario One [Member]",
        "terseLabel": "After The Effective Date [Member]"
       }
      }
     },
     "localname": "ScenarioOneMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_ScenarioTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario two.",
        "label": "Scenario Two [Member]",
        "terseLabel": "After The First Sale [Member]"
       }
      }
     },
     "localname": "ScenarioTwoMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award award cliff vesting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period",
        "terseLabel": "Share based compensation, vest period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by share based payment award award remaining vesting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Award Remaining Vesting Period",
        "terseLabel": "Share based compensation remaining vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingPeriod",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award award vesting period month and year.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Month And Year",
        "terseLabel": "Restricted stock units vesting period month and year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMonthAndYear",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share based payment award, vesting frequency.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Frequency",
        "terseLabel": "Share based compensation vesting frequency"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingFrequency",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_ShionogiCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shionogi collaboration agreement.",
        "label": "Shionogi Collaboration Agreement [Member]",
        "terseLabel": "Shionogi Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "ShionogiCollaborationAgreementMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_StockPurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement description.",
        "label": "Stock Purchase Agreement Description",
        "terseLabel": "Biogen stock purchase agreement, description"
       }
      }
     },
     "localname": "StockPurchaseAgreementDescription",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of operating expenses category related to collaboration agreement.",
        "label": "Summary Of Operating Expenses Category Related To Collaboration Agreement Table [Text Block]",
        "terseLabel": "Summary of Operating Expenses Category Related to Collaboration Agreement"
       }
      }
     },
     "localname": "SummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementTableTextBlock",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sage_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sage_ThirdAndFourthClinicalDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third and fourth clinical development milestones.",
        "label": "Third And Fourth Clinical Development Milestones [Member]",
        "terseLabel": "Third and Fourth Clinical Development Milestones [Member]"
       }
      }
     },
     "localname": "ThirdAndFourthClinicalDevelopmentMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_ThirdAndFourthRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third and fourth regulatory milestones.",
        "label": "Third And Fourth Regulatory Milestones [Member]",
        "terseLabel": "Third and Fourth Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "ThirdAndFourthRegulatoryMilestonesMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_TimeBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time based restricted stock units.",
        "label": "Time Based Restricted Stock Units [Member]",
        "terseLabel": "Time Based Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "TimeBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_TwoThousandElevenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eleven stock option plan.",
        "label": "Two Thousand Eleven Stock Option Plan [Member]",
        "terseLabel": "2011 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandElevenStockOptionPlanMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen employee stock purchase plan.",
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_TwoThousandFourteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen stock option plan.",
        "label": "Two Thousand Fourteen Stock Option Plan [Member]",
        "terseLabel": "2014 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFourteenStockOptionPlanMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_TwoThousandSixteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Option Plan.",
        "label": "Two Thousand Sixteen Stock Option Plan [Member]",
        "terseLabel": "2016 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenStockOptionPlanMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_UniversityOfCaliforniaLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California license agreements.",
        "label": "University Of California License Agreements [Member]",
        "terseLabel": "University of California License Agreements [Member]"
       }
      }
     },
     "localname": "UniversityOfCaliforniaLicenseAgreementsMember",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sage_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up front payment.",
        "label": "Up Front Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.sagerx.com/20230331",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r265",
      "r368",
      "r381",
      "r405",
      "r406",
      "r418",
      "r423",
      "r431",
      "r467",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r265",
      "r368",
      "r381",
      "r405",
      "r406",
      "r418",
      "r423",
      "r431",
      "r467",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r190",
      "r369",
      "r419",
      "r430",
      "r462",
      "r463",
      "r468",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r190",
      "r369",
      "r419",
      "r430",
      "r462",
      "r463",
      "r468",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r258",
      "r265",
      "r293",
      "r294",
      "r295",
      "r344",
      "r368",
      "r381",
      "r405",
      "r406",
      "r418",
      "r423",
      "r431",
      "r461",
      "r467",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r258",
      "r265",
      "r293",
      "r294",
      "r295",
      "r344",
      "r368",
      "r381",
      "r405",
      "r406",
      "r418",
      "r423",
      "r431",
      "r461",
      "r467",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r156",
      "r266",
      "r439",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r156",
      "r266",
      "r439",
      "r440",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r455",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r429"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r92",
      "r93",
      "r118",
      "r448"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable Related Parties Current",
        "terseLabel": "Collaboration receivable - related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r119",
      "r377",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r83",
      "r337",
      "r382",
      "r383",
      "r442",
      "r443",
      "r444",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r449",
      "r450",
      "r451",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r77",
      "r78",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive common stock equivalents"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r36",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of assets",
        "totalLabel": "Asset Impairment Charges, Total"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r101",
      "r114",
      "r142",
      "r181",
      "r184",
      "r188",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r313",
      "r317",
      "r326",
      "r429",
      "r465",
      "r466",
      "r502"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r110",
      "r120",
      "r142",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r313",
      "r317",
      "r326",
      "r429",
      "r465",
      "r466",
      "r502"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r193",
      "r207"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r50",
      "r207"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r112",
      "r408"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r32",
      "r38",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r91"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates Of Deposit [Member]",
        "terseLabel": "U.S. Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r142",
      "r159",
      "r160",
      "r164",
      "r166",
      "r173",
      "r174",
      "r200",
      "r229",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r326",
      "r407",
      "r438",
      "r446",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement Accounting Policy",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r308",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "U.S. Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r96",
      "r105"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r223",
      "r224",
      "r404",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Leases, Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r449",
      "r450",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r429"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value per share; 120,000,000 shares authorized at March 31, 2023 and December 31, 2022; 59,765,034 and 59,512,158 shares issued at March 31, 2023 and December 31, 2022; 59,762,001 and 59,509,125 shares outstanding at March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r126",
      "r128",
      "r134",
      "r373",
      "r379"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Net Of Tax [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "U.S. Corporate Bonds [Member]"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r194",
      "r207",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Credit Losses",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r199",
      "r211",
      "r415"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer",
        "terseLabel": "Greater than 12 months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r199",
      "r211"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss",
        "negatedLabel": "Greater than 12 months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r199",
      "r211",
      "r415"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months",
        "terseLabel": "Less than 12 months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r199",
      "r211"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss",
        "negatedLabel": "Less than 12 months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Summary of Gross Unrealized Gains and Losses of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r197",
      "r208",
      "r415"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r198",
      "r209"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss",
        "negatedTotalLabel": "Unrealized Losses",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue Additions",
        "terseLabel": "Net income from up-front"
       }
      }
     },
     "localname": "DeferredRevenueAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r36",
      "r62"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r270",
      "r298",
      "r299",
      "r301",
      "r305",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r135",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r157",
      "r159",
      "r164",
      "r165",
      "r166",
      "r170",
      "r321",
      "r322",
      "r374",
      "r380",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "Net loss per share\u2014basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r135",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r159",
      "r164",
      "r165",
      "r166",
      "r170",
      "r321",
      "r322",
      "r374",
      "r380",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Net loss per share\u2014diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Employee-related",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Total unrecognized stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period of unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options [Member]",
        "verboseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r66",
      "r108",
      "r129",
      "r130",
      "r131",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r172",
      "r201",
      "r246",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r320",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r337",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesByInvestmentObjectiveAxis": {
     "auth_ref": [
      "r258",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by investment objective.",
        "label": "Equity Securities By Investment Objective [Axis]",
        "terseLabel": "Investment Objective"
       }
      }
     },
     "localname": "EquitySecuritiesByInvestmentObjectiveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesInvestmentObjectiveMember": {
     "auth_ref": [
      "r258",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Objective of investment.",
        "label": "Equity Securities Investment Objective [Member]",
        "terseLabel": "Investment Objective"
       }
      }
     },
     "localname": "EquitySecuritiesInvestmentObjectiveMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Summary of Company's Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r238",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r324",
      "r341",
      "r342",
      "r343",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r238",
      "r259",
      "r264",
      "r324",
      "r341",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r238",
      "r259",
      "r264",
      "r324",
      "r342",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r238",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r324",
      "r343",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement Inputs Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r238",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r341",
      "r342",
      "r343",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r210",
      "r212",
      "r215",
      "r239",
      "r244",
      "r319",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r415",
      "r457",
      "r458",
      "r459",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "verboseLabel": "Initial Public Offering [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Accounts Receivable Related Parties",
        "negatedLabel": "Collaboration receivable - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
     "auth_ref": [
      "r161",
      "r162",
      "r166"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.",
        "label": "Incremental Common Shares Attributable To Conversion Of Preferred Stock",
        "terseLabel": "Dilutive effect of shares of common stock equivalents resulting from common stock options and restricted stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income Net Amortization Of Discount And Premium",
        "negatedLabel": "Amortization of premium (discount) on marketable securities",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "verboseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expire date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LessorOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessor's operating lease.",
        "label": "Lessor Operating Lease Option To Extend",
        "terseLabel": "Operating lease option to extend"
       }
      }
     },
     "localname": "LessorOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor Operating Lease Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LessorOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r142",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r314",
      "r317",
      "r318",
      "r326",
      "r413",
      "r465",
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r95",
      "r103",
      "r429",
      "r447",
      "r460",
      "r498"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r111",
      "r142",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r314",
      "r317",
      "r318",
      "r326",
      "r429",
      "r465",
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "U.S. Municipal Securities [Member]"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r37",
      "r97",
      "r106",
      "r109",
      "r124",
      "r127",
      "r131",
      "r142",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r163",
      "r181",
      "r183",
      "r187",
      "r189",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r322",
      "r326",
      "r414",
      "r465"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedTotalLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Basic [Abstract]",
        "terseLabel": "Basic net loss per share:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash operating and investing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs And Expenses",
        "terseLabel": "Expenses related to the Biogen Collaboration Agreement incurred by Sage",
        "totalLabel": "Operating Costs and Expenses, Total"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs And Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r181",
      "r183",
      "r187",
      "r189",
      "r414"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use operating asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Change in unrealized loss on available-for-sale securities",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r66",
      "r125",
      "r128",
      "r133",
      "r327",
      "r332",
      "r333",
      "r372",
      "r378",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "totalLabel": "Total other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive items:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r121",
      "r123"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "negatedLabel": "Other expense, net",
        "terseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Payment of employee tax obligations related to vesting of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r29",
      "r49",
      "r136"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments To Acquire Available For Sale Securities Debt",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r429"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued or outstanding at March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds From Collaborators",
        "terseLabel": "Up-front payments receive"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r31",
      "r76"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options",
        "terseLabel": "Proceeds from stock option exercises and employee stock purchase plan issuances",
        "totalLabel": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r49",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale And Maturity Of Available For Sale Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Revenue [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r109",
      "r124",
      "r127",
      "r139",
      "r142",
      "r146",
      "r154",
      "r155",
      "r181",
      "r183",
      "r187",
      "r189",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r312",
      "r315",
      "r316",
      "r322",
      "r326",
      "r375",
      "r414",
      "r427",
      "r428",
      "r444",
      "r465"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r104",
      "r376",
      "r429"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r79",
      "r107",
      "r510"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r38",
      "r42",
      "r403"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r67",
      "r102",
      "r385",
      "r387",
      "r429"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r108",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r201",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r320",
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract": {
     "auth_ref": [
      "r216",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.",
        "label": "Revenue Practical Expedient Incremental Cost Of Obtaining Contract",
        "terseLabel": "Incremental costs incurred expected amortization period of asset"
       }
      }
     },
     "localname": "RevenuePracticalExpedientIncrementalCostOfObtainingContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Standalone selling price of license performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r132",
      "r142",
      "r179",
      "r180",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r326",
      "r375",
      "r465"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale Of Stock Consideration Received On Transaction",
        "terseLabel": "Sale of stock, consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfAntiDilutiveCommonStockEquivalentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Summary of Anti-Dilutive Common Stock Equivalents Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense by Award Type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of Activity Relating to Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Activity Relating to Time Based and Performance Based Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule Of Unrealized Loss On Investments Table [Text Block]",
        "terseLabel": "Summary of Fair Value And Unrealized Losses of Marketable Securities In Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Share based compensation granted under plan vested period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Forfeited, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Granted, Shares",
        "verboseLabel": "Restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Outstanding, Shares at ending balance",
        "periodStartLabel": "Outstanding, Shares at beginning balance",
        "terseLabel": "Outstanding and unvested restricted stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted Average Grant Date Fair Value at ending balance",
        "periodStartLabel": "Outstanding, Weighted Average Grant Date Fair Value at beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Vested, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value",
        "terseLabel": "Fair value of restricted stock units vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Total number of shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common stock available for issuance under stock option plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Exercisable, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Forfeited, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options granted",
        "verboseLabel": "Granted, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Ending balance, Outstanding Shares",
        "periodStartLabel": "Beginning balance, Outstanding Shares",
        "terseLabel": "Total number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease",
        "terseLabel": "Common stock shares annual increase added to plan",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, Outstanding Weighted Average Exercise Price",
        "periodStartLabel": "Beginning balance, Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByAwardTypeDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Restricted Stock Units Vest One Year Anniversary [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Restricted Stock Units Vest Two Year Anniversary [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Restricted stock units vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Share based compensation, term of plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Exercisable, Weighted Average Remaining Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "terseLabel": "Number of shares outstanding and unvested stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Outstanding, Weighted Average Remaining Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Restricted stock units vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balances, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-Term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-Term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r142",
      "r159",
      "r160",
      "r164",
      "r166",
      "r173",
      "r174",
      "r200",
      "r229",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r326",
      "r407",
      "r438",
      "r446",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r66",
      "r108",
      "r129",
      "r130",
      "r131",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r172",
      "r201",
      "r246",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r320",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r337",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r172",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "terseLabel": "Stock issued"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r1",
      "r2",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Public offering of common stock, net of offering costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r66",
      "r67",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Exercised, Shares",
        "terseLabel": "Issuance of common stock from exercises of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToTimeBasedAndPerformanceBasedStockOptionsDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r1",
      "r2",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercises of stock options, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r48",
      "r429",
      "r447",
      "r460",
      "r498"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r239",
      "r244",
      "r319",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r457",
      "r458",
      "r459",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock Common Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r18",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock Common Value",
        "negatedLabel": "Treasury stock, at cost, 3,033 shares at March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r16",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreements",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureCollaborationAgreementsSummaryOfOperatingExpensesCategoryRelatedToCollaborationAgreementDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesCydexLicenseAgreementAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureLeasesCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformationDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Type Of Revenue Extensible List",
        "terseLabel": "Revenue, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_USTreasuryBondSecuritiesMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "U S Treasury Bond Securities [Member]",
        "terseLabel": "US Treasury Bond Securities"
       }
      }
     },
     "localname": "USTreasuryBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r411",
      "r420",
      "r422",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Government Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueAndUnrealizedLossesOfMarketableSecuritiesInLossPositionDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r158",
      "r166"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "terseLabel": "Weighted average number of common shares outstanding\u2014 diluted",
        "totalLabel": "Weighted average common stock outstanding \u2014diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r157",
      "r166"
     ],
     "calculation": {
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted average number of common shares outstanding\u2014 basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sagerx.com/20230331/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.sagerx.com/20230331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL51790836-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130569-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000950170-23-016436-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-016436-xbrl.zip
M4$L#!!0    ( *4ZHE9D 2%%G?$% &L_"0 1    :6UG.3,Q.3@X.#%?,"YJ
M<&?LO =45,W6+;JAR2B(@)*;I"!1,I(:4)(H2<E)R4&2DE.#* B2$5!008*
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M2]TS)H.^C4%EGZW3^3L%+M5*=Y]FLJGLP:( #['Y2:F^KK!G+.Y:)1,Q0JX
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M_PUCBQY;Q'519XJ.&8Z'&#J_0_1:QT$7NRFU;M)WL[O^O8U'/?NPI2HQK^9
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M/NO'E4*"?]N+SB[^:NET"=U8/UWN093%FE&#8_[[I0S6TUQ90H$0D 4H7N$
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M>?@E_H/.'. 9JO$QJ@!]MVXL?4<!1ERMUIAXV=SF8651.&VERD@=2DUW[-5
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MW*RH\PUT>,2P&+%O]'ZNZ0I\A#/>L6EDCL-"=-#=VK;4*(%%NE2@2<XZ]G4
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MU-&\XW;J47!??D+SCA!3$Q<>G8K+7]Q[DC8MTDS28+X+^Y;,'/0Q#CUC$4(
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MG"+K8^7\8<:67\*5N%Y0$&MOP_T&RCK)5KI7!7=++]4<VRO>D#IO*#4X%ML
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M*F/Q[Y(-S]Z ")&^A[[8V$DUPOU>04(K*1%0:03<S^F1&OZ-O!H1,,TDN)A
M*_/QD;Y\9P%(PFLCBPH)HQJL1.UIP<L:E.EG>&L5W%[G^.J^SLDI_.Q"D&!@
M+V27&GOMS"OD6,&O$::V.4@$./OIX.-VT(3Q^@$2BUN!@W.[NOM$X/3B>0/9
MUF7Y&[_!DW*$!QP91.#95R*P_[*29 -R ;F4L(8\&(.?,8W..LB&AJ78\G3F
M>KHXO2S4;-AF=)N3.2%48:MC,>,=!,Y!AJ=#E39UY:]:K#309%O2TH^FZF(?
M_%ZN2!X[+MZAV^)5FQ#HB\KC2F7_$17E:RE!8F,W=MHNII9S?\&V7M">2?JE
M.#YDHZNL1A)Y##A #S9$"<&./8&,>,[!RL3OV/LG.<;M2SZ)3D [15ST+_E$
MMH-.\,L8!1,3(O#^4C81,/]^[GK>($5!C"EF$K?1-GZ-'D5-Y^#5SQU_2U^%
MOH [H1EP3SX%$QB0("(P,'X^<N8[(02!)J$ACXFJ-!N4)L)NS&_J[1;:GH*2
M^1<_'Y!J=<)RH(.SA3#!!S3O$0'D'AQ;"!P1 9PV'G(^:\W#B4 ($QQ7.!/Q
M="64-^Q^_,TK8K*W!'I\R.A&#'_",7V*MXA 9N+Y8_#?1 "MOQ_SSIHW)7-M
M3%Q,HGJL_.XRA8#1$]*HPW..)(.+>^Z>Z_\02^9-3MJ(1U#$O7^D*I(?UT\-
M-3[2N1PXD,XZ(C3BB-7*G>4GZ5$=:E\9?1#<-D[FMNY8BMUI,[N&&L.FH(4;
M]RD-J&IT?F:7#N6'F>YMK*IJP;01IXHXI+8]J[:CPB-&9@L!'1%5(A#4!"C
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M"8AP4IKWCZP*_VG_IT;"^F_E24:GIK43?4W1!B*@K'3MOY*T"'PLP_M#!XB
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MZO=$R= +,:^B,)3V9TXB@*[:)-S&SH;..Y+5CHFPR>>\=<HR&_H14Z^JU'S
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M"2VM-Y-N<>]^];<";GWJ_ $CAK6&;PF#R9:\"5FXX&D!4V,S)NI"I"*3LWD
MR;WQ>K>1\4*<IC$1>!/;*JO]S6NGOEJ#FVI \=9\ !.=$JODX\<C)1(!(AN/
MFCZH.#HR: JFNV9:8:=/O8L\ERPJ5?,.TX'J\NB>E*D1(V"UJ_"G,A%X308-
M!5RY'F/S45#:?DM[N;4Z,C6Q&PG+]QL1: [+#.WT9JMQ1]#FS,+'ZBFW8H<A
MG5@DJVIDQM$#AI-Q-8R.6K@&[GE>5^2[LLB9A].O-&F1N%7C?5G@.+9#D1S+
MUY+2U:"VT&AN7_G[ W>X,R41\+31V_V>KAK@-A!GOC4O>JT%#:<PWJ 3R$'=
M-FU'[O99G[:M=7%-A#JM^UHGEN?UYZ]?77.SE]U*Y%MMS1STN,S7E@A],;B/
M$RK9JRG6C$:-QAHH_@Y2],6=$0$>0Q4B4$8.W?>OVD0RRM^1U\/L/:E0?Y.D
MFS]94M--SR=M\:H^B7#17!)[2GA0>IYIS&GAJ\>.:[X UF)BO+W 9Z&HGZ;W
MNM15L<]9CS,.1'Q0@[OP>?TM_3VM#SJ8_L,(VKIC6:^LVT^.O^51]/_H_]($
M@DY#C4^,@V0@[V:Y+:C\H:.B;[[(?;YQY[ AZK/%ZR#?]V)S*I)M@7VSS*>@
MT&W\O9L_DS^DF]X[+5=5[Q^IWCE=,H"@SAX$.':80S">D3:JUG$?SL82#2:8
M%'#GDF(N8&-&PHQWZNZ@4&61DDICCB"E;0%@R3=]D$EUD%&ZEC$5R#&RGR'7
M?>J94SWK/#,EE67VJZM//-7*(/0Y;LBGQ)]JD372QRH,5ODC*4;]5Q$7^:=@
M\B5:GU[@A;\DSN>/[9%:316$$<+ Z9-6,R)@NUL];\DT/5$ZV^!W&#A69>:H
M-,8]ZBGW8XVK3E^U+BU7X(['Q7?-I2Z++C&>+A3^5F%V.SM3.@A$C,&WF.6Q
MFR:.SQC[;FF+N<)9@).K$9CG"QE1Z>*1I]HK[3>S<C*[+^<8BBE7<H30!2NA
MCMY)JK7.*F S@@G7IV"&G4D9#HC:."Z;SVV??F:XC6G7OU)5GJ?>SP2[8K7#
MB0"%:.@!^[4MB,VI%:^HG,W9YQT$%S3-TE\:(XH7/)< IO;02:C+7NGD2N^N
M?+$UG1?:'>XNT^^;L:@RTQO;5N*U/K1HXO>VQ"@[\1K_ZBL9LE>77V4 54Z:
M1ACA@\Z"KV9SVG6I;[^;/1SZ9B' %?0T(2K>;=N.=)2_[#HN%_M8;^#@$_[F
MPE.RD^DL PWYQBVJ.Y0"!4PVG"%]2EWSARTZX5 FYZV.)8(D3*0)4TT8_$32
M?^^;$\$R?YYDYX-A.$QTT>*=!^1:Q_S<6]HX^0Y+1/VS+,1M.6^ZMB(/:EFZ
MD#F.MI*-.X$<@R('3LH3PDZ68NI/K#*40 72I!M*+%<,^^XHWL!]QOH9UCI=
MPJPF/^2SMUN^G>-#8+@1O8W;GW=UK<TVCEU$ME;%&M6,QY3GA5^PD%W8IF5H
MIBD+ ])#=9RSY8,"&-ROAXW9/[G0%1KFZRK8'DB*BS7$0M\V:'YUO#8T8RJA
M2]* _RHE,UDTJ/:M-/Q)PF-<$>94<Q0O4ZJ3]6WVR)$M)N?]K<%E]2XR-MNO
MJ =8EU!%1NRU")$JB0%Y-<6(9^H_>Z]\OY[$\XVF53R*HZF29-^B'7Z!"+0V
M8PZ:$LZR#\&\6\[^<UR]?73CSE*B1WNIAR495'9P3#3,0GLP</ PH[SUQE[U
MR[F8TU=NQ^.I_O9-8_Y2&*3*U;JJI6MK/F0,,R:FLO(U85H3SY0Y/X*2MP)9
M9Z;G_&4'2DNW>6IJ$D>--6Q>;:_PQ>MP#X >J\"NO6NZ"<OHY!!1O(;SV;T?
MHU]&*RB1!;.=?D6O^$E!AVTO0H/ X?_\VW<_G+RM\.A0\.]!3XH4;W\1+$)Q
M&@S7!0=^:8A=T.E(B66PZ%[HI[_/.<XENERCE>XUUQ"%;-T(=EL%/W2_MD5:
MXE G\CJ[.]?!.U%,PZ-GRU'N_M.7JP_BXI0XVE1@%Q.SL-#%T.^]F;/1#'??
MW;\]+=_!G>%"O?SAFG#<%.#1+2,97>( OQ)(OWXUB26]VE...?7+\7!5^RMT
M?#Z\+S\]FUTV3@GR4.^)A].C.=/!EU4F]SZ)S&LDI"L]3X6X#9Q&-/[7RQ-_
M-):!H*W9-G=PD$\$5@<MU PC8/W-YKRC35)VA.O?A_UG!&;]I!+ABI*3]$JF
M6T),\[Z4P&'='ZO%QS\6*O+#D'9:WEI-%YA%HGL;.-,IQ(0*^NO*F _8<679
MCC\#>?WY+)C,.DI6CUZTF0=1/]"@$AG<M8K1?]W)Y'70W S*-^RS8#.'TOGK
M#<@KV)"-J\>U"81ULAAV/5[;G5\9#'42Q8MVE2 KVN_$7WP4C&ML6E0(/#*?
M$,RP,)[%>6+B=<#K6XLN]!9PNXVA911WL4CS]@O4#D*Z7[G?_#+@T22+W0EO
M8&5L1+[EK$D67':-R[F@XEHS3:,.:9<^*G:RG?=^?5"RIVPKDL$=1'LHMF4^
M'2ICT07N3Y[&A<^;G$N5EVM#O8=^7S-ZJS*8R<]DV%O8(/U5/HF?L_V=,9X?
M?+4_"57)\8?]TDCDI7O]BYGRCLRJ>Q3UBR#I.08[X_P6,),]PM>@<OS6M(UN
MD(_UH#:E>D,P^<M+)ZG4AM_]W;GQ/",:%S7B:<!ZIQVEMBHX_<4,!ECI7#N<
M3I)I^4X?M9?>1Z<6;?U BX^/%92ZY5=*'8?E/1?<T)!+ZRR<G^YQKY=<"?]2
M]\VZOUH57"Y!$H+1)&C0A!(!%\B)'H_/3%\N3=*ID89P^SNV1Y6N5]V#J";Y
M+7HC8CO+SB?D40><TM'8ZZ,WA06UBMQQ%R_"D]*])_4S,!/6C'J,XJW585N%
M8#X$#B9-2DT:3Y1&*?/JQ4<),WY KY_+LWL6<OYZ[V&QZ/[P2L<;1EO1#>*,
M9AU,75:6X^]I0Z8:'5G!,2=.!4/7:RJ;(FU&1\@&K^E%6;IOO8*M/TGW/?'(
MH YD.(\IUSU%:DO,A E(Q9W92T+EETY_\26^<$^$AK]2$FN2A^WI8T;3,[)7
M][KM%78;$LQ4O>HRFRGSOW(GQ-]2O22;7)1%Z&?QJ"Z?@648(FM'K'6'<F@*
M"]M?4=%VE&^@'FPH"N+OG',M(J#^NH1/7=+DAE;] YW$]5_3T3%I)"#VQHVH
MX><X;)Y2\@L5>_G;T>^\W81H])6:5[S0!YP9QL!*H 0,TAI(@2%\I(FV>S$B
MXLQ4&?^P;X>EH)]LGOK[/FFN'R+HEU1;_V5&SMC-HN>HLU?&V#)Z_%6L<_D7
MG9)UXYQD5(15O$+UQ@TA>^:^Y1_/7+656)\\FV<;+X==Z-<;]J?(7CNI^ES9
M6(6@U:"+L]C&T#R)ZP(.=I0X9$XEX%WWVN$'/>#?!_L*L/'FG0NXA):CY)'D
MP[1#E=J8ZW1[Z 2W1Q.G46XCGF76F>!T13"\VPMK>_:J@0@,?=HH/,OFLL5Y
MVO2(,3R)3OGE\RKVMXJ[[$J;SEL.9NRYT'CK#Q;H07S7X+2*Y[$R8G7G$LIW
M!-Q"^I5@"@J*+M2SN.&%*%G12.^60BW*LR_W?QG+?%B2_N65'C3OQ>WVZP*J
MC?5M:2 SS$O]DU@D=]1[Y>.DY><X6A57B\J8+.=TNB&/12*P)FYQO([<Y';.
M(;P2?FX?2(/[,?_*HY]FNLT][_A-*4]H-K."UX\]$??X:\@2:#L4A+<HAOGN
M&8RYT%0M?LZ)4J9V+U0A@W<<59?Z/7.5LY4!.&HQ:((&(ARZ"0$3@@511, F
M]I@<%DNH5<;/-N:W&'N.Q<U',V@W1?;45U?$W+2<9G6\"$0%*^,%^Q1!L&OM
MZ>"&L9SQRIWOPC_=R&,SV%(B$ONG+6.R2P#O.3HBL)1R_JZ6/?@J;XW+!(J@
M\3N+"#PW@NX_T5\UEQPNK8*3.?IZ1ID[S?2FQJEPS-=_*@"LWH/0IF4M.E2.
MBG08I^6P6MM#S0))T.?'O1IB8=+-,G?5]*$?@7O8/8*&)^HLX!X1R#) MH*/
M>5A 9VY_W%8*Z9BC66_BQUR9M(EV/$SI3.>C.XY()>W^00LU'L*YY5C80<&5
MT:*/0[H:$=&)3X^*G'A^'3Q2GH\)"Y)-_IM%OXT!P5A<[A<'12Z<6Y&]K!9R
M4C1_U[\&4>@\)79[^2UID YOT*U DG.1*8(XI]H%R'V!_?7C"B7,#DJ4:LTQ
MSVX,:5-A8$MWG*C3O?ZJ/6.LTD(+1P0*!4U,9ZJ*7^8P7W5\6KYOU_0LH ,P
M/OO2H.=\Z,7!4/6^&S8L/-K:J=.32?M6:5W#Z1<1L.)8;*12PT1-PEOF<"K!
M))Z\24(T6;@]:P/A[K4]F1-#OGEPL*WJV"7DXH]?!PI:)OYN%_K>GE-F&V>S
M1NEF^;T6C@XER"U_>DS&FX:G)TUIB^QR6RS13=W/#=*?]B?U(,C;LIWZX V"
MXT1@0<-?_MRO?D2 SQF*6W;G$,?=*YS")1'HRP#SW+#,IPV)'8<74#M7%&ZY
M]R#8 S_>71]'=U8YG)@U5Y6'/2R:00F1=P2(O?EV$@2^0E(P;T=@A+R%6&.J
M$UXE=[Q+LNY/$5<)HI2[,$2K2B/#WJG@F(Y#?%7)]??%I.&W"\AHC1M*9Q@5
M!WG1..KQ;'\QG+7MN>+6B9O5KQLM5141 :[?7;E.RQ$R5P -XC#$#G5(0J,4
M(<-+7NK;Q5M9-N:9DNT1ZD?G*NB] 776A^ <*[J!\?ZY2J?5IE%_F<S)FXE[
M1_%,(U;+/84DVP\0:\:T=ADL>![*-5FMY;SR9[7JO'%H84K23O]6UJRU1%(F
M-L\A7  FAH!JY^M(%V^X-MGM(L;?'MKN<K;BLOCL%L &#KQ%4H$-G-J$DWEJ
MFIWB/Y58SD39,MP7CVV-?6VQJ[$_=[(!)40YC/\[0^D+3B=S/9 %YV>9NWXX
M9],8H:&)^BTX+QXO\TCMWH826](6<[Z6^[P?ZZ\/WXW-8Z5 VT4%S$2@J3JV
M,V4>' :GP>O-FW'I!US1<N.IR_UQ]MWUX8_=)B772T\9HCRXV R+'%E48I Y
MIFN^:77]MJ]2N*/KC\@XVFG)%=XR+M+ZR^(^8O9T:Q7)1UXT#=L$S-G&#=#+
M.1O=JB^/^OY>&TH)K#>H8% ++J'[K(VVCP8^.SDEN),UI%:DOW[BDQJO3IJY
M$@^2+,-T-'#,LC4T8FS2W)U>[-$)=)E6=!52D/K=GJ>51DNNC,]>Q!5@:7[/
MSG4@$D^<DUA!L+C!,#5F"F:YE#/TZXS6QJ*V$YJ,A32:<?7A&[<G34JO,"2^
MT-9DF([7D"!I^V6.A^)^NF3+ZM7&=W':YT=V)U";L)II;_HW*J!*7A%NGJ7M
MP\M-S59E<PY?J3'#>7?H[[LV2E&+K; '.N,?XU4PL>TG4E&V6&C;V0-!'UZA
M+1>N+6N;TQZI"Z4Y>V&=TON]]_R>8U'MAR6Y%KEY2;9NI[7+&M?)LC9ZQ.\H
MN$6ML/-?V-D\6VQ\;#AP$"VGE^A7-6PL%:;FM%-UA$_=];FK9EZ#OH H%@V$
MX&VD!M/XI[NM:"6&.Y:ZPX2C2_.]%,W3T6,(1788Y7@S!\>=VUJ'D;5SO74U
M4]%;40#(FKTIYZC#Y^AM$QTN0Q4;1>##P0M47+@[TDJ6 HJ+YWQ4Y_5'TEU_
MH3@^9UZ"Y1]Z#Q(ZW+PSUQ,FNMFL\2D-&G2M^].W?J1Z'M=C#:&V95<<DL>B
M"]>2HW:G2].QE>(/3C\)I1#NZO!=I&#W14=19OWOH0H.$OZW'05\H&W08^E^
M1B(P;D($SO@9KW4*V4%9&F3*ICM5WM\9KHAQ7]9,8CH@=?DMF(^1>NVOD8VW
MQX+>BN[O\&G6QV^V0#-87<"WK(_O765FVQ6LQQZ]]B "'*N76K>BI&[3'R($
MQ%[X^WH_GH;?(,FDR6+GB;:*_C@89&TM0\;QAF778I+U274EAHS%K^94:VOR
M6"/=*U]H3ODC!'/]J7'@.VQ12R(1F)"5J1SU6(WYQ;S\]MA!EN2WV#<F%-OK
M&('.N/.QD"Z(O>*[TQY]_^&-E\)1+VD.V$)[\%]K%4!\Z6EVI)F#$FL>R(GO
MCO;9N].KANZ,?:[<&MR0&-9\A^ZS%.32PU'X)B=\W]@P'U;8&G"OQ7<VS9+6
M+S):%L8919OU.=M:+R%(AM.]PPU.UL!7@E-KDPU-K[<^U%ANV-.3'TD0+%=]
M]28F<P!D@D8>\Z7S$(%O^N.$"(>]V(EZPOU>0T(KB BHY/K"(X6<):&7-A*O
MNATG&1H'M-_*FY>24VU1U2'ECJGJ.(_IZ8@%"/7Z5=^MI F^Q+W>^WN/'I9V
M,/?0RX8H<:3\)]^;>4%J!OJ@P/HH8U5@*F!XOS#1PH<0'"3RMQ=8HNO&\>&>
MX)/C!")P5U*US-%BEWT$NO%;YXQ\E 5GC&Q/*H+>R\9+GW!^B1"X_)^Y+OFG
M_3>TJDIA2K1)_:_/ZK2$0U./0XY].V/&3H1WN=C[ZV>;-6N;"ALCQ<4E^Z?W
MJZNCN.VD.9I69AL?(D4]Y^0)D)^[XO*]S\<K\K$$96MKE_Q)GJK*YUS*S0='
MB@<O(@37N1@9K<MWZ1,2ZJ?YOT2\^ _?E7N,.O0B @^QI<BOT)/.JIWNXR5J
M'R(01)#<]_1?P81PL.&F%B]?T"KG#EXD?[_L?>6]V!;HZR^F6&<[TM6>8_1\
MZ)O'>'VLPL;NX0^!S'U14;Y=TT#>IO"R#_(@-%,#(U93']FD2OA1FVYB4A!\
M===;W<@D2&,9S-X9P$^Z?G*,ZD!B><_R/8HB=6:J1D?SSC)$3W[>G_O4%_ J
ML&KS"$[GSVZ=%WGLKY%7R4/U-6;!;(HT4\F;82NF:G&6_!J<H4E*9[&%>M"^
M6HQ"[1/I2\KZ%SI*VE)LMDQ08V 5^3_]6*!1M)F.^_]C[[O#HMB6?1M)$D>0
M($$&!$6)$B4/B("("@9 0!@E2!@1R9DAB&1&0$ 1 27'D9R39)",(#EG@1GB
M ,/,FWWN._ML]_&^>^YY;]^[SWW\4=]'TVM^O:JZJE95=?<J"&V5>'Z&MHQ9
MY2GYFU;JV#:)A<3?]"8P>C^E2?!BK+]X,20N6!_8K!W1WW79AH.^92A<&Z+_
MLOC)5)OJX/K7Z.G)P%JZ(CC-<H53(@KGFBNX%BF5RL3,^T4KF2:BOMM(:J%2
M$V'$7#941<=X]%I3L#GVTMMDI4CCQP%UNY\3DR1TI]6:/&GW/N^R2A9F-)ED
M#C>73(U+77M[__%UD^;G .=6XL,><HD<[%5,=)Y%[(CV4,,[/](Q$!4>:*R8
M>W7&A'O,D6.F%&Y>+6O8)[[FU*+;MT-UTF/IB<^S*1<_,3+:^Y=9ID]+[>82
MILE4!*7!N"W(<VL75PVF78UILS[7?LX$#PBRAV:,QGM[H>N:154F7XRT!,LI
M3RMGN[Q]7=R8N.1]E?L"I\(^X,R+> 1R RK15QIDH$%5(#A3NH#3I%E0WN-*
M#]ST@#DO\#[EN2(Y)[J+?P%R0E]E%L2\)$,>*"&M>_-%@1*5='V;X#QRSYD0
M?[OIIF(?HSTG0SQ4K%%;#=:+-F4/UH?% MZ RZ[C& X[6TC=K<4):2B$;+K7
M@S0=BO$\LQ(GYYXW_^+4'O>&^'L[ROB(,6'V*2WRZB:&YU=?-;"J,5@QTC&0
M:K,#P!)_EX=UAH<T"A'$A:8M);&>H0LR9IJ/<_J\1I+Q*,G$VX 8\4P >P'C
M!PZ7$V=:[G4,$5!S/#/K@F,AS]]84EH2,1+)Z$A/'#FWC9GR>U2:5_;:Z[M:
MZ1Y;RY[DZ^YGBZ$]Y(ZVAVJ6!=?/]7E(9$S<;#D9V9I/6)MKE(?B7%H:61>#
MO,Y;Z(=7)DM&\%,YEI8ZFIF<?/NIQ9E7 !I/"\R6'\ .W3]7""4\,=2\7EBD
M?4:DDU5(%B!:_$:Y']LR(5Z,AC>QG37NY,%UE;A83]F5B?(IS#RW#7^(7@X&
M#GAG8K%1H%.$&"49+O(0^GV24MA'XE+=_N0]4]YO*BS@ [J\_A^&.'^?Q0,\
M6UH$1<Y)/.#C [813%FU?HY-CUAN)SX_R<V)$,QNAS^IW6?:J3TXU"18![0)
MOLF["M^9AN!"K#81PTB<2K4-KJ8?#R@FT=I_I@LSWWWWU;SZ_,C@YEHR<?IZ
M6YC8]AFL(C(%MI!X1G#Q\T8XQ8R?1=]R::'X_OTZQU=T?'Z)-12\&8MGP]S#
M8AN%3T*781E-,X(2@M],]X>HV(0+^4\I[7+W#WK+M>R^[I_Q/*T\4'(Q3C;
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ML:]5LC.!$X,CT[Y5S:(>I0_7O&22R>1"\0#%,D%1E F*XM#![6Q+4)26HH+
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M5'1^9NX_]7G'P,? Q\#'P,? Q\!_-F":/<V^+#W/Q0-*VX15\B,0X4>42)C
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M7$.*,4G"4*M+!+?9>_)]=Z\,91X]^@H\5B-X<3<M,N&6[OWS0^"='1#.GQ!
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MI)<?'E" [+/@ 4S6V$=$%@$PPK-5H3P(#R1&'@X'_&X(9!K4 U]LP0/<$#S
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MD5C^U+JM@@+ZDU" 529!)DL9^(LX,QIV>MK)A-'@@NPYA?"<T=DEU[Z)R/#
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M2[G0XWA;<W(B"KD;RI5]5=XB]G*3+ <_6U2'>#A(U'\\UM!#-WFW1BFX-7S
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M&^Z)R#_5=&?G0H,/_?>4UMJN'P1E^W67=?,_]<N?0,+.&]\?*\[?J-N+,<R
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M1T)5YJX=PIZ:2U-D0)H^<H1'R8FK';(@JIW2-&<Q0:FY4O:05(WASJGBVT=
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MN#1L5W#LM_^XNMN,>=A=VU%<:,=!\W7OL\B-7?X;]8LLI>%+?$"Q-7+30@H
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M:T,VGX5]KQRA01VF&BXC'AP%S2,DOE.XJ!*OZ)KE',28 ,6)V0+.=)T;0,[
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M^H9/'X-+UZ-K?S=V<)T;Q(9-A9<^%7P,37I.;UD!+@5.>Y=,Y2CBQH+ 6_N
M*SF;<#2B ;45NC)[8?!::'?N+Q CGP97.700UC/LOX]H3/^979#FS--7U4XJ
M5]0F6>??/SBA>:$0PXKKFT&V\32*3163&"[C65 ZO?%VZWQF*=:^,Y?#U1KJ
M!['HIC+KSZBU[>T1YIDF%(8??_Z>6.OI=AHF2;/1Z0'S* Z8"S2L8@X.(M*6
M2"./GNX%.EP+M2ON3W-, W'#6M4U?W&+2O5,^75L."]39U,@O'"?$ON,P  9
M\0W^N.-8;,VRL%!DP?]\-G-.(D@)-6.%7_DMW7>.I12$I&FCJYD_]T"I0@PQ
MT86*&B:9/%R0R^S9!T1:VNT#P#!"$HS0OH41292-\RC1G6#<49/6>U;QF!D<
M%>JX\[?5/9\6(K3'UK-G0\+#-YI%I8CM6[!ZK%5B"9]2(X4$JM^)#'P87!?T
M\V\%O2DQL,E1-4]3V@>,P)S6$W7Q\DS4R2A&WS#B@>D":VU9M;X/0>U9G$*@
MREZ0_(I]F%5@KH5U%U5OO^IR;:>BQC\C SQ04?1VU->"Y:=?D4//C</4QFJ\
M'TOR=Z75"//%?)RK;V0N[P+C%ZX&_8[DW\E9CA[>8 J<Y9H-%;'C8N5ND3%7
M[T[X/QW,O,=2$=PHNKCH?%KY7(#ZTHZF3<AR0^!FH>(5N5*?8NPBO^D\X&>C
MGT"LWX%+@WZEC3G$",BL'F9)#B;FD#'QYYB*^<$39]L'A,T-(')_A>3K-\+W
M0"SL2YAV9D!_&JO&YM\UMKTKP@>66RQAO8OV9=7@'>;*Q%#Q+ZV<CGQ;]-)
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M$'^AENUPZZ+^L48'1B9L.H=%DX]W8%1Q1*'M.4N\"H\M/X_CDP]:"\<_<WS
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M&F&SMVS>B&6'WIS!L-$?36#8[19HF1>E0 -.CMHUJ9([=Z85G:.RL%(7V&)
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MO:PX&-Y53*>#Q;+'6BP#P4;0236T6M=@Z4_^,O6=8_T8OYG355.C%@=EPI_
M- 9K[0/*DN!=P[U(K+V_4'-J[+M2NJY??D JLO8N3SO\ MYBF9Y5G1X4.?^_
M[6UU2&@9GONP8@]+Y8$TDG?-#.58R4KK-M__W1JXO@_@[L[5#[EJ23#DZ<=>
MJ/%35\$>=(2F<8/[B 1P$IR DQCB$6B(BVJO.>C8QPQQ _':2W03;M<]KK[>
M,][%OKOLD1E&&=@LN EVZM_L!-Y87*CWU=_PJG'_?=X?:-$QM+UP$SF$ETNE
M,/PTL1PY5_+1F;N-:8;YF[^LSX_Y?X9]5P_]P2\JA9V#=FPXJ]5M4.ZADD'5
M0W)MF"/)G@%1)_Z:FAOU$RENU;S(0$R&S< 78Z][H&+E6,7X$"5V*%ISR;O4
MBO&L7+!,.,'+*UU^IT[9R@2)"_+2"(2- U?_2%SL)R6Z!AG"9O<!83NQ?>-#
MXJNT+(G$4?F1RS!-95&%X/2I&0UTZX,-*G210VHQ >8&PSZGPX,TE&%^,8F:
MR?GHGH@0S[IBZVM:&^X<YR:\&!/#^7>-F'V@;1WM9)K!\CX /NJUM<$@-9<:
M]]K@@Q AH<O-Q.R98:(%JAZ'V CD I]U6YM7]2*.W95(N[K#^7GG V0*>'EI
MV4WHW359GS3.S]\DBG?><G?]9U[9%1];C:4JZY-O!@6G#8JT:X$+%;7M!T>D
MW$MWR#ZV3UL=*@3-'SWP7(M"$>?1P%Q5.!<(YA=BWT'ET7B:2B 2M#=B[Z/W
M 3IKAK#O=YG)*!&_N+:5A)DV)>H4+E?_<WN(5PD1]K@KJ>CNC9WF6[%^;-E>
M.+K;%>#D@TDX$=9"Z*34P__CP@S]R) <1-JZ4=O]O4N6$TZVW2!Y%5&Q9&,^
M6C6EBTK9![R"?>->6H3B$L%0EJH]='#UMC?WB5*""-PWN;JBT_=G:,^\_]T8
MA8TSS#9$R>_+KM?K#RZ[-L?"5V)I!PTHB_-(N=7)06RN[ST=38],PXIV]+!W
M-Q>NFN%&MTT0,*3E9>#:3"8']K<1TY4BZK=CAP]A=!;G,)8T9C#H+;G*!:T0
MS6C)1(AP1DX?29:DJ@N4#L8H:3J0,E]7W=Q&"D$,FB@;[7Z\GG^*L3OI3/0%
MW'Q@,F ZIUU5+6A 4 Q2\&2_\?NFZ'!AL2 ZV]4J(ZPCU,>D0;--9;YY9F',
M+;,\P3JHWJ417"BMKZW!6-J$7?$60TK[_#XH/M;U(1@!S,A_,I:^O)0:*7!M
MZ>"@>#Z3<FJ!J/^?T63TW8=9&"0=Q!\-JU N!""$KN?#)UCQF^+P0K$T<*.K
M2K!L;(T^NJP6@>U# ^VJ$LO@QLX((TPR$Z V4M90;+A'V <HTT7EO5U\]!4S
M3!;=GT:.7)*<..])0=:<%QE9OEIDE!/]AU[JT(/"I!U)]FDV,0;B'JVP*HVW
M%G=3(-E4Z3M_)S\KR=@>6"]QPKO]$KMR;V8JF%WF3L\9E><176=4@QP0@>&Y
M-T.Q(8%46V">]5!.K<]6$MY[@3F<_P-9I%4B]>;YL_KZ-X;'KAQT,[?_>!#$
MF;/9M<GW:@>H,ZN,ANJ$G2;W3]/N![TF>^?V 0C] O(*>T3)<DP1KB3<PPW$
M.://7"-'>:^8+B@7%RVH>GN0I_0UW4GR.JJ).W5R!D.!MAJ,L4V85._/S&HP
MN!/"UP-TL=73!T]:QK[CM[L<*WMA2HP=:H0F*SZLJSTX,19)E#D4';DS=2O6
M<^V'NU>D+->>:,O7%''F+WQ*LU?]A2@8GW'5F!);,7C+22TA9]D\6$XH0%3.
M;)-QI7C/VF>64$;JW@<<,2:V,53\4/68=5C394O#/%UP,(JVWOF"_-[I[LO?
MW?D)E/XRK3,%P6(^U_SD3RL:'/D0M\'[<_W69GOHH+T1VMI:YHXDKK4O5>.+
M*7!@E:1\<-I_5>_Y([J\1P CQ\3T-L8!R_%S8YB$0SJ +,ET!$1S:WA79],[
M"=,MO+F7#++;_3!FE-,8"^5!EA062'.HF@.E3YV?FMUL?V*5NFB56+5K#1[F
M'+-V%Q<78W\L7>-MI]<>F!40FN"B5!UVS])*Z<C8H:YT$=6@75IQ:FF:JY_5
MLWXW]H='MP*N>47QJ 6B[.#A5D/GP&!=""_#XH%RSF3F5M(NN@Y8R;CX55$Y
M5 (I(GCWV<SQ@WE-2B U3$2DPTTDXFU9^]LI<!O;J<=3<FT<1_W;W'0_@#7%
MJRTGF6U=CGYR_$T.K$#N3X->[Z/?]15'";:=S;-.9^#JLT. @J7*Y&[,"&$'
M-LY5-A;@BT%C-I:VH_HF!QPK!DE&-3%"CK$*.6$2N-,O;ZE/:;1;Y9["/^Z3
MBK0.L#9Q/13Y.-3,/OFW*6DPXT8W0L;G41)]Y&U"P%^BFPWRA(% ARR*B59@
MX00E32&?W57\E.Q:%\QOYN V9\4>)\85BABM@]TC!/P<FZJ.=:RG,*UXY2X.
M\GU/,L5Z<;EVRUYZRY%B/3N]QMP*I7:^\R8O>P_TE4Y7UYYA:\B_T&CANN#?
M$V1J:UD5*E15KQJ7^"S!I0K+R5@./+@6"D7PF:3="[]V+-WL=4"3@^]_^=8*
M(66TF%U, IEQ2:RX#K_.2L7VX%W':#.GJC6>\C7ITH4 E2?0-HO9IBGHFI=^
M3LE6Z*5:34&?"I#45:FYD^O37O7;M5^6%;+]8P9STO; G+SXT3FU-Z1)\E!\
MCUC)=@PY.VU/2-X=W^ @I$.:H PAA_'6""42&,HJ;Z\=\BLPQK9+RROT-.91
M-5?O>8F!!Q:H^,GI<DYUW4/VLQWJ,0HQ@Q(EJFG^QNN694]M51P/6^KMI#0:
M'\Q;6M(.GR3//0A?//;9_K*DV++#B['>S9Y 6L%222KHM"WQ])]MY3^Y\<[O
M-%<T0AAJYO($XWZ"[D8(+ <J(U)OI[;0:'C@1'OM6M7\18O;?+WL2P77M19Z
M"4;Y[]%,NUU644IXPX5D3NSSCD^F\J\+PW^HG_&(F<M]F+EIWSPTY&!\O.^'
MY=A4BN96YX%[#50X@HQ2M>D.A?[UON$.:+<!HA:86=MN/-#84HI78R5C!+4=
MJ4<*Z@RQ&Q,=8<:)0Z ^DVI:$U5@)>EPA8V(G8H F;;K5W"*2ID2=2(2.FC8
MM6-*=,>O->H0ILCE5),2_\A!AY<N(T;UR5$.'F-]@=1\\3"=-8G^#@[:D-C)
MVMJ>.QFD5EPN)!>!2X-5HEAZJ4E^B$;I1#)8<A<.;?%]QYOM(5FT*]SB6]TT
M$_\D_L$L7E7Y@C/:R;H[5S;:@Z>U"E&@X'3E(;WH%F4C),BO>-<VS<UK(4%B
M!W>X>A\@8:S\K)PPX-VFZE>4A.K@?>7CXOU-6F_Z?8F7Z-A4/@H1&+&JLV=E
MO8":KQ.4<19'-?CV+0TR$.1SH\V%L2>L#&6ZC/)2]"+/:CH^1QTT]-\J&HXG
M5WQ[7!?2$&=3-#DQ.JTV[JFB[JP18944) DZA2<*_UG7D*N=YV]LG=E(S"#7
MA4^.X<E?RS)E3EVI.I!SW.[S&@JDTC^I,>CL1HP7*X[)%!E@JO7!T]Y9L!TR
MG1UNX<6LQNFAW,2.-L3<2'&_=;+'RS#OA#M=5WZ5</*FO.,1^L2+^@BU^HU[
M Q=5==_*W$MFM_C.WNR5J4<81"MLXTKO4S3%,[(3]H2\@ZH10B^X#UQKI4B6
MGNA&X0D[F/%/KBPYD1P4]-OB?EC:U;L38FAB&TJTKH^]];(W_713]=1@8#IL
MLW#WN6#]]M-=0^L"TV^/&N8_!7?YEGFL9_Y:ON)-&>Q';%[.P;45!8\U@D]1
M93:\W=&P/]XT@P+H:@'>-W5>.3@=&Q 1;V('^OOTJ/H6OJDV##*$B'9O7@VT
M12.$-^TO,^*K$EQU[T:*5W]TTZK8X%J/2V .YZF99;@)&VLH&( IGW)1_I7/
M"U2T\0TB[,\#J04YC3JKTTJPD5>/[('/VV4Z;I%78M"%/F!))*YJQ-I$^8X+
MZOB[ P_FVL#N%,J@FW+"NH)@C+:P)Z>67M5-V\EM1*MJ9L(OKFOD]F"<&:^X
M\.?,+'I46M)B-:QCX!.FHQ^1:^K[@-6X,/\[L0H_IJ1<"%&0I4C(4M.@SQY0
M=L!5K;I]?0TU"P1JL\H; 5-.!UV. U8K719P]YO1PJYYD[?-4Z&X%# ..K,/
M>.F$^$+Y23U(RK!O4JMTJ\1NYN>#IOL?EGM&WAA_-^[KJSU<69+?EZ!?&[/>
M[RI'\$NX"D\,-4$!KZ]DMB%<:!!6!?\K;H'=0&@KP,UC )Y<1"W"AWY)VA4>
M*^PWG\@AO8]7B;W*O@4R1NM:\<:]#PHBL)+$Y\S*5.N]>A>FY\*]5;>I;WU=
MP_<SKJ,ZSVB^\(/30CP#!X5VJ@JOR9S[B;<L2[Q]0"5-!WV6-<(?A6BTASN@
MF0-/<\MIZJN:3Q6V,"(9"S+&.[+>!'Z^>[QMW("#( 9@M387 @<>]JON ZZ2
M[&NILDF56SY;F?@0RE)@$G)^!8+L!"V1XRE_1!'UVAQ&/0]FBFE6$?Z91_2+
MK962RQ[M)#N;$2I :1G-'K^]E_U)_P@D918'PKCJ;V%\28FF3/ZYB6)%\DM6
M\E@7@,K"(27VT:$G9*<W^+E.M&-KEC4L(M-TPRP3FO%_)5F\:'^61=\>#>Y>
M]XK]2-OB[OXGO''_%R;1UNBWWB.X,*$%#_MET.@Q5@Q3+_PSUD MPRQBM7"9
MM 6!:R,6/Z+9N\*@ CNZ4*_[^P"7?+K8I<X]"3\8=EEE[_?MSV0S'(LJOM9
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M\_%+ROC$BLIR\U>6Z04"TS'I:\/]]0:7$9^;)R;N_,'"W@A-,,^[3,GL]'W
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M@9JP'3]$$Q*@2]=#-7LF))!.["$$.G5"7;H(MFNO-20P'-Z871P-,DH^9^)
M M,B>M</F+>=@6^G>S@BG2NG:^U66NVCW:M++W)Z0*'%8<?3ZXA2^ _R_0&>
MLRE)&8"RR]Q+T!'$UIMJL^TR57]E/2D?=M!X_EB%LFKT>=JCFD%HC6^EDH9Z
MDON \^N>7+.XOHY^=BDP(<JQ.T9_Q+S"@(!L1&G$T^B4"JSSTABQ\M*!.\-W
MY-/\ 41GQVQ;$^G*[VJW .W#;I4>U7@SO'8#=^Y3.U=]@<IL>)S$Z[HBU]>B
MS&,LUK-'Q64Y_ZF]B_^/1\8<I[]F:MZV6JU<0DQ,>(%B)X?,C5=-:A!S'3%]
MG0^Z451EWC<9AA2B@3XXIL3E&T5-EHFK<*.[$W<ZA;]*6 M,EDPA)NQR>F<.
M7W*-6AD@ ?!U$VO4D#:B3JW:9X%15Y!O22<5K&Y,6[(Q6IJH2C#1NE96.'PB
MN^C'XVS[S&R 1MV'8U:<BQTJDB!LNN7.-,K]XYV:^C,950<.![2%>BY$C.8G
MK]PY:D>ZD(-"+85'OW47.X0/*[RWW-D*;K0-/EI@\F^,9G%'?)DX_#'JRQUB
MBXOWUMXLX&#(C]5[>H0[).Y$W9:$D2-&"0FXB#16_,9-4'_M(!7$QU?'/AZ;
M)<>E!N<J>QLFF?YRKT7T(D);[JQC$6WKK.SWG)DIO6>O]&,2Z[!-T98KQB=[
M-I*F28EY&MN3/VRRYR6L"?*JV:OY'G)P"+KAT-4VQEKR?P-+CC*)M4C%JGI>
M$(B2R'20$29".O-E<Z;%O[)D-E3)^G0^,WG//_3NX;H'RWJ$G9B-$_B+Y][>
M4\\'S2;:C S;)G YRH."DNYPR;87F\W?A/U2'O ^5*I68VU:*<1K(PZR*3#%
MUTH+Q=JPL1E;(P-E?M)PU3Z0S(1@!%56^CC-/;OW8]AH+LP3,8QI6:V\GH[^
MZF'&(R=T2B]5PTG;'#KCS/%=J"V?H=/X([=.X[NGQEGIS"F&'[O;GGB%2KR/
MT1A[$IL:KU0>_-%*WVG\E<A/>@]6(T(+PN\VVM$5<,Y6:NIQ\B[E2=K@-:E^
MOR!Z$!&Z(J9.F.2R_T:],-02%Y%+=>PFS]0+BJGPE&0@6]9"AV_I8 "LQG/,
M(-5)6QA6KU;#VT-F8_W7JW5?17<\QV^(^K<6B5T)\K8?3<^8&1O]A(G"!>ZZ
M]0!8 *Q,-NYS;:V/,IE6J%@WMY)=T*LYMP13GB1W),#6=S1EOPLE';2!B9+D
M_!^P)_._'MUP>5\D\(#-^X2*!$;SY=* GDWPRW7L?A4M*-'P2NA [^J).SF8
MYE(<]KO:J7Z1H?>R^:&^C;/SE/K_NXZ6UFWL."]:S^GF6V'5/.AMKN%9\B;C
MW;7_+XVK<@42"/&]H-E0-XTJOG(%H9J^ % G0:AXYS]QB&U)8&8"*K\N]X_S
MH^3[]IM&B_XS7X0ZT%!"I[8HKEK0%'*0S_'/^4@1H_8_A W!^C,-F1SW-(TW
M#0^C\_R!E.1_^+.V]S^6RO[_LJ17X5^Y)8H8_O^I\_Q?.1#'HNZ45V;2C:I>
M"N-3%#\]6.8"#9(OOEPC <U+K'K!T^\'*HO36HA?/61996(8,XR#GWM>((&#
MQ](B_: Z46JH+@:<<\D0=E,L4K',_>-F]')][/=W%SW*7^Q\+4)+4'1X%]K(
M#:%CB6-=,X^Z<K79K-*I5FD(5/35XL'S%W/6X5*FL!PT:#R88"7:BV9Z]V6]
MNLDC_L/=2:M$A3.^D_P94"L>M6/>E;;>[R'C7Z&&=>,)OKO\R@X1(1;S$F[6
M$H#-#=Y!9L@W5\Y[(=D^H5*QSR,]R)WPU$2N &$ 34A],"ZF5<&OD18N,9@.
M2;M.AIU]D3$PZZ9[E,\KA-F#A2<V;:VG.B+ZZ(.F6/;T[&^M)\'8CM&,PP\Q
M5$G1#HF$"14QA_2(;QXC0K3A_3--OEP=M57UWM3F<H1:S]%,2+^0=:OR4_44
M*R)4LLUF>#U@ML7X']RB]P:E_-G7,^)7!M?X)6D1_DB@V:PBS4,H?\6W919"
MUF_G]DRZX"3A#CW<;P^@M&CNMO!R$'I(W>X8F82.B%FZ[+K$32QHWK6/+<]V
MP+UG98//0*-M5UR2DX(7W.7A3H?(@]/5CU8$_(@/$53^\AJS)M(K&-4SG'T]
M;@#(%U.>BV)_-MHD:3)#_][Q1$]?6I?0!UTII-W;4ICSC"FX-ETS.NL52\)&
M<F/+1T5[8'\)ZJ6Z^& .:30X]Q'-%1.;'^28#;(*NUUJ>HO(P L%+<NXBO]C
MB2;X=I,6S4%&XRU[H0$)1%2BK.;7QJ8T#SZ4WZ^E3U\>\B67C\C7NDZZP!/L
M#W!NG!\3Q'T?ZOCDP*P$50\#<+1M=H2+$I@:#Z1\*1B@<8;1__V3$QUNM;"$
M:^9_&=J8=RX8T5;Q$,IZMQP/7230,PNYX==:N(^0@B;2=I&SIKNEGJM%3X7U
MO4PV\ZS,$4K I+LA.L$A!-19X#32C5.--*87NK&8R2[6Y 5*^ZISXKG;J-%%
M6,Z.2Q'3TY4<8;TRA.6X(">E-=K89VR^ZB=SZI>\_C+C(3/!]%3CB 3@9-F)
M^DF.7ATSU#&&*=,4E?YKF9%.I9V$X.:U:>>D*% +Z($9]:.#Q).LFB]@UO5&
M$V(0-QV&4#FP]H!*W &F&R,!$(EKC4-';%G$W\=0ZR361X2ZP)2M+U0OX*C!
M%KM#ZNU!H !1?:J%G=3UYL8S='X^VBPMXS,*'T:T/G?,S3&S)@+8?J8)V4O\
MO?70U3W]PQR6[0]E^^53DZKKBQCUA N$!Z;:"^)KVYK1##]?G8>Q'SY=PO?X
M*K8I4RSSOP=_5!WD!*IR-3))YQJNJ$AS*S)^Z_.\\Z[75MN7.N?5XSH-BJ[&
M)W6,0B?&^C@W/=ZX+PR')R/*++N/AL@11N]+JF-4ZNJTNN]39'8.)"PQZKV%
M=B.!'?7AI"?!_%SQF79JU"I6;;29KL?I:WJBF-P=/_SE-R_F0O!?!$0=$]HL
MQM5DF3AH=NS:VUO'.%QV_<)3-DW6M1XR/1[R5K/OQ.[K5#I-YNR=3UYJYNN:
M+$NE-LK=_#(Q3\Z2MI>=LK!Y0_:K1F9A>^?M1SBI;]3/ZKD,AR6[HNW6'=B,
M6T.WSC?C2;F:RQJR#M4IU%RJ,P[9F52X1I]0N#=D8[.L1<8*N_J!_LG>.8<4
M$TXYE58^C>#O&=!)$K\4-[M(4+^P]%VN/2R__(D^FB+H4'F8PK[7@ LB+TV[
M D;WZ\G08\BS[,P\?A7.USF%IB6XYMUI"S1:[][1B>E@\[%"["AHY:OCFQ'G
M5F)^MN^N3PS:&D^ %CJ"XZX4$$Z?N'?M+X*\8[$IRKM_/0N\2D%+^.JB2IJ(
MV2;'VR%R'Q$*AI2>R)37;)CQTQTF\?VT:.UW?.+!?^4\Q0G70(.'J*%*-P95
M]>C%<@AU>/B&YOCG85=I^'7>ZS>\!N C[:1''J_PA-1_NFHOB+":T8-.OAE7
M7MNS,N*?K$#R]5**$X6<,:^XHL.0@$X!$OB9?JD';;JZ6(0LO00M:Q<0(,(W
MH/3># &/WTP$K948AA'A#K198G< SETP4LRK)]&@TT=ZUW=VM-K(KYN\;]"W
MXAK:.+HP/&94>5U70^N=#?Q[KM-0\7Y3B@1*OD$V\=YS0\ZYXRTOCE$>4=+_
MGE/7]RNF0M=/<)YT""3W7!(4M[+L<^A=5J'*>>8HC"CR;4<"93?IZ<8JBUNU
MZ:8VKWFY?\V"O^A>6LDK5-A!RBJ*8FE\[2C\6,6WE7LQ^OG7N<BF(=1FOQ?W
MV*E]/(0XEVB"#&MYDR@F6!,W, >KPE>@+YW1R'./6X1<IL*N)!7=:1V]0L[=
M(I([*VX((#V?1\N0@/ Z2AVIT^%$!22+%'M@UO0CEHW)-U^SK&O>>> G9]X5
M7ES:"-*'@[ZG_JI)Q,W]F,:D_Z!LE?(I=1,C&:J/@AZ+HL1T) \E$6PC$+K"
M@)]L(@^O-(*7WVQER#U]DN9S5-B#GC)DW3R$Z=^)\-]AZ)1[*_$D?T&TV6LZ
MCQPX!04G\42(#J>,<LU6^BK56PW0D5#0>1)Z)>!:S07/XSB=>=W<WZ9F&X[0
M&N?^P'7.FABK'SU75SVT2!<V5:AZG>)[I9V*!'3Q(3S%&4(L2.!9L#]DJQ7O
MFIC)\X@MN)'2-!D[:ZPBGD6[WT>T=*Y3*)<V)L*#P[%Y1W=G6<%/K3:[#820
ML<P.E#/#ETU#_-"T4[0/A/<\P2M40D"I@Y$ ;I&6B@$)XW(!+SOZ "PXVV*O
M8LU9#U1&7P[9I@<=,V[="7LH0H_X#54^))$U,(_F9__P1D%LUEXDOE2'P:_)
MZ/S8$F_15"UN/.9HMJN!);V\369(S >D.7T=#X+.MNM7(OBNJ(L=%Z%J^<MZ
MI*;D+)7>EC8XI8J_ZOA8HC!+SCI>45R*("J/WI>.<S%WQMF7M\.'7F;ZJ;7N
M L=H9%=F?6EH-R2K4C1''-DWD5BGEM^3'RD$<<O)SVT*N,>?.BK+G:9C'$ZW
MK-1;@,[9PB#3O<D7BHQD)ZC!0/I_.WWN/WR@_W.+GVKE/U?[ =K_TY]%2BKP
MB+<T;7UXG.C#--(SWCY0%MB@4[%P_6!BZ$#5L):Y5M?S[:%_-9!@L!Q"99:X
MLDD_%CZ\%8R-3Q?G-;Z85D+2,4F@=QT\2A&?"_K>FN\#92#[]$;DU>C"N@8#
MIV;]FWRG;0&O;WST(87#-X;73B';&B&K;E<WL($+YKN+'=%G:N'S8I_<#R22
MV5OI2= 8$ U,30>QFTC@TZ5"+/W^^7*Y4Z+U3HA[ Y/;5^_B?J]MC8#9L%,!
M<N;D:KAA16$!+^>T'ATGH/_UAT]W]PW;VP_UGS(S^]4.G*84F.ZX>I/V\*&%
M\Z>N;+*L8F/XN4@@@3:*8S4TQ\96"B10.B]N8_;DLM-0FXV,K(WFT 1<_\'$
MQ8ZE(3%SK4\J_)UI]1-* T-?PILJL3H;,\1U\X'&]^*^K+.ML_AQ=4',(-L?
M*='*A^V*CVG#)#>@E0]H8@GA*WTVV?'P3Y!3I4F='\'5-V>%SP-33I1%#_B^
M[RY-B;O[;V3!DT)P"FP>T$4ED_T@M-0./ K'K-(,W^C@J>1L(X(EKI5&'HR^
M^/@0RO#0$?75XN>A;K+X5;1(P(?7N.#."DQ$ZZ2LPG]]3Y*&R5L=,S I0UD"
M2L5>M%J9H& *7V6/E>3 O;^4!&F-F=R$<-S4M_T=\,%O_AN%5SIF#NA'+?JN
M<-&ZC(\_#@,)KO?UI87,,BCHJQ<9/UJO1E$,@;3=R_\$V_>$4@+6/>COWYS<
M$7TZJ:0K]\D]^A"J'_F.,C!DY9BPS+%.5B;5YU[TMDR\:0$6+JXHL$=;9')M
M\6WAM<9+\1FV&]*%M!(#N&%0P^&,KIB=\:J1;6\UVN)#-T:OCFB'F'"M#S/S
M<[5W97ZHHZ,%!I9 PZ0F-Q?F9FY 5F[R#7]%>M=227N5FF>4WM](GTN2/32<
ML>]DV4I!R*%+\RNB=F*7^MS<,N@7SV3$YX_4F&<-':AHGX93-*\0E'FADB0Q
MHK/VC7W8(+6Z$1_[BZ"=DYZNG87,:KA<160HRUKB6NV@5?&S+$&#!/8E Z63
M6HJCI_\2:]J5 1'931C+8Y<>;4-4*NU)G_MMH'$%K,"X='O,OI;-R)">UY^0
M#E&Z9AP-@&[3>[9OGV0<3M-]>7X]BTH1$&9 (6MZ=?A"[ZD&K'.+3.E5>I+[
M66D66U"Y3YG+MR]J:LW?<Q;F^2FAE!>G7(TUXNX&ZN/6)%6T @+,21$=DZ4:
M7<ZGO'U@6K ,#_V#C>MB??F83@%EK@</HI?7^1Y@!>9"@=4039$:\8+0QDR_
M+4PD\-!R1$,9D3<X>2JH->N2+V4W1VZHDV+3TT;S3HG$OV"OV*#B5U5MG:U.
M1ZIJ"^57CK8IPIL*R=/U*?BE]XG :1-K_&+V8FF=A W<L>^MC4#OERI'1Z87
M@:4;GM_<0)IOX&X9T1RZF4'PRJ#*^G@" -ZU<$:3R%:DN$4'RED1:$&55R(.
MT2 HJ-R[3-;CRY<O+=\9%QJ<A*"4SF>$ER'$,YHL=7._=5MCT-CKGGT,YE]N
MZ*#13C4[>GHMA>_RE3,EK42KH]9&M\O$M&R^YTGO.1;[8LC/8,=,ZI=CHZ>R
MLN5)@QI3+!LY7>9XD4E6-@H[MJ!8^\/+GHLDVG,:B*"SA<6(AMK-BXIZDX[,
M1%AKL[M#D KI!F8T)26Y/XA\"\^$;BU34MP3F_%/T)N*3?6T4ILX:,9+*;Z"
M$#9I:34;J!.TQU_D#CJH#*O,B"= /^I:. 5%T2UPCWX.OB?.-<#8(SUN*&#U
MFS;)Q2@3CTS,DH[;LUTX!54C+<D=]O8Q8;.Z6CHS=4'-O?D>_*O+(:F9(1WV
MZKQ#)D88$[-Y>_-81?>A61K.8Q?S%+/Q>EU[#-MV,'<=WB:%)GW[7$W4)-5V
MC7=4L.FJDUD_UB$H:T;'4A%M1YDDAH9^W*%6!G_)9LE]9<];#*86KWY_KH!Y
MN7#L9N$K@[>MX5VO=\4_-J*]XS@E32QK7:O<;[WJ3=$EK,!W[3(ZAV@<'26E
M3^H\ITUT>--!L$Z*"7*94[Y8P]:+Q=OF0RDJZJIY,@1RM3A1550G;:TVJ]P-
M-$C0#^='#7K?JQ3\KPOVH-7E89(:_?F>G5*OW5 U[GO$MM.OI]P.H=W?.+.P
M5-)06V"J;(PSWBW89W5-]S&>>.5VOP\7]P6?JU%ZGQE=IPRMP> S.XI9-*&/
M8;#)VVY@0*/<#D8-#<N#/OX;0P$L/DEL ]YGOV6:(S[K%X$:=N224<7[2N*)
MB2''P\@@R55H:@_:X0!#8$K%5]$2/I_=E$7QM+02UG_?J8SU2#3D(*>"TA86
M&3<$6$44@0F&WJ@B;:BIN')?NHA^-K4VYG)\>=N%:$A-+&U>$L06ZCY3K3^A
M$FNA))!H"F#9*WQ>^ZWU>BE 1/_[.]9["G!G98U:/!.TEL_$<,C!^C71$*35
M*/W:%R9B$-^TX3.R;M=5)'QQG/GO^Y)(S>NI=;&3ERA!O:3"(/+D#>0JK_%?
MP!/86GO"%II.Q@!\E>+B#=A]VG1)-<[+\PNO_HMJ*SPL@1T)_-TZ?<=+_R$M
MQVHX50$L;!:9567E]37&AS)!?PGH2KH7*F3#LDQ.GQD?X'>GV\!GT4/Z_5$"
M\:>)7(7<4&[FH'K(_]2C>"S)-@]FNEZ%RWR _PR3/.D>XG_B8I>^$TE<)%O]
MDOAI'2/OV+HMEQK1D#_8W,B'>5:P3Y]I.>-],UFG/.D!4WK'C&O5CI$9T<!<
MH(@*5A$>F;!T%MQ6I2RZ*60.&U,G/V?K5E::;F6EZYU9#4LVP4R]T\,O2H$H
M9\"0?)!1!;<KG",8P@@ZZKB[%_:-H?>5PEE#$$K+CY4QO[6S:--<\0^/:&_"
MBT+-XZ"NJ9Y=X>\MA:ZM+\8VX(8-%9'J$1IZF?75TVL$F+2TB :,6TW)?7(1
M_.S4RBWH@OF>)8F)"=>KYM%Y&4ZPJJ=82S= U6XW\-CQ5^?".9CM26WY5\Y:
M0^T[^SXBD;<--^9D_;D7*K&OW6$#V\SW\(@_+.C*@(W,'+YN/J!_KOT(EX.C
M+5A" C.H_$=:[/0 ?J !G3_'M:,VP1 5?#)FBA&"DA1KFC^9'>R_$=,Q6?SQ
MK$_?%1Q667ZKF3=3U1G_KB^%%"GNW,HHCZ);L+]_Z[_O4HJN'[)[W*@RTQ2<
MF .+0].I>FC8*9>^)$_F9!NQ0&BJH[R*)L9M]\?VI^?32M0[9HP;PB?7C,K#
MV8^<MMF3^,YE-N+,J5G+:X-79%V8?^M74608OFD-=KI<Z$3Y!7 _*/<SB[NZ
MY9$ %G."'H4)SI<S]/Z"0L\'2@VU7_D[^4]V348=:R>92?=U.\_!&>!<^O86
M(210L6M\L88;+GX13&N$.;UI7/# 53^35C0TUH):WR,TIS?I%:[T2;;L2KZ@
MUC3,$KQ72#5E91)E[SG$\-"-_8^*0W0_7T2C1'SG[%;#E1SS!K=/9;687?*K
M).8TB;3QNVA?"EN_"^C45(F=5.&N:VN1>6\8(O208.MBY*26YM86AJQ"IL*&
ME;0/'1M'9<G8E#L1LY*SNG(_/!RA^RXA@W$W/*/$ ZQW8F/C[SU*=SY9/0JT
MWKF50-Q?.ETGE K2(EU28EO:5S<LY>5:#C6_&KQ9[^G;OVFAM&ES\;=QK)(W
MZX:QJ+G4T)'I/97D'$(%'8[ZX6P68 E431?WPA FZR8?W,XN5'O7"^ME]<$0
MEL+M 9-GC R#2L%=E 2#N*8=3?Z%EN36)D8N5B4TB=#WG?PM:[Z8]T(*1_YH
MTK*;?*VZ]=B?3N"_H8]*]=-P><WW!GR/?@7!QL(&!2].,R$D,U*?J(XT%K%-
M*$QE2E\I"+GMZY_?GD2XA)L4?IG7KBV7NB!OD.W/=,_0 <ZW',K<9/()/-(;
M2;^WE!56Z@1ENV'%+$4PG<XE0]5FRD.KKN&1DUZ:?N^3EU*'((2^LW_KOVU7
MH^(K,);U)*89K0]/P05E.:N']TD9LIC^;@(J_ZR59-^.Z"EBY06)3ZZ3\,?4
MHC\\/?!0IHR[WBP#^WGU/-,7OL/70="D[ 3WABVWKSY[TA"E=MU>O-(1)>V3
MH0 8R]-O)KN6X?Q3MN^41#YYV* ^*J! :O+M4-#,6GBLQR,+ ^7GN^ALI*88
M62A1U]PWS^O6JFT6T"!D;1'%,X-[@@$RA(:!O=64!K8,D]&S'3Q38W)448EK
M0Y%6 ^19>*EDGUHZN /2YB-O(RY$95L$S79/=N^$$0V)0X6IM3[0<\A0T%L3
MY"Q,DT'10RS*LSNBVQ1(UELO=S.69$K9IV@63C)/>G%T9!Q0KN'![Y935*$D
M_ML^);+1$1VM;CV[H*FK5?_S27>^QP.45L(G456.ZGQ*J)#]]=,QX';?IY"
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M+^;+T3:TZ96?I-/BS;WHPOL?:ZYG2BD/*WDOS^=[#V>4^]9CKCQ=UZIEILN
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M'MGF!0=KYK-]D5]SF-UZ:N6^]FYH>.:W"]PU0U-W0>< 2%9>(5K#]EW'\J$
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M)+0QN.5OWK'=^['%9^'$X!X>A?KX^E&'S;"$3%,7-XBB!HN:IQ[)/^K17?2
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M_Z[H^>>I%^H7)++?Q,^2S^@ H7_B'";M!&KGC2K_RR\ _.]>=TQ /0WCO)>
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M5%3&>Y>Z9,QRG@]TLNPS+Y AO"SR=L7/7I9C GVR<Y:,JP@/W:L(#U>Y<PV
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MOZ.[Q\ZFL.VBGS16J1X]!/ ?2[S^W5/FE!:Y5''NA20]7$KI6F2^89.<8#S
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M2H?PA:ZU^::N[1"N+_<U UM_;U4Q3N^L#!GBLB;@38QBM'CUAMY3@+SOZBG
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MZ(XJD6[<Q0Y>;Z(OQKLZ796(8SFGB(LY?);W5_3GG + 5=(E>^;C4R\=T*<
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MI";P2VGF+Y6YZJFW#V+"&G9(AJO<WDR89\AJ;#0I$Y=?CS3#^N6H*SMO'G1
MW217*[ <CK84#NK"\>WGHT+9FFHH-=N+AO>N<H95:B1TJ.P4\KT &1ZP_LJW
M=M"UJ@MK+/Y>JDQGM"CYW]>UQQ2&47W##L(XXKU?_]E9C(X,\F]:ACWW5QLQ
MF AT5WA'E(SZSZ+OMY$_+\;_V]XSO_O?GX?77_NOA6"R%_^NO_E_QO^S44=H
M96?TE9LN]*J :?3JQ\W8F%("E9FYF7,$IA<WBA6+D_RX?E"C\3?3L./*+'V:
M<O[J+,%,%D_?7E6<]I=L ;A;;?1/TIX"OD*J3P%^)$.&0R*_$ATWC&I=6$OK
MJ@878RO3IY1+;IQLQ>D>1%E(_(^=,[QZ6X4#)V\%?4?5C"1D Y?V*V5L]>W]
MQ:),F\K*WH4'<8S3C'VE?54DHO/)6]3J&H7_V0ELPM.RXD0.'9XO[U,\(+_A
MM>CM@G5_L^$>Y$9G^T3[EB:( W,8[FQJ, _G>JYPQ;1QQAS>A&6#$L-KT>R;
MF^@.QE- -GQY\Q2P\I56*;V$J#E[3-E$WV?N@)JR#?;@8_82YEX@ESRDF\UW
M. 5<]>6?\?@@%O:"'\3U;(E1-:HS>3KVF1H+F]I7FKC@YHU30&B=S.S7J=%$
M9#WN[OKKH5@W*[U0<K(#HWD G9%\_6PA9?/5R\A"(TS[?8$0#N(:A46N_"LB
MV8I)(K0E]9P]^C$&_=.]26D0?VF#_!1P+LK ;O,K34_5A/ZL45BFY_)@DP0]
M&I]KP3C,&2[Z@/I81)/\R/BEE9PG]D3;0?$44!27^JN/HJ]"USR\>%/UAS1K
M%W#*,W#H::CNP-7!F]9#[ +BE_:_TI!4LZO5)TOJ3>H!LZ6:XX+XZRR<>I!/
MR8L 7L?+\LV)R[F ]&H?]H\--X: >O1'OSP'Z9 X3>;64FJL=]E;+USH@"=\
M5N*]KZZW0 4,PK06KM'4OBDS;8NG(7M#A7CX7?XSV="(0K"ONMT,.XW%2OQF
M+U=A4??2.?]%EV]4YQXM-]>_,4XE@D\!T4I%IP!LX\EGU4<LIP"BJ ?)R/]F
M+H)/?80?X#4I\#>GQVPO[27^Y#\^%,3=AD^)W#@RM/*WI-_8*]R8I2Q451Q8
M%Z+^]>UE57FXZFVVBR8W+(Y[FQLO6GSOZY@!WS'8?6#&2?H*C/>\GRN933.;
M2)^L]>O]6]QIK+WQ$>)WKW0P*4SJ^\O7T]!<;H$:__*3W>A&_VAD!#7<V6CY
ME6?C^%, ,H91D7C2=A ;Q"&[N4Q6G.%J843MHE0Z#"Z=FWP4PTLA.4[6-N1*
MY#UW?#,U?R71Z-UK(23L,:;SG'M^[VV+MJ*+WJG6YBVIK;2 *>V2YEG)FU_>
M4FVJ7]D^&<PE7TD$X']G9V26%D25U=RG*LBY'= 78)*(#JV@I;6/DWZ5#]_S
MZ=JC!+/'<*QS^8<;JK%$#04#)M*KY7QFK0+J'N:*!186ME!CC@^BI;ALI]F3
M7J3471NI%%6X_KJ!J](GC%D/51]VB79>7N/&H..RPBW 4'K><DT6(B1KW-[L
M_:165ADT3BNKLK@(P'ERKGK_(&'Z=YT<?2TWZA9H4*U?F4/YMMW+Y7/@2:>H
MZ L M\]&$D%UQFF>11C-,%K]P%V.[Y'<2MS>$#URJFD<1^E.KJP2#DYU8( ?
M028YF#HR=W#65?$ 5I\!V0Y67Y-_3:\&T\ZJ!A!5W>,2+>O!@EW'[<FBVHO]
M2F_5]UC0^H\NW(PJ\LQXO#&DSEW^#3-&<3Z]ZS;5M!NF7@<24/]\U-=\@RW'
ML03H&4S&09+<P6J*G-/.RQ< [A5Z_!>?=2KJB5SZ[<!COJGR828W6LO.$%E&
M<UDY[A'3]Q6D-V*"PAN 3J_*IPU!D ^MT5-"KSWB?$'GU:]^B3.9QN)14;^)
M2*#>E:A(5:5'+&ZI/PMO$=JV/<7Y'39S?UJ8&87)QB ]6%C'EO 6L5X+J:>
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M9U6]R6)\[77#[;I;[RGS;DXPB4S/E\E#7'HIMO->>8SX:EY"QZ_>ZPB2W-H
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M/8U J3?A%_E5TQW '-G[A\>I2TQM1H@]9[0#'-OH<&2#Y$U5W&2MM7=F-1
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M')QQH?$,L.A$B.'P(LZ0=/T=>'"%E*PB8'O//= G7F< ^.??%Z):0'C>B3,
M%BM)_&B2:F*Q0TM4]H"=!JB= 3+U\S0IO_H'5!E%?430BQ9(X#1[L@]Y-GL(
MS$0/4*O?MO#<2JI<ZQT9,Y<8:1D])?&P$P5[.D/O.T,JU])MFAKT)GWQ-E0\
MOOZ=E OVVNVL'(.))W+*>6\WO"2B/82NQ%OYZ$Y2>UQT)-_)H)7:B8P&=9T!
MN.P,T9]YO]C>>/P$Q1W]M@/OPK_Y@,I<>NADBK.HT/_&CD163K)499#E_*/(
M!:0B_2V./66:,\"%H=4!;VA;V2=<H&3Y6-I0IS[K4\.>H/G@.P'S0>WLP#.
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ML& 9==IRK@B]8")<CF*A<S-Z*_N+Z.LOHN^7%Z6&+/ 31H\E*[2JL&#>4<(
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M$O6KGXO!ZCN83 HIX\O7OEW\;GTIC*[_@/"V[+M-QC70PKN/1\8+ES0OA$D
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MVE2;&:]5<NW[B(\49LY3B<I^*(:]KY]HM&(UZYSLTVDW50RSN]IBD RU9BT
MDLE=B67:JE2FP@C@\<[-VL&.CSWVUJ(JOS]N58_4=#9PMIE8,0DVYT%+H3F8
MQAK79W1/BHZM&SGZIC=#DI.C:^P*L@H*3)*>+FX]C(WP1S#25W+N>ZLQ@ N4
MBH@V1@Q.C=;<DI4YPCE"WCO&-+]L.8F/>K1;/C21]/T$'AC!@E=Y6:H[MA/$
M2>+AV*Q]F)@8-M6G)&G:^#+V3GCIJJ;NLL&TL_<D1+EY$$FD.*K06%E6NE^0
MI<$:U?U\[,H'=WIB"6M=51B)/RT*NSY:OC)RG0VCT9([)HDC?ED!"WEB8L%6
M-TF;A6\]Y*&9(F@W0K0:,I(ZH.3T&(2Q?JKEVU5"<\CII ]<F1>922<L9%4/
M@\&^YW[,O98T-%@7UP1K1-7RR-!I#I4K)5WI'=GH[BH+MHP1BNYNO"*UM.LD
MLI QM+55%JKQ[< VI:*#7MAXD^T[]1.OAG+[35F$\4P*7B+B,M?\Y!=>!%$5
M-?VYQ,9VR;SU?'U9@G0)W\?>0W-VX2?2^"OF*OT%MSE^W%:,--[2N?7N-K5S
MIH\=F5&C4 U?4H(^0I3HA?>[1U51:'TXCJKDH6/B%?L$9]>,S5'(V*YWI3UJ
M=/F>A1!)PO()L8>S006:87@'N;;MVFTJ>H$@YMW[ZJ9$[T$2(TWF?G'IK(U1
MS77!!8+Q3^:W!QI?U=[P:CFY0G&E\U15%R%AM^,]B=ORV';<67[>P'1ZM@$#
M^+<)QIE!IZTGWHV^\E'>;:^YN$_AU>SK^+9SB3BY#(4D4O#BXPH:7_F6P 6*
MG6+X>KZ=)$51D@5^X @U#9518UUK1P<];/;_=O#"M=W@C0N(@COZ!/SNJHX(
MGT,XRQ)C==]CL:&[$E;2GG^^J*C&<@([9Z@U6YX.!JBT:SS^=.*?E&6X)ACG
M-MI@M^3G->8U+'8O(QF?^8/H<)+."0;0;81]'K'S::7Z<60Y<)91N!A[0)$)
MF:<4I4@MA;T?<FIPWP]0@4H8,C@.?A(,75#1..G8Z ^$+WZP;VZK>B"W4R.]
MQJE@MM&&>&QS5L.R=0Z9HVDFD]-)B'?[>5\MZKWRXGT\3V":*)EW?<1EZ10A
MEIR?=Q69L!>+HW4*SHRY/;8L;U*>?@CPD>_"M2P1=UTHYZD3RM&WM79.-7#G
M^^R5/\C1?$UZ/G#+-K7_ %1<.S-SKR>[[WOD$S/G,9VR8E<VW4CU,JR7T=>=
MQU<0!KUBA(A96K0]SSL^>*1&N 8:<W-8D=P,+'[6+ATR1_)]9)E<MUXQVEKZ
M 1WS*J=VDG5-E$?QYR!.&=X_AV%\@>0YI.6.F+:CM#_])1DN^X5I<G4IO%\A
M?Z2^/7DVNV&Z9G6!CJ=JUJ!4._]GG.DOBUJ4_>N@4N@4I+T6AMV AE*.LB^T
M_JI^_I;_L%#[W-[U]ULXM>)"3C*5M^+&A7JMAMN2AIR%W#<8B2T>&_]F;9]P
MPU<@2*!33%L.Z%S:O6/SS\<@%7JV2%[:70TJXK)'%HC!-2="'J"] LLL)2A>
MBY^,ROSGQ]K^/6'VAAWDQIJZHWT+*J=!BCD61REK[!>6_Y43HU&. <(#3IA6
M=6UBBLZ\0/T80!2HE25_C/,K1'I=%C\3T/QRNG.0%Z/:O=,X6/AK*L(*[E^%
MV.?=^XM=?(Q7\XLR<U_Y:06M#WX&W?=?%/R9!SQ/W[OM9#@>^+>!</^G)&@1
M+3'SR1*=@0'JU?XZ-?ACO*!?U4^LW'%PV&'J#86?+Q[#K%+Q?Z/?Z#?ZC7ZC
MW^C_083'/0;B.]M@5[@X%W&00Z(8Q)WUFFUF=@:41#=YVKZ?-2!%_!O]BY$,
MZ:T'TC<6,K+33U=^3\;_-F(]1"/.UME3">99R'SE![-^_J$TE:9&/VYEY5'X
MJMS/OR][_!O],^A":05LGS&YG/RNW-9UR>C]([7!3U0>0((G!(QV^6E2$F0!
ML=_HGT:C;NQ.[= "\M CDL'7=%>O02^&>6K5_EC!V4_7;!0!MQ\#O_9ST0H&
M_4;_%%*@"7E&R8;(\/O(=C',VPI297WK-"444*IOK(.("OU8SBJ?7S/\1O]N
M] _)M(U'B*AJ@L3!!IR<L_K=$TKQQ9 (H\-/B*MRPP+4+]+#MFE8[;)AM_SZ
MS)H9Z^\<A8*6U(8:-S]@@'X_\-,2'<(,7V)IAKSIKKT-X=SKT4?U<5/.(WGL
M"BS>S'K)-Q$JX?X-/8<=A2RG<O!DQ9RV*4L1YM.F/!1/"VCRA/U>Q&&MESQO
MGXFP0SL^XE)U2C#3/@$&J)@]O>TX__)56[Z$Q0P&<+;HA6X??W:+O]1HN\!)
M55L6]BST-A\I+[ $>)*UW\JQ1=^'U8EYQ<:]G!8/OQ9-K?WH&\LKL[Y+7QHH
M,4!'J3,&, W% *FWG2'DC4O/*S! D0"V]3,U5G-6?4QWQ5#:G3$*=VR,5:/0
ME&&!&$"R)N#\5 W-'8XR$&4[.]E@.H*#4#7?=L-]^:<A,J=V0T?6//&=[Y.D
MOK;GQF.;YV?\&=(WDH8!(&08X'U![F#7N@HL3F" 8\1FK3$=O*,T*B"\Q95:
MI_",4#J&G =(_N[-J68Z"O<2>QKWRO$[HN[SC9M X@<U)^&YD>>A<RH\,D.+
MC17)B.40W@NZ&G6^8NS(7"9LR_5_M+P5VW+&JN&[7"^,. 8:F:=J>WGM#>/1
M3 B?E 6Q3T]*_9=I66;:+![S)3KZ"_3KQIQQ8H /K4?GGN'G!+JY.OJQC-1>
M,E UNRN9;.S3B0VEB_78ZI:*JWVQU7&PLFC4O?8L1A;T<&H$Z,%N-%;J4W*\
MN<,"\'YC3B1;-Y%!7$7+B_4=F6,;@>>A]J9Q21G6..UP3I0'I?'-5,)7+?/A
M,,   DXW-533@SDV0-<.0N^K)W?9>H[$XK.WDA*P>%CD%IUQ,9"AO5U)3@]3
MSHS==X(A2R^&09OS>=6P!CJK40^+S.]Q0O,K?BQ/OK#BW+G<WFT<PZMWA=Q,
M=/0H;NU!CH:&S>TR5$J:F%EJ@_3&0"%(3@"V[E$?5FI[F'!Y1.];L]L=;P*X
M$67C[L1(MV)5'6Q[FV8NI,,\P=8>-\H7:&<R24;VHL@>Q[:WNKWWJZM]N_SH
M]1Q]&,F<HWXW3Y-N<U<A16U[U;!"FX+RX43'J+A2%MB'UR%+TI8P@R^TMWE]
M<N/EG;;RG*S0=&,;XMIW'!\:\E6!LXZB:_X2,JVB)^F/+&IK?(Q/<#;;I?#W
M"I4K><)8D7=J'XC%Z11Q!SM712W423>ZIM?RY!GA@4XNYTTXM,"Y-V3##B=L
M[[40C1._W0"#,O6+40ZID](5&R(.MR6,EYXQO=8 &8W>7R3!D<W4JTC/K"L@
M!.^;.5=EHW<EDQN3W!Z(:%N?LF<EC&^B'1 /A0PX/R5G$@X8/2B5N:5 %I*7
M?H':DU1;P%N#B$HIX7&U B.UVS;I:[UE7T2D6/P^Q'_B+'8B[E"\+\$SY&,E
M4]4<6?OH\1OCN/#&)84A$#P%'6(PE_?ZD+JC/SFG_$C0*M=9NO-R&FI6911)
M:F&+-Z%4W& ABXN[UE9C@.CS;]P3##^9PP"#]6&QUOY0_Z*M=?B3="'A:3]R
M70H$5<N]=0\7'<K(>T;&STJ+\,SI?SQP)F-4]4*\A$*;W;X[,5I[W%(?]3;#
M6I.?U*'NDP+QK=-<^:?M)\^+VUO]IGM#W$[.H2GG%ZJ+", J9TK.S-W,,I:7
M+\B;UF'+N8(!PFT.!%&OYIOMEJ_JRRR>O_Q4"1'WB8$/I\>:W=[*A7*XH@O#
MP%WY2(/K:\G" \AJ'3RWBNH7..0HNL M:-HY2;E+^7SRG=VA!IHA#3YF)8<[
MVT%&YALD5>C/]3Q?XP_B9_PJEKNG)RKCF,DB%U%Z:'H?FAVCJK.&1(Z[J@PS
M)+O<23K+W5R]GZO@I@N"$5#E7<.,N"]IW_@^D*%/=E"X^BG7D<<W'AW8NDVN
M%'T2XUBU?W05M<BVFP^ZA&*W190CM\(9(BN&M>8SF(LD_$S(<.3X)4N#?'8>
M<@Q%Q;$0^:&*[^];99#8YF. K9A!*Q^A08%.G6D&^+8A(,N+ZWB@(0Q*.\QF
MFA\-8"3ALLN4PP#)P??MSYU BOM<GLVC/DPC*K$&FF4*A!%A^LZCN&D= @-*
M)''F/%<XVDQ'$VYW%4A8Y&R_ND_G:?W\6B=?J)*[(Z!?,G9!3L5Q'0&2<:=0
MJ3_QE9H:R,*O/L[S;*8:%0T/*&"K"QU<M5; 3=-X)-PG686/*!)"^<WW;=5K
MGCZ8N,7%'69HM2 B%MY>M+INY.Y#Z:>XUSPZFZY6B4S+5.B4560K8LY_7QA"
MH_>,5^2BQ["=''I6";;:4&-7W%2;P*"6RK@TYR/0?B8TVG.8?*+='"7Q^2TI
MV^WT]7#4Y:\GI.MZC=?+$:X>\;*U*YS.-4])\$Y)O$B&3K4TNBWO6@XO?YD^
MAGS#UW9R9LXH185FFLXT6SM89-?!A!\R&KB"=B5CQG13O 1W=\;A"0;5(>Y1
M1!7'&WG3]:5G#>5K F%F5\@W15T$#4]B%#K;]K#;997*?_K#CK_E?Q+@(/OS
MAHWFX.?@G-3+5K_HLN/OR1UV]'&.#?;GUU8;Q)V5^:.'!K^L!ID_R*#[*71=
M.;@>4/A5=W"/9E^><UC3;3-E O>X_3.R%W[PI%_5*=OS9@6JJ3-KTVW:1PVK
MBU(D_X$<$_^[@HO?EK+'MF&*[("L/:@+;XX7.H0?C"A.6IR*U<F+.U!_E6R'
M+II4+ZH=DR%Y3I9 !S=-7'='T7(#&,"(Z41WT,+UMAJ.CN.TT#%S[!?5S\K=
MNR.E//Y(U.H'WO=",8Y,WM7?%H=<SSCS4- [:L3!=Y5IA?3U]5QN'#^C?;N@
M%A!:/K&I@UB@Z=#_NG6>L"9UABYOG]Z S:P+4I(Q=#][MC>&G)@$GQ& DCS(
MTPBU%?4F//.@1Z!.]"4-^\LPRRPO+@P0\7P5W4B' :045] <D(X>.PQ@8HL!
MTNI=4JY"EO2KL5YI&]8AO%[=&&2Z=]\0,AJ/ =8<C*@=CNG45JQ!<^E",HB&
MS%3KV:?EO@,+,Z;WTLFB#LP,3'?+7!N/D3 ,L#.) 1"NC;NGCV .7KRW:V!P
MMK@^QP8][3#A119=;0Q L(UURZ7L0!@ 1_.,XVG)1W:=:$LYN(3>_)4PCAQZ
M#.!;9PA94,JK*KI9(>M'$=>I<W'IJ%. JI7GF-*N<1,!.< OK( I%Q<_MQ6C
MLW4S\^=MR58;O5#M$)B:<B4+7RFC;VGX6T".*ABE&.VN/>(?J:)I79J,TL4
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M6>T%]IKXV!\]M/IE&;Y(ID&*SXS75[=3,N]Q'^#<_E41:<S>S0>9&0Y5/M%
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M#*%T LN=9G8:B4V2N:.S. =*R"AGWSE'6 WD;SM3AC/I)>%,U4Q"TD&:6)A
M]D)Z7_#:2XG-C@-0 .--5-Q"@9HNXG@H_X;?8;.=;Y+J SF]:\SJ4Y8LR%X5
MC[[7VZDE*.TTXVG%$L-OF>UWOP@]U%:.]'Y-L;)W9HFP#!;0SQ?'G8_@=_Q
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MGR3[US1C0.3)FZ\A=K,R9RT[]5I%CI(R*]T'#_C>ZE.6^$G-9%75R ==\20
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MW!3T!'NS/,#DBHF7%T/DQO&LLBU$R$4S#MG]"<'YP+'VN^0$8$#2C  TT1$
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M/#9@/*WJ['3939'ACYB['^]]BPDA:2;R$[+HQ>=82TSN3T/_E;#A=EDSY4J
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MH?(>6>9EV33G%T:A7+K7J9/[+5G608OC>S]0:R:*-<7U7Z382"_0=<$;Y,6
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M6H4TW6OR9=E"5:A\1X;+.5@=Z\$9;GQ(Y97;X96:;@D.7?USCW8IOHJJ9LK
M90R]%A#,\R<N0A\:OE-V2;^)>9<QGN2T,-1E(R#)IC8EX:%7XHGURO/B>.0L
MJSV._CJ$T%%?W)]:(;D%D$:O409YC@1-Y<:#S?EV!1Q<\+[?&QKK. ^4 P^<
M<]J$PH3$R<9X(NQSKM;Z\7AE\A^ 4B _ [CJ3DU'Q*57]U00N971O _;)5::
MN-&?< 3@[FE0O^>)8[IZ<:;NV>2&D\/JT2G5%L?@KI=AZ*9,H(S\6*2G<^&=
M'SN+2LXLESL4'UU[YU+3^734T^!+O?H2&V]#%9B5QN59_8PS:8#+,I_>/@%(
M?0ZSSG7@/Z]T.4:O!.!)C_$FZ9-$V!$K"O7L8,JW=0E48Z1YL[#F)DN[0WH(
M$3IM?S9<CO5V$"],B3862WK_A7'N$<FGM,X7/4)/K+]NJ1[+&,;G[TS*3C<E
M[#3._SG:"3%Z)N;*69"-B!T-+B>RV-%.A9"_5ET^U>[9EH4WZ+MX35CM9:=G
MU/[TZ+W?SJ9]V>6]+=[ZP ZK^O*D2?8_U)H;/[PJ5.1#!%B<"0LR^*\2N4X9
MT]I9C8D?<Q.K'ER]=HG.E46'&-#\1XHO$=&A2<"D.8C^!OPW%46?^HS$GF7L
M.";/6'1E+/@H/9&H5-#T5NEVI640/L&C&D6-[9#7-JH9WBU*>5(',,]_J7GY
MII.;8V:->>.PY%=]\L@]G21!Y5?.+/P"&=\B!&Z]_2><0OP[T>1?G:3QY^D'
MD:7T-E8LG@<@Z&;5*L=]"TZ&WVI>MCOM#_YY=@'2.$]O?(7-W_,T*!TK.6H"
MF<COI+BAQ3X^]M4DC4\\=8^KD;/F]=V((T'7NKZ1(W_PY9H1-$"IICS6D[W'
ME7VZ,^_C,J+$J0-\*Y!VM#."%4:V ?;Y(F>E D?39[Q[\O$7Z7>I>?HCG@H_
M<%K)5B-':DE:OJ7#ONJ=U1A^$TBJFZ_0(VC+Y0##'*SU\1\8QC2QAUM[2@4F
MI.&QSY6E6#:OGCXEMR(+4C4!C@G .YG@FBPH^=/A0"7G94L3E_="G^'GWSOM
M[JG-TT$HM[8@C\>*Y)0RIQUK;5O['=Q28L-U-J]N*\['=-1H1X%ON=(&2HR\
M>J<2L[K+Z":22M>?-B$?T[RV>9=TM>D:RBQ0$9OM=1QEMLG4X^R$V+&YQ:6X
M'Z*]=%0P)[5WF'X5LX+_XLS;55E&X7RGVW#"K4N)=DFJ:P>DL0VSVP7!'+%'
M1^K7O%B?DREH+/LA$Q1/77EFG9 767)2O*5#]:K42H%/G1^PZ,452=[D&Z!K
M0^R"?I*.XVZ7Y'ZHOYV]===0TF=SY_JRP*$WCODA[AZ,SA%CS\DYXNWWSKJL
MRB^" $#SNK@^-..<NB!VD&N1:9P$H$T/;%L.JS!]JWI6R?V0=+*& +P9U\*L
MVD4NZ&_R+QHOJ)RYTN":,T"I]P4K+#^ (1$LN>3/1EW4XW3KN3N,WJP7T))G
MM >I?PV\O6<19LU.JE31&*O:+W]H9><99;<Z'P1<JM<^]OK BXV$]F64^]M$
M_7$,ME&"Q/)@D#G>5!.'LQ*;9[8^$5-,7UH!HX*W3T51$<!^_P=+LG)S0X6:
MQKV=M!LQA:^C[RDY<8Y4-W=KA03M@,VLX_NKV/9,VRPD]\:C;M54#^PZET=V
M_?8-=C/:>Z@A;,"]_/"PCZ*D[A].V$H<(%R! D5;$C+FC8BBHI,J^NF.(26Z
M9WTMBE(?4VW.6($1[#0!X TW)P!5L(N[,8U!6,6%7H%VL!Q<:\PY>-3>.<N3
MZW/W ?6+%35(<= 53!5>G;:. +@0@#,=CL#\!0) O]G(.$J6G6D>E+A]4Y$O
M$;F?GDE]]>(NZ6835M<2!%FW( #=TW"\M"J.7R@<<2@$6T9W$@#V/PNSPZ8Q
M(/P[+EP<$9LN>6<OH**"Y1LQ$@EVGDC7MP%=5K'@3F"F:)[^XQ=V5N L?6B,
MC4U*4'#8ADZE5*6&SS&OF87(Q;2('L6P5Q)RN=ZN!#J.KMU2/#;=JDS<7YU:
M,.K(O>_&1GX1&^+>R7SCL.(ZR3P78_ UJ&%;\)5XX\%O<7V;@TNZK#[N;BQO
MTYD1*6DS+UYPWH-OCP=XB3>X-,NR252J?PF@('W!9:4(,0-I+.""BK!K%M/>
MBU+>SX<2#9RTP;_;:"EDU4Z?"[=L^K4'^#;WP,F%PN^4[QW^J,S>;R  4Q]Y
M]^F;7U]2:8D#+B_)[?L!K5A,)K3JIW\ZPC;+P3 I6;\<[/19C_OW;]6GN91,
M^#/P81,-F&(]R8(Q5 ?SZHO765B+A[.='_?^<PFF>]FFO-3[_I(:)S*]X]YH
MT3:3Y[7I2%^.XJ(@X[/2[0*9N* K0& F)J"%T8(<\]JGU@DRX9)QK9VM]!4\
M+MMSQL;]"/D-3.?H:U+5.LNXN'OG<?0\M>?!?9>N7(0MZ:; ZBZ#XUEG.^(]
MV#8ZOGYXD4K36WI_45=MQI\V^_/A\O@8F'& >Z\J[/""86(G9H@[K*GQYTH*
MQDI[28$!&FE9NM<1ZEOD*/*ZLE*KL\8*JL^Y_!'"BJW[.;6:O=C@<O"3:=W7
M3(/D;FX/')Y  @[Q.N[UA[0CF6>Q!*## ']]@"6WM K1K4C/:];WE(JSW3!#
M'HSI S'B!:'@X18(-4XR:_H/A[#IAM^;PFL:>HEG/IS-S\B-SR5A75\*","$
M @%8+T?:(9DO4IJ6GXS"MKEAAR:&90/_ZG=(R3^C?D[9'E;66-'-,PC'&DL:
MLO1I^6>O1EK#O)(DZ9EB%4A7N=T\1 12QW"L\19L*0;TK9,.3%Q>YP'>9X:!
M[L\T]J5R'YF#Q-(E:S\Q+I L. 6H#=Q)Y''[I7,M0:_%VIP#$>Y\?QEUYU6L
MZ3W3$ CM46$40 YX(26OP76?BM4>$8!;^8,P^S8%Q;9+H*_%0;>X9/8?ZGF$
MQG>>'N>#?S\P>O ;X5)1DSMQ^Y,=0.Y2L?JLK4I\DD.M!1O5'LCBH<A]&GM(
M]*:&4:;9*S.-YC_Z19=DK:_$@-\VI"Q"<!]\(4=#D(NKAE1[=7B5#@* M,,[
M69J'(NZPZE7VXL,3(L/!MX1W/)LF3<9Q6$L"@$HB )1IXDUT]OWL9)O[J)Z;
M?X@PZA" P/310QHWQ'5!KX.OMW]_$PXL8;R6*DH=W8:"_TJX[U$H3J'J/MHB
M\\PSJE((R]7NNBC+K[O[R[1+^Z8:V\@)%7JHF@!$Q&PMLID7M5TP>T'0XH98
M4P+ \P1QM$T >IT*,,B(I8$*(V>4>D6]X-6@_2/VV)CPH=SX22NTEJ56Q-IQ
MM6GOM'F/)0V%Z]5\*_4#%'+!/.P%5LG W.D1DX/=C0P1D5-WKR7VP^N[#-#T
MGC:?@A/RP'U889A_5<TAYU&[@4C:J[C1AIA?NE%W<^829V:^U9?A&6?[+RZ]
M) !-G3@!P\=8A%V =*1>B/%R2$QQ3=#)M2A]S2L6]W9X55E4GG:G'5V/^+7.
MHG:OC3MFL4:( 7K6]BC.5.WYS%R.2,C"];6/VB6R5M]SGWK?[KGAXRH3FU.3
MU5<;L=^/-36$'%*$XPD UUZ>2Z, JL>9U\U(^7(1V/AQ2B7^\HMQC69#-#9U
MET.I:=Z_]\8:F&),3BG?*6<5SV);41WIFE+E>&?FHP*[![0DZ6>ZT#!.EJJP
M.O' 1?>*W!J[W8"!7EN?N'SRZ"FK$CV%TI0\TY>!00MC D#EN(9_\Y"HT27\
MC<(,G%;%B$MO8^:ER9WFZ-$3?O!IQ[V5M\@;O@P\49E\-GUG$?9N71QJ]U04
M.;9ZK;"YGK?W36&V/R75KH$=CCJS[33"-*J635E'D90&JP'I7Y3=.?FPX60?
M@N]OSVO6Z-VRLJ0,'XZY\#260#!JSJI4F3BJDD!D.V^^(AVA]C11)3?16=54
MDK9:[S K3D]15G;VI)FM]V7<O_^Q2Y(GO^M6=HE!D=?.?X/T#D ='-KGUY:B
M8XJ73U$O&9/ !NBZ8PET34N'>]3\^/#H ?RG]JFT$ @V/H8@ )G* #&BO4LF
M /FJ!.">Y44!'.N //L$V\\F>OO"=<J[I(@][0\$8$%X+RRFZ1A2>E'X^Z(S
M9=5YFH=OKKG/9RW7_W2W<^I5=C%^H#8F-MM,CDER3K].+0O#9I(1+[59)VGC
M;SB2,.]P7P<_?HT"Z,E[SL<N.9%T9A,L1C([B;NQ)UCYL9)AX])*Y96 +[8O
M!>@\Z^ZI@(9)*_S"WRW68Y4P!4*T#5O=F8YA]$\0'<A8-CHIZA*)^(VZ'.C9
MHT9?[&#EP9)D6!%ZU&++]@?=U<WARE&^*B2X\9!D)'@0M:\M1@#.*8DA^EMV
M26$K8E_Y$'5^"7YQPPSY#U=H;-;S$_N66L3^70(P^)QD#?7WB2C/P;=0FY;T
M^/LF6+*^A>+R:0=W_C7J%M_NFQS')8]"4</BL&-[ O#1[GW35CE7]U8X)TL-
MAJ\SR%>%]7>M_N^3*E>.5@%1^D2W#!>]DZ#S9^0U4X&L>QPE:<>B7WGGX<D.
MV9X\7.;-;V5@M%?\/%0E6RPCQ_R#B@^1"[.&/2*J G97?^:8PNNCXZYR^<:L
M$A'&PJ,MRT,=5P*PQT( L$>VFY:7,DVK#9]CX[ZML7UE,B  8'E#KTGT5(BL
M-ARQKUD"V=KDNJ"L$?H#1?6Z7NFK*32I/?+V:>QC XD?=9=CKI\J\D2MD9/F
M//3KYW#M[#^]/<YU= 3"AYDSM;'P)"TDA9O<=V94R^7,##T+5>"TQ#@M2*1\
M6R]>1%#^/ L<N_]#^_*#"1ZWG^_5?_U()?J4/55P^'STT^%%[38!R;$7[PYZ
M+>\<,UDF9$6'\P8LF&(*$=?OO .] ]_R^_6'A$NH#_@@L'"\<5$@]B+M12)7
MN*3VK857(]G0/E6!E8X:W B\-42. +2FLPP*-4*<6 7[4EP??*&:>8_^$JQ,
MJ3(#<CR$1"=[I\?O^16)G4/1Z)?58=81PF$ZU>F0:V9);V'+JQ6[9QN^N'8?
MHD^!+">9P<9'(&<W %.L0[;1EN650W.(;D7,YI"]]A?JT'L3"9_M, #^QG)E
M(_,@V_$G5U!E"LE08#?YY%59R-)($SZL-T"R%71ZFY7\PAUVP3RZ<@S;]^DE
M6@J1X@Y)9-#V++XK=MWK7-B=J!=^G>PU?O#YFST3IX&*>>>Y$4 Z+8TVAE W
MTMB[+O3(>_ZL+(;E6:KPT?U>Z_G S%!/[6*5=:U.2A[@N0-'"U]+X:)]PE)?
M$;>@UGDYEH4+_@LF:M&_L)%9O3>6(/:44_K^@M?+@;<A1)U(8@P7.!.R[46A
MB-9!]=PYAY57<<PVLL:**^-\]WI:YI<HH;V^*(IZ<TA4/<65HP7!(%<>DYGN
M$,G:$%_WS:*L\]6*0-@]I;VMG\4\5_1RS.[RC70T@WZ_L? \E^A8:F6MSZKL
M:)HBD^J*]L1U;BAP.LV[4K8O"474IL<'W,]\:IQ;4QLAP=-+<0>0DO-80B"+
M@VYF0:E:IV@+:M,3,DVG+.X[T\7=:EN1ZF?I=*GNA:XUC^IA3-NUWE0K/R1G
M#['CFA=8=P1.A5K2F5(Z$ S>T5>0JY7#K'XNR+@[+5]XDDB"1&LZS99*I)"&
M&&0+[*KR?+2&,]]3"=]CGR%MZA[1&H^0RC'J"=G2J.-^SH0>W%^NZ4#/"1"
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MUVA<\>=K$;REQ;?@DVIK8"S$LA/Q(S:DDVI\]%'J.9ZO#T]T0-T=4"2^%D4
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M&VTYO4XN)\R^^1C93)6Z%'66? #_T$@&H?+FD&R?HTT/4 LD /R+#\P>8;N
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M,]8Y6?;FTFK[%9TWU\,^!Z9(O%N[3[;HYI_N'W$,H[B7&^HE_NR&"L(%( 5
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MMV4<YG_VO0T>=+%,RO1,_3_8>^^@IMJW773YHJ(B(#8$!"P@*DV0WB+RTD1
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M-58A%6^,?ZE.[<@16EBP6"-!-Q"3+-7>VS=H@.2!-58E3KZ4[(FHG:^>4&N
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M]36);">R^;@WE1;U[LNSO8/,W]JO@H^0A@(J3)8^?ZGUYFG4:_K+81R^X7V
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M73Z2LW!)H:7KM>I";J#83_LPWTR!Y#I=I/8LH8//P.9A\(M'N\]_$B-G!"/
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MCK,#[&??FWL:78HV,LNE$VC<#.Y/04CX[E>MOP=FZ@?D;<)'S-O'FRUMDIB
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MWU6^&UF?2\=G@-(/5D71[<&%B&MA^2]2>5RZ2DH_@7X/+0C<$X3[8\@>@^B
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M7T9=>86O5CKG-7+^7?VWY(X\DGSVZL1+&XIGMK$CD9J>-F466/)$:9\\<_'
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M3A+(Q'CJ%2!3PIU.]R5:;_0*\%U4X-?FK$+RR7T3NQ7+J29]RZDD6J.'_40
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M*\&^R@2W(<D3RBWXNGN'R282P!@2Q@+;WH/UY:&$3M\E!R=SVZR0ND@]8N(
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M.G#F'E@#784K^YRN/((P@_>5JX4'"-<D2D=7LRN+-XA]7H5FJ+*10%C*8F9
MPV+T_-4J+*-C05.ZR.KF)K5L5 PWA79 K"5./QA-]+0P6TL3Q2K?Y&XK&Y@3
M\>87J6-;> ?C*I KS*=8.F_SY59M3K"5659'ND#\,\03 *EZ./Z"VNX2T/6D
M*+VDT*S[9,AM H&)GSLCVRJTT5NBX5E2IU0.T5SYF=LM0[<@A2-(-'#V\UF
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M5/=P]#^.>_ \2.4*Q=H4X,9A\T\\H.7T??<D=/*@-GG%[Z-?._&,&3?K8Z
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M&;1=UZ25"G> EZ7BU5 #G6"")^Y]5QU,--0BFUWS];\%ND*H;UIM=1/3;Z0
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MH'_!]C3X._2.$**@=V.X46U!OTIU@-J>NS6)2K^(HEL (!8&F6P(72M8&?N
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MPC>P<^,6[B=0TY!=&CL$ _GL.S?_S[UEBJ\>D'GOR5[5_+"2&MHOX;FKV?8
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M>:3%>":"2W8DAL!;W!R8L+!:XM8JEY&"N4@[U:+P[NK*XAC.M"E:)QI6DA@
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MAGI\J>HG;<F]8C*[8;1F>?"72G47[QLYU)6:Y>C\OICEIRT4"?O#TA5(!1:
MN7W1P0)9X-W'E\)^EIR_Z!?AB/)OYTYJ3N[ TY]^/>L]H,9S_$E)Z[]+?XUH
M.:4/1S%2H#5H$F#PDU:, 2D'J0$#?K?'?8Y/-3K_DJG_M+/H\;[^U6-I?/Q#
M3=3IGS6)SF]WR'L@>/J[#[.XP,A;,:M;K)'[E\J:/RMYD?MC5IXQ!6VK'KR#
M!8;@QYD7OOW$!0,TPN7'L%7Y(PP2O5[R&+_\%_>+^\7]XGYQO[C_][@+[U^"
M/F!<J-G][15/GX:DR]&J2U/MVNV">B*WSQ=/!BU2".U^<?]GN4^AT==9WSBH
M/7UROO^K,_Y_<[%>4'>,\]O'%^UC+C>RK:O__F5*>%:6!=[DY%G;?MKOOT]P
M_N+^2YS.I.4)#*(;=HW-]3+HH<=9QOJC\%I I;:^!BHF_,.EJ*3Z,?_B_LN<
M=36UJ/'@2)C\6<BZ-&E0J+J_@F2VP0\+'N)S%KH)B/^N^-^--D'N%_=?XM@C
M6OF)J5 #LM^I_!6D2L!3@M$^O:U^-V=F9\!)C#_,^4N_--DO[K_-_:-DFB3^
MJ?^M=_(3X1TBW9HA3[]6Q+T(\^F9)A@0. E3T</(N(%VL(#NXO!'9@,ED@S6
MJ-:JM>>+FJ3E69/!3:TEC';JM=G'PF5'7MXG]^UZ9M\F+JX??K$<33WM-UE;
M7';8U?&]B07>&Z% ![E9 [6&2G0#:=U:X]_'RZJ"=P38R6ME)E2)5I&9.RZ,
M>DH7G;J*0J<(!MS1E]00J^B )2R0GW%RI1<)0@>RX3X_.(D?$+RQ*>9#^CPD
M(J?*SMCXS!J"!> PM$-]$VP[#XSQ!2-;L<"5;X,'=N5Z'K,6X_N4D1\QI=88
MRH)3+RS0#CWWK%1K_C;>@06,V)2>-'W;JQ3' H;RGQF2DKZG<II-K:9,*.S3
M\'0/W8]^S>$3IMIG#P$'F6NOP5]4*V'ZZVU]#3YL\&TJA&*!)1#HW 74/F+8
MDYC-V;CV73+IML;C@"K33>LSZW)3?X-E><4?39E5UI-B@;:AV1VH[CJ7]>#3
MU<[7+6I/-T12/Y\F)95\N?UE8C%S K)'(R&@X'"UB\I6?LTA;+FT]X18^<!H
MB1NJ@ 7>/ (]0'<;Z/(%<7;;=G/U1=R6MW:]4U4:P5_B" E1][\O#$H7_H,F
M*FLA&%DWT&Y\?TASW4O*CJ-<N\=C>Z<F/M9:LA$O$B='3[=>(H:NT]PN*SAW
M%6PMSBAJJ "%%6+B'$753,@9<[+69+J=W.))WHWL\C]B)^*7GV)ZZGESL-$W
MVE9*/^.BUY$0?_/@6Z:LZK&/SRT[R9S3O9@-Y"2_W\^JLZ0AK(>F[,JUK-O8
M[H.G9>(7E]\MJM5<1 ^(-F6N20:9RX:4#*]%1X'(MVTGO\J?N0=WJU[X/C.O
M@!H:.1V.:[ZT3_+2DY#NW%-#Q%N4 C+[?;E^/1D )3T9*G$K@O4H[-_H(9._
M,M*9S *)DU09OG-GEEVO<OBI%BV?[K>51V?J(CV7,1JO4XR*H$7M2G3?38X.
M:9Q:0'LD6.!56&/_<O8G-L(0A]RL]O?_P&Y6!3=!V\3!X=_W$$'%Y9(-F-)4
M#(-]?765IIW\(_(5:X_^3X1=MW]8C,)O")2%\CLU-TQ-9,7=N:J+S5QU8GX>
MH" 5?;&2$2V=BY^+RKCSXO=MWXU:B/+MX.=?SLUY?L*P[/:HM8YVO+1SYX.!
ME6N939F.%'0GLR,;BHC663W7GS5(0UM?Z1D_).YG5/(?-S/NR"N>[_+Y0/40
M-+0(BK/F>GI[73BK)'-^75>(L?*3-=3&G3R6]07!PVA_+IW5J FV.WFEA.K^
M#B=:=$UZQ$UX+47"%[5,&7FZLXN,8IY>S#I@2S<U#/LRJ/O%.+2Y-59-%6GJ
M7FI-GZZ]"+_;!MBP<>SEE+9:78LT=N]?VCYK]ZG64DF?.:_JUH?/\';B7AE=
METS.;ZH,GQ;N(0.IYW8^FGDLE(5V"6S+# V[N^C=7M9._5!<+DU9WU0DM#DK
MM;JU-EL=NK\S>VY5FS+F<<_GB]SY4L!RKRD6V.Q;DQ>L7*TF# GD/%/:.;IO
M+;6H\[7<)UAV2VR+OFWQ:>FT7!K8)*A0\7R>V6']:<DT?8%Z3UR87/(]42OG
M-;D'$T\]R=ZQ7&$9R/DJI-YR[='8C:<LN?5SUO+T:1412E0AZE.:/+TA%/(J
M)?GZ9#3(WL6)8L'-CCN\!$I$>B_#H+U6!<]5/^M]/I23D.0JL@T?9@ZX]]N=
M-H D]NGB\)9IM+'2WI8]0>L21N/%*D;2# LXU,<YG+JA VWJ-U.Q@%A/$-U0
M1,*:><@GAC=OX0]*,^_:L19K"'04"N/[0^,@VK[L6$#=#H/,S6Q4M;K3&B2D
MEAJ^8:5G.#ECN\<^6\Q8I\8'+Q@(3YCTDJSS3A!>M>M4=3@X'5$(KE_>Q."=
M6R!YT558H $+I-MLL6V?PR$H BR@!1N1? ]!T=[GR9^KUK0 N:O[VROL9VW2
M-D.1F\)G6&"@+(>A\'%"V+V\2ZII86L:%4,V/.R4W?='V$1P'N9S@'IQY5LY
MDLG$ T9%S(M*KP[=,S575;>ZH5-GZO899>*Y:1:.1I JJ>L=)@^WD3;'AF_-
M4,\VF\?Z,S)FV>:QSVP)+V(!KH_T!C1#R]HF(*OT+,O9B=L,)W6&39#I'JCN
M@C],*"-5XM3JKA+D-XZC$3@6 (-0B] @T*0N%(V&+D9B:#X*AWAGLL=NZXRE
M%RT?-IR.R)6 +2NCF"?=R@0B%JK90CX)3ND-GFZY-9.&Q-OR>T(-HG+^\++F
M*GE<O-]EO_?B5B-I0(^G)AC-9G1PC'.16.#T4*J(-CI5X9K;2\[*5H%781V#
MJ4MI!-.XN-%Z-XZ0LS4QH1I3=0U:5H(%3E XE\R(YL1,#&*!U44LP&2'R'=2
M*<3T):7M2]3F5(L[S93T!D>)5*]B*K' X:92?W/CA!ITM'W$^5Z?]]?8^L,E
M:YE,7?U[VAF:QGW.X#P(>SBU#5LB5T1L!%+?=/ES&:VA>OGW>YU=4YZC3]+U
M2V?@3%&.BUQM0V$]I41-7 YN\AJ(_@P:$?$O@M9B7O<N+,8X'#.BN<X==;_!
MQG;V BB5.L\\P\;[=NL&K9=%SY>DR;./4O.(,KG>C'$_7\C*?CO=G\[^&G?+
MLN$G,1"K+U7? JI2>Y3Y&O 88T\TW4)Y/772H*6WP#+GEH+$)+$>-Q B,'!6
MJN"-+"^E0'O$4Y]T2'3?$SF:3H>@?_;NO_]'"&_]B=S04,;OPS-7?U:5YW^/
M?HQ!J W]&(CXF;?%HS904?XA8<E/$R1D!Y[.?_=@_Q@R\)'6$XCY67.2T77S
MIVH#PE/@AX") :G2DV]]0V]_FE"C9\$QO)6H@?I_271 _X0S>2[Q_!7G+^?Q
MZ.XH1$JA9#LE%;<-5/.P &LU[!B:]]P"M$>%!?P8=IN56B/B)>_<2;1XJ/SI
M6ISGRP*"A=\@>Q68^B +][?^/(JB(/!!]L0V;'Q' C5*J>C1)CV[&I_AX#YZ
M[1T2S$,V#W_L %O6X\R.C=1&]X1^>YIHW;9ZS%C'A'/CWO##(2QP70>#@_MO
M J&'[5 !799_\(...A;P,*.NGQF;!NN<D9;''OE@ 3[16=BZ9OT\+NG(@*!?
M8X&1-(5!F[NYWAVI4V>A/0O@Z#SR+0,P!O=7Y!$68-#@"%'W[L>AN&^:[J;"
MW;30S>^V"=E8P$(B?.G$"P![B9YS@2AQF8,4^'0#')US-')MY&4KT=$U.C ?
MN"<3%8*1^5$,DW!/*(*)V62NY-Z7.>3E1AUJ;V$L %*'5IY;?\ZWP\7G0^$S
M^$C50S[HM^>1& %1'B>,[, Y[<F5V7Y<)D%%V(<%!+095M%!Z:>\>S1]EN"]
M*^58P.UT9!@'7<G?+]GA)'$-Z=H33?H7:#\68%0:-L,Y(?HUE'I>X?EAKL^_
M_# ,(6\6^NS(/L#]E>"D4%XQS\I+2O'L@55=UWCS1&3MZ&+\^((_QZ6A+/.&
M5JODUR\'-R[?(FNO,P.W:_!_&5G[W$_ .6;"$7"B99#1;2>46OHU2*:U3PST
M,+XL3;5/[_!&.<\5S2_E&T^1^'&#TCA@#T#5S[F%FXMRC,2C.SE D9;NKX@M
M4Z)>LW(<@D:*:\19]58?# _",H6HL<!T4F@Z9IV;64C!@2Y^1K&]9YD-%*3T
M1+^3M>R=FD.14C[=S$9;$N.T]N++I7LSC:P86OI3LRHP!;1= $/ G5 ,ZZY]
M!:Z] 1NI@OS+=P,%=C;X(RUZDX-\)7J9-KPL2K,O/G0&^'NT'^2UC;ZD<;QI
M+A46 LYSFG"!'04URZUXN,N.3R;/074'61CH5W9Q)H4+[^M:D;3BW9OG'L24
M3.)9GI&SIWM\.V;6U6UO[Y)$-F&!AYN7DK=OVS &+%^2:@,M/AY;.SIZQ+ZB
MI"!O.RNC99;,[3Q[)RP\T31*-)=[1-U*\)1I+$(V(<)R*^JNXNK72J[)M&CR
MBPZHL+Z %EJ'9XI7-8[IP!_R&F\&?V&X\WG2@S4*#L&4JB<TE_4(4,,H>\^:
MT1BA\O(,'J[6[[.;@AD[(Y'PP_U;Q2/;^1_8S&Z3FZU!&0;R;^R,*'._"WYD
MR^0O'K8IV!&_J.*O(/JB@F.4D/Z<FTF.KO%VL]GSL.;6RZJ,?/%YL,F7[4_.
MADYBT=P?BVOCORWQ88&K<:RG1^ @U[CV38NBC9AMNBE\4!:-N]*^86*98"/D
MHYC:\.5T'<;-QAHJ!N\>'Y]ZALT&X!G)E9Y^MM\&%DP?$R\5'8H*I6DO6(EV
MYX<VTVH,98[^YN 9^WXH7XD=@XCRJ<@OZ[Z@(YT-7!!:/\A75GO DFY/[G$9
M?8(I'=%N_SK6L"%SB1"B[Z2W4!_"R$S7.R\["6VX\_3%#(WC ETS54RCO).:
MIC22M/!C=']3,*O($LAS,9"#>R]1<+W';4D^KA?MV8U9A'(M;*_LW35.L-V.
M8*1O=3!(;^S^G('Y"%_6MTFTYMFBK.@4\%/(['9]MMW!G33&Z*BZTH9FKS]8
MQP+1X--A!;5A<(F:T)YW;2"\-A$35WL>GH$%>NLQ4K.+.F+3D:6)CS^PC6F_
M\7T!31+C3UFI?+%[[A$5B.A)?1P..=V_A1A%UT(;P'DL_SK0D=9LM'>(!0!,
MB?M[C %T#CH .PG'5!.B<2FFP>L?GH&E&%I_SK63YW1D("4/\JB3.X5CRJS>
M!V.!Q1$[')Q-UT0RMZXOE!,&,L)P;@\^\JD93F4L#(%?ZS>2+=\OI5CR+B*=
MA<E@?+(A%'I$=IJF=#KRD+/F@H-,Y^DGSFO3OKTK HGO9J,DQ7PL)Z+RJP*)
MZ<O'-,H)9N'K!F1"DO5")6,;#CF'45Y>U8P,S.UPR%,.7MI.C^U)])EFDN/$
MI;8XZ'+L7F?%YI0CN&#50,5^X7G'DY-DW[OPFUJK6:2K: ]]Z.A]C$:')7R/
M"N>IO+7T/'!B:8$.N^OC''7-T8';6&"6IC\(P]03 4)DG#N+BW4A"=$!X+D7
MI=R\_YJ3+W]"*R9^@"ZT#;4,V*465GC<U+H>:S%!F)GGM"#^R('ZY)0<F1MY
MJY7[+"1*TYY&F/2S9]A[]0'2L,O&CDBJ@.AVH5DU:G.U@:F#[*; C;U>Q[)/
MGG8[-=,)THP:3LG<7P9LXD<AD4P4JW<:CKJ-+=RN98E$:;]]J'H5 GVXGD/R
M="M.,#>Z.P+.]33FJYS7IEQMB;N>OX?ZFI?633N)"9>=.2+GFSH0J-6V]4?D
M5:Z9UKEG7YUVE2^+EZML-5\2+W^HQQ^7>]5*:UZ)O7)J>TT\?LM8+DSHM\?9
M:0#9<.S\6)^.$NN3VD1_'S^:(O6PK&XIP] (4ZW;>SQO?B'O7\C[%_+^A;S_
M@+R;^L!+'+BH(338?15")7=C1WXN8B&E?-"&QW3_>KCU(OT49%]H4+7$^.%C
MK^+L./>FB)1CD_+[ZRZVB'8I368?\CP']::C_1I^$OY$AIWLO-8D2S?6& NW
M>W0XU!M'YXGI7-^2N,LQ5I9>I-P,WR./Q53!E[C!+= ]"ABFDGS%^E-9:?"
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M(=<5)]I-R-B_2*SI(9GJ+ M6.?@J\+XS>6G7-Q_:N&W'%G3R3807+Z>HO#B
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M:H+6B,),)A6S<"[^M>;(L^J*@)7>,HMXDKO0("IKV,"H,^;&X$$[:_WCQ[,
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M.^1?+Q^25X3HY8U#RW0;YO_6\[>>_[9Z^F];<[Q\#>T+IZLW)0$F-;;9<!(
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M'!%L)].V%@HGV@(#[8-/)"@47-0N>\#'OJ;PT8A2!B3#:DW2=[ZNX888)4]
M7M*<\QMD;N"&7P]2[?]MPC:5,6R6D*%1QB''J &H(B<\"BCI:S@K;7N.&(=M
M/9LH<1N6.%RKKHU2(+>U6<38VU73\(Y7RL3S?0*O5!*7$2"FM=J2:?' CZ_=
MD%*3VETLD/C,3G]./UNN,VQ"[0M97:$'>X^[]7XY,] [H1NXK;;T0;;4/TMM
M[?):ITOBK;W/6F]X@:'09>K*8-SEH("=*?M6PT+"D12#$1@-_ /UTSD^' W\
M?85^-<;F!1X*OPWA!U6D"!&FC+O<5'MD*L9.[S;T(OMD;Z*U5$')5(_-W.TU
MC9ZJ-&[6K69>(]C%^='^<,XPK4/]I'T\_'&#F [+Y;Y0/&25M:DLN)59D@5A
MG=<<H[_>3_<@XBR6#@+O#(=G$@F?!TSEMR5T+1-6.#G4$"0FSOJ+9O \EMK7
M2[G1;'-P[1"UHP4=L-W_9-/TNEJ))0I26?X:\G )UJP";9O'U85CV,_[!_FF
M2!]*6<TR=D<PE7K[<8EUH8%C=]KP&[=?3_1L##<'J0<OS5T%X<_OIAI2)JAQ
M[QI4+K'QA7(>Q-5\W.(4NYHI_5*D5N;+]UZ[47'"9_C1,&LWGOHPS5\Z&V<)
M_[YQH+$,'S) -0G9QP>=:@%>%_OCOY*,41+(K!4H8=8'3K7N_PF&6N;,>;=L
MXTG02/?,K]Y8_D)\S>7)KE>?; S!^2]G],'R7=M>-=/ 'J]\J*_YM8H-O_%:
MUB3'QV(-PO9+ZFBI?4D[X:W%L5M#3.2H^UWXN[/+V-KC#7'-15[:6K$2+KKG
M#,\#5W)=DE#WRN&.!\1?]T2=$_9/FID>O0^3)WGS\89(7H'B],!WP2O+P(JI
M>C.T)97=8W(Q][M\)*"R[0+0FSJ)G+,&2,9_C>3$VF**I:W9>B?NGH,0'1@K
MMGA2+FP0H4KEF4=>*I%R-=L,=NQJ] QU$_/C4 Y\6Q?B(O53_G#?)P$-S&QS
MM2-E=G /M+!&VMB,YW$61=@[:(/X4=-^]Z1PO(2R8?ZK2,WPGD:>;/M\@^+Q
MQ696(0MK/M^. *GYKE\S,*+1-$/O-UZ1:'1Z7+Y:@0T5R<*\09:7^8=53C0@
MT33[7@7>U)W.-K59#>,(F3\627%(W61\44K\J$ JEIW>/,9YU^F1_P1M<VTK
MS81;P::9P5YXO!Q6N&[[:D9185]=C;=P@ "!"2&"3FGRX*7"E:@R?^!0?/V=
M(0A97R;@D4DL4('8+-[V;O;VC&U^?.69XKJUD)TWO>'PH_O(\.SA4@R&N$Z-
MOM'"BKZLI[6 Z\)0(#1):+$T_X-TJ>SZ2+!MF:_PC/8:U5!5G4\_>Q\GO-!!
M,I/BBG8==1N<==!*LD=F)*;8R#;*^H"!E20"N+BL&[M5%MO*)[U6HFNECQ-[
MWEK19/<NYV-$6\/Q\>@NKIHA7-<6[M,GR1A/]QO+-'-B,>!DOG-;G=[TB)_'
M&YE3ZO<M?!^>*U=H0WL1R1LT6N 5Q+GYYGORH.+R)Q#GZ)3;_9;UXY$5]<KT
MD4/RU'FW)X-T4;_9@3*)N1'N< -U>%LW@XG"XSE"5CR+] FKK^Z)X^9R,@LI
M,5J58/HKMR((J23[KB0^W#@P7YHA_(?C.V&-Q2+*:,]0]KOM=S#5F&<S?(DG
M(16M?(A89<)Z/?W%A<,1U\IUP5'IG>V')O-\O* >1H9PCQ4^7$.HR&"@%%W=
M"HVX5LG2BU]^]=*Q^.V'@I;TVV9Z4J=:"]5;F8]4Q8AFQ0G@E4:VW2\1CMWS
M"N<.^>SI&N)O$GU'#_F$A\+K- ?Z&&RGJX>%)A4FN4_W\$@)#-QNTUL]!IAF
M&R0&R@#$ ;8^I'N4</=#;Y% !,V'S'G#/E[L#,.[_+\":1_'J+.B#"*$L-8,
M-RE'?77  .W0;1F% FQZ?\$A,%7OU='[5EH;_8L?Q0LZX0>W[1TQ'\<H/,/!
MP(G8C!&-[:SQ?P 9> PGOO$6/J$81(V:'*N8H-HVT<"81H"XJ^9,LR5OS[61
MQIY<76SW]_&4?0HZT[LIAM&7&ZX71<LL<,?W=JV4N\LLL]6?E;DMQL3D[$S?
MT+RLPX[>N)#H>WXR>A<R,&6-!LXFB&_(C$O@RBBE\%_QXGA;2B8^A-#W31$"
MVGY!6S.D_7@7T_K-._D8UG[U5^6/U#1'B)_W(;3@8EKP]*JB[:NS+[FY-ZGA
MB@?CR0$+9G=H/G]XCK+(ODEOVTAMNX$,HH',7!?C!WT!(*LO8OK4,5U:#R?2
M/0+00%,"2#8<J3 1(!E2]@C&T?W%MG<9-'VZS5U]!KL)3]%>HXBJ)%PPO:R#
M_MQL/9*.]=Y!W4,$("S7#LL*V!+3.M\$1)DIH@%.-LE/2P@=+AAN5[X"C,Q&
M\YD&5"ME^.3^S''RIEK!]9#$9S@S[<I=%)=U.C9X7V/NC,'8_$Y21>U80!KF
M07#420 &!T-5ZOKG]=@>16ZF5_4P=E,5&@CB[).1.F/)"5D4ULB8V&DI0<?R
M8Q@20N'.1 G^IF>A<:QL_4XYCN7U76CM5#_-MO.B3B6D$PGC12*7T< JE_JM
MK5_F/X)6+?;TPD=+J X6-6K.%F;&M*S9NWF01NPD,FINPF,M^6!"\SRD>KI9
MP$C@0'63)5Y8H\$Z0 =Z<](T*7+0XZ?P/[S;[$*5G*SLYU3D^O@E&X =#EAD
M7;NO(&]^N5L(H?LC+IL+,4HB%>,M6SEG$X<F-)!1B :.UK(/9B$G9Z ;I #J
MVW7XU.;B@54IU]_^YM=XA/+/1P-M8;'?6M?.GGJ*Z7-%_LM5F?YPG=VR>C]5
MHY&9R/76)4\T -)$ RM="@NE:&!K%W*-L+HJ.F323':M^5I?5F>$!D:GT, %
M;/Q\K^WR*@.%HI7\<_0_1_^W1__;(4<#Y%^N,@UV= C)I^(G FUE_;?[./^O
M_"W\.?I_U=$E_C@ 2VM3']+OKV-I^77MNARZ:YOXH1)=ZD5X'0)%&E(@"[*:
M-_^O?47_DZ-O<+O;%GEU59<]=#/WX&!M+/)Y5YJE]]:N$-E746SS,E%BR&8L
M4>+\WM=(+K:[7_\L>/JSX.G_4O&=A6:C 0)>:$U&^&L+(6W[<R4:</N+YKZ]
M#A,$7EGVH2_<5GCNF07TS7%(3@AWC+!IFF4IUW=_"N2#:5^&=0D%@]G2?8?2
M_/>#(0O\D@1"6Z8-.K@!(J.:D_78&;!18WPTD)Z:C\(N0P-D>I(<-QE("<>U
M+_+09_%HX/HY-:TNI9[6])S70A11YETB,#OM^3PG5C?(4HV<H(3THHO_^[#@
MY\^?W=^*1+Q;Q/6G_Y7/8Q7[_!TLA&R6+_ML,Q=<!2G]U<@Z;CM6S*'6BUZ1
MV5\/..Z_5%O:0L@K_JS.1U@7#\+[P7,.=J JK&PO>863^CJ2TX6Z M2%VO<
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MY;5^%!72:&P-MG337<8ER]?#Y?N=5B9,R+QWTXYQKN-HZMRC#1_% ?9G*D=
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M7@W &+')+:W+6;$^MJ%,S4WL^6@6WA"YQBC89U@N0CUL"3Y"*6U%0/8IW-'
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MNF$]?_C)2QAY4M<4(X_\F#I31C<+LLP@'LQ[,E9Z9%=#G>RFQA[TS(.Z=RU
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MW/V11%!8V&2LS%7V(>^L7 6VG$]:='M#?H5(+W*7K8)]_<+-JTUZZ^F$W(_
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M!]>POLK<F?_-*B_NQA0ZPXN/VMW"/4YE_'7[;1N>R=2\$7T]!>(2MN0S?L>
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MU!Q(B7=J 9X+3SGD\=*O;37?$?Z& QIFCVG+BG<,'J(EF]3IKZVA.S_0,D)
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M&D:GEX:!1PZ3(#2L" /L)D'0M[Z2OD0SH5N0=A8"KZN6-$P]3O09BUJ<I^T
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M.EGGWOR I9\.. E<;*AF#VO@L 8_O_5TX>U3/<ZJ%]>VYT^IN>5&/Q<;CTB
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M!NS*#SF,5ZZD6CG* ^_3M7M%7*G8BK)3WILEC"; =75;2,;3I>B8-QQ!>/6
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MB4"RGM9 PX O)'E%Z2@_SFTB68YHG@1@(%IK^.T1OWJX$EJ!!"MD#N!3=39
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M@8CK$W5_(/(S4,)Y_@$#+.N-8H#-;<@!$=".Q&H7MJD6V&$7=M4HFI6D;[9
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M@UHR3KND ,YFA18H1,QFH>_Z:\CG0TO[R7N)$9<4*%UZVW%*=R.T-G]?_$X
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M+7)S =2?,MU - ;7<7[_,%M"D!5UA=OBSC+)V6.*T\=,3,C !2B5/KT=O6[
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M&#A8]R3G-0^2=;OU!XL.Q45,!9-;=L,>1B0%.WV\B^^RP_4&81&*PBE RK9
MR69H7>S46W6C.1>4"W/S"/&B.QAEW$1\@Q(BLZ?&=1Y5'6F5$BY)>LBH;WA"
M-#LW+'%GJ+Y9@ZG%0#D&XI5]H6E\Z9RSRAK*..#MFS&G8TI9-A^T&BWM*R(?
M3AX!;N7-S':YQ20B8%/)*T4VNK"0BM>'!EK+>A-Z_N980UUS0X[HLMB;^XSK
MDZI%YL566J<IR?<^]"ZX?[LAJ])ZOY<&5\2=ZN=<A6H>CQB!S3.:U[P.CZE
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MJ[5168QX,U33M7X[?4A_&E3(J.,C.R][H2E>OJ%7DL<JA ^L>=W7&<N6**)
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M?BEECHP1"\J4V\_J95>RS5/ERG8)_M=O-]^BCD\R??6;=P"Z5SYJ?CY5Y!2
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ML')AN\WRU4XE :#R!5QZ.@>#V"1Q)7NM^6DN;K=TZQ=.7B?30:0ESC[.U7P
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M E$4.LQ_#B+R91[6K$T)>%'V6L<<*;KR3(V8::@TH4#3=P!DE3P7 IK>=,2
MV6DQ-I<=U>_ZB\7[>&Z'/[R;)_U)SA#AE#P-DX9I8[:>+[0QKZV:+BYK>#_L
MM.6N$@"]/FJNHR9^6ZNE]>K45'FX.SV^?YU\MXVIICJLK\O:/GT6Q_"#X@=H
M8F8'/@DRLA)V$=Z0=-3?'02,E(<5KQ]U#$+XB*2 U;Q[\D"5+ABAO;]*Z!G)
MXO,R$:25\\[/;J<LWU./A?78%0'DP704 HI3WV->PQ#M57>SY:VP\;6/:$"
M.D&EE,NR-?+(,9@<X^(W!SESEIG,>.Q^HIS6%^ F,!1LJ_Z$(O*\PL9[5>C\
MHL\JIJYW3 O!I4WP,D$+7;19@2P8.2F*J&%8LG@-2U<0P##PKZ 48TC9'*==
M@^@P_*<ODU^SL?T.99(H1[^DMY:+3[N,HRC9^;79<G#ATQ0YYDIM-Q^[O7\@
MTY(X@/#$7ZF(\UM:'+_N:C7NRQ*L0ME&5GHY+E+*E!C[QAL6<&UKRUY? 30
M?N.'UR7KF9)F*.1AH>Z4L/;+Y6%\BA8ZDSB&9TF0-3F!V&K4-50#<[#YC&<F
M<2_AU<%'-)AT4EE?7-X@1F(B*"2K=@%*/;V#N@RI76?8MP@W/VJZ@?=A<O5E
MQPL-\Y$3> .<J1<?_R1@7(WF;)VGULV=;*2&G4RV;D7% 0Y05916>(UYQ%7/
M;SOFP.KE#E*Q_$<?# 1Q;T]9XD?DMTZG:H-(2!)1V4J2PB:)(JG)232CSGDG
MV$B![)M<+P7[#0%C0(]:@'].L9P.CM75(4P-U??M.83$WNB=:>'4G-0/]\NP
MV/XX:>GG.&5FXM<OHT_AS@+#:F,_A$_])[TW'JPBDQ;&F?IK X3\+A+1]-,]
M$,K:>+QUNSVB.D,ZZQ0+SA4D!]7OXC[=E'U?@A QJ%P^E@==&9+NG6A14'42
M1GORR>!KZ$P5RR!PF9O52SP 7A_B==]8TBO#-XD/O80X[>N-%)+Y(Z37@*8
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MHK%DJ/A.9M49\4"J#N]E6BHSS:FA@ @"A>D2[A (E6E]]PV7PC14A&S\\UE
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M /-?S@V1O@,08$Q!0#B+$ %)=@W+^W^9><NM:='4NFQI3E9R@+]_P*Q067.
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M7_[+?_DO_^7_9?#N%O\/4$L#!!0    ( *4ZHE;X5BQY\#$# *\X+@ 1
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M_"?+M17<Y"R3SY+IN&R_\/NGWP]? 3,VY=ZX' &+P.;"^7V^O.0K#H4QW(?
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MPS-*M&$NR[+<!MW;].#K\,1O(#S /*__\),WTYM[MCPHH-H:3Z? #OK(NK+
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MLYDA@-\P:DX!5 N:$T&#S82715KTUC_</\"PSL%^WF29<XIXKB1Z)PO U!H
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M&6HU79<$?A]?\74;<5F2OWL.HQ'PD&.GS\Z\KOUXRPG\&P;2DHSN/" M:>&
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M6)&W=F7D:<'-=IX ,H]YP3VQ<Y_U79*:_ZQ'ODL'F:W@!!O7Q13W<9OV%;L
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MY"OC^8D'6\]=*" LP;A'[T<(,<0POAPAF OXJZ)D _H9T,^ ?O2HJ:Z'0)?
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MS IU+[N&GJ94K;59__*. W[9$<"+BO]]U]3TE#'19$'M#\]D)90C&4 R@&1
M2P%",F!T,B"J8HTH#'2G )3W$CPR";$DP:70A1?61T[H066 G!K36V6&9,!8
M$DFW-^((M\=$TL6;-^"] :+6K\M-F%//S9C4(B7:&S<X5?R&AY,WJSOF,K=6
M.(A<)U"A$VDJ^JK4,F;/98CBVJ;R>R5Y>J_M\:E@<JHD#8$AU&G1Y$2W+7AA
M% 8GNAT+W9H4@E*^\BMJ!)6- ,=MK-0I@TA.B,A#+\F4/="ME&;J'?6S-HDZ
M=.K%2-,;+U;+LVK7M]O]1=WXW+/3^L!TLL!-&RG_QEP\'-E%VS$;-SC)KN'!
MY<VR2VCC=?$*M H&5- *O*TJS!=99.22)5;ZV5FT ^L7\[#8/%WD[R_Q^F?L
M1X6)J3&RR;H5 1 Q+S'OX;TP"H,3\XZ%>7.R*L580'!5F;=H!.^B IZ-<,P7
M5$SWLZ-H[\SK/(U!:Q* ]M8 0KF/PT+*+[C>K&:IVPO4G1[41K:],;<.1W51
MPK=Q@Y/J&AY$WJ*ZNC9=;A"<4@C*:K4K.#G#HD7.@E381[[C/4#??&C S\M%
MZK?EPWBJ/Q$<-6ARXN$6O# *@Q,/CX6'C4HJ*.6 N]BE,VP$'Z,"YNNB8(P5
M(:_Q\'VR'\3#!$?4!S+N7$CW(; L<+[&29?K#)O9XM5NOTL;6?G&?#P<04;9
MX,8-3H)L>'AY2R.(RC(;EL%XKD!QZ2 48[M3 H1%;1)+N8_$R/-+@/X)PQJW
MV/V\_+;&;5]N/P?S3)EI<Y )(1!1+U'OX;TP"H,3]8Z%>E7TOD0;ML-D05FA
M*XUF!\6X^I"V!FTO6U_V3[V<3;4D[FT2@J@79*3YC^V$Z,E\N7@%%>9/:=#'
M&.17K[E?&@O7;,F*QL*-3L[I$M$JM!!",:"$,.!=$A!T%"BY-RQ=DW/WRJ2\
M/QF@YRJ6ZC17DU4LF@'7/J0U9G+B?.+\M@*$.']TG.^,"MI;#HQ+#LIE#B[8
M#$HFE-KX*'PO)ROOD_.M;7.""7%^,ZTN-/=U"!"UF_OZ16D@JL*UH3SV.$!;
M/!8=DN;E>7>V5-.B\!XQ^(#A]N<V8NSSO4NZLD'0OJ5-6O,2;%!5'EJL:K(8
M<")$,#I&F4)FS*?^AM#VU0(MV-2XW@Z7?%@,)#G9 )8U9G+2"Z072"^07FA?
M+WA=M+&J@&<E@4I.@)/* I>,R>)RL,SV-T6WK_&YVDR5ZFW;%.F%\:2?J-/H
M#V%.7,[SWA#GIUF(L_FL.W%L.W+WY6:9_GU2/Q%7Z[_^Z8U@W'\SZ;96WOMH
M:BI$/I2*K%;O'OGVD7@TF"W:_7OI1BW1DIO(->0:0C)",@H7<DWC2IUF(K24
M';@XWV8R?Z_9G[21=FK,MXT$XA^DLG;V"AX77@YJ&R>YAI",D(S"I9%P(=<<
M.GU^U<9<[;%[\^+-&P#% 4KWIRG5[[M93\["VQ#GV,8M-9%="ZWPC7EAG'T6
M[22CJ'OB8;LGA'4N"K0@>;&@@A,0?'%@"Y=.82Q6];)S]Q+B7^P0OM?#B,54
M]'<.WIC!:Q1L0:S=AA^&M/")M8FUQ\3:GH><)5/@L,3*VBQ#R,6#9@JM],;'
MGGH>]\C:;NIUF[MO&P.O0:=C;M],2^F85C&G1OWJ'/,$WYSA8HVTH7;8PHYF
M2C9N<-)EP\/(VPXXSCS%&"$76T!Q;B &KB$59Y )%84V/653.H2^TI[>IS0S
M:FI5;\/0"'Z&#3^-F9QXMP4OC,+@Q+MCX=U@?4;."IC$*^_F5"#(G$$A0XPY
M,V=43_F0/?*N%5-CVIPA<?3P0QTJ1YT2>7>.Q&3>'23QKLG\[71R,9%P<K9<
M=>':1BZ_L7@=CFBC@;2-BCL:2$LB\&X1B%X[';T$([P"I9B%&$J&J@%373:F
M"KK8_W%^EUKP;:]*<&J<:K(V1I-IV\>VQDQ.Y$_DWU: $/F/COR%\#&HK""B
M**",L>!S]*!U<3P+5#I>.\OWRP\4W!?YJS;;68G\F^RDH;'TK6+5;BQ]NCZ9
MH(T*1V/A.1RA2+GUQ@U.I;WA@>7-PHXAJSJMRCDK615VVB<(F QH#,)AK,HM
M73MFZ#Y9G3W5])R:&D_'0Q/NM&AR(MP6O# *@Q/ACH5PK?;"9:7 %.U Q>Y4
M7YD3&.DP)>LST[Z/3,J>"-?[NFC;'*Q^]+A#4])'FN>XHSUF@9O)LE"7S*CD
M&&VW;-S@),>&!Z*W;/6.,CBC,G 1J[Z2(H$KHH U#J-11O+KA:T>NUIZ/G)9
M3"V-:B$4:M+D1+\M>&$4!B?Z'0O].IDY<TF#X%: ,B5#0.; V)"RCBEH>VT^
M6H]])3W3KYHJSXE^6T0A.I=BK+F1S0FNJ/=C-.)KCV=M4I-P0R4K:A(>HYBS
MZ$(!QK*NZJQPB,5+8 998M&JHJ]M$[]7+J6#_"OUK9Y5'&=M-I10>W#[J-:8
MR8GVB?;;"A"B_?'1/N:05)$@!).@G#'@3&5T3 :C*2'PZRVD]\KA[)OV>QN7
M2[0_EES/[<-D:%=0JRBUVQ7TY1DA*L>UH4!HVWBCTI"VC9,TO%L:1N\8R[RN
M"\&[[AKM(&AI08>042F'C/62$;JB"OO95F2G6MLF*WDD!]M'LL9,3E1/5-]6
M@!#5CX[JN3,YNX+@NN,.52H&(EKLSCQT-J*RD?>2!>J;ZCF34]?H24G$]<?6
MYM,_:NW#+Q^]':PQP>P-G,QRO:HG/_RN:O#F)"2((D7%@ES &V[ \J 82N]R
MY)]\$^=59A&[>02Z>Y/@Z[U#46!E2$9)]&C,"+)5SY:GI[/-*7;G<X=%WB+D
M;/$*%ZDBW.2KGY<;G.BOWZWU&_^BDF>;8K=:O7ODVT>5^8:R'[Q_+]VHFUIR
M$[F&7$-(1DA&X4*N:?RFA.8RM*3=7VZ6Z=\GRWF]25__]4]O!./^FPG^YWRV
M>?NDC41;8SYN)"#_(*6ULSWQN'!S4#M'R36$9(1D%"Z-A NYYM 5@ZLV/OC)
M@P]35QB@A'^QPH*K%7:^K6)^.OGSY2*A*N]-)\'JDJQ6"%J$#,HK!U$S#LXQ
M*3 5C[[TT=#USBW;6ZP78?5\]7(3-IC_-\S/\06N7IZ$%7Y8 *X_=L^OSUH_
M+T]/Z]6E\-UR/@^K]<6SWQ>%?_SYASNKPC=??>*)L5 X\( )E"@)HO0&5,:(
M07N4YMKY\_>I<1_ZZFNP,W;3((M;:N0#QX =.9R%U>1U9]_)&58FZ&SVS83
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M1X<DL>J-O9GT95UJDPH=]4/QO)+_>CKY<9$>;_/P+\_C>I9G857%3UM&WXK
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MY?Z%^O0*&YO5+-4';DOF[%(^'3!0P7;8<I#V#C<J&VGO,+4V'H=,CEYRE;T
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M]LO!2(Y*=@<BPY.PPG4;<4JE.@+<8_,+ >Z1 >[3T_I=-VW$*0$N >ZQ^84
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MU9%\(OE$\FE \HETQU9W&":E2NA E(R@+-<0N8X0/$O1Z>RCOJ8[T!B9% O
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MQZ+0TE]&)2\4.YQ)R%21NGE"@B$2QQ&BB11($<F2),JDR'<#5K_X767VJYG
M;)+(?EZ_T]+]<^G:K5TNI>V'\6 EH 7\="O7D>_85L#[1+XN,4"C6PU7;-Q7
M7V^KNLS/>I4.^KK ;I_5YY1#99VXU58[9$+?15]J4%T'P=[^\G.'?IRFJ#R3
MS".'S[&]6>9=X+U;ED_4=@^O7#JIOJNK#%W<V;B$B:%KC;W0OA?2U^ZMIKUK
M;1%=!R_]ZVRU,F,[F%)]4&+K:Z"$R0-VF[I+,[X?[!VI<#0)5YU2!)UQG\[
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M-JT$0+_$QX&^+NIGLWI-\FS3,V2G@*IGR,HSQ'^S;WBGWV#%UIVW_D7][I]
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M7)+BX"(/HDUMLUOEEIO:,C-K:''G$^P7KI'>3I/YDTAZ5(F) /G' 'B  <"
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M%AQACI4&!VF)"I*E2 ,&3B378"-)SI&.\;B @I)\3O,<  4 "@ 4X^$%  H
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M'(N#O'$>4TRB"*/,-)DFO$@0BT5LJHJ)E%REI4J?(TJ0SC-\UB !Z*+QZZ+
MR [&.!1.3(;H$"0899  9&O\LA48V<&XA,*)R1 =/+WQ&:<3GEY2)$10B:1(
M4D0BD_I+$H5X5!#&<1&K"!^TBBXQCV61(87S#!&:1(@5D4(D4T3[BHF^202>
M'NBB('118&0'8QP*)R9#=/#TP-,#V7J<XV"H$!Z?;-KCX!L-*$6U8@M]L=BN
MJTVE8&[P-$#)6?-HN+Y:K7MJI:O-K*D7E9SM;NK .#89YGQ$4![*'H@X!*B(
MCT<<4IP0; ('.:>FDS26B*9%B7"L,"EHQK(T.>@^30G'>8J18#%&^F>&"J8B
M%">XS$E$"Q[GSQ%QP(G>Z5&P&>@?D9XA!-6;&+0<P &  P ' A:4)X #$/,8
M2PH\6+=Q"&U@9 ?K!M8M3$$!9W=RSBXMHR(AI7Z-4DI$:&Y.UE6&9$;BB$A,
ML_A@U%(<,ZY$+A$N\E@[N\J46TN&N':<RS0J2YX4X.P"'!BIE@N,[  '  Z$
M*2C@[(*S"]8MM(R TP7B<?&(&0'^Y@%P<H3"_%N]88N9?M<_U(;QA3I/3@ D
M*H9C>L^:3 6X*.B$1@B33"Y,DN5EF0N6HHQ&?B)UH4J.>,1$F5.5J>2@*YV,
M\U311%\N68((E0HQ0O4_2<I$3G@:/T^89(XC.L]IN*/* $J.0\\%1G8 !  (
MPA04")2,.U "UNTK%-K R [6#:Q;F(("[N[DW-TTC4JA4HE('AO_-4M0D<@8
M%6D4L42[KBS/#IJP%Z7D'&L761#C(B<8%9'2M\ 1*6@N94:?I0D[N+N@YP 0
MC(T7  @"9L[S P)P=\'=G;+0/GJG@/,E 03 HW&90DA7'"\O/D'5Q1>QT76R
MWIJ$CJ"!R6>8N2>T:/\1CJP]G,,0[ @0&QT/=C"E2$XBO3.B'"-2I (QFDM4
M$!(S%<=IQ@YZR7_.V?YETZC'C'/$>32G.1U)_<,1X0$L&(B:"XSL "D 4@"D
M $@Q'DB!:<)8DA6()%@@$O,"%2HO42*SM, T$QD['&)+><%CI2]2N?Y.7F!4
MQ)2C$N>IC$C!RE(\,:3(\!P7*0 * !0 *,;#"P 4 "@ 4$P+4.2E$C$Q/18R
MTZ8A2W)41%ACA4)2Q5DB>7*6A(S'CE$\0BX&0 J %,]/=H 4 "D 4D!*1Z I
M'6 D S"2PZ0._;,I]/];BX1^VM[H.PO]NZQN3Q/K3X\+PC_'LAT^]*P$U.11
M'\1B*]7G4@7'7TJ67I6-7)/@8D!:MQ/_<MTE%ZW8E7)J ;%2O_!+MGC/[II7
M+V9_'M6.?&R1_NB6)!=IDCP#84:X(]]LU]7R:K:Y5OK_:Z5F-_I/U\U,:4K*
MV8]L+:YG"9[/XBA.9FPIS0]QRXV1O_O<O/9:S=Z;?XZ]$X0_VGH45>1,B1CA
M-&*(E&6"BD@*%.=%*<I(T;P\&,F09JG4FT6AA//4!#TP8C'%J,2Q9*5(,<MH
M&_YHM.9[V44]7!#DMS5;-J5:-Y=Z2U[]0]VJ!;;_QI=+:7](]%^VR\UA:*0/
MB+S]Z8>=B AJE#!1$0.X&K4\^;Z2Q5E)"I0G,46D2"CB64(08WG.6"(B0@ZZ
M<N99A,N22I0D<8Q(3"EB2A.*9S1)&64)H^KYWW=9'XG]G @&C5R\9YN6HC-F
M2&J5G"7D3"LT]T-L=9K[.9D)ME%7];I2S<70X&A$>"Z-T&TXCS?]?I,\S3%5
M!2*TU'LG2<W>H0J1*!4X9RF.:;J_WTC"HRA-.,IQQK5,1C'2^[1$3&:$)%)C
M?W*0 O5&\<V[KK75Y2VK%@8%_U"OW[&%^LW\_)M^PG>+6OSQ8J8:P5;&M*ZW
MZI0#\0!3^^7X;R*V]C>]_\IZL:C?6Y-KJ-W,FNV-?GO],+L]]1LUC99O#0(7
M^C,YNV+5LK&;=*'_HJ^O2WOAZ_I&$^/.N:;T57.\>=F,V2],1*"/H)$W2J@;
MKM;MI_'+H> "9MYQ-69_\?OCL'L@VV[J-JY@%JDWZ,OHE;T<+=A=O=WH1WQ0
M\I5['+5$]-?KK;)@JT:];-2*K;4*;>ECXS_NUB^.%5/<5DW%JT6UN7O9WN-$
M285[:A)?Y.F?#&5/15_<=?@"I\F#KHL><!6]R)/SW>V\:].J%1,<[N(B7 2Z
MN/RB"'9M>L?EY#/O]I'"I>+3ZY8>;]IPJR<?%)DLSJZFCT>5/J*HBZ#.D9ZI
MPOK\O/@,D_G4G-!T-W_]ZPNL877H];Q!BM9C0$Y>+^1C;8I=O!F.F'YR26_H
M&R,<20?S.1E6@OD,BA.=^8S!>GX5UO/RIM;L^+>2?^'KV9__]KIN-N&(*IA0
MT+N@=T'O3E#O_MT>(?S>'2$X]?MW<XX0CLB"_@7]"_H7].]7HW__84]OPY%9
M4, 34L# &U#)H))/[XG7:R6KS0QT\-<EYP""0^$$:-RO3..:W.:936X.1T)!
MW<*Q*; 2+.<X+>>39QV%+C)C,XG?5,O9YKK>-FPIFV_#$;_0^1R.0,)0@.<N
MT-F3S_-63;@RO)=?()G/U6(GC!*61VY$\ 5.Y9GY$G[?MM!8!>P!]H!6 ZT&
M8@/LF29[0*N!5@.Q ?8 >[YN]H"B&PVK@#W 'H!OH-5 ;( ](ST^VCT*'-(;
M$WNW\YTH#;M%^9M/])#ID;N8_7[Q[F)V56MR+V_T)X-N;>&<"0=VE/C<#8<?
MEQ?W]GH/C!/3'=GP>%D5@5K&+V7""%7OB?G3'(NHS/5K%#%&!#.*"B43%/,B
MPQF.BT3B_>:K+(X2@CE#4HH$$9$*Q/,D0T5<D"A3BHI,'LQVVFNWNM>,M6V7
M8!HE?,>:JCG+R*<X(?,T/>L,R2GKM\D8%3#PX?!B3 ( !AX,_-0,?!FE1+$B
M1H4LE3;60J("RPBE)5-,\81B&CV!@1=B>[-=L(V2MD2\KQ WO3F^4]J(J]_8
MA_-8_2(&BP\6/V"R@\4/A1-@\2=C\4=HL;^!N4OW(!<1I84JLPR))&>(8&S&
MNY ,I9$L95GD9:'BYT0NIJ/"F9'+'!,*V&4*JCO,&K= Q^("'@*A^GKP$,R:
M/BV:7SQK>LK".1F-"-YZ.+P8DP" =9J,MPY>;GL GY&LX$F"$COS5&4I8E26
MVLN-N5(Y$3CGC^'E]A[NKK_[>KM>JV-S=C_K_#V>9T4!'FW(]OW1&WM 9N88
MM)/-S!3U>E6;*:8S7B_EE^1D/E>) D#"+^<%Z$PH-@!$]]F(CN1EP0G!*(Z3
M%)&RR!"E)4.\R'.5R(Q+F>\C.I42GF:I0HF^U*1A8L0DY4@0BDMALC9B&D9*
M94;G47K6! M03^-73X&1'>QS*)R8#-'!/D_%/B=96M \3E%BPB[:MFK3G%"%
M2DP+J61*E#C(B'P$^_R$&9%9!O8:U%7 9 =['0HG)D/TT=OK$=I;R&>\MQ*#
M*"RC6 ,-JG)$.$]1$:<IDCDEN<PYY_@IX@)/F,^(YT5TUM.?*6O>L ^WOR2?
M,1S5#?F,7YE038;HHY>)$9KQ,Z0C@FR-7[8"(SL8EU X,1FBC]Y7!A_3^YB%
M4)B4BB%&A40DSS3GHX*C(B(L3TLN4Y,9>'X?\TFR";-\GN (_,F0M1/T>0PB
M,O#<VNFM,1-+9N23+<Z85@B5)N&@#$C%'@'1 =J-3WF>2"MD*2\D3TPR(4:D
M*')4: "#THC&6%$-WB*Z#^UR44:,<8(BGE$-!_7E+,8YRD@1,Q;)DC$21%IA
MGFEHET"A"&BG@,D.YCD43DR&Z&">IV*>,<&TH%FBK2Q6B% >(9Z4%*58&]PH
MEZ7,LB<PST^859B#N09M%3#9P5R'PHG)$'WTYGJ$YA:2"N^#'7E<LCC-8Q0S
MFB$BL@PQ0?1/2@J)L8BSN'Q.V''^I,(T)0 \OO:4PG 4-Z04?F5"-1FBCUXF
M1FC$H<,AR%9X9 ?C$@HG)D/TT7O*X&%Z#S/&1<X)Y=H]C+2W&/$8,5PP5&2)
M(B3+XT2)Q_ PGR*E,$_G^7F+XT$YC2"C$/H3CD\Y^?Z$-S=J+2JVF*W82JW#
MR9$/3%3'A>@@#7L$1 =$-SZE>:(!DDBCDF8*$1D7B)1"<U[2!,51$A5* R+]
M_WU$1XM4EJF^*(U2C>BPP(CF5"!1,EG@B'&IRB R";-XGL9G':($VFG\VBDP
MLH-Y#H43DR$ZF.>IF&><$E6D3/,;9Z6;[L!DE*(\%H4JLI)$6?$$YODI)S:#
MN09M%3#9P5R'PHG)$'WTYGJ$YA8R">^#'1FG:4*X1(2:J( L<C.(*D%Y1,LH
M2M(X/ARW_)2PXQ':$T9GK3B<LMZ=;B9A.(H;,@F_,J&:#-%'+Q,C-.+0G!!D
M*SRR@W$)A1.3(?KH/67P,+V'&6G',DIQ@F1&M;<8%REB),>(X4B*G'-6TH,&
M^.?P,)\BDS"+Y_J%P)T,63E!;\(@ @//K9SV>Q.>+:40BD3"01F0AST"H@.T
M&Y_V/#5341:2E#F*F52(Y-2T*>0%*HLR+C):9HD@!T4B!:922H&*)&.(%"I"
MM"@C1$12%!H0BKCD0:04XHC.<7'6QM.@GL:OG@(C.]CG4#@Q&:)#7'^4<7V0
MK?'+5F!D!^,2"B<F0_31.W\C-"Z0 7>?$YMBEJ=)4NH'1"4B-.5(+U"_59ER
M(2.9RB)Y B?V*3/@"@Q>[=>> 1>.XH8,N*],J"9#]-'+Q B-.'C*(%OAD1V,
M2RB<F S11^\I@X?9'I,REF0931&)2HZ(S$K$:!0A5D2Q$"S':9$^AH?Y%!EP
M."KFE)ZU\PIHIQ&DP$$SO?%I)]=,SQ"[U.3>Z!O4I9;T5=U4FW!2NP.3V'$A
M.T@?'@'1 =F-3W<>1W9,T)*+2*!4R0R17"G$6:J0PH5B(B<%)P?(CJ8LRXI4
MOSK%1.,Y6B*>YARE@B541%$>!=)3#VL,5IRU33)HI_%KI\#(#N8Y%$Y,AN@0
MU1]E5!]D:_RR%1C9P;B$PHG)$!V,"Q@7D"V0K0FD*(%,C(#HHY<)L#<@6^.4
MK<#(#L8E%$Y,ANAPD#4^XW3\((L(1I5D!:(8EV9T9XIH'"LD<6G:=E%19O(Q
M#K*>)$4)SK&"5T[0I LRE-H,I1LM\Z):L86^N-4'X>3=!B:NXT)U9TWMY/IJ
MM>ZIE:XVLZ9>5'*VNZD#X]ADF/,107DH>P E!JB(3Y1*)SB*56*JI$N!2(Q3
MQ&B:(L)$&5.:$YY&^RA1L3+.<E*@7'"NO\ABQ"(<H0+G>2D(IK&D8:0[97B.
M:;B5T1^1I^'#]+8&O0<  0 " (2 !04 P@0!0IDQE44(X]PT!,4<<<5CE!-6
M%)PD1<GP$P"$)QQBBI.SMG\'Q/ 5*L+ R Z( 1!#F((R'<0P0HL/7>3N0SY2
M2,RS,D-E@A-S@)8@%E.)TIS&+"-QJOBS(I_S=Y'+<T ^ 1W=/*$$0-NYR>9T
M IH"-'5&- 4YHF-I8S=VB_FU"&U@9 ?K!M8M3$&93JP ?&SO8V,J"U7$$D4\
M2Q%)5:E][)*C)$FI2&*9*4(?P\=^DB35+)JG*60?3$OM/7KCO?/EL ; HW&!
M":@6&B\O/D'5Q1>QT76RWFJ#$#:T"SMJ^!_AR-K#.0SH<#SH,$_+(HH3E"6D
M1"2+2D0Y82B-)"4DYDG!#DJ8TBR5<10KE'"N$26.L#FUP:C$L62E2#'+PDA.
MI7$QQU&X14P?E2@ B('HOL#(#C@#< ;@#, 9X\$9)%.4)CA"<9&:R0PD0ZPL
M]$\D%B3)>,E9^00XXPES7 E- 7@ \ #@,1Y> /  X#$1X#%"X "ILO<&:E(5
ME:4BB&-5()+0!-$BSQ$N6)Q&A<QYDC\G@#I_JFPZ3_,$(-17:A>^)%TVG(Y<
MD"[[['((L Q@63"".D(X$EI?UO$;WLDH9HA=A,,+,))@)"<2NP"?W_O\,6,L
MBLL$Y2HW_<+2%%$58T0$892FD8CB@T&)Y_#YGR)UE\;)/(K/6@P+,", F#%,
MWM4_FUUUFBQ_>ESM$AX*: ECZ=(N:=@(EVTW=;OWS"*KY=7+Z)6]'"W87;W=
MZ$=\4'HCV\=12T1_O9:%!5LUZF6C5FS--JJEC]6R[M8OCB56WU9-Q:M%M;E[
MV=[C1'JU>VH27V2D^),A[2D1=1=B+38/NBQZR%7111R?[VZP-%C:HRSM(^4+
MQ:=7+SQ>^7^K(1]DMXJS*^@>@'Z"BBZ"\M.>J5+U_+SX#&/YU)S0=#=__>L+
M7+P(OBXR2-%Z#->(UPOY6)OBC1+JAJOU+,'SF79KXG D]9-K^T+?&^$(.UC0
MR; 2+&A0G.@L: P&]*LPH%UEU5_X>O;GOYGZJG!$%4PHZ%W0NZ!W)ZAW;7;D
MK$^/=.K75)D$-)4+]"_H7]"_H'^_&OUKDM1#&HL("GA""AAX RH95/+I/?%Z
MK62UF8$._KKD''1PN+P!'?R5Z> ?6+6>_2=;;%4X,@L*& Y2@97AV5((* 69
MBA2ZR(S-)'Y3+6>;ZWK;L*5LPAS2%"2?PQ%(Z!?^R"5UGRJ?YRVB^'_LO5MS
M(T>2)OI^?@5,,SW6:X:HB?NE-"NS:JDUJSVMEDQ2[\-Y68MK$2,08.-2)<ZO
M/QZ9  @0(.L&D)E);[,ND40B,](]W/US#[^\62[S:OFZ.[5VSU@O]SD5+<</
M[8I3V9T^'4]4V=@U5B%[D#VHU5"KH=@@>X;)'M1JJ-50;) ]R)Z7S1Y4=+UA
M%;('V8/P#;4:B@VRIZ?'1X='@?OT9K*YV_E.E/:;1VUN/M!#I@NWX/O'JU]?
MC=[.@=RS:_@+7+UM>]>=,^&.'27VJZ/J62=[=XP3P^V3>KFLBHY:QB]E0@]5
M[^GNIR:'%+C)Q'(KB&0B$,]\)LS"S]*[8(N_W_TTF5!$UHQD&3F1WE#BLZ8D
M"2L$%SPF)3HQFE8 XF/G'6\R9/TV&*."!KX[O.B3 *"!'\RPGAX:Z#/, !FR
M< Y&(Z)UZ@XO^B0 :)T&XW[VT#KAX-#'W&@A S6&.J)+]$3F4DC(CL(_*4C#
M2W&./X$;_82#0^68:XZ>]1!4=S?KL3KJ6" >0J%Z.7@(O77TUM%;[P_9T3IU
MA1-HG0;CK:.7N_%RHU6<L6B),U83&;,@L$!%K'2%!YZ3X>D27NY3C,H4E(\=
M8^C1=MF^7[P)!681]D$[-5F$<;ZXF=<!G*,PGZ4OR1_$B>S=@81G'2_<,4X,
MANB(Z/JG,Q] ="$+EK4@+#M =#IHXF0QA/J0K93"6T;O(SKJ(S7<2%*B\$1:
M)XGE.9+LX?M".J=U1]+_E!U3YCH[_1S5$]IGM,_=X<1@B([V>2CV66@I,@4S
M&RT'6ZLE)<%E0Q33)3NE94I'$9<+V.<'\PKJK*WSYA5H-->HK3I,=C377>'$
M8(C>>W/=0W.+Z8R/P@[NO70Q$:UH(I)*17PRFB3OHQ2RT$35<\*.\Z<SBK$2
M%*''$,ZVOR2=L3NJ&],97YA0#8;HO9>)'IKQ,V0CHFSU7[8Z1G8T+EWAQ&"(
MWGM?&7W,C8_)@C$R2' O@]1$%L^(ET(0&E4LMI@09+B$C_DDR81*CJ53Z$]V
M63MA2\).1 :>6SO]4,W$S%?Y]-,S9A5BH4EW4 9F8O> Z CM^J<\3T,[I;(0
MB5DB&'=$)FJ(MQ6FT:)RY"44Y>Y#.VY9B59;PDL*1#KIB#?6$&N\,]E(;6,W
ML@H9MV-A)!:*H'KJ,-G1/G>%$X,A.MKGH=AG'ZGT14?"?*!$RA)),#Z02(V.
M+FDK97P"^_R$684&S35JJPZ3'<UU5S@Q&*+WWESWT-QB5N&C6851%JD=)U3R
M3&32C@0'O\(J2W&"%X 6SPD[SI]5R,9,X/B!%Y]5V!W5C5F%+TRH!D/TWLM$
M#\TX]CA$V>H>V=&X=(43@R%Z[WUE]#$W/F:27C%G(WB641)I:21664:<*IG&
MXK6^S-'S4V05,EYS "WZDUW63MBBL!.1@>?63IL6A=?7>1$G?CJZ\3=YT9T\
M^8Z):K\@':9B]X#H".GZIS0?*!3A/$>I#:%2,B(Y]<2[6BU"8Z"%)FFRO0_I
M!+=!"$Z)C3D2F:TDOMA,=$K9N<*\2*P3V81:C+DX:S(A:J?^:Z>.D1W-<U<X
M,1BB8SB_E^%\E*W^RU;'R([&I2N<& S1>^_[]="X8.K;8SZLUL4'2BUAPEDB
MDW7$VY((2U'I$D405C^!#_N4J6\<V^F]^,2W[BAN3'Q[84(U&*+W7B9Z:,31
M4T;9ZA[9T;ATA1.#(7KO/67T,#<>IG%2.1X*$5D8(CV+Q'KEB*9*I&)$E,Q<
MPL-\BL0W+<:,X2%IIY43=M/K1&#@N973_6YZ9TN PYJ&[J ,S!KN =$1VO5/
M>SXPI%=S;[S3A G*B63.D4"])$919KABV86CNOE,);.*"R(*8$(IE"!!-7U^
M9/&:&Y6XZD0"'!-B+ 06-:!ZZC+9T3YWA1.#(3K&]7L9UT?9ZK]L=8SL:%RZ
MPHG!$+WWSE\/C0MFP#WFQ%KAJ"S:$Y9E[0F?)0F.42)42,GSG!@]JN*Z@!/[
ME!EPYJP#@(:L=X>; =<=Q8T9<"],J 9#]-[+1 ^-.'K**%O=(SL:EZYP8C!$
M[[VGC![FKD\(#=1E\!&]341&XXC7PA-;. LAYE1XN82'^22MWX08,XVMQ#NM
MG;#U6R<B \^MG=K6;Y78!<B]@AO,"TCZS7PY674GM;MC$MLO9(?IPST@.B*[
M_NG.T\@N<"$"4P#J7 Q$ZJ!J IPE0@NJC%<Q)7X?V:D '_@@B19%$ZDT R"H
M8<N(E)F522C5C0YP3(TU.RNR0^W4?^W4,;*C>>X*)P9#=(SJ]S*JC[+5?]GJ
M&-G1N'2%$X,A.AH7-"XH6RA; TA10IGH =%[+Q-H;U"V^BE;'2,[&I>N<&(P
M1,>#K/X9I],'651ZI0O3)&M9B'0^$&NX(E0YK6PL*N:C)EWG.,AZDA0E/,?J
MO'+")EV8H;3-4+H&F8^3&S^%B[?ZH#MYMQT3UWZANK.F=@:X.B_NJ*5N5J/E
M?#I)H\--W3&.#88Y'Q"4CV4/HL0.*N+3*-$K1644@6CO#9&T)J6++(G0/OH<
MJ4TVWD>),6BKF##$ "X$9!D2L8DJDEWVCA>72J'=2'=B$E"=ZVPF^P?D:?]A
ML*U1[R% 0("  *'#@H( 87  P686?4J>%%4!@E2:!$4I29P7*W0T(1[U4KD
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M_V"L?P^M-TX5? S%*$NC3)P1:H0B,AI&O,N12,6%M\4P[4KW4,S>%,)ZV7E
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M(E883J(0(:008DAF , ,K-#. !W\I^?O5?VA)T10Q97D$Z=$F3J;D%M'K)(
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M98,MQ92CJL*<7"R&.Z*$TN#@J@16KD:A14[:Y!*MU(<32$ =_%1^:KC[:R7
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M_+##<36CCQ[TTZ6R[N<>S/GE6Q(-6$O<R6 ,V![Z3.V1_7X99ZTX62]'^0;
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M^U"[V<BF3@JP^*]G:R]L0VI?&7*#VO6A]VF7U][WYD TZ[W5I;*9"7#?L7H
M2.G U&V4LF/D=R>(U]!1^K9!1SL@3R986B\L#MX#)/!5V-BAAI!@XH\N6VHU
M_3KO EY?QE.;#M&6MA3[WW$;:%L6]SQND?O@P*)TBM)YYA2%1MHV36M2>^_<
M7F<Q_F.]?_8N$9 OSQ,8-G^3OHJCE.2P]59=.5DW4NM^D74C^,Y6D^;2S1H!
MFX1?72\NPDJ;\Z3&EA(UM:M) BFMH1MYL,O^2IN3E-MJ5Z-43+DQ4W YU*&9
MPIE*\6[ZC8>N>4WZ5;I;SLC*-U@O7A[NL?3KO.#]J5/$1Q$?SU)</$X5;TT7
MR(PZ@IF-1UU5[KW5GPV(G(]2R[#$UAL5G\A>H\TJT"P34GWK=?J^_3,UI1HE
M*VX^&C=C!W+3IFX>WW<FEP WO3&;'^S$'UF.M.9A9O0D7,*?E\MA 0F(;90:
MY]L/UBJ6FT&!>89/?F2#D[ZS?UF3?</5WOZ--,GH/:3>8KE3R< %TY0"KY?_
M[KN.I93,?JP-4;FDWSY4:X;#3*["9)3 <7I:;I,%^SX+<WC%Z<;C$Y76]Z6A
M53-^,'=:R6_O%F.3S/<O&;9G4&[\5>ZO]G66K(])ZI:66FZM(;@\OW5R"V+G
MO8)5SKJQA-N*UE?Q6\;+V^NOVQW9^\52._8QX/I.6713?#J%L;;2=2_&U^EB
MG$:I@F4R^0+J8:OUL\6"N8U$F_O8<#-H<<5IN4RTNNT">:*SL2EBOTEIW'"K
M%BU4M-"+SHY]0"'V/;V;@!,[E@(9;',;Q/S3E-(1?#-'-55RIVG(LSR+>BDN
MV_E>N8'A8G8Y30S;RN E=FQ[+:XUH,JO> &8&-3 =%&/&Y#=U,BF+\9+ [X9
MPY>[.ZS+QFTMFF_6?_/P<P.Z>]S-B<TNGCQ-K(&QN3+=32^S!/L\O1RY@<0R
MKZ;YE\+J2)E;]).W9>'MO*,?EA59MXVDM0:H:5N;<%Y.R5IJWS2E?51O^)IV
M=JU;'ORN2>GJ%)E-#GBWUM VC<LR6Y'&SKSCI=)^WPRNVHI [OSQ;?2:;[3'
M0G;YL=+OK^Y;R#X>*[@1W*=I<;%L>[MJT*[/'-SM;7C JV=T?34ZW&-/V36W
M^="#2KY2YG?(,C]>ROQ.> ;W$9[(M9!=SHY9:LROYZ'IN]V:F<TDW=Q";)QQ
MYPJJO$<A+^.&\*OU2;8=2LV@_$N.,HT::WWG7-[&;[1F'TP2<+ZQRO,RL]L@
MA4!OC<Z]<02LSW-.!GIJXMXUKDFUY'>/0J[WWX%C52[%9#X>[DT.I+J;P)RB
MK3>P>=>4G^WNM.UH[<Y\MV4& S#3N&M0'('YKL+$3V?(+6J@0T[J::S=^GQT
M>8L!ET)B'W;;!/&-P?P V+[?"ZV(@[B8N-8E!G9]&*<73?D1\-LTRK(QZ[<.
ME._HL#I*MADEWJSZ,$38#'KM7/]-O\]T%-)URW4O4S-R NR^;?#J95M18*A=
MTSSJ;ESF].LD>8V[YI]-7EBS5P!__"BY2*[,:)SC;6D2Q&+F4I#P0WW'L;WM
M.YUOW]B[-JLU Y-/I1V#E7INIS!?-E0W=C0GI.W04MO&Q;=G]-"&U,.R/&Z_
MQ+-2_M8KAME5GDZV3OFU(Y('<T18;#.&>BW3J2'*<CLW(K=Y?QMQ,ES.'&F$
M2O;KW:W/;Z*]2\KEY<&_._%UEQ=A!\F+YB^:_]F=Y9F7.^&X9-24/+N26W8K
M#[>5I&N9N/#O;9EW&7&C=5Y^>%)\%Y]+F7$=)Z8RAR;;L'&NWZ'C%5:=NWU;
MZB,(-:#Y>?/&;1PV96Q-;A;PD(R4)@B6)R\E3W\.O*W,=TIFRA]UFPSVU303
MICM5&BY#/M#=:*7=STUA9;?2;78S-W0E"+$9+MTZN7%/-?),V3^W<N=<"J<V
M+EU3[QB]VJ17LO>WFF3=J*.#C-;^<27KY^V-I2XE87?UH-$VS6B6*/KH$&<,
M(R691]81243%K=[LK>JT8Y75$8G ".+:2&0,M@C^Q6QEN LW99/W#QS<W<YO
MS['3UE?45-$@7*4*->P,,JJ22!CC#=65]YLS$Y700@@G$>,\%6&3@!35!M'*
M,'AG)@.NGN45RK3I'2+O:YZ]N)PW>FM0X5-=3*5;_NOOQ1$>X=^6 RNGR6B?
MA=&%7<SJ5OEF2Z\]F;?.ZQ/ Y2T<MIZ>VW7A;#/M$C!;2Z_J*DO:"^LU6-4!
MDQ9O=IF .?4,C+99EZ&7WS0AG-;.3%9DQ@B-+^T&T $^;'T;LVY4]K"K?FLS
MJ6!G1VGH9@:FW?7#%B=F+-U G8G)K1'6L> >@<G"V*^_%T?(V ]!Q!N3*M(D
M/CC;N4IZ322DXWLBRKLT4K@+-1O#.9$F(!UBA;@C&BD>,!(DS?NCQ)EJH]'[
M0U!S;J3P^^K1^KT3R/7'6==AX?/T8V/[3;[\U$K6@W2_(OR,GBPH;;LJ#&_:
M*K2#HCU@TU6-;IKFURMZ,)==+[.#.U7?:?YI1XM.S0T<?/ZEF3VUIT%_>'N>
M%NE5I-<MZ46IL9X)C(*5#*27T,ABSY$+6DF)B:5./L5@?G[I]?W;:HZTMX1Z
M'7ETE#W\>X6@BS5QU!S;I'CO:36L^[!NNFG?.,9^;SGXMVY@QHD(MJ*5[]+*
ME2>^(AHG-4P1!^9#VAB:.A)JK&V%@]ZP*2PUP41)4: $@TVA K*",B1H5>'*
M,NVBN>W&_M!X?^J;D]>>M]\:I](/S7#YPU@2;Z&-[MVZU)IQSK6HST.8;U?I
M76O=^QP1#PODG<@VWVZ1Y4,)Z-T9T NT(I%(%+6V .ZI15H3@JAGV'A2T2@W
MV@L_V#71^<4_3]=EQYY"0SXB1G82A_FF3GDC%7MS%.Z)O'/1^G>Q:S0A6H8]
MBD1YL*MYA31E"GG'' O>1LHWYNUAXXA5Q"#.0=?SRF>0$!"#70FV$EQBO<ZN
MLZD+P=<_@_'X*(:]1\O3,WVR'+LTQE<,[P=J\>7<Z\XG=[QAK5)Q=SQ'EXI2
M<7?8BCL_NCJ4 EOJ@U\7%_"!Z\:OXN K20V*RD?$61KPKJ- RDA/&"&$T8V1
M8)Q9C 6SJ"(2$%_$%"D&8,YXR3GS5 BNUM3!I\4%$.+Z8]QPP/[0> BO6R7Q
M>;I]>MCG9#5^AA7\?3QU?WPS"* T+M-IF2W"-SV3:$?(N)_7&@#,LW.HSC2#
M9]4W61</RI%:Z0PPFKC%UAJ#%HEV]UV/#JTJP%S TOYCV!4^-3=LG<S7*Z[C
M&Q=T_>YH-=_SRIE&/ _^UA*[65+[%FFU[\QB/GUODP]QEA<)F_H.O\^7H[&Y
MGB[F\(@_@W_?/$YG8=U>G_/P+NOPKDL][_8G5X4VM_ZF6P*L8:DCKD9=L[YW
MW3U6+H0K_7+W\E.%/*LP^39M[5_G_HX+R9E08J_K\#Y7J3,L^>%NUY_%P3]F
MVPASWL@AE<_D=HILEWN@#(;=?Y*D@P/2@(!W#11('VR7?ZD/6:K<:EFH8:UM
M3+4+.W3<D]E)'9RGM\.V>[A:/3-XV$'PEZ'-Z]'B$?+UI2D!^YZ^S8;NBU*E
ME<G+K1.7\T'V%@_604C?.>LY<)6=COUSG8G/V2[_9V.7_[3N+^\/S]YS.E8?
M!W0Z@F/2'[8ONO1D2%ET::\HL=2EM.C2-Z%+5\/+K\^;16>>D*#=EZ6+0"X"
MN0CD%8%,CX:'BT N1DPA93%B^D6)5W,(]IUCCDT7?I?S<:>+VDQ\_9?^<%_?
MZ=P??KQ'R;6AV =I.5P-*<= 2_HT6EZ,O!^'O6G7+K7D.&R<@)\>E<3P-SL;
M_+4]/:O_O9K1\,E\"4_@^D.=E ?JW!<Z*:^=3?6\M)A,CX<2C^#9UTC:?GT.
MVJJX]J/DX3.'<L;,;5*69/9E6PPK.*D\,IYAQ"NLD&&1HDI)+;417D1[B&9R
MR[S%']*\Z \3?V\!.5M+9V=WIK,+.21,[DQH+W+LH(>_-\JC*/+^T.*8&* H
M\J+(3TV1,^I"D(XBR;U /%J'M,$&Z4"DL919J39JT1_34O5Y%3E7PTKPHLC[
MK,B?P==S*+]=\?4<Z 3\NM%I;#X=?)?J2?YRTSZU*R%INBGL<O0\IB/Z[GO=
M[F3TKC_>XIZ=NK[!S5?+<'@"B#D\I;:"F+Z1JI"GD*=(M2+5"ML4\ARI1;%N
M]JWN-^'Y;@<U,E;+?MO[]T!6'J'=\?M]<POZXQLKBK%X97KDE2G.X4T5=X0"
M\+O2>NT.)[>6(75<-8@;[!#G!"/+54"5$,H'3UVE-CHE^D@M]U8A$TA ',,/
MM?0682-"T))&2>T^;= _3UM/]T$<W01X4>T>V5!$ZA$%[)Z2L5I R?'JQV/B
MH)/9] )*"BCI&2@Q040-H,1'PQ /6"!C8T X5(2)(#!)O5UO=8%GE?:*!T0U
MC? ;QY!B6*-( ]/:>..Y>P50HH:"E.C[:8.29P_?%V?;D8BS3P^8_]D?SWK/
MI,!Q0=R'TN).>7SHQ@]O'0J_?F>'GD+F C6[@4.*2&<%1L1BBCCV!&DBX"]%
M*^\<9MYN0,U##3']/&WUQ3\:;?%AXC^LZ8J')X+60''XZTY,RH:8'122OJ0(
MW.R;461A 0T%-!30T%=&.1W0<(1*O_C9[@(_SGBGA:5(:FT0ES8BI3%'RI#(
M>,4<%NRY9B _ _BYRP\WY%7!/#WRU)RHWZXDR1T;%"OAXN.E18'%/29.@<7]
MA8,%%M_I$V3**A\84A)P+C>A0EH2A822'OX7:^N?U,'E;EB\,8_N, "8 _>J
MW@:B"P(NZ70%'_6)Y0H^*OBHX*."C[;@(XL%_)^(B$G* 1\Y@Y1@%$D:*%'!
M5D1OC&L_G-OPF?"1'FI5\%'!1Z4QSQO+V?L\G9OQ8!+F#YLIO:NASLVLZ::)
MSV"O;CV[[G:KB\]FMY[^Q#E[=A*/"]D_8SB)GM&D+?QTD:9J]QK;]UM+/*6+
MY+/F%-Q%X?Z;!P56M[ Z8DXL5PJ%:#'B45JD@@Q(8.$P4TY;M1&-?U+CZ,/V
MF21#=5@ _;(RL?<0^F1T5\$1_:%%P1$%1Q0<<6(XHN)*.!<1B4XC^!O.2! D
M5<]:9Z(UW)J#]JT^*(Z@:EC)@PZ>*#BB!SABU9,&?QO8K^\[(O^ZN( [._BW
M'UWMV"Q^)AC[]GG%2@_5?Z_VX@@EY.?S,/AA>@$O<0TB"-067)@<>_#Q?&8F
M=2LX+^'X!9!>P-J#S]/+D1M(+ =FGB\<35RXS)=-XQ[CV9+7T(;!OY<0TATZ
M2EA:$4PUPBS-5F ,[%9" UB]Q'!.*V_YQFR%((EC46($!J]'G%J.%#,8B2H8
M7PGNB"-K(:05 EV%)7T^W]#]MT3VG5I+KVDM]<WWY(SLU$M'SB<#.QJ/X7V&
MV4D]JI-:[X[[XC+.X,+!I;G.YQL^+H?[KL--'<7,A@IYKS'BP1)DO:/P%R<&
M$X$%H4\^W/]U^7.BRF\-478>8KEVB,4WWZM*G.&3/<87S3$>7(X7=3FE=YY2
MI36607H0P5+!V:Q(BN([Q!PFQMD8&-N(XC_XE/XV"Q>CQ<6'"]BP^<?)3_]:
MC.;7OTRN0CU_V+&EC)Z)DS^VH\D@_.E"70,BF;H0?#U($T*R& YY[^"2;O-:
MO+*"2#[-I^Z/P6^+F3LW=;B!),/!UW/X^B*8>I$&Q *PB68T&UR9\2(,&V:)
MBSE\!Q_-1@F<-WK M]''9+ -X'46$39^,4O*H5Y<7HZODS)PX]$D&4J##[_]
MDJ.4=C'^8^!GBR_I+5+B1O[YRCH_A]EL-)_.KL\&":"9?#K2K78\_58\MEWJ
MK?6$V15H\WKPU=2#R70.7P/<&YEQ\XRM(!#V(7UV_U.7K[C:0#F]ZBQ\6<!5
M\"J)AD"8Z026,*KA0MAYWV+!N!C#5J6[ ^C,STZ_A5>9!=B9U!+&C1<>/EX2
M>Q.<^D7HWO\<SB0\(%$W;=H"\.EL#O>%TY'7-*K_&)BZGKI17O_7T?P\_0Y.
MQ.4TG3C8E$Z9UT.X,M]TUP:-YK#PQ=CG/86[PJ.67Z2M!A+;O'G-=N8.!*,(
MFS5)\V[ B*[A:6TH_(;0;G&1]BU%L=-%DT7Z7S>%G_Z_O.+Q.#]OZMQBMDY
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MP_-FO%PQRBMNG_LPP9$?O,R'KV\PS>WZ\*<K^*>[RD](P^^HC+ZI#;I)#;L
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M.VB<7 ,@=U(-TTE &9J9R60$2J$VL^M.;5PU6PQO:V;S@4^#A=(LT_35+%R
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MJ,_= W!<<0W?,Y4B:$IT<(B;*F7Y.;#'I!#(5<)*;RHEZ$:&.>,@W"M=(4"
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MWR(N:40VX0>%*X]%<,K&C=:OKPP87C=V6(D\^*^G**-G$O-DU%2!#/VA16&
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M,0UC:U(?1XRL)!8I[3TU7"N<*K]>\54GTRU6\8F:R1W,.C=U(PA6HK(K.1W
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M>QU%\@P.GD,YZXJ#YQ#D_Q3&X]R&^DN8A)D99T>/\7#YJ)[/3&J<VDO';,&
MKQ#(NE->[IMDT#.>/1GB'#X'I$#"ODCI'>W<3:6%X1P)'%-O*8Z1=1(CY0V
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M+2NT3GXE;S">+IMK;[F<FED4\==/&(HU=FC/KQ[+*(^=NC607ZD,,+,#KO\
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M\VVE?66 S>F2^O8_.L$BX="W(24:1\*0P4TLY_/VOK^)2-G_3=0%UST9=H#
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M1=,*@X%"+7SZ7Y)(P($(59E/HX>,R$Y)8'VZB4M#7QK?KAWGT#7HG-&*DT4
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MM,&MPO&*F0ARWCP^7Y,6EBCRL:%A7(1\R"@+.RN1Y>N-%>@E/LB4X(N8XP<
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MU6<:B^02 1:.&TH":Z0K%QBR\+)+5SI2!(#PAJ;)ZFY@(WG/5%2UVL EBV[
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MJX.UM3H05"RPO+6RC;'V;3\UP5:B>QKF#?Q=,0ALHHQ?KC44H5.&;V(M?9M
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M"*L/(:!6VR*38QUST[!+&0: .AB.G"%D$1(0'".IWCGTQ+*BZ9=[Z0'@^FB
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M)JF[98W_NW'I%I:F-FJAV6@HXL;X.VC3@GN_K@(.D5<R9\>CK!^7154O<"2
M6'F>LT$HL:7(@!GDU0QIO&#:V;TMNUR\&4R(M:6XB48&,0;#&K/P8P;>'QGR
MTDS\*2](#@(,H*S-Y=&-LT_2P\-L%RC6NSV$&>C["KR,V/X>J,D<\VL1NA&-
M AA>#$B#)T)C(HB]1'UQ]<.7,]#/'8T%^87)M:,7+J*$>ORF&2PY?@JOLAYS
M+=JJM7)=*KD<.V_'HE>_(&LLKF GPF9!]R'I04E];L!\K,?AHXF :P@IX GW
M!(Z0UC6*SS,D 5L)TH8!*-)\T HZ*63"*.JE:A$>Z'BRKU@?DDX?VF5DB!%F
M-!?4?ZL%]3_-!?6YH/[@R_#VHBS;3R:88^ _X\14;Q=M.W'.>)\^]?KR$T4B
M33>=BXC\IYLCAP-1R'@E)^(1M0@]%ZEKQP<3?I."BJ+.^;CET%7C2_(J8HFK
MOCKPPN(S7NA*B:_H0W*;<X-#%O&VK<#A"'V'(B48FG?::C.J+!QR7^0'84J,
M']4A/"[-"6TQE=L14MPI;MU>PU"L9=VC_]-$J:ES2=D_)L_&"/K^HJTYI^V7
MNJPKLD!45@^YX1@7HNNYMY;)B:^=T"X1'2?FX9JV:#L!BOI?A&H/E<=UN2Y\
MBCRFM8\V0.)):9^^>=4D=H?U=]=D;P=S>A.K,N/%%4+@9=CAAA=XPP/=13*U
MUYBUV55EX4$4D@#G*)1S:KJE)U3MPC1!C'A=\'3Q/M<=3JWU[UW6><WVDZV&
MG$&B/4_4P1*7I@1N:.3\*6J#UQ\&IQQP4T$#8CHB/I=+7CO%6-"4)UC3U=8(
MR?S[SA5"0_>&K@T_)FZ'[]+$!0B%QAK]'S,?M]H%#^DQ/0DXL00I G-!D^P+
M,9B% S.R6ETNGH)-ZDJ*DD5*WL-J]!5D"-! ?,@R]%90#Z&/L^#:V.,A%?\=
MTHN^(RH@W^B P#*,N.B"U$-=U3E5[G&^S.R_ZMT<#.VLU?[0-G$6D'J 8XC%
M,G"7$C6'W4!$)[[!;M0U-12U;>WI$H+R1<Z_3F)-%,[4($2GQ>Q<.\L@GLT[
MG[?9 VPSGXXT(8$-&0S.<MXIY_+:YIUR+CM%H#7?(<SJJ;JHKW'S%)F05WSW
M]#7_PX@R#71HZ*)%2H)-3=.Y>;.=S9N?-]L#;#:"]*\KHFI;<\P4M^HL78:4
M![Z6N"5FU189QUW^9#'OGC-YE?/N>8BC"KMDB$8!_;9-L8]@ YBTD.R9L)Z$
MWJ.E\AAY3MM9ROJ,7NV\FQY@-S'Y54IED.7!'TG2&[9+L[J"PZBL=B+=NG;5
MOL)F.O0%77E=U%7I0<-,/5'=8/[!I;L _/-94K[\G62L9RS9G2#[,,LK>)W:
MZJH55NQ#').HQOI>4:Z9ZRP Y>F-3=3WR(;&&>O$@XN:;ODC7IM1+%WI:VPD
M9J;=ND9\T[302/+]$IX:6Y W#C/SB0+0L6T1Y0&Q)$>5@[+I:M;HADL1Z%O)
MYGKI=.3]Y+%+1UB6575.\8AOKS650B3>K.#M)HBA]-@Y'\T( $Q(2BA=1SA?
M[&@+5<90Z$.L$=VK*KG&DE<"2JVE:[CS%9SH-O*XTKJ*]93IRI+>C&[ LT6C
MS/M!G=R!F^IP/W=%[J3V&0"D'-8QI2A-'-4$I")$_ZY=1EG^M4P/@KI$,%T*
M+,U818=$/INN]H!7*28)_(U^1MT&?DIIZ<*JR>G%LXPNH\34Y,AUF%O4Z_<0
MP7,.L\!XLJ)$O\'EVA<=<&0(/6;!24*.%7M/OCRH:/'VBJ:0^*'@TAG;3Y'-
M8/X EI''$/I*B 7(O^<!O'0$TGS;,K21/WS>U=7>@0EZKC;W2CF(GC\7KB;J
M=ZQ3V09@5N*ZM+G32A3BQWF1QOM/:N%(&-2S:*N*NC!O)07O29&.EEX5:O)8
M^NK0%,';%L['_F)L!_/)O(XX%?#BV!+5\L(SQ928D>/2X=H\[FSJ&86'W16(
M5<T9KT!=/'!O6G,5+ EZ/$':^ROIGF]&A73MEH]1J!Y\+41'.$U=J; !K1+'
M Q8V+00#"-I@&>]7V$THNS&H\F*6!46B>-MTM1+O)!$1 C7Z$ AAU!KB*H:9
MN@F\0+)GA] &^'\966!>=O@#JA7&-EZ6/R.#,AI2MZ>I+G-C4K+BNF!;FM4D
MW S7=_"_'@9JV$)'O/MAI5K;W67-I/@Q]40T GZ%:=S"09Q/@3IL7=QB-QDY
MLA4J-+#/=+_"-/;ND&*]#GU#EXLKBWCB))?,6*QA+CRL6-(F7-04*^V1JK<'
M($^*H\/7<=,Q(02#"%@NG(O>$5D%WBA@EM4$[]!9P;EB%$H2^%_EJ?QJTX-G
MK,-..;N(.R2T[_&!KS)B ?]"<W,BY&5NB/Y0L-=5<T<:8*&S24S#'#N#'A+6
M7^*!S@&^'QI#L4W_X"TEM227\/)I%_8Q! 2;8'\B$,'[P=)E&P)D6\8)",[J
M;L]K6L@5L7EOAE#=:XSQ78$]3P++1W((W/9$/$ER/]B[&Q@RX[8&[_1'79[3
M_!\]IH> J+NQA!(P?S?JB/*"4R8_67.^GY6LZA:-=SY84\80^Y4?M;T>V0!*
M%!5OA(B:*/3D.)BTZN"<QPC-T/[?*K3_RQG:_W#0_MF>\Y0V&9R5ZG.:8S/N
M>>?(K<?-)#U2D5TFP+@:Q-IE-3;ZD:6CAD'#IT(1'E&%-2F2.,.M(98JW58#
MCF!@"QR$-]7%CGO<<,",KZRII=H/7I(VP:]M#@TFV*>(?3A/R?3& G'%Q_-N
MQG!V6%#BI(?SCR61%_>?H9]-S6&PQ3'YQFX/WJ0H5W7:M'67>>J)M;1(.T,;
M+;2Y L?4UDIX!]N*^3J"A('MN M_C\\AY4B2=\E\;\RZ!($O/!RA3?4G%+"%
MZ6?&C,9$OA,S&K(NE@/*N'/,I,/D]4+5)X<H-<L1,%93BLE8\#%&+\)S. 7@
M/QYM^6"FSS4HP0WY%11CC5V@=@;Y[P,=G6M+CMSCDO#K/6H5D*;O [=FRNX+
MJUPHY"C9.#(UM^Y?W_0QSM$B&' NG[GH%=.F9^Q\PBK:=9N,D*^,+(LX&2<C
M&NP\\>3FV/"CJ_3(&U#B'R7Z&;Y+1*82-[2TJE(%H(*7B[MES/S-<=C]UGHJ
M*F0@M*IA+O&*TG(L+'3C4XK("M/6:,B-L6ZQ/$>)+@)NM06SY7B* .+SL\PJ
MH]GBT<3!Y>)JVVZHKV%4LX /$?Y]KQW%%G&D,02/>4P-.*QRZ-^)JA:EU?@\
MRA=,-)4]0?,%IHC_,W_BJU(A68@G,)AR@@J$@=#=.R):0;N(:3[R%:17",\_
M6N-Z'V0!Y87M;U5@68-,KZ;=^P]B<LOF('W#7D2HI+1RV(YL(4IQUU)\E12V
MDI]-N#:R2\VUM0G'7W2$GY \CA#DJW0G^P,0RKH:N]7OJ K3, ^S=8C^(2*<
M_S][;]ODMG%UB_X5UKG)+;L*,Y%D.XZCJE,UENS8>>)8)3DW=>XWD 1G8)$
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M$3;48+<)J<'<LSQE#"TH 9>N*+^B2"?%\#%1;JR21Y# J-*/5^S^.02+X?9
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M,C1RT>%\\5N),3'=?])30OP;@FG-8V$J7-]EG9@\T7'@.,<H/FGFCK.I#YZ
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MUL@2H2\&% UQ26A3IFRC=0#<]I1#GI42;3/%5GM=B!IWA,5TO0Q6?@2!RMV
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M?;-\63<Y^DWE2;2_3SLL8FL#K7V7Y8AR32G]J57%:672U!5@;HU5:S2%<TL
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MOJ<LIO :_%*:K(JGN F1RW27C+7JS 0<6(=P976+:&"QK!D*[)>W@OA$[@$
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M8("6XFB"-^FFFEA,CE_1?2UZ\TI_W>GE@XVKF\ZA6!U'C&T06OU%T]#31C"
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MA&2'%>%3]K6WNDU\25?RF"(.7"N?:7P+1)O715)E?'W'ZP9N7*RQ"R!;D[L
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M-^&E4GU!WNB%5Z$>2@XJM_)#Y:P*[-L$' Q-8O5<0\O8F.5'@E"'(O^N>IO
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M=A&&OPQ_O]/8_5Z_>_'AFE/"C'JWU=>&P\[PY\YNWP5WNR#ASW^]O7KO721
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M4%9J/Y7]&D6;"F 2\G,OLH F',:&@]VQ-,I(7EEHX"D,\(P2NEMK,L%[??F
M$$Z"G]]-HA$<]H:5XD_WGMV6_P^OP'\N,_@/=A_U7H"[.=89+HYNS]WNVL"Y
MXB</_P/30NA-1"9@!NBNI(L7@>++[.*_4!=_G @OL#GC<F]<9DF43VI3IP>T
MCVB)(D6BC! T\T)@>O.#()W*OIA[Q23*O3]*/Y.S>SSWKL0LS0I/3L@HS-?O
M[?P3I^;;*(Z1JF-D'O-__WLWZ/6#XS$8G'X(CSTYHP.GW"S-Y>>EXXIX[N [
MB)J[WG493)K?VM(6^4DC8!@)4OGF#*6J1W,O$V/Y\4 Y$B7PT?)S96.CY";W
MRDHVL&I.U8IAG2XZ7;CT88II<1>(&=+JP:T8].1/$[_ GZ_$3907&1#OY3,1
MX-?%LO^M3Y#AM*A]Q6I\J3]XK#.!<*+(ML"=#ON-'IV8]>$,^"<)<OIC^;5'
M?GSKS_/C5]X;UT+%BX49>AQZ4?C+JUS^QB_*3.3/,"Y':1P^61=?7_SZX>2C
M[N*-_I1/5^?77S-6=KM[P^%33UM;@@$N+<)6B"29^&\992B&FW]UB*4;30B:
MR, 5EC+\(,562* @(RA H17<2_X!%FWR-2,Q\>,Q!"=X$,92=4$!<*.$:(O/
M\\MBDF:R$\+5!*\MG4!Q^=J6.Y+]EQZ/TDQV,#908I>CWC%>OA/[\[0LY./O
M1'A,K^KWL ?5#7+TQOXL%T>YF/F *'3G9#A.\=FOFHG1+U$NL6,<%?,C?7]+
M>I1>M[<+;WO5GME1+7KP"OF,@T<_9'C8/1S4KG$JZ4NC\>OS41NU)%]LVXJ6
MY"\^8>A2OE9V-OSEEU?#5\ZY"Z=OET')DU_/O8]_/[\ZN3S_]/'B]+KC77PX
M[7[K)MF@.]AS>\(<..&/BQ#UA>R?</>S VR;!=@!V %<M<#]P=KQQ0VCM27V
M_LV?>X..-^@-ACSK.>=S3OK2\UC@>7QII79\.S]B'WK1/J22H*:7Y K6R],X
M"EVSS09ZUYO\C??6S[*Y=][U?LV$2(3SA;><@]VR'*P;FT,K[7DW9D['+, N
MPML4&^LBO-A=!M ?!Q^<SW+PW.CXW,CP@5V$7<2!]>\+S$TX9@&',Q!T/S3S
M*"KD%P3+CZI-(C'VSN]$4.(9M=_'XR@060?I#2+H7CS(<!9E(BC2S!X";(L5
MV^+U918E033SXT6#/*C"RM4G/$]RF.(P]:(MP [ #N"J!38Z+\,).:X^V4"?
M<]*77OR*B*M/V(>X^F0=U2?_C*:1=W%3!I.(*T\X+\Y;1ULQ:SIF 781KCS9
M6!?AA>X2.SX".CB?W>!YT?%YD:$#NPB[B /KWA>8DW#, @YG'KZUZN1=E/A)
M$/FQ+G+@ZI+GJ2ZI.AYJ>TZ"0'Y:$24W7U5LLIFTT8=/.C%M5E\\,9!ADM55
MD*P.OI-D]:]O1FDX_]O__/7-I)C&?_M_4$L#!!0    ( *4ZHE;P?8B.TQ
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M=B"0IA=?;TY/?LFBR#TTT_ ZAAT2J:9\3 JYRL*HHB3!: "%CK<DP4P *Z[
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M)@;$!0QD\VZ2_H*B5&HU<^WP #QM0>@Z/I0AEV!(^%'JWO&XD"  OF4^_=(
MTP..XM><C!'VIB%EHG'&:!8ZXHCC,SG2FQ(^WV79QU,VZU;Y2F?*'VW0K.(%
MV<&S0FT#F>X!B66\)[0Y-18S'%_Y=G@@@-T0""U5S! >^T5T1#3KOX*E%^@A
M]*:(\C,O0N?->>?',&"![?.C<3*64XC(U!7V: SS'<$P8ILS=^GXC7:B5C\(
M*)Z&8N&0CW(^/(&)DT;)]SH;G":O:9P4+U658@Y0E6]7@:F0H6N7_R%^*H5]
MJ-1<IM]^S_^9V@Q]^1]02P,$%     @ I3JB5KI6WU;!*   _SX# !4   !S
M86=E+3(P,C,P,S,Q7V1E9BYX;6SM75MSVSBR?M]?X>/SLEOG.(Z=G9U-:K-;
M\BWK*MMR6<I>SLL434(2-Q2I 4G;FE]_ %+B%0!!"B  FB\S281+XV.CT=WH
M;OSE;V]K[^@%P- -_*_'9Q\^'A\!WPX<UU]^/?X^.YG,+F]OC__VU]_]Y;].
M3HZN;FX?CA[ Z]'$CMP7<.6&MA>$,01'OY_=_^'H7Q=/=T=WKO_CV0K!T55@
MQVO@1T<G1ZLHVGPY/7U]??W@+%P_#+PX0A.&'^Q@?7IT<K(;_A(""__[T945
M@:,OYQ_//YU\_.GDX]G\[.S+V><O'S]_^/FGC^?_\_'CEX\?"]V"S1:ZRU5T
M]'O[#T>X%YK;]X'G;8]N7-_R;=?RCF;[2?_WZ-:W/QQ-/._H"?<*CYY ". +
M<#ZD8WIH!5^\_3+>0O=+:*_ VKH+[(2\K\>%];P]0^]# )>GYQ\_?CK->E%;
MX+^=[)N=X'\Z.3L_^73VX2UTCH_0U_##9&Z.2?;-\:].E'4H-O[I-/TQ:UH;
M^O53TO;L\^?/I\FO6=/0)35$@YZ=_NO^;I9 <H(^9H0 !L=__=W148J<!6T8
M>. )+(YV?_S^=%NGSO6C4\==G^[:G%J>AZ9.1EA!L*"N?[\DC-U/&+7_+O2,
MMAOP]3ATUQL/')\>3!/Z,_#QUCAQP,**O:@CA=1QY-$;K"W7/YS<TC"BJ4T&
M/UF#]3. 74DEC2&8SA4:#MKQ,SC)@.E(+6,D&LU[@JO4XLE":PG@6R)$L=3[
M^.G3V6EDO05^L-Z>)J0_H?_\,HN0.,62^#+P'30K<- ?D QV'?3O3O9K.%U,
M$7F)B LG/FJTWD"PPF2^@+L@#,N+QI.?[*=-5B=E,BUPN5Q9_A*$M_XL"NP?
MJ\!ST(EY_6OL1MOOOA4[+FHO&)TV4TK$*#_B+P//LYZ#])--EA"DE'(MFWN4
M7E;R8$7HO]/%11RZ/@C#B8/01.18WJV_". ZH>T*1);KM5Q=AY%[6?$L7J\M
MN)TN9N[2=Q>N;?G1Q+:#V(^0HO>(^,]V@4 <A,W7"SHWE@O_87DQN <6_GO"
MD=D2L&2R_.WLT@I7>/^]6![^'<FL>PO^0-0^>V &[!BBM8"P$USR"%"'GSAF
MZCJ\!KSS#:*3[+N/S!K/_0TXWY"J@K\;/M\ DO$],=#!5&B 9/8K(CQ?"FL)
MMS[^]3$(7;&<)XFD7C"^0^L (1(H:S=:[X0(4D"P4$96/Z)PIY/YR[2EN$TL
M868]$+O<.N#MSK6Q,I?I,SWBUG5^/=#[[KN)\RG"YQS:0(A8W[6JR^F3#\51
MI%(K%P=8]PE4KC\3TIE8N7[;X"\87B(3:QG [1/PL,DU#\@CB,1*,#']6 S8
MZKRP$@-UC8E-*1)G(70=7^'JL^^8>+^1A$@^&_J<\^ )A!%T[<2&1UV1$(FZ
M:7(29M83L;F[!DE[)( ? 4R^MF^G_Y0,-MTDOJ%^4.Q&C0[(DG_>"9@G8 ?(
M $=JJ0P8.TTM![,*S<]LFFL_[VB^V$Y>+>C,$8E\>$F>MA]O&(@2JP3 V<HJ
MN&XF2"FZ<O&=V0O ^E*0>B(+'HAI'.'+'WQ7V,U;)GYF&F(.6+A^<K3@Z\E2
M8_ 6 =_)G:D8(Z5>=DSUGFXOL$O$>O@*,B!<EH3["XR%%3XG%Q!Q>+*TK VF
M^?P4>%&X_Q?\3<Z3[['[AYQT! ZX17_,_+%(&0'>UV-&PU.%Y,ZQ>=U$:MI(
M%)DAC HDHK_EY*&__/(( R>VHRF< ?B";(;)FUO%DMJL7Q(Q[^UF#Z]*MWQU
M.@EM32+VE_VEJP)>S53^RR!,2-NK_I-GI+=9=D1AW^9^[1=3%\CX7W[!,Z 3
M"DG6&JM6?U8 8$D^WOI("N-S8[J86V\-$/+T5+ @1$-*3/&6LT)ZN8T"(I_
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M2HBRI!*]DX)E7%O01W1D[J +*W1M"O7DMAH0G;BM<E]2 ]G[U@H(_R? H>_
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M)/[."BZ@TG33_-2[V.:;8OK\'V GQ6;IP6#\_358'($TYI4;?_\A+TYE_-?
M@G;UC65H2)%[PL6F*:E[^6]]$D,.5:C\JAM!PK=2 V'WUIN[CM=4TLJ_*]_?
MVH>#YQZ8%ANXH9,P):7B24D*32T #"?KP%^FSOW4?89]+(G!CWZ)_6IN\6%C
M"2S%673#XW2DO=K= 'O;WGUM1:3>,[=BZ7=A,)*2N)[ NIS$&5O>/:[9D/Q*
M@K/#*.(JX\<8D>F"1,-#$#U:,)HNV,1,%U,?_!M8< KO0$@N\2]^%JG?\._
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M) $R?PUX!4C>='PBJL VUV\;%Z:'/=*-SE@<5FTJZYNBMMS'0K&Q,'JP0S&
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M*! F/: C4)@P8@J,K45Z*-/T)U=^-@>4UI$4@\HX_.XC(PB&:#G(,+0\=Q%
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M[[""@^GU##BB]66)3?Y;<6.A$_7J6?&:VE@PY!1XZ"^S<'QNN'^L&O.IY,=
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M8M&WADK- A\N@OT*.GJRN9X(ZR'8*K<M8J'ZHT;,*$ACH:;W#Q>Y?K<QL9J
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MNWG5+G;U!%JN#9<C>@Z"0=D2:$LR3_!+3&]V>J70K0&Z:AS61YT9R@U]C$X
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MX,MR5(.\MBZ\]?'AV.K,ZBLA\[%[G"5H'F>Z[Z$U0IW)2)<O(G+VD)]?'G
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M7E,9.:W7?/VS _$*\C8,AW5T./S](0"BM%< ['$A'$JE7Y0XIC]-4_9MQ)7
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MN4F3.!??=]TY47K"=1;1-)5(7K-D7[^TM].Q)L5%E"QQ7'_7-ON:#WC+GN9
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MJR='+L.( 4RT%WP5Y$%]YLS>QP?B(2TX+EG'+'H.0/:9?4=I\U ^S*[6YF(
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M/^L>"KU+Z:+3@L4)/6JGB^EB :@DFZ!2*-+PD#W?88WE^2=, "R,@P'NFN"
MCG[=WIPUIJ1D[+*;Q@*'#7XT75SR(U>[46JGN"O-T:7[ :XC>*=E1AZUS+?K
M+;/%WYQGVG5,GY:UT=Q6J_]_BNB7G\Y7N]9+XS@:/FX0WL\<;FF&/1"0?29<
MVQM>\H#J@)UC_)7G^#2F [6_90\&VFA\*:NCIBGO;"Y4(?"3Y/5GSQ%O#\(9
MJ,$>@DV4!V3/5CJ"@+U$!]$XKK5VO?J0<^?C9?)"K?#Z^:K^WM=JP_G%,_)E
M==(DS]/H><MN>DC<@-KFC)7S%HN;V[9 !ZH]@5L+[#YFS'"@N*SVW&]_=DP^
MB+U!ZY]9Q%JF(_4>,R\-;S']SNRJ3==0):KM00P_]FV_1OUA1EG+"WVAR@>O
M[:CRA=];VP6@S.K-IQ2VRR!-=_1V8O^X:^L@?QP!7VEC-<W8M'K^IX2 "_ 3
M/;E !9_&AG:?1AE$2+:I\A'*!FYM26<NAO-;D',(>*AHA\UNKW*_1X9T<D3)
MCN7Q!MV(IF$VCB!@\5+(Z'9CC0?J3WW]:[^H9MV:\AX(^FUC$%\P\[REBWF2
M<(73;)PF 5(:E9KC"=E#?(W2+&>:Y9QJ&&],+#J>B$_WB]'2Z^/13< ^>LR,
M4E],&2H:?&(5K=?(J#-/\/HSGIWC%[L'$L1'5GWVR8N/)C\97)/T(E@'59]*
MPT-#.XM*";;,'FHM+'D;L>&(S3Y:"R=P"QVK&"H-'<Y:#8*#WK/H=L3K:+OF
M"-W36%K3,HNEWM?8_HK%4%P+B%>U(TT+XND;*7G8^!7\K,DV7R5I2U^"MC>\
M^)&2- ?7.!BV *O4&O9H>MJY%W66!F!$/NW6SPFI\:(6?S^XR-Q!=_E1) 9;
M#-6I"JHO[],LRD%GNHU#:E*&VX#\.<I7[&"!VV45;68)1U%J= 8?2\%'"%"7
M]O"3IKV+3</3?@[5LCMICQ>J[0U_J/B9"*GN;7)7][ /MDM'3NE TI%[IF<6
MX_T7F.X>W+Q"=FC[^(JH^0/)8"U)B85'?)U@-?PU/^?EHU:EWR_8,$3+$"2-
M7_B!K_M5 A^@?RHK8.9&BW2.[5<&&]^TB-A'KZ9D&1V+E7_0>_YQ!45UQTV*
M_[&E]E=Y(UDF_JY"OD4$BMY#OJ7AASBUC<6PM2*X@ 6WR,%@<K,/CBW4=C>S
M2]O'O5';A_3PZJ7#WQ]&$IEHGB= 28ZLV*]_VT>@D_) 9US')>-05*7$2^;M
MV]>Y[.#WB\(!%?2Z)O1O\?*/W^'X],O3=P5YJ=&6;-/*$:,Q@2=A2)_)+NE?
MI^DL^1K_E3PK;TJ:$,RGA\[.UZ]??V0S!)-S_N'#QY_@US_E.,WP'9#][C\X
M221HGB"@BI(4 =U__TDS,#@A2!W_G/VI*_8KH2S]<:KU?J,<0!(QFL@@BGZ1
M9/\_=])4CM)NDDARB-)#C& O4M2%%\^X6MOE^]#K<H(XY1/$:*,S] LG/PZA
MJON,T^32]"&,D:-0Z:-7](MV63"!8X:2!1+#(%G],T;1Q++) =!4BV6,@=@@
MZ!<8!K%Q7)X7S!+0.MJ%$8>:/O\-,[1Z<%!T649-$BF:(Q1)GHF,/M(#H(L=
MJA.1'I5T%(>+UQJ4X\Z7+LLFR:,@#I$Q &)I".RGLBQE5#*2DGB3DGB"..+4
MW8G6D%ZG5$^=7O?66]Q<31@*+4CR-4,+:H"AA1P&!6J<,<LJ5I4.A)BH<BCX
M.F$P^HDB-1S2XSE5:%I OZ\7"RQ[@>!."VN21X&DC[ < (5TA/'(1NK$4J21
MHHVN1B56*(",&,FV53,6[4>7YRH#,'Y@#6GF 8%#+XPH!X4R(4BVG3Y#E2T'
M8NU\"AG4T9Q=(Q'W'X0(4PX@>0H%ZR3-11M#M&'.,]   _ OO(L)41<0&Q&I
M(9$:$YGS!*."KJC&17)@-T;]A(X;LEH*$BR[++8BA(#2 )DE_?#9=XG6+*';
M1IF;;[52F+7/6$$FN\C@%^Y6\SG!,V),(Z$H&VPCQC<"QI'@'''6X7;FS"/&
M/=*V[;>^'A4/Q@NS^.F)F*J$4Y1!P!)MXXA.,@>X=3=MHF"8J<EAE(-OZU8<
MXA?;_#[)_X+SAR *NPCZ0,=?T6G/0,Y-"OA2="N!R8'IW',]G=X<+)Y _T)U
M6)ZR@38\9V-\TDNUAY-')GTD!T!T!$2'0'0,!(,,\-LH==96J91==@,_$F)&
M&39$QFC#_F?M4-$B25$DBO;?\918.YDY0Z!3<):0YLG=])4@(" :.EU0RXS%
MC3KY*8#4:;(XW5*C72'1N=87K8HC5E;11(PH8E1AF2A=-'$CCPFR^I_;(*4S
M2W:/>$-U\"Z+(DDB11-QHH.6@/3.?+%?QU.TC*,%M04J:51F\8(-ESI\^WHP
MI$=#<CCT"PR(V(BN7"..!2??H,PE/X,10LD,V0,M^T:,Z,#94$'6*>),=U(0
M!57NS$PY7:K]I6[\F)8E(24A@"(2)-'#2(0H[;36%7&UN1I:)Y:K:KN%0>00
MS/[0@R ]BL.(JTLQ247"R3N3L+1'2VLYUY*NM:1K-I)#WZMJI\0BO9UN<TD)
M_<)HN8SX=V*:],YO43^7\?6=SE?K,N]:42=,42>2_ F*J6E.+ULQ" *MD6Z]
M$<G98(LHRDB3=G 64)W]<A7AQ?4KGK/\48ZXFG8_QQE9I.@B0=CEP697&.)-
MCD)_*@.S7/0-50&R+LNCZ*-$#S B64A9#(,V$L1U&'-$@I6NT-IUH@<@%U %
M,IU>GRT@# JWB57P""\RE(-URV 2SD5VLK,*(>5Q#^FGEZ\PPF)@\8N-&!IM
MZ-@GPL\V^CE1USB(R(=#?#P9O1$.13DDXH_*01$;U=TT%"$K.2_&IW"LN#SX
M?!V'RN@4Y+E8<EG-3_T$7?,OXB(@;MW13F2E"EJ:'R/M!5Y&<3Q&@8O>!"EJ
MQD45$0:G5Y$CN4CMZM4LW@ C)8?W[RR54[%:*TC+>7.8M?RM%W:Y' V)X1 ;
MCV4@&9%J%.0(\Z__V?7',-XI-H^8-T[RLSIT_GN>]\0)3_?$"9]%G/"T)DYX
MTIS"D1LI'"=(B7+H(HYQO8HY'=87S;R.?O[OR1S9%R"RF"*9Q>1_[60C99%E
M*'NK=#*#(+DZ8E@NW,F_W9S2_[NP9FU+(0.[4B>2N9>*H".#7!C?JKM!E]F_
M2/%K$"<$;&_'SIZN;(OIEFZ/Z? Y+GDY).=TKEUZ,IA.SNWH[LJ4,,"R'KP-
MG?G6>K;@>MA,F_=))AP?;OS%HJ7%-!7 XUUK[P0]%NX2)(?+."GR/$TER\Y*
MZ=C9T=(<IU-RU^^X5#%>LN9:(MC::[::4_F*JR9'07(8R.GVD='6A\REZT+)
M'DK9J2:8E(*$*9,]62!8>;;>#J\6Z8 5*1[5]B)''RJ0@ROVL"1^*K,\#/(G
M2 QPPC/YQR2BB:51$G%$8I"B!"JOR*PQOW06P#T\Q:U[]L,1>7VNT@U<RTN^
M'5&'E+E8_C@-J/.WV1<O.'U.C+P=<,G+$BCW<!W6Q"@F'XU4B/(!:0K2@QS[
M.G9WN9EYI0PQ3GI0_#-CC'_YU;^=G_WV#ZR.*G>(;F!;2N52T*)!LJ))6#CK
M'$;J!*PL1Y#N9)912@A(#9594N(3_<+I./PN2E[@8M64$2FR@89QA>-D'<60
M"OK[\4HD%JGB:J[4=YFY2"[Q+C0F'$!^\P:-$<#I4@7T$J[M='>9A)V4/@$2
M5Z!_@M@(@'4G1D$PS&CD(\VB"<G<BF5@/"9KK))T.VY+3@T9.;\]0,=-TV40
M"_"(2ZJ74!4QY%&K.'R @M%8HHX*,)B * 8SC=9G!;[L/H#R75!@(4'L8IM%
M,<X<>CA]RR[6W60#%?A@-[;)"1Q1BA>]4S(#-[$G(#3>Z9MI$W#=31>S-(@S
M .9(XN[7/5"'?<#HCTD(8O _%?QS?8#^RZ#N4#W@9J>9NJA26:]P-D\CIK=W
M"JQ%R1+'Y<1-E<IZ@D(]SECDDPM73+_4,$I7XQ.I[!]H6"YSM1QZ!NQZ5+G=
M)HM&#/MMR +4F&1N_8J?@_3OF'6J-WI\PR5+U2:>=]&I D%11YD&=UQA$IZ@
MM1A%X%&-1CY2$<W K92D1<[*:(0J5R34KEMIQ?JO1V#Y/8VI]QZK$48^$X6;
MK;8&@>>)MI4@N*JMQO07=%\NJ>IUCW/6IOH1'&TI#F^2]#'9!23?,3./="Z8
MTH/!/H"RPPS&0YL@"E&0H92-YK"0W+6PI"(GU3DA!8T-A>18B Z&Q&C(&&ZL
M8I=+EH5D&V.Y8[W<KK.3JMF?D!<)FO]\A6=?$QOU]0K%C'^I7QB*&614(CH
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MJ8J]9;CXG](D,S#)/E%]Y0(ODA3/@M<N"\OHF@AC0-GE;>]#8'FO'P!UJAE
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M^!N?0*+GK?)A5S[Z2?M!T'P.3)K/ 8<=0\!QP5W!$,OE]ELG3 H@R'K@G.:
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M7SA2D0N]"[G*G=F,=>-:; %%<\@PVQ)>V3G(MB0T:I!MI[-E:J!V(+85NT,
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M(0A)"R'\+4M(% 8\\B6RU#/6)EIU$&*^O:H:__M1S9G8" 7B"*BCHEOZ%SF
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M3!<7VRRBPV1W-F)(G"B8CI)L'S$9:Z*0=R%%:7\):>C-^RPHN]I2MS'="W'
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M&N#.PEE=P,XS2,O#H ^?KCW)BEK!/ES D0A5\DW7BC0244A)BDG]IG/6(]6
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M9L,03=)ITY1DC16R&*22P$:X2M9!%'?+W&1]M!1E)$F/1!:R1PST"Z?KTG;
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M0$>MM?K*>89R#'2J4@8V=)S=*"4^P."38QDEA2KO1 SGII3_2N@=-U%&M0L
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MI%$RC2WT#9@L<@;Z@]'U8H'G+!9W134TUS7AG840BR+I4!-P^#R7#@O%.S7
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M[9I_\M-8YM1);....,) &@6,-D141<U'I,B/0RA2E(>3A4"GRNP;ESRE?7?
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MH*P_8:FF:Y0)K6XV7C0[D&^'""V-FG#.3!N&R:H$IRP*Q0G)J64WCL2#Q@=
M+_;8E/ &N6LDM7&*P?%N2:X9:>WA:IJ1CC0Y]QP%;4]U$]EDE80E#- [6_1N
M<N@!Y<R,5I_["%3VLAV;[\5Q"+C+I40U-<K@7)F/*5W:^Y3W:+&NYPI[@[!5
M]-/=C2*QC+.$A/W&:O!V2BQ\:QZK-"JA?#+U1-[\^#)+5]+K&.5 JURGH'47
MI^U0JRPQO*]>M=6BC^X[O>*K]3H6FCF^Z1V$D!^H9^@+H/8U]"'1ZA'6A*PR
M-=I0K$.,;728/L<J)YS@[UDN2DJ>#'YBW3_&FXTU$;I-@0ZY;394F14+S>+*
M.G\VTN;$&8I66.2[:DG4@E(ME3UMG]V1SD,U\T7(4%5_ZE4E]L9BDT[P&SPL
M$8YFLL'1YVU;!6AT99N[P\+P3J#L]9N8 ,V^&06*\UX"02U>,N%<&5 $X-6L
M%"$N[LS1H(^5TUJ^6D7N5&.C/7')0VHJO-.\=.(29@NY&Z@]L\U;X<;Y;GQH
MI_G.T#ZS*LQC>D[%O"Y40P(:9^=ND148>O7U6;;+M0;[5YPW&%&%872=J?)?
MIOJ+=<:]Z1V@/YH3$4U:6;V.O;H_3.KH/OXVPBF[73RJV*WNMD6)3F=UR(7F
M71$V#__IH\*568<Z&-L3\!H@F!S@=OM$QL)U8H"G*@VK'>_N?\AFB)4!O@W3
MG59?5D4$<#Q<8Z-''U UZBI_$'.OH4C6*32:@[%Q[>K?M%,$_L#:U6O3/:/Q
M49'"J@[XS,5LG"$)7-]_:1DC*DOUK\LB/\TY#.L[!EQLN569N="'XOHKZI%,
MPXX/\F%B(0\CVNH190TDNCIB^18-3$_-/;&,@D58WNTRU;4=:D.HL"2T"30,
M,3OR09/CJ\Q/*@36MK06<>;;'[:P<R /0-X)RKZG;1# 0CJ"6&XH*)""%_#C
M?J%,R.3@$H&0J8'=&[[ICW2[WS+BN7\QF&?M&O&Q<T"S=THH7Z[VYGN64R>D
M^9IS07VC9!Y#-E]KC?.O.%)S1>)WF/8S^1308)%3RE9(65HG _L,P<XG1]>8
M9FITB,NGF6N8?5RK3[7>N67+XJ%>(I."L_G:[<3K<N+Z+IEH]0@'^JL= )?;
MM'R9&KR,6M^P5X(P9.CG7_N-Y+1HAXY+(\S!^([Y*F_J"26+,G=N]+L\-] V
M-?T+#'3/Y\[P::H45)&E0X< ?=C7I;1"97Z'X'?-27C3](/W*CTDA#BSZ&[?
MH#,JS]9Y0PC&ZRV1==N,6G*-[1S06NIN6JLI]%QK=>QBFY$+\CG>_%%XQRGA
ME7[YJ*_LF3S*8P?"ZQ+:4%^2'M#J.FQYE58&;-%!&]VK0J86T<'LY/ BA%E,
MCA7]W:_BUW_&0AU"CP@?^6AUCK '-X:$4"_1L3+;_)AMDO7Z9Q&7&=96GV4"
MM#8UR%JUO6Z9.D0(AYZ;1XLY<W@U0:KF&K?84\=$'^W5+9%&1S?JU$VT3XQ6
M_1SL^!LK<HW/ $C!]>/I6F5I7DJ,@=CI7@XP?6^N*CC+169M8'OT(,A%7R;9
M0YSRBH80B1AG@:I8^A_),MJT%+_1V(H#3SBIT7*^ED"'EG3'ZA7=GJ!M*6?\
M3),:MB-SH1L(U6G.\W4W"].$%LS1-EB7O;[GQ"'A%N%*RQMZ0ZWZ[%L5:V-6
ME2FIMBQE1V:TGJ,>HC3Y7^F\:F4C$]2>WJ7ZA93E9]=)&J4&,*V"L[,JNY,,
M_%ZERFAUS-E#SXY3PS\QBP_%6@(PQ@9?6+>1IFTM'"76?R1G]]*35\\Q%=-1
M_ABU9JD,O::W'^-B.G'$('+8!V#?O1C\4$]W9P5OUV_Z'@]%HM/UGH40LE/"
MOS9.'K2$996=M<C*GD)ZMQG/P^[R8 N&33)P2"D,Y9=H/L+11(8V,5H@%5BM
MXT:62!J"*G%,H:WY4?H\[^@@W_&"]JP3P:, !KR,<$>?XT]1'C$):F.T[]>M
MWG%XFZZI6AQ15NG$WG5Q'K1A:FTT2^A-+Z0UZ+]GVK1*\N,:UO+C! 3Q5PFV
MV^@I5FX8?PQ+>(>1F$ @T0:]'6>>?8_]-ZKO#$#9?9,M]>9[U(=PX?KJR^O^
M=?0974<[^E [!-JU)"60T'JT_NY1MNLU%/H!3'=^\%V@)AP_O R+#MYM(WRO
MGFEAM**F8UG?,"P UOOIN.>>Z[WNMAMKR/+D4<&/Q0 $SM>]9 &7JG,W3O#R
M3-BHAPDDF=\2[7O=N,.RH.&Y>+9)H'71R9)<LS)289\ G1!S.Y==8/7%8(Z@
MLJ67Z!.12-%>QWV:+).G:"/ EMOHWKD(, '?.K/YLQ),UC-, _6#[+?;2!WF
MZT%VRBS*XP>MS=0.<E[MD17O<XR/?%2?LZ*H>*GM><O1/T:+CBZ3*[P+G&LI
MR)*IT<>!2=)MVK@17+C>-G)?&2L#6G3%&_W?A\]QJK^1C38?+E;;)#6=7LEE
M6GTQLCCV&B"HR-UX@ [];LY63U<7+IU!X_2=/(P]4<3KR./;PYFS!+*]N/%"
MJY> ?:OBIRA9?2J3D,H/M4K"'L:P3QL)_2F- .>Y]!UU*) ^<7"T.[[2$VR9
M7 ,BY/>[>$S42F^TZVRO\L=C\G"]1T!OY.DRP<[G;1A,@C8M&= >"ZJ)A3PX
M*5XU2FW\N*510XA$/L4XUE$"Z$YUG>STATD!Z&O]G\ZZ+&2AX$^>VAW&K<WC
M9+. 'UL9VY$MJ@X!&I: "^EQ-\T2HDL6BQUC*U/L4,#E'UD.1I&J-WU35L#+
M.AL''"O$*,ZLPFPYGQS8X.\ICY5^[AT\@S;0P?>879D+W^^C@/$]%,ZLD/&3
MHL_)JNBC<1M(44"!%%K06+:"O4MV_Z'3]P?Y7BF/G\[?,7>M#S,Z6-NIU?;#
M='/E19^';!,NZCPF*R-C//!#)EO+:9#-5?23;Q]?XPI)CS# (NX32K<#*]B^
MT$?$?#U?KPD(ZRE:#CVA PJH4Y<QW[_$&X+#++!X#RR*G2\O](V(^5P[HP+,
MTQ+'E/XU7\^*$Z5Q90U?X(D#ONLL7$)CIOA$E2M[L5SNMWOC_S@N>_S$"='*
M6+7#2]=!UWCZDFC)I):/!_E ]!H ?3I&!WIQI)081)IH8[6&+>1HY8QM&I'&
M+T6B'*N3V5F@_25:_=NK0M"Y^;;FZU)A)"=6SH@R=U:XD2RV&)Y%3TD>;6P[
MT9T;FN-3]AR6$40&%$!?\RQ[CA7WT <70]@Z)%:+NIZJ+/,BSU7R:V_T%TIJ
M(JB)G4%5Z&)-B/OI^"&!+3=*0%UC5Q9HK;OAV60E?*\NI=%4BY\FSZ+*^'O;
M-(_NW-CLV%:K>GK[=0JIK>V))ROZ^!^T8'#TQ@1B2%-WG.C5TCJG?1&YF4CS
M;W9]K=7.(J4.^NPU?]QP)2G^W"&D:S)M@!N;YDNV(9?R9RU"R6Z9IRV32"4[
MBM#M5>USKEH'<QOR7'.A)7M3^.>")TY5Q\L2!ZG?L-S 8[E6&4X[&1Y U['I
M'_=4W+FQ1]1.;UC3<(DY@^IKP6QGWN=]];K<[/5#)M.+MMJ^ O7JA[Y=>HU,
M, /Z<9%B7#36:\NF0K%NM^JM0+AX#<U[%"AP?*)VN5&P->7JF(P\[Q%"<9>U
MFL9^].LQ^S&(A33?7K^'!;DU!T9 *ZFU?93PAXTY4"X/MYLH]2F7?\,;0;=C
MW-&YK4^D;93S!UF7 KU7;$*IEP-OS$6YJ.VHD<)<OOFN3Q7L\B!HU"VAZZUL
M[;@P8;W,\3;9;XN.(_.T<FE4&6.,:]E*CPU"6T PA_T )6CTXX8!?XT#0,F+
M??Z8*:FUDX4<+5;T;>04>B$W 0$&RC$V@13H/%^HB ST^\/V5[9IW_+@8M#!
MXG'UQ(<?O:&<BC/9_>7$"?06+I*<-,2OZ4J;[ZM]M/E7DC\:"45GYF/RM,@*
M $ ^%N#)CHY2-P6&A<BRM!?D2?$BNN_:L[D#+>3H-+6R4J9,!+#W1F8HT;??
MDU8]6=;DH1@MNYN]<AGKC14+;VR2@=%?F38**6U32CUN7P])\O7O5R2""X$:
M9>,Y;IGM?8@J7B*X\<*76.N6MY&:*P/Z4)ATE6=R1"65V+"(M?I0S!X2KYX]
M+DSO$H:W+#Z[5O%_]]J8/3 KGVADM/9XMMR +A+1V^8E=.<._1&+@ 'L:B;O
M*S+=]&C%Y[1PTK"[[:0#HT\MMN.]8X6E,W,(.7/=A,FR_7()*^4#><*RHN/D
MFD2_A":RG:[*8KGTP;A:K<UG79F;1?[C[\T:;_1O?_ZM^H_^00T%_OP_4$L#
M!!0    ( *4ZHE;U@+MPY3H  $W6!  5    <V%G92TR,#(S,#,S,5]P<F4N
M>&UL[7U;=]LXEN[[_ J?G)>9-2>5.*GNZM3JZEGR+>UU',O'EKNGYZ4634$2
MNRA2#9*.5;_^ +Q(O  @0 $$"/*E*HD <./#QL;&ON'/__6V]<]> 8R\,/CE
MW?D/']^=@< -EUZP_N7=\]/[V=/E[>V[__K+O_WY?[U_?W9U<WM_=@^^G\W<
MV'L%5U[D^F&40'#V[T_?_N/LOR\>[\[NO."W%R<"9U>AFVQ!$)^]/]O$\>[G
M#Q^^?__^PW+E!5'H)S'Z8/2#&VX_G+U_GP]_"8&#__WLRHG!V<^?/G[Z_/[C
M']Y_/%^<G_]\_N7GCU]^^.G3'W_\SX\??_[XL=0MW.VAM][$9__N_L<9[H6^
M'03 ]_=G-U[@!*[G^&=/Q4?_S]EMX/YP-O/]LT?<*SI[!!& KV#Y0S:FCV;P
MLU],XRWR?H[<#=@Z=Z&;DO?+N])\WEZ@_T,(UQ\^??SX^<.A%[4%_MO[HME[
M_$_OSS^]_WS^PUNT?'>&5B.(TF]S?*1H_M9H__USVOK\RY<O'])?#TTCC]00
M#7O^X;^_W3VE\WR/5BA&J(%W?_FWL[,,#ACZX!&LSO#_GQ]O*X-$SAK MW0M
M,?@?/W\^_Q [;V$0;O<?<(</C^@_OQ;\4/Q_%BRO@]B+][?!*H3;%%I$9_JY
M#02K7][A@=\70V* _K?P0/%^!]! WG;G@W<?I,[G*49<BK]_&09+$$1@B?Z
M6-M;HG]?7C@^AO!I T <<4VKPWAFS.[!@:C=!L2>Z_BRITH<7-N\#[]&\]5\
M!V#*:Q%BP,MPNX-@@SH@N7@71C*67/QC1N!RZ42;&S_\+AN"QKAFS';C!&L0
MW09/<>C^M@G])3I,K_^5(''T'#C)TD/M90,A\$F%&!U/_WLG1O^=KRZ2R L
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M,TO/MEZ!E>=ZM&L61T<=544+%:SEDMAL)[%<XF'GWH<Q()<"9;641LD##%T
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MY/%U1.L>*AUAJW9>K<'[/65$=AAO>T<-T_D6!F"?[;J;)%BR'T.F--:^"HR
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M+^-1)--YE_V0?>I]2T"SXA$K/MFV3".1VNY1Y^B[WDREMFWDGZ)[#)\SVW-
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MQ.\LN=<*4Y"JE'D$WLO4$H+C8L6:05RW984./CT(#NL F_) H\D/1I-/RO(
M_\1^K1Q1A[V;8L<'E"/)$V;AVYJ;8BJ @W5*#VF\P5LSK9(R/BC4!1-H2CF#
M(IZ0M09G':(OQA<.BJ!M>F*P @!G=YV:W^#!R=MAB7H.%F:.Z?>/7&KVANN/
MH/"_4&>0TORERL$Q.T0=/G44O2^/<M%Q;GQ:WS_\F*HE%?J=->)HS7SYH$[9
M@IO*4R,5D8AR,'%$<<:I=.(<."S^*#'LJ=IRV[$+,4N B^<QG#ND^0*B#Q5"
MZE_T&/#PQ#I$+?[(I79V-.9+S]@B1MG9Y]AQLA!S6A<Y6!!#YNDJ&P>&"B;8
M41;%Y@E&?*!W\$V:Y2!#(1A:ZH0Z40JP5K)1,:+..ATCE7D=U$PKBKZ !.);
MI*@OJ3;$J(IP96HDQD%@Z.DL,P6;K];Z,*T=89;X),+<N@@10%B=AS=$O:\8
MMY:'"U^9!LZM-6S/<TTA>;\H$X&+B6,PLNTSB@.'U0:UEJXI6Z^NYN2$D\@E
MUH-F5MK88</9YBF4AXVG#/R-E'!,K!/W!;A5A3=4J2R+?:912$A$,@A TW5!
MK>F#G/DXM_8XR6%M/9D-\-5>?+D7M?HNV#ET+EW7DQ0WQ$ (^'K5=AX08$9!
M[\X07V22B$@B2*^!3JSJ^!3 G1'P HW<7^-O38O611$;FIM(X"%$(I;(X%V-
MQPU5=]U D#,XU+HQ!=:X40B/1\UFF5I_+^$1&*XF)FAB@EMB@N=%3%!$P,^.
M7O2K#!*DR#?GM^-UJAD#_M8UV4AC.4A>FKI,WTDJ]>$,V5&:WZ'0W-?QA06=
M)*!%A$[:C$X$[%62U333"WSI,*]#%VUH88/- FQ%&W,&G'$1&MQF.:"$ZR)A
M0BT#A_Y-](M"<U>[(@YOF':%0[51 1Z&(@;/;7WG7[B! 5!TJA]D6':P_LNZ
MRZ[CU:3KC4+?IM _% H]4NRBBMQ!Y<Y@O4PAJJRW T>U+E3AL(HN5-F[6Z$7
M\H&'DTI< 7X: \<\MO6,V85Q:Q:#BE]^[XUQDUH'<;,G1L#2;6B^MH?&!U3(
M#:U@E8NOJB:DB[<WZF#;5*$=*KMT5'BLT%'KL15:,XP!X'@:+6RT\#8M?%$5
MS:R8:Q^O;WA2>!1<ALVM,+[L;<'JN^"9%@3"+H4/K3,.<:\P7U<]JNGZ/61.
M-!WCKZ1CO#=6:;O85<X=T\!_CK,T(L(2!*4N6/LHS;$K]472A+EQ"<T.^XQ&
M/10Z+6LV15<CX1#=ZR9V:&*'6V('.&YW<<XM9Y=:7O%PA<&[H8!]B!$V53<5
MX[ZA58^8MT>SW2VL>V5%MHV&%RM\.80;LYS^P933%J\'K7736S3(9^J#?%3S
MGLUD+&F8CQIR0N.@+J@+J8HMWV-2<X$?',@B-1]#+GR%S76W!\"LJJ"8-&=:
MX<@;*U[%(74LYMQPYDVKF2 MA,\1,*K>^0O<$!Z+94)58Z!]HD(L14,RG6LD
MLZR72]2X:IK ]15:;*&PR!U%VB&![]3$(EO@>T?%$E>4G+% :NHX1 7$6I';
M%4 -Y#5(#:8<E/H;J?V\ACLX7C4F:Z7-XCB?;.= !SMY.:QV+KG98:]6C'[I
M SD#6=/V_$(]S<'7#WAN%TJ#C)NU](FRN#@&6]8JCJ<%MG3NY(]X5+S8X>L[
MVX=,Y[@+WYY[86'):7 1M\N\X/LAASJ2*"!4ZMS5N[@6^C9E._##\0BKM*CH
M 1%RAKQ^KIBY(B>T2F6(QYCT_%L75UN[V-KK+M<AZ KL*_8[2*>)W+LRU=3+
M-;AB^B!]85TKX!<(I*M6K?<UW,P(C9#"/M602=F4"A<\G?N6R"[L.KMQ=D7[
M-%YA>:MXVVSS_9'UHG_C_AKW=^M[8\=5!0L'J4VGN*!&F^LEE47HA,NXJ*A2
MB;;J%I>O<EIR8* @:2@S\ )9S-U<79 ;F186_G- UJI!SFX[!P'* +Y0[!J"
M;Y&M<%6MD&/CL6AN.6]1^AA#+[5B%+DB X?^%GPR\">F@6WP#XL"#?>H6XM6
M EP:MO$?AG+MC5!>\U-$#X/+C0F[8VEYM>HR^KV4R?#UJ#]].WXXO^#1R,I=
M_QP/SB)T&^%HA&.7<"PH,11S&G.J<CYIBI_PP%@^HS?3?"2_<RRVR,"+AQ"0
MFUMQLRH42+E7U#ML4&4S#GKQZL%&XIEM_ S*KMFK:G!J(VHZJ _GNJE [!>F
M,01A]6U]=GF()/O;D#\TCK?1EYVY _YX5M2]-XTQMO.W+/<4U<_Y>V#D?#[!
M^VB(]I+Q#U%"[HD0[(>[N3/5VX._?3[X>^B^MWY48@+$<6Q)/9B??'XXL=;6
M8>'/];D&G:MCWJ,P[/Y@^C!LTY[RMA&#9G[J*^3$Y\W>G3[!_\'0RV].G]#_
MF.B_4$L#!!0    ( *4ZHE:-<@,*TP<  #(V   /    <V%G92UE>#,Q7S$N
M:'1M[5MM;]LX$OZ^OX*7Q18)8#MVG/1:.UN@UV8/^;#=O38'W%=:&EE$*%$E
M*3O>7W_/D/)+$J=Q$:?;Q0H!8HL:#H<S#Y\94O)Y[@O]Y@=QGI-,\2G.O?*:
MWES\KSL<G!_'"]P^;NZ?3TRZ$,XO-/U\4$@[5>5(R-J;?ZBB,M;+TH\KF::J
MG([$J^IF?!"45LLNGFY\5Y4IE7[4[_5_&F>F]%VG_J#1 ->5'T>E76^J46P(
M$IDLE%Z,KE1!3GR@N?AH"EDNA2?&>U,T\F$(J=6T'%DUS3U,.&<=2Q,F,KF>
M6E.7:3<QVMB1G4[D8;\3_H[&]]H&1^-YKCQU7243&E66NG,KJVC7G'B(T<3H
M]/Y4-BU_\;DV?GS'_MC8$8ZLRL8%9C)7J<]'F?*PK?3P$JR_N,G51'DQ'/00
M$E;ZYORX>H)?!R=/=6R"<<A^"\^6QA92/YMOWUU\O+K\Y?+=VZO+WSY\$O_]
M\/[BH_AT\8XOQ;!_\IWX6U/V37#\S-Z^[(A_26L7XJ(G_FV)2NJ(A*Q7V4+X
M7/K1+NX^[9T-AZW#=W+XH"<N12YG)"S-%,TIA9^5$Y]K:;& ]0+M3-O"E.(7
MF"(&_>Y_1&8LQ$A4T&U20?![*GZ5-LG!01UQTC\9"I.)3W)*XBHGS(EJKQ+7
M$9=ETANW0=QO$$]Z6#4.(4"0BH6X+LU<4SK%V@FQ;"*8&F@NC1?<4:I2R'(A
MZM+;FC!WZ:F -@Z;% 6NK)):9#)!DQ6F0'KQ)LK=$R@I(><DEBU$"GE- 1PK
MG0YM*8S!D)K=P6.P0*)L4A<0*]$=EJ1D!5P)$+F:_ZW[S\E2HX0G4"BG46V@
MA!!SY7-,T%64! ,W4)F8&;JE8K+8=$,+OCV#;_@%\)'(5(GP,E+6X>P >1#'
M;;MQ7Y49&^H5]*@RT35S"B"S$;L.X*:8DS!/QV!E$&N]1F,#!'=G:!B;*E;<
M88E:0P 0-,!)&,X%>Q+I<I%I,W=+?%J:*N<M*E8AN3':#2L[&S!S2V/N6=LB
M;<](.^UQ,MD(RXL?;T[Z@]=CUX"IJ128%TR6*5P>NJ,0M$LA+05X(-QJHBFD
M, (F)UJYG'NP6 %:9&KDZU2Y1!M7HQ^;8(V..*FL22A%LQ.'@$5*P%F,_<5-
MDLL2*>\MN.ACK2$Q&,KNX.R0HA6#LS1>Q4O%)7(9\1GU,V-MX#;BB(W9>:3L
MUD@91EKFZDTT0X)S?EM-[1FAA_)(O">'&2%.(8D]CJ(.Y]=$UF[W+ISH)@1
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MM7@3Y>X)E)20<](N6*20UQ3 L=+IT);"&$RIV1T\!PLDRB9U ;$2PV%)2E;
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M5V><.<EK3KFQ1@M)-U27X3)S>?'S36!KCB/Q'F$+I<D4 QVM&.UA8#9%*<8
M7*@=.S'Q.V1]5Q>()IP75M-DDZUW9"W;/=/IYRUR=V9!%AU$G +' 3/AVKD!
M5R?F/57.C)X1)[]23IO;<]O0(A65-@M"[SPWD0CE+>@":OLI#GKMIX_[A,![
M!'DH?I,+<1H_R-J+>Y_\DL(V[S[LJF?PRXN?^R]/[IY9?3B!+X,-*B,;[.$7
M.TY&H;>KY0*'(6B[H704-9\%?S7R (&6E:.ABX=PBF^#0+E=:N8+@$B:PZ5T
M(P2I=.6.H+M_UGOY^O4O[*MCGSXDU'M]=O:(S,O>X-5C>DY[@\&K1V3^#H,&
MMV3PCUTN<3T(*X/KRE\/!@<[;I\Y'-B=(!E=#\/O+C=LWT SKM)0VC=H*E2:
M:O;A@W!> B<@Z:1W_L?#.1KQ7&C>&L!G\S]\V#K_CW)^"_X'_;_)3$O+\IAV
MFVQRL(6PSI^?L'C#-/EBY55X1(1/)'8.Y7?*RW_"JN?8'6^^=/5D;/Q(!-I&
M_:&H?Y3%K<^ ?]PD^)>HJ&^[_WO6@]%'/UHT_H0[JN70OUK$K_C+#RV)MB3:
MDNC>OFZ1*\K$A]55Y^_Q<R5Q^*_X\@2:UIU\3_YV_7Y%(WOT-?;%7[Z9:J_S
M[E[GY:ND5,DIQ5W0E9DG.Y1Z+A<NI*?Q,7^]Z\U/X^/PM;#_ U!+ P04
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MG[WOGPS'SNCSG\._H#^8V)9.N]WY'NQ?-?>[W?M.V9Q&#[(5WC/XQP+P0M#
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M_ M02P$"% ,4    " "E.J)69 $A19WQ!0!K/PD $0              @ $
M    :6UG.3,Q.3@X.#%?,"YJ<&=02P$"% ,4    " "E.J)6^%8L>? Q P"O
M."X $0              @ ',\04 <V%G92TR,#(S,#,S,2YH=&U02P$"% ,4
M    " "E.J)6\'V(CM,0  !LOP  $0              @ 'K(PD <V%G92TR
M,#(S,#,S,2YX<V102P$"% ,4    " "E.J)6#=B,C:,,  #JI0  %0
M        @ 'M- D <V%G92TR,#(S,#,S,5]C86PN>&UL4$L! A0#%     @
MI3JB5KI6WU;!*   _SX# !4              ( !PT$) '-A9V4M,C R,S S
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( *4ZHE8[1F-@)8@  ()8!@ 5
M      "  ;=J"0!S86=E+3(P,C,P,S,Q7VQA8BYX;6Q02P$"% ,4    " "E
M.J)6]8"[<.4Z  !-U@0 %0              @ $/\PD <V%G92TR,#(S,#,S
M,5]P<F4N>&UL4$L! A0#%     @ I3JB5C&JB*=,#P  ,*L   \
M     ( !)RX* '-A9V4M97@Q,%\Q+FAT;5!+ 0(4 Q0    ( *4ZHE:) 0TU
M9PX  )]H   /              "  : ]"@!S86=E+65X,3!?,BYH=&U02P$"
M% ,4    " "E.J)6C7(#"M,'   R-@  #P              @ $T3 H <V%G
M92UE>#,Q7S$N:'1M4$L! A0#%     @ I3JB5OD^4#3'!P  '38   \
M         ( !-%0* '-A9V4M97@S,5\R+FAT;5!+ 0(4 Q0    ( *4ZHE9A
M43[O?04  %PR   /              "  2A<"@!S86=E+65X,S)?,2YH=&U0
52P4&      P # #Z @  TF$*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
